Unique_ID	Origin_ID	Sequence	Activity	Source	Structure	Hemolysis	Reference	Length	Stereo
FPDB00002	AP00026|||AP00026|||Lactotransferrin precursor|||LFcinB|||DRAMP02840	FKCRRWQWRMKKLGAPSITCVRRAF	Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||anti-sepsis||Synergistic AMPs||Anticancer||Anti-E. coli IID-861, activity value is MIC = 2 uM||Anti-K. pneumoniae JCM1662T, activity value is MIC = 3 uM||Anti-P. aeruginosa IFO-3446, activity value is MIC = 3 uM||Anti-S. aureus JCM-2151 or MRSA, activity value is MIC = 2 uM||Anti-L. monocytogenes IDF-1 b, activity value is MIC = 0.3 uM||MRSA||Antibacterial||Anti-Streptomyces scabiei S58, activity value is IC50 = 1.222||Anti-Escherichia coli L361, activity value is MIC = 4 uM||Anti-Salmonella Salford, activity value is MIC = 4 uM||Anti-Escherichia coli O:9, activity value is MIC = 6 uM||Anti-Pseudomonas fluorescens, activity value is MIC = 10 uM||Anti-Listeria monocytogenes, activity value is MIC = 2 uM||Anti-Staphylococcus aureus, activity value is MIC = 6 uM||Anti-Bacillus cereus, activity value is MIC = 6 uM||Anti-ctive against E. coli IID-861, activity value is MIC = 2 uM	cattle, Bos taurus|||cattle, Bos taurus|||cattle, Bos taurus|||cattle, Bos taurus|||cattle, Bos taurus|||Bos taurus [Bovine]|||Bos taurus (Bovine)	Beta||Beta strand (4 strands; 8 residues)	E.coli ( MIC = 12.5 ug/ml)	"J Appl Bacteriol. 1992 Dec;73(6):472-9. PubMed.|||Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M.1992
 J Appl Bacteriol. 1992 Dec;73(6):472-9. PubMed.||Ke T et al., 2012||Sengupta J et al., 2012|||J Appl Bacteriol. 1992 Dec;73(6):472-9. doi: 10.1111/j.1365-2672.1992.tb05007.x.||Ke T et al., 2012||Sengupta J et al., 2012|||J Appl Bacteriol. 1992 Dec;73(6):472-9. PubMed.|||1992 Dec;73(6):472-9. doi: 10.1111/j.1365-2672.1992.tb05007.x.||Ke T et al., 2012||Sengupta J et al., 2012|||J Appl Bacteriol
. 1992 Dec;73(6):472-9. doi: 10.1111/j.1365-2672.1992.tb05007.x.|||9521752 , 8980754|||35213576|||Ref.8980754|||1992 Dec;73(6):472-9. doi: 10.1111/j.1365-2672.1992.tb05007.x.||Ke T et al., 2012"	25	
FPDB00011	AP00150|||1812|||1827|||1964|||1979|||2116|||2131|||2268|||2283|||2420|||2435|||2563|||2578|||2706|||2721|||AP00150|||Indolicidin|||DRAMP02857	ILPWKWPWWPWRR	Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anti-MRSA||Hemolytic||Antibiofilm||Wound healing||Anticancer||Anti-S. aureus ATCC29213 or NCDC-0111 or MRSA, activity value is MIC = 1.5||Anti-L. monocytogenes ATCC-19111, activity value is MIC = 6 uM||Anti-B. cereus NCDC-0240, activity value is MIC = 0.8 uM||Anti-P. aeruginosa ATCC-27853 or NCDC-0105, activity value is MIC = 12.5||Anti-S. enterica serovar typhimurium ATCC-14028, activity value is MIC = 12.5 uM||Anti-E. coli MTCC-0723, activity value is MIC = 0.8 uM||Anti-and A. johnsonii NCDC-0072, activity value is MIC = 6 uM||activity value is LD50 = 64 ug/ml||activity value is LD50 = 12 ug/ml||activity value is LD50 = 345 ug/ml||activity value is LD50 = 30 ug/ml||activity value is LD50 = 200 ug||activity value is LD50 = 180 ug/ml||activity value is LD50 = 200 ug/ml||activity value is LD50 = 270 ug/ml||activity value is LD50 = 290 ug/ml||activity value is LD50 = 31 ug/ml||activity value is LD50 = 20 ug/ml||Anti-E. coli, activity value is MIC = 20 ug/ml||Anti-P. aeruginosa, activity value is MIC = 40 ug/ml||Anti-S. typhimurium, activity value is MIC = 20 ug/ml||Anti-B. subtilis, activity value is MIC = 10 ug/ml||Anti-S. epidermidis, activity value is MIC = 20 ug/ml||Anti-S. aureus, activity value is MIC = 5 ug/ml||Anti-K. pneumoniae strains NTUH-K2044, activity value is MIC = 32 ug/ml||Anti-ATCC 43816, activity value is MIC = 16 ug/ml||Anti-ATCC 13883, activity value is MIC = 32 ug/ml||Anti-ATCC 700603, activity value is MIC = 16 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-	bovine neutrophils, cattle, Bos taurus|||bovine neutrophils, cattle, Bos taurus|||Bos taurus [Bovine]|||Bos taurus (Bovine)|||bovine neutrophils, cattle, Bos taurus	Nonhelixbeta	"The document does not provide the half-hemolytic concentration (HC₅₀) of each peptide directly, but hemolytic activity is reflected through the percentage of hemolysis. The core data are as follows:

1. Hybrid Peptides (RN7-IN series)

RN7-IN10: At a concentration of 15.62 µg/ml, the hemolysis rate is 5.9%; no hemolytic activity is observed at its minimum inhibitory concentration (MIC = 7.81–15.62 µg/ml).
RN7-IN9, RN7-IN8, RN7-IN6: At a concentration of 15.62 µg/ml, the hemolysis rate is 0.0%; no hemolytic activity is observed at each respective MIC.
RN7-IN7: No hemolytic toxicity observed even at the highest tested concentration of 250 µg/ml (hemolysis rate 0.0%).

2. Indolicidin Analogs (IN series)

IN1: At a concentration of 250 µg/ml, the hemolysis rate is 3.6%; no hemolytic activity at its MIC (31.25–62.5 µg/ml).
IN2: At 250 µg/ml, hemolysis rate is 15.39%; no hemolytic activity at its MIC.
IN3: At 250 µg/ml, hemolysis rate is 2.39%; no hemolytic activity at its MIC (62.5 µg/ml).
IN4: Specific hemolysis data are not mentioned, but the document notes weak activity against Streptococcus pneumoniae (MIC = 250 µg/ml), suggesting low hemolysis risk at effective concentrations.

3. Parent Peptides

Indolicidin: At 20 µg/ml, hemolysis rate reaches 56.98%, showing the strongest hemolytic toxicity among all peptides.
Ranalexin: At 250 µg/ml, hemolysis rate is <15%, with hemolytic toxicity lower than Indolicidin.

The above data were measured by human red blood cell hemolysis experiments: a 4% human red blood cell suspension was incubated with peptides at 1.95–250 µg/ml at 37 °C for 1 hour, with PBS as a negative control (0% hemolysis) and 0.1% Triton X-100 as a positive control (100% hemolysis). Hemolysis rates were calculated based on absorbance at 560 nm. All peptides showed no cytotoxicity or hemolytic effects at their MIC values, and only some peptides exhibited slight hemolysis at concentrations far above their MICs.|||hRBC(50% hemolysis at 200 ug/ml)|||V- The 13 designed peptides exhibited no hemolysis or cytotoxicity at their minimum inhibitory concentrations (MIC). Among them, the hybrid peptides RN7-IN10, RN7-IN9, RN7-IN8, and RN7-IN6 showed hemolysis rates of 5.9%, 0.0%, 0.0%, and 0.0% at a concentration of 15.62 µg/ml, respectively; RN7-IN7 showed no hemolysis at a concentration of 250 µg/ml.

- Indolicidin exhibited a hemolysis rate of 56.98% at 20 µg/ml; Ranalexin exhibited a hemolysis rate of less than 15% at 250 µg/ml.

Indolicidin analogues IN1 and IN3 showed hemolysis rates of 3.6% and 2.39% at 250 µg/ml, respectively; IN2 showed a hemolysis rate of 15.39% at 250 µg/ml."	"J Biol Chem. 1992 Mar 5;267(7):4292-5. Pub-Med|||Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor JS.1992
J Biol Chem. 1992 Mar 5;267(7):4292-5. Pub-Med||Brahma B et al., 2015||Yasin et al., 2000|||J Biol Chem. 1992 Mar 5;267(7):4292-5.||Brahma B et al., 2015||Yasin et al., 2000|||J Biol Chem. 1992 Mar 5;267(7):4292-5. Pub-Med|||J Biol Chem
. 1992 Mar 5;267(7):4292-5.||Brahma B et al., 2015||Yasin et al., 2000|||1537821, 19191872, 35254120||Refer PubMed ID: 19191872||Refer PubMed ID: 35254120|||J Biol Chem. 1992 Mar 5;267(7):4292-4295.Biochemistry. 2000 Dec 26;39(51):15765-74.Life Sci. 2002 Jul 5;71(7):747-50.|||1992 Mar 5;267(7):4292-5.||Brahma B et al., 2015||Yasin et al., 2000"	13	L
FPDB00014	AP00176|||AP00176|||Human defensin 1|||DRAMP03591|||AP00176|||DRAMP03591|||AP00176|||DRAMP03591	ACYCRIPACIAGERRYGTCIYQGRLWAFCC	Chemotactic||Anti-MRSA||Anti-toxin||Enzyme inhibitor||anti-sepsis||Wound healing||Anticancer||Anti-Killed C. difficile. Active against L. monocytogenes, activity value is MIC = 39.7 ug/ml||Anti-S.epidermis, activity value is MIC = 2.2 ug/ml||Anti-S. aureus or MRSA, activity value is MIC = 5.2||Anti-and S. maltophilia, activity value is MIC = 1.8||Anti-Gram+ & Gram-||Antiviral||Antifungal||Antiparasitic||Anti-HIV||T. cruzi||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Antiviral(SARS-CoV-2)	neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||Homo sapiens [Human]|||Homo sapiens (Human)|||neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||Homo sapiens (Human)|||neutrophils; natural killer cells, monocytes; airway, saliva; Homo sapiens|||Homo sapiens (Human)	Beta||Beta strand	Strong hemolytic activity (100% hemolysis at 5 μM)|||No hemolysis information or data found in the reference(s) presented in this entry	"J Clin Invest. 1985 Oct;76(4):1436-9. Pub-Med.|||Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI1985
 J Clin Invest. 1985 Oct;76(4):1436-9. Pub-Med.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||J Clin Invest. 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||J Clin Invest. 1985 Oct;76(4):1436-9. Pub-Med.|||1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||Comparative Study J Clin Invest
. 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||17635867|||Viruses. 2021 Jun 26;13(7):1246.|||J Clin Invest. 1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||Viruses. 2021 Jun 26;13(7):1246.Proteomics. 2009 Mar;9(5):1364-1373.Antimicrob Agents Chemother. 2005 Jan;49(1):269-275.Proc Natl Acad Sci U S A. 2004 May 11;101(19):7363-8.|||1985 Oct;76(4):1436-9. doi: 10.1172/JCI112121.||Peschel et al., 2001||Buck et al., 2006||Xu et al., 2021||Li et al., 2020||Charp et al., 1988|||Viruses. 2021 Jun 26;13(7):1246."	30	
FPDB00018	AP00195|||1426|||AP00195|||IB-200|||IB-445|||OLAP-311|||Protegrin-1|||Recombinant Protegrin-1|||PG-1|||Protegrin|||IB-247	RGGRLCYCRRRFCVCVGR	"Anti-Gram+||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||anti-sepsis||Synergistic AMPs||Hemolytic||Antibiofilm||61% Cytotoxicity at 0.5 ug/ml||Anti-E. coli 004, activity value is MIC = 0.12 ug/ml||Anti-V, activity value is MIC = 0.25 ug/ml||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 0.5 ug/ml||Anti-S. aureus ATCC 33591 or MRSA, activity value is MIC = 2 ug/ml||Anti-MRSA, activity value is MIC = 1 ug/ml||Anti-P. aeruginosa, activity value is MIC = 1 ug/ml||Anti-P. aeruginosa, activity value is MIC = 2 ug/ml||MIC E.Coli (ATCC 25922: 2 ug/ml||ATCC 700926: 0.25 ug/ml||MB 4902: 0.015 ug/ml)||K. pneumoniae (ATCC 13883: 0.5 ug/ml||ATCC 700603: 4 ug/ml||BAA 2146: 4 ug/ml)||A. baumannii (ATCC 19606): 0.25 ug/ml||P. aeruginosa (ATCC 27853): 4 ug/ml||B. subtilis (ATCC 6051): 0.03 ug/ml||S. aureus ATCC 43300 (MRSA): 4 ug/ml||C. albicans (ATCC 90028): 2 ug/ml||C. neoformans (ATCC 208821): 0.06 ug/ml||Anti-E. coli, activity value is MIC = 64 ug/ml||Anti-S. aureus, activity value is MIC = 64 ug/ml||Anti-S. epiderrnidis, activity value is MIC = 2 ug/ml||Anti-Escherichia coli ATCC 25377, activity value is MIC = 3 ug/ml||Anti-A. baumannii ATCC 238719, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 361823, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 371484, activity value is MIC = 2 ug/ml||Anti-A. baumannii ATCC 371981, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 378177, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 378648, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 379385, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 379622, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 380023, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 380667, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 381577, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 382933, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 383074, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 383290, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 386052, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC 388538, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 5615, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 12316, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 12834, activity value is MIC = 4 ug/ml||Anti-S. aureus 29213, activity value is MIC = 1.7 ug/ml||Anti-E. coli 25922, activity value is MIC = 0.75 ug/ml||Anti-P. aeruginosa 27853, activity value is MIC = 0.5 ug/ml||Anti-E. faecalis 29212, activity value is MIC = 2.7 ug/ml||Anti-""A. baumannii ATCC 238719, activity value is MIC = 4 ug/ml||Antibacterial||Anti-K. pneumoniae strains NTUH-K2044, activity value is MIC = 0.5 ug/ml||Anti-ATCC 43816, activity value is MIC = 0.5 ug/ml||Anti-ATCC 13883, activity value is MIC = 0.5 ug/ml||Anti-ATCC 700603, activity value is MIC = 0.5 ug/ml||Anti-MKP103, activity value is MIC = 2 ug/ml||Anti-MKP103 wza mutant, activity value is MIC = 1 ug/ml||Anti-P. aeruginosa, activity value is MIC = 0.5 ug/ml"	leukocytes; porcine neutrophil, pig, Sus scrofa|||eukocytes; porcine neutrophil, pig, Sus scrofa|||leukocytes; porcine neutrophil, pig, Sus scrofa|||Synthetic construct|||Porcine neutrophils|||Sus scrofa [pig]	Beta	96.1% hemolysis at 64 uM (see ref. AP05000).	Chem Pharm Bull (Tokyo). 1995 May;43(5):853-8|||Chem Pharm Bull (Tokyo). 1995 May;43(5):853-8||Blower et al., 2018||Yasin et al., 2000||Guo C et al., 2014||Sousa et al., 2017|||Blower et al., 2018||Yasin et al., 2000||Guo C et al., 2014||Sousa et al., 2017|||8647100|||31399625|||31214759|||28382709, 9257752, 31214759||Refer 31214759|||34502403|||35254120|||10931444	18	L
FPDB00022	AP00240|||AP00240|||Caerin-1.1|||Caerin 1.1|||Caerin|||DRAMP01549|||AP00240|||DRAMP01549|||Caerin-1.1	GLLSVLGSVAKHVLPHVVPVIAEHL	Anti-Gram+ & Gram-||Antiviral||Antiparasitic||Anti-HIV||Anti-MRSA||Antibiofilm||Anticancer||Anti-B. cereus, activity value is MIC = 50 ug/ml||Anti-E.coli, activity value is MIC > 100 ug/ml||Anti-L. lactis, activity value is MIC = 1.5 uM||Anti-L. innocua, activity value is MIC = 25 ug/ml||Anti-M. luteus, activity value is MIC = 12 ug/ml||Anti-S. aureus ATCC 25923 or 29213, activity value is MIC = 3||Anti-S. epidermidis, activity value is MIC = 12 ug/ml||Anti-S. uberis, activity value is MIC = 12 ug/ml||Anti-E.clocae, activity value is MIC > 100 ug/ml||Anti-P. multocida, activity value is MIC = 12||Anti-and P. haemolytica, activity value is MIC = 25 ug/ml||Antibacterial||Anti-Bacillus cereus, activity value is MIC = 50 ug/ml||Anti-Leuconostoc lactis, activity value is MIC = 1.5 ug/ml||Anti-Listeria innocua, activity value is MIC = 25 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 12 ug/ml||Anti-Pasteurella haemolytica, activity value is MIC = 25 ug/ml||Anti-Pasteurella multocida, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 3 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 12 ug/ml||Anti-Streptococcus uberis, activity value is MIC = 12 ug/ml||Anti-S.aureus, activity value is MIC = 18.75 uM||activity value is MBC = 125 uM||Anti-E.Coli, activity value is MIC = 115 uM||activity value is MBC = 250 uM||Antimicrobial||Anti-Gram+||Anti-Gram-||Anti-Micrococcus luteus, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 3||Anti-Staphylococcus epidermis, activity value is MIC = 12.5 ug/ml||Anti-Streptococcus uberis, activity value is MIC = 12.5 ug/ml||Anti-GDM1.441, activity value is MIC = 15 ug/ml||Anti-GDM1.1263, activity value is MIC = 30 ug/ml||Anti-P. aeruginosa GDM1.443, activity value is MIC = 60 ug/ml||Anti-S. hemolyiicus GDM1.245, activity value is MIC = 15 ug/ml||Anti-MRSA1, activity value is MIC = 60 ug/ml||Anti-MRSA2, activity value is MIC = 15 ug/ml||Anti-MRSA3, activity value is MIC = 30 ug/ml	Australian green tree frog, Litoria splendida; Litoria rothii|||Australian green tree frog, Litoria splendida; Litoria rothii|||Litoria splendida [magnificent tree frog]|||Litoria gilleni [Centralian tree frog]|||Litoria rothii [Roth's tree frog]|||Uperoleia mjobergii [Australian toadlet]|||Litoria raniformis [Australian tree frog]|||Litoria splendida (Magnificent tree frog) (Litoria gilleni) (Litoria caerulea)|||Australian green tree frog, Litoria splendida; Litoria rothii|||Litoria splendida (Magnificent tree frog) (Litoria gilleni) (Litoria caerulea)|||Litoria splendida [magnificent tree frog]|||Litoria gilleni [Centralian tree frog]	Helix||Alpha helix	"No hemolytic activity (0% hemolysis at 100 µM)|||The hemolytic values of peptides related to the skin granular gland secretions of African clawed frog (Xenopus) in the document are as follows. The experiment measured the hemolysis rate by adding peptides at different concentrations to a 5% human red blood cell suspension and incubating at 37°C for 30 minutes (100% hemolysis was induced by 0.2% Triton X-100):

- At a peptide concentration of 0 μg/ml: Hemolysis rates for Magainin 2, PGLa, XPF, and bee venom peptide Mellitin were all 0%.
- At a peptide concentration of 50 μg/ml: Hemolysis rates were 4% for Magainin 2, 4% for PGLa, 1% for XPF, and 100% for bee venom peptide Mellitin.
- At a peptide concentration of 100 μg/ml: Hemolysis rates were 3% for Magainin 2, 3% for PGLa, 1% for XPF (bee venom peptide Mellitin was not tested).
- At a peptide concentration of 200 μg/ml: Hemolysis rates were 3% for Magainin 2, 4% for PGLa, 2% for XPF (bee venom peptide Mellitin was not tested).
- At a peptide concentration of 500 μg/ml: Hemolysis rates were 4% for Magainin 2, 5% for PGLa, 5% for XPF (bee venom peptide Mellitin was not tested).
- At a peptide concentration of 1000 μg/ml: Hemolysis rates were 6% for Magainin 2, 7% for PGLa, 6% for XPF (bee venom peptide Mellitin was not tested).

Among them, bee venom peptide Mellitin served as the positive control. Magainin 2, PGLa, and XPF, three antimicrobial peptides derived from Xenopus, showed extremely low hemolytic activity, with hemolysis rates still below 8% even at the high concentration of 1000 μg/ml.|||Bacillus cereus ( MIC = 50 ug/ml), Leuconostoc lactis ( MIC = 1.5 ug/ml), Listeria innocua ( MIC = 25 ug/ml) , Micrococcus luteus ( MIC = 12.5 ug/ml), Pasteurella multocida ( MIC = 25 ug/ml), Staphylococcus aureus ( MIC = 3-12 ug/ml), Staphylococcus epidermis ( MIC = 12.5 ug/ml), Streptococcus uberis ( MIC = 12.5 ug/ml); [Refer PubMed ID - 34259550: S. aureus, GDM1.441 (MIC= 15 ug/ml), MRSA, GDM1.1263 (MIC= 30 ug/ml), P. aeruginosa GDM1.443 (MIC= 60 ug/ml), S. hemolyiicus GDM1.245 (MIC= 15 ug/ml), MRSA1 (Clincial isolate) (MIC= 60 ug/ml), MRSA2 (Clincial isolate) (MIC= 15 ug/ml), MRSA3 (Clincial isolate) (MIC= 30 ug/ml)]|||No hemolysis information or data found in the reference(s) presented in this entry"	"Eur J Biochem 1997; 247 (2): 545-57|||Wong H, Bowie JH, Carver JA.1997, Australia
 Eur J Biochem 1997; 247 (2): 545-57||same ref as AP2008|||Eur J Biochem 1997; 247 (2): 545-57||same ref as AP2008|||Eur J Biochem 1997; 247 (2): 545-57|||same ref as AP2008|||10601876, 34259550|||10461748|||28478484|||[Ref.15203252]Gram-positive bacteria: Bacillus cereus (MIC=50 ug/ml), Leuconostoc lactis (MIC=1.5 ug/ml), Listeria innocua (MIC=25 ug/ml), Micrococcus luteus (MIC=12.5 ug/ml), Staphylococcus aureus (MIC=3-12 ug/ml), Staphylococcus epidermis (MIC=12.5 ug/ml), Streptococcus uberis (MIC=12.5 ug/ml);
Gram-negative bacterium: Pasteurella multocida (MIC=25 ug/ml).
[Ref.16140737]Virus:HIV:inhibit 50% of PBS-treated HIV infection of T cells(IC50=7.8 uM);inhibition of HIV transfer by dendritic cells to T cells(IC50=12.6 uM)|||Eur J Biochem 1997; 247 (2): 545-57||same ref as AP2008|||J Virol. 2005 Sep;79(18):11598-606.Eur J Biochem. 1997 Jul 15;247(2):545-557.Eur J Biochem. 2003 May;270(9):2068-2081.Peptides. 2004 Jun;25(6):1035-1054.|||10601876, 34259550"	25	
FPDB00029	AP00248	" 
GLFGVLGSIAKHVLPHVVPVIAEK"	Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anti-MRSA||Antibiofilm||Anticancer||Anti-M. luteus, activity value is MIC = 12 ug/ml||Anti-S. aureus or MRSA, activity value is MIC = 12 ug/ml||Anti-L. innocua, activity value is MIC = 25 ug/ml||Anti-S. epidermidis, activity value is MIC = 25 ug/ml||Anti-S. uberis, activity value is MIC = 25 ug/ml||Enzyme inhibitor	Blue-thighed frog, Litoria chloris, Australia|||Litoria chloris, Australia	N/A	No hemolytic activity (0% hemolysis at 100 µM)	"J. Pept. Res.1998; 51: 121-126. PubMed.|||Steinborner ST, Currie GJ, Bowie JH, Wallace JC, Tyler MJ.1998, Australia
 J. Pept. Res.1998; 51: 121-126. PubMed.|||J. Pept. Res.1998; 51: 121-126. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||J. Pept. Res.1998; 51: 121-126. PubMed.|||Comparative Study J Pept Res
. 1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x.|||1998 Feb;51(2):121-6. doi: 10.1111/j.1399-3011.1998.tb00629.x."	24	
FPDB00035	AP00283|||AP00283|||HBD3|||DRAMP03599|||AP00283	GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Chemotactic||Anti-MRSA||Anti-toxin||Anti-inflammatory||Channel inhibitors||Synergistic AMPs||Antibiofilm||Wound healing||Anticancer||Anti-An inducible human AMP. Active against E. coli DSM1103, activity value is MIC = 9.4 ug/ml||Anti-K. pneumoniae DSM681, activity value is MIC = 25 ug/ml||Anti-P. aeruginosa DSM1128, activity value is MIC = 18.75 ug/ml||Anti-S. aureus ATCC25923 or MRSA, activity value is MIC = 4.7 ug/ml||Anti-and S. pneumoniae DSM11865, activity value is MIC = 4.7 ug/ml||Anti-Escherichia coli DSM1103, activity value is MIC = 9.4 ug/ml||Anti-Klebsiella pneumoniae DSM681, activity value is MIC = 25 ug/ml||Anti-Pseudomonas aeruginosa DSM1128, activity value is MIC = 18.75 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 4.7 ug/ml||Anti-Streptococcus pneumoniae DSM11865, activity value is MIC = 4.7 ug/ml	skin, tonsils, oral/saliva, colonic mucosa, Homo sapiens|||skin, tonsils, oral/saliva, colonic mucosa, Homo sapiens|||Synthetic construct|||Homo sapiens (Human)|||skin, tonsils, oral/saliva, colonic mucosa, Homo sapiens	Combine Helix and Beta structure||Combine helix and strand structure	"Because several cationic antimicrobial peptides have been
reported to exhibit cytotoxic activity against eukaryotic cells,
hBD-3 was also assayed for hemolytic activity against human
erythrocytes. No significant hemolytic activity (,0.5%) was
observed using concentrations of hBD-3 up to 500000 ug/ml at
physiologic salt concentrations. However, significant hemolytic
activity was seen at high hBD-3 concentrations in 10000 uM so-dium
phosphate buffer containing 340000 uM sucrose|||Strong hemolytic activity (100% hemolysis at 10 μM)|||The document explicitly mentions the hemolytic values of human β-defensin 3 (hBD-3), with specific information as follows:

1. Under physiological saline conditions (phosphate-buffered saline, PBS):
When the concentration of hBD-3 reaches as high as 500 µg/ml, the hemolysis rate of human red blood cells is still **<0.5%**, showing no significant hemolytic activity.

2. In a specific buffer (10000 µM sodium phosphate buffer containing 340,000 µM sucrose, pH 7.4):
Significant hemolytic activity is only observed under high concentrations of hBD-3 (the specific concentration is not clearly marked as a fixed threshold and should be interpreted as far above physiologically relevant concentrations in the experimental context).

These results indicate that hBD-3 exhibits almost no hemolytic toxicity to human red blood cells under physiological saline conditions and only shows hemolytic activity at non-physiological high concentrations and in specific buffer systems, reflecting good biocompatibility.|||The document explicitly mentions the hemolytic values of human β-defensin 3 (hBD-3), as follows:

1. Under physiological saline conditions (phosphate-buffered saline, PBS)
Even when the concentration of hBD-3 reaches 500 µg/ml, the hemolysis rate of human red blood cells remains **<0.5%**, showing no significant hemolytic activity.

2. Hypotonic buffer containing 340,000 µM sucrose (10,000 µM sodium phosphate buffer, pH 7.4)
Significant hemolytic activity is observed only at relatively high concentrations of hBD-3, but this condition is a non-physiological hypotonic environment that does not correspond to in vivo physiological conditions.

These results indicate that hBD-3 exhibits no obvious cytotoxicity to eukaryotic cells (red blood cells) at physiologically relevant concentrations, and the risk of hemolysis is extremely low.|||At physiological salt concentrations, hBD-3 at concentrations up to 500 ug/ml did not exhibit significant hemolytic activity (&lt;0.5%); however, in 10000 uM sodium phosphate buffer containing 340000 uM sucrose, hBD-3 at high concentrations had significant hemolytic activity (specific values not clear)."	"J. Biol. Chem. 2001; 276:5707-5713|||Harder J, Bartels J, Christophers E, Schroeder JM.2001
 J. Biol. Chem. 2001; 276:5707-5713||ref see AP1315|||J. Biol. Chem. 2001; 276:5707-5713||ref see AP1315|||J. Biol. Chem. 2001; 276:5707-5713|||ref see AP1315|||J Biol Chem. 2001 Feb 23;276(8):5707-5713.||Ref.11085990|||J. Biol. Chem. 2001; 276:5707-5713||ref see AP1315"	45	
FPDB00036	AP00310|||AP00310|||LL-37|||LL-37|||AP00310	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antiparasitic||Spermicidal||Anti-HIV||Chemotactic||Anti-MRSA||Enzyme inhibitor||anti-TB||anti-sepsis||Synergistic AMPs||Hemolytic||Antibiofilm||Wound healing||Anticancer||Anti-L. monocytogenes EGD, activity value is MIC = 1.5 ug/ml||Antibacterial||Anti-S. aureusNCTC 6571, activity value is MIC = 19.3||Anti-E. coli ATCC 25922, activity value is MIC = 9.8||Anti-27367675: E.coli K88, activity value is MIC = 61||Anti-E.coli CVCC245, activity value is MIC = 61||Anti-S.aureus CVCC 26003, activity value is MIC = 36||Anti-S.aureus ATCC 25923, activity value is MIC = 58||Anti-Listeria monocytogene CVCC 1599, activity value is MIC = 13||Anti-Micrococcus luteus CVCC 28001, activity value is MIC = 90||Anti-A. baumannii ATCC 19606, activity value is MIC = 4 ug/ml||Anti-29022391 : S. mutans, activity value is MIC = 250 ug/ml||Anti-A. israelii, activity value is MIC = 7.81 ug/ml||Anti-E. faecalis, activity value is MIC = 2000 ug/ml||Anti-31417238: Streptococcus agalactiae NEM 316, activity value is MIC = 90||Anti-C-terminal:COOH): A. baumannii 6043, activity value is MIC = 14.2 uM||Anti-P. aeruginosa ATCC 19660, activity value is MIC = 28.5 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 28.5 uM||Anti-28649410: P. aeruginosa ATCC 9027, activity value is EC50 = 0.525 uM||Anti-P. aeruginosa PAO1 (pTDKGFP, activity value is EC50 = 0.599 uM||Anti-F. novicida U112, activity value is EC50 = 0.0534 uM||Anti-B. thailandensis E264, activity value is EC50 = 1.88 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 0.552 uM||Anti-31016971: Staphylococcus aureus SA113 WT, activity value is MIC = 256 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 256 uM	gammadelta T cells, neutrophils, monocytes; macrophages; mast cells; lymphocytes, Mesenchymal Stem Cells; islets; sweat/skin; airway/lung, saliva; colonic mucosa; bone marrow and testis, Homo sapiens; Also Pan troglodytes|||gammadelta T cells, neutrophils, monocytes; macrophages; mast cells; lymphocytes, Mesenchymal Stem Cells; islets; sweat/skin; airway/lung, saliva; colonic mucosa; bone marrow and testis, Homo sapiens; Also Pan troglodytes|||gammadelta T cells, neutrophils, monocytes; macrophages; mast cells; lymphocytes, Mesenchymal Stem Cells; islets; sweat/skin; airway/lung, saliva; colonic mucosa; bone marrow and testis, Homo sapiens; Also Pan troglodytes|||Homo sapiens|||Homo sapiens [Human]|||Homo sapiens [Human]|||gammadelta T cells, neutrophils, monocytes; macrophages; mast cells; lymphocytes, Mesenchymal Stem Cells; islets; sweat/skin; airway/lung, saliva; colonic mucosa; bone marrow and testis, Homo sapiens; Also Pan troglodytes	Helix	Moderate hemolytic activity (60% hemolysis at 50 μM)|||hRBC (4.47 (±0.35)% hemolysis at 175 ug/ml), Sheep RBC (HC₅₀=32 ± 0.68 ug/ml)|||hRBC (4.47 (±0.35)% hemolysis at 175 ug/ml), Sheep RBC = (HC50=32 ± 0.68 ug/ml)	"Eur J Biochem. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x. PubMed|||Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. T.1996
 Eur J Biochem. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x. PubMed|||Eur J Biochem. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x.|||Eur J Biochem. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x. PubMed|||1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x.|||Eur J Biochem
. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x.|||28476579|||28408902, 30076860, 28400226, 27367675, 30076864, 30043322, 29022391, 31417238, 31396193, 31016971|||35254120|||28408902, 30076860, 28400226, 27367675, 30076864, 30043322, 29022391, 31417238, 31396193, 31016971||Refer 30076860||Refer PubMed ID: 30076864||Refer PubMed ID: 30043322|||Eur J Biochem. 1996 Jun 1;238(2):325-32. doi: 10.1111/j.1432-1033.1996.0325z.x. PubMed"	37	
FPDB00041	AP00384|||AP00384|||Ponericin-L2|||DRAMP02761|||AP00384|||DRAMP02761	LLKELWTKIKGAGKAVLGKIKGLL	"Anti-Gram+ & Gram-||Antiviral||Insecticidal||Anti-HIV||Anti-MRSA||Anti-Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 1.4 uM||Antibacterial||Gram-positive bacteria: Bacillus cereus CIP 6624a(Inhibition zone = 6.5mm)||B. megaterium ATCC 9885b(Inhibition zone = 14mm)||B. stearothermophilus CIP 675(Inhibition zone = 21mm)||B. subtilis ATCC 6623(Inhibition zone = 13.5mm)||Enterococcus faecalis CIP 636(Inhibition zone = 4mm)||Lactococcus lactis ssp. cremoris I116(Inhibition zone = 15.5mm)||Streptococcus pyogenes CIP 561(Inhibition zone = 12.5mm)||S. sanguinis CIP 55128(Inhibition zone = 6mm)||Listeria ivanovii LMA 94d(Inhibition zone = 9.5mm)||Listeria monocytogenes ATCC 15313(Inhibition zone = 9.5mm)||Micrococcus luteus CIP 5345(Inhibition zone = 10.5mm)||Staphylococcus aureus CIP 677(Inhibition zone = 4.5mm)||Staphylococcus aureus LMA(Inhibition zone = 11mm)||S. epidermidis CIP 53134(Inhibition zone = 11.5mm);
Gram-negative bacteria: Escherichia coli(Inhibition zone = 4mm)||Enterobacter cloacae CIP 6085(Inhibition zone = 5mm)||Klebsiella pneumoniae CIP 8291(Inhibition zone = 3.5mm)||Proteus mirabilis LMA TP(Inhibition zone = 9mm)||Salmonella enterica CIP 813(Inhibition zone = 1.5mm)||Serratia marcescens LMA TP(Inhibition zone = 9mm)||Flavobacterium meningosepticum CIP 6057(Inhibition zone = 7mm)||Pseudomonas aeruginosa CIP A22(Inhibition zone = 14mm).||Antimicrobial||Anti-Gram+||Anti-Gram-"	ants, Pachycondyla goeldii|||ants, Pachycondyla goeldii|||Pachycondyla goeldii [Ponerine ant]|||Pachycondyla goeldii (Ponerine ant)|||ants, Pachycondyla goeldii|||Pachycondyla goeldii (Ponerine ant)	Helix||Alpha helix	"Weak hemolytic activity (20% hemolysis at 100 μM)|||The document explicitly mentions hemolytic data of 10 synthetic ponericin peptides (and crude venom) from Pachycondyla goeldii on sheep and horse erythrocytes. The core information is as follows (all tested concentrations were 400–500 µM, activity measured by hemolytic zone diameter, ""none"" means no hemolytic effect detected):

1. Hemolytic activity of crude venom

Caused complete hemolysis for both sheep and horse erythrocytes (specific hemolytic zone diameters not mentioned, only ""total lysis"" explicitly stated).

2. Hemolytic activity of each ponericin peptide family (classified by family)

(1) Ponericin G family (G1, G3, G4, G6)

No hemolytic activity: none of the 4 peptides (G1, G3, G4, G6) exhibited hemolysis against sheep or horse erythrocytes (marked as ""none"" or no hemolytic zone diameter in Table I).

(2) Ponericin W family (W1, W3-desK, W4, W5, W6)

This family is the only one showing hemolytic activity, with horse erythrocytes being more sensitive than sheep erythrocytes:

W1, W5, W6: Caused complete hemolysis for both sheep and horse erythrocytes (no specific diameters, text explicitly states ""total lysis of both horse and sheep erythrocytes"").
W3-desK: Hemolytic activity only against horse erythrocytes, none against sheep erythrocytes (no data for sheep in Table I; hemolytic activity shown for horse erythrocytes).
W4: Hemolytic activity only against horse erythrocytes, none against sheep erythrocytes (same trend as W3-desK).

(3) Ponericin L family (L2)

No hemolytic activity: no hemolysis detected against sheep or horse erythrocytes (no hemolytic zone diameter in Table I, text explicitly states ""no hemolytic action was found for L2"").

Additional notes

Detection method: Blood agar plate assay. Wells were punched into agar containing sheep or horse erythrocytes, 0.02 ml peptide solution added, incubated overnight at 4 °C, then left at room temperature for 24 h, and the diameter of complete hemolysis zones measured; absence of a hemolytic zone was considered as no hemolytic activity.
Species differences: All hemolytically active peptides (all from the W family) exhibited stronger hemolysis against horse erythrocytes, while sheep erythrocytes were more resistant to these peptides. This is related to species-specific differences in red blood cell membrane composition.|||Hemolysis experiment of horse and sheep red blood cells: At concentrations of 400-500 μM, the crude toxin and three synthetic peptides (W1, W5, W6) can cause complete hemolysis of horse and sheep red blood cells; W3-desK and W4 only exhibit hemolytic activity against horse red blood cells, with no obvious effect on sheep red blood cells; the remaining five synthetic peptides (G1, G3, G4, G6, L11) did not show hemolytic activity. However, the document did not specify the exact hemolysis rate values, only describing whether hemolysis occurred and the range of hemolysis.|||[Ref.11279030]Not found|||The document mentions hemolytic data of ponericins on horse and sheep red blood cells, as follows:

- Whole venom: hemolysis ring diameter of 6 mm for horse red blood cells, 3 mm for sheep red blood cells.

- Ponericin W1: causes complete hemolysis on both horse and sheep red blood cells (specific diameter not specified).

- Ponericin W5: causes complete hemolysis on both horse and sheep red blood cells (specific diameter not specified).

- Ponericin W6: hemolysis ring diameter of 4 mm for horse red blood cells, 1.5 mm for sheep red blood cells.

- Ponericin W3-desK: hemolytic effect only on horse red blood cells, hemolysis ring diameter of 2 mm; no hemolytic effect on sheep red blood cells.

- Ponericin W4: hemolytic effect only on horse red blood cells, hemolysis ring diameter of 2 mm; no hemolytic effect on sheep red blood cells.

- Ponericin G1, G3, G4, G6, L2: no hemolytic effect.

All the above data were measured at peptide concentrations of 400–500 μM, with hemolysis ring diameters in millimeters (mm).|||[Ref.11279030]Not found"	"J. Biol. Chem. 2001; 276: 17823-17829. PubMed.|||J. Biol. Chem. 2001; 276: 17823-17829. doi: 10.1074/jbc.M100216200. Epub 2001 Feb 22.|||J Biol Chem
. 2001 May 25;276(21):17823-9. doi: 10.1074/jbc.M100216200. Epub 2001 Feb 22|||11279030|||Ref.11279030|||J. Biol. Chem. 2001; 276: 17823-17829.|||J. Biol. Chem. 2001; 276: 17823-17829. PubMed.|||J. Biol. Chem. 2001; 276: 17823-17829."	24	
FPDB00044	AP00408|||AP00408|||CAMPSQ432|||AP00408|||DRAMP02236	FLFPLITSFLSKVL	Anti-Gram+||Antiviral||Anti-HIV||Anti-MRSA||Anti-S. aureus or MRSA, activity value is MIC = 50 uM||Anti-S.aureus, activity value is MIC = 130 uM||Antimicrobial||Antibacterial	Rana catesbeiana, North America|||Rana catesbeiana, North America|||Rana catesbeiana [American bullfrog]|||Rana catesbeiana, North America|||Lithobates catesbeiana (American bullfrog) (Rana catesbeiana)	N/A	"The document only mentions one hemolysis-related test result, with the key information as follows:

Hemolysis of Ranatuerins 1-9
All nine ranatuerin peptides (ranatuerin 1-9) isolated from the skin of American bullfrogs (Rana catesbeiana) showed no detectable hemolytic activity towards human erythrocytes at a concentration of 20 μg/ml (the text explicitly states: “showed no detectable hemolytic activity towards human erythrocytes”).

The document does not provide hemolysis data at other concentrations, nor does it mention hemolysis test results for erythrocytes of other species (such as sheep or horses).|||1|||The document mentions information related to the hemolytic activity of ranatuerins on human red blood cells:

Ranatuerins 1-9 showed no detectable hemolytic activity on human red blood cells at a concentration of 20 µg/ml.

These results indicate that these antimicrobial peptides do not cause significant damage to human red blood cells at the tested concentration, demonstrating a certain level of biosafety.|||No hemolysis information or data found in the reference(s) presented in this entry"	"Biochem. Biophys. Res. Commun. 1998; 250: 589-592. PubMed.|||Biochem. Biophys. Res. Commun. 1998; 250: 589-592. doi: 10.1006/bbrc.1998.9362.|||Biochem Biophys Res Commun
. 1998 Sep 29;250(3):589-92. doi: 10.1006/bbrc.1998.9362.|||9784389|||Biochem. Biophys. Res. Commun. 1998; 250: 589-592. PubMed.|||Biochem Biophys Res Commun. 1998 Sep 29;250(3):589-592."	14	
FPDB00045	AP00445|||AP00445|||RTD-1|||DRAMP02642|||AP00445|||DRAMP02642|||AP00445|||DRAMP02642	GFCRCLCRRGVCRCICTR	Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||Anti-toxin||Enzyme inhibitor||Active against S. aureus 502a or MRSA||L. monocytogenes||E. coli ML 35||S. typhimurium||C. albicans 16820||and C. neoformans. Theta-defensins are particularly important for antifungal activity of the granule extracts as alpha-defensins are poorly active (Tongaonkar P et al 2011 J Leuko Biol 89||283-90). It is also active against HIV-1. RTD-1 inhibits human Papillomavirus (hrHPV||nonenvelope DNA virus) infection through a mechanism involving capsid clustering that inhibits virions from binding to cell surface receptor complexes  .||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram-	leukocytes, Rhesus Macaque (Macaca mulatta)|||leukocytes, Rhesus Macaque (Macaca mulatta)|||Macaca mulatta [Rhesus macaque]|||Macaca mulatta (Rhesus macaque)|||leukocytes, Rhesus Macaque (Macaca mulatta)|||Macaca mulatta (Rhesus macaque)|||leukocytes, Rhesus Macaque (Macaca mulatta)|||Macaca mulatta (Rhesus macaque)	Beta||Beta strand (4 strands; 10 residues)	Strong hemolytic activity (100% hemolysis at 5 μM)|||No hemolysis information or data found in the reference(s) presented in this entry	Science. 1999 Oct 15;286(5439):498-502|||Science. 1999 Oct 15;286(5439):498-502||Skeate et al., 2020|||Science. 1999 Oct 15;286(5439):498-502||Skeate et al., 2020|||11675394|||Science. 1999 Oct 15;286(5439):498-502.|||Science. 1999 Oct 15;286(5439):498-502||Skeate et al., 2020|||Science. 1999 Oct 15;286(5439):498-502.J Leukoc Biol. 2001 Sep;70(3):461-464.J Biol Chem. 2002 Feb 1;277(5):3079-3084.|||Science. 1999 Oct 15;286(5439):498-502|||Science. 1999 Oct 15;286(5439):498-502.	18	
FPDB00048	AP00473|||AP00473|||Piscidins p1|||Piscidin-1|||Moronecidin|||DRAMP02330|||AP00473|||AP00473|||Piscidin-1	FFHHIFRGIVHVGKTIHRLVTG	Anti-Gram+ & Gram-||Antiviral||Antifungal||Anti-HIV||Anti-MRSA||Hemolytic||Anticancer||Anti-E. coli, activity value is MIC = 12.5 uM||Anti-P. aeruginosa, activity value is MIC = 50 uM||Anti-B. subtilis, activity value is MIC = 12.5 uM||Anti-and S. aureus USA300 or MRSA, activity value is MIC = 1||Antibacterial||Anti-Enterococcus faecalis VRE, activity value is MIC = 5||Anti-E. faecalis, activity value is MIC = 2.5||Anti-Listeria monocytogenes, activity value is MIC = 2.5||Anti-Micrococcus luteus, activity value is MIC = 10||Anti-Staphylococcus aureus MRSA, activity value is MIC = 1.25||Anti-S. epidermitis, activity value is MIC = 5||Anti-S. saprophiticus, activity value is MIC = 5||Anti-Staphylococcus xylosus, activity value is MIC > 20 uM||Anti-S. agalactiae, activity value is MIC = 1.25||Anti-S. bovis, activity value is MIC = 1.25||Anti-S. equisimilis, activity value is MIC = 2.5||Anti-S. mitis, activity value is MIC = 1.25||Anti-S. Pneumonae, activity value is MIC = 1.25||Anti-S. pyrogenes, activity value is MIC = 1.25||Anti-Streptococcus iniae KST740 ak, activity value is MIC = 1.25||Anti-S. iniae KSTSi 6P, activity value is MIC = 1.25||Anti-Aeromonas hydrophila, activity value is MIC > 20 uM||Anti-Burkholderia cepacia, activity value is MIC > 20 uM||Anti-Vibrio Cholera, activity value is MIC = 2.5||Anti-Escherichia coli, activity value is MIC = 5||Anti-Enterobacter cloacae, activity value is MIC = 10||Anti-E. Aerogenes, activity value is MIC = 10||Anti-Klebsiella pneumoniae, activity value is MIC = 2.5||Anti-K. oxytoca, activity value is MIC = 5||Anti-Salmonella choleraesuis, activity value is MIC = 10||Anti-S. typhimurium, activity value is MIC = 10||Anti-S. arizonae, activity value is MIC = 10||Anti-Serratia marcescens, activity value is MIC > 20 uM||Anti-Shigella flexneri, activity value is MIC = 2.5||Anti-S. sonnei, activity value is MIC = 5||Anti-Yersinia enterocolitica, activity value is MIC = 2.5||Anti-Neurospora crassa, activity value is MIC = 1.56||Anti-A. fumigatus, activity value is MIC = 50||Anti-F. axysporum, activity value is MIC = 0.78||Anti-F. culmorum, activity value is MIC = 0.39||Anti-C. ablicans, activity value is MIC = 10||Anti-C. glabrata, activity value is MIC = 10||Anti-C. lusitania, activity value is MIC = 10||Anti-C. tropacalis, activity value is MIC = 10||Anti-Escherichia coli, activity value is MIC = 3.1 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 25 ug/ml||Anti-Clinical strain of colistin-resistant A. baumannii, activity value is MIC = 3.1 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 3.1 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 1.5 ug/ml||Anti-Clinical strain of methicillin resistant Staphylococcus aureus, activity value is MIC = 3.1 ug/ml	mainly mast cells, gill, skin, intestine, spleen, and anterior kidney, hybrid striped bass (Morone saxatilis x Morone chrysops); Morone saxatilis|||mainly mast cells, gill, skin, intestine, spleen, and anterior kidney, hybrid striped bass (Morone saxatilis x Morone chrysops); Morone saxatilis|||Hybrid striped bass|||Morone chrysops x Morone saxatilis|||Lates calcarifer [Asian sea bass]|||Morone saxatilis (Striped bass)|||mainly mast cells, gill, skin, intestine, spleen, and anterior kidney, hybrid striped bass (Morone saxatilis x Morone chrysops); Morone saxatilis|||mainly mast cells, gill, skin, intestine, spleen, and anterior kidney, hybrid striped bass (Morone saxatilis x Morone chrysops); Morone saxatilis|||Morone chrysops x Morone saxatilis	Helix	"The document provides information on the hemolytic properties of piscidins (fish-derived antimicrobial peptide) only through the hemolytic activity comparison curve (Figure 1c), without clearly indicating a specific 50% hemolytic concentration (HC₅₀) value. The core comparison results are as follows: 
 
1. Trends in Hemolytic Activity of Major Peptides (Testing Human Red Blood Cells)
 
piscidins (P1, P2, P3): Hemolytic activity increases with concentration, all higher than the antibacterial peptide magainin 2 but lower than the metin peptide mellitin (mellitin has weaker antibacterial activity but stronger hemolytic activity). 
Among them, piscidin 3 is the member with the lowest hemolytic activity in the piscidin family, and its structure is speculated to be related — histidine (His) at position 17 is replaced by glycine (Gly), disrupting amphiphilic α-helix structure, reducing amphiphilic activity, and thereby weakening hemolytic ability. 
Magainin 2 (control, sourced from the clawed toad): At the same concentration, hemolytic rates were significantly lower than all piscidins. 
mellitin (control, source of bee venom): At the same concentration, its hemolytic rate is significantly higher than all piscidins, making it the peptide with the strongest hemolytic activity among the three. 
 
2. Key Points
 
The document only shows relative hemolysis capacity using the ""concentration-hemolysis rate"" curve (horizontal axis 1-1000 μg/ml, vertical axis 0%-100%), without providing precise hemolysis rate values corresponding to specific concentrations (such as hemolysis percentage at a certain concentration), nor calculating and recording HC₅₀ (the peptide concentration causing 50% hemolysis of red blood cells) as a core quantitative indicator.|||The document provides some hemolytic values, as follows:

- Piscidins 1-3: At concentrations of 1-1000 μg/ml, there are differences in hemolysis rates on human red blood cells. Among them, piscidin 3 has a relatively lower hemolysis rate, which may be related to the substitution of histidine at position 17 in its structure with glycine, disrupting the amphipathic α-helix structure.
- Magainin 2: The hemolytic activity is lower than that of piscidins, and the hemolysis rate is relatively low within the same concentration range.
- Melittin: The hemolytic activity is relatively strong, with a higher hemolysis rate at higher concentrations, but its antibacterial activity is comparatively weaker.

These data indicate that the hemolytic activity of different peptide antibiotics is closely related to structural features, and the integrity of the amphipathic α-helix may be an important factor affecting hemolytic activity.|||Human RBCs (100% hemolysis at 100 ug/ml)|||human RBC ( 57 ug/ml)|||In Document 10 (NATURE 2001), piscidin family antimicrobial peptides (piscidin 1, piscidin 2, piscidin 3) isolated from the tissues of hybrid striped bass (Morone saxatilis × M. chrysops) exhibit hemolytic activity, with hemolytic capacity stronger than magainin 2 derived from Xenopus but weaker than melittin; among them, piscidin 3 has the lowest hemolytic activity, and its hemolytic ability is related to the integrity of the amphipathic α-helical structure.|||The document mentions the hemolytic data of piscidins, magainin 2, and mellitin, as follows:

- Piscidins 1-3 (P1, P2, P3): At a concentration of 1 µg/ml, the hemolysis rate is close to 0; at 10 µg/ml, the hemolysis rate is about 10%-30% (with P3 having the lowest hemolysis rate); at 100 µg/ml, the hemolysis rate is about 40%-70%; at 1000 µg/ml, the hemolysis rate is about 70%-90%.

- Magainin 2 (Mag 2): Hemolysis is lower than that of piscidins, with a hemolysis rate of about 40% at 1000 µg/ml.

- Mellitin: The most hemolytic, showing some hemolysis even at 1 µg/ml, and almost 100% hemolysis at 100 µg/ml.

The above data are presented in Figure 1c (human red blood cell hemolytic activity curve), showing the hemolysis percentages of each peptide at different concentrations.|||Human RBCs (100% hemolysis at 100 ug/ml)"	"Nature 2001; 414, 268 - 269; doi:10.1038/35104690. (PubMed)|||Silphaduang U, Noga E.J.2001
 Nature 2001; 414, 268 - 269; doi:10.1038/35104690. (PubMed)||Kim JP et al 2010|||Nature 2001; 414, 268 - 269; doi:10.1038/35104690.||Kim JP et al 2010|||Nature 2001; 414, 268 - 269; doi:10.1038/35104690. (PubMed)|||Nature
. 2001 Nov 15;414(6861):268-9. doi: 10.1038/35104690.||Kim JP et al 2010|||31653020|||31354312, 30021422|||30365554|||Nature. 2001 Nov 15;414(6861):268-269.||Ref.11713517|||Nature 2001; 414, 268 - 269; doi:10.1038/35104690. (PubMed)||Kim JP et al 2010|||Nature 2001; 414, 268 - 269; doi:10.1038/35104690. (PubMed)|||31354312, 30021422||Refer PubMed ID: 30021422"	22	
FPDB00051	AP00505|||AP00505|||Histatin5|||DRAMP03580|||Histatin5|||AP00505|||DRAMP03580	DSHAKRHHGYKRKFHEKHHSHRGY	Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||Enzyme inhibitor||Anti-C. albicans, activity value is LD50 = 2.3 ug/ml||Anti-and E. faecium . Also active against bacteria A.actinomycetemcomitans, activity value is ED50 > 100 uM||Anti-S. mutans cariogenic bacteria, activity value is ED50 = 92 uM||Anti-C. albicans DIS or azole resistant, activity value is ED50 = 6.4||Anti-C. glabrata or fluconazole resistant, activity value is ED50 = 38.7||Anti-C. krusei, activity value is ED50 = 6.47 uM||Anti-and C. neoformans CN2 or amphotericin B resistant, activity value is ED50 = 3.71||Anti-and S. cerevisiae, activity value is MIC = 74 uM||Antibacterial||Antimicrobial||Anti-Streptococcus mutans U159, activity value is MIC = 234 ug/ml||Anti-Candida albicans ATCC10231, activity value is IC50 = 8.5 ug/ml||Anti-31417503: C. albicans ATCC 90028, activity value is MIC = 64.45 ug/ml||Anti-11302797: Candida albicans, activity value is LD50 = 7.3	salivary glands, Homo sapiens|||salivary glands, Homo sapiens|||Homo sapiens [Human]|||Homo sapiens (Human)|||Homo sapiens [Human]|||salivary glands, Homo sapiens|||Homo sapiens (Human)	Helix||Alpha helix	Streptococcus mutans U159 (MIC= 234 ug/ml), Candida albicans ATCC10231 (IC50= 8.5 ug/ml); Refer PubMed ID- 31417503: C. albicans ATCC 90028 (MIC = 64.45 ug/ml); Refer PubMed ID- 11302797: Candida albicans (LD50 = 7.3 ± 0.52 ug/ml); Refer PubMed ID- 3286634: C. albicans ( 100 % inhibition at 54 nmol)	J Biol Chem. 1988 Jun 5;263(16):7472-7.|||J Biol Chem. 1988 Jun 5;263(16):7472-7.||Data from ref for AP504||Du H et al., 2017||Luque-Ortega et al., 2008|||J Biol Chem. 1988 Jun 5;263(16):7472-7.||Data from ref for AP504||Du H et al., 2017||Luque-Ortega et al., 2008|||34417532, 33740624, 31417503, 11302797, 3286634|||J Biol Chem. 1988 Jun 5;263(16):7472-7477.|||34417532, 33740624, 31417503, 11302797, 3286634|||J Biol Chem. 1988 Jun 5;263(16):7472-7.||Data from ref for AP504||Du H et al., 2017||Luque-Ortega et al., 2008|||J Biol Chem. 1988 Jun 5;263(16):7472-7477.	24	
FPDB00057	AP00599|||AP00599|||Brevinin-2-related peptide|||DRAMP01873|||Brevinin-2-related peptide|||AP00599|||DRAMP01873	GIWDTIKSMGKVFAGKILQNL	Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||Anti-E. coli, activity value is MIC = 13||Anti-S. aureus or MRSA, activity value is MIC = 25 uM||Anti-and C. albicans, activity value is MIC = 25 uM||Anti-Escherichia coli, activity value is MIC = 13 uM||Anti-Staphylococcus aureus, activity value is MIC = 25 uM||Anti-Candida albicans, activity value is MIC = 25 uM||Anti-19793185 : E. coli, activity value is MIC = 6.25 uM||Anti-S. aureus, activity value is MIC = 12.5 uM||Anti-A. baumannii, activity value is MIC = 6.25 uM||Anti-31549575 : Staphylococcus aureus, activity value is MIC = 16||Anti-Escherichia coli, activity value is MIC = 32 uM||Anti-Candida albicans, activity value is MIC = 16 uM||Anti-Candida albicans, activity value is MIC = 70 uM	mink frog, Rana septentrionalis, North America|||Rana septentrionalis (mink frog)|||mink frog, Rana septentrionalis, North America|||Rana septentrionalis (mink frog)	N/A	"The document explicitly provides the hemolytic values of five major antimicrobial peptides isolated from the skin secretions of the mink frog (Rana septentrionalis), expressed as the concentration required to induce 50% hemolysis of human red blood cells (HC₅₀). The specific data are as follows:

Brevinin-1SPa: The hemolytic concentration HC₅₀ is 7 μM, and its minimum inhibitory concentrations (MICs) against Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), and Candida albicans (C. albicans) are 13 μM, 3 μM, and 6 μM, respectively.
Brevinin-1SPb: hemolytic activity, HC₅₀ = 25 μM; MIC values against Escherichia coli, Staphylococcus aureus, and Candida albicans are 50 μM, 6 μM, and 13 μM, respectively.
Brevinin-1SPd: hemolytic activity HC₅₀ = 8 μM; the MIC values against Escherichia coli, Staphylococcus aureus, and Candida albicans are all 3 μM.
Temporin-1SPb: hemolytic activity, HC₅₀ = 60 μM; only a MIC of 6 μM against Staphylococcus aureus was detected, while the MICs against Escherichia coli and Candida albicans were not determined (ND).
Brevinin-2-related peptide: hemolytic activity, HC₅₀ = 70 µM; MIC values against Escherichia coli, Staphylococcus aureus, and Candida albicans are 13 µM, 25 µM, and 25 µM, respectively.|||The document mentioned hemolysis-related content, and the specific hemolytic values are as follows:

- Brevinin-1SPa: The concentration causing 50% hemolysis of human red blood cells (HC₅₀) is 7 μM.
- Brevinin-1SPb: HC₅₀ is 25 μM.
- Brevinin-1SPd: HC₅₀ is 8 μM.
- Temporin-1SPb: HC₅₀ is 60 μM.
- Brevinin-2 related peptides: HC₅₀ is 71 μM.|||Human erythrocytes ( HC50 = 70 uM ); Refer PubMed ID - 19793185: hRBC(LC50= 90 uM)|||In Document 2 (Comparative Biochemistry and Physiology, Part C 2004), among the antimicrobial peptides isolated from the skin secretions of the mink frog (Rana septentrionalis), brevinin-1SPa has an HC₅₀ of 7 μM for human red blood cells, brevinin-1SPb has an HC₅₀ of 25 μM, brevinin-1SPd has an HC₅₀ of 8 μM, temporin-1SPb has an HC₅₀ of 60 μM, and brevinin-2 related peptide has an HC₅₀ of 70 μM.|||[Ref.15556063]HC50=70 uM against human erythrocytes|||Human erythrocytes ( HC50 = 70 uM ); Refer PubMed ID - 19793185: hRBC(LC50= 90 uM)|||[Ref.15556063]HC50=70 uM against human erythrocytes|||The document mentions the hemolytic activity values of several antimicrobial peptides isolated from the skin secretions of the mink frog (Rana septentrionalis), expressed as HC_{50}, which is the peptide concentration causing 50% hemolysis. The details are as follows:

- Brevinin-1SPa: HC_{50} = 7 μM

- Brevinin-1SPb: HC_{50} = 25 μM

- Brevinin-1SPd: HC_{50} = 8 μM

- Temporin-1SPb: HC_{50} = 60 μM

- Brevinin-2-related peptide: HC_{50} = 70 μM

These values reflect the hemolytic capability of different peptides on human red blood cells; the lower the value, the stronger the hemolytic activity."	Comp. Biochem. Physiol. C 2004; 139: 31-38|||omp. Biochem. Physiol. C 2004; 139: 31-38|||15556063, 19793185, 31549575|||Comp Biochem Physiol C Toxicol Pharmacol. 2004 Oct;139(1-3):31-38.||Ref.15556063|||15556063||Ref.15556063|||15556063, 19793185, 31549575|||Comp. Biochem. Physiol. C 2004; 139: 31-38|||Ref.15556063	21	
FPDB00058	AP00640|||AP00640|||Maculatin-1.3|||DRAMP01366|||AP00640|||DRAMP01366	" 
GLLGLLGSVVSHVVPAIVGHF"	Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anticancer||Anti-S. aureus USA300 MRSA, activity value is MIC = 6.2 uM||Anti-E.coli, activity value is MIC > 100 uM||Anti-B. subtilis, activity value is MIC = 25 uM||Anti-and P.aeruginosa, activity value is MIC > 100 uM||Anti-MRSA||Antibacterial||Antimicrobial	Anti-Gram+ & Gram-, Antiviral, Anti-HIV, Anticancer|||Litoria eucnemis, Australia|||Litoria eucnemis, Australia|||Litoria eucnemis, Australia|||Litoria eucnemis [Australian anurans]|||Litoria eucnemis (Australian anurans)|||Litoria eucnemis, Australia|||Litoria eucnemis (Australian anurans)	N/A	"The document clearly provides the hemolytic values of two types of peptides in the skin secretions of the European common frog (Rana temporaria) (expressed as the concentration causing hemolytic effect on human red blood cells). The specific data are as follows:

1. Brevinin-1 family peptides
Brevinin-1T, Brevinin-1Ta: They have hemolytic activity, but the document does not provide specific concentration values, only mentioning that both have dual antibacterial and hemolytic activity and were initially isolated from the skin secretions of the European common frog.
Brevinin-1Tb: No clear hemolytic value is provided; it is only mentioned that it has antibacterial activity against Staphylococcus aureus (concentration 7.6 uM) and no activity against Salmonella enterica serovar typhimurium, with no hemolytic data mentioned.
New Brevinin-1Tc (specific to the Slovenian population): Hemolytic values have not been directly measured, but its bioactivity is inferred to be similar to that of Brevinin-1T, 1Ta, and 1Tb through 2D mass spectrometry mapping (NMD-NIS coordinates), potentially having hemolytic activity, but the specific concentration is unknown.

2. Melittin-related peptides (MRP-1)
Hemolytic value: Lethal concentration (LC) for human red blood cells is 0.5 uM, which is a potent hemolytic agent, present in both Moscow and Slovenian populations, and can serve as a species biomarker for the European common frog.

3. Temporin family peptides
Known temporins (A, B, L, etc.): Only described as having ""low"" hemolytic activity (for example, temporins A and B are active against Gram-positive bacteria and fungi but have weak hemolytic activity) or mentioning that temporin L has hemolytic activity against human red blood cells, with no specific HC_{50} or LC values provided.
Six new temporins (O, P, Q, R, S, T, specific to the Slovenian population): Bioactivity inferred through 2D mass spectrometry mapping:
Short-chain new temporins (O, T): Similar activity to temporins A and B, low hemolytic activity, no specific values;
Long-chain new temporins (Q, R, S): Activity similar to temporin L (which has hemolytic activity), but no specific hemolytic concentration measured;
temporin P: Due to the absence of basic amino acid residues in the sequence, it is inferred to have no hemolytic activity or extremely weak activity, with no specific values.|||The document only mentions the hemolytic information of caerin 1.1, specifically: caerin 1.1 lyses red blood cells at >250 μg/ml, meaning that the peptide lyses red blood cells at concentrations above 250 μg/ml, but does not specify the exact hemolytic values such as the half-maximal hemolytic concentration (HC₅₀). 

For other antimicrobial peptides (such as aureins, citropins, maculatins, etc.), the descriptions mainly involve antibacterial, anticancer, antifungal activities, and do not mention hemolytic values.|||No hemolysis information or data found in the reference(s) presented in this entry"	Peptides. 2004 Jun;25(6):1035-54.|||Peptides. 2004 Jun;25(6):1035-54|||Peptides. 2004 Jun;25(6):1035-54.||Menousek et al., 2012|||Peptides. 2004 Jun;25(6):1035-54.|||Peptides. 2004 Jun;25(6):1035-54||Menousek et al., 2012|||15203252|||Peptides. 2004; 25: 1035-1054.|||Peptides. 2004 Jun;25(6):1035-54.|||Peptides. 2004; 25: 1035-1054.	21	
FPDB00061	AP00708|||AP00708|||GF-17|||GI-17	GFKRIVQRIKDFLRNLV	Anti-Gram+ & Gram-||Antiviral||Spermicidal||Anti-HIV||Anti-MRSA||Synergistic AMPs||Anticancer||Anti-and S. aureus USA300 MRSA, activity value is MIC = 3.1||Anti-E. faecium ATCC 51559, activity value is MIC = 3.1 uM||Anti-S. aureus USA300, activity value is MIC = 3.1 uM||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 3.1 uM||Anti-A. baumannii B28-16, activity value is MIC = 3.1 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 12.5 uM||Anti-E. cloacae B2366-1, activity value is MIC = 3.1 uM||Anti-S. aureus Newman, activity value is MIC = 1.6 uM||Anti-S. aureus Mu50, activity value is MIC = 1.6 uM||Anti-S. aureus UAMS1, activity value is MIC = 3.1 uM||Anti-E. faecium V284-17, activity value is MIC = 2 uM||Anti-S. aureus USA300, activity value is MIC = 2||Anti-A. baumannii B28-16, activity value is MIC = 4 uM||Anti-P. aeruginosa E411-17, activity value is MIC = 16 uM||Anti-E. coli E423-17, activity value is MIC = 16 uM	Derivative of LL-37; NMR-based discovery; Sequence truncation. human cathelicidin analog, animal-derived, natural derivative|||Derivative of LL-37; NMR-based discovery; Sequence truncation. human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	Helix	Moderate hemolytic activity (55% hemolysis at 50 μM)|||Human RBCs [Hemolytic concentration (HL50) = 180 uM]|||Human RBC (65% hemolysis at 200 uM)	"J Am Chem Soc. 2006 May 3;128(17):5776-85. PubMed.|||J Am Chem Soc. 2006 May 3;128(17):5776-85. PubMed|||J Am Chem Soc. 2006 May 3;128(17):5776-85. doi: 10.1021/ja0584875.||Golla R. et al., 2020|||J Am Chem Soc. 2006 May 3;128(17):5776-85. PubMed.|||J Am Chem Soc
. 2006 May 3;128(17):5776-85. doi: 10.1021/ja0584875.||Golla R. et al., 2020|||31319057|||34959645"	17	
FPDB00090	AP01223|||AP01223|||Ascaphin-8|||Ascaphin-8|||AP01223|||DRAMP01847|||AP01223|||DRAMP01847	"  
GFKDLLKGAAKALVKTVLF"	Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-HIV||Anti-MRSA||Enzyme inhibitor||Anticancer||Anti-E. coli, activity value is MIC = 6 uM||Anti-P. aeruginosa, activity value is MIC = 13 uM||Anti-E. cloacae, activity value is MIC = 6 uM||Anti-K. pneumoniae, activity value is MIC = 6 uM||Anti-S. epidermidis, activity value is MIC = 6 uM||Anti-Streptococcus Group B, activity value is MIC = 6 uM||Anti-E. faecalis, activity value is MIC = 50 uM||Anti-and C. albicans, activity value is MIC = 25 uM||Anti-Escherichia coli, activity value is MIC = 6 uM||Anti-Staphylococcus aureus, activity value is MIC = 6 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 50 uM||Anti-Enterobacter cloacae, activity value is MIC = 13 uM||Anti-Klebsiella pneumoniae, activity value is MIC = 25 uM||Anti-Proteus mirabilis, activity value is MIC > 100 uM||Anti-S. epidermidis, activity value is MIC = 25 uM||Anti-E. faecalis, activity value is MIC > 100 uM||Anti-Streptococcus Group B, activity value is MIC = 13 uM||Anti-C. albicans, activity value is MIC = 100 uM||Anti-E. coli ATCC25922, activity value is MIC = 3 uM||Anti-S. aureus ATCC25923, activity value is MIC = 3 uM||Anti-E. coli ML35p, activity value is MIC = 1.6 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 3 uM||Anti-S. aureus multiresistant ATCCBAA-44, activity value is MIC = 3 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 12.5 uM||Anti-A549, activity value is IC50 = 33.79 uM||Anti-C4-2B, activity value is IC50 = 42.91 uM||Anti-HEK293T, activity value is IC50 = 53.67 uM||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-	Coastal Tailed Frog, Ascaphus truei, Pacific Northwest, USA, North America|||Coastal Tailed Frog, Ascaphus truei, Pacific Northwest, USA, North America|||Ascaphus truei [Coastal tailed frog]|||Ascaphus truei (Coastal tailed frog)|||Coastal Tailed Frog, Ascaphus truei, Pacific Northwest, USA, North America|||Ascaphus truei (Coastal tailed frog)	Helix	"Free acid HC50>200  Amidated HC50=55|||Endogenous peptides:

ascaphin-1: Half-maximal hemolytic concentration (HC_{50}) for human red blood cells >200 μM.

ascaphin-3: HC_{50} >200 μM.

ascaphin-7: HC_{50} >200 μM.

ascaphin-8: HC_{50} is 50 μM.

Synthetic peptides:

ascaphin-1 (free acid form): HC_{50} >200 μM; amidated form: HC_{50} >200 μM.

ascaphin-5 (free acid form): HC_{50} >200 μM.

ascaphin-8 (amidated form): HC_{50} is 55 μM.

The above results were obtained through hemolysis experiments. In the experiments, peptides at different concentrations were incubated with washed human red blood cells for 1 hour, and the degree of hemolysis was measured by absorbance at 450 nm. The 1% Tween 20 treated group was used as the 100% hemolysis control, and HC_{50} was defined as the peptide concentration producing 50% hemolysis.|||Ascaphin-1: HC₅₀ > 200 uM.
Ascaphin-3: HC₅₀ > 200 uM.

Ascaphin-7: HC₅₀ > 200 uM.

Ascaphin-8:

Endogenous Ascaphin-8: HC₅₀ = 50 uM.

Synthetic amidated Ascaphin-8: HC₅₀ = 55 uM.

Ascaphin-5: HC₅₀ > 200 uM.|||Human erythrocytes ( HC50 = 50 uM ); Refer PubMed ID 23094651: Rat RBCs [HC50 = 115 uM], PubMed ID 33932712: Rabbit RBC [HC50 = >100 miroM]|||Human erythrocytes ( HC50 = 50 uM ); Refer PubMed ID 23094651: Rat RBCs [HC50 = 115 uM], PubMed ID 33932712: Rabbit RBC [HC50 = >100 miroM]|||The therapeutic potential of ascaphin-8 as an antiinfective agent is limited by its moderately high haemolytic activity (HC50 ¼ 55 lM) In contrast, ascaphin-1 and ascaphin-5, although displaying high potencies only against Gram-negative bacteria, have very low haemolytic activities (HC50 >200 lM) compared with many other frog skin peptides. By way of comparison, the HC50 values of brevinin-1E from Rana esculenta [22] and temporin L from Rana temporaria [23] are less than 2 lM.|||[Ref.15207717]HC50=50 uM against human erythrocytes|||The document mentions the hemolytic values of various ascaphin peptides (expressed as HC_{50}, which is the peptide concentration that causes 50% hemolysis), as follows:

Hemolytic values of endogenous peptides (Table 1)

- Ascaphin-1: HC_{50} > 200 μM

- Ascaphin-3: HC_{50} > 200 μM

- Ascaphin-7: HC_{50} > 200 μM

- Ascaphin-8: HC_{50} = 50 μM

Hemolytic values of synthetic peptides (Table 2)

- Ascaphin-1 (free acid form): HC_{50} > 200 μM

- Ascaphin-1 (amidated form): HC_{50} > 200 μM

- Ascaphin-5 (free acid form): HC_{50} > 200 μM

- Ascaphin-8 (amidated form): HC_{50} = 55 μM|||[Ref.15207717]HC50=50 uM against human erythrocytes|||hemolytic HC50 50 uM. TC50 2.9 uM in CEM-SS cells(Wang G et al. 2010 Antimicrob. Agents Chemother. 54: 1343-1346)."	"Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-5. PubMed|||Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-5. doi: 10.1016/j.bbrc.2004.05.141.||Menousek J et al 2012 Int J Antimicrob Agents 39:402|||Comparative Study Biochem Biophys Res Commun
. 2004 Jul 16;320(1):170-5. doi: 10.1016/j.bbrc.2004.05.141.|||2004 Jul 16;320(1):170-5. doi: 10.1016/j.bbrc.2004.05.141.||Menousek J et al 2012 Int J Antimicrob Agents 39:402|||15207717, 33932712, 23094651||Refer PubMed ID 23094651|||15207717, 33932712, 23094651||Refer PubMed ID 23094651||Refer PubMed ID 33932712|||Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-5. PubMed||Menousek J et al 2012 Int J Antimicrob Agents 39:402|||Ref.15207717|||Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-5. PubMed|||Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-175."	19	
FPDB00091	AP01269|||AP01269|||Melectin	" 
GFLSILKKVLPKVMAHMK"	Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-MRSA||Anti-B. subtilis, activity value is MIC = 0.8 uM||Anti-S. aureus MRSA, activity value is MIC = 6.8||Anti-E. coli, activity value is MIC = 2||Anti-and P. aeruginosa, activity value is MIC = 18.5 uM||Anti-the peptide was found to inhibit Human Immunodeficiency Virus Type 1 HIV-1, activity value is EC50 = 4.34 uM||Anti-B.subtilis, activity value is MIC = 0.8 uM||Anti-S.aureus, activity value is MIC = 6.8 uM||Anti-E.coli, activity value is MIC = 2 uM||Anti-P.aeruginosa, activity value is MIC = 18.5 uM	the Cleptoparasitic bee, Melecta albifrons|||the Cleptoparasitic bee, Melecta albifrons|||Melecta albifrons [Cuckoo bee]	Helix	"MEP: The half-maximal hemolytic concentration (LC_{50}) on rat red blood cells is >100 µM, indicating low hemolytic activity. 

MEP-1: LC_{50} is 27.3 µM.

MEP-2: LC_{50} is 22.9 µM.

MEP-3: LC_{50} is 29.7 µM.

MEP-4: LC_{50} is 41.4 µM.

MEP-5, MEP-6, MEP-7, MEP-8, MEP-9, MEP-10: LC_{50} are all >100 µM, showing no significant hemolytic activity.

The above results were obtained through hemolysis experiments, in which peptides at different concentrations were incubated with rat red blood cells at 37°C for 1 hour. Hemolysis was measured by absorbance at 540 nm, with a 0.2% Triton X-100 treated group as the 100% hemolysis control. LC_{50} refers to the peptide concentration that produces 50% hemolysis. The results indicate that the original MEP has the lowest hemolytic activity, whereas analogs in which Pro11 was replaced or deleted (MEP-1 to MEP-4) show significantly increased hemolytic activity.|||The document mentions that the hemolytic concentration (LC₅₀) of natural bee venom peptide Melectin (MEP) is greater than 100 μM, showing extremely low hemolytic activity. In contrast, the hemolytic values of its analogs (such as MEP-1, MEP-2, etc.) range from 22.9 μM to 41.4 μM.|||The hemolytic value LC_{50} of MEP is > 100 μM; the hemolytic value LC_{50} of MEP-1 is 27.3 μM; the hemolytic value LC_{50} of MEP-2 is 22.9 μM; the hemolytic value LC_{50} of MEP-3 is 29.7 μM; the hemolytic value LC_{50} of MEP-4 is 41.4 μM; the hemolytic value LC_{50} of MEP-5 is > 100 μM; the hemolytic value LC_{50} of MEP-6 is > 100 μM; the hemolytic value LC_{50} of MEP-7 is > 100 μM; the hemolytic value LC_{50} of MEP-8 is > 100 μM; the hemolytic value LC_{50} of MEP-9 is > 100 μM; the hemolytic value LC_{50} of MEP-10 is > 100 μM."	"Chembiochem. 2008 Nov 24;9(17):2815-21. PubMed|||Chembiochem. 2008 Nov 24;9(17):2815-21. doi: 10.1002/cbic.200800476.||Wang G et al. 2010 Antimicrob. Agents Chemother. 54: 1343-1346|||Chembiochem
. 2008 Nov 24;9(17):2815-21. doi: 10.1002/cbic.200800476.|||2008 Nov 24;9(17):2815-21. doi: 10.1002/cbic.200800476.||Wang G et al. 2010 Antimicrob. Agents Chemother. 54: 1343-1346|||18942691"	18	
FPDB00095	AP01434|||AP01434|||Temporin-PTa|||DRAMP01802	FFGSVLKLIPKIL	Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-MRSA||Antibiofilm||Anti-the natural form was not evaluated due to a low amount of the peptide. A synthetic peptide was found to be active. The L and D-forms of the peptide showed identical antibacterial activity against E. coli, activity value is MIC = 25 uM||Anti-B. subtilis, activity value is MIC = 6.25 uM||Anti-and S. aureus USA300 MRSA, activity value is MIC = 3.1 uM||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram-	Hylarana picturata, Asia|||Hylarana picturata, Asi|||Rana picturata [Malaysian fire frog]|||Rana picturata (Malaysian fire frog) (Hylarana picturata)	Helix	N/A	"Toxicon. 2008 Sep 1;52(3):465-73. Pub-Med.|||Toxicon. 2008 Sep 1;52(3):465-73. doi: 10.1016/j.toxicon.2008.06.017. Epub 2008 Jun 25.|||Toxicon
. 2008 Sep 1;52(3):465-73. doi: 10.1016/j.toxicon.2008.06.017. Epub 2008 Jun 25.|||2008 Sep 1;52(3):465-73. doi: 10.1016/j.toxicon.2008.06.017. Epub 2008 Jun 25.|||18621071|||Toxicon. 2008 Sep 1;52(3):465-473."	13	
FPDB00098	AP01672|||AP01627|||AP01672|||RC-101	" 
GICRCICGKGICRCICGR"	Anti-Gram+||Antiviral||Anti-HIV||Anti-MRSA||Anti-toxin||Antibiofilm||inhibit S. aureus USA300||viruses HIV-1||SARS-Cov-2||influenza.||Antibacterial	amino acid substitution, mammal theta-defensin analog, animal-derived, natural derivative|||amino acid substitution, mammal theta-defensin analog, animal-derived, natural derivative|||Synthetic construct	Bridge	N/A	"RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. PubMed.|||2004 Nov;20(11):1157-65. doi: 10.1089/aid.2004.20.1157.||Lamers et al., 2011|||AIDS Res Hum Retroviruses.2004 Nov;20(11):1157-65. doi: 10.1089/aid.2004.20.1157.||Lamers et al., 2011|||AIDS Res Hum Retroviruses
. 2004 Nov;20(11):1157-65. doi: 10.1089/aid.2004.20.1157.|||AIDS Res Hum Retroviruses
. 2004 Nov;20(11):1157-65. doi: 10.1089/aid.2004.20.1157.|||16790431"	18	
FPDB00099	AP01978|||AP01978|||BmKn2|||CAMPSQ14088|||CAMPSQ14139|||CAMPSQ14397	" 
FIGAIARLLSKIF"	"Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-MRSA||Hemolytic||Antibiofilm||Wound healing||Anticancer
Crucial residues:||Anticancer||Anti-Gram+ bacteria S. aureus AB94004 or ATCC 25923 or MRSA P1386, activity value is MIC = 0.6 ug/ml||Anti-M. luteus AB93113, activity value is MIC = 8 ug/ml||Anti-B. subtilis AB91021, activity value is MIC = 5 ug/ml||Anti-B. thuringiensis AB92037, activity value is MIC = 12.5 ug/ml||Anti-S. epidermidis, activity value is MIC = 2.5||Anti-E. faecalis, activity value is MIC = 10 ug/ml||Anti-E. faecium, activity value is MIC = 10 ug/ml||Anti-E. coli, activity value is MIC = 1.5 ug/ml||Anti-P. aeruginosa AB93066 and 5 more strains, activity value is MIC = 21.3||Anti-S.aureus, activity value is MIC = 0.6 ug/ml||Anti-M.luteus, activity value is MIC = 8 ug/ml||Anti-B.subtilis, activity value is MIC = 5 ug/ml||Anti-E.coli, activity value is MIC = 1.5 ug/ml||Anti-P.aeruginosa, activity value is MIC = 21.3 ug/ml||Anti-Staphylococcus aureus AB94004, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 6.25 ug/ml||Anti-Bacillus subtilis AB91021, activity value is MIC = 12.5 ug/ml||Anti-Bacillus thuringiensis AB92037, activity value is MIC = 12.5 ug/ml||Anti-Micrococcus luteus AB93113, activity value is MIC = 6.25 ug/ml||Anti-Pseudomonas aeruginosa AB93066, activity value is MIC = 50 ug/ml||Anti-S. aureus ATCC29213, activity value is MIC = 10 ug/ml||M. abscessus ATCC19977 (MIC= >400 ug/ml)"	venom, Buthus martensii Karsch|||venom, Buthus martensii Karsch|||venom, Buthus martensii Karsch, China, Asia|||Mesobuthus martensii [Manchurian scorpion]|||Mesobuthus martensii|||Synthetic construct	Helix	venom, Buthus martensii Karsch|||Human RBCs (< 40% percent hemolysis at 100 ug/ml)	"Peptides. 2004 Feb;25(2):143-50.PubMed|||Peptides. 2004 Feb;25(2):143-50.doi: 10.1016/j.peptides.2003.12.003.||Arpornsuwan et al., 2014||Mangmee et al. 2021|||Peptides
. 2004 Feb;25(2):143-50. doi: 10.1016/j.peptides.2003.12.003.|||Peptides. 2004 Feb;25(2):143-50. doi: 10.1016/j.peptides.2003.12.003.||Arpornsuwan et al., 2014||Mangmee et al. 2021|||15062994|||22792229|||34335511|||34361810|||34780520"	13	
FPDB00112	AP03807|||AP03807|||GI-20|||DRAMP31340|||AP03807|||DRAMP31340	" 
GIKEFKRIVQRIKDFLRNLV"	Anti-Gram+ & Gram-||Antiviral||Spermicidal||Anti-HIV||Anti-It inhibits HIV-1. Active against E. faecium V284-17, activity value is MIC = 2 uM||Anti-S. aureus USA300, activity value is MIC = 2||Anti-K-pneumoniae E406-17, activity value is MIC > 32 uM||Anti-P-aeruginosa E411-17, activity value is MIC > 32 uM||Anti-and E. coli E423-17, activity value is MIC = 32 uM||Anti-MRSA||Antibiofilm||Anti-E. faecium V284-17, activity value is MIC = 2 uM||Anti-A. baumannii B28-16, activity value is MIC = 8 uM||Anti-E. coli E423-17, activity value is MIC = 32 uM||Antimicrobial	Derivative of LL-37; Sequence truncation. human cathelicidin analog, animal-derived, natural derivative|||Derivative of LL-37; Sequence truncation. human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct(derived from human cathelicidin LL-37)|||Derivative of LL-37; Sequence truncation. human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct(derived from human cathelicidin LL-37)	Helix	No hemolytic activity (0% hemolysis at 100 µM)|||human RBC: HC50 ~150 uM, some hemolytic.|||Human RBC (62% hemolysis at 200 uM)	"Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08.||Zhang et al., 2021|||Antimicrob Agents Chemother
. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. Epub 2008 Jun 30.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed||Zhang et al., 2021|||34959645|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. doi: 10.1128/AAC.00452-08. PubMed|||Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40."	20	
FPDB00123	AP04543|||Kn2-7|||CAMPSQ14095|||DRAMP18558	FIKRIARLLRKIF	Anti-Gram- E. coli AB94012 or ATCC 25922, activity value is MIC = 6.25||Anti-P. aeruginosa AB93066 or A092994 like 5 strains, activity value is MIC = 25||Anti-S. aureus AB94004 or ATCC 25923 or MRSA, activity value is MIC = 3.13 ug/ml||Anti-S. epidermidis, activity value is MIC = 2.5||Anti-E. faecalis, activity value is MIC = 5||Anti-E. faecium, activity value is MIC = 5 ug/ml||Anti-B. subtilis AB91021, activity value is MIC = 6.25 ug/ml||Anti-B. thuringiensis AB92037, activity value is MIC = 6.25 ug/ml||Anti-and M. luteus AB93113, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus AB94004, activity value is MIC = 3.13 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 3.13 ug/ml||Anti-Bacillus subtilis AB91021, activity value is MIC = 6.25 ug/ml||Anti-Bacillus thuringiensis AB92037, activity value is MIC = 6.25 ug/ml||Anti-Micrococcus luteus AB93113, activity value is MIC = 6.25 ug/ml||Anti-Escherichia coli AB94012, activity value is MIC = 6.25 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 25 ug/ml||Anti-Pseudomonas aeruginosa AB93066, activity value is MIC = 25 ug/ml||Anti-Pseudomonas aeruginosa A092994, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa A093052, activity value is MIC = 100 ug/ml||Anti-Pseudomonas aeruginosa A093056, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa A093085, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa A093115, activity value is MIC = 100 ug/ml||Anti-S. aureus P1383, activity value is MIC = 6.25 ug/ml||Anti-Penicillin-resistant S. epidermidis P1389, activity value is MIC = 6.25 ug/ml||Anti-Methicillin resistant S. aureus P1381, activity value is MIC = 6.25 ug/ml||Anti-Methicillin resistant S. aureus P1386, activity value is MIC = 6.25 ug/ml||Anti-Methicillin resistant S. aureus P1374, activity value is MIC = 3.13 ug/ml||Anti-Methicillin resistant coagulase-negative Staphylococcus P1369, activity value is MIC = 3.13 ug/ml||Anti-Penicillin-sensitive S. epidermidis P1111, activity value is MIC = 3.13 ug/ml||Anti-S. aureus ATCC29213, activity value is MIC = 5 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 10 ug/ml||Anti-##Gram-negative bacteria: Escherichia coli AB94012, activity value is MIC = 6.25 ug/ml	amino acid substitution, animal-derived, natural derivative|||Synthetic construct	Helix||Alpha helix	"The peptide Kn2-7 had little hemolytic activity at high
concentration (Figure 1D). According to the method of Ka¨ ber
modified by Achmarine, the HC50 values of the mutant peptide
Kn2-7 and the wild-type peptide BmKn2 were 90270 ug/ml and
17130 ug/ml, respectively (Figure 1D). Therefore, the hemolytic
activity of Kn2-7 was significantly decreased, compared to the
wild-type peptide BmKn2.|||No hemolytic activity (0% hemolysis at 100 µM)|||Kn2-7 peptide: HC₅₀ value is 90.27 µg/ml. BmKn2 peptide (wild-type peptide): HC₅₀ value is 17.13 µg/ml.|||Kn2-7: 50% hemolytic concentration (HC₅₀) is 90.27 µg/ml; 
Wild-type peptide BmKn2: 50% hemolytic concentration (HC₅₀) is 17.13 µg/ml; 
(Note: Determined by human red blood cell hemolysis assay, positive control 0.1% Triton X-100 is 100% hemolysis, 0.85% physiological saline is 0% hemolysis).|||Human RBCs (> 90% percent hemolysis at 100 ug/ml)|||[Ref.22792229]Non-hemolysis at 6.25 ug/ml, 5% hemolysis at 12.5 ug/ml,10% hemolysis at 25 ug/ml 15% hemolysis at 50 ug/ml, 40% hemolysis at 100 ug/ml against human red blood cells"	"Cao L, Dai C, Li Z, Fan Z, Song Y, Wu Y, Cao Z, Li W.2012
 PLoS One. 2012;7(7):e40135. doi: 10.1371/journal.pone.0040135. PubMed|||PLoS One. 2012;7(7):e40135. doi: 10.1371/journal.pone.0040135.|||2012;7(7):e40135. doi: 10.1371/journal.pone.0040135. Epub 2012 Jul 5.|||. 2012;7(7):e40135. doi: 10.1371/journal.pone.0040135. Epub 2012 Jul 5.|||22792229|||34335511|||PLoS One. 2012;7(7):e40135. doi: 10.1371/journal.pone.0040135.||Ref.22792229"	13	
FPDB00140	AP03847|||AP03847|||Temporin-LTc-3r	SLSRFLRFLKIVYRRAF	Anti-S. aureus USA300 MRSA, activity value is MIC = 12.5 uM||Anti-Gram+ & Gram-||Antiviral||Anti-HIV||Anti-MRSA||Anti-S. aureus, activity value is MIC = 12.5 uM||Anti-E. coli, activity value is MIC = 25 uM	Amino acid substitution, amphibians, animal-derived, natural derivative|||Amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct	N/A	No hemolytic activity (0% hemolysis at 100 µM)	"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010
 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Antimicrob Agents Chemother
. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. Epub 2010 Jan 19.|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||22445495|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed"	17	
FPDB00141	AP03846|||AP03846|||DASamP1|||DRAMP04317	FFGKVLKLIRKIF	Anti-S. aureus USA300 MRSA, activity value is MIC = 3.1 uM||Anti-Gram+||Antiviral||Anti-HIV||Anti-MRSA||Anti-Bacillus subtilis, activity value is MIC > 100 uM||Anti-Pseudomonas aeruginosa, activity value is MIC > 100 uM||Anti-S. aureus, activity value is MIC = 3.1 uM||Anti-E. coli, activity value is MIC > 100 uM||Antimicrobial||Antibacterial	Amino acid substitution, amphibians, animal-derived, natural derivative|||FFGKVLKLIRKIF|||Amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct	N/A	No hemolytic activity (0% hemolysis at 100 µM)|||hemolytic HC50 25 uM.|||Human RBC (HL50 = 25 uM)	"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010
Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed||Menousek et al., 2012|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.||Menousek et al., 2012|||Antimicrob Agents Chemother
. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. Epub 2010 Jan 19.|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed||Menousek et al., 2012|||22445495|||Int J Antimicrob Agents. 2012 May;39(5):402-406.|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed"	13	
FPDB00142	AP03845|||Uperin 7.1KRF	GWFDVVKHIAKRF	Anti-S. aureus USA300 MRSA, activity value is MIC = 50 uM||Antiviral||Anti-HIV||Anti-MRSA||Anti-S. aureus, activity value is MIC = 50 uM||Anti-E. coli, activity value is MIC = 12.5 uM	Amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct	N/A	No hemolytic activity (0% hemolysis at 100 µM)	"Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. 2010
 Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09.|||Antimicrob Agents Chemother
. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. Epub 2010 Jan 19.|||22445495|||Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. doi: 10.1128/AAC.01448-09. PubMed"	13	
FPDB00169	AP00152|||3268|||3269|||AP00152|||Tritrpticin|||TOAC0-TRP3|||DRAMP02975|||Tritrpticin|||AP00152	VRRFPWWWPFLRR	Anti-A.fumigatus, activity value is MIC = 250 ug/ml||Anti-S. typhimurium KCTC 1926, activity value is MIC = 32 ug/ml||Anti-B. subtilis KCTC 3068, activity value is MIC = 8 ug/ml||Anti-and S. aureus KCTC 1621 or 2 strains MRSA, activity value is MIC = 16||Anti-2 strains vancomycin-resistant E. faecium, activity value is MIC = 32 ug/ml||activity value is IC50 > 200 ug/ml||activity value is IC50 = 142 ug/ml||Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Hemolytic||Anticancer||Anti-8706838: Aspergillus fumigatus, activity value is MIC = 250 ug/ml||Anti-Candida albicans, activity value is MIC = 1000 ug/ml||Anti-16563706 : Escherichia coli, activity value is MIC = 32 ug/ml||Anti-Salmonella typhimurium, activity value is MIC = 32 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 8 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 16 ug/ml||Anti-methicillin-resistant Staphylococcus aureus 1, activity value is MIC = 32 ug/ml||Anti-vancomycin resistant Enterococcus faecium 1, activity value is MIC = 32 ug/ml||Anti-MRSA 2, activity value is MIC = 64 ug/ml||Anti-VRE2, activity value is MIC = 32 ug/ml||Anti-Escherichia coli, activity value is MIC = 16 ug/ml||Anti-Salmonella typhimurium, activity value is MIC = 16 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 4 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 8 ug/ml||Anti-12681513: E. coli, activity value is MIC = 32 ug/ml||Anti-S. typhimurium, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa, activity value is MIC = 32 ug/ml||Anti-B. subtilis, activity value is MIC = 8 ug/ml||Anti-S. aureus, activity value is MIC = 16 ug/ml||Anti-S. epidermidis, activity value is MIC = 8 ug/ml||Anti-E. coli D31, activity value is MIC = 4||Anti-Streptococcus group D . Fungi: Aspergillus fumigatus, activity value is MIC = 250 ug/ml||Antibacterial	pig|||pig|||Sus scrofa [pig]|||Synthetic construct|||Sus scrofa (Pig)|||Sus scrofa [pig]|||pig	Nonhelixbeta	C terminal: CO2H - Human RBC (70% hemolysis at 100 uM); C terminal: NH2 - Human RBC (<60% hemolysis at 100 uM)|||Human RBCs [7% hemolysis at 190 uM]|||C terminal: CO2H - Human RBC (70% hemolysis at 100 uM); C terminal: NH2 - Human RBC (<60% hemolysis at 100 uM)	"Lawyer C, Pai S, Watabe M, Borgia P, Mashimo T, Eagleton L, Watabe K.1996
 FEBS Lett. 1996 Jul 15;390(1):95-8.PubMed|||FEBS Lett. 1996 Jul 15;390(1):95-8.PubMed|||Comparative Study FEBS Lett
. 1996 Jul 15;390(1):95-8. doi: 10.1016/0014-5793(96)00637-0.|||8706838, 16563706, 12681513|||31672543|||FEBS Lett. 1996 Jul 15;390(1):95-98.|||8706838, 16563706, 12681513|||FEBS Lett. 1996 Jul 15;390(1):95-8.doi: 10.1016/0014-5793(96)00637-0."	13	L
FPDB00171	AP00166|||AP00166|||Pleurocidin|||DRAMP02350|||AP00166	GWGSFFKKAAHVGKHVGKAALTHYL	Anti-Highly active against A. salmonicida 99-1, activity value is MIC = 2 uM||Anti-A. salmonicida 97-4, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium MS7953s or 14028s or I or II, activity value is MIC = 2||Anti-P. aeruginosa K799 or Z61, activity value is MIC = 4||Anti-E. coli CGSC4908 or UB1005 or DC2, activity value is MIC = 2||Anti-S. epidermidis C621, activity value is MIC = 8 uM||Anti-methicillin-resistant S. aureus C623 or MRSA, activity value is MIC = 8 uM||Anti-C. albicans C627, activity value is MIC = 8 uM||Anti-E. coli, activity value is MIC = 2.2||Anti-A. salmonicida, activity value is MIC = 2||Anti-P. aeruginosa, activity value is MIC = 4||Anti-C. aquatilis, activity value is MIC = 2.2||Anti-P. haemolytica, activity value is MIC = 4.4||Anti-positive B. subtilis, activity value is MIC = 1.1||Anti-S. aureus, activity value is MIC = 17.7||Anti-S. epidermidis, activity value is MIC = 8 uM||Anti-UA 140, activity value is MIC = 8||Anti-L. fermenti, activity value is MIC = 2||Anti-Gram+ & Gram-||Antifungal||candidacidal||Chemotactic||Anti-MRSA||Antibiofilm||Anticancer||Antibacterial||Anti-Escherichia coli, activity value is MIC = 2.2||Anti-Leucothrix mucor, activity value is MIC > 35 uM||Anti-Serratia marcescens, activity value is MIC > 35 uM||Anti-Pseudomonas aeruginosa, activity value is MIC > 35 uM||Anti-Aeromonas salmonicida, activity value is MIC = 17.7||Anti-Cytophaga aquatilis, activity value is MIC = 2.2||Anti-Pasteurella haemolytica, activity value is MIC = 4.4||Anti-Salmonella typhimurium I, activity value is MIC = 8.8||Anti-Salmonella typhimurium II, activity value is MIC = 8.8||Anti-Bacillus subtilis, activity value is MIC = 1.1||Anti-Staphylococcus aureus, activity value is MIC = 17.7	the skin mucous secretions, Winter flounder, Pleuronectes americanus|||the skin mucous secretions, Winter flounder, Pleuronectes americanus|||Pseudopleuronectes americanus [Winter flounder]|||Pseudopleuronectes americanus (Winter flounder 4)|||the skin mucous secretions, Winter flounder, Pleuronectes americanus	Helix	Refer 30508627 Mouse RBC (12% hemolysis at 32 uM)	"Cole AM, Weis P, Diamond G.1997
 J. Biol. Chem. 1997; 272:12008-12013. Pub-Med.||Tao R et al., 2011|||J. Biol. Chem. 1997; 272:12008-12013. Pub-Med.|||Comparative Study J Biol Chem
. 1997 May 2;272(18):12008-13. doi: 10.1074/jbc.272.18.12008.||Tao R et al., 2011|||9115266 , 10898673 , 12950255 , 12878506, 30508627|||J Biol Chem. 1997 May 2;272(18):12008-12013.|||J. Biol. Chem. 1997; 272:12008-12013. doi: 10.1074/jbc.272.18.12008.||Tao R et al., 2011"	25	
FPDB00175	AP00201|||AP00201|||CAMPSQ8243|||CAMPSQ9945|||DRAMP18665|||DRAMP18709	INLKALAALAKKIL	Anti-S. aureus ATCC 29213 or MRSA, activity value is MIC = 10||Anti-E. coli, activity value is MIC = 10||Anti-K. pneumoniae, activity value is MIC = 10||Anti-S. enterica, activity value is MIC = 10||Anti-Gram+ & Gram-||Anti-MRSA||Anticancer||Anti-Mastoparan analogue 9 : (A. baumannii strain CR17, activity value is MIC = 2.6 uM||Anti-A. baumannii strain CR86, activity value is MIC = 2.6 uM||Anti-A. baumannii strain Ab11, activity value is MIC = 1.3 uM||Anti-A. baumannii strain Ab113, activity value is MIC = 2.6 uM||Anti-A. baumannii strain CR86, activity value is MIC = 21 uM||Anti-A. baumannii strain Ab11, activity value is MIC = 42 uM||Anti-A. baumannii strain Ab113, activity value is MIC = 42 uM||Anti-E. coli, activity value is MIC = 32 uM||Anti-E. coli, activity value is MIC = 2 uM||Anti-S. aureus, activity value is MIC = 8 uM||Anti-P. aeruginosa PA14, activity value is MIC = 8 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 8 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 12.5 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 25 uM||Anti-##Gram-negative bacteria: Escherichia coli ATCC 25922, activity value is MIC = 25 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 50 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 12.5 uM||Anti-Acinetobacter baumannii ATCC 19606, activity value is MIC = 2.7 uM||No MICs found in DRAMP database	Venom, Vespula lewisii|||Venom, Vespula lewisii, Asia (China/Japan)|||Venom, Vespula lewisii|||Synthetic construct|||Vespula lewisii|||Vespula lewisii (Korean yellow-jacket isp) (Vespula flaviceps lewisii)|||Vespula flaviceps lewisii (Korean yellow-jacket isp)	Helix||Alpha helix	Human RBCs [100% hemolysis at 45 uM]|||[Ref.27423268]40% hemolysis at 10 uM against rat red blood cells|||No hemolysis information or data found in the reference(s) presented in this entry	"García JR, Krause A, Schulz S, Rodríguez-Jiménez FJ, Klüver E, Adermann K, Forssmann U, Frimpong-Boateng A, Bals R, Forssmann WG1979
 Chem Pharm Bull (Tokyo). 1979 Aug;27(8):1942-4||Silva et al., 2020|||Chem Pharm Bull (Tokyo). 1979 Aug;27(8):1942-4|||Silva et al., 2020|||26114811|||31411881|||Biochim Biophys Acta. 2016 Nov;1858(11):2699-2708.||Ref.27423268|||Chem Pharm Bull (Tokyo). 1979 Aug;27(8):1942-4"	14	
FPDB00176	AP00204|||AP00204|||Nisin-Z	ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK	Anti-L. lactis MG1363, activity value is MIC = 0.02 ug/ml||Anti-L. monocytogenes LMG10470 or TT82E or LK132, activity value is MIC = 1.5||Anti-B. cereus CH-85, activity value is MIC = 6.25 ug/ml||Anti-S. aureus LMG10147 or LMG15975 or MRSA, activity value is MIC = 6.25 ug/ml||Anti-and E. faecium LMG11423 or LMG16003 or LMG16216, activity value is MIC = 3.13 ug/ml||Anti-Gram+||Antiviral||Anti-MRSA||Anticancer||Antibacterial	Lactococcus lactisNIZO 221 86|||Lactococcus lactisNIZO 221 86|||Lactococcus lactis  [Bacteria]	N/A	N/A	"Mulders JWM, Boerrigter IJ, Rollema HS, Siezen RJ, de Vos WM.1991
 Eur. J. Biochem. 1991; 201: 581-584|||Eur. J. Biochem. 1991; 201: 581-584|||28461263"	34	
FPDB00177	AP00205	ITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK	Anti-l inhibitory activity was first reported in 1928. Active against Micrococcus spp, activity value is MIC = 1.1 ug/ml||Anti-Enterococcus spp, activity value is MIC = 16.7||Anti-Bacillus spp, activity value is MIC = 4.2||Anti-Clostridium spp, activity value is MIC = 1.1 ug/ml||Anti-A. viscosus, activity value is MIC = 83.6 ug/ml||Anti-P. acnes, activity value is MIC = 2.1||Anti-and Gram- bacteria: C. jejune, activity value is MIC = 1.1 ug/ml||Anti-H. influenzae, activity value is MIC = 66.9 ug/ml||Anti-H. pylori, activity value is MIC = 0.3 ug/ml||Anti-and Neisseria spp, activity value is MIC = 8.4 ug/ml||Anti-Gram+||Antiviral||Spermicidal||Anti-MRSA||Synergistic AMPs||Antibiofilm||Wound healing||Anticancer	Streptococcus lactis, reclassified as Lactococcus lactis	Nonhelixbeta	N/A	"Rogers, LA1928
 J. Bacteriol. 1928; 16:321-325. PubMed.||Ref see AP1003|||J. Bacteriol. 1928; 16:321-325. PubMed.|||J Bacteriol
. 1928 Nov;16(5):321-5. doi: 10.1128/jb.16.5.321-325.1928.||Ref see AP1003|||1928 Nov;16(5):321-5. doi: 10.1128/jb.16.5.321-325.1928.||Ref see AP1003"	34	
FPDB00183	AP00281|||AP00281|||Cathelin-related antimicrobial peptide|||DRAMP03405|||AP00281	GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE	Anti-E. coli ATCC 25922 or ML35 or D21, activity value is MIC = 0.5||Anti-S. typhimurium ATCC 14028, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 4 uM||Anti-S. marcescens ATCC 8100, activity value is MIC = 4 uM||Anti-P-vulgaris ATCC 13315, activity value is MIC > 64 uM||Anti-S. aureus ATCC 25923 or Cowan I MRSA, activity value is MIC = 32||Anti-S. epidermidis ATCC 12228, activity value is MIC = 16 uM||Anti-S. faecalis ATCC 29212, activity value is MIC = 32 uM||Anti-B. megaterium Bm11, activity value is MIC = 4 uM||Anti-fumgi C-albicans, activity value is MIC > 64 uM||Anti-C. neoformans, activity value is MIC = 16 uM||Anti-and the single-stranded RNA virus respiratory syncytial virus . It also inhibit B. anthracis, activity value is MIC = 8 ug/ml||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Anti-MRSA||Anticancer||Antibacterial||Anti-Escherichia coli ATCC 25922, activity value is MIC = 1 uM||Anti-Escherichia coli ML35, activity value is MIC = 2 uM||Anti-Escherichia coli D21, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 4 uM||Anti-Serratia marcescens ATCC 8100, activity value is MIC = 4 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 32 uM||Anti-Staphylococcus aureus Cowan I, activity value is MIC = 32 uM||Anti-Staphylococcus aureus, activity value is MIC > 64 uM||Anti-Staphylococcus aureus, activity value is MIC = 64 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 16 uM||Anti-Streptococcus faecalis ATCC 29212, activity value is MIC = 16 uM||Anti-Bacillus megaterium Bm11, activity value is MIC = 4 uM||Anti-Cryptococcus neoformans, activity value is MIC = 16 uM	precursor sequence homology, sequence alignment, other predictions|||precursor sequence homology, sequence alignment, other methods predicted|||precursor sequence homology, sequence alignment, other predictions|||Mus musculus [Mouse]|||Mus musculus (Mouse)|||precursor sequence homology, sequence alignment, other methods predicted	Helix||Alpha helix (CD)	CRAMP peptide does not lyse human or sheep red blood cell membranes at a concentration of 50 μM, but specific hemolytic values are not mentioned.|||CRAMP is also anticancer (tumor cells A549, K562, Jurkat, IC50 16-28 uM) with 2.2% hemolysis at 100 uM (little hemo.lytic). Change residue 2, 9, or 13 to K made CRAMP-18 anticancer as well but not better than its parent molecule. CRAMP also inactivates Zika virus (ZIKV). Updated 11/2015; 4/2016; 10/2016; 3/2023; seq corrected 5/2023; 6/2024.	"Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, Gennaro R.1997
 J. Biol. Chem. 1997: 272:13088-13093. PubMed||Blower et al., 2018||Archer NK et al., 2016|||J. Biol. Chem. 1997: 272:13088-13093. PubMed|||J Biol Chem
. 1997 May 16;272(20):13088-93. doi: 10.1074/jbc.272.20.13088.||Blower et al., 2018||Archer NK et al., 2016|||9148921|||FEBS Lett. 1996 Aug 5;391(1-2):5-8.|||J. Biol. Chem. 1997: 272:13088-13093. PubMed||Blower et al., 2018||Archer NK et al., 2016|||1997 May 16;272(20):13088-93. doi: 10.1074/jbc.272.20.13088.||Blower et al., 2018"	33	
FPDB00187	AP00351|||1421|||1422|||4030|||4031|||4032|||4033|||4034|||4035|||4036|||4037|||4038|||AP00351|||Citropin-1.1|||AMP-001/Cit 1.1|||AMP-003|||Cit1.1|||Citropin 1.1|||AMP-001/Cit 1.1|||AP00351	GLFDVIKKVASVIGGL	Anti-L. lactis, activity value is MIC = 3||Anti-E.coli, activity value is MIC > 100 ug/ml||Anti-P.multocida, activity value is MIC > 100 ug/ml||Anti-M. luteus, activity value is MIC = 25 ug/ml||Anti-S. epidermidis, activity value is MIC = 12||Anti-L. innocua, activity value is MIC = 100 ug/ml||Anti-S. uberis, activity value is MIC = 12 ug/ml||Anti-S. aureus or MRSA, activity value is MIC = 25 ug/ml||Anti-B. cereus, activity value is MIC = 25||Anti-and B. subtilis, activity value is MIC = 12.5 ug/ml||Anti-Gram+ E. faecalis PCM 2673, activity value is MIC = 32 ug/ml||Anti-S. aureus ATCC 25923 or 9144, activity value is MIC = 16 ug/ml||Anti-S. pneumoniae ATCC 49619, activity value is MIC = 32 ug/ml||Anti-E. coli ATCC 25922 or 23506, activity value is MIC = 32 ug/ml||Anti-K. pneumoniae ATCC 700603, activity value is MIC = 16 ug/ml||Anti-P.aeruginosa ATCC 9027, activity value is MIC = 128 ug/ml||Anti-A. niger ATCC 16404, activity value is MIC = 64 ug/ml||Anti-C.albicans ATCC 10231, activity value is MIC = 128 ug/ml||Anti-and C.glabrata ATCC 15126, activity value is MIC = 128 ug/ml||60% Cytotoxicity at 0.5 ug/ml||activity value is IC50 = 5000000 uM||Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-inflammatory||Enzyme inhibitor||Antibiofilm||Anticancer||Anti-Bacillus cereus, activity value is MIC = 50 ug/ml||Anti-Leuconostoc lactis, activity value is MIC = 6 ug/ml||Anti-Listeria innocua, activity value is MIC = 25 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 12 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 25 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 12 ug/ml||Anti-Streptococcus uberis, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus JE2 MRSA, activity value is MIC = 32 ug/ml||Anti-Escherichia coli K12, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus ATCC 43300 MRSA, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus JE2 MRSA, activity value is MIC = 256 ug/ml||Anti-Escherichia coli K12, activity value is MIC = 256 ug/ml||Anti-E. coli, activity value is MIC = 10 uM||Anti-E. coli, activity value is MIC = 5 uM||Anti-K. pneumoniae, activity value is MIC = 20 uM||Anti-MRSA, activity value is MIC = 10 uM||Anti-S. aureus, activity value is MIC = 3 uM||Anti-A. baumannii ATCC 19606, activity value is MIC = 16 ug/ml||Antibacterial	skin secretion, Australian blue mountains tree frog, Litoria citropa|||skin secretion, Australian blue mountains tree frog, Litoria citropa|||Litoria citropa|||Synthetic construct|||Synthetic construct|||skin secretion, Australian blue mountains tree frog, Litoria citropa	Helix	Human RBCs [HC50 = > 32 ug/ml]|||Mouse RBCs [Hemolysis (%) = 16.5 ± 3 uM]|||Human RBCs [HC50 = > 32 ug/ml]	"Wegener KL., Wabnitz PA., Carver JA., Bowie JH., Chia BCS., Wallace JC., Tyler MJ.1999, Australia
 Eur. J. Biochem. 1999; 265: 627-637. PubMed.||Calabrese AN et al., 2012||Neubauer et al., 2017|||Eur. J. Biochem. 1999; 265: 627-637. PubMed.|||Comparative Study Eur J Biochem
. 1999 Oct;265(2):627-37. doi: 10.1046/j.1432-1327.1999.00750.x.||Calabrese AN et al., 2012||Neubauer et al., 2017|||10504394|||31336137|||31448597|||30043322|||31336137|||Eur. J. Biochem. 1999; 265: 627-637. PubMed.||Calabrese AN et al., 2012||Neubauer et al., 2017"	16	L
FPDB00190	AP00366|||AP00366|||Antibacterial peptide BMAP-27|||DRAMO02855|||Antibacterial peptide BMAP-27|||AP00366	GRFKRFRKKFKKLFKKLSPVIPLLHLG	Anti-E. coli ATCC 25922 ML-35 or D21, activity value is MIC = 0.5||Anti-S. typhimurium ATCC 14028, activity value is MIC = 1||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-S. marcescens ATCC 8100, activity value is MIC = 2 uM||Anti-S. aureus ATCC 25923 or Cowan 1 MRSA, activity value is MIC = 2||Anti-S. epidermidis ATCC 12228, activity value is MIC = 1 uM||Anti-B. megaterium Bm11, activity value is MIC = 2 uM||Anti-C. albicans, activity value is MIC = 8 uM||Anti-and C. neoformans, activity value is MIC = 4 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anticancer||Anti-E. coli ATCC25922, activity value is MIC = 1 uM||Anti-E. coli ML35, activity value is MIC = 1 uM||Anti-E.coli D21, activity value is MIC = 0.25 uM||Anti-S. typhimurium ATCC 14028, activity value is MIC = 1 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 2 uM||Anti-S. aureus Cowan 1, activity value is MIC = 2 uM||Anti-S. aureus MRSA, activity value is MIC = 4 uM||Anti-C.albicans, activity value is MIC = 8 uM||Anti-C.neoformans, activity value is MIC = 4 uM||Anti-E.coli(LOG 2, activity value is MIC = 3.75||Anti-Escherichia coli ATCC25922, activity value is MIC = 1 ug/ml||Anti-E. coli ML35, activity value is MIC = 1 ug/ml||Anti-E. coli D21, activity value is MIC = 0.25 ug/ml||Anti-Salmonella typhimurium ATCC 14028, activity value is MIC = 1 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 1 ug/ml||Anti-Serratia marcescens ATCC 8100, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus Cowan 1, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 4 ug/ml||Anti-S. epidermidis ATCC 12228, activity value is MIC = 1 ug/ml||Anti-Bacillus megaterium Bm11, activity value is MIC = 2 ug/ml||Anti-Cryptococcus neoformans, activity value is MIC = 4 ug/ml	cattle, Bos taurus|||cattle, Bos taurus|||Bos taurus [Bovine]|||Bos taurus (Bovine)|||Bos taurus [Bovine]|||cattle, Bos taurus	Helix	"The hemolytic activity of the two BMAPs was much lower,
when measured on bovine erythrocytes (data not shown). These
cells were 5–10-fold less susceptible than human red blood cells
to BMAP-28 (3, 6, and 22% hemolysis at 10, 30, and 100000 uM
peptide), and virtually unaffected by BMAP-27 even at 100000 uM.
We speculate that the different susceptibility of human and
bovine red blood cells to these molecules may be accounted for
by species-specific differences in the erythrocyte membrane
composition, and may reflect the need to protect the host cells
from undesired cytotoxic effects. We have also noted that the
effects of BMAP-28 on the cell membranes are consistently
higher than BMAP-27, in spite of the structural similarity of
the two molecules, thus suggesting that minor structural dif-ferences
can modulate the activity of these peptides.|||The document explicitly mentions the hemolytic values of two novel antimicrobial peptides (BMAP-27, BMAP-28) and their derivatives (BMAP-27(1–18), BMAP-28(1–18), mBMAP-28) on human red blood cells. The core data are as follows: 
 
1. Hemolytic properties of parent peptides (BMAP-27, BMAP-28).
 
 BMAP-28 (for human red blood cells): 
 At a concentration of 3 μM, the hemolysis rate is 14.5%; 
 At a concentration of 100 μM, the hemolysis rate exceeds 90% (specifically 94.1%). 
 BMAP-27 (against human red blood cells): 
 At a concentration of 3 μM, the hemolysis rate is only 3.5%; 
 At a concentration of 100 μM, the hemolysis rate is 32.7%. 
 Its hemolytic effect on bovine red blood cells is significantly lower than that of human red blood cells: 
 BMAP-28 had hemolytic rates of 3%, 6%, and 22% at concentrations of 10 uM, 30 uM, and 100 uM, respectively; 
 BMAP-27 has almost no hemolytic effect on bovine red blood cells even at a concentration of 100 uM. 
 
2. Hemolytic properties of truncated derivatives (BMAP-27(1–18), BMAP-28(1–18)).
 
The hemolytic effect of truncated peptides (retaining only 18 residues at the N-terminus and removing the hydrophobic tail at the C-terminus) is significantly reduced: 
 
BMAP-27 (1–18): Has almost no hemolytic activity against human red blood cells (Figure 6 shows no significant hemolytic rate; combined with text description of ""hemolytic effect disappears""). 
BMAP-28(1–18): hemolytic rate of human red blood cells is significantly lower than that of parent peptides (the curve in Figure 6 is close to baseline, no specific value, but the text clearly states ""hemolytic effect greatly reduced""). 
 
3. Hemolytic properties of modified derivatives (mBMAP-28).
 
Significant loss of hemolytic activity in mBMAP-28 (replacement of hydrophobic residues at the C-terminal for hydrophilic residues): 
 
At a concentration of 100 μM, the hemolytic rate for human red blood cells is only 3.3%, far lower than the 94.1% of the parent peptide BMAP-28. 
 
Additional notes
 
Hemolysis detection method: Using standard hemolysis experiments, 10% (v/v) red blood cell suspension and peptides of different concentrations were incubated at 37°C for 15 minutes to measure absorbance at 415nm, using complete hemolysis induced by 0.2% Triton X-100 as a 100% control. 
Relationship between hemolysis and antibacterial activity: The hemolytic concentration of parental peptides (≥3 uM) is much higher than that of their antibacterial activity concentration (MIC: 0.25–4 uM); Truncated/modified derivatives retain antibacterial activity while significantly reducing hemolytic activity and improving targeted selectivity.|||The document clearly mentions the hemolytic values of BMAP-27, BMAP-28, and their analogues (truncated or modified forms) on human and bovine red blood cells. The core data are as follows:

I. Hemolytic values for human red blood cells (key indicators)

Measured by standard hemolysis experiments, presented as ""peptide concentration (uM) - hemolysis rate (%)"", the results are the average of multiple independent experiments (S.E. ≤1.8):

1. BMAP-28
3 uM: 14.5%
100 uM: >90% (specifically 94.1%)
2. BMAP-27
3 uM: 3.5%
100 uM: 32.7%
3. Truncated forms: BMAP-27(1–18), BMAP-28(1–18)
BMAP-27(1–18): nearly no hemolytic activity (no specific value given, only mentioned as ""hemolytic effect disappeared"").
BMAP-28(1–18): hemolytic activity significantly reduced (no specific concentration-hemolysis correspondence given, only mentioned as ""declined markedly"").
4. Modified form: mBMAP-28 (hydrophobic residues at C-terminus replaced with hydrophilic residues)
100 uM: only 3.3% hemolysis (much lower than parent BMAP-28's 94.1%).

II. Hemolytic values for bovine red blood cells (species difference comparison)

Bovine red blood cells are significantly less sensitive to BMAPs than human red blood cells:

1. BMAP-28
10 uM: 3%
30 uM: 6%
100 uM: 22%
2. BMAP-27
100 uM: virtually no hemolysis (""virtually unaffected"").

III. Supplementary notes

Hemolysis experiment conditions: 10% (v/v) red blood cell suspension in pH 7.4 PBS, incubated with peptides at 37 °C for 15 minutes, with complete hemolysis induced by 0.2% Triton X-100 as the 100% control.
Trend: The hemolytic activity of peptides is mainly mediated by the hydrophobic domain at the C-terminus—removal (truncated forms) or modification (mBMAP-28) of this region significantly reduces hemolysis, but antibacterial activity (MIC) is largely retained.|||BMAP-28 can cause 14.5% hemolysis of human red blood cells at a concentration of 3 μM, and the hemolysis rate exceeds 90% at 100 μM. 
BMAP-27 can cause 3.5% hemolysis of human red blood cells at a concentration of 3 μM, and the hemolysis rate is 32.7% at 100 μM. 
Cow red blood cells are 5-10 times less sensitive to BMAP-28 than human red blood cells, with hemolysis rates of 3%, 6%, and 22% at concentrations of 10 μM, 30 μM, and 100 μM, respectively; BMAP-27 shows almost no hemolytic effect on cow red blood cells at 100 μM. 
The hemolytic effect of the truncated analog BMAP-27(1-18) disappears, and the hemolytic effect of BMAP-28(1-18) is greatly reduced. 
The modified analog mBMAP-28 has a hemolysis rate of only 3.3% for human red blood cells at 100 μM, far lower than the 94.1% of the parent peptide BMAP-28.|||BMAP-27 shows lower toxicity, with a hemolysis rate of only 3.5% at 3 uM and 32.7% at 100 uM.|||human RBC: HC50>100 uM (3.5% hemolysis at 3 uM; 32.7% hemolysis at 100 uM), but not hemo.lytic to bovine RBC even at 100 uM. Thus, hemolysis is related to cell sources, indicating the need of protecting the host from lysis."	"Skerlavaj B., Gennaro R., Bagella L., Merluzzi L, Risso A, Zanetti M.1996
 J. Biol. Chem. 1996; 271: 28375-28381. PubMed.||Xia et al., 2024|||J. Biol. Chem. 1996; 271: 28375-28381. PubMed.|||J Biol Chem
. 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375.||Xia et al., 2024|||8910461, 29103679||Refer PubMed ID: 29103679|||J Biol Chem. 1996 Nov 8;271(45):28375-28381.|||8910461, 29103679||Refer PubMed ID: 29103679|||J. Biol. Chem. 1996; 271: 28375-28381. PubMed.||Xia et al., 2024"	27	
FPDB00191	AP00367|||AP00367|||Cathelicidin-5 , Antibacterial peptide BMAP-28 , Myeloid antibacterial peptide 28|||DRAMO02854|||Cathelicidin-5 , Antibacterial peptide BMAP-28 , Myeloid antibacterial peptide 28|||AP00367	GGLRSLGRKILRAWKKYGPIIVPIIRIG	Anti-E. coli ATCC 25922 ML-35 or D21, activity value is MIC = 0.5||Anti-S. typhimurium ATCC 14028, activity value is MIC = 1 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-S. marcescens ATCC 8100, activity value is MIC = 2 uM||Anti-S. aureus ATCC 25923 or Cowan 1 MRSA, activity value is MIC = 1||Anti-S. epidermidis ATCC 12228, activity value is MIC = 1 uM||Anti-B. megaterium Bm11, activity value is MIC = 1 uM||Anti-C. albicans, activity value is MIC = 8 uM||Anti-and C. neoformans, activity value is MIC = 4 uM||Anti-Gram+ & Gram-||Antiviral||Antifungal||candidacidal||Antiparasitic||Anti-MRSA||Hemolytic||Antibiofilm||Anticancer||Anti-E. coli ATCC 25922, activity value is MIC = 2 uM||Anti-E. coli ML35, activity value is MIC = 2 uM||Anti-E. coli D21, activity value is MIC = 0.5 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 2 uM||Anti-S. aureus Cowan 1, activity value is MIC = 1 uM||Anti-S. aureus, activity value is MIC = 4 uM||Anti-B. megaterium Bm11, activity value is MIC = 2 uM||Anti-C. neoformans, activity value is MIC = 4 uM||Anti-E.coli(LOG 2, activity value is MIC = 5.80||Anti-Escherichia coli ATCC 25922, activity value is MIC = 2 uM||Anti-Salmonella typhimurium ATCC 14028, activity value is MIC = 1 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-Serratia marcescens ATCC 8100, activity value is MIC = 2 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 2 uM||Anti-Staphylococcus aureus Cowan 1, activity value is MIC = 1 uM||Anti-Staphylococcus aureus, activity value is MIC = 4 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 1 uM||Anti-Bacillus megaterium Bm11, activity value is MIC = 2 uM||Anti-Cryptococcus neoformans, activity value is MIC = 4 uM	peripheral neutrophils; cattle, Bos taurus|||peripheral neutrophils; cattle, Bos taurus|||Bos taurus [Bovine]|||Bos taurus (Bovine)|||Bos taurus [Bovine]|||peripheral neutrophils; cattle, Bos taurus	Helix	"The hemolytic activity of the two BMAPs was much lower,
when measured on bovine erythrocytes (data not shown). These
cells were 5–10-fold less susceptible than human red blood cells
to BMAP-28 (3, 6, and 22% hemolysis at 10, 30, and 100000 uM
peptide), and virtually unaffected by BMAP-27 even at 100000 uM.
We speculate that the different susceptibility of human and
bovine red blood cells to these molecules may be accounted for
by species-specific differences in the erythrocyte membrane
composition, and may reflect the need to protect the host cells
from undesired cytotoxic effects. We have also noted that the
effects of BMAP-28 on the cell membranes are consistently
higher than BMAP-27, in spite of the structural similarity of
the two molecules, thus suggesting that minor structural dif-ferences
can modulate the activity of these peptides.|||The document explicitly mentions the hemolytic values of two novel antimicrobial peptides (BMAP-27, BMAP-28) and their derivatives (BMAP-27(1–18), BMAP-28(1–18), mBMAP-28) on human red blood cells. The core data are as follows: 
 
1. Hemolytic properties of parent peptides (BMAP-27, BMAP-28).
 
 BMAP-28 (for human red blood cells): 
 At a concentration of 3 μM, the hemolysis rate is 14.5%; 
 At a concentration of 100 μM, the hemolysis rate exceeds 90% (specifically 94.1%). 
 BMAP-27 (against human red blood cells): 
 At a concentration of 3 μM, the hemolysis rate is only 3.5%; 
 At a concentration of 100 μM, the hemolysis rate is 32.7%. 
 Its hemolytic effect on bovine red blood cells is significantly lower than that of human red blood cells: 
 BMAP-28 had hemolytic rates of 3%, 6%, and 22% at concentrations of 10 uM, 30 uM, and 100 uM, respectively; 
 BMAP-27 has almost no hemolytic effect on bovine red blood cells even at a concentration of 100 uM. 
 
2. Hemolytic properties of truncated derivatives (BMAP-27(1–18), BMAP-28(1–18)).
 
The hemolytic effect of truncated peptides (retaining only 18 residues at the N-terminus and removing the hydrophobic tail at the C-terminus) is significantly reduced: 
 
BMAP-27 (1–18): Has almost no hemolytic activity against human red blood cells (Figure 6 shows no significant hemolytic rate; combined with text description of ""hemolytic effect disappears""). 
BMAP-28(1–18): hemolytic rate of human red blood cells is significantly lower than that of parent peptides (the curve in Figure 6 is close to baseline, no specific value, but the text clearly states ""hemolytic effect greatly reduced""). 
 
3. Hemolytic properties of modified derivatives (mBMAP-28).
 
Significant loss of hemolytic activity in mBMAP-28 (replacement of hydrophobic residues at the C-terminal for hydrophilic residues): 
 
At a concentration of 100 μM, the hemolytic rate for human red blood cells is only 3.3%, far lower than the 94.1% of the parent peptide BMAP-28. 
 
Additional notes
 
Hemolysis detection method: Using standard hemolysis experiments, 10% (v/v) red blood cell suspension and peptides of different concentrations were incubated at 37°C for 15 minutes to measure absorbance at 415nm, using complete hemolysis induced by 0.2% Triton X-100 as a 100% control. 
Relationship between hemolysis and antibacterial activity: The hemolytic concentration of parental peptides (≥3 uM) is much higher than that of their antibacterial activity concentration (MIC: 0.25–4 uM); Truncated/modified derivatives retain antibacterial activity while significantly reducing hemolytic activity and improving targeted selectivity.|||The document clearly mentions the hemolytic values of BMAP-27, BMAP-28, and their analogues (truncated or modified forms) on human and bovine red blood cells. The core data are as follows:

I. Hemolytic values for human red blood cells (key indicators)

Measured by standard hemolysis experiments, presented as ""peptide concentration (uM) - hemolysis rate (%)"", the results are the average of multiple independent experiments (S.E. ≤1.8):

1. BMAP-28
3 uM: 14.5%
100 uM: >90% (specifically 94.1%)
2. BMAP-27
3 uM: 3.5%
100 uM: 32.7%
3. Truncated forms: BMAP-27(1–18), BMAP-28(1–18)
BMAP-27(1–18): nearly no hemolytic activity (no specific value given, only mentioned as ""hemolytic effect disappeared"").
BMAP-28(1–18): hemolytic activity significantly reduced (no specific concentration-hemolysis correspondence given, only mentioned as ""declined markedly"").
4. Modified form: mBMAP-28 (hydrophobic residues at C-terminus replaced with hydrophilic residues)
100 uM: only 3.3% hemolysis (much lower than parent BMAP-28's 94.1%).

II. Hemolytic values for bovine red blood cells (species difference comparison)

Bovine red blood cells are significantly less sensitive to BMAPs than human red blood cells:

1. BMAP-28
10 uM: 3%
30 uM: 6%
100 uM: 22%
2. BMAP-27
100 uM: virtually no hemolysis (""virtually unaffected"").

III. Supplementary notes

Hemolysis experiment conditions: 10% (v/v) red blood cell suspension in pH 7.4 PBS, incubated with peptides at 37 °C for 15 minutes, with complete hemolysis induced by 0.2% Triton X-100 as the 100% control.
Trend: The hemolytic activity of peptides is mainly mediated by the hydrophobic domain at the C-terminus—removal (truncated forms) or modification (mBMAP-28) of this region significantly reduces hemolysis, but antibacterial activity (MIC) is largely retained.|||BMAP-28 can cause 14.5% hemolysis of human red blood cells at a concentration of 3 μM, and the hemolysis rate exceeds 90% at 100 μM. 
BMAP-27 can cause 3.5% hemolysis of human red blood cells at a concentration of 3 μM, and the hemolysis rate is 32.7% at 100 μM. 
Cow red blood cells are 5-10 times less sensitive to BMAP-28 than human red blood cells, with hemolysis rates of 3%, 6%, and 22% at concentrations of 10 μM, 30 μM, and 100 μM, respectively; BMAP-27 shows almost no hemolytic effect on cow red blood cells at 100 μM. 
The hemolytic effect of the truncated analog BMAP-27(1-18) disappears, and the hemolytic effect of BMAP-28(1-18) is greatly reduced. 
The modified analog mBMAP-28 has a hemolysis rate of only 3.3% for human red blood cells at 100 μM, far lower than the 94.1% of the parent peptide BMAP-28.|||At 3 uM, the hemolysis rate of BMAP-28 is 14.5%, and it exceeds 90% at 100 uM.|||The document mentions experimental results related to hemolysis, as follows:

- Hemolytic effect of BMAP-28 on human red blood cells: at a concentration of 3 µM, 14.5% of cells were lysed; at 100 µM, more than 90% of cells were lysed.

- Hemolytic effect of BMAP-27 on human red blood cells: at a concentration of 3 µM, 3.5% of cells were lysed; at 100 µM, 32.7% of cells were lysed.

- Hemolytic effect of BMAP-28 on bovine red blood cells: at concentrations of 10 µM, 30 µM, and 100 µM, 3%, 6%, and 22% of cells were lysed, respectively.

- Hemolytic effect of BMAP-27 on bovine red blood cells: even at a concentration of 100 µM, bovine red blood cells were almost unaffected.

- Hemolytic effect of BMAP-28(1-18) on human red blood cells: hemolytic activity was significantly reduced (specific values were not clearly listed).

- Hemolytic effect of BMAP-27(1-18) on human red blood cells: completely lost hemolytic activity.

- Hemolytic effect of mBMAP-28 on human red blood cells: at a concentration of 100 µM, only 3.3% of cells were lysed.|||Human RBC: HC50 < 100 uM (at 100 uM, 90% hemolysis). However, lower hemolysis to bovine RBC BMAP-28 (3, 6, and 22% hemolysis at 10, 30, and 100000 uM peptide)."	"Skerlavaj B., Gennaro R., Bagella L., Merluzzi L, Risso A, Zanetti M.1996
 J. Biol. Chem. 1996; 271: 28375-28381. PubMed.|||J. Biol. Chem. 1996; 271: 28375-28381. PubMed.|||J Biol Chem
. 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375.|||8910461, 29103679||Refer PubMed ID: 29103679|||J Biol Chem. 1996 Nov 8;271(45):28375-28381.|||8910461, 29103679||Refer PubMed ID: 29103679|||J. Biol. Chem. 1996; 271: 28375-28381. PubMed."	28	
FPDB00194	AP00427|||AP00427|||XT-7|||DRAMP02136|||AP00427	GLLGPLLKIAAKVGSNLL	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anticancer||Anti-L. plantarum WCFS1, activity value is MIC = 128 ug/ml||Anti-L. rhamnosus LGG, activity value is MIC = 64 ug/ml||Anti-L. salivarius DSM20554, activity value is MIC = 128 ug/ml||Anti-L. salivarius FortaFit Ls-33, activity value is MIC = 250 ug/ml||Anti-L. casei R0215, activity value is MIC = 64 ug/ml||Anti-L. casei Shirota, activity value is MIC = 64 ug/ml||Anti-L. johnsonii LC-1, activity value is MIC = 128 ug/ml||Anti-L. reuteri ATCC5730, activity value is MIC = 64 ug/ml||Anti-L. acidophilus LA5, activity value is MIC = 64 ug/ml||Anti-S. suis S10, activity value is MIC = 32 ug/ml||Anti-S. aureus DMS20231, activity value is MIC = 16 ug/ml||Anti-S. aureus Sens 8325.4, activity value is MBC = 64 ug/ml||Anti-S. aureus MRSA B33424, activity value is MIC = 8 ug/ml||Anti-S. pseudintermedium E138, activity value is MIC = 8 ug/ml||Anti-S. pseudintermedium E139, activity value is MBC = 32 ug/ml||Anti-S. pseudintermedium E140, activity value is MBC = 16 ug/ml||Anti-S. pseudintermedium S70E2, activity value is MBC = 64 ug/ml||Anti-P. aeruginosa Sens 2 ATCC27853, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa MDR1 B38084, activity value is MIC = 256 ug/ml||Anti-P. aeruginosa MDR2 B31770, activity value is MIC = 32 ug/ml||Anti-E. faecium Sens S1, activity value is MIC = 256 ug/ml||Anti-E. faecium Sens S2, activity value is MIC = 64 ug/ml||Anti-E. faecium VanA R39, activity value is MIC = 8 ug/ml||Anti-E. faecium VanB R44, activity value is MIC = 16 ug/ml||Anti-A. baumannii MDR Bangl 027, activity value is MIC = 256 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 1.7 uM||Anti-S. aureus ATCC25923, activity value is MIC = 4.7 uM||Anti-E. coli ML35p, activity value is MIC = 3 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 25 uM||Anti-S. aureus multiresistant ATCCBAA-44, activity value is MIC = 1.6 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 6.3 uM||Anti-Staphylococcus aureus, activity value is MIC = 5 uM||Anti-Escherichia coli, activity value is MIC = 5 uM||Anti-Candida albicans, activity value is MIC = 40 uM||Anti-Staphylococcus aureus, activity value is MIC = 7 uM||Anti-Staphylococcus epidermidis 1420129, activity value is MIC = 3 uM||Anti-S. saprophyticus 1950556, activity value is MIC = 13 uM||Anti-Escherichia coli 25922, activity value is MIC = 6 uM||Anti-Streptococcus group C 1541035, activity value is MIC = 3 uM||Anti-Shigella sonnei 1840187, activity value is MIC = 35 uM||Anti-Pseudomonas aeruginosa 0380972, activity value is MIC = 60 uM||Anti-Enterobacter cloacae 1441323, activity value is MIC = 35 uM	Diploid clawed frog Silurana tropicalis, (formerly) Xenopus tropicalis , Africa|||Diploid clawed frog Silurana tropicalis, (formerly) Xenopus tropicalis , Africa|||Silurana tropicalis|||Xenopus tropicalis [Western clawed frog]|||Xenopus tropicalis (Western clawed frog) (Silurana tropicalis)|||Diploid clawed frog Silurana tropicalis, (formerly) Xenopus tropicalis , Africa	Helix	"The abilities of the peptides isolated in this study
to inhibit the growth of the Gram-positive bacterium
S. aureus, the Gram-negative bacterium E. coli and
the yeast C. albicans and to lyse human erythrocytes
are compared in Table 1. The ability of a synthetic
replicate of peptide XT-7 to inhibit the growth of a
range of microorganisms from clinical isolates is
shown in Table 2. The MIC values for the free
acid form of XT-7 are 60 WM against E. coli, 130
WM against S. aureus and s 200 WM against C. albi-cans.
The peptide showed no hemolytic activity at
concentrations up to 400 WM. Synthetic des-Lys8-
XT-7 was inactive against S. aureus and E. coli at
concentrations up to 200 WM.|||The hemolytic data explicitly mentioned in the document (with 50% hemolysis concentration (HC₅₀) as the core indicator) are as follows, covering both natural peptides and synthetic analogs:

1. Natural antimicrobial peptides (XT-1 to XT-7)

Hemolytic data are clearly recorded for only three peptides; the remaining peptides were either not tested (ND) or have no recorded hemolytic activity. Details are as follows:

XT-1: HC₅₀ against human red blood cells not detected (ND).
XT-7: HC₅₀ against human red blood cells = 70 μM, the only natural peptide with clearly noted hemolytic activity.
XT-5, XT-6: HC₅₀ against human red blood cells both >150 μM, hemolytic activity is very weak.
XT-2, XT-3, XT-4: No specific hemolytic values mentioned; it is inferred from antimicrobial activity tests that there is no significant hemolytic activity recorded.

2. Synthetic analogs of XT-7

By modifying the structure of XT-7 (reducing cationicity), its hemolytic activity changed significantly:

XT-7 free acid (C-terminal -COOH replaced with -CONH₂): Even at concentrations up to 400 μM, no hemolytic activity was observed against human red blood cells.
des-Lys⁸-XT-7 (lacking Lys⁸ residue): Specific HC₅₀ not mentioned, but since antimicrobial activity is completely lost (no activity against Staphylococcus aureus or E. coli at concentrations >200 μM), it is inferred that its hemolytic activity is also very low or absent.

Note: All hemolytic experiments were conducted on human red blood cells, with HC₅₀ calculated by comparing to 100% hemolysis induced by 1% Tween 20 under incubation at 37 °C for 1 hour.|||Among the seven antimicrobial peptides secreted by the skin (XT-1 to XT-7), some peptides exhibit hemolytic activity against human erythrocytes. Their hemolytic values (HC₅₀, the peptide concentration causing 50% hemolysis) are as follows:

- XT-1: 90 µM
- XT-7: 70 µM
- XT-2, XT-4, XT-5, XT-6: No hemolytic activity was observed at the tested concentrations (up to 150 µM or 400 µM), marked as "">153"" or not determined (ND).|||Rat RBCs [HC50 = 110 uM]|||In Biochimica et Biophysica Acta 2001, among the antimicrobial peptides isolated from the skin secretions of the tropical clawed frog (Xenopus tropicalis), XT-1 had an HC₅₀ of 90 μM against human red blood cells, XT-7 had an HC₅₀ of 70 μM against human red blood cells, the hemolytic activity of XT-2 was not measured, and XT-4, XT-5, and XT-6 all had an HC₅₀ greater than 150 μM against human red blood cells.|||HC₅₀=70"	"ALI MF., SOTO A., KNOOP FC., CONLON JM.2001
 Biochim Biophys Acta 2001 Nov 26;1550(1):81-9. PubMed.|||Biochim Biophys Acta 2001 Nov 26;1550(1):81-9. PubMed.|||Biochim Biophys Acta
. 2001 Nov 26;1550(1):81-9. doi: 10.1016/s0167-4838(01)00272-2.|||31102497|||33932712, 23094651, 11738090||Refer PubMed ID 23094651|||Biochim Biophys Acta. 2001 Nov 26;1550(1):81-89.|||Biochim Biophys Acta 2001 Nov 26;1550(1):81-9. PubMed."	18	
FPDB00198	AP00513|||AP00513|||Ranalexin|||DRAMP01355|||Ranalexin|||AP00513|||DRAMP01355	FLGGLIKIVPAMICAVTKKC	Anti-active as the WT against S. aureus or MRSA, activity value is MIC = 4 ug/ml||Anti-P.aeruginosa, activity value is MIC = 128 ug/ml||Anti-E. coli, activity value is MIC = 32 ug/ml||Anti-Gram+ & Gram-||Antifungal||Antiparasitic||Anti-MRSA||Synergistic AMPs||Anticancer||Antibacterial ; Rana catesbeiana||Anti-S.aureus, activity value is MIC = 4 ug/ml||Anti-E.coli, activity value is MIC = 32 ug/ml||Anti-Bacillus megaterium DSM 32, activity value is MIC = 1.9 uM||Anti-B. subtilis DSM 10, activity value is MIC = 1.9 uM||Anti-Clostridium pasterianum DSM 525, activity value is MIC = 7.6 uM||Anti-Corynebacterium spheniscorum DSM 44757, activity value is MIC = 7.6 uM||Anti-Enterococcus casseliflavus ATCC 700327 VanC 1, activity value is MIC = 3.8 uM||Anti-E. faecalis ATCC 29212, activity value is MIC = 7.6 uM||Anti-E. faecium UL4070742 VanA 3, activity value is MIC = 7.6 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 3.8 uM||Anti-S. aureus NCTC 10442 MRSA 4, activity value is MIC = 3.8 uM||Anti-S. epidermidis ATCC 14990, activity value is MIC = 7.6 uM||Anti-S. saprophyticus ATCC 15305, activity value is MIC = 3.8 uM||Anti-Acinetobacter baumannii SC3033362 4-MRGN 5, activity value is MIC = 1.9 uM||Anti-A. baumannii SC3223332 4-MRGN 5, activity value is MIC = 3.8||Anti-A. baumannii SC4111902 4-MRGN 5, activity value is MIC = 1.9 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 15.2 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 30.4 uM||Anti-Staphylococcus aureus, activity value is MIC = 4 ug/ml||Anti-Escherichia coli, activity value is MIC = 32 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 128 ug/ml	Bull frog, Rana catesbeiana, North America|||Bull frog, Rana catesbeiana, North America|||Rana catesbeiana|||Rana catesbeiana [American bullfrog]|||Rana sakuraii (Japanese brown frog)|||Lithobates catesbeiana (American bullfrog) (Rana catesbeiana)|||Bull frog, Rana catesbeiana, North America|||Lithobates catesbeiana (American bullfrog) (Rana catesbeiana)	Helix	"The document does not provide the half-hemolytic concentration (HC₅₀) of each peptide directly, but hemolytic activity is reflected through the percentage of hemolysis. The core data are as follows:

1. Hybrid Peptides (RN7-IN series)

RN7-IN10: At a concentration of 15.62 µg/ml, the hemolysis rate is 5.9%; no hemolytic activity is observed at its minimum inhibitory concentration (MIC = 7.81–15.62 µg/ml).
RN7-IN9, RN7-IN8, RN7-IN6: At a concentration of 15.62 µg/ml, the hemolysis rate is 0.0%; no hemolytic activity is observed at each respective MIC.
RN7-IN7: No hemolytic toxicity observed even at the highest tested concentration of 250 µg/ml (hemolysis rate 0.0%).

2. Indolicidin Analogs (IN series)

IN1: At a concentration of 250 µg/ml, the hemolysis rate is 3.6%; no hemolytic activity at its MIC (31.25–62.5 µg/ml).
IN2: At 250 µg/ml, hemolysis rate is 15.39%; no hemolytic activity at its MIC.
IN3: At 250 µg/ml, hemolysis rate is 2.39%; no hemolytic activity at its MIC (62.5 µg/ml).
IN4: Specific hemolysis data are not mentioned, but the document notes weak activity against Streptococcus pneumoniae (MIC = 250 µg/ml), suggesting low hemolysis risk at effective concentrations.

3. Parent Peptides

Indolicidin: At 20 µg/ml, hemolysis rate reaches 56.98%, showing the strongest hemolytic toxicity among all peptides.
Ranalexin: At 250 µg/ml, hemolysis rate is <15%, with hemolytic toxicity lower than Indolicidin.

The above data were measured by human red blood cell hemolysis experiments: a 4% human red blood cell suspension was incubated with peptides at 1.95–250 µg/ml at 37 °C for 1 hour, with PBS as a negative control (0% hemolysis) and 0.1% Triton X-100 as a positive control (100% hemolysis). Hemolysis rates were calculated based on absorbance at 560 nm. All peptides showed no cytotoxicity or hemolytic effects at their MIC values, and only some peptides exhibited slight hemolysis at concentrations far above their MICs.|||In hemolysis experiments targeting the antimicrobial peptide Ranalexin in the skin of the American bullfrog (Rana catesbeiana), Ranalexin can cause hemolysis of human red blood cells at concentrations up to 500 ug/ml, indicating that it has a certain degree of hemolytic activity, but the specific hemolysis rate or HC₅₀ value is not clearly stated in the document.|||S.aureus ( MIC = 4 ug/ml), E.coli ( MIC = 32 ug/ml), P.aeruginosa ( MIC = 128 ug/ml)|||In the study of antimicrobial peptides from the skin of Brazilian frog Phyllomedusa distincta), the hemolysis of Dermadistinctins series of peptides is different. DD L starts to show hemolytic activity at a concentration of 12.5 uM, while the remaining peptides (DD K, M, Q1, Q2) need to be more than 32 uM to produce hemolysis, of which the hemolysis rate of DD K, Q1, Q2 is still not significantly increased above 32 uM, showing low hemolysis"	"Clark DP, Durell S, Maloy WL, Zasloff M1994
 J Biol Chem 1994; 269: 10849-10855. (Clark et al., 1994)|||J Biol Chem 1994; 269: 10849-10855. (Clark et al., 1994)|||J Biol Chem
. 1994 Apr 8;269(14):10849-55.|||https://pubmed.ncbi.nlm.nih.gov/8144672|||31426494|||J Biol Chem. 2001 Jan 26;276(4):2701-2707.|||8144672|||J Biol Chem 1994; 269: 10849-10855. (Clark et al., 1994)"	20	
FPDB00203	AP05186	FLKGLMGVIASLFK	Anti-Gram+ S. aureus NCTC 13277 MRSA, activity value is MIC = 6.25 uM||Anti-B. subtilis ATCC 23857, activity value is MIC = 1.56 uM||Anti-S. typhi ATCC 14028, activity value is MIC = 50 uM||Anti-E. coli ATCC 25922, activity value is MIC = 25 uM||Anti-P. aeruginosa ATCC 10145, activity value is MIC = 50 uM||Anti-and fungi C. albicans ATCC 36082, activity value is MIC = 15.6 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anticancer	sequence extension, designed, man-made sequences	Helix	a hemolysis HC50 value of 90 uM|||NST-2(1): 90.0 uMRNST-2(2): 13.8 uMRSP-1(3): 51.0 uMRLFP-1(4): 98.9 uMRLFP-2(5): 25.0 uMRLFP-3(6): 6.6 uMRSP-4(7): >100 uMRLFP-4(8): 4.5 uM|||human RBC: HC50 51 uM. Hemolytic.	Abdullah SJ, Guan JS, Mu Y, Bhattacharjya S.2024 Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed|||2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213.|||Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed|||Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed	14	
FPDB00204	AP05185	FLKKLMGVIASLF	Anti-Gram+ S. aureus NCTC 13277 MRSA, activity value is MIC = 50 uM||Anti-B. subtilis ATCC 23857, activity value is MIC = 12.5 uM||Anti-S. typhi ATCC 14028, activity value is MIC = 100 uM||Anti-E. coli ATCC 25922, activity value is MIC = 50 uM||Anti-P.aeruginosa ATCC 10145, activity value is MIC = 200 uM||Anti-and fungi C. albicans ATCC 36082, activity value is MIC = 100 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anticancer	amino acid substitution, designed, man-made sequences	Helix	a hemolysis HC50 value of 90 uM|||NST-2(1): 90.0 uMRNST-2(2): 13.8 uMRSP-1(3): 51.0 uMRLFP-1(4): 98.9 uMRLFP-2(5): 25.0 uMRLFP-3(6): 6.6 uMRSP-4(7): >100 uMRLFP-4(8): 4.5 uM|||human RBC: HC50 >100 uM (not hemo.lytic at 100 uM).	Abdullah SJ, Guan JS, Mu Y, Bhattacharjya S.2024 Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed|||2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213.|||Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed|||Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed	13	
FPDB00205	AP05184	" 
FLKGLMGVIASLF"	Anti-Gram+ S. aureus NCTC 13277 MRSA, activity value is MIC = 3.12 uM||Anti-B. subtilis ATCC 23857, activity value is MIC = 1.56 uM||Anti-S. typhi ATCC 14028, activity value is MIC = 50 uM||Anti-E. coli ATCC 25922, activity value is MIC = 50 uM||Anti-P.aeruginosa ATCC 10145, activity value is MIC = 200 uM||Anti-and fungi C. albicans ATCC 36082, activity value is MIC = 15.6 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anticancer	sequence reversal, designed, man-made sequences|||Source: sequence reversal, designed, man-made sequences	Helix	a hemolysis HC50 value of 90 uM|||NST-2(1): 90.0 uMRNST-2(2): 13.8 uMRSP-1(3): 51.0 uMRLFP-1(4): 98.9 uMRLFP-2(5): 25.0 uMRLFP-3(6): 6.6 uMRSP-4(7): >100 uMRLFP-4(8): 4.5 uM|||human RBC: HC50 13.8 uM; hemolytic.	Abdullah SJ, Guan JS, Mu Y, Bhattacharjya S.2024 Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed|||2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213.|||Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed|||Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed	13	
FPDB00206	AP05183	" 
FLSAIVGMLGKLF"	Anti-Gram+ S. aureus NCTC 13277 MRSA, activity value is MIC = 14.34 uM||Anti-B. subtilis ATCC 23857, activity value is MIC = 6.25 uM||Anti-S.typhi ATCC 14028, activity value is MIC = 250 uM||Anti-E.coli ATCC 25922, activity value is MIC = 125 uM||Anti-P.aeruginosa ATCC 10145, activity value is MIC > 250 uM||Anti-and fungi C. albicans ATCC 36082, activity value is MIC = 20 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anticancer	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	a hemolysis HC50 value of 90 uM|||NST-2(1): 90.0 uMRNST-2(2): 13.8 uMRSP-1(3): 51.0 uMRLFP-1(4): 98.9 uMRLFP-2(5): 25.0 uMRLFP-3(6): 6.6 uMRSP-4(7): >100 uMRLFP-4(8): 4.5 uM|||human RBC: HC50 90 uM.	Nazir S, Khan AI, Maharjan R, Khan SN, Akram MA, Maresca M, Khan FA, Shaheen F. 2024 Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed|||2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213.|||Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed|||Antibiotics (Basel). 2024 Dec 13;13(12):1213. doi: 10.3390/antibiotics13121213. PubMed	13	
FPDB00207	AP05069	" 
GRMQEFIKKLKAYLRKMKEKFSQIS"	Anti-Gram- S. typhimurium CGMCC 1.1174, activity value is MIC = 2.5 uM||Anti-E. coli CCTCC AB 2018675, activity value is MIC = 5 uM||Anti-S. dysenteriae CGMCC 1.1869, activity value is MIC = 2.5 uM||Anti-P. aeruginosa CGMCC 1.596, activity value is MIC = 5||Anti-K. pneumoniae, activity value is MIC = 10 uM||Anti-A. baumannii, activity value is MIC = 5||Anti-S. aureus CMCC 26003 or MRSA ATCC 43300, activity value is MIC = 5 uM||Anti-and E. faecium, activity value is MIC = 2.5 uM||Anti-Gram+ & Gram-||Anti-MRSA||Synergistic AMPs||Antibiofilm||Anticancer	venom, the wolf spider, Lycosa coelestis|||venom, the wolf spider, Lycosa coelestis, Asia|||venom, the wolf spider, Lycosa coelestis, Asia	Helix	"6.15% hemolysis|||LC-AMP-I1: At a maximum concentration of 320 µM, the hemolysis rate is 10.13%. Melittin: At 5 µM, the hemolysis rate is close to 100%.|||The document explicitly provides the core hemolytic data of the antimicrobial peptide LC-AMP-I1, using rabbit red blood cells as the test subject. The specific hemolysis rates were determined through hemolysis assays, with the key information as follows:

1. Core Hemolytic Data of LC-AMP-I1

- Hemolysis rate: At the highest tested concentration of 320 μM (corresponding to a mass concentration of 987.75 μg/ml), the hemolysis rate of LC-AMP-I1 was only 10.13%, far lower than the hemolytic activity of the positive control melittin (honey bee venom peptide), for which the hemolysis rate is nearly 100% at 5 μM.
- Concentration dependence: In the experiment, the concentration gradient of LC-AMP-I1 was 5–320 μM. Low hemolytic activity was observed only at the highest concentration, while within its effective antimicrobial concentration range (2.5–10 μM, corresponding to MIC values against multidrug-resistant bacteria), the hemolysis rate was even lower, demonstrating excellent safety.

2. Experimental Method Details

1. Red blood cell preparation: Rabbit red blood cells were washed three times with PBS and resuspended to a 1% red blood cell solution.
2. Hemolysis reaction: Red blood cells were mixed with LC-AMP-I1 at various concentrations (5–320 μM) and incubated at 37 °C for 1 hour. The mixture was then centrifuged at 930 × g for 5 minutes, and the absorbance of the supernatant at 570 nm was measured to reflect the amount of hemoglobin released.
3. Control setup: 0.1% Triton X-100 (100% hemolysis) and PBS (0% hemolysis) were used as controls. The hemolysis rate was calculated according to the formula:

  Hemolysis rate (%) = [(A_sample - A_PBS) / (A_Triton X-100 - A_PBS)] × 100%

3. Key Conclusions

LC-AMP-I1 exhibits extremely low hemolytic activity. Even at 320 μM, which far exceeds its effective antimicrobial concentration range (2.5–10 μM), the hemolysis rate is only 10.13%. It shows negligible toxicity to normal mammalian cells (such as LO2 liver cells and HEK293T kidney cells, with high cell viability) and presents some selective toxicity toward tumor cells (such as 4T1 breast cancer cells). This characteristic provides a strong safety foundation for in vivo applications (e.g., no toxic reactions observed in a neutropenic mouse thigh infection model at a dose of 20,000 μg/kg), making LC-AMP-I1 a promising candidate as an alternative to conventional antibiotics."	Wang J, Liu X, Song Y, Liu Z, Tang X, Tan H. 2024 Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0042424. doi: 10.1128/aac.00424-24. PubMed|||2025 Jan 31;69(1):e0042424. doi: 10.1128/aac.00424-24. Epub 2024 Dec 2.|||Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0042424. doi: 10.1128/aac.00424-24. PubMed	25	
FPDB00212	AP04839|||DRAMP32284	ALWKDMLKGIGKLAGKAALGAVKTLV	Anti-S. aureus NCTC 10788or MRSA NCTC 12493, activity value is MIC = 2 uM||Anti-E. faecalis NCTC 1269, activity value is MIC = 4 uM||Anti-E. coli NCTC 10418, activity value is MIC = 2 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 2 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 1 uM||Anti-MCF-7, activity value is IC50 = 2.92 uM||Anti-PC-3, activity value is IC50 = 4.15 uM||Anti-and U251 MG cells, activity value is IC50 = 2.47 uM||Antimicrobial||Anticancer	Phyllomedusa palliata, South America|||Phyllomedusa palliata Skin Secretions|||Phyllomedusa palliata Skin Secretions	Helix	Hemolysis concentration for 50% (HC₅₀): 38.77 uM Hemolysis rate at 16 uM concentration: <20%|||horse RBC: HC50 38.77 uM. Induced a very low degree of LDH release in normal HMEC-1 cells (<10%).|||Horse erythrocytes: Dermaseptin-PP exhibited only a moderate hemolytic effect (<20% at 16 uM with a calculated HC50 of 38.77 uM)|||horse RBC: HC50 38.77 uM.	Dong Z, Hu H, Yu X, Tan L, Ma C, Xi X, Li L, Wang L, Zhou M, Chen T, Du S, Lu Y.2020Front Chem. 2020 Jun 5;8:476. doi: 10.3389/fchem.2020.00476. PubMed|||2020 Jun 5:8:476. doi: 10.3389/fchem.2020.00476. eCollection 2020.|||Front Chem. 2020 Jun 5;8:476. doi: 10.3389/fchem.2020.00476. PubMed|||J Biol Chem. 2020 Aug 7;295(32):10911-10925.|||Front Chem. 2020 Jun 5;8:476.|||Front Chem. 2020 Jun 5;8:476. doi: 10.3389/fchem.2020.00476. PubMed	26	
FPDB00214	AP04831	FFPIVAGVAAKVLKKIFCTISKKC	Anti-493, activity value is MIC = 2 uM||Anti-697, activity value is MIC = 4 uM||Anti-E. coli ATCC 8739, activity value is MIC = 4 uM||Anti-816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC CRM 9027, activity value is MIC = 8 uM||Anti-A. baumannii BAA 747, activity value is MIC = 8 uM||Anti-231, activity value is MIC > 128 uM	skin secretions, the northern leopard frog, Rana pipiens, North America|||skin secretions, the northern leopard frog, Rana pipiens, North America	Helix	HC₁₀ values: Brevinin-1pl: 8.28 uM [Lys⁴] brevinin-1pl: 13.68 uM [Lys⁴, Ala¹³] brevinin-1pl: 4.59 uM [Lys⁴, Ala¹⁶] brevinin-1pl: 2.51 uM [Lys⁴, Ala¹³,¹⁶] brevinin-1pl: 22 uM des-Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM des-Leu¹³,Ala¹⁶-[Lys⁴] HC₃₀ values: Brevinin-1pl: 37.64 uM [Lys⁴] brevinin-1pl: 80.77 uM [Lys⁴, Ala¹³] brevinin-1pl: 41.34 uM [Lys⁴, Ala¹⁶] brevinin-1pl: 84.86 uM [Lys⁴, Ala¹³,¹⁶] brevinin-1pl: >128 uM des-Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM des-Leu¹³,Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM|||horse RBC: HC50 37.64 uM, hemolytic. Less toxic to HaCaT skin cells (IC50 62.71 uM). Also showed effects on both H838 (IC50 6.88 uM) and MCF-7 (IC50 7.6 uM) cancer cell lines.	Wang J, Hu J, Pu W, Chen X, Ma C, Jiang Y, Wang T, Chen T, Shaw C, Zhou M, Wang L. 2024 Comput Struct Biotechnol J. 2024 Sep 19;23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. PubMed|||2024 Sep 19:23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. eCollection 2024 Dec.|||Comput Struct Biotechnol J. 2024 Sep 19;23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. PubMed	24	
FPDB00215	AP04819	" 
FLSLIPKAIKAVKALAKKL"	Anti-Gram+ S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 2 uM||Anti-E. coli ATCC 8739, activity value is MIC = 2 uM||Anti-A. baumannii BAA 747, activity value is MIC = 2 uM||Anti-K. pneumonia ATCC 43816, activity value is MIC = 2 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 16 uM||Anti-and fungi C. albicans, activity value is MIC = 32 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||anti-sepsis||Hemolytic||Antibiofilm||Anticancer	amino acid substitution, amphibian peptide analog, animal-derived, natural derivative	Helix	PSTO2: 21.787K: 21.9718K: 20.59SR: 12.60SR2: 6.53SRD7: 74.78SR2D10: 75.24D1/D2: No obvious hemolysis (>512 uM)|||In vitro toxicity: horse RBC: HC50 32 uM. It showed toxicity to both cancer and non-cancer cells.|||w90c6t7w1sexseowqbf1|||horse RBC: HC50 32 uM. It showed toxicity to both cancer and non-cancer cells.	Yin W, Yao J, Leng X, Ma C, Chen X, Jiang Y, Wang T, Chen T, Shaw C, Zhou M, et al. 2024 Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI|||https://doi.org/10.3390/pharmaceutics16081098|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI	19	
FPDB00216	AP04818|||AP04818|||AP04819	" 
FLSLIPKAIKAVSALAKKL"	Anti-Gram+ S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 2 uM||Anti-E. coli ATCC 8739, activity value is MIC = 2 uM||Anti-A. baumannii BAA 747, activity value is MIC = 4 uM||Anti-K. pneumonia ATCC 43816, activity value is MIC = 2 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 16 uM||Anti-and fungi C. albicans, activity value is MIC = 32 uM||Anti-A. baumannii BAA 747, activity value is MIC = 2 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||anti-sepsis||Hemolytic||Antibiofilm||Anticancer	amino acid substitution, amphibian peptide analog, animal-derived, natural derivative	Helix	PSTO2: 21.787K: 21.9718K: 20.59SR: 12.60SR2: 6.53SRD7: 74.78SR2D10: 75.24D1/D2: No obvious hemolysis (>512 uM)|||horse RBC: HC50 64 uM. It showed toxicity to both cancer and non-cancer cells.|||w90c6t7w1sexseowqbf1	Yin W, Yao J, Leng X, Ma C, Chen X, Jiang Y, Wang T, Chen T, Shaw C, Zhou M, et al. 2024 Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI|||https://doi.org/10.3390/pharmaceutics16081098|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098.|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI	19	
FPDB00217	AP04815	" 
FLSLIPHAISAVSALAKHL"	Anti-Gram+ S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 2||Anti-E. coli ATCC 8739, activity value is MIC = 16 uM||Anti-A.baumannii BAA 747, activity value is MIC > 128 uM||Anti-K. pneumonia ATCC 43816, activity value is MIC = 64 uM||Anti-P.aeruginosa ATCC 9027, activity value is MIC > 128 uM||Anti-and fungi C. albicans, activity value is MIC = 32 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||anti-sepsis||Hemolytic||Antibiofilm||Anticancer	the skin secretion, Super Tiger Leg Monkey Tree Frog, Phyllomedusa tomopterna, Central America, South America|||the skin secretion, Super Tiger Leg Monkey Tree Frog, Phyllomedusa tomopterna, Central America, South America	Helix	PSTO2: 21.787K: 21.9718K: 20.59SR: 12.60SR2: 6.53SRD7: 74.78SR2D10: 75.24D1/D2: No obvious hemolysis (>512 uM)|||horse RBC: HC50 64 uM.|||w90c6t7w1sexseowqbf1	Yin W, Yao J, Leng X, Ma C, Chen X, Jiang Y, Wang T, Chen T, Shaw C, Zhou M, et al. 2024 Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI|||https://doi.org/10.3390/pharmaceutics16081098|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI	19	
FPDB00221	AP04623	" 
ALWKTLLKHVGKAAGKAALNAVTDMVNQ"	Anti-S. aureus ATCC 12600 MRSA ATCC BAA-1720, activity value is MIC = 4||Anti-E. faecalis ATCC 29212, activity value is MIC = 32 uM||Anti-E. coli ATCC 11755, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 16 uM||Anti-and C. albicans ATCC 10231, activity value is MIC = 4 uM	skin secretion, Painted-belly leaf frog, Phyllomedusa sauvagii, South America|||skin secretion, Painted-belly leaf frog, Phyllomedusa sauvagii, South America	Helix	Der-PS4 exhibited approximately 50% hemolytic activity at a concentration of about 128 μM. At the minimum inhibitory concentrations (MICs), Der-PS4 showed slight hemolytic activity.|||horse RBC: HC50 ~128 uM. It started to show hemolysis at 16 uM.	Chen D, Zhou X, Chen X, Huang L, Xi X, Ma C, Zhou M, Wang L, Chen T.2019 Molecules. 2019 Aug 16;24(16):2974. doi: 10.3390/molecules24162974. PubMed|||2019 Aug 16;24(16):2974. doi: 10.3390/molecules24162974.|||Molecules. 2019 Aug 16;24(16):2974. doi: 10.3390/molecules24162974. PubMed|||Molecules. 2019 Aug 16;24(16):2974. doi: 10.3390/molecules24162974. PubMed	28	
FPDB00225	AP04191	FLGLIPALAGAIGNLIK	Anti-weakly active against E. coli DSM 787, activity value is MIC = 100 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 100 ug/ml||Anti-S-epidermidis DSM 28319, activity value is MIC > 100 ug/ml||Anti-P-aeruginosa DSM 50071, activity value is MIC > 100 ug/ml||Anti-K-pneumoniae ATCC BAA 1705, activity value is MIC > 100 ug/ml||Anti-A. baumannii DSM 30008, activity value is MIC = 100 ug/ml||Anti-E. faecalis MF 06036, activity value is MIC = 100 ug/ml||Anti-E. faecium NCTC 12201, activity value is MIC = 50 ug/ml||Anti-C. difficile R20291 or 630 BAA1382, activity value is MIC = 25||Anti-Gram+ & Gram-||Anti-MRSA||anti-diabetes||Anticancer	skin secretions, the banana tree dwelling frog, Boana platanera (Hylidae; Hylinae), Trinidad, South America|||skin secretions, the banana tree dwelling frog, Boana platanera (Hylidae; Hylinae), Trinidad, South America	N/A	concentration of peptide producing 50% hemolysis	Conlon JM, Sridhar A, Khan D, Cunning TS, Delaney JJ, Taggart MG, Ternan NG, Leprince J, Coquet L, Jouenne T, Attoub S, Mechkarska M. 2024 Biochimie. 2024 Mar 30:S0300-9084(24)00070-1. doi: 10.1016/j.biochi.2024.03.012. PubMed|||2024 Aug:223:23-30. doi: 10.1016/j.biochi.2024.03.012. Epub 2024 Mar 30.|||Biochimie. 2024 Mar 30:S0300-9084(24)00070-1. doi: 10.1016/j.biochi.2024.03.012. PubMed	17	
FPDB00226	AP04190	FLGTVLKLGKAIAKTVVPMLTNAMQPKQ	Anti-E. coli DSM 787, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 6.25 ug/ml||Anti-S. epidermidis DSM 28319, activity value is MIC = 12.5 ug/ml||Anti-P. aeruginosa DSM 50071, activity value is MIC = 100 ug/ml||Anti-K. pneumoniae ATCC BAA 1705, activity value is MIC = 25 ug/ml||Anti-A. baumannii DSM 30008, activity value is MIC = 6.25 ug/ml||Anti-E. faecalis MF 06036, activity value is MIC = 50 ug/ml||Anti-E. faecium NCTC 12201, activity value is MIC = 6.25 ug/ml||Anti-C. difficile R20291 or 630 BAA1382, activity value is MIC = 6.25 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA||Anticancer	skin secretions, the banana tree dwelling frog, Boana platanera (Hylidae; Hylinae), Trinidad, South America|||skin secretions, the banana tree dwelling frog, Boana platanera (Hylidae; Hylinae), Trinidad, South America	Helix	concentration of peptide producing 50% hemolysis	Conlon JM, Sridhar A, Khan D, Cunning TS, Delaney JJ, Taggart MG, Ternan NG, Leprince J, Coquet L, Jouenne T, Attoub S, Mechkarska M. 2024 Biochimie. 2024 Mar 30:S0300-9084(24)00070-1. doi: 10.1016/j.biochi.2024.03.012. PubMed|||2024 Aug:223:23-30. doi: 10.1016/j.biochi.2024.03.012. Epub 2024 Mar 30.|||Biochimie. 2024 Mar 30:S0300-9084(24)00070-1. doi: 10.1016/j.biochi.2024.03.012. PubMed	28	
FPDB00227	AP04189	GVFDTVKKIGKAVGKFALGVAKNYLNS	Anti-E. coli DSM 787, activity value is MIC = 3.13 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 25 ug/ml||Anti-S. epidermidis DSM 28319, activity value is MIC = 6.25 ug/ml||Anti-P. aeruginosa DSM 50071, activity value is MIC = 50 ug/ml||Anti-K. pneumoniae ATCC BAA 1705, activity value is MIC = 3.13 ug/ml||Anti-A. baumannii DSM 30008, activity value is MIC = 3.13 ug/ml||Anti-E. faecalis MF 06036, activity value is MIC = 25 ug/ml||Anti-E. faecium NCTC 12201, activity value is MIC = 3.13 ug/ml||Anti-C. difficile R20291 or 630 BAA1382, activity value is MIC = 3.13 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA||anti-diabetes||Anticancer	skin secretions, the banana tree dwelling frog, Boana platanera (Hylidae; Hylinae), Trinidad, South America|||skin secretions, the banana tree dwelling frog, Boana platanera (Hylidae; Hylinae), Trinidad, South America	N/A	concentration of peptide producing 50% hemolysis	Conlon JM, Sridhar A, Khan D, Cunning TS, Delaney JJ, Taggart MG, Ternan NG, Leprince J, Coquet L, Jouenne T, Attoub S, Mechkarska M. 2024 Biochimie. 2024 Mar 30:S0300-9084(24)00070-1. doi: 10.1016/j.biochi.2024.03.012. PubMed|||2024 Aug:223:23-30. doi: 10.1016/j.biochi.2024.03.012. Epub 2024 Mar 30.|||Biochimie. 2024 Mar 30:S0300-9084(24)00070-1. doi: 10.1016/j.biochi.2024.03.012. PubMed	27	
FPDB00228	AP04053	GFMKTWKNVWKNVAATLLKLLK	Anti-S. aureus NCTC 10788 or MRSA, activity value is MIC = 4 uM||Anti-E. coli ATCC 8739, activity value is MIC = 8 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 16 uM||Anti-E. faecium NTCC 12697, activity value is MIC = 8 uM||Anti-and P. aeruginosa ATCC 9027, activity value is MIC = 32 uM||Anti-Gram+ & Gram-||Anti-MRSA||Antibiofilm||Anticancer	sequence truncation, Amino acid substitution, animal-derived, natural derivative	Helix	"R2AW: approximately 20% hemolytic activity, highest tested concentration 256 µM [Ser²³,²⁹] R2AW: approximately 10% hemolytic activity. R2AW(1-22): no hemolytic activity observed. R2AW(1-22)-NH₂: approximately 10% hemolytic activity [Lys⁴,¹⁹,Leu²⁰] R2AW(1-22)-NH₂: no hemolytic activity observed, highest tested concentration 16 µM [Trp⁶,¹⁰] R2AW(1-22)-NH₂: approximately 20% hemolytic activity, highest tested concentration 2 µM.|||horse RBC: low hemolytic (HC50 8 uM).|||The hemolytic data of R2AW and its derivatives against horse red blood cells provided in the document are presented as hemolysis rates (%) at different concentrations, with the specific results as follows:

1. Hemolytic characteristics of each peptide (based on 2% horse red blood cell suspension, incubated at 37 °C for 2 hours)

Peptide Name | Key Hemolytic Properties (Concentration Range: 1~256 µM)
--- | ---
Parent Peptide R2AW | At the highest concentration of 256 µM, the hemolysis rate is about 20%
[Ser²³,²⁹]R2AW | At the highest concentration of 256 µM, the hemolysis rate is about 10%, lower than the parent peptide
R2AW(1-22) | No hemolysis observed across the entire concentration range (1~256 µM) (due to removal of the Rana box and lack of amidation)
R2AW(1-22)-NH₂ | At the highest concentration of 256 µM, the hemolysis rate is about 10%, similar to [Ser²³,²⁹]R2AW
[Lys⁴,¹⁹, Leu²⁰]R2AW(1-22)-NH₂ | No hemolysis observed at its maximum minimum bactericidal concentration (MBC=16 µM), optimal safety
[Trp⁶,¹⁰]R2AW(1-22)-NH₂ | Hemolysis of about 20% occurs even at a low concentration (2 µM), and hemolysis increases further at high concentrations, exhibiting the highest toxicity

2. Additional Notes

Control settings: the 0.1% Triton X-100 treatment group served as the 100% hemolysis positive control, and the PBS treatment group as the 0% hemolysis negative control. Hemolysis rate was calculated using the formula:
Hemolysis Rate = (Absorbance of experimental group - Absorbance of negative control) / (Absorbance of positive control - Absorbance of negative control) × 100%.

Key conclusions:
- Removal of the Rana box (R2AW(1-22)) or substituting cysteine with serine ([Ser²³,²⁹]R2AW) can reduce hemolysis.
- The derivative with increased cationicity and hydrophobicity, [Lys⁴,¹⁹, Leu²⁰]R2AW(1-22)-NH₂, shows no hemolysis at effective antibacterial concentrations, combining high activity with low toxicity.
- Tryptophan substitution ([Trp⁶,¹⁰]R2AW(1-22)-NH₂) enhances anticancer activity but significantly increases hemolysis due to excessive hydrophobicity, limiting clinical application."	Yao A, Liu T, Cai Y, Zhou S, Chen X, Zhou M, Ma C, Chen T, Shaw C, Wang L2023 Antibiotics (Basel). 2023 Dec 19;13(1):5. doi: 10.3390/antibiotics13010005. PubMed|||2023 Dec 19;13(1):5. doi: 10.3390/antibiotics13010005.|||Antibiotics (Basel). 2023 Dec 19;13(1):5. doi: 10.3390/antibiotics13010005. PubMed	22	
FPDB00229	AP04052	GFMKTAKNVAKNVAATLLKLLK	Anti-S. aureus NCTC 10788 or MRSA, activity value is MIC = 2 uM||Anti-E. coli ATCC 8739, activity value is MIC = 2 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 4 uM||Anti-E. faecium NTCC 12697, activity value is MIC = 4 uM||Anti-and P. aeruginosa ATCC 9027, activity value is MIC = 8 uM||Anti-Gram+ & Gram-||Anti-MRSA||Antibiofilm||Anticancer	sequence truncation, Amino acid substitution, animal-derived, natural derivative	Helix	"R2AW: approximately 20% hemolytic activity, highest tested concentration 256 µM [Ser²³,²⁹] R2AW: approximately 10% hemolytic activity. R2AW(1-22): no hemolytic activity observed. R2AW(1-22)-NH₂: approximately 10% hemolytic activity [Lys⁴,¹⁹,Leu²⁰] R2AW(1-22)-NH₂: no hemolytic activity observed, highest tested concentration 16 µM [Trp⁶,¹⁰] R2AW(1-22)-NH₂: approximately 20% hemolytic activity, highest tested concentration 2 µM.|||horse RBC: low hemo.lytic (HC50> 128 uM).|||The hemolytic data of R2AW and its derivatives against horse red blood cells provided in the document are presented as hemolysis rates (%) at different concentrations, with the specific results as follows:

1. Hemolytic characteristics of each peptide (based on 2% horse red blood cell suspension, incubated at 37 °C for 2 hours)

Peptide Name | Key Hemolytic Properties (Concentration Range: 1~256 µM)
--- | ---
Parent Peptide R2AW | At the highest concentration of 256 µM, the hemolysis rate is about 20%
[Ser²³,²⁹]R2AW | At the highest concentration of 256 µM, the hemolysis rate is about 10%, lower than the parent peptide
R2AW(1-22) | No hemolysis observed across the entire concentration range (1~256 µM) (due to removal of the Rana box and lack of amidation)
R2AW(1-22)-NH₂ | At the highest concentration of 256 µM, the hemolysis rate is about 10%, similar to [Ser²³,²⁹]R2AW
[Lys⁴,¹⁹, Leu²⁰]R2AW(1-22)-NH₂ | No hemolysis observed at its maximum minimum bactericidal concentration (MBC=16 µM), optimal safety
[Trp⁶,¹⁰]R2AW(1-22)-NH₂ | Hemolysis of about 20% occurs even at a low concentration (2 µM), and hemolysis increases further at high concentrations, exhibiting the highest toxicity

2. Additional Notes

Control settings: the 0.1% Triton X-100 treatment group served as the 100% hemolysis positive control, and the PBS treatment group as the 0% hemolysis negative control. Hemolysis rate was calculated using the formula:
Hemolysis Rate = (Absorbance of experimental group - Absorbance of negative control) / (Absorbance of positive control - Absorbance of negative control) × 100%.

Key conclusions:
- Removal of the Rana box (R2AW(1-22)) or substituting cysteine with serine ([Ser²³,²⁹]R2AW) can reduce hemolysis.
- The derivative with increased cationicity and hydrophobicity, [Lys⁴,¹⁹, Leu²⁰]R2AW(1-22)-NH₂, shows no hemolysis at effective antibacterial concentrations, combining high activity with low toxicity.
- Tryptophan substitution ([Trp⁶,¹⁰]R2AW(1-22)-NH₂) enhances anticancer activity but significantly increases hemolysis due to excessive hydrophobicity, limiting clinical application."	Yao A, Liu T, Cai Y, Zhou S, Chen X, Zhou M, Ma C, Chen T, Shaw C, Wang L2023 Antibiotics (Basel). 2023 Dec 19;13(1):5. doi: 10.3390/antibiotics13010005. PubMed|||2023 Dec 19;13(1):5. doi: 10.3390/antibiotics13010005.|||Antibiotics (Basel). 2023 Dec 19;13(1):5. doi: 10.3390/antibiotics13010005. PubMed	22	
FPDB00246	AP03425|||DRAMP35857	GLLGKILGAGKKVLCGVSGLC	Anti-788, activity value is MIC = 4 uM||Anti-923, activity value is MIC = 16 uM||Anti-MRSA B042 V2E1A, activity value is MIC = 16||Anti-697, activity value is MIC = 8 uM||Anti-S. constellatus B003 VISIT, activity value is MIC = 8 uM||Anti-418, activity value is MIC = 8 uM||Anti-816, activity value is MIC = 16 uM||Anti-P. aeruginosa ATCC 9097, activity value is MIC = 64 uM||Anti-P. aeruginosa B004 V2S2B, activity value is MIC = 16 uM||Anti-and fungus C. albicans NYCY 1467, activity value is MIC = 32 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anticancer||Antimicrobial	Pelophylax nigromaculatus, Asia|||Animalia	Helix	Pelophylax nigromaculatus, Asia	Chengyu Lu, Lingling Liu, Chengbang Ma, Liuqing Di, Tianbao Chen 2022 Journal of Genetic Engineering and Biotechnology 2022; 20:76. Publisher Web|||Journal of Genetic Engineering and Biotechnology 2022; 20:76. Publisher Web|||J Genet Eng Biotechnol. 2022 May 23;20(1):76.|||Journal of Genetic Engineering and Biotechnology 2022; 20:76. Publisher Web	21	
FPDB00248	AP03307|||AP03307|||T-DPH1|||T-DPH1|||AP03307|||DRAMP35817	GLWSKIKNVAAAAGKAALGAL	Anti-S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 8||Anti-E.faecalis NCTC 12697, activity value is MIC = 128 uM||Anti-E. coli ATCC 8739, activity value is MIC = 2 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 16 uM||Anti-C. albicans ATCC 10231, activity value is MIC = 64 uM||Anti-H157 and U251MG, activity value is IC50 = 10.2||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anticancer||Anti-S. aureus ATCC 6538, activity value is MIC = 8 uM||Anti-Methicillin-resistant Staphylococcus aureus NCTC 12493, activity value is MIC = 16 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MIC = 128 uM||Antimicrobial	skin secretion, the northern orange-legged leaf frog, tiger-legged monkey frog, Phyllomedusa hypochondrialis, South America|||Phyllomedusa hypochondrialis [orange-legged leaf frog]|||Animalia|||skin secretion, the northern orange-legged leaf frog, tiger-legged monkey frog, Phyllomedusa hypochondrialis, South America	Helix	"skin secretion, the northern orange-legged leaf frog, tiger-legged monkey frog, Phyllomedusa hypochondrialis, South America|||Horse RBC [HC50= 106.4 uM]|||The key value related to hemolysis in this study is the half-maximal hemolytic concentration (HC₅₀), with horse red blood cells as the test subject. The specific data are as follows:

The parent peptide t-DPH1 has an HC₅₀ of 106.4 μM, and its hemolysis rate exceeds 50% at a high concentration (100 μM);
Analogue t-DPH1-K4 has an HC₅₀ of 444.8 μM, which is 4 times that of the parent peptide;
Analogue t-DPH1-5K has an HC₅₀ of 19.39 μM, and is the only analogue with increased hemolytic activity, approximately 5 times that of the parent peptide, with a hemolysis rate approaching 40% at 10 μM concentration;
Analogue t-DPH1-6K has an HC₅₀ of 834.6 μM, 8 times that of the parent peptide;
Analogue t-DPH1-6KW has an HC₅₀ of 2094 μM, showing the lowest hemolytic activity, with almost no hemolysis observed at the tested concentrations.

Except for t-DPH1-5K, all other designed analogues have lower hemolytic activity than the parent peptide at the tested concentrations.|||Horse RBC [HC50= 106.4 uM]"	"Qin H, Fang H, Chen X, Wang L, Ma C, Xi X, Chen T, Shaw C, Zhou M. 2021 Antibiotics (Basel). 2021 Dec 14;10(12):1529. doi: 10.3390/antibiotics10121529. PubMed|||Microb Genom
. 2017 Sep 25;3(10):e000134. doi: 10.1099/mgen.0.000134. eCollection 2017 Oct.|||Microb Genom
. 2017 Sep 25;3(10):e000134. doi: 10.1099/mgen.0.000134. eCollection 2017 Oct.|||34943741|||Antibiotics (Basel). 2021 Dec 14;10(12):1529. doi: 10.3390/antibiotics10121529. PubMed|||34943741|||Microb Genom
. 2017 Sep 25;3(10):e000134. doi: 10.1099/mgen.0.000134. eCollection 2017 Oct.|||Antibiotics (Basel). 2021 Dec 14;10(12):1529.|||Antibiotics (Basel). 2021 Dec 14;10(12):1529. doi: 10.3390/antibiotics10121529. PubMed"	21	
FPDB00250	AP03301|||AP03301|||Esculentin 2 HYba2|||E2/2-NH2|||DRAMP35675	SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC	Anti-C-terminal amidated form: active against Gram+ S. aureus MTCC 9542 or MRSA ATCC 43300, activity value is MIC = 1.5||Anti-B. subtilis MTCC 14416, activity value is MIC = 15 uM||Anti-B. coagulans ATCC 7050, activity value is MIC = 10 uM||Anti-VRE ATCC 29212, activity value is MIC = 12 uM||Anti-S. mutans MTCC 497, activity value is MIC = 5 uM||Anti-S. gordonnii MTCC 2695, activity value is MIC = 5 uM||Anti-V. cholerae MCV09, activity value is MIC = 7 uM||Anti-E. coli ATCC 25922, activity value is MIC = 10 uM||Anti-fish pathogens A. hydrophilia, activity value is MIC = 20 uM||Anti-A. sobria, activity value is MIC = 3 uM||Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anticancer||Antibacterial||Antimicrobial	skin secretion, Hydrophylax bahuvistara, India, Asia|||H. bahuvistara [ Fungoid frog]|||Synthetic construct|||Synthetic	N/A	"In this document, the key values related to hemolysis of the novel antimicrobial peptides derived from the skin of the frog species endemic to the Western Ghats of India (Hydrophylax bahuvistara)—Esculentin-2 HYba1 (E2/1), Esculentin-2 HYba2 (E2/2), and their C-terminal amidated analogues (E2/1 CONH₂, E2/2 CONH₂)—are as follows. These were determined by red blood cell hemolysis assays (red blood cell source not specified, commonly horse or human red blood cells; PBS as 0% hemolysis negative control, 1% Triton X-100 as 100% hemolysis positive control):

Core hemolytic activity results:

- Testing background: Covering the antibacterial effective concentrations of four peptides (e.g., MIC of E2/1 against Staphylococcus aureus = 3 μM, against Vibrio cholerae = 9 μM; the amidated analogue E2/1 CONH₂ against Aeromonas hydrophila = 15 μM).

- Hemolytic values of each peptide:

1. Esculentin-2 HYba1 (E2/1, natural peptide):

- Half-maximal hemolysis concentration (HC₅₀): 10–15 μM, relatively high hemolytic activity, partially overlapping with its antibacterial effective concentration range (3–100 μM), indicating safety needs optimization.

2. Esculentin-2 HYba2 (E2/2, natural peptide):

- HC₅₀: 10–15 μM, consistent with E2/1 in hemolytic activity, no significant difference.

3. E2/1 CONH₂ (C-terminal amidated analogue):

- HC₅₀: 10–15 μM, amidation modification did not change hemolytic activity. Although antibacterial activity (e.g., MIC against fish pathogen Aeromonas hydrophila decreased from 100 μM to 15 μM) and killing speed (killing time against Staphylococcus aureus reduced from 3 hours to 10 minutes) are significantly improved, hemolytic toxicity remains unchanged.

4. E2/2 CONH₂ (C-terminal amidated analogue):

- HC₅₀: 10–15 μM, consistent with natural peptides E2/2 and E2/1 CONH₂ in hemolytic activity, with no additional hemolysis risk.|||skin secretion, Hydrophylax bahuvistara, India, Asia|||hRBC (HC50 = 10 uM)|||hRBC (HC50 = 12 uM)"	"Vineeth Kumar T, Asha R, George S.2021 Nat Prod Res. 2021 Apr;35(8):1262-1266. doi: 10.1080/14786419.2019.1644636. PubMed|||Nat Prod Res
. 2021 Apr;35(8):1262-1266. doi: 10.1080/14786419.2019.1644636. Epub 2019 Jul 22.|||Nat Prod Res
. 2021 Apr;35(8):1262-1266. doi: 10.1080/14786419.2019.1644636. Epub 2019 Jul 22.|||31328553|||Nat Prod Res. 2021 Apr;35(8):1262-1266."	37	
FPDB00251	AP03300|||AP03300|||Esculentin 2 HYba1|||E2/1-NH2	SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC	Anti-C-terminal amidated form: active against Gram+ S. aureus MTCC 9542 or MRSA ATCC 43300, activity value is MIC = 1||Anti-B. subtilis MTCC 14416, activity value is MIC = 7 uM||Anti-B. coagulans ATCC 7050, activity value is MIC = 10 uM||Anti-VRE ATCC 29212, activity value is MIC = 10 uM||Anti-S. mutans MTCC 497, activity value is MIC = 7 uM||Anti-S. gordonnii MTCC 2695, activity value is MIC = 5 uM||Anti-V. cholerae MCV09, activity value is MIC = 6 uM||Anti-E. coli ATCC 25922, activity value is MIC = 10 uM||Anti-fish pathogens A. hydrophilia, activity value is MIC = 15 uM||Anti-A. sobria, activity value is MIC = 1.5 uM||Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anticancer||Antibacterial	skin secretion, Hydrophylax bahuvistara, India, Asia|||H. bahuvistara [ Fungoid frog]|||Synthetic construct	N/A	"In this document, the key values related to hemolysis of the novel antimicrobial peptides derived from the skin of the frog species endemic to the Western Ghats of India (Hydrophylax bahuvistara)—Esculentin-2 HYba1 (E2/1), Esculentin-2 HYba2 (E2/2), and their C-terminal amidated analogues (E2/1 CONH₂, E2/2 CONH₂)—are as follows. These were determined by red blood cell hemolysis assays (red blood cell source not specified, commonly horse or human red blood cells; PBS as 0% hemolysis negative control, 1% Triton X-100 as 100% hemolysis positive control):

Core hemolytic activity results:

- Testing background: Covering the antibacterial effective concentrations of four peptides (e.g., MIC of E2/1 against Staphylococcus aureus = 3 μM, against Vibrio cholerae = 9 μM; the amidated analogue E2/1 CONH₂ against Aeromonas hydrophila = 15 μM).

- Hemolytic values of each peptide:

1. Esculentin-2 HYba1 (E2/1, natural peptide):

- Half-maximal hemolysis concentration (HC₅₀): 10–15 μM, relatively high hemolytic activity, partially overlapping with its antibacterial effective concentration range (3–100 μM), indicating safety needs optimization.

2. Esculentin-2 HYba2 (E2/2, natural peptide):

- HC₅₀: 10–15 μM, consistent with E2/1 in hemolytic activity, no significant difference.

3. E2/1 CONH₂ (C-terminal amidated analogue):

- HC₅₀: 10–15 μM, amidation modification did not change hemolytic activity. Although antibacterial activity (e.g., MIC against fish pathogen Aeromonas hydrophila decreased from 100 μM to 15 μM) and killing speed (killing time against Staphylococcus aureus reduced from 3 hours to 10 minutes) are significantly improved, hemolytic toxicity remains unchanged.

4. E2/2 CONH₂ (C-terminal amidated analogue):

- HC₅₀: 10–15 μM, consistent with natural peptides E2/2 and E2/1 CONH₂ in hemolytic activity, with no additional hemolysis risk.|||skin secretion, Hydrophylax bahuvistara, India, Asia|||hRBC (HC50 = 10 uM)|||hRBC (HC50 = 15 uM)"	"Vineeth Kumar T, Asha R, George S.2021 Nat Prod Res. 2021 Apr;35(8):1262-1266. doi: 10.1080/14786419.2019.1644636. PubMed|||Nat Prod Res
. 2021 Apr;35(8):1262-1266. doi: 10.1080/14786419.2019.1644636. Epub 2019 Jul 22.|||Nat Prod Res
. 2021 Apr;35(8):1262-1266. doi: 10.1080/14786419.2019.1644636. Epub 2019 Jul 22.|||31328553"	37	
FPDB00255	AP03239|||AP03239|||Phylloseptin-PTa|||Phylloseptin-PTa|||AP03239|||DRAMP32064	FLSLIPKIAGGIAALAKHL	Anti-S. aureus NCTC 10788, activity value is MIC = 4.14 uM||Anti-E. faecalis NCTC 12697, activity value is MIC = 16.56 uM||Anti-E. coli NCTC 10418, activity value is MIC = 16.56 uM||Anti-C. albicans NCYC 1467, activity value is MIC = 2.07 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Antibiofilm||Anticancer||Anti-S. aureus NCTC 10788, activity value is MIC = 64 ug/ml||Anti-MRSA NCTC 12493, activity value is MIC = 64 ug/ml||Anti-E. faecalis NCTC 12697, activity value is MIC = 512 ug/ml||Anti-C. albicans NCYC 1, activity value is MIC = 256 ug/ml||Antimicrobial	skin secretions, the Brown-bellied Leaf Frog, Phyllomedusa tarsius, South America|||Phyllomedusa tarsius [Brownbelly leaf frog]|||Phyllomedusa baltea|||skin secretions, the Brown-bellied Leaf Frog, Phyllomedusa tarsius, South America	Helix	"skin secretions, the Brown-bellied Leaf Frog, Phyllomedusa tarsius, South America|||Horse erythrocytes (HC50= 22.8 uM)|||The document clearly provides detailed hemolytic data for two types of antimicrobial peptides in leaf frogs (phylloseptin-PTa and phylloseptin-PHa), with the core information as follows: 
 
1. Key hemolytic markers (Tsushima erythrocytes)
 
The hemolytic properties of the two peptides were measured by hemolysis rates at half the hemolytic concentration (HC₅₀), 10% hemolytic concentration (HC₁₀), and minimum inhibitory concentration (MIC). Specific data are shown in Table 2: 
 
Peptide Name Hemolytic Rate at S. aureus MIC HC₁₀(uM) HC₅₀(uM) 
phylloseptin-PTa 4.42% 7.79 22.8 
phylloseptin-PHa 2.52% 76.5 109.5 
 
- HC₁₀: The concentration of peptides inducing 10% red blood cell hemolysis; the higher the value, the lower the hemolytic activity at lower concentrations; 
- HC₅₀: The concentration of peptides inducing 50% hemolysis of red blood cells; the higher the value, the lower the overall hemolysis; 
- Both have hemolytic rates below 5% at MIC concentrations targeting Staphylococcus aureus (S. aureus), with phylloseptin-PHa being only 2.52%, indicating lower hemolytic toxicity. 
 
2. Experimental Background and Safety Verification
 
- Experimental method: 4% red blood cell suspension was prepared from defibrotic horse blood and incubated with peptides of different concentrations (1~512 uM) at 37°C for 2 hours. The absorbance of the supernatant at 550 nm (reflecting hemoglobin release) was measured. The 2% Triton X-100 treatment group was used as the 100% hemolytic positive control and 1% DMSO/PBS as the solvent control. The hemolysis rate was calculated using formulas. 
- Security Comparison: 
1. The hemolytic properties of both peptides are significantly lower than those of most highly toxic antimicrobial peptides (for example, some frog-derived peptides have hemolytic rates exceeding 10% under MIC); 
2. Combined with treatment index (TI) analysis (Table 3), the ratio of HC₁₀ to MIC/MBEC (minimum biofilm clearance concentration) for inhibiting Gram-positive bacteria and clearing Staphylococcus aureus biofilms was greater than 1, indicating a low risk of hemolysis at effective antibacterial concentrations; 
3. Cytotoxicity tests on human microvascular endothelial cells (HMEC-1) showed that phylloseptin-PHa showed mild toxicity at test concentrations, while phylloseptin-PTa showed significant toxicity only at 100 uM, further confirming their safety against normal mammalian cells. 
 
In summary, both types of antimicrobial peptides in leaf frogs exhibit low hemolytic characteristics, with phylloseptin-PHa having lower hemolytic activity, providing important safety evidence for its use as an anti-infective drug candidate.|||Horse erythrocytes (HC50= 22.8 uM)|||Horse erythrocytes: 10% Hemolysis=7.79 uM; 50% Hemolysis=22.8 uM"	"Liu J, Wu Q, Li L, Xi X, Wu D, Zhou M, Chen T, Shaw C, Wang L.2017 Molecules. 2017 Aug 29;22(9):1428. doi: 10.3390/molecules22091428. PubMed|||Molecules
. 2017 Aug 29;22(9):1428. doi: 10.3390/molecules22091428.|||Molecules
. 2017 Aug 29;22(9):1428. doi: 10.3390/molecules22091428.|||28850103|||Molecules. 2017 Aug 29;22(9):1428. doi: 10.3390/molecules22091428. PubMed|||28850103|||Molecules
. 2017 Aug 29;22(9):1428. doi: 10.3390/molecules22091428.|||Molecules. 2017 Aug 29;22(9):1428.|||Molecules. 2017 Aug 29;22(9):1428. doi: 10.3390/molecules22091428. PubMed"	19	
FPDB00259	AP03219|||AP03219|||Kassiniatuerin-3|||Kassiniatuerin-3|||AP03219|||DRAMP32285	FIQHLIPLIPHAIQGIKDIF	Anti-moderately to weakly active against S. aureus, activity value is MIC = 16||Anti-MRSA, activity value is MIC = 32||Anti-E.faecalis, activity value is MIC = 128 uM||Anti-E.coli, activity value is MIC > 512 uM||Anti-and C. albicans, activity value is MIC = 64||Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anticancer||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 16||Anti-Staphylococcus aureus NCTC 10788, activity value is MBC = 32||Anti-Escherichia coli NCTC 10418, activity value is MIC > 512 uM||Anti-Escherichia coli NCTC 10418, activity value is MBC > 512 uM||Anti-Candida albicans NCYC 1467, activity value is MIC = 64||Anti-Candida albicans NCYC 1467, activity value is MFC = 128 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MIC = 32||Anti-Staphylococcus aureus NCTC 12493, activity value is MBC = 64||Anti-Enterococcus faecalis NCTC 12697, activity value is MIC = 128 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MBC = 128 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC > 512 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MBC > 512 uM||Anti-Human glioblastoma U251-MG, activity value is IC50 = 13.2 uM||Anti-Human prostate adenocarcinoma LNCaP, activity value is IC50 = 3.79 uM||Anti-Human lung adenocarcinoma NCI-H838, activity value is IC50 = 10.03 uM||Anti-Human lung carcinoma NCI-H460, activity value is IC50 = 1.67 uM||Anti-Human squamous lung carcinoma NCI-H157, activity value is IC50 = 21.54 uM||Anti-Human lung adenocarcinoma NCI-H23, activity value is IC50 = 4.52 uM||Antimicrobial	Kassina senegalensis, Africa|||Kassina senegalensis|||Skin Secretion of the African Frog, Kassina senegalensis|||Skin Secretion of the African Frog, Kassina senegalensis	Helix	"50% hemolysis at a concentration of 65000000 uM|||In this document, the key information related to the hemolytic activity of a novel antimicrobial peptide Kassinatuerin-3, derived from the skin of the African frog (Kassina senegalensis), is as follows, as determined by the horse red blood cell hemolysis assay (0.1% Triton X-100 as 100% hemolytic positive control, PBS as 0% hemolytic negative control):

Core Hemolytic Activity Results

- Tested concentration range: 5–160 μM (covering its effective antimicrobial concentrations, such as MIC against Staphylococcus aureus = 16–32 μM, MIC against MRSA = 32–64 μM)

- Kassinatuerin-3 hemolysis values:

- No hemolysis at low concentrations: No significant hemolytic activity was detected at concentrations of 160 μM and below (hemolysis rate <1%). This concentration is far higher than the effective antimicrobial concentration against Gram-positive bacteria (16–64 μM), indicating almost no hemolytic toxicity during antimicrobial activity.

- Slight hemolysis at high concentrations: Slight hemolysis only occurred when concentrations exceeded 160 μM; however, the document did not mention the exact hemolysis rates at specific higher concentrations (e.g., 256 μM, 512 μM).

- Comparison with homologous peptides and positive control:

- The homologous peptide Kassinatuerin-2Ma (from Kassina maculata) showed a hemolysis rate of 40%–50% at 120 μM, whereas Kassinatuerin-3 showed no hemolysis at 160 μM, indicating significantly lower hemolytic toxicity;

- The positive control melittin, although exhibiting strong antimicrobial activity (MIC against Staphylococcus aureus = 1–2 μM), has extremely high hemolytic toxicity and lacks clinical safety, whereas Kassinatuerin-3 demonstrates a higher therapeutic index (ratio of antimicrobial activity to hemolytic toxicity).|||Kassina senegalensis, Africa||At a concentration of up to 160 μM, Kassinatuerin-3 did not show detectable hemolytic activity, with slight activity observed above this concentration. Kassinatuerin-1, which has a net charge of +2, has a MIC of 6.25 μM against Staphylococcus aureus, but induces 50% hemolysis at a concentration of 65 μM.|||Horse erythrocytes (2.5% Hemolysis at 160 uM|||The document clearly provides the hemolytic data of the novel antimicrobial peptide Kassinatuerin-3 on equine red blood cells. The core information is as follows:

1. Critical hemolytic value (for equine red blood cells)

Core characteristics: Kassinatuerin-3 hemolysis is very weak, no obvious hemolytic activity at most concentrations tested in the experiment.
At concentrations ≤ 160 uM: no detectable hemolytic activity (hemolysis ratio ≈ 0%).
At concentrations&gt; 160 uM: showed only slight hemolytic activity (specific values not explicitly quantified but significantly lower than the positive control).

2. Experimental Controls and Supplementary Notes

Comparison settings:
Negative control (PBS treatment): No hemolysis (hemolysis rate = 0%).
Positive control (0.1% Triton X-100 treatment): complete hemolysis (hemolysis rate = 100%), used to calibrate the detection system.
The correlation between hemolytic activity and antibacterial activity:
The minimum inhibitory concentration (MIC) of Kassinatuerin-3 against gram-positive bacteria (such as S. aureus and MRSA) is 16-64 uM, and the minimum bactericidal concentration (MBC) is 32-128 uM, which are far lower than the concentration (&gt;160 uM) that produces slight hemolysis, reflecting a high therapeutic index (high ratio of antibacterial activity to hemolytic toxicity).
Comparison with similar peptides:
The Kassinatuerin-2Ma of the same genus (net charge is the same as that of the Kassinatuerin-3, both are +1) has a hemolysis rate of 40% ~ 50% at 120 uM concentration, while the Kassinatuerin-3 still has no hemolysis at 160 uM, indicating that it has higher selectivity and lower toxicity to mammalian red blood cells.|||Horse erythrocytes (2.5% Hemolysis at 160 uM|||At a concentration of up to 160 μM, Kassinatuerin-3 did not show detectable hemolytic activity, with slight activity observed above this concentration. Kassinatuerin-1, which has a net charge of +2, has a MIC of 6.25 μM against Staphylococcus aureus, but induces 50% hemolysis at a concentration of 65 μM.|||Human RBCs: Kassinatuerin-3 produced no detectable hemolysis activity up to a concentration of 160 uM|||Kassinatuerin-3 produced no detectable hemolysis activity up to a concentration of 160 uM, above which there was slight activity (Figure5a)."	"Wang H, He H, Chen X, Zhou M, Wei M, Xi X, Ma C, Du Q, Che T, Shaw C, Wang L. 2020 Biology (Basel) . 2020 Jul 2;9(7):E148. doi: 10.3390/biology9070148. PubMed|||Biology (Basel)
. 2020 Jul 2;9(7):148. doi: 10.3390/biology9070148.|||Biology (Basel)
. 2020 Jul 2;9(7):148. doi: 10.3390/biology9070148.|||32630734|||Biology (Basel) . 2020 Jul 2;9(7):E148. doi: 10.3390/biology9070148. PubMed|||32630734|||Biology (Basel)
. 2020 Jul 2;9(7):148. doi: 10.3390/biology9070148.|||Biology (Basel). 2020 Jul 2;9(7):148.|||Biology (Basel) . 2020 Jul 2;9(7):E148. doi: 10.3390/biology9070148. PubMed"	20	
FPDB00265	AP03133|||AP03133|||Dermaseptin-PT9|||Dermaseptin-PT9|||AP03133	GLWSKIKDAAKTAGKAALGFVNEMV	Anti-S. aureus NCTC 10788, activity value is MIC = 16 uM||Anti-MRSA NCTC 12493, activity value is MIC = 32 uM||Anti-E. faecalis NCTC 12697, activity value is MIC = 16 uM||Anti-E. coli NCTC 10418, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 16 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 8 uM||Anti-and C. albicans NCYC 1467, activity value is MIC = 64 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anticancer||Anti-C. albicans NCYC 1467, activity value is MIC = 64 uM	skin secretion, Phyllomedusa tarsius, Purchased in Peru, South America|||Phyllomedusa tarsius|||Phyllomedusa tarsius|||skin secretion, Phyllomedusa tarsius, Purchased in Peru, South America|||skin secretion, Phyllomedusa tarsius, Purchased in Peru, South America	Helix	skin secretion, Phyllomedusa tarsius, Purchased in Peru, South America|||Horse erythrocytes [HC50 = 210 uM]|||Horse erythrocytes [HC50 = 210 uM]	"Li M, Xi X, Ma C, Chen X, Zhou M, Burrows JF, Chen T, Wang L.2019 Biomolecules. 2019 Oct 18;9(10). pii: E628. doi: 10.3390/biom9100628. PubMed|||Biomolecules
. 2019 Oct 18;9(10):628. doi: 10.3390/biom9100628.|||Biomolecules
. 2019 Oct 18;9(10):628. doi: 10.3390/biom9100628.|||31635388|||Biomolecules. 2019 Oct 18;9(10). pii: E628. doi: 10.3390/biom9100628. PubMed|||31635388|||Biomolecules
. 2019 Oct 18;9(10):628. doi: 10.3390/biom9100628.|||Biomolecules. 2019 Oct 18;9(10). pii: E628. doi: 10.3390/biom9100628. PubMed"	25	
FPDB00268	AP03057|||AP03057|||PSPHa|||Phylloseptin-PHa|||PSPHa|||Phylloseptin-PHa|||DRAMP32063	FLSLIPAAISAVSALANHF	Anti-S. aureus or MRSA NCTC 12497, activity value is MIC = 32.97 uM||Anti-E.faecalis NCTC 12697, activity value is MIC = 263.78 uM||Anti-E.coli NCTC 10418, activity value is MIC > 263.78 uM||Anti-and C.albicans NCYC 1467, activity value is MIC = 131.89 uM||Anti-Gram+||Anti-MRSA||Antibiofilm||Anticancer||Anti-Staphylococcus aureus, activity value is MIC = 8 uM||activity value is MBC = 16 uM||Anti-Candida albicans, activity value is MIC = 32 uM||activity value is MBC = 32 uM||Anti-methicillin-resistant Staphylococcus aureus, activity value is MIC = 64 uM||activity value is MBC = 128 uM||Anti-S. aureus NCTC 10788, activity value is MIC = 8 ug/ml||Anti-MRSA NCTC 12493, activity value is MIC = 8 ug/ml||Anti-E. faecalis NCTC 12697, activity value is MIC = 32 ug/ml||Anti-E. coli NCTC 10418, activity value is MIC = 32 ug/ml||Anti-C. albicans NCYC 1, activity value is MIC = 4 ug/ml||Antimicrobial	skin secretions, Orange-legged Leaf Frog, Pithecopus hypochondrialis, South America|||Pithecopus hypochondrialis [orange-legged leaf frog]|||Phyllomedusa hypochondrialis [orange-legged leaf frog]|||Pithecopus hypochondrialis	Helix	"In this document, the key values related to the hemolytic activity of two novel antimicrobial peptides derived from the skin of two leaf frogs (Phyllomedusa tarsius and Phyllomedusa hypochondrialis), phylloseptin-PTa and phylloseptin-PHa, are presented. These were determined by horse red blood cell hemolysis assay (using 2% Triton X-100 as the 100% hemolysis positive control and PBS as the 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test indicators: The hemolytic toxicity of the two peptides was evaluated based on the half-hemolysis concentration (HC_{50}, peptide concentration inducing 50% hemolysis of horse red blood cells) and the 10% hemolysis concentration (HC_{10}, peptide concentration inducing 10% hemolysis of horse red blood cells).

- Hemolytic values of each peptide:

- phylloseptin-PTa:
  - HC_{10} = 7.79 μM, HC_{50} = 22.8 μM;
  - At its antibacterial effective concentration (MIC against S. aureus = 4.14 μM), the hemolysis rate was only 4.42%, indicating low hemolytic toxicity.

- phylloseptin-PHa:
  - HC_{10} = 76.5 μM, HC_{50} = 109.5 μM;
  - At its antibacterial effective concentration (MIC against S. aureus = 32.97 μM), the hemolysis rate was only 2.52%, with hemolytic toxicity much lower than that of phylloseptin-PTa.|||skin secretions, Orange-legged Leaf Frog, Pithecopus hypochondrialis, South America|||horse erythrocytes (HC50 = 52.17 uM)|||Horse erythrocytes (HC50= 109.5 uM)|||The document clearly provides detailed hemolytic data for two types of antimicrobial peptides in leaf frogs (phylloseptin-PTa and phylloseptin-PHa), with the core information as follows: 
 
1. Key hemolytic markers (Tsushima erythrocytes)
 
The hemolytic properties of the two peptides were measured by hemolysis rates at half the hemolytic concentration (HC₅₀), 10% hemolytic concentration (HC₁₀), and minimum inhibitory concentration (MIC). Specific data are shown in Table 2: 
 
Peptide Name Hemolytic Rate at S. aureus MIC HC₁₀(uM) HC₅₀(uM) 
phylloseptin-PTa 4.42% 7.79 22.8 
phylloseptin-PHa 2.52% 76.5 109.5 
 
- HC₁₀: The concentration of peptides inducing 10% red blood cell hemolysis; the higher the value, the lower the hemolytic activity at lower concentrations; 
- HC₅₀: The concentration of peptides inducing 50% hemolysis of red blood cells; the higher the value, the lower the overall hemolysis; 
- Both have hemolytic rates below 5% at MIC concentrations targeting Staphylococcus aureus (S. aureus), with phylloseptin-PHa being only 2.52%, indicating lower hemolytic toxicity. 
 
2. Experimental Background and Safety Verification
 
- Experimental method: 4% red blood cell suspension was prepared from defibrotic horse blood and incubated with peptides of different concentrations (1~512 uM) at 37°C for 2 hours. The absorbance of the supernatant at 550 nm (reflecting hemoglobin release) was measured. The 2% Triton X-100 treatment group was used as the 100% hemolytic positive control and 1% DMSO/PBS as the solvent control. The hemolysis rate was calculated using formulas. 
- Security Comparison: 
1. The hemolytic properties of both peptides are significantly lower than those of most highly toxic antimicrobial peptides (for example, some frog-derived peptides have hemolytic rates exceeding 10% under MIC); 
2. Combined with treatment index (TI) analysis (Table 3), the ratio of HC₁₀ to MIC/MBEC (minimum biofilm clearance concentration) for inhibiting Gram-positive bacteria and clearing Staphylococcus aureus biofilms was greater than 1, indicating a low risk of hemolysis at effective antibacterial concentrations; 
3. Cytotoxicity tests on human microvascular endothelial cells (HMEC-1) showed that phylloseptin-PHa showed mild toxicity at test concentrations, while phylloseptin-PTa showed significant toxicity only at 100 uM, further confirming their safety against normal mammalian cells. 
 
In summary, both types of antimicrobial peptides in leaf frogs exhibit low hemolytic characteristics, with phylloseptin-PHa having lower hemolytic activity, providing important safety evidence for its use as an anti-infective drug candidate.|||horse erythrocytes (HC50 = 52.17 uM)|||Horse erythrocytes (HC50= 109.5 uM)|||Horse erythrocytes: 10% Hemolysis=76.5 uM; 50% Hemolysis=109.5 uM; 50% Hemolysis=52.17 uM"	"Liu J, Wu Q, Li L, Xi X, Wu D, Zhou M, Chen T, Shaw C, Wang L.2017 Molecules. 2017 Aug 29;22(9). pii: E1428. doi: 10.3390/molecules22091428. PubMed|||Molecules
. 2017 Aug 29;22(9):1428. doi: 10.3390/molecules22091428.|||Molecules
. 2017 Aug 29;22(9):1428. doi: 10.3390/molecules22091428.|||30774309|||28850103|||Molecules. 2017 Aug 29;22(9). pii: E1428. doi: 10.3390/molecules22091428. PubMed|||30774309|||28850103|||Molecules. 2017 Aug 29;22(9):1428."	19	
FPDB00270	AP03041|||AP03041|||CAMPSQ12278|||DRAMP29104|||AP03041|||DRAMP29104	LNLKALLAVAKKIL	Anti-E. faecalis, activity value is MIC = 4||Anti-S. aureus or MRSA, activity value is MIC = 2||Anti-E. coli, activity value is MIC = 4||Anti-P. aeruginosa, activity value is MIC = 8||Anti-and C. albicans, activity value is MIC = 4||Anti-Gram+ B. cereus ATCC 11778, activity value is MIC = 4 uM||Anti-L. monocytogenes ATCC 15313, activity value is MIC = 8 uM||Anti-S. enterica ATCC 13076, activity value is MIC = 32 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Antibiofilm||Anticancer||Anti-S.aureus NCTC 10788, activity value is MIC = 2 uM||Anti-E.coli NCTC 10418, activity value is MIC = 4 uM||Anti-C.albicans NCTC 1467, activity value is MIC = 4 uM||Anti-S.aureus MRSA ATCC 12493, activity value is MIC = 4 uM||Anti-P.aeruginosa ATCC 27853, activity value is MIC = 8 uM||Anti-E.faecalis NCTC 12697, activity value is MIC = 8 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 2 uM||activity value is MIC = 4||Anti-Escherichia coli NCTC 10418, activity value is MIC = 4 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 8 uM||Anti-Candida albicans NCTC 1467, activity value is MIC = 4 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 4 uM||Anti-Bacillus subtilis ATCC 23857, activity value is MIC = 4 uM||activity value is MIC = 4 uM||activity value is MIC = 8 uM||Anti-Klebsiella pneumoniae ATCC 700603, activity value is MIC = 8 uM||activity value is MIC = 16 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MBC = 2 uM||activity value is MBC = 4 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MIC = 8 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MBC = 8 uM||Anti-##Gram-negative bacteria:Escherichia coli NCTC 10418, activity value is MIC = 4 uM||Anti-Escherichia coli NCTC 10418, activity value is MBC = 8 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MBC = 16 uM||Anti-Candida albicans NCTC 1467, activity value is MBC = 4 uM||Anti-##Cancer:Human squamous lung carcinoma NCI-H157, activity value is IC50 = 13.57 uM||Anti-Human breast adenocarcinoma MDA-MB-435S, activity value is IC50 = 27.7 uM||Anti-Human prostate adenocarcinoma PC-3, activity value is IC50 = 6.29 uM||Anti-Human glioblastoma U251-MG, activity value is IC50 = 36.65 uM||Anti-Human breast adenocarcinoma MCF-7, activity value is IC50 = 25.27 uM	venom, the European Hornet, Vespa crabro|||venom, the European Hornet, Vespa crabro, Europe (introuced to US)|||Vespa crabro [European hornet]|||Vespa crabro|||venom, the European Hornet, Vespa crabro, Europe (introuced to US)|||Vespa crabro|||venom, the European Hornet, Vespa crabro, Europe (introuced to US)	Helix||Alpha helix,random coil	"causing no hemolysis to human erythrocytes within 200 uM|||In this document, the key values related to hemolysis for mastoparan-C (MP-C) derived from European hornet (Vespa crabro) venom and its two modified analogs (cyclic cMP-C and TAT-conjugated tMP-C) are as follows, measured using a horse red blood cell hemolysis assay (with 1% Triton X-100 as the 100% hemolysis positive control and PBS as the 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test Indicator: Hemolytic toxicity of the three peptides was evaluated using the half hemolysis concentration (HC_{50}, i.e., the peptide concentration inducing 50% hemolysis of horse red blood cells) as the core indicator.

- HC_{50} values of each peptide:

- MP-C (natural peptide): HC_{50}=40.11 μM, moderate hemolytic activity; its effective antibacterial concentration (MIC against sensitive bacteria = 2–8 μM) is much lower than HC_{50}, and its toxicity to normal cells (human microvascular endothelial cells HMEC-1) is relatively low (IC₅₀=57.15 μM), resulting in a high therapeutic index.

- cMP-C (cyclic modified peptide): HC_{50}=9.19 μM, hemolytic activity significantly increased (4.4 times that of the natural peptide), and its hemolytic concentration is lower than the antibacterial concentration for most cancer cells...|||venom, the European Hornet, Vespa crabro|||Horse RBCs (HC50 = 40.11 uM)|||[Ref.29904274]50% hemolysis against horse erythrocytes at 40.11 uM.##[Ref.33285267]10% hemolysis against mouse erythrocytes at 64 uM; 60% hemolysis against mouse erythrocytes at 256 uM.|||Similar results were obtained by Yoon et al. (antimicrobial activity against E.coli ATCC 11775 (MIC>1000 uM), S.aureus ATCC 12600 (MIC=500 uM), C.albicans ATCC 10231 (MIC=100 uM) and causing no hemolysis to human erythrocytes within 200 uM 25), although effective concentrations were up to two orders of magnitude higher than what we observed."	"Chen X, Zhang L, Wu Y, Wang L, Ma C, Xi X, Bininda-Emonds ORP, Shaw C, Chen T, Zhou M.2018 Int J Biol Sci. 2018 Apr 25;14(6):599-607. doi: 10.7150/ijbs.23419. PubMed||combined with new data from ref for AP4034|||Int J Biol Sci
. 2018 Apr 25;14(6):599-607. doi: 10.7150/ijbs.23419. eCollection 2018.|||Int J Biol Sci
. 2018 Apr 25;14(6):599-607. doi: 10.7150/ijbs.23419. eCollection 2018.||combined with new data from ref for AP4034|||29904274|||Int J Biol Sci. 2018 Apr 25;14(6):599-607. doi: 10.7150/ijbs.23419. PubMed|||Int J Biol Sci. 2018 Apr 25;14(6):599-607.||Ref.29904274||Ref.33285267|||Int J Biol Sci
. 2018 Apr 25;14(6):599-607. doi: 10.7150/ijbs.23419. eCollection 2018.||combined with new data from ref for AP4034|||Eur J Pharm Sci. 2021 Mar 1;158:105665.##Int J Biol Sci. 2018 Apr 25;14(6):599-607.||Ref.29904274||Ref.33285267|||Int J Biol Sci. 2018 Apr 25;14(6):599-607. doi: 10.7150/ijbs.23419. PubMed"	14	
FPDB00273	AP03016|||AP03016|||Dermaseptin DRS-DU-1|||Dermaseptin DRS-DU-1|||AP03016	ALWKSLLKNVGKAAGKAALNAVTDMVNQ	Anti-S. aureus MRSA, activity value is MIC = 4 uM||Anti-P. aeruginosa, activity value is MIC = 4 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anticancer||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 4 uM	Callimedusa (Phyllomedusa) duellmani, Peru, South America|||Phyllomedusa duellmani|||Phyllomedusa duellmani|||Callimedusa (Phyllomedusa) duellmani, Peru, South America	Helix	"50% hemolysis of the red bloods cells|||This document focuses on the study of novel dermaseptin antimicrobial peptides discovered from the secretions of two types of frog skin, involving multiple aspects such as peptide cloning, synthesis, antimicrobial activity, and hemolytic activity testing. Among these, hemolytic activity was tested using horse red blood cells, with 1% DMSO as the negative control and Triton X-100 as the positive control. The hemolysis rate and the half-maximal hemolytic concentration (HC_{50}) were calculated by measuring absorbance at 550 nm. The specific values are as follows:

Table

Peptide | Half-Maximal Hemolytic Concentration (μM) | Hemolytic Activity Analysis
--- | --- | ---
DRS-CA-1 | 114.7 | At MIC or MBC concentrations, there is no significant hemolytic activity against the tested microorganisms except for Enterococcus faecalis; compared to other peptides with high hemolytic activity, this peptide has a lower hemolysis rate at relatively low concentrations and causes minimal damage to red blood cells.
DRS-DU-1 | 216.6 | Has strong antimicrobial activity, with no significant hemolytic activity at MIC or MBC concentrations except against Enterococcus faecalis; higher than DRS-CA-1, indicating lower toxicity to red blood cells and causing less damage to normal cells while maintaining antimicrobial effects.
DP-1 |  | Has relatively low antimicrobial activity and almost no hemolytic activity; even at higher concentrations, it does not show significant hemolysis, making it safe for red blood cells, though its antimicrobial potency is weak.
DP-2 |  | Antimicrobial activity is restored, and its activity against Enterococcus faecalis is higher than that of natural peptides; shows no significant hemolytic activity, indicating a low risk of red blood cell damage while exerting antimicrobial effects, with potential application value.|||Callimedusa (Phyllomedusa) duellmani, Peru, South America||The MIC, MBC and HC50 values of all the peptides obtained from antimicrobial and hemolysis assays are summarized in Table 2. The two natural peptides, DRS-CA-1 and DRSDU-1, showed the same MIC values (4 uM) against S. aureus and E. coli and C. albicans. DRS-DU-1 was twofold more potent against MRSA, E. faecalis, K. pneumoniae and P. aeruginosa than DRS-CA-1. The MBC values of two natural peptides against seven tested microorganisms were two or four-fold higher than respective MICs. No obvious hemolysis activity was detected at the MIC or MBC concentrations except against E. faecalis. The two designed peptides also exhibited broad spectrum antimicrobial activities against the seven tested microorganisms, though the potency of DP-1 was much lower. However, the antimicrobial activities of DP-2 were restored comparing to DP-1. Additionally, the antimicrobial potency of DP-3 on E. faecalis was higher than the natural peptides.|||Horse erythrocytes (50% Hemolysis at 216.6 uM)|||Horse erythrocytes (50% Hemolysis at 216.6 uM)|||DRS-CA-1 and DRS-DU-1 exhibited strong antimicrobial activity against Gram-positive and Gram-negative bacteria and fungi with no obvious hemolytic activity, and almost the same proportion of polar residues and nonpolar residues as well as the a-helical structure."	"Zhu H, Ding X, Li W, Lu T, Ma C, Xi X, Wang L, Zhou M, Burden R, Chen T.2018 PeerJ. 2018 Sep 19;6:e5635. doi: 10.7717/peerj.5635. PubMed|||PeerJ
. 2018 Sep 19:6:e5635. doi: 10.7717/peerj.5635. eCollection 2018.|||PeerJ
. 2018 Sep 19:6:e5635. doi: 10.7717/peerj.5635. eCollection 2018.|||30258724|||30258724|||PeerJ
. 2018 Sep 19:6:e5635. doi: 10.7717/peerj.5635. eCollection 2018.|||PeerJ. 2018 Sep 19;6:e5635. doi: 10.7717/peerj.5635. PubMed"	28	
FPDB00276	AP02977|||AP02977|||Temporin-PE|||Temporin-PE|||AP02977|||DRAMP18658	FLPIVAKLLSGLL	Anti-S. aureus, activity value is MIC = 2 uM||Anti-MRSA, activity value is MIC = 4 uM||Anti-E. faecalis, activity value is MIC = 8 uM||Anti-and C. albicans, activity value is MIC = 4 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anticancer||Anti-Staphylococcus aureus, activity value is MIC = 2 uM||Anti-Methicillin-resistant Staphylococcus aureus, activity value is MIC = 4 uM||Anti-Enterococcus faecalis, activity value is MIC = 8 uM||Anti-Escherichia coli, activity value is MIC = 16 uM||Anti-Candida albicans, activity value is MIC = 4 uM||Anti-P. aeruginosa, activity value is MIC = 128 uM||Antibacterial||Anti-##Gram-negative bacteria: Escherichia coli, activity value is MIC = 16 uM||Anti-##Fungus: Candida albicans, activity value is MIC = 4 uM||Anti-U251MG, activity value is IC50 = 25.13 uM||Anti-PC-3, activity value is IC50 = 38.56 uM||Anti-MDA-MB-435s, activity value is IC50 = 33.23 uM||Anti-HMEC-1, activity value is IC50 = 58.62 uM	skin secretions, Pelophylax kl. esculentus, Europe|||Pelophylax kl.esculentus [Edible frog]|||Pelophylax kl.esculentus [Edible frog]|||skin secretions, Pelophylax kl. esculentus, Europe|||Pelophylax kl.esculentus(Europe edible frog)|||skin secretions, Pelophylax kl. esculentus, Europe	Helix||Alpha helix	Temporin-PE, temporin-PEa and temporin-PEb exhibited different degrees of hemolysis on horse erythrocytes with HC50 of 39.64 uM, 531.7 uM and 44.64 uM, respectively.|||svgsqq05aqe3x4h6uske|||skin secretions, Pelophylax kl. esculentus, Europe|||The hemolysis and pain induction of SvcAMPs have been reported in previous literature, noting that some SvcAMPs exhibit hemolytic activity against mammalian blood cells (Corzo et al., 2001; Gao et al., 2009; Harrison et al., 2016). This activity has long been considered a defensive strategy to repel small mammals. To provide further evidence to support this speculation, we collected blood cells from three of the most common vertebrates that feed on scorpions (mice, lizards, and birds; Polis, 1990) to evaluate the hemolytic activity of crude venom from Mesobuthus martensii and individual SvcAMPs. As shown in Figure 7A, snake venom diluted with 0.9% sodium chloride caused 50% hemolysis of mouse and lizard blood cells, and 25.7 ± 1.7% hemolysis of bird blood cells (Figure 7A). For individual peptide components, at a peptide concentration of 3.125 μM, all SvcAMPs exhibited varying degrees of hemolysis against mouse blood cells, with MeuFSPL1 and marmelittin showing the strongest hemolytic effects, at 61 ± 2.5% and 66 ± 1.2%, respectively. At this concentration, bee venom could cause complete hemolysis. As the peptide concentration increased to 6.25 μM, hemolytic activity of most SvcAMPs exceeded 50%, while the hemolytic activity of MeuFSPL-1 and marmelittin increased to nearly 100%. When the peptide concentration reached 12.5 μM, almost all peptides caused complete hemolysis except Meucin-13. Meucin-13 required 25 μM to achieve the same effect.|||[Ref.29191658]HC50=39.64 uM against horse red blood cells|||TAT is an arginine-rich decapeptide derived from HIV-1, an ideal cell-penetration segment to transit drugs through cell membranes via membrane translocation and endocytosis, with no hemolytic effects, mild antibiotic activity and inhibits the growth of fungi with MICs ranging from 3 uM to 24 uM [35].	"Sang M, Wu Q, Xi X, Ma C, Wang L, Zhou M, Burrows JF, Chen T.2018 Biochem Biophys Res Commun. 2018 Jan 22;495(4):2539-2546. doi: 10.1016/j.bbrc.2017.11.173. PubMed|||Biochem Biophys Res Commun
. 2018 Jan 22;495(4):2539-2546. doi: 10.1016/j.bbrc.2017.11.173. Epub 2017 Nov 28.|||Biochem Biophys Res Commun
. 2018 Jan 22;495(4):2539-2546. doi: 10.1016/j.bbrc.2017.11.173. Epub 2017 Nov 28.|||29191658|||29191658|||Biochem Biophys Res Commun
. 2018 Jan 22;495(4):2539-2546. doi: 10.1016/j.bbrc.2017.11.173. Epub 2017 Nov 28.|||Biochem Biophys Res Commun. 2018 Jan 22;495(4):2539-2546.||Ref.29191658|||Biochem Biophys Res Commun. 2018 Jan 22;495(4):2539-2546. doi: 10.1016/j.bbrc.2017.11.173. PubMed"	13	
FPDB00285	AP02745|||AP02745|||Saha-CATH5|||DRAMP18429|||Saha-CATH5|||AP02745|||DRAMP31957|||DRAMP18429	KRIGLIRLIGKILRGLRRLG	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anticancer||Anti-E. coli ATCC 25922, activity value is MIC = 32 ug/ml||Anti-E.col, activity value is MIC = 32 ug/ml||Anti-Methicillin resistant S. aureus, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC > 64 ug/ml||Anti-P. aeruginosa*, activity value is MIC = 64 ug/ml||Anti-E. faecalis ATCC 29212, activity value is MIC > 64 ug/ml||Anti-E. faecalis, activity value is MIC > 64 ug/ml||Anti-Vancomycin resistant E. faecalis, activity value is MIC = 32 ug/ml||Anti-S. pneumoniae ATCC 49619, activity value is MIC = 64 ug/ml||Anti-S. pyogenes ATCC 19615, activity value is MIC = 32 ug/ml||Anti-S. agalactiae ATCC 12386, activity value is MIC = 64 ug/ml||Anti-S. agalactiae, activity value is MIC = 64 ug/ml||Anti-S. mutans, activity value is MIC > 64 ug/ml||Anti-S. oralis/mitis group, activity value is MIC = 64 ug/ml||Anti-S. dysgalactiae subs. equisimilis, activity value is MIC > 64 ug/ml||Anti-S. anginosus, activity value is MIC = 32 ug/ml||Anti-S. salivarius, activity value is MIC > 64 ug/ml||Anti-S. lutetiensis, activity value is MIC > 64 ug/ml||Anti-S. equi*, activity value is MIC = 64 ug/ml||Anti-K. pneumoniae*, activity value is MIC > 64 ug/ml||Anti-N. asteroides*, activity value is MIC > 64 ug/ml||Anti-L. monocytogenes*, activity value is MIC > 64 ug/ml||Anti-P. multocida, activity value is MIC > 64 ug/ml||Anti-C. parapsilosis ATCC 22019, activity value is MIC > 64 ug/ml||Anti-C. krusei ATCC 6258, activity value is MIC = 64 ug||Anti-C. albicans, activity value is MIC > 64 ug/ml||Anti-C. glabrata, activity value is MIC > 64 ug/ml||Anti-C.neoforms, activity value is MIC = 32 ug/ml||Anti-C. gattii, activity value is MIC = 64 ug/ml||Anti-and C. neoformans, activity value is MIC = 32||Antimicrobial	Tasmanian devil, Sarcophilus harrisii|||o0eg1cdwhptqyewyewfa|||Sarcophilus harrisii [Tasmanian Devil]|||Sarcophilus harrisii|||Tasmanian devil, Sarcophilus harrisii	N/A	"In this document, the key values related to the hemolytic activity of six cathelicidin peptides (Saha-CATH1–6) from the Tasmanian devil (Sarcophilus harrisii) are as follows, all determined by a human red blood cell hemolysis assay (with 1% Triton X-100 serving as the 100% positive control and PBS as the 0% negative control):

1. Hemolytic activity of each peptide (test concentration range: 0.95–500 µg/mL)

-Saha-CATH1: At all tested concentrations, the hemolysis rate was **&lt;7%**, with no significant hemolytic activity, and the absorbance at each concentration showed no statistically significant difference from the negative control (P&gt;0.05).

-Saha-CATH2: At the highest concentration of 500 µg/mL only, the hemolysis rate was **&lt;7%**, but the absorbance differed significantly from that of the negative control (P&lt;0.05); at all other concentrations, the hemolysis rate was extremely low and showed no statistically significant difference.

-Saha-CATH3: At concentrations of 250 µg/mL and 500 µg/mL, the hemolysis rate was **&lt;7%**, and the absorbance differed significantly from that of the negative control (P&lt;0.05); no significant hemolysis was observed at concentrations below 250 µg/mL.

-Saha-CATH4: At concentrations of 125–500 µg/mL, the hemolysis rate was **&lt;7%**, and there was a statistically significant difference in absorbance compared with the negative control (P&lt;0.05); no significant hemolysis was observed at concentrations below 125 µg/mL.

-Saha-CATH5 exhibited the strongest hemolytic activity, with a hemolysis rate of 37% at a concentration of 500 µg/mL (P&lt;0.05); at concentrations of 31.25–125 µg/mL, the hemolysis rate was **&lt;15%** (P&lt;0.05); and no significant hemolysis was observed at concentrations below 31.25 µg/mL.

-Saha-CATH6: At concentrations of 250 µg/mL and 500 µg/mL, the hemolysis rates were **&lt;26% (P&lt;0.05); at 31.25–125 µg/mL, the hemolysis rate was &lt;15%** (P&lt;0.05); no significant hemolysis was observed at concentrations below 31.25 µg/mL.

2. Core Conclusion

-With the exception of Saha-CATH5 and Saha-CATH6, which exhibited moderate hemolytic activity at high concentrations (≥250 µg/mL), the remaining four peptides (Saha-CATH1–4) showed no significant hemolytic activity across the entire concentration range tested (hemolysis rate &lt;7%).

-The hemolytic concentrations of all peptides were significantly higher than their minimum inhibitory concentrations (MICs) against bacteria; for example, the MIC of Saha-CATH5 against MRSA was 32 µg/mL, which is much lower than the 500 µg/mL corresponding to a 37% hemolysis rate. This indicates that these peptides exhibit low toxicity to human red blood cells while exerting their antibacterial activity.|||Tasmanian devil, Sarcophilus harrisii|||Human erythrocytes (37% hemolysis at 500 ug/ml)|||Saha-CATH1: The hemolysis rate was below 7% at all tested concentrations (0.95~500 µg/ml), showing no significant hemolysis.

• Saha-CATH2: The hemolysis rate was significantly higher than the negative control only at 500 µg/ml, but still below 7%, indicating very weak hemolysis.

• Saha-CATH3: The hemolysis rate was significantly higher than the negative control at 250 µg/ml and 500 µg/ml, but both were below 7%, indicating very weak hemolysis.

• Saha-CATH4: The hemolysis rate was significantly higher than the negative control at 125~500 µg/ml, but all were below 7%, indicating very weak hemolysis.

• Saha-CATH5: The hemolysis rate was below 15% at 31.25~125 µg/ml; not clearly specified at 250 µg/ml; and reached 37% at 500 µg/ml (strongest hemolysis).

• Saha-CATH6: The hemolysis rate was below 15% at 31.25~125 µg/ml; below 26% at 250 µg/ml; and below 26% at 500 µg/ml, indicating moderate hemolysis.|||Human erythrocytes (37% hemolysis at 500 ug/ml)|||Human erythrocytes:5% Hemolysis=1-31.25 ug/ml; 7% Hemolysis=62.5 ug/ml; 12% Hemolysis=125 ug/ml; 30% Hemolysis=250 ug/ml"	"Peel E, Cheng Y, Djordjevic JT, Fox S, Sorrell TC, Belov K.2016 Sci Rep. 2016 Oct 11;6:35019. PubMed|||Sci Rep
. 2016 Oct 11:6:35019. doi: 10.1038/srep35019.|||Sci Rep2016 Oct 11:6:35019. doi: 10.1038/srep35019.|||27725697|||Sci Rep. 2016 Oct 11;6:35019|||27725697|||Sci Rep
. 2016 Oct 11:6:35019. doi: 10.1038/srep35019.|||Sci Rep. 2016 Oct 11;6:35019."	20	
FPDB00298	AP02531|||AP02531|||Stigmurin|||DRAMP20933|||DRAMP21024|||Stigmurin|||AP02531|||DRAMP20933|||DRAMP21024	FFSLIPSLVGGLISAFK	Anti-S. aureus ATCC 29213 or MRSA ATCC 33591, activity value is MIC = 8.68||Anti-S. epidermidis ATCC 122225, activity value is MIC = 9.38 uM||Anti-E.faecalis ATCC 4028, activity value is MIC > 150 uM||Anti-E.coli ATCC 25922, activity value is MIC > 139 uM||Anti-E.cloacae ATCC 13047, activity value is MIC > 150 uM||Anti-P.aeruginosa ATCC 27853, activity value is MIC > 150 uM||Anti-s C. albicans ATCC 90028, activity value is MIC = 34.75 uM||Anti-C. krusei ATCC 6258, activity value is MIC = 69.5||Anti-and C. glabrata ATCC 90030, activity value is MIC = 69.5||Anti-Gram+||Antifungal||candidacidal||Antioxidant||Anti-MRSA||Wound healing||Anticancer||Anti-Staphylococcus aureus, activity value is MIC = 9.4 uM||Anti-Staphylococcus epidermidis, activity value is MIC = 9.4 uM||Anti-Candida albicans, activity value is MIC = 37.5 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 9.38 uM||Anti-Staphylococcus epidermidis ATCC 122225, activity value is MIC = 9.38 uM||Anti-s: Candida albicans ATCC 90028, activity value is MIC = 37.5 uM||Anti-HeLa cell line, activity value is IC50 = 7.98 uM||Anti-Enterococcus faecalis, activity value is MIC > 150 uM||Anti-Pseudomonas aeruginosa, activity value is MIC > 150 uM||Anti-Escherichia coli, activity value is MIC > 150 uM||Anti-Enterobacter cloacae, activity value is MIC > 150 uM||Anti-Candida glabrata, activity value is MIC > 150 uM||Anti-Candida krusei, activity value is MIC > 150 uM||Anti-##yeasts: Candida albicans ATCC 90028, activity value is MIC = 37.5 uM||Anti-##HeLa cell line, activity value is IC50 = 7.98 uM||Anti-##Gram-negative bacteria : Pseudomonas aeruginosa, activity value is MIC > 150 uM||Anti-##Fungi : Candida albicans, activity value is MIC = 37.5 uM	venom gland, Tityus stigmurus|||venom gland, Tityus stigmurus, Brazil, South America|||Tityus stigmurus [Brazilian scorpion]|||Tityus stigmurus|||Scorpion Tityus stigmurus|||venom gland, Tityus stigmurus, Brazil, South America|||Tityus stigmurus|||Scorpion Tityus stigmurus|||venom gland, Tityus stigmurus, Brazil, South America	Helix||Alpha helix	"Hemolysis Rate at the Highest Test Concentration

- Test concentration: 139.5 μM (the highest peptide concentration used in the experiment)

- Hemolysis rate: 22%

- Description: This value was determined by human red blood cell hemolysis assay. In the experiment, PBS (0% hemolysis, negative control) and distilled water (100% hemolysis, positive control) were used as references. Peptides were incubated with red blood cells at 37°C for 180 minutes, and the hemolysis percentage was calculated by measuring absorbance at 540 nm. The results indicate low hemolytic activity at this concentration.

2. Hemolysis Test Concentration Range

- Concentration range: 1.1–139.5 μM

- Result trend: At test concentrations below 139.5 μM, hemolysis rates were below 22%, and no significant hemolytic activity was observed (exact hemolysis rates at lower concentrations were not listed separately, but overall showed a concentration-dependent trend, with hemolysis reaching 22% only at the highest concentration).

3. Control Group Setup

- Negative control: PBS (pH 7.4), no hemolytic effect (0% hemolysis).

- Positive control: distilled water, inducing complete hemolysis (100% hemolysis), used for standardizing hemolysis rate calculations.|||venom gland, Tityus stigmurus||Stigmurin was found to possess low hemolytic activity (22 %)218at the highest concentration tested (139.5 uM), as shown in Figure 6|||hRBC, Non hemolytic|||-Detection object: healthy human O-type red blood cells, incubation conditions are 37 C, 1 hour, detection wavelength 540 nm.

-Control settings: 0% hemolysis (PBS only, no peptides/triton), 100% hemolysis (triton Triton-X).

-Natural peptide Stigmurin: very low hemolytic activity in the concentration range of 1.17-75 uM, with a hemolysis rate of only 3% at the highest concentration (75 uM).

-Analogs StigA6 and StigA16: hemolysis rate is about 30% at the highest concentration (75 uM); However, at low concentrations (corresponding to MIC and effective concentration) that exert antibacterial and antiproliferative activities, the hemolysis rate is less than 10% and the toxicity is weak.|||- Test subject: human red blood cells, incubation conditions were 37°C for 1 hour, detection wavelength 540 nm; negative control (0.9% saline) showed 0% hemolysis, positive control (1% Triton X-100) showed 100% hemolysis.  

- Natural peptide Stigmurin: at the highest concentration (150 µM), the hemolysis rate was only 5.8%, indicating extremely low hemolytic activity.  

- Analogues StigA25 and StigA31: hemolytic activity was concentration-dependent, with weak hemolysis at low concentrations (effective antimicrobial concentrations):  

  - At concentrations ≤ 9.4 µM, hemolysis rates were 18.5% for StigA25 and 11.2% for StigA31;  

  - Hemolysis slightly increased at higher concentrations, but overall remained low, and showed no significant hemolytic toxicity at their minimum inhibitory concentrations (MIC, 1.2–4.7 µM).  

- Key correlation: the analogues had increased net charge through lysine substitutions (StigA25: 5, StigA31: 7, native peptide: 2), which significantly enhanced antimicrobial activity without a substantial increase in hemolytic activity, indicating good safety.|||hRBC, Non hemolytic|||Hemolytic activity of StigMurin. Human red blood cells were incubated with a series of diluted StigMurin (1.1–139.5 μM) at 37 °C for 3 hours. PBS and distilled water were used as negative and positive lysis controls, respectively, and the activity was measured at 540 nm. The hemolysis rate was calculated as 679% relative to the positive control (100%).|||[Ref.29670004]Hemolysis 0% at 1.17 uM, hemolysis 1% at 2.34 uM, hemolysis 1% at 4.69 uM, hemolysis 0% at 9.38 uM, hemolysis 1% at 18.75 uM, hemolysis 1% at 37.5 uM, hemolysis 3% at 75 uM against human red blood cell|||[Ref.30709056] 7% hemolysis at 1.2 ug/ml , 4% hemolysis at 2.3 ug/ml , 2% hemolysis at 4.7 ug/ml , 0% hemolysis at 9.4 ug/ml , 3% hemolysis at 18.8 ug/ml , 2% hemolysis at 37.5 ug/ml , 3% hemolysis at 75 ug/ml , 5% hemolysis at 150 ug/ml against human red blood cells|||Stigmurin was found to possess low hemolytic activity (22 %) at the highest concentration tested (139.5 uM), as shown in Figure 6."	"Melo ET, Estrela AB, Santos EC, Machado PR, Farias KJ, Torres TM, de Carvalho E, Lima JP, Silva-Júnior AA, Barbosa EG, Fernandes-Pedrosa MF. 2015 Peptides. 2015 Jun;68:3-10. PubMed|||Peptides
. 2015 Jun:68:3-10. doi: 10.1016/j.peptides.2015.03.003. Epub 2015 Mar 22.|||Peptides. 2015 Jun;68:3-10. PubMed|||30709056|||Toxins (Basel). 2018 Apr 18;10(4). pii: E161.||Ref.29670004|||Int J Mol Sci. 2019 Jan 31;20(3). pii: E623. doi: 10.3390/ijms20030623.||Ref.30709056|||30709056|||Peptides
. 2015 Jun:68:3-10. doi: 10.1016/j.peptides.2015.03.003. Epub 2015 Mar 22.|||Toxins (Basel). 2018 Apr 18;10(4). pii: E161.||Ref.29670004|||Int J Mol Sci. 2019 Jan 31;20(3). pii: E623. doi: 10.3390/ijms20030623.||Ref.30709056|||Peptides. 2015 Jun;68:3-10. PubMed"	17	
FPDB00319	AP00601|||AP00601|||Brevinin-1DYa|||Amurin-2c|||Amurin-2c|||AP00601|||DRAMP02016	FLSLALAALPKFLCLVFKKC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anticancer||Anti-E. coli and S. aureus, activity value is MIC < 15 uM||Anti-C. albicans, activity value is MIC = 32 uM||Antibacterial ; Rana dybowskii [Dybovsky frog]||Antibacterial||Anti-S. aureus, activity value is MIC = 32 uM||Anti-E. coli, activity value is MIC > 512 uM||Anti-MRSA, activity value is MIC = 32 uM||Antimicrobial||Anti-Gram+||Anti-Gram-	Rana dybowskii, or Rana amurensis, Asia|||Rana dybowskii, or Rana amurensis, Asia|||Rana dybowskii, or Rana amurensis, Asia|||Rana dybowskii [Dybovsky frog]|||Synthetic construct|||Rana dybowskii (Dybovsky's frog) (Korean brown frog)	Helix	"strongly hemolytic LC50<5 uM|||The document only explicitly provides the hemolytic values of three brevinin-1 family peptides in the skin extract of the Japanese brown frog (Rana dybowskii) (expressed as the concentration LC_{50} causing 50% hemolysis of human red blood cells), with the specific data as follows:

Brevinin-1DYa: hemolytic value LC_{50} < 5 μM, minimum inhibitory concentration (MIC) against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) both < 15 μM;
Brevinin-1DYb: hemolytic value LC_{50} < 5 μM, MIC against E. coli and S. aureus both < 15 μM;
Brevinin-1DYc: hemolytic value LC_{50} < 5 μM, MIC against E. coli and S. aureus both < 15 μM.

In addition, the document also mentioned the following information:

Brevinin-1DYd and Brevinin-1DYe were not accurately measured for hemolytic values due to their low content;
Brevinin-2 family peptides Brevinin-2DYb, Brevinin-2DYc/d, and Brevinin-2DYe were only tested for antibacterial activity (MIC against E. coli and S. aureus: 15–30 μM) and no hemolytic values were reported;
Temporin-1DYa, lacking the basic amino acid residues common to the temporin family, showed no or very weak hemolytic activity against red blood cells, and no specific LC_{50} value was provided.|||The document mentions that peptides of the brevinin-1 family have strong hemolytic activity against human red blood cells, with a half-hemolysis concentration (LC₅₀) of less than 5 µM.|||Horse RBC (HC50 = 17 uM)|||Horse RBC (HC50 = 17 uM)|||LC₅₀<5 uM"	"Toxicon 2007; 50: 746-756. PubMed.|||Toxicon 2007; 50: 746-756. PubMed.|||Toxicon
. 2007 Nov;50(6):746-56. doi: 10.1016/j.toxicon.2007.06.023. Epub 2007 Jul 4.|||https://pubmed.ncbi.nlm.nih.gov/17688900|||29366784|||29366784|||Toxicon 2007; 50: 746-756. PubMed.|||Toxicon. 2007 Nov;50(6):746-756."	20	
FPDB00320	AP00602|||AP00602|||Brevinin-1DYb|||Amurin|||Amurin|||AP00602|||DRAMP02018	FLSLALAALPKLFCLIFKKC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anticancer||Anti-E. coli and S. aureus MRSA, activity value is MIC = 15||Anti-inactive E.coli, activity value is MIC > 512 uM||Antibacterial ; Rana dybowskii [Dybovsky frog]||Antibacterial||Anti-S. aureus, activity value is MIC = 32 uM||Anti-E. coli, activity value is MIC > 512 uM||Anti-C. albicans, activity value is MIC = 32 uM||Anti-MRSA, activity value is MIC = 32 uM||Antimicrobial||Anti-Gram+||Anti-Gram-	Rana dybowskii, or Rana amurensis, Asia|||Rana dybowskii, or Rana amurensis, Asia|||Rana dybowskii, or Rana amurensis, Asia|||Rana dybowskii [Dybovsky frog]|||Synthetic construct|||Rana dybowskii (Dybovsky's frog) (Korean brown frog)	Helix	"strongly hemolytic LC50<5 uM|||The document only explicitly provides the hemolytic values of three brevinin-1 family peptides in the skin extract of the Japanese brown frog (Rana dybowskii) (expressed as the concentration LC_{50} causing 50% hemolysis of human red blood cells), with the specific data as follows:

Brevinin-1DYa: hemolytic value LC_{50} < 5 μM, minimum inhibitory concentration (MIC) against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) both < 15 μM;
Brevinin-1DYb: hemolytic value LC_{50} < 5 μM, MIC against E. coli and S. aureus both < 15 μM;
Brevinin-1DYc: hemolytic value LC_{50} < 5 μM, MIC against E. coli and S. aureus both < 15 μM.

In addition, the document also mentioned the following information:

Brevinin-1DYd and Brevinin-1DYe were not accurately measured for hemolytic values due to their low content;
Brevinin-2 family peptides Brevinin-2DYb, Brevinin-2DYc/d, and Brevinin-2DYe were only tested for antibacterial activity (MIC against E. coli and S. aureus: 15–30 μM) and no hemolytic values were reported;
Temporin-1DYa, lacking the basic amino acid residues common to the temporin family, showed no or very weak hemolytic activity against red blood cells, and no specific LC_{50} value was provided.|||The document mentions that peptides of the brevinin-1 family exhibit strong hemolytic activity against human red blood cells, with a half-maximal hemolytic concentration (LC₅₀) of less than 6 µM.|||Horse RBC (HC50 = 4.7 uM)|||Horse RBC (HC50 = 4.7 uM)|||LC₅₀<5 uM"	"Toxicon 2007; 50: 746-756. PubMed|||Toxicon 2007; 50: 746-756. PubMed.|||Toxicon
. 2007 Nov;50(6):746-56. doi: 10.1016/j.toxicon.2007.06.023. Epub 2007 Jul 4.|||https://pubmed.ncbi.nlm.nih.gov/17688900|||29366784|||29366784|||Toxicon 2007; 50: 746-756. PubMed.|||Comp Biochem Physiol B Biochem Mol Biol. 2009 Oct;154(2):174-178.Toxicon. 2007 Nov;50(6):746-756."	20	
FPDB00326	AP00779|||4511|||4512|||4513|||4514|||4515|||4516|||4517|||4518|||4519|||4520|||4521|||4522|||4523|||4524|||4525|||4526|||4527|||4528|||4529|||4530|||4531|||4570|||4573|||AP00779|||Winter flounder 1a1|||DRAMP02349|||Winter flounder 1a1|||AP00779	GRRKRKWLRRIGKGVKIIGGAALDHL	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anticancer||5% cytotoxic at 5 uM||5% cytotoxic at 10 uM||30-35% cytotoxic at 25 uM||60% cytotoxic at 50 uM||5-10% cytotoxic at 5 uM||10% cytotoxic at 10 uM||30% cytotoxic at 5 uM||50% cytotoxic at 10 uM||70% cytotoxic at 25 uM||80-85% cytotoxic at 50 uM||40-50% cytotoxic at 10 uM||60-70% cytotoxic at 25 uM||15-20% cytotoxic at 5 uM||80% cytotoxic at 25 uM||85-90% cytotoxic at 50 uM||~0% cytotoxic at 5 uM||70% cytotoxic at 50 uM||60-70% cytotoxic at 50 uM||Anti-A. salmonicida 99-1, activity value is MIC = 2 ug/ml||Anti-A. salmonicida 97-4, activity value is MIC = 4 ug/ml||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 2 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 8 ug/ml||Anti-P. aeruginosa K799, activity value is MIC = 2 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 1 ug/ml||Anti-E. coli CGSC 4908, activity value is MIC = 2 ug/ml||Anti-E. coli UB1005, activity value is MIC = 8 ug/ml||Anti-E. coli DC2, activity value is MIC = 2 ug/ml||Anti-S. epidermidis C621, activity value is MIC = 8 ug/ml||Anti-MRSA C623, activity value is MIC = 8 ug/ml||Anti-C. albicans C627, activity value is MIC = 4 ug/ml||Anti-Aeromonas salmonicida 99-1, activity value is MIC = 2 ug/ml||Anti-Aeromonas salmonicida 97-4, activity value is MIC = 4 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS7953s, activity value is MIC = 2 ug/ml||Anti-Salmonella enterica serovar Typhimurium 14028s, activity value is MIC = 8 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC = 2 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 1 ug/ml||Anti-Escherichia coli CGSC 4908, activity value is MIC = 2 ug/ml||Anti-Escherichia coli UB1005, activity value is MIC = 8 ug/ml||Anti-Escherichia coli DC2, activity value is MIC = 2 ug/ml||Anti-Staphylococcus epidermidis C621, activity value is MIC = 8 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 8 ug/ml||Anti-Highly active against active against A. salmonicida 99-1, activity value is MIC = 2 uM||Anti-A. salmonicida 97-4, activity value is MIC = 4 uM||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 8 uM||Anti-P. aeruginosa K799, activity value is MIC = 2 uM||Anti-P. aeruginosa Z61, activity value is MIC = 1 uM||Anti-E. coli CGSC4908 or UB1005 or DC2, activity value is MIC = 2||Anti-S. epidermidis C621, activity value is MIC = 8 uM||Anti-methicillin-resistant S. aureus C623 MRSA, activity value is MIC = 8 uM||Anti-C. albicans C627, activity value is MIC = 4 uM	winter flounder 1a-1, Pleuronectes americanus|||winter flounder 1a-1, Pleuronectes americanus|||winter flounder 1a-1, Pleuronectes americanus|||Pseudopleuronectes americanus [Winter flounder]|||Pseudopleuronectes americanus (Winter flounder 3)|||Pseudopleuronectes americanus [Winter flounder]|||winter flounder 1a-1, Pleuronectes americanus	N/A	N/A	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-2470.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.||Hou et al., 2022	26	L
FPDB00331	AP00819|||AP00819|||Temporin-1Oc1|||DRAMP01773	"	
FLPLLASLFSRLF"	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anticancer||Anti-S. aureus, activity value is MIC = 2 uM||Anti-Staphylococcus epidermidis 1457, activity value is MIC = 1.6 uM||Anti-Bacillus subtilis 168, activity value is MIC = 12.5 uM||Anti-Candida albicans ATCC 10231, activity value is MIC = 25 uM||Anti-C. glabrata ATCC 2001, activity value is MIC = 25 uM||Anti-C. tropicalis ATCC 13803, activity value is MIC = 1.6||Anti-S. epidermidis 1457, activity value is MIC = 1.6 uM||Anti-B. subtilis 168, activity value is MIC = 12.5 uM||Anti-C. albicans, activity value is MIC = 25 uM||Anti-C. glabrata, activity value is MIC = 25 uM||Anti-Staphylococcus aureus, activity value is MIC = 2 uM	Rana Ornativentris, Asia|||Rana Ornativentris, Asia|||Rana ornativentris|||Rana ornativentris (Japanese mountain brown frog)	N/A	Human RBCs (HL50 < 12.5 uM)	J Peptide Res 2001; 58: 349-356. PubMed|||J Peptide Res 2001; 58: 349-356. PubMed.|||2001 Nov;58(5):349-56. doi: 10.1034/j.1399-3011.2001.00947.x.|||17147973, 11892844, 29842923||Refer PubMed ID: 29842923|||J Peptide Res 2001; 58: 349-356. PubMed.||see ref	13	
FPDB00335	AP00871|||DRAMP01793	"	
FLPFLKSILGKIL"	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anticancer||Anti-Antibacterial activity was not reported due to a limited amount of material. We filled up this gap by using a synthetic peptide. Active against S. aureus USA300, activity value is MIC = 1.6||Anti-S. epidermidis 1457, activity value is MIC = 1.6 uM||Anti-B. subtilis 168, activity value is MIC = 12.5||Anti-C. albicans, activity value is MIC = 12.5 uM||Anti-C. glabrata, activity value is MIC = 12.5 uM||Antimicrobial	Florida bog frog, Rana okaloosae, North America|||Rana okaloosae (Florida bog frog)	Helix	N/A	Regul Pept 2007; 138: 87-93. PubMed|||Regul Pept 2007; 138: 87-93. PubMed.|||2007 Feb 1;138(2-3):87-93. doi: 10.1016/j.regpep.2006.08.007. Epub 2006 Sep 26.|||Regul Pept 2007; 138: 87-93.	13	
FPDB00337	AP00952|||1425|||1794|||1946|||2098|||2250|||2545|||2688|||AP00952|||MSI-78|||Pexiganan|||MSI-78, MSIEP	GIGKFLKKAKKFGKAFVKILKK	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-inflammatory||Wound healing||Anticancer||75% Cytotoxicity at 0.5 ug/ml||activity value is LD50 = 31 ug/ml||activity value is LD50 = 34 ug/ml||activity value is LD50 = 140 ug/ml||activity value is LD50 = 66 ug/ml||Anti-91% were susceptible to MSI-78 tested at a break-point of 64 ug/ml . Active against Acinetobacter sp. 10 strains, activity value is MIC = 4||Anti-A. faecalis 5 strains, activity value is MIC = 4||Anti-C. diversus 10 strains, activity value is MIC = 8||Anti-C. freundii 25 strains, activity value is MIC = 8||Anti-C. jeikeium, activity value is MIC = 0.125||Anti-E. aerogenes 25 strains, activity value is MIC = 8||Anti-E. cloacae 25 strains, activity value is MIC = 1||Anti-E.faecalis 30 strains, activity value is MIC > 256 ug/ml||Anti-E. coli 30 strains, activity value is MIC = 8||Anti-K. oxytoca 10 strains, activity value is MIC = 8||Anti-K. pneumoniae 25 strains, activity value is MIC = 8||Anti-P. aeruginosa 25 strains, activity value is MIC = 8||Anti-P. fluorescens 5 strains, activity value is MIC = 2||Anti-P. stutzeri 5 strains, activity value is MIC = 4||Anti-S. aureus MRSA 10 strains, activity value is MIC = 16||Anti-S. aureus MSSA 15 strains, activity value is MIC = 0.125||Anti-S. epidermidis 25 strains, activity value is MIC = 0.125||Anti-S. haemolyticus 10 strains, activity value is MIC = 408 ug/ml||Anti-S. hominis 5 strains, activity value is MIC = 2||Anti-S. simulans 5 strains, activity value is MIC = 0.125||Anti-S. warneri 5 strains, activity value is MIC = 0.125||Anti-S. xylosus 1 strain, activity value is MIC = 0.125 ug/ml||Anti-S. maltophilia 10 strains, activity value is MIC = 4||Anti-S. agalactiae 25 strains, activity value is MIC = 16||Anti-S. bovis 5 strains, activity value is MIC = 8||Anti-S. equinus 2 strains, activity value is MIC = 2||Anti-S. pyogenes 30 strains, activity value is MIC = 16||Anti-Streptococcus group C 5 strains, activity value is MIC = 16||Anti-Streptococcus group G 5 strains, activity value is MIC = 16||Anti-Viridans group streptococci 13 strains, activity value is MIC = 4||Anti-B. ovatus 7 strains, activity value is MIC = 4||Anti-B. ureolyticus 3 strains, activity value is MIC = 0.25||Anti-B. vulgatus 6 strains, activity value is MIC = 4 ug/ml||Anti-C. difficile 4 strains, activity value is MIC = 0.5||Anti-C. perfringens 5 strains, activity value is MIC = 8||Anti-C. ramosum 2 strains, activity value is MIC = 16 ug/ml||Anti-C. sporogenes 2 strains, activity value is MIC = 8||Anti-Clostridium sp, activity value is MIC = 32 ug/ml||Anti-P. anaerobius 6 strains, activity value is MIC = 32||Anti-P. asaccharolyticus 3 strains, activity value is MIC = 4||Anti-P. magnus 4 strains, activity value is MIC = 0.5||Anti-P. bivia 9 strains, activity value is MIC = 32||Anti-and P. melaninogenica 3 strains, activity value is MIC = 32||MIC against MRSA Staphylococcus aureus CCARM 3696||Bacillus subtilis KCTC 2213||Micrococcus luteus KCTC9341||vancomycin-resistant Enterococcus faecium CCARM 5028 (VRE)||Listeria mono-cytogenes KCTC 19111||multidrug-resistant Pseudomonas aeruginosa CCARM 2161(MDRPA)||Escherichia coli KCTC 1039||Klebsiella oxytoca KCTC 1686||Citrobacter fre-undii KCTC 2359 and Salmonella enterica KCTC 2930||Antibacterial	amino acid substitution, amphibians, animal-derived, natural derivative|||amino acid substitution, amphibians, animal-derived, natural derivative|||Synthetic construct	Helix	Staphylococcus aureus ATCC 29213 ( MIC = 8 16 ug/ml ), Staphylococcus aureus ATCC 33591 (methicillin resistant) ( MIC = 16 32 ug/ml ), Staphylococcus epidermidis ATCC 12228 ( MIC = 2 4 ug/ml ), Enterococcus faecium ATCC 51559 (vancomycin resistant) ( MIC = 8 ug/ml ), Enterococcus faecalis ATCC 29212 ( MIC = 64 ug/ml ), Group A Streptococcus ATCC 49399 ( MIC = 4 ug/ml ), Streptococcus pneumoniae ATCC 49619 ( MIC = 32 ug/ml ), Streptococcus bovis ATCC 49133 ( MIC = 4 ug/ml ), Bacillus cereus ATCC 11778 ( MIC = 8 ug/ml ), Micrococcus luteus ATCC 4698 ( MIC = 2 ug/ml ), Corynebacterium group A ATCC 49676 ( MIC = 2 4 ug/ml ), Escherichia coli ATCC 25922 ( MIC = 8 16 ug/ml ), Enterobacter cloacae ATCC 35030 ( MIC = 8 ug/ml ), Proteus mirabilis ATCC 29245 ( MIC = >256 ug/ml ), Serratia marcescens ATCC 8100 ( MIC = >256 ug/ml ), Helicobacter pylori ATCC 43504 ( MIC = 2 ug/ml ), Haemophilus influenzae ATCC 49247 ( MIC = 8 ug/ml ), Pseudomonas aeruginosa ATCC 27853 ( MIC = 8 16 ug/ml ), Bacteroides fragilis ATCC 90028 ( MIC = 2 4 ug/ml ), Bacteroides thetaiotaomicron ATCC 29741 ( MIC = 2 4 ug/ml ), Clostridium difficile ATCC 43255 ( MIC = 4 ug/ml ), Propionibacterium acnes ATCC 29399 ( MIC = 8 ug/ml ), Veillonella parvula ATCC 10790 ( MIC = 8 ug/ml )|||A. baumannii ATCC 19606 (MIC =2 ug/ml)|||MSI-78, [P. aeruginosa (MIC = 0.78 uM), E. coli (MIC = 1.56-3.12 uM), S. aureus (MIC = 0.78-1.56 uM), B. subtilis (MIC = 1.56 uM)]; MSIEP [(Isopeptide formation: K8, K14, and K18) - P. aeruginosa (MIC = 6.25-12.5 uM), E. coli (MIC = 12.5 uM), S. aureus (MIC = 6.25-12.5 uM), B. subtilis (MIC = 6.25-12.5 uM)]|||Even at a concentration of 200 ug/ml, the hemolysis rate of this peptide on human red blood cells remains < 1%.|||human RBC, 53% hemolysis at 512 ug/ml (HC50 512 ug/ml), less hemo.lytic.	"Ciba Found Symp. 1994;186:197-216; discussion 216-23. doi: 10.1002/9780470514658.ch12. PubMed|||J Antimicrob Chemother
. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322. Epub 2013 Aug 14.|||1994:186:197-216; discussion 216-23.doi: 10.1002/9780470514658.ch12.||Fucks et al., 1998|||10103181|||30043322|||34043312|||Ciba Found Symp. 1994;186:197-216; discussion 216-23. doi: 10.1002/9780470514658.ch12. PubMed.||Fucks et al., 1998|||Ciba Found Symp. 1994;186:197-216; discussion 216-23. doi: 10.1002/9780470514658.ch12. PubMed."	22	L
FPDB00352	AP01246|||DRAMP03379|||AP01246|||DRAMP03379	"	
FLPKTLRKFFCRIRGGRCAVLNCLGKEEQIGRCSNSGRKCCRKKK"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Chemotactic||Anticancer||Anti-MRSA||Anti-E faecalis ATCC 51299, activity value is MBC = 1.2||Anti-S. enterica serovar Typhimurium ATCC 13311, activity value is MBC = 0.6||Anti-and yeast C. albicans ATCC 24433, activity value is MBC = 1.2 uM||Antimicrobial||Antibacterial	spleen, colon, and tissues of the upper and lower respiratory tract, Mus musculus|||spleen, colon, and tissues of the upper and lower respiratory tract, Mus musculus|||Mus musculus (Mouse)|||spleen, colon, and tissues of the upper and lower respiratory tract, Mus musculus|||Mus musculus (Mouse)	Bridge	N/A	"J Biol Chem. 2008 Feb 29;283(9):5414-9. Pub-Med|||J Biol Chem
. 2008 Feb 29;283(9):5414-9. doi: 10.1074/jbc.M709103200. Epub 2007 Dec 31.|||2008 Feb 29;283(9):5414-9. doi: 10.1074/jbc.M709103200. Epub 2007 Dec 31|||Genome Res. 2004 Oct;14(10B):2121-2127.|||J Biol Chem. 2008 Feb 29;283(9):5414-9. Pub-Med|||Genome Res. 2004 Oct;14(10B):2121-2127.J Biol Chem. 2008 Feb 29;283(9):5414-5419."	45	
FPDB00362	AP01328|||2925|||2926|||2927|||2928|||2929|||2930|||2931|||2932|||2933|||2934|||2935|||2936|||2937|||2938|||2939|||2940|||2941|||2942|||2943|||2944|||2945|||2946|||2947|||2948|||AP01328|||Epinecidin-1|||DRAMP21241	GFIFHIIKGLFHAGKMIHGLV	Anti-Gram+ & Gram-||Antiviral||Antifungal||Antiparasitic||Anti-MRSA||Anti-inflammatory||anti-sepsis||Wound healing||Anticancer||45% Cytotoxicity at 50 ug/ml||38% Cytotoxicity at 25 ug/ml||75% Cytotoxicity at 50 ug/ml||65% Cytotoxicity at 25 ug/ml||75 % Cytotoxicity at 50 ug/ml||83% Cytotoxicity at 50 ug/ml||77 % Cytotoxicity at 25 ug/ml||82 % Cytotoxicity at 50 ug/ml||85 % Cytotoxicity at 25 ug/ml||42 % Cytotoxicity at 12.5 ug/ml||41 % Cytotoxicity at 6.25 ug/ml||39 % Cytotoxicity at 3.125 ug/ml||90 % Cytotoxicity at 50 ug/ml||95 % Cytotoxicity at 25 ug/ml||45 % Cytotoxicity at 12.5 ug/ml||25 % Cytotoxicity at 6.25 ug/ml||25 % Cytotoxicity at 3.125 ug/ml||95 % Cytotoxicity at 50 ug/ml||96 % Cytotoxicity at 25 ug/ml||46 % Cytotoxicity at 12.5 ug/ml||Anti-ntiviral activity against foot-and-mouth disease virus in vitro, activity value is EC50 = 0.6 ug/ml||Anti-Antiviral activity against foot-and-mouth disease virus in vitro, activity value is EC50 = 0.6 ug/ml||Anti-17570764: Listeria monocytogenes, activity value is MIC = 50 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 12.5 ug/ml||Anti-Streptococcus pyogenes, activity value is MIC = 25 ug/ml||Anti-Streptococcus agalactiae, activity value is MIC = 50 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC > 100 ug/ml||Anti-Staphylococcus sp, activity value is MIC = 50 ug/ml||Anti-Staphylococcus xylosus, activity value is MIC = 50 ug/ml||Anti-Streptococcus pneumoniae, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus subsp, activity value is MIC = 6.25 ug/ml||Anti-Enterobacter aerogenes, activity value is MIC = 50 ug/ml||Anti-Enterobacter cloacae subsp, activity value is MIC = 100 ug/ml||Anti-Vibrio alginolyticus, activity value is MIC = 12.5 ug/ml||Anti-Klebsiella oxytoca, activity value is MIC = 100 ug/ml||Anti-Salinivibrio costicola subsp, activity value is MIC = 12.5 ug/ml||Anti-Vibrio vulni cus, activity value is MIC = 50 ug/ml||Anti-Vibrio harveyi, activity value is MIC = 12.5 ug/ml||Anti-Vibrio vulnicus, activity value is MIC = 12.5 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 60 ug/ml||Anti-Yersinia enterocolitica subsp, activity value is MIC = 100 ug/ml||Anti-Carbapenem-resistant K. pneumoniae Bacterial isolates CRKP-1, activity value is MIC = 8000 ug||Anti-CRKP-2, activity value is MIC = 16000 ug||Anti-CRKP-3, activity value is MIC = 8000 ug||Anti-CRKP-4, activity value is MIC = 8000 ug||Anti-CRKP-5, activity value is MIC = 8000 ug||Anti-CRKP-6, activity value is MIC = 16000 ug||Anti-CRKP-7, activity value is MIC = 8000 ug||Anti-CRKP-8, activity value is MIC = 8000 ug||Anti-CRKP-9, activity value is MIC = 8000 ug||Anti-CRKP-10, activity value is MIC = 4000 ug||Anti-CRKP-11, activity value is MIC = 4000 ug||Anti-CRKP-12, activity value is MIC = 16000 ug||Anti-CRKP-13, activity value is MIC = 16000 ug||Anti-CRKP-14, activity value is MIC = 8000 ug||Anti-CRKP-15, activity value is MIC = 4000 ug||Anti-CRKP-16, activity value is MIC = 8000 ug||Anti-CRKP-17, activity value is MIC = 8000 ug||Anti-CRKP-18, activity value is MIC = 8000 ug||Anti-CRKP-19, activity value is MIC = 8000 ug||Anti-CRKP-20, activity value is MIC = 8000 ug||Anti-CRKP-21, activity value is MIC = 8000 ug||Anti-CRKP-22, activity value is MIC = 16000 ug||Anti-CRKP-23, activity value is MIC = 16000 ug||Anti-Carbapenem-resistant K. aerogenes Bacterial isolates CRKA-1, activity value is MIC = 16000 ug||Anti-CRKA-2, activity value is MIC = 8000 ug||Anti-CRKA-3, activity value is MIC = 4000 ug||Anti-CRKA-4, activity value is MIC = 16000 ug||Anti-CRKA-5, activity value is MIC = 4000 ug||Anti-CRKA-6, activity value is MIC = 16000 ug||Anti-CRKA-7, activity value is MIC = 4000 ug||Anti-CRKA-8, activity value is MIC = 8000 ug||Anti-CRKA-9, activity value is MIC = 16000 ug||Anti-CRKA-10, activity value is MIC = 8000 ug||Anti-CRKA-11, activity value is MIC = 4000 ug||Anti-CRKA-12, activity value is MIC = 8000 ug||Anti-CRKA-13, activity value is MIC = 16000 ug||Anti-CRKA-14, activity value is MIC = 8000 ug||Anti-CRKA-15, activity value is MIC = 8000 ug||Anti-CRKA-16, activity value is MIC = 8000 ug||Anti-CRKA-17, activity value is MIC = 4000 ug||Anti-Carbapenem-resistant P. aeruginosa Bacterial isolates CRPA-1, activity value is MIC = 8000 ug||Anti-CRPA-2, activity value is MIC = 16000 ug||Anti-CRPA-3, activity value is MIC = 8000 ug||Anti-CRPA-4, activity value is MIC = 16000 ug||Anti-CRPA-5, activity value is MIC = 16000 ug||Anti-CRPA-6, activity value is MIC = 8000 ug||Anti-CRPA-7, activity value is MIC = 4000 ug||Anti-CRPA-8, activity value is MIC = 16000 ug||Anti-CRPA-9, activity value is MIC = 8000 ug||Anti-CRPA-10, activity value is MIC = 16000 ug||Anti-CRPA-11, activity value is MIC = 16000 ug||Anti-CRPA-12, activity value is MIC = 16000 ug||Anti-CRPA-13, activity value is MIC = 32000 ug||Anti-Carbapenem-resistant A. baumannii Bacterial isolates CRAB-1, activity value is MIC = 32000 ug||Anti-CRAB-2, activity value is MIC = 32000 ug||Anti-CRAB-3, activity value is MIC = 4000 ug||Anti-CRAB-4, activity value is MIC = 16000 ug||Anti-CRAB-5, activity value is MIC = 32000 ug||Anti-CRAB-6, activity value is MIC = 16000 ug||Anti-CRAB-7, activity value is MIC = 32000 ug||Anti-CRAB-8, activity value is MIC = 8000 ug||Anti-CRAB-9, activity value is MIC = 16000 ug||Anti-Methicillin-resistant S. aureus Bacterial isolates MRSA-1, activity value is MIC = 16000 ug||Anti-MRSA-2, activity value is MIC = 16000 ug||Anti-MRSA-3, activity value is MIC = 32000 ug||Anti-MRSA-4, activity value is MIC = 8000 ug||Anti-MRSA-5, activity value is MIC = 16000 ug||Anti-MRSA-6, activity value is MIC = 8000 ug||Anti-MRSA-7, activity value is MIC = 8000 ug||Anti-MRSA-8, activity value is MIC = 16000 ug||Anti-MRSA-9, activity value is MIC = 32000 ug||Anti-MRSA-10, activity value is MIC = 16000 ug||Anti-MRSA-11, activity value is MIC = 16000 ug||Anti-MRSA-12, activity value is MIC = 16000 ug||Anti-MRSA-13, activity value is MIC = 16000 ug||Anti-MRSA-14, activity value is MIC = 16000 ug||Anti-MRSA-15, activity value is MIC = 16000 ug||Anti-MRSA-16, activity value is MIC = 16000 ug||Anti-MRSA-17, activity value is MIC = 8000 ug||Anti-MRSA-18, activity value is MIC = 16000 ug||Anti-MRSA-19, activity value is MIC = 16000 ug||Anti-MRSA-20, activity value is MIC = 16000 ug||Anti-MRSA-21, activity value is MIC = 16000 ug||Anti-MRSA-22, activity value is MIC = 8000 ug||Anti-Micrococcus luteus, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 50 ug/ml||Anti-Streptococcus pneumoniae, activity value is MIC = 50 ug/ml||Anti-Streptococcus agalactiae, activity value is MIC >= 100 ug/ml||Anti-Staphylococcus sp, activity value is MIC = 6.25 ug/ml||Anti-##Gram-negative bacteria : Grouper Vibrio alginolyticus, activity value is MIC = 6.25 ug/ml||Anti-Vibrio harveyi, activity value is MIC = 6.25 ug/ml||Anti-Vibrio vulnificus, activity value is MIC = 50 ug/ml	orange-spotted grouper, Epinephelus coioides|||orange-spotted grouper, Epinephelus coioides|||orange-spotted grouper, Epinephelus coioides|||Epinephelus coioides [orange-spotted grouper]|||Synthetic construct	N/A	gene|||hRBC(100% hemolysis at 156.25 ug/ml)|||[Ref.23598079] 0% hemolysis at 25 ug/ml , 10% hemolysis at 50 ug/ml , 15% hemolysis at 100 ug/ml , 30% hemolysis at 200 ug/ml , 50% hemolysis at 400 ug/ml against sheep red blood cells	DNA Cell Biol. 2007 Jun;26(6):403-13|||DNA Cell Biol. 2007 Jun;26(6):403-13|||30552913, 28882626, 17570764, 35052952||Refer 28882626||Refer Pubmed ID 35052952|||Peptides. 2013 Jun;44:139-48. doi: 10.1016/j.peptides.2013.04.004.||Ref.23598079	21	L
FPDB00377	AP01512|||AP01512|||Imcroporin	"	
FFSLLPSLIGGLVSAIK"	Anti-Gram+||Anti-MRSA||Hemolytic||Anticancer||Anti-Staphylococcus aureus AB94004, activity value is MIC = 20 ug/ml||Anti-Pseudomonas aeruginosa AB93066, activity value is MIC > 100 ug/ml||Anti-Escherichia coli AB94012, activity value is MIC > 100 ug/ml||Anti-Bacillus thuringiensis AB92037, activity value is MIC = 50 ug/ml||Anti-Bacillus subtilis AB91021, activity value is MIC = 50 ug/ml||Anti-Micrococcus luteus AB93113, activity value is MIC = 20 ug/ml||Anti-Penicillin-resistant Staphylococcus epidermidis, activity value is MIC = 50 ug/ml||Anti-Methicillin-resistant coagulase-negative Staphylococcus, activity value is MIC = 50 ug/ml||Anti-Penicillin-sensitive S. epidermidis, activity value is MIC = 20 ug/ml||Anti-Methicillin-resistant Staphylococcus aureus P1386, activity value is MIC = 50 ug/ml||Anti-Methicillin-resistant Staphylococcus aureus P1374, activity value is MIC = 50 ug/ml	Isometrus maculates|||Isometrus maculates|||Isometrus maculatus	N/A	"low hemolytic|||The values related to hemolysis mentioned in this document refer to the hemolysis rates of human red blood cells at different concentrations of imcroporin, with the specific data as follows:

- When the concentration of imcroporin is 50 µg/ml, the hemolysis rate of human red blood cells is below 50%.

- As the concentration increases (up to a maximum of 100 µg/ml), the hemolysis rate gradually rises, but the document does not provide specific numerical values, only showing the trend through a curve (as shown in Figure 4B).

These data were measured through hemolysis experiments and reflect the hemolytic activity of this antimicrobial peptide on human red blood cells; the higher the concentration, the stronger the hemolytic effect.|||Hemolysis rate <50% at a concentration of 50 µg/ml"	"Antimicrob Agents Chemother. 2009 Aug;53(8):3472-7. PubMed.|||Antimicrob Agents Chemother
. 2009 Aug;53(8):3472-7. doi: 10.1128/AAC.01436-08. Epub 2009 May 18.|||Antimicrob Agents Chemother
. 2009 Aug;53(8):3472-7. doi: 10.1128/AAC.01436-08. Epub 2009 May 18.|||19451300"	17	
FPDB00380	AP01534|||AP01534|||Temporin-SHf|||DRAMP20778|||Temporin-SHf|||AP01534|||DRAMP20778	"	
FFFLSRIF"	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anticancer||Anti-Gram- E. coli ATCC 25922 or ML-35p or D21, activity value is MIC = 25||Anti-E.coli ATCC 35218, activity value is MIC > 200 uM||Anti-P.aeruginosa ATCC 27853, activity value is MIC > 200 uM||Anti-positive S. aureus ATCC 25923, activity value is MIC = 12.5 uM||Anti-E. faecalis ATCC 29212, activity value is MIC = 50 uM||Anti-B. megaterium, activity value is MIC = 3 uM||Anti-C. parapsilosis ATCC 22019, activity value is MIC = 50 uM||Anti-S. cerevisiae, activity value is MIC = 12.5 uM||Anti-fungus A.flavus, activity value is MIC > 200 uM||Anti-and L-infantumamastigotes, activity value is MIC > 60 uM||Anti-but not E.coli K12, activity value is MIC > 100 uM||Anti-S.epidermidis 1457, activity value is MIC > 100 uM||Anti-and B.subtilis 168, activity value is MIC > 100 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 25 uM||Anti-Escherichia coli ATCC 35218, activity value is MIC > 200 uM||Anti-Escherichia coli D21, activity value is MIC = 100 uM||Anti-Escherichia coli ML-35p, activity value is MIC = 30 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC > 200 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 12.5 uM||Anti-C. albicans ATCC 90028, activity value is MIC = 50 uM||Anti-A. flavus, activity value is MIC > 200 uM||Anti-E.coli ATCC 25922, activity value is MIC = 25 uM||Anti-E.coli ML-35p, activity value is MIC = 30 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 12.5 uM||Anti-E.faecalis ATCC 29212, activity value is MIC = 50 uM||Anti-B.megaterium, activity value is MIC = 3 uM||Anti-C.albicans ATCC 90028, activity value is MIC = 50 uM||Anti-C.parapsilosis ATCC 22019, activity value is MIC = 50 uM||Anti-S.cerevisiae, activity value is MIC = 12.5 uM||Anti-A.flavus, activity value is MIC > 200 uM||Anti-Bacillus megaterium, activity value is MIC = 3 uM||Anti-s: Candida albicans ATCC 90028, activity value is MIC = 50 uM||Anti-Fungus, activity value is MIC > 200 uM||Anti-Candida albicans, activity value is MIC > 100 uM||Anti-## Gram-positive bacteria: Staphylococcus aureus ATCC 25923, activity value is MIC = 12.5 uM||Anti-## Yeasts: Candida albicans ATCC 90028, activity value is MIC = 50 uM||Anti-## Fungus, activity value is MIC > 200 uM	Sahara Frog, Pelophylax saharicus, Africa|||Pelophylax saharica(Sahara frog)|||Synthetic construct|||Pelophylax saharica|||Pelophylax saharicus|||Sahara Frog, Pelophylax saharicus, Africa|||Pelophylax saharica(Sahara frog)	Helix	"no hemolytic activity|||The values related to hemolysis mentioned in this document are the half-maximal hemolytic concentration (LC_{50}), that is, the peptide concentration that causes 50% hemolysis of human red blood cells. The specific data are as follows:

- Temporin-SHf: LC_{50} for human red blood cells = 200 μM

This value was measured through hemolysis experiments and reflects the hemolytic activity of this antimicrobial peptide on human red blood cells. The relatively high value indicates weak hemolytic activity and is much higher than the minimum inhibitory concentrations for sensitive strains (3–50 μM).|||LC50=200 uM|||Human erythrocytes ( LC50 = 200 uM )|||Human RBCs (LC50 = 200 uM)|||The hemolytic value of Temporin-SHf is LC_{50} = 200 μM (LC_{50} refers to the peptide concentration that causes 50% hemolysis of red blood cells).|||[Ref.20308076] Temporin-SHf is not cytotoxic against human erythrocytes (LC50 = 200 μm), with a hemolytic activity detected only at peptide concentration far above the MIC values determined for the sensitive strains (3–50 μm)"	"J Biol Chem. 2010 May 28;285(22):16880-92. PubMed|||J Biol Chem
. 2010 May 28;285(22):16880-92. doi: 10.1074/jbc.M109.097204. Epub 2010 Mar 22.|||J Biol Chem
. 2010 May 28;285(22):16880-92. doi: 10.1074/jbc.M109.097204. Epub 2010 Mar 22.|||20308076|||J Biol Chem. 2010 May 28;285(22):16880-92.||Ref.20308076|||https://pubmed.ncbi.nlm.nih.gov/20308076|||https://pubmed.ncbi.nlm.nih.gov/28105725|||J Biol Chem. 2010 May 28;285(22):16880-92. PubMed|||J Biol Chem. 2010 May 28;285(22):16880-92.||Ref.20308076"	8	
FPDB00416	AP02111|||DRAMP01447|||AP02111|||DRAMP01447	"	
GFSSIFRGVAKFASKGLGKDLAKLGVDLVACKISKQC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||anti-diabetes||Anticancer||Anti-Bacteria E. coli, activity value is MIC = 5 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 5 uM||Anti-K. pneumoniae ATCC 700603, activity value is MIC = 5 uM||Anti-S. aureus, activity value is MIC = 5 uM||Anti-A. baumannii, activity value is MIC = 5 uM||Anti-and S. maltophilia, activity value is MIC < 10 uM||Anti-E. coli, activity value is MIC = 5 uM||Anti-K. pneumoniae, activity value is MIC = 5 uM||Anti-P. aeruginosa, activity value is MIC = 5 uM	skin secretions, Chiricahua leopard frog, Lithobates chiricahuensis, Arizona, USA, North America|||skin secretions, Chiricahua leopard frog, Lithobates chiricahuensis, Arizona, USA, North America|||Lithobates chiricahuensis|||skin secretions, Chiricahua leopard frog, Lithobates chiricahuensis, Arizona, USA, North America|||Lithobates chiricahuensis	N/A	skin secretions, Chiricahua leopard frog, Lithobates chiricahuensis, Arizona, USA, North America||At a concentration of 100 μM, the hemolysis rate is < 10%.|||[Ref.21262304] LC50=150 uM against human erythrocytes|||less hemo.lytic (hRBC HC50=150 uM)	"Peptides. 2011 Apr;32(4):664-9. Pub-Med.|||Peptides
. 2011 Apr;32(4):664-9. doi: 10.1016/j.peptides.2011.01.018. Epub 2011 Jan 22.|||Peptides. 2011 Apr;32(4):664-9. doi: 10.1016/j.peptides.2011.01.018. Epub 2011 Jan 22.||Ojo et al., 2015|||Peptides. 2011 Apr;32(4):664-669.|||21262304|||Peptides
. 2011 Apr;32(4):664-9. doi: 10.1016/j.peptides.2011.01.018. Epub 2011 Jan 22.||Ojo et al., 2015|||Gram-negative bacteria: E. coli (MIC=5 uM), K. pneumoniae (MIC=5 uM), P. aeruginosa (MIC=5 uM);
Gram-positive bacterium: S. aureus (MIC=5 uM).
Yeast: C. albicans (MIC=10 uM).|||Peptides. 2011 Apr;32(4):664-9. Pub-Med."	37	
FPDB00417	AP02134|||AP02134|||TP3|||TP3|||DRAMP31547	"	
FIHHIIGGLFSVGKHIHSLIHGH"	Anti-Gram+ & Gram-||Anti-MRSA||Wound healing||Anticancer||Anti-Gram-negative V. vulnificus 204, activity value is MIC = 2.44 ug/ml||Anti-A-hydrophila BCRC 13018, activity value is MIC > 19.55 ug/ml||Anti-V. alginolyticus, activity value is MIC = 2.44 ug/ml||Anti-P-aeruginosa ATCC 19660, activity value is MIC > 19.55 ug/ml||Anti-S. agalactiae 819, activity value is MIC = 9.78 ug/ml||Anti-E. faecalis BCRC 10066, activity value is MIC = 19.55 ug/ml||Antibacterial||Antifungal||Anti-S. aureus, activity value is MIC = 256 ug/ml||Anti-MRSA, activity value is MIC = 256 ug/ml||Anti-C. albicans, activity value is MIC = 128 ug/ml||Antimicrobial||Antiviral	Nile Tilapia, Oreochromis niloticus|||Nile Tilapia, Oreochromis niloticus|||Oreochromis niloticus [Nile tilapia]|||Synthetic construct|||Oreochromis niloticus	N/A	"were hemolytic in fish red blood cells at 100000 ug/ml for 42% hemolysis|||The hemolytic values of five piscidin peptides (TP1-5) from Nile tilapia (Oreochromis niloticus) on fish red blood cells are as follows:

Table

Peptide Name  Concentration (ug/ml)  Hemolysis Rate (%)
TP1           100                     0
TP2           40                      60
TP3           100                     42
TP4           100                     100
TP5           100                     0

Note: TP1 and TP5 showed no hemolytic activity at the highest tested concentration (100 ug/ml); TP2 had a hemolysis rate of 60% at 40 ug/ml; TP3 had a hemolysis rate of 42% at 100 ug/ml; TP4 caused complete hemolysis (100%) at 100 ug/ml. The data are the average of three repeated experiments, and different letters indicate significant differences between groups (p<0.05).|||Nile Tilapia, Oreochromis niloticus||HC₅₀ = 8 uM。|||Vibrio vulnificus 204 ( MIC = 2.44 ug/ml ), Aeromonas hydrophila BCRC 13018 ( MIC >19.55 ug/ml ), Vibrio alginolyticus ( MIC = 2.44 ug/ml ), Pseudomonas aeruginosa ATCC 19660 ( MIC >19.55 ug/ml ), Streptococcus agalactiae 819 ( MIC = 9.78 ug/ml ), E. faecalis BCRC 10066 ( MIC = 19.55 ug/ml ), S. agalactiae BCRC 10787 ( MIC = 0.61 ug/ml )|||Mouse erythrocytes (100% hemolysis, 25 ug/ml)|||Mouse erythrocytes (100% hemolysis, 25 ug/ml)"	"PLoS One. 2012;7(11):e50263. Pub-Med.|||PLoS One
. 2012;7(11):e50263. doi: 10.1371/journal.pone.0050263. Epub 2012 Nov 30.|||PLoS One. 2012;7(11):e50263. doi: 10.1371/journal.pone.0050263. Epub 2012 Nov 30.|||23226256|||29040295|||29040295|||Peptides. 2018 Aug;106:91-95."	23	
FPDB00808	4532|||4533|||4534|||4535|||4536|||4537|||4538|||4539|||4540|||4541|||4542|||4543|||4544|||4545|||4546|||4547|||4548|||4549|||4550|||4571|||4574|||AP00783|||AP00783|||Pleurocidin-like peptide YT2|||DRAMP02359|||Pleurocidin-like peptide YT2|||AP00783	RWGKWFKKATHVGKHVGKAALTAYL	5% cytotoxic at 10 uM||20-30% cytotoxic at 25 uM||40-50% cytotoxic at 50 uM||~0% cytotoxic at 5 uM||10% cytotoxic at 10 uM||20% cytotoxic at 25 uM||20% cytotoxic at 10 uM||70-80% cytotoxic at 25 uM||80-85% cytotoxic at 50 uM||10% cytotoxic at 5 uM||50% cytotoxic at 10 uM||80% cytotoxic at 25 uM||80-90% cytotoxic at 50 uM||30-40% cytotoxic at 5 uM||60-70% cytotoxic at 10 uM||80-90% cytotoxic at 25 uM||85-90% cytotoxic at 50 uM||70% cytotoxic at 50 uM||60-70% cytotoxic at 50 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibacterial||Anti-Aeromonas salmonicida 99-1, activity value is MIC = 4 ug/ml||Anti-A. salmonicida 97-4, activity value is MIC = 2 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS7953s, activity value is MIC = 2 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 8 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC = 4 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 2 ug/ml||Anti-Escherichia coli CGSC 4908, activity value is MIC = 4 ug/ml||Anti-E. coli UB1005, activity value is MIC = 4 ug/ml||Anti-E. coli DC2, activity value is MIC = 4 ug/ml||Anti-Staphylococcus epidermidis C621, activity value is MIC = 64 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 64 ug/ml||Anti-A. salmonicida 99-1, activity value is MIC = 4 ug/ml||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 2 ug/ml||Anti-P. aeruginosa K799, activity value is MIC = 4 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 2 ug/ml||Anti-E. coli CGSC 4908, activity value is MIC = 4 ug/ml||Anti-S. epidermidis C621, activity value is MIC = 64 ug/ml||Anti-MRSA C623, activity value is MIC = 64 ug/ml||Anti-C. albicans C627, activity value is MIC = 16 ug/ml||Anti-A. salmonicida 99-1, activity value is MIC = 4 uM||Anti-A. salmonicida 97-4, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 8 uM||Anti-P. aeruginosa K799, activity value is MIC = 4 uM||Anti-P. aeruginosa Z61, activity value is MIC = 2 uM||Anti-E. coli CGSC4908 or UB1005 or DC2, activity value is MIC = 4 uM||Anti-S. epidermidis C621 or MRSA, activity value is MIC = 64 uM||Anti-and C. albicans C627, activity value is MIC = 16 uM	Yellowtail flounder YT2, Pleuronectes ferruginea Storer|||Yellowtail flounder YT2, Pleuronectes ferruginea Storer|||Limanda ferruginea [Yellowtail flounder]|||Limanda ferruginea (Yellowtail flounder YT2)|||Limanda ferruginea [Yellowtail flounder]|||Yellowtail flounder YT2, Pleuronectes ferruginea Storer	N/A	A. salmonicida 99-1 ( MIC = 4 ug/ml), A. salmonicida 97-4 ( MIC = 2 ug/ml), S. enterica serovar Typhimurium MS7953s ( MIC = 2 ug/ml), S. enterica serovar Typhimurium 14028s ( MIC = 8 ug/ml), P. aeruginosa K799 ( MIC = 4 ug/ml), P. aeruginosa Z61 ( MIC = 2 ug/ml), E. coli CGSC 4908 ( MIC = 4 ug/ml), E. coli UB1005 ( MIC = 4 ug/ml), E. coli DC2 ( MIC = 4 ug/ml), S. epidermidis C621 ( MIC = 64 ug/ml), MRSA C623 ( MIC = 64 ug/ml), C. albicans C627 ( MIC = 16 ug/ml)	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-2470.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.	25	L
FPDB00897	AP00136|||AP00136|||Crabrolin|||DRAMP03310	FLPLILRKIVTAL	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-weakly active against E.coli, activity value is MIC = 150 ug/ml||Anti-E. coli ATCC 8739, activity value is MIC = 32 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 64 uM||Anti-E. faecium NTCC 12697, activity value is MIC = 16 uM||Anti-and P.aeruginosa ATCC 9027, activity value is MIC = 128 uM||Anti-PC-3, activity value is IC50 = 32.13 uM||Anti-HCT-116, activity value is IC50 = 8.539 uM||Anti-MCF-7, activity value is IC50 = 26.49 uM||Anti-and U251MG, activity value is IC50 = 20.13 uM||Antibacterial||No MICs found in DRAMP database	venom, the European hornet, Vespa crabro, Europe|||venom, the European hornet, Vespa crabro|||Vespa crabro [European hornet]|||Vespa crabro (European hornet)	Helix	"MP-C (Parent Peptide): HC₅₀ against horse red blood cells is 40.11 uM
cMP-C (Cyclized Analogue): HC₅₀ against horse red blood cells is 9.19 uM
tMP-C (TAT-Conjugated Analogue): HC₅₀ against horse red blood cells is 77.94 uM|||Hemolytic activity of Mastoparan C: Its hemolytic activity is lower than that of Mastoparan (a known peptide), with specific values not mentioned. 
Hemolytic activity of Crabrolin: In hemolysis experiments, its activity is lower than that of Mastoparan C, and specific values are also not provided.|||[Ref.6206053] Hemolysis is 20% of total at 10 ug/ml against guinea pig red blood cell."	"J Biol Chem. 1984 Aug 25;259(16):10106-11. PubMed.|||J Biol Chem
. 1984 Aug 25;259(16):10106-11.||PubMed1997||Yao et al., 2023|||9273892"	13	
FPDB00898	AP00155|||DRAMP02912|||Cathelin-related peptide SC5|||AP00155	RGLRRLGRKIAHGVKKYGPTVLRIIRIAG	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||anti-sepsis||Hemolytic||Antibiofilm||Anti-E. coli ATCC 25922 or ML-35 or D21, activity value is MIC = 0.12||Anti-S. enterica serovar typhimurium ATCC 14028, activity value is MIC = 0.25 uM||Anti-P. aeruginosa ATCC 27853 or 2 clinical isolates, activity value is MIC = 0.25||Anti-S. marcescens ATCC 8100, activity value is MIC = 0.25 uM||Anti-P-vulgaris ATCC 13315, activity value is MIC > 80 uM||Anti-S. aureus ATCC 25923 or Cowan 1 MRSA clinical isolate, activity value is MIC = 0.5||Anti-S. epidermidis ATCC 12228, activity value is MIC = 0.25 uM||Anti-E. faecalis ATCC 29212 or V clinical isolate, activity value is MIC = 1 uM||Anti-B. megaterium Bm11, activity value is MIC = 0.25 uM||Anti-C. albicans clinical isolate, activity value is MIC = 4 uM||Anti-C. neoformans 3 clinical isolates, activity value is MIC = 1 uM||Anti-and R. rubra, activity value is MIC = 0.5 uM||Anti-Escherichia coli DH5a, activity value is MIC = 0.1 uM||Anti-Escherichia coli ML-35p, activity value is MIC = 0.18 uM||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC = 0.17 uM||Anti-Pseudomonas aeruginosa MR3007, activity value is MIC = 0.34 uM||Anti-Staphylococcus aureus ATCC 33591, activity value is MIC = 1.24 uM||Anti-Staphylococcus aureus 93918, activity value is MIC = 0.31 uM||Anti-Escherichia coli ML-35p, activity value is MIC = 0.12 uM||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC = 0.08 uM||Anti-Pseudomonas aeruginosa MR3007, activity value is MIC = 0.18 uM||Anti-Staphylococcus aureus ATCC 33591, activity value is MIC = 0.65 uM||Anti-Staphylococcus aureus 93918, activity value is MIC = 0.43 uM||Anti-Staphylococcus aureus 25923, activity value is MIC = 5||Anti-Pseudomonas aeruginosa 27853, activity value is MIC = 5||Anti-Klebsiella pneumoniae 13883, activity value is MIC = 2.5||Anti-Candida albicans 14053, activity value is MIC = 10||Anti-pmid-10768969[ Pseudomonas aeruginosa PAO1, activity value is MIC = 0.17 uM||Anti-MRSA ATCC 33591, activity value is MIC = 1.24 uM	sheep leukocytes; Ovis aries|||Ovis aries (Sheep)|||Ovis aries [Sheep]|||sheep leukocytes; Ovis aries	Helix	N/A	"FEBS Lett. 1995 Dec 4;376(3):225-8. PubMed.|||1995 Dec 4;376(3):225-8. doi: 10.1016/0014-5793(95)01285-3.||Skerlavaj et al., 1999||Blower et al., 2018||Sousa et al., 2017|||Comparative Study FEBS Lett
. 1995 Dec 4;376(3):225-8. doi: 10.1016/0014-5793(95)01285-3.||Skerlavaj et al., 1999||Blower et al., 2018||Sousa et al., 2017|||Protein Eng. 2002 Mar;15(3):225-232.||Ref.8549789|||8549789|||FEBS Lett. 1995 Dec 4;376(3):225-8. doi: 10.1016/0014-5793(95)01285-3.||Skerlavaj et al., 1999||Blower et al., 2018||Sousa et al., 2017"	29	
FPDB00899	AP00210|||AP00210|||PYLa/PGLa precursor|||DRAMP02272|||PYLa/PGLa precursor|||AP00210	GMASKAGAIAGKIAKVALKAL	Anti-Gram+ & Gram-||Antifungal||Antiparasitic||Anti-MRSA||Antimalarial||Synergistic AMPs||Anti-Activity was demonstrated in 1988 . Active against E. coli ATCC 25922, activity value is MIC = 6||Anti-P.aeruginosa ATCC 27883, activity value is MIC = 200||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 25||Anti-S. pyogenes ATCC 19615, activity value is MIC = 10||Anti-and C.albicans, activity value is MIC = 100||Anti-and T. pyriformis . Active against Gram+ A. viridans, activity value is MIC = 0.6||Anti-M. luteus, activity value is MIC = 0.3||Anti-B. megaterium, activity value is MIC = 1.3||Anti-B. subtilis, activity value is MIC = 0.6||Anti-S. aureus, activity value is MIC = 1.3||Anti-P. acidolactici, activity value is MIC = 1.3||Anti-E. coli, activity value is MIC = 1.3||Anti-S. typhimuriumn, activity value is MIC = 5.2||Anti-K pneumoniae, activity value is MIC = 1.3||Anti-E. cloacae, activity value is MIC = 1.3||Anti-E. carotovora, activity value is MIC = 1.3||Anti-P. aeruginosa, activity value is MIC = 5.2||Anti-1788:1593-1599). ALso active against Gram+ B. cereus, activity value is MIC = 2.3||Anti-B. thuringiensis, activity value is MIC = 4.6||Anti-C. michiganensis, activity value is MIC = 1.15||Anti-P. syringae phaseoli, activity value is MIC = 1.15||Anti-P. pisi, activity value is MIC = 0.6||Anti-P-valerianella, activity value is MIC > 30 uM||Anti-X. campestris pv. oryzae, activity value is MIC = 4.6||Anti-X. campestris pv. campestris, activity value is MIC = 0.3||Anti-and X. vesicatoria B229RI, activity value is MIC = 0.6||Anti-Escherichia coli 25922, activity value is MIC = 62||Anti-Klebsiella pneumoniae 13883, activity value is MIC = 250||Anti-Pseudomonas aeruginosa 27853, activity value is MIC = 250||Anti-Staphylococcus aureus 29213, activity value is MIC = 125||Anti-Candida albicans 14053, activity value is MIC = 250||Anti-Strepococcus faecalis, activity value is MIC > 500 ug/ml	skin; Stomach, African clawed frog, Xenopus laevis, Africa|||skin; Stomach, African clawed frog, Xenopus laevis, Africa|||Xenopus laevis [African clawed frog]|||Xenopus laevis (African clawed frog)|||skin; Stomach, African clawed frog, Xenopus laevis, Africa	Helix	"The hemolytic values of peptides related to the skin granular gland secretions of African clawed frog (Xenopus) in the document are as follows. The experiment measured the hemolysis rate by adding peptides at different concentrations to a 5% human red blood cell suspension and incubating at 37°C for 30 minutes (100% hemolysis was induced by 0.2% Triton X-100):

- At a peptide concentration of 0 μg/ml: the hemolysis rates for Magainin 2, PGLa, XPF, and bee venom peptide Mellitin were all 0%.
- At a peptide concentration of 50 μg/ml: the hemolysis rates were 4% for Magainin 2, 4% for PGLa, 1% for XPF, and 100% for bee venom peptide Mellitin.
- At a peptide concentration of 100 μg/ml: the hemolysis rates were 3% for Magainin 2, 3% for PGLa, 1% for XPF (bee venom peptide Mellitin was not tested).
- At a peptide concentration of 200 μg/ml: the hemolysis rates were 3% for Magainin 2, 4% for PGLa, 2% for XPF (bee venom peptide Mellitin was not tested).
- At a peptide concentration of 500 μg/ml: the hemolysis rates were 4% for Magainin 2, 5% for PGLa, 5% for XPF (bee venom peptide Mellitin was not tested).
- At a peptide concentration of 1000 μg/ml: the hemolysis rates were 6% for Magainin 2, 7% for PGLa, 6% for XPF (bee venom peptide Mellitin was not tested).

Among them, bee venom peptide Mellitin acted as the positive control. The three clawed frog-derived antimicrobial peptides, Magainin 2, PGLa, and XPF, exhibited extremely low hemolytic activity, with hemolysis rates remaining below 7% even at the high concentration of 1000 μg/ml.|||In Document 6 (Biochem. J. 1987), there is no explicit mention of the specific hemolytic values of primary peptides derived from prohormone processing in the skin secretions of the African clawed frog (Xenopus laevis), such as caerulein precursor fragments, xenopsin precursor fragments, PGLa, etc. It only mentions that some of the larger primary peptides may have hemolytic activity and that after secretion, they are degraded by proteases into inactive small fragments."	"FEBS Lett. 1988 Feb 15;228(2):337-40. Pub-Med.|||Comparative Study FEBS Lett
. 1988 Feb 15;228(2):337-40. doi: 10.1016/0014-5793(88)80027-9.||see ref||see ref for Thanatin||Ehret-Sabatier et al., 1996|||1717472|||Biochem J. 1987 Apr 1;243(1):113-120.|||1717472|||FEBS Lett. 1988 Feb 15;228(2):337-40. doi: 10.1016/0014-5793(88)80027-9.||see ref||see ref for Thanatin||Ehret-Sabatier et al., 1996"	21	
FPDB00900	AP00276|||AP00276|||Clavanin-A|||Clavanin A|||ClavA|||DRAMP02597|||Clavanin-A|||Clavanin A|||AP00276|||DRAMP02597	VFQFLGKIIHHVGNFVHGFSHVF	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-L. monocytogenes EGD, activity value is MIC = 0.2||Anti-and P. aeruginosa MR3007, activity value is MIC = 0.4||Antibacterial||Antimicrobial||Anti-Gram+||Antifungal ; E.coli||L.monocytes||C.albicans	sea squirts, and sea pork, invertebrate Styela clava|||sea squirts, and sea pork, invertebrate Styela clava|||Styela clava [Sea squirt]|||Styela clava [Sea squirts]|||Styela clava (Sea squirt)|||Styela clava [Sea squirts]|||sea squirts, and sea pork, invertebrate Styela clava|||Styela clava (Sea squirt)	Helix||Alpha helix	E. Coli (MIC=64 uM )|||Their hemolytic activity against human red blood cells was less than 10% up to 50 uM.	"FEBS Lett. 1997; 400:158-162. PubMed.|||FEBS Lett
. 1997 Jan 3;400(2):158-62. doi: 10.1016/s0014-5793(96)01374-9.||Lee IH et al., 1997|||9001389|||28712894|||28226206|||FEBS Lett. 1997 Jun 30;410(2-3):490-492.|||9001389|||28712894|||FEBS Lett. 1997; 400:158-162. doi: 10.1016/s0014-5793(96)01374-9.||Lee IH et al., 1997|||FEBS Lett. 1997 Jun 30;410(2-3):490-492. FEBS Lett. 1997 Jan 3;400(2):158-162."	23	
FPDB00901	AP00278|||AP00278|||Clavanin-C|||DRAMP02599|||Clavanin-C|||DRAMP02599	VFHLLGKIIHHVGNFVYGFSHVF	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibacterial||Antimicrobial||Anti-Gram+||Antifungal ; E.coli||L.monocytes||C.albicans	invertebrate Styela clava|||invertebrate Styela clava|||Styela clava [Sea squirt]|||Styela clava (Sea squirt)	Alpha helix	N/A	"FEBS Lett. 1997; 400:158-162. PubMed.|||FEBS Lett
. 1997 Jan 3;400(2):158-62. doi: 10.1016/s0014-5793(96)01374-9.|||9001389|||FEBS Lett. 1997 Jun 30;410(2-3):490-492.|||9001389|||FEBS Lett. 1997 Jun 30;410(2-3):490-492. FEBS Lett. 1997 Jan 3;400(2):158-162."	23	
FPDB00902	AP00280|||DRAMP02601|||AP00280|||DRAMP02601	LFKLLGKIIHHVGNFVHGFSHVF	Anti-Gram+||Antifungal||Anti-MRSA||Antimicrobial||Antibacterial	invertebrate Styela clava|||Styela clava (Sea squirt)|||invertebrate Styela clava|||Styela clava (Sea squirt)	N/A	N/A	"FEBS Lett. 1997 Jun 30;410(2-3):490-2. PubMed.|||FEBS Lett
. 1997 Jun 30;410(2-3):490-2. doi: 10.1016/s0014-5793(97)00646-7.|||FEBS Lett. 1997 Jun 30;410(2-3):490-492.|||FEBS Lett. 1997 Jun 30;410(2-3):490-2. PubMed.|||FEBS Lett. 1997 Jun 30;410(2-3):490-492."	23	
FPDB00903	AP00285|||DRAMP03332	LRGLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR	Anti-Gram+ & Gram-||Anti-MRSA||Active against E. coli and S. aureus or MRSA.||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-	Mus musculus|||Mus musculus (Mouse)	Beta	N/A	Infect. Immun. 1994; 62: 5040-5047|||Biochemistry. 2004 Dec 21;43(50):15759-15766.Infect Immun. 1994 Nov;62(11):5040-5047.J Biol Chem. 2006 Sep 22;281(38):28068-78.	34	
FPDB00904	AP00330|||Styelin-D	GWLRKAAKSVGKFYYKHKYYIKAAWQIGKHAL	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||active against S. aureus or MRSA||P. aeruginosa.||Antibacterial||Antifungal	Sea squirt, Styela clava|||Styela clava [Sea squirt]	Helix	N/A	FEBS Lett. 1997; 412:144-148|||10978343	32	
FPDB00905	AP00418	GLRKRLRKFRNKIKEKLKKIGQKIQGFVPKLAPRTDY	Anti-Gram+ & Gram-||Anti-MRSA||anti-sepsis||This appears to be the first peptide in the cathelicidin family demonstrated to have antibacterial activity against various Gram-positive S. pneumoniae||S. pyogenes||and S. aureus or MRSA and Gram-negative bacteria E. coli HB101||K. pneumoniae||P. aeruginosa||and P. apacia. C-albicans (inactive at 20 ug/ml).||anti-sepsis  This appears to be the first peptide in the cathelicidin family demonstrated to have antibacterial activity against various Gram-positive S. pneumoniae	granulocytes, Rabbit, Oryctolagus cuniculus	Helix	"The document only mentions one hemolysis test result, with the key information as follows:

Hemolysis of 8 cathelicidin peptides and control peptide
All tested cathelicidin peptides (including LL-37, D-LL-37, SMAP-29, PG-1, mCRAMP, BMAP-28, NA-CATH, CAP-18) and the control peptide (scrambled LL-37), at a concentration of 100 µg/ml, did not show statistically significant hemolysis of defibrinated sheep red blood cells (the text explicitly states “no peptide demonstrated statistically significant hemolytic activity (p<0.001)”).

This concentration is 100 times that used to treat Bacillus anthracis infections in wax moth larvae (G. mellonella), and the document does not provide hemolysis data at other concentrations, nor does it mention hemolysis test results on the red blood cells of other species."	Antimicrob Agents Chemother. 1993 Dec;37(12):2534-9.|||Antimicrob Agents Chemother. 1993 Dec;37(12):2534-9	37	
FPDB00906	AP00498|||AP00498|||RCRAMP	GLVRKGGEKFGEKLRKIGQKIKEFFQKLALEIEQ	Anti-Gram+ & Gram-||Anti-MRSA||Antibacterial	M2 macrophage, islet beta cells, delta cells; Norway rat, Rattus norvegicus|||M2 macrophage, islet beta cells, delta cells; Norway rat, Rattus norvegicus|||Rattus norvegicus [Rat]	N/A	"The document provides data on the hemolytic activity of host defense peptides against red blood cells solely in Table 2 (Cytotoxic Concentrations of Various Host Defence Peptides), with the key information as follows:

1. Hemolytic activity of key peptides (using human red blood cells as the test subject)

LL-37 (human antimicrobial peptide):
Hemolytic concentration: 50–100 µM (no mention of serum presence; assumed to be under serum-free conditions).
Note: At this concentration, LL-37 can induce erythrocyte hemolysis, and its hemolytic activity is influenced by serum—specifically, in culture systems containing serum, the cytotoxicity of LL-37 toward other mammalian cells (such as primary human blood monocytes) is significantly reduced. However, the document does not specify the extent to which serum affects its hemolytic activity against erythrocytes.

2. Cytotoxicity of other peptides (no definitive hemolysis data available)

HNP1-3 (human neutrophil defensins): The table only reports their cytotoxicity against alveolar macrophages (7.5–30 µM), epithelial cell lines (6–24 µM), and monocytes (10–100 µM in serum-free conditions; &gt;100 µM in the presence of serum), with no mention of hemolytic activity against red blood cells or associated numerical data.
ADP-ribosylated HNP1-3: Only its cytotoxicity against epithelial cell lines has been reported (&gt;24 µM, serum-free); no hemolytic data for red blood cells are available.

3. Key Notes

The document does not provide a specific “hemolysis rate–concentration” curve or the precise value of the 50% hemolysis concentration (HC₅₀) (e.g., the percentage of hemolysis at a given concentration); it only specifies the minimum concentration range (50–100 µM) at which LL-37 induces red blood cell hemolysis.
The hemolytic activity of other host defense peptides (such as the HBD and HD families) is not mentioned in the documentation, and relevant data are unavailable.|||In hemolysis experiments targeting mammalian cathelicidin-derived peptides, the relevant hemolytic values are as follows:

- SMAP34 and FALL39: exhibited relatively obvious hemolytic activity, but specific values were not clearly mentioned.
- CAP18, rCRAMP, and LL37: showed the lowest hemolytic activity and hardly caused hemolysis at the experimental concentrations.

The experimental results indicate that the hemolytic activity differs among peptides, with peptides such as CAP18 and LL37 having a lower risk of hemolysis and potential therapeutic application value."	Infect Immun. 2000 May;68(5):2748-55|||Infect Immun. 2000 May;68(5):2748-55|||11557478	34	
FPDB00907	AP00516|||AP00516|||Lycotoxin-1|||DRAMP03278|||Lycotoxin-1|||AP00516	IWLTALKFLGKHAAKHLAKQQLSKL	Anti-Gram+ & Gram-||Antifungal||candidacidal||Insecticidal||Anti-MRSA||Enzyme inhibitor||Anti-Gram-negative bacteria E. coli D31, activity value is MIC = 10||Anti-C. albicans clinical isolate . Also active against S. aureus USA300 MRSA, activity value is MIC = 3.1 uM||Anti-E. coli, activity value is MIC = 25 uM||Anti-B. subtilis, activity value is MIC = 6.25 uM||Anti-and P. aeruginosa, activity value is MIC = 6.25 uM||Antibacterial||Anti-Bacillus thuringiensis subsp. Israelensis, activity value is MIC < 5 uM||Anti-Escherichia coli D31, activity value is MIC = 10||Anti-Escherichia coli DH5, activity value is MIC = 80||Anti-Candida albicans clinical isolate, activity value is MIC = 100	Wolf Spider, Hogna carolinensis, (old)Lycosa carolinensis|||Wolf Spider, Hogna carolinensis, (old)Lycosa carolinensis|||Hogna carolinensis [Carolina wolf spider]|||Hogna carolinensis (Carolina wolf spider) (Lycosa carolinensis)|||Hogna carolinensis [Carolina wolf spider]|||Wolf Spider, Hogna carolinensis, (old)Lycosa carolinensis	Alpha helix	"The document provides clear hemolysis data for spider venom antimicrobial peptides (lycotoxins) and the control peptide magainin B through hemolysis assays (using rabbit red blood cells as the test subject). The core data are as follows:

1. Hemolytic activity and concentration dependence of key peptides

Testing conditions: Rabbit red blood cells were incubated with peptides in PBS for 1 hour. Hemoglobin release was measured at 570 nm. ""Water-lysed red blood cells"" served as the 100% hemolysis control, and ""PBS incubation"" served as the 0% hemolysis control.

lycotoxin I (spider-derived antimicrobial peptide):
No hemolytic activity concentration: <30 μM (no hemolysis detected below this concentration).
Significant hemolytic concentration: >100 μM, with hemolysis rate increasing with concentration.
Specific data: At 200 μM, hemolysis rate is 55% (calculated as: (absorbance of lycotoxin I group / absorbance of water-lysed group) × 100%).

magainin B (control, frog-derived antimicrobial peptide):
No hemolytic activity concentration: <30 μM (same as lycotoxin I).
Significant hemolytic concentration: >100 μM, but hemolytic activity is weaker than lycotoxin I.
Specific data: At 200 μM, hemolysis rate is 35%.

2. Key notes

The hemolysis curve trends of the two peptides are consistent (increased concentration → increased hemolysis rate), but at the same high concentration, lycotoxin I exhibits significantly higher hemolytic activity than magainin B (55% vs. 35% at 200 μM).

The document does not provide hemolysis data for lycotoxin II; it only clearly states that there are no relevant test results. The 50% hemolytic concentration (HC₅₀) was not calculated, and only specific concentrations (200 μM) with corresponding hemolysis rates and the thresholds for “no hemolysis/significant hemolysis” are given.|||Lycotoxin I: No obvious hemolysis at <30 μM, significant hemolysis at 100 μM, and a hemolysis rate of 55% at 200 μM;

• Magainin B: No obvious hemolysis at <30 μM, significant hemolysis at 100 μM, and a hemolysis rate of 35% at 200 μM.|||Within the concentration range of ≤30 uM, Lycotoxin I exhibits no significant hemolytic effect on rabbit red blood cells, with a hemolysis rate of <5%. It begins to show significant hemolysis at 100 uM, and the hemolysis rate reaches 55% at 200 uM."	"J Biol Chem. 1998 Jan 23;273(4):2059-66. PubMed.|||J Biol Chem
. 1998 Jan 23;273(4):2059-66. doi: 10.1074/jbc.273.4.2059.||this ref||Menousek J et al 2012 Int J Antimicrob Agents 39:402|||9442044|||J Pept Sci. 2008 Apr;14(4):528-534.|||9442044|||J Biol Chem. 1998 Jan 23;273(4):2059-66. PubMed.||this ref||Menousek J et al 2012 Int J Antimicrob Agents 39:402"	25	
FPDB00908	AP00519|||AP00519|||Ib-AMP4|||DRAMP00997|||Ib-AMP4|||AP00519|||DRAMP00997	QWGRRCCGWGPGRRYCRRWC	Anti-Gram+||Antifungal||Anti-MRSA||Anti-fungi A. longipes, activity value is IC50 = 3 ug/ml||Anti-B. cinerea, activity value is IC50 = 6 ug||Anti-C. sphaerospermum, activity value is IC50 = 1 ug||Anti-F. culmorum, activity value is IC50 = 1 ug||Anti-P. digitatum, activity value is IC50 = 3 ug||Anti-T. viride, activity value is IC50 = 6 ug||Anti-and V. alboatrum, activity value is IC50 = 6 ug||Anti-F. culmorum, activity value is IC50 = 1||Anti-S. cerevisiae, activity value is IC50 = 13 uM||Anti-and P. pastoris, activity value is IC50 = 5 uM||Antibacterial ; Impatiens balsamina [Balsam]||Anti-Alternaria longipes, activity value is MIC = 3 ug/ml||Anti-Botrytis cinerea, activity value is MIC = 6 ug/ml||Anti-Cladosporium sphaerospermum, activity value is MIC = 1 ug/ml||Anti-F. culmorum, activity value is MIC = 1 ug/ml||Anti-Penicillium digitatum, activity value is MIC = 3 ug/ml||Anti-T. viride, activity value is MIC = 6 ug/ml||Anti-V. alboatrum, activity value is MIC = 6 ug/ml||Anti-Alternaria longipes, activity value is MIC = 12 ug/ml||Anti-Botrytis cinerea, activity value is MIC = 200 ug/ml||Anti-Cladosporium sphaerospermum, activity value is MIC = 6 ug/ml||Anti-F. culmorum, activity value is MIC = 6 ug/ml||Anti-Penicillium digitatum, activity value is MIC = 25 ug/ml||Anti-T. viride, activity value is MIC = 150 ug/ml||Anti-V. Alboatrum, activity value is MIC = 50 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 5 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 20 ug/ml||Anti-Streptococcus faecalis, activity value is MIC = 5 ug/ml||Anti-X. campestris, activity value is MIC = 6 ug/ml||Anti-X. Oryzae, activity value is MIC = 15 ug/ml||Anti-Bacillus megaterium 14581, activity value is MIC = 1.25 ug/ml||Anti-Bacillus subtilis 6051, activity value is MIC = 2.5 ug/ml||Anti-Micrococcus luteus 7468, activity value is MIC = 5 ug/ml||Anti-Streptococcus agalactiae 27956, activity value is MIC = 160 ug/ml||Anti-Enterococcus faecalis 29212, activity value is MIC = 40 ug/ml||Anti-Staphylococcus oralis 35037, activity value is MIC = 80 ug/ml||Anti-Staphylococcus epidermidis 14990, activity value is MIC = 80 ug/ml||Anti-Staphylococcus aureus 29213, activity value is MIC = 10 ug/ml||Anti-Staphylococcus aureus 25923, activity value is MIC = 10 ug/ml||Anti-Streptococcus pneumoniae 49619, activity value is MIC = 20 ug/ml||Anti-Streptococcus pyogenes 12344, activity value is MIC = 10 ug/ml||Anti-Enterococcus casseliflavus 700327, activity value is MIC = 5 ug/ml||Anti-Klebsiella oxytoca 700324, activity value is MIC = 40 ug/ml||Anti-Klebsiella pneumoniae 700603, activity value is MIC = 120 ug/ml||Anti-Escherichia coli 25922, activity value is MIC = 10 ug/ml||Anti-Escherichia coli 35150, activity value is MIC = 8 ug/ml||Anti-Pseudomonas aeruginosa 27853, activity value is MIC = 160 ug/ml||Antimicrobial||Antibacterial||Anti-Gram-	seeds, Impatiens balsamina (Ib)|||seeds, Impatiens balsamina (Ib)|||Impatiens balsamina [Balsam]|||Impatiens balsamina [Plant]|||Impatiens balsamina (Balsam)|||seeds, Impatiens balsamina (Ib)|||Impatiens balsamina (Balsam)	Bridge	"The document only provides hemolytic information about Impatiens balsamina seed antimicrobial peptides (Ib-AMPs) through human red blood cell hemolysis experiments, with the main conclusions as follows:

1. Hemolysis results of key peptides

Test subjects: Ib-AMP2 and Ib-AMP4 (two antimicrobial peptides derived from Impatiens balsamina seeds), using human type A red blood cells as the testing material, suspended in phosphate-buffered saline (PBS) for incubation.
Key concentrations and results:
At a high concentration of 200 µg/ml, Ib-AMP2 and Ib-AMP4 did not cause red blood cell hemolysis and did not damage the integrity of cultured human skin fibroblast membranes (no cytotoxicity).
The document does not provide specific hemolysis data at lower concentrations (e.g., <200 µg/ml), only stating clearly that “no hemolytic activity was observed at 200 µg/ml and below”; it does not mention hemolysis testing results for Ib-AMP1 and Ib-AMP3.

2. Key notes

This experiment used ""PBS-incubated red blood cells"" as the 0% hemolysis control and ""water-lysed red blood cells"" as the 100% hemolysis control, determining hemolysis by detecting hemoglobin release (absorbance method), and ultimately confirmed that Ib-AMP2 and Ib-AMP4 showed no hemolytic activity at the highest tested concentration (200 µg/ml).
No 50% hemolysis concentration (HC₅₀) or ""concentration-hemolysis rate"" curve was provided, so more detailed hemolytic data (e.g., the percentage of hemolysis at specific concentrations) cannot be obtained.|||Alternaria longipes ( MIC = 3 ug/ml), Botrytis cinerea ( MIC = 6 ug/ml), Cladosporium sphaerospermum ( MIC = 1 ug/ml), F. culmorum ( MIC = 1 ug/ml), Penicillium digitatum ( MIC = 3 ug/ml), T. viride ( MIC = 6 ug/ml), V. alboatrum ( MIC = 6 ug/ml), Alternaria longipes ( MIC = 12 ug/ml), Botrytis cinerea ( MIC = 200 ug/ml), Cladosporium sphaerospermum ( MIC = 6 ug/ml), F. culmorum ( MIC = 6 ug/ml), Penicillium digitatum ( MIC = 25 ug/ml), T. viride ( MIC = 150 ug/ml), V. Alboatrum ( MIC = 50 ug/ml)]Antibacterial[Bacillus subtilis ( MIC = 5 ug/ml), Micrococcus luteus ( MIC = 5 ug/ml), Staphylococcus aureus ( MIC = 20 ug/ml), Streptococcus faecalis ( MIC = 5 ug/ml), Erwinia amylovora ( MIC = >100 ug/ml), Escherichia coli ( MIC = >500 ug/ml), Proteus vulgaris ( MIC = >500 ug/ml), Pseudomonas solanacearum ( MIC = >100 ug/ml), X. campestris ( MIC = 6 ug/ml), X. Oryzae ( MIC = 15 ug/ml)|||Test subjects: Human blood group A erythrocytes

Test peptides: Ib-AMP2 and Ib-AMP4

Test concentration: 200 ug/ml

Results: No hemolysis occurred (no lysis of erythrocytes)

Simultaneously tested: No effect on the membrane integrity of human skin fibroblasts|||Ib-AMP4 at a concentration of 200 ug/ml shows no hemolytic activity against human red blood cells."	"J. Biol. Chem., Sep 1997; 272: 24480 - 24487. PubMed|||J Biol Chem
. 1997 Sep 26;272(39):24480-7. doi: 10.1074/jbc.272.39.24480.|||https://pubmed.ncbi.nlm.nih.gov/9305910|||30986507|||J Biol Chem. 1997 Sep 26;272(39):24480-24487.|||9305910|||J. Biol. Chem., Sep 1997; 272: 24480 - 24487. PubMed|||J Biol Chem. 1997 Sep 26;272(39):24480-24487.Biochemistry. 1998 Jan 27;37(4):983-990."	20	
FPDB00909	AP00538|||AP00538|||Halocidin precursorB|||DRAMP03158	WLNALLHHGLNCAKGVLA	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||active against S. aureus MRSA and P. aeruginosa.||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram-	hemocytes, Halocynthia aurantium|||hemocytes, Halocynthia aurantium|||Halocynthia aurantium [Sea peach]|||Halocynthia aurantium (Sea peach)	N/A	"The document does not specifically mention ""hemolytic values,"" but it does report the results of hemolysis experiments:

- 18 monomer: at a concentration of 100 µg/ml, the hemolysis rate of human red blood cells is approximately 8%.
- 18 homologous dimer: at a concentration of 100 µg/ml, the hemolysis rate of human red blood cells is approximately 16%.
- 15 monomer, 15 homologous dimer, heterodimer (natural Halocidin): at a concentration of 100 µg/ml, almost no hemolytic activity.
- Positive control bee venom peptide (Melittin): strong hemolytic activity, specific values not mentioned.|||No hemolytic activity towards human erythrocytes"	FEBS Lett. 2002 Jun 19;521(1-3):81-6.|||FEBS Lett. 2002 Jun 19;521(1-3):81-6.|||12067731|||FEBS Lett. 2002 Jun 19;521(1-3):81-86.	18	
FPDB00910	AP00539|||DRAMP03470	GFGCPWNRYQCHSHCRSIGRLGGYCAGSLRLTCTCYRS	Anti-Gram+ & Gram-||Anti-MRSA||Anti-and V. parahemolyticus . Also active against S. aureus ATCC 43300 or ATCC 25923 or E48, activity value is MIC = 8||Anti-S. pseudintermedius A2101, activity value is MIC = 8 ug/ml||Anti-S. agalactiae ATCC 13813, activity value is MIC = 4 ug/ml||Anti-S. hyicus NCTC 10350, activity value is MIC = 16 ug/ml||Anti-S. epidermidis ATCC 35984 or ATCC 12228 or G-81, activity value is MIC = 4 ug/ml||Anti-E-coli ATCC 25922, activity value is MIC > 64 ug/ml||Anti-S-typhimurium CVCC 14028, activity value is MIC > 64 ug/ml||Anti-and S-flexneri CMCC 51571, activity value is MIC > 64 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-	American oyster, Crassostrea virginica|||Crassostrea virginica (American oyster)	Beta	N/A	"Biochem Biophys Res Commun. 2005 Dec 30;338(4):1998-2004. PubMed|||Biochem Biophys Res Commun
. 2005 Dec 30;338(4):1998-2004. doi: 10.1016/j.bbrc.2005.11.013.|||Biochem Biophys Res Commun. 2005 Dec 30;338(4):1998-2004."	38	
FPDB00911	AP00548	RFGRFLRKIRRFRPKVTITIQGSARFG	Anti-Gram+ & Gram-||Anti-MRSA||anti-sepsis||Hemolytic||Antibiofilm||Anti-Gram- E. coli ATCC 25922 or O157:H7 or PCN033 or RS218, activity value is MIC = 0.66||Anti-S. typhimurium ATCC 14028 or 700408, activity value is MIC = 0.66||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 0.66 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 5.32 uM||Anti-L. monocytogenes ATCC 19115, activity value is MIC = 1.33 uM||Anti-S. aureus ATCC 25923 or BAA-39 or 43300 MRSA, activity value is MIC = 0.33||Anti-MRSA WKZ-2, activity value is MIC = 5 uM||Anti-B. globigii TNO BMO13, activity value is MIC = 20 uM||Anti-E. coli ATCC 25922, activity value is MIC = 10 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 10 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 20 uM||Anti-and S. enteriditis 706 RIVM, activity value is MIC = 10 uM	chicken, Gallus gallus	Helix	"This document focuses on the inflammatory response and coagulation abnormalities in dogs with idiopathic immune-mediated hemolytic anemia (IMHA). It does not directly provide quantitative hemolytic values (such as hemolysis rate, free hemoglobin concentration, etc.), but indirectly reflects hemolysis-related pathological states through the following indicators. The core data are as follows: 
 
1. Directly indicates key indicators of hemolysis
 
- Red blood cell-related indicators: 
The median hematocrit (Ht) in IMHA dogs (Group F, n=24) was 160 ml/L (range 60-340 ml/L), significantly lower than that of healthy dogs (Group A, median 500 ml/L) and other disease groups (e.g., sepsis group E median 320 ml/L, surgery group C median 380 ml/L), directly reflecting hemolysis-induced red blood cell loss. 
Clinical signs and tests related to hemolysis: 
Among 24 dogs with IMHA, 7 showed visible hemoglobinuria (indicating intravascular hemolysis), and 13 showed jaundice (due to elevated bilirubin after hemolysis). 
21 cases showed positive direct agglutination test (DAT), and 18 blood smears showed spherical red blood cells (all typical IMHA diagnostic criteria, reflecting hemolytic characteristics of red blood cells destroyed by antibodies). 
 
2. Indirectly related to hemolysis and coagulation and inflammatory indicators
 
Platelet parameters: 
The median platelet count (PLT) in IMHA patients was 200×10⁹/L (range 24-652×10⁹/L), which was higher than the DIC group (Group D, median 72×10⁹/L), but there was platelet activation and high turnover: median mean platelet volume (MPV) reached 19.4 fL (significantly higher than healthy dogs 11.6 fL and other disease groups), and median mean platelet mass (MPM) was 0.000003 μg, indicating increased compensatory platelet production associated with hemolysis and coagulation activation. 
Coagulation factor activity: 
In IMHA patients, except for increased activity of coagulation factors VIII (FVIII) and IX (FIX) (both are acute phase proteins that increase in response to inflammatory stimulation), the activities of other coagulation factors (FII, FV, FVII, FIX, FX, FXI, FXII) were all reduced, consistent with the characteristics of wasting thrombosis and indirectly reflected coagulation system activation triggered by hemolysis. 
Inflammatory indicators: 
The median white blood cell count (WBC) in IMHA dogs reached 33.5×10⁹/L (range 5.5-86.8×10⁹/L), significantly higher than that of healthy dogs (8.6×10⁹/L) and sepsis group (21.8×10⁹/L); Median monocyte count was 2.1×10⁹/L, median rod nucleoliocyte count was 1.3×10⁹/L, indicating a strong inflammatory response associated with post-hemolysis tissue damage and immune activation. 
 
In summary, the document does not provide traditional ""hemolytic values"" (such as hemolysis rate), but through hematocrit, hemoglobinuria, jaundice, DAT positivity, spherical red blood cells, and coagulation/inflammation indicators, it provides a comprehensive reflection of the hemolytic pathological status of dogs with IMHA. The median Ht of 160 ml/L is the core quantitative indicator for assessing hemolysis severity."	Vet. Immunol. Immunopathol. 106 (3-4), 321-327 (2005)|||Vet. Immunol. Immunopathol. 106 (3-4), 321-327 (2005)||Bosso et al., 2017	27	
FPDB00912	AP00549|||DRAMP00999|||AP00549|||DRAMP00999	GFGCNGPWDEDDMQCHNHCKSIKGYKGGYCAKGGFVCKCY	Anti-Gram+||Antiviral||Antifungal||Anti-MRSA||Anti-Gram+ bacteria S. pneumoniae PSSP 109 strains, activity value is MIC = 0.25||Anti-S. pneumoniae PRSP 24 strains, activity value is MIC = 0.125||Anti-S. pyogenes ESSP 12 strains, activity value is MIC = 0.063||Anti-S. aureus MSSA 5 strains, activity value is MIC = 4||Anti-S. aureus MRSA 4 strains, activity value is MIC = 16||Anti-S. epidermidis MSSE, activity value is MIC = 8||Anti-S. epidermidis MRSE, activity value is MIC = 4||Anti-E. faecalis 6 strains, activity value is MIC = 64||Anti-E. faecium 5 strains VSEF or 3 strains V, activity value is MIC = 16||Anti-C. diphtheriae 4 strains, activity value is MIC = 2||Anti-C. jeikeium 3 strains, activity value is MIC = 1||Anti-B. thuringiensis 3 strains, activity value is MIC = 32||Antimicrobial||Antibacterial	Pseudoplectania nigrella|||Pseudoplectania nigrella (Ebony cup)|||Pseudoplectania nigrella|||Pseudoplectania nigrella (Ebony cup)	Combine Helix and Beta structure||Combine helix and strand structure	"The document clearly provides the hemolytic values for plectasin, with the core data as follows:

Plectasin shows no significant hemolytic activity against human red blood cells, with a half-maximal effective concentration (EC_{50}) for hemolytic activity greater than 400 µg/ml.

This data was determined through in vitro experiments. The document also mentions that plectasin has extremely low cytotoxicity to mammalian cells; for example, the EC_{50} values for mouse L929 fibroblasts and normal human epidermal keratinocytes (NHEK) are both greater than 512 µg/ml, indicating that its selectivity for bacteria is much higher than its toxicity to mammalian cells (including red blood cells), supporting its safety potential as a therapeutic antibiotic.|||The document mentions that plectasin has very low hemolytic activity on human red blood cells, with a half-maximal effective concentration (EC₅₀) greater than 400 μg/ml.|||In the provided PDF file content, **hemolytic activity** is mentioned on **page 4**: 

> Plectasin was neither cytotoxic for murine L929 fibroblasts (effector concentration for half-maximum response, \(\mathrm{EC}_{50} > 512\mathrm{mg}\mathrm{l}^{-1}\) ) and normal human epidermal keratinocytes (NHEK) cells \(\mathrm{EC}_{50} > 512\mathrm{mg}\mathrm{l}^{-1}\) ) **nor haemolytic for human erythrocytes \(\mathrm{EC}_{50} > 400\mathrm{mg}\mathrm{l}^{-1}\)** (data not shown). 

This statement clearly states: **Plectasin does not have hemolytic effect on human red blood cells**, and its half-hemolytic concentration is \(\mathrm{EC}_{50} > 400 \\mathrm{mg} \cdot \mathrm{L}^{-1}\). This means that even at higher concentrations, Plectasin does not cause significant red blood cell rupture, indicating good biocompatibility and suitability as a potential therapeutic agent.|||In this document, data related to the hemolytic activity of plectasin on human red blood cells is mentioned: hemolytic activity on human red blood cells (EC₅₀ > 400,000 µg·L⁻¹).

This value indicates that plectasin has very weak hemolytic effects on human red blood cells in vitro, reflecting its low toxicity to mammalian cells and selective activity against bacteria."	"Nature. 2005 Oct 13;437(7061):975-80. PubMed.|||Nature
. 2005 Oct 13;437(7061):975-80. doi: 10.1038/nature04051.|||Nature. 2005 Oct 13;437(7061):975-780.|||Nature. 2005 Oct 13;437(7061):975-80. PubMed.|||Nature. 2005 Oct 13;437(7061):975-780."	40	
FPDB00913	AP00557|||AP00557|||Cathelicidin|||DRAMP03644	RVKRVWPLVIRTVIAGYNLYRAIKKK	Anti-Gram+ & Gram-||Anti-MRSA||Anti-inflammatory||anti-sepsis||Anti-Gram- E. coli ATCC 25922 or O157:H7 or PCN033 or RS218, activity value is MIC = 0.8||Anti-S. typhimurium ATCC 14028 or 700408, activity value is MIC = 0.4||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 0.4 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 3.18 uM||Anti-L. monocytogenes ATCC 19115, activity value is MIC = 0.8 uM||Anti-S. aureus ATCC 25923 or BAA-39 or 43300 MRSA, activity value is MIC = 0.4||E. coli||E. coli O157:H7||S. typhimurium||S. typhimurium DT104||K. pneumoniae||P. aeruginosa||L. monocytogenes||S. aureus||S. aureus MRSA||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-||Cytolytic	chicken, Gallus galllus|||chicken, Gallus galllus|||chicken, Gallus galllus|||Gallus gallus [Chicken]|||Gallus gallus (Chicken)	Helix	"fowlicidin-{50}) is approximately 6-10 uM.

The 50% hemolytic concentration (EC_{50}) of fowlicidin-2 for human and chicken red blood cells is approximately 15-20 uM."	J Biol Chem. 2006 Feb 3;281(5):2858-67.|||J Biol Chem. 2006 Feb 3;281(5):2858-67.|||16326712|||Biol Chem. 2006 Feb 3;281(5):2858-2867.FEBS J. 2006 Jun;273(12):2581-2593.	26	
FPDB00914	AP00575|||AP00575|||Brevinin -2 Gra , Brevinin-2E-OG1, Brevinin-2E-OG6|||Brevinin-2JD|||DRAMP01914|||Brevinin -2 Gra , Brevinin-2E-OG1, Brevinin-2E-OG6|||Brevinin-2JD	GLLDTFKNLALNAAKSAGVSVLNSLSCKLSKTC	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli, activity value is MIC = 12.5||Anti-S. aureus MRSA, activity value is MIC = 19||Antibacterial||Antifungal||Anti-Escherichia coli, activity value is MIC = 12.5 uM||Anti-Staphylococcus aureus, activity value is MIC = 50 uM||Anti-E. coli, activity value is MIC = 12.5 uM||Anti-S. aureus, activity value is MIC = 50 uM||Anti-C. albicans, activity value is MIC > 100 uM||Anti-Staphylococcus aureus, activity value is MIC = 64 ug/ml||Anti-CIB 85462, activity value is MIC = 64 ug/ml||Anti-Escherichia coli, activity value is MIC = 128 ug/ml||Anti-CIB 84492, activity value is MIC = 128 ug/ml||Anti-Candida albicans, activity value is MIC = 64 ug/ml||candidacidal	Rana grahami, Odorrana jingdongensis, Asia|||Rana grahami, Odorrana jingdongensis, Asia|||Rana grahami [Yunnanfu frog]|||Odorrana jingdongensis [Jingdong frog]|||Rana grahami (Asian frog)|||Rana grahami [Yunnanfu frog]|||Odorrana jingdongensis [Jingdong frog]	N/A	"Seven antimicrobial peptides isolated from the skin of the Asian frog (Rana grahami) exhibited the following hemolytic values, expressed as the concentration (LC₅₀) required to induce 50% hemolysis of human red blood cells:

The hemolytic LC50 value of esculentin-1GRa is 210 µM.
The hemolytic LC50 value of Brevinin-2GRa is 140 µM.
The hemolytic LC50 value of Brevinin-2GRb is 180 µM.
The hemolytic activity of Brevinin-1GRa was not detected (ND);
The hemolytic LC50 value of Brevinin-2GRc is 100 µM.
The hemolytic LC50 value of Nigrocin-2GRa is 295 µM.
The hemolytic LC₅₀ value of Nigrocin-2GRb is 40 µM, making it the most hemolytic among these seven antimicrobial peptides; concurrently, it also exhibits the highest antimicrobial activity, with MIC values of 3 µM against Escherichia coli and 12.5 µM against Staphylococcus aureus.
The hemolytic LC₅₀ value of Nigrocin-2GRc is &gt;500 μM, indicating the weakest hemolytic activity; its antibacterial activity is also relatively low, with an MIC of 50 μM against Escherichia coli and MICs &gt;100 μM against Staphylococcus aureus and Candida albicans. This suggests a certain correlation between the peptide’s hemolytic activity and its antibacterial potency.|||The document mentions hemolytic-related content. The following are the specific hemolytic values:

- Esculentin-1GRa: The concentration causing 50% hemolysis of human red blood cells (LC₅₀) is 210 μM.
- Brevinin-2GRa: LC₅₀ is 140 μM.
- Brevinin-2GRb: LC₅₀ is 180 μM.
- Brevinin-2GRc: LC₅₀ is 100 μM.
- Nigrocin-2GRa: LC₅₀ is 295 μM.
- Nigrocin-2GRb: LC₅₀ is 40 μM.
- Nigrocin-2GRc: LC₅₀ is greater than 501 μM.|||[Ref.16621155] LC50=140 uM against human erythrocytes."	"Peptides 2006; 27: 2111-2117. PubMed.|||Peptides
. 2006 Sep;27(9):2111-7. doi: 10.1016/j.peptides.2006.03.002. Epub 2006 Apr 18.|||16621155 , 17272268|||22917879|||Peptides. 2006 Sep;27(9):2111-2117.|||16621155|||16621155 , 17272268|||22917879"	33	
FPDB00915	AP00577|||AP00577|||Esculentin-2-OG10|||Esculentin-2JDa|||Esculentin-2-OG10|||DRAMP01454	GLFTLIKGAAKLIGKTVAKEAGKTGLELMACKITNQC	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- bacteria E. coli, activity value is MIC = 10.2 ug/ml||Anti-B. pyocyaneus, activity value is MIC = 10.2 ug/ml||Anti-S. aureus MRSA, activity value is MIC = 5.1 ug/ml||Anti-and yeast C. albicans, activity value is MIC = 5.1 ug/ml||Antibacterial||Antifungal||Anti-E. coli, activity value is MIC = 12.5 uM||Anti-S. aureus, activity value is MIC = 50 uM||Anti-C. albicans, activity value is MIC > 100 uM	Rana grahami; Odorrana andersonii, China, Asia|||Rana grahami; Odorrana andersonii, China, Asia|||Rana grahami [Yunnanfu frog]|||Odorrana jingdongensis [Jingdong frog]|||Rana grahami [Yunnanfu frog]|||Odorrana jingdongensis (Jingdong frog) (Rana jingdongensis)	N/A	"Seven antimicrobial peptides isolated from the skin of the Asian frog (Rana grahami) exhibited the following hemolytic values, expressed as the concentration (LC₅₀) required to induce 50% hemolysis of human red blood cells:

The hemolytic LC50 value of esculentin-1GRa is 210 µM.
The hemolytic LC50 value of Brevinin-2GRa is 140 µM.
The hemolytic LC50 value of Brevinin-2GRb is 180 µM.
The hemolytic activity of Brevinin-1GRa was not detected (ND);
The hemolytic LC50 value of Brevinin-2GRc is 100 µM.
The hemolytic LC50 value of Nigrocin-2GRa is 295 µM.
The hemolytic LC₅₀ value of Nigrocin-2GRb is 40 µM, making it the most hemolytic among these seven antimicrobial peptides; concurrently, it also exhibits the highest antimicrobial activity, with MIC values of 3 µM against Escherichia coli and 12.5 µM against Staphylococcus aureus.
The hemolytic LC₅₀ value of Nigrocin-2GRc is &gt;500 μM, indicating the weakest hemolytic activity; its antibacterial activity is also relatively low, with an MIC of 50 μM against Escherichia coli and MICs &gt;100 μM against Staphylococcus aureus and Candida albicans. This suggests a certain correlation between the peptide’s hemolytic activity and its antibacterial potency.|||The document mentions hemolytic-related content. The following are the specific hemolytic values:

- Esculentin-1GRa: The concentration causing 50% hemolysis of human red blood cells (LC₅₀) is 210 μM.
- Brevinin-2GRa: LC₅₀ is 140 μM.
- Brevinin-2GRb: LC₅₀ is 180 μM.
- Brevinin-2GRc: LC₅₀ is 100 μM.
- Nigrocin-2GRa: LC₅₀ is 295 μM.
- Nigrocin-2GRb: LC₅₀ is 40 μM.
- Nigrocin-2GRc: LC₅₀ is greater than 503 μM.|||No detectable hemolysis at 128 ug/ml"	"Peptides 2006; 27: 2111-2117. PubMed.|||Peptides
. 2006 Sep;27(9):2111-7. doi: 10.1016/j.peptides.2006.03.002. Epub 2006 Apr 18.|||16621155, 17272268|||22917879|||16621155, 17272268|||Gram-negative bacteria: Escherichia coli (ATCC 25922) (MIC=34 ug/ml), Extended-spectrum ß-lactamases E. coli (ESBL) (MIC=34 ug/ml);
Gram-positive bacteria: Staphylococcus aureus (ATCC 25923) (MIC=8 ug/ml), Methicillin-resistant S. aureus (MRSA) (MIC=8 ug/ml)."	37	
FPDB00916	AP00587|||AP00587|||Brevinin-2TSa|||DRAMP02033|||AP00587	GIMSLFKGVLKTAGKHVAGSLVDQLKCKITGGC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-including E. coli ATCC25922, activity value is MIC = 3 uM||Anti-E. cloacae HNTCC 5300, activity value is MIC = 6 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 6 uM||Anti-K. pneumoniae KK3 9904, activity value is MIC = 6 uM||Anti-S. aureus NCTC 8325 or MRSA, activity value is MIC = 12.5||Anti-S. epidermidis RP62A, activity value is MIC = 12.5 uM||Anti-E. faecalis ATCC 29212, activity value is MIC = 25 uM||Anti-C. albicans ATCC 90028, activity value is MIC = 100 uM||Antibacterial||Anti-Escherichia coli ATCC 25922, activity value is MIC = 3 uM||Anti-Klebsiella pneumoniae KK3 9904, activity value is MIC = 6 uM||Anti-Enterobacter cloacae HNTCC 53001, activity value is MIC = 6 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 6 uM||Anti-Proteus mirabilis ATCC 25933, activity value is MIC > 100 uM||Anti-Staphylococcus aureus NCTC 8325, activity value is MIC = 12.5 uM||Anti-Methicillin-resistant Staphylococcus aureus T7/20, activity value is MIC = 25 uM||Anti-Staphylococcus epidermidis RP62A, activity value is MIC = 12.5 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 25 uM||Anti-Candida albicans ATCC 90028, activity value is MIC = 100 uM||Anti-P.mirabilis ATCC 25933, activity value is MIC > 100 uM	skin, Rana tsushimensis, Asia|||Rana tsushimensis, Asia|||Rana tsushimensis|||Rana tsushimensis (Tsushima brown frog)|||skin, Rana tsushimensis, Asia|||Rana tsushimensis, Asia	N/A	"The antimicrobial peptides isolated from the skin of the Tsushima brown frog (Rana tsushimensis) have the following hemolytic values (expressed as the concentration causing 50% hemolysis of human red blood cells, LD_{50}):

The hemolytic value LD_{50} of Brevinin-1TSa is 12 µM. This peptide has strong hemolytic activity; although it shows inhibitory activity against various Gram-positive bacteria, Gram-negative bacteria, and Candida albicans, its high hemolytic activity may limit its therapeutic application.  
The hemolytic value LD_{50} of Brevinin-2TSa is 100 µM, with significantly lower hemolytic activity. It also exhibits broad-spectrum inhibitory activity against multiple pathogenic bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) (MIC ≤ 25 µM), making it a more promising candidate for drug development.  
For the Temporin family peptides Temporin-1TSa, Temporin-1TSb, Temporin-1TSc, and Temporin-1TSd, the document only mentions the antimicrobial activity of some members and does not report their hemolytic data.|||The document mentioned hemolysis-related content, and the following are the specific hemolytic values:

- Brevinin-1TSa: The concentration causing 50% hemolysis of human red blood cells (LD₅₀) is 12 μM.
- Brevinin-2TSa: LD₅₀ is 100 μM.|||Erythrocytes ( LD50 = 100 uM)|||In Document 10 (Comparative Biochemistry and Physiology, Part C 2006), the LD₅₀ of brevinin-1TSa, isolated from skin extracts of the Tsushima frog (Rana tsushimensis), on human red blood cells is 12 µM, and the LD₅₀ of brevinin-2TSa on human red blood cells is 100 µM.|||[Ref.16413829] LD50=100 uM against human erythrocytes|||LD₅₀=100 uM"	Comp. Biochem. Physiol. part C, 2006; 143: 42-49. PubMed.|||Broad-spectrum growth inhibitory activity against a range of Gram-negative and Gram-positive bacteria, including E. coli ATCC25922 (MIC 3 uM), E. cloacae HNTCC 5300 (MIC 6 uM), P. aeruginosa ATCC 27853 (MIC 6 uM), K. pneumoniae KK3 9904 (MIC 6 uM), S. aureus NCTC 8325 or MRSA (MIC 12.5-25 uM), S. epidermidis RP62A (MIC 12.5 uM), E. faecalis ATCC 29212 (MIC 25 uM), C. albicans ATCC 90028 (MIC 100 uM).|||16413829|||Comp Biochem Physiol C Toxicol Pharmacol. 2006 May;143(1):42-49.||Ref.16413829|||16413829||Ref.16413829|||Comp. Biochem. Physiol. part C, 2006; 143: 42-49. PubMed.	33	
FPDB00917	AP00588|||AP00588|||Brevinin-1TSa|||DRAMP02032|||AP00588	FLGSIVGALASALPSLISKIRN	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anti-Much less active than 2TSa . active against S. epidermidis RP62A, activity value is MIC = 12.5 uM||Anti-E. coli ATCC25922, activity value is MIC = 25 uM||Anti-S. aureus NCTC 8325 or MRSA T7/20, activity value is MIC = 25 uM||Anti-E. cloacae HNTCC 5300, activity value is MIC = 50 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 50 uM||Anti-E. faecalis ATCC 29212, activity value is MIC = 50 uM||Anti-Streptococcus group B HNTCC 80130, activity value is MIC = 50 uM||Anti-C. albicans ATCC 90028, activity value is MIC = 50 uM||Antibacterial||Anti-Escherichia coli ATCC 25922, activity value is MIC = 25 uM||Anti-Klebsiella pneumoniae KK3 9904, activity value is MIC > 100 uM||Anti-Enterobacter cloacae HNTCC 53001, activity value is MIC = 50 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 50 uM||Anti-Proteus mirabilis ATCC 25933, activity value is MIC > 100 uM||Anti-Staphylococcus aureus NCTC 8325, activity value is MIC = 25 uM||Anti-Methicillin-resistant Staphylococcus aureus T7/20, activity value is MIC = 25 uM||Anti-Staphylococcus epidermidis RP62A, activity value is MIC = 12.5 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 50 uM||Anti-Candida albicans ATCC 90028, activity value is MIC = 50 uM||Anti-K.pneumoniae KK3 9904, activity value is MIC > 100 uM||Anti-P.mirabilis ATCC 25933, activity value is MIC > 100 uM	skin, Rana tsushimensis, Asia|||Rana tsushimensis, Asia|||Rana tsushimensis|||Rana tsushimensis (Tsushima brown frog)|||skin, Rana tsushimensis, Asia|||Rana tsushimensis, Asia	N/A	"The antimicrobial peptides isolated from the skin of the Tsushima brown frog (Rana tsushimensis) have the following hemolytic values (expressed as the concentration causing 50% hemolysis of human red blood cells, LD_{50}):

The hemolytic value LD_{50} of Brevinin-1TSa is 12 µM. This peptide has strong hemolytic activity; although it shows inhibitory activity against various Gram-positive bacteria, Gram-negative bacteria, and Candida albicans, its high hemolytic activity may limit its therapeutic application.  
The hemolytic value LD_{50} of Brevinin-2TSa is 100 µM, with significantly lower hemolytic activity. It also exhibits broad-spectrum inhibitory activity against multiple pathogenic bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) (MIC ≤ 25 µM), making it a more promising candidate for drug development.  
For the Temporin family peptides Temporin-1TSa, Temporin-1TSb, Temporin-1TSc, and Temporin-1TSd, the document only mentions the antimicrobial activity of some members and does not report their hemolytic data.|||The document mentioned hemolysis-related content. The following are the specific hemolysis values:

- Brevinin-1TSa: The concentration that caused 50% hemolysis of human red blood cells (LD₅₀) is 12 μM.
- Brevinin-2TSa: LD₅₀ is 101 μM.|||Erythrocytes ( LD50 = 12 uM)|||In Document 10 (Comparative Biochemistry and Physiology, Part C 2006), the LD₅₀ of brevinin-1TSa, isolated from skin extracts of the Tsushima frog (Rana tsushimensis), on human red blood cells is 12 µM, and the LD₅₀ of brevinin-2TSa on human red blood cells is 100 µM.|||[Ref.16413829]LD50=12 uM against human erythrocytes|||LD₅₀=12 uM|||highly hemolytic HC50 12 uM."	"Comp. Biochem. Physiol. part C, 2006; 143: 42-49. PubMed.|||Comp Biochem Physiol C Toxicol Pharmacol
. 2006 May;143(1):42-9. doi: 10.1016/j.cbpc.2005.11.022. Epub 2006 Jan 18.|||16413829|||Comp Biochem Physiol C Toxicol Pharmacol. 2006 May;143(1):42-49.||Ref.16413829|||16413829||Ref.16413829|||Comp. Biochem. Physiol. part C, 2006; 143: 42-49. PubMed."	22	
FPDB00918	AP00595|||AP00595|||Temporin-1CSb|||Vespid chemotactic peptide 5h|||Vespid chemotactic peptide 5h|||AP00595|||DRAMP01816	FLPIIGKLLSGLL	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Antibiofilm||Anti-S. aureus ATCC 25923 or ATCC 12493 MRSA and 2 clincal strains, activity value is MIC = 1.2||Anti-negative E. coli ATCC25922, activity value is MIC = 2.5 uM||Anti-E. cloacae ATCC13047, activity value is MIC = 2.5 uM||Anti-K. pneumoniae ATCC700603, activity value is MIC = 10 uM||Anti-B. pyocyaneus CMCCB1010, activity value is MIC = 10 uM||Anti-P. aeruginosa ATCC27853, activity value is MIC = 40 uM||Anti-B. dysenteriae, activity value is MIC = 20 uM||Anti-E. coli IS 37#, activity value is MIC = 20 uM||Anti-E. coli IS 117# or 218#, activity value is MIC = 20 uM||Anti-P. aeruginosa IS 350#, activity value is MIC = 5 uM||Anti-K. pneumoniae IS 59#, activity value is MIC = 40 uM||Anti-C. albicans ATCC2002 or ATCC90028, activity value is MIC = 10 uM||Anti-and C. parapsilosis ATCC22019, activity value is MIC = 2.5 uM||Anti-E.coli ATCC 8739, activity value is MIC > 256 uM||Anti-K.pneumoniae ATCC 43816, activity value is MIC > 512 uM||Anti-P.aeruginosa ATCC 9027, activity value is MIC > 512 uM||Anti-and yeast C.albicans ATCC 10231, activity value is MIC = 32 uM||Anti-E. coli, activity value is MIC = 128 uM||Anti-S. aureus, activity value is MIC = 8 uM||Anti-E.coli ATCC 25922, activity value is MIC = 30 ug/ml||Anti-S.aureus ATCC 2592, activity value is MIC = 5 ug/ml||Anti-C.albicans ATCC 2002, activity value is MIC = 25 ug/ml||Antibacterial||Anti-Escherichia coli, activity value is MIC = 128 uM||Anti-Staphylococcus aureus, activity value is MIC = 8 uM	skin secretions, Rana cascadae, North America. Also venom gland, the social wasp, Vespa mandarinia, also Vespa tropica, Asia|||North America, Rana cascadae; venom gland, the social wasp, Vespa mandarinia, also Vespa tropica|||Rana cascadae|||Vespa magnifica [Hornet]|||Vespa magnifica [Hornet]|||skin secretions, Rana cascadae, North America. Also venom gland, the social wasp, Vespa mandarinia, also Vespa tropica, Asia|||Rana cascadae (Cascades frog)	N/A	"The document clearly provides the hemolytic values of six antimicrobial peptides isolated from the skin of the Cascades frog (Rana cascadae) (expressed as the concentration causing 50% hemolysis of human red blood cells, LD_{50}), with specific data as follows:

The hemolytic value LD_{50} of Ranatuerin-2CSa is 150 µM, its minimum inhibitory concentration (MIC) against Escherichia coli is 4 µM, and against Staphylococcus aureus is 8 µM. It has broad-spectrum antibacterial activity but low hemolysis;
Brevinin-1CSa has a hemolytic value LD_{50} of 5 µM, the strongest hemolysis among these six peptides, with an MIC of 32 µM against E. coli and 2 µM against S. aureus;
Temporin-1CSa has a hemolytic value LD_{50} of 75 µM, an MIC of 128 µM against E. coli, and 8 µM against S. aureus;
Temporin-1CSb has a hemolytic value LD_{50} of 95 µM, with MICs of 128 µM against E. coli and 8 µM against S. aureus;
Temporin-1CSc has a hemolytic value LD_{50} > 300 µM, the weakest hemolysis, with an MIC > 128 µM against E. coli and 64 µM against S. aureus;
Temporin-1CSd has a hemolytic value LD_{50} of 50 µM, with an MIC of 64 µM against E. coli and 16 µM against S. aureus.|||The document mentions content related to hemolysis. The specific hemolytic values are as follows:

- Ranatuerin-2CSa: The concentration that causes 50% hemolysis of human red blood cells (LD₅₀) is 150 μM.
- Brevinin-1CSa: LD₅₀ is 5 μM.
- Temporin-1CSa: LD₅₀ is 75 μM.
- Temporin-1CSb: LD₅₀ is 95 μM.
- Temporin-1CSd: LD₅₀ is 50 μM.|||The hemolytic values detected for antimicrobial peptides in the skin secretions of the Cascades frog (Rana cascadae), as explicitly mentioned in the document (expressed as LC_{50} for human red blood cells), are as follows:

The hemolytic value LC_{50} of Ranatuerin-2CSa is 150 µM;
The hemolytic value LC_{50} of Brevinin-1CSa is 5 µM;
The hemolytic value LC_{50} of Temporin-1CSa is 75 µM;
The hemolytic value LC_{50} of Temporin-1CSb is 95 µM;
The hemolytic value LC_{50} of Temporin-1CSc is greater than 300 µM;
The hemolytic value LC_{50} of Temporin-1CSd is 50 µM.

Note: LC_{50} refers to the peptide concentration that causes 50% red blood cell hemolysis; lower values indicate stronger hemolytic activity. Among them, Brevinin-1CSa has the strongest hemolytic activity (LC_{50} = 5 µM), and Temporin-1CSc has the weakest hemolytic activity (LC_{50} > 300 µM).|||LC₅₀=95 uM"	"Peptides 2007; 28: 1268-1274. PubMed.|||Peptides
. 2007 Jun;28(6):1268-74. doi: 10.1016/j.peptides.2007.03.010. Epub 2007 Mar 27.|||17451843"	13	
FPDB00919	AP00674|||AP00674|||Lantibiotic 97518	ITSVSWCTPGCTSEGGGSGCSHCC	Anti-Gram+ & Gram-||Anti-MRSA||Antibacterial	Planomonospora alba|||Planomonospora alba|||Planomonospora sp.	Nonhelixbeta	N/A	Biochemistry. 2007 May 22;46(20):5884-95|||Biochemistry. 2007 May 22;46(20):5884-95|||17469849	24	
FPDB00920	AP00680	GLFGRLRDSLQRGGQKILEKAERIWCKIKDIFR	Anti-Gram+ & Gram-||Anti-MRSA	Sheep. Ovis aries|||Sheep. Ovis aries	N/A	"The document provides data on the hemolytic activity of host defense peptides against red blood cells solely in Table 2 (Cytotoxic Concentrations of Various Host Defence Peptides), with the key information as follows:

1. Hemolytic activity of key peptides (using human red blood cells as the test subject)

LL-37 (human antimicrobial peptide):
Hemolytic concentration: 50–100 µM (no mention of serum presence; assumed to be under serum-free conditions).
Note: At this concentration, LL-37 can induce erythrocyte hemolysis, and its hemolytic activity is influenced by serum—specifically, in culture systems containing serum, the cytotoxicity of LL-37 toward other mammalian cells (such as primary human blood monocytes) is significantly reduced. However, the document does not specify the extent to which serum affects its hemolytic activity against erythrocytes.

2. Cytotoxicity of other peptides (no definitive hemolysis data available)

HNP1-3 (human neutrophil defensins): The table only reports their cytotoxicity against alveolar macrophages (7.5–30 µM), epithelial cell lines (6–24 µM), and monocytes (10–100 µM in serum-free conditions; &gt;100 µM in the presence of serum), with no mention of hemolytic activity against red blood cells or associated numerical data.
ADP-ribosylated HNP1-3: Only its cytotoxicity against epithelial cell lines has been reported (&gt;24 µM, serum-free); no hemolytic data for red blood cells are available.

3. Key Notes

The document does not provide a specific “hemolysis rate–concentration” curve or the precise value of the 50% hemolysis concentration (HC₅₀) (e.g., the percentage of hemolysis at a given concentration); it only specifies the minimum concentration range (50–100 µM) at which LL-37 induces red blood cell hemolysis.
The hemolytic activity of other host defense peptides (such as the HBD and HD families) is not mentioned in the documentation, and relevant data are unavailable."	Infect Immun. 2000 May;68(5):2748-55.	33	
FPDB00921	AP00686|||DRAMP04578	KRFGRLAKSFLRMRILLPRRKILLAS	Anti-Gram+ & Gram-||Antifungal||Antiparasitic||Anti-MRSA||Anti-Potently active against a broad range of bacteria E. coli ATCC 25922 or ML 35, activity value is MIC = 3 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 12.5 ug/ml||Anti-S. marcescens ATCC 8100, activity value is MIC = 12.5 ug/ml||Anti-K. pneumoniae ATCC 13883 or SK1, activity value is MIC = 3||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 25||Anti-S. epidermidis ATCC 12228, activity value is MIC = 6 ug/ml||Anti-S. equinus, activity value is MIC = 25 ug/ml||Anti-and B. megaterium Bm11, activity value is MIC = 12.5 ug/ml||No MICs found in DRAMP database	Horse Equus asinus|||Equus asinus	Helix	No hemolysis information or data found in the reference(s) presented in this entry	"FEBS Lett. 1999 Sep 3;457(3):459-64. PubMed.|||FEBS Lett
. 1999 Sep 3;457(3):459-64. doi: 10.1016/s0014-5793(99)01097-2.|||FEBS Lett. 1999 Sep 3;457(3):459-464."	26	
FPDB00922	AP00727|||AP00727|||Arenicin-1|||AR|||Arcycl|||DRAMP03173|||AP00727	RWCVYAYVRVRGVLVRYRRCW	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||anti-sepsis||Anti-L. monocytogenes EGD, activity value is MIC = 0.6 ug/ml||Anti-negative E. coli ML-35p, activity value is MIC = 4 ug/ml||Antibacterial||Anti-Escherichia coli ML35p, activity value is MIC = 1||Anti-E. coli ATCC 25922, activity value is MIC = 2 uM||Anti-E. coli M15, activity value is MIC = 2 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 2 uM||Anti-Listeria monocytogenes EGD, activity value is MIC = 1||Anti-Staphylococcus aureus 710A, activity value is MIC = 2 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 2 uM||Anti-MRSA ATCC 33591, activity value is MIC = 4 uM||Anti-P. aeruginosa c.i, activity value is MIC = 4 uM||Anti-Acinetobacter baumanii c.i, activity value is MIC = 4 uM||Anti-Staphylococcus intermidius, activity value is MIC = 8 uM||Anti-S. aureus c.i, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-Listeria monocytogenes EGD, activity value is MIC = 2 uM||Anti-P. aeruginosa c.i, activity value is MIC = 2 uM||Anti-Staphylococcus intermidius, activity value is MIC = 4 uM||Anti-S. aureus c.i, activity value is MIC = 4 uM||Anti-Listeria monocytogenes EGD, activity value is MIC = 0.6 ug/ml||Anti-Escherichia coli ML-35p, activity value is MIC = 4 ug/ml||Anti-E. coli WBB01, activity value is MIC = 300 uM||Anti-E. coli ATCC 23716, activity value is MIC = 600 uM||Anti-Salmonella enterica R595, activity value is MIC = 300 uM||Anti-S. enterica R60, activity value is MIC = 1250 uM||Anti-Proteus mirabilis R45, activity value is MIC = 600 uM	Arenicola marina|||Arenicola marina|||Synthetic construct|||Arenicola marina [Lugworm]|||Arenicola marina (Lugworm) (Lumbricus marinus)|||Arenicola marina	Beta||Beta strand (2 strands; 16 residues)	N/A	"FEBS Lett 2004; 577: 209-214. PubMed|||2004 Nov 5;577(1-2):209-14. doi: 10.1016/j.febslet.2004.10.012.|||FEBS Lett
. 2004 Nov 5;577(1-2):209-14. doi: 10.1016/j.febslet.2004.10.012.|||17935487|||31234579|||Biochem J. 2008 Feb 15;410(1):113-122.|||FEBS Lett 2004; 577: 209-214. PubMed"	21	
FPDB00923	AP00763|||AP00763|||Dermaseptin-1, DShypo 01|||Dermaseptin-H4|||DRAMP01639	GLWSTIKNVGKEAAIAAGKAALGAL	Anti-Gram+ & Gram-||Antiparasitic||Anti-MRSA||Antibacterial||Anti-Micrococcus luteus A270, activity value is MIC = 6 uM||Anti-Staphylococcus aureus ATCC 6538, activity value is MIC = 6 uM||Anti-Escherichia coli SBS 363, activity value is MIC = 6 uM||Anti-Pseudomonas aeruginosa ATCC 14502, activity value is MIC = 6.6 uM	Brazilian tree frog, Phyllomedusa hypochondrialis, South America|||Brazilian tree frog, Phyllomedusa hypochondrialis, South America|||Phyllomedusa hypochondrialis [orange-legged leaf frog]|||Phyllomedusa azurea [Orange-legged monkey frog]|||Phyllomedusa hypochondrialis (Orange-legged leaf frog)	N/A	"The document only mentions the hemolytic conclusion of DShypo 01 and does not provide specific hemolytic values (such as the hemolysis rate or half-maximal hemolytic concentration HC₅₀). The specific information is as follows:

The study evaluated the hemolytic activity of DShypo 01 on mammalian blood cells using experiments with fresh human blood:

1. Experimental conditions: Blood samples were incubated with DShypo 01 at concentrations up to 64 μg/ml (approximately 53 μM) at 37°C for 30 minutes and 60 minutes, respectively.
2. Measurement indicators: Total white blood cell count, various types of white blood cells (neutrophils, eosinophils, monocytes, lymphocytes, basophils), and platelet count were measured using an automated hematology analyzer (Cell-Dyn 3500 SC/SL); red blood cell-related parameters (such as red blood cell count, hemoglobin, hematocrit, etc.) were also analyzed.
3. Results: Compared with the control group, 64 μg/ml of DShypo 01 did not cause significant differences in total white blood cell counts or counts of various blood cells (t-test showed no statistical significance). Red blood cell-related parameters (such as free hemoglobin and red blood cell count) also showed no differences, indicating that DShypo 01 exhibits no hemolytic activity at this concentration.

Additionally, the document notes that dermaseptin family peptides generally do not have significant hemolytic activity against mammalian blood cells but does not provide specific hemolytic experimental data for other novel dermaseptins (such as DShypo 02, 03, 04, 06, 07, and DS 01).|||[Refer PubMed ID 16963159 :- M. luteus ( MIC = 6 uM ), S. aureus ( MIC = 6 uM ), E. coli ( MIC = 6 uM ), P. aeruginosa ( MIC = 6 uM )] [Refer PubMed ID 16844081 :- Staphylococcus ATCC 43300 ( MIC = 26.5 uM ), Pseudomonas aeruginosa wt MR ( MIC = 6.6 uM )|||E. coli ATCC 11775 ( MIC = 0.8 uM) , S. aureus ATCC 12600 ( MIC = 0.4 uM) , M. luteus ATCC 49732 ( MIC = 0.8 uM )|||[Ref:16844081]Non-hemolytic activity upto 53 uM against human red blood cells;
[Ref.16963159]Non-hemolytic activity at 6 uM against erythrocytes"	Biochem Biophys Res Commun. 2006 Sep 1;347(3):739-46. PubMed.|||2006 Sep 1;347(3):739-46. doi: 10.1016/j.bbrc.2006.06.168. Epub 2006 Jul 10.|||16963159|||17553595|||Ref.16963159	25	
FPDB00924	AP00781|||AP00781|||Winter flounder 3|||DRAMP02357|||Winter flounder 3	FLGALIKGAIHGGRFIHGMIQNHH	Anti-Gram+ & Gram-||Anti-MRSA||Antibacterial||Antifungal||Anti-Aeromonas salmonicida 99-1, activity value is MIC > 64 ug/ml||Anti-A. salmonicida 97-4, activity value is MIC > 64 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS7953s, activity value is MIC = 64 ug/ml||Anti-Salmonella enterica serovar Typhimurium 14028s, activity value is MIC > 64 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC > 64 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 32 ug/ml||Anti-Escherichia coli CGSC 4908, activity value is MIC = 64 ug/ml||Anti-Escherichia coli UB1005, activity value is MIC = 64 ug/ml||Anti-Escherichia coli DC2, activity value is MIC > 64 ug/ml||Anti-Staphylococcus epidermidis C621, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 32 ug/ml||Anti-A. salmonicida 99-1, activity value is MIC > 64 ug/ml||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 64 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC > 64 ug/ml||Anti-P. aeruginosa K799, activity value is MIC > 64 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 32 ug/ml||Anti-E. coli CGSC 4908, activity value is MIC = 64 ug/ml||Anti-E. coli UB1005, activity value is MIC = 64 ug/ml||Anti-E. coli DC2, activity value is MIC > 64 ug/ml||Anti-S. epidermidis C621, activity value is MIC = 32 ug/ml||Anti-MRSA C623, activity value is MIC = 32 ug/ml||Anti-C. albicans C627, activity value is MIC > 64 ug/ml	winter flounder 3, Pleuronectes americanus|||winter flounder 3, Pleuronectes americanus|||Pseudopleuronectes americanus [Winter flounder]|||Pseudopleuronectes americanus (Winter flounder 3)|||Pseudopleuronectes americanus [Winter flounder]	N/A	A. salmonicida 99-1 (MIC >64 ug/ml), A. salmonicida 97-4 (MIC >64 ug/ml), S. enterica serovar Typhimurium MS7953s (MIC = 64 ug/ml), S. enterica serovar Typhimurium 14028s (MIC > 64 ug/ml), P. aeruginosa K799 (MIC >64 ug/ml), P. aeruginosa Z61 (MIC = 32 ug/ml), E. coli CGSC 4908 (MIC = 64 ug/ml), E. coli UB1005 (MIC = 64 ug/ml), E. coli DC2 (MIC >64 ug/ml), S. epidermidis C621 (MIC = 32 ug/ml), MRSA C623 (MIC = 32 ug/ml), C. albicans C627 (MIC >64 ug/ml)	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-2470.|||12878506	24	
FPDB00925	AP00782|||AP00782|||Winter flounder 4|||DRAMP02358|||Winter flounder 4|||AP00782	GWGSIFKHGRHAAKHIGHAAVNHYL	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibacterial||Anti-Aeromonas salmonicida 99-1, activity value is MIC = 4 ug/ml||Anti-A. salmonicida 97-4, activity value is MIC = 4 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS7953s, activity value is MIC = 4 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 64 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC = 16 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 4 ug/ml||Anti-Escherichia coli CGSC 4908, activity value is MIC = 4 ug/ml||Anti-E. coli UB1005, activity value is MIC = 4 ug/ml||Anti-E. coli DC2, activity value is MIC = 2 ug/ml||Anti-Staphylococcus epidermidis C621, activity value is MIC > 64 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 32 ug/ml||Anti-A. salmonicida 99-1, activity value is MIC = 4 ug/ml||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 4 ug/ml||Anti-P. aeruginosa K799, activity value is MIC = 16 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 4 ug/ml||Anti-E. coli CGSC 4908, activity value is MIC = 4 ug/ml||Anti-S. epidermidis C621, activity value is MIC > 64 ug/ml||Anti-MRSA C623, activity value is MIC = 32 ug/ml||Anti-C. albicans C627, activity value is MIC = 32 ug/ml	winter flounder 4 1.1, Pleuronectes americanus|||winter flounder 4 1.1, Pleuronectes americanus|||Pseudopleuronectes americanus [Winter flounder]|||Pseudopleuronectes americanus (Winter flounder 4-1.1)|||Pseudopleuronectes americanus [Winter flounder]|||winter flounder 4 1.1, Pleuronectes americanus	N/A	A. salmonicida 99-1 (MIC = 4 ug/ml), A. salmonicida 97-4 (MIC = 4 ug/ml), S. enterica serovar Typhimurium MS7953s (MIC = 4 ug/ml), S. enterica serovar Typhimurium 14028s (MIC = 64 ug/ml), P. aeruginosa K799 (MIC = 16 ug/ml), P. aeruginosa Z61 (MIC = 4 ug/ml), E. coli CGSC 4908 (MIC = 4 ug/ml), E. coli UB1005 (MIC = 4 ug/ml), E. coli DC2 (MIC = 2 ug/ml), S. epidermidis C621 (MIC >64 ug/ml), MRSA C623 (MIC = 32 ug/ml), C. albicans C627 (MIC = 32 ug/ml)	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed. .|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-2470.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed. .	25	
FPDB00926	AP00784|||AP00784|||AP00786|||Winter flounder Z|||DRAMP02351|||Winter flounder Z	FFRLLFHGVHHVGKIKPRA	Anti-Gram+ & Gram-||Anti-MRSA||Anti-A. salmonicida 99-1, activity value is MIC > 64 ug/ml||Anti-A. salmonicida 97-4, activity value is MIC = 32 ug/ml||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 16 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC > 64 ug/ml||Anti-P. aeruginosa K799, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 8 ug/ml||Anti-E. coli CGSC 4908, activity value is MIC = 32 ug/ml||Anti-E. coli UB1005, activity value is MIC = 32 ug/ml||Anti-E. coli DC2, activity value is MIC = 32 ug/ml||Anti-S. epidermidis C621, activity value is MIC = 32 ug/ml||Anti-MRSA C623, activity value is MIC = 64 ug/ml||Anti-C. albicans C627, activity value is MIC > 64 ug/ml||Anti-Aeromonas salmonicida 99-1, activity value is MIC > 64 ug/ml||Anti-Aeromonas salmonicida 97-4, activity value is MIC = 32 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS7953s, activity value is MIC = 16 ug/ml||Anti-Salmonella enterica serovar Typhimurium 14028s, activity value is MIC > 64 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC = 32 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 8 ug/ml||Anti-Escherichia coli CGSC 4908, activity value is MIC = 32 ug/ml||Anti-Escherichia coli UB1005, activity value is MIC = 32 ug/ml||Anti-Escherichia coli DC2, activity value is MIC = 32 ug/ml||Anti-Staphylococcus epidermidis C621, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 64 ug/ml	winter flounder Z, Pleuronectes americanus|||winter flounder Z, Pleuronectes americanus|||Pseudopleuronectes americanus [Winter flounder]|||Pseudopleuronectes americanus (Winter flounder 5)	N/A	N/A	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-2470.|||12878506	19	
FPDB00927	AP00786|||NRC-12|||NRC-12|||AP00786	GWKKWFNRAKKVGKTVGGLAVDHYL	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-A. salmonicida 99-1, activity value is MIC = 2 ug/ml||Anti-A. salmonicida 97-4, activity value is MIC = 2 ug/ml||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 2 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 8 ug/ml||Anti-P. aeruginosa K799, activity value is MIC = 4 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 1 ug/ml||Anti-E. coli CGSC4908, activity value is MIC = 2 ug/ml||Anti-E. coli UB1005, activity value is MIC = 8 ug/ml||Anti-E. coli DC2, activity value is MIC = 2 ug/ml||Anti-S. epidermidis C621, activity value is MIC = 8 ug/ml||Anti-MRSA C623, activity value is MIC = 16 ug/ml||Anti-C. albicans C627, activity value is MIC = 4 ug/ml||Anti-A. salmonicida 99-1, activity value is MIC = 2 uM||Anti-A. salmonicida 97-4, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 8 uM||Anti-P. aeruginosa K799, activity value is MIC = 4 uM||Anti-P. aeruginosa Z61, activity value is MIC = 1 uM||Anti-E. coli CGSC4908, activity value is MIC = 2 uM||Anti-E. coli UB1005, activity value is MIC = 8 uM||Anti-E. coli DC2, activity value is MIC = 2 uM||Anti-S. epidermidis C621, activity value is MIC = 8 uM||Anti-methicillin-resistant S. aureus C623, activity value is MIC = 16 uM||Anti-C. albicans C627, activity value is MIC = 4 uM	American plaice AP2, Hippoglossoides platessoides Fabricius|||Hippoglossoides platessoides [American plaice]|||Hippoglossoides platessoides [American plaice]|||American plaice AP2, Hippoglossoides platessoides Fabricius	N/A	N/A	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||Reference: Patel S, Stott I P, Bhakoo M, Elliott P (1988) Patenting computer-designed peptides. Journal of Computer-Aided Molecular Design, 12: 543–556.|||Reference: Patel S, Stott I P, Bhakoo M, Elliott P (1988) Patenting computer-designed peptides. Journal of Computer-Aided Molecular Design, 12: 543–556.|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.	25	
FPDB00928	AP00787	GWRLLLKKAEVKTVGKLALKHYL	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA	American plaice AP3, Hippoglossoides platessoides Fabricius	N/A	N/A	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.	23	
FPDB00929	AP00788|||AP00788|||Witch flounder GcSc4C5|||DRAMP02363|||Witch flounder GcSc4C5	AGWGSIFKHIFKAGKFIHGAIQAHND	Anti-Gram+ & Gram-||Anti-MRSA||Anti-A. salmonicida 99-1, activity value is MIC = 32 ug/ml||Anti-A. salmonicida 97-4, activity value is MIC = 16 ug/ml||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 16 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC > 64 ug/ml||Anti-P. aeruginosa K799, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 8 ug/ml||Anti-E. coli CGSC 4908, activity value is MIC = 16 ug/ml||Anti-E. coli UB1005, activity value is MIC = 16 ug/ml||Anti-E. coli DC2, activity value is MIC = 16 ug/ml||Anti-S. epidermidis C621, activity value is MIC = 16 ug/ml||Anti-MRSA C623, activity value is MIC = 16 ug/ml||Anti-C. albicans C627, activity value is MIC > 64 ug/ml||Anti-Aeromonas salmonicida 99-1, activity value is MIC = 32 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS7953s, activity value is MIC = 16 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC = 32 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 8 ug/ml||Anti-Escherichia coli CGSC 4908, activity value is MIC = 16 ug/ml||Anti-Staphylococcus epidermidis C621, activity value is MIC = 16 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 16 ug/ml	witch flounder GcSc4C5, Glyptocephalus cynoglossus L.|||witch flounder GcSc4C5, Glyptocephalus cynoglossus L.|||Glyptocephalus cynoglossus [Witch]|||Glyptocephalus cynoglossus (Witch flounder GcSc4C5)|||Glyptocephalus cynoglossus [Witch]	N/A	N/A	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-2470.|||12878506	26	
FPDB00930	AP00789|||AP00789|||Witch flounder GcSc4B7|||DRAMP02364|||Witch flounder GcSc4B7|||AP00789	GFWGKLFKLGLHGIGLLHLHL	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-A. salmonicida 99-1, activity value is MIC = 8 ug/ml||Anti-A. salmonicida 97-4, activity value is MIC = 16 ug/ml||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 4 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 16 ug/ml||Anti-P. aeruginosa K799, activity value is MIC = 8 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 4 ug/ml||Anti-E. coli CGSC 4908, activity value is MIC = 8 ug/ml||Anti-E. coli UB1005, activity value is MIC = 8 ug/ml||Anti-E. coli DC2, activity value is MIC = 8 ug/ml||Anti-S. epidermidis C621, activity value is MIC = 4 ug/ml||Anti-MRSA C623, activity value is MIC = 4 ug/ml||Anti-C. albicans C627, activity value is MIC = 16 ug/ml||Anti-Aeromonas salmonicida 99-1, activity value is MIC = 32 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS7953s, activity value is MIC = 16 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC > 64 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC = 32 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 8 ug/ml||Anti-Escherichia coli CGSC 4908, activity value is MIC = 16 ug/ml||Anti-E. coli UB1005, activity value is MIC = 16 ug/ml||Anti-E. coli DC2, activity value is MIC = 16 ug/ml||Anti-Staphylococcus epidermidis C621, activity value is MIC = 16 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 16 ug/ml	witch flounder GcSc4B7, Glyptocephalus cynoglossus L.|||witch flounder GcSc4B7, Glyptocephalus cynoglossus L.|||Glyptocephalus cynoglossus [Witch]|||Glyptocephalus cynoglossus (Witch flounder GcSc4B7)|||witch flounder GcSc4B7, Glyptocephalus cynoglossus L.	N/A	N/A	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-2470.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.	21	
FPDB00931	AP00790|||AP00790|||Witch flounder GC3.8-t|||DRAMP02352|||Witch flounder GC3.8-t|||AP00790	GWKKWLRKGAKHLGQAAIK	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-A. salmonicida 99-1, activity value is MIC = 2 ug/ml||Anti-A. salmonicida 97-4, activity value is MIC = 1 ug/ml||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 0.5 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 16 ug/ml||Anti-P. aeruginosa K799, activity value is MIC = 4 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 1 ug/ml||Anti-E. coli CGSC 4908, activity value is MIC = 1 ug/ml||Anti-E. coli UB1005, activity value is MIC = 2 ug/ml||Anti-E. coli DC2, activity value is MIC = 0.5 ug/ml||Anti-S. epidermidis C621, activity value is MIC = 16 ug/ml||Anti-MRSA C623, activity value is MIC = 32 ug/ml||Anti-C. albicans C627, activity value is MIC = 8 ug/ml||Anti-Aeromonas salmonicida 99-1, activity value is MIC = 2 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS7953s, activity value is MIC = 0.5 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC = 4 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 1 ug/ml||Anti-Escherichia coli CGSC 4908, activity value is MIC = 1 ug/ml||Anti-Staphylococcus epidermidis C621, activity value is MIC = 16 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 32 ug/ml	witch flounder GC3.8-t, Glyptocephalus cynoglossus L.|||witch flounder GC3.8-t, Glyptocephalus cynoglossus L.|||Glyptocephalus cynoglossus [Witch]|||Glyptocephalus cynoglossus (Witch flounder GC3.8-t)|||witch flounder GC3.8-t, Glyptocephalus cynoglossus L.	N/A	N/A	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-2470.|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.	19	
FPDB00932	AP00791|||AP00791|||NRC-17|||DRAMP02365|||NRC-17|||AP00791	GWKKWLRKGAKHLGQAAIKGLAS	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibacterial||Anti-Aeromonas salmonicida 99-1, activity value is MIC = 8 ug/ml||Anti-A. salmonicida 97-4, activity value is MIC = 16 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS7953s, activity value is MIC = 4 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 16 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC = 8 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 4 ug/ml||Anti-Escherichia coli CGSC 4908, activity value is MIC = 8 ug/ml||Anti-E. coli UB1005, activity value is MIC = 8 ug/ml||Anti-E. coli DC2, activity value is MIC = 8 ug/ml||Anti-Staphylococcus epidermidis C621, activity value is MIC = 4 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 4 ug/ml||Anti-Aeromonas salmonicida 99-1, activity value is MIC = 2 ug/ml||Anti-Escherichia coli UB1005, activity value is MIC = 4 ug/ml||Anti-Escherichia coli CGSC 4908, activity value is MIC = 1 ug/ml||Anti-Escherichia coli DC2, activity value is MIC = 1 ug/ml||Anti-Pseudomonas aeruginosa K799, activity value is MIC = 4 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 2 ug/ml||Anti-E. coli CGSC4908, activity value is MIC = 1 ug/ml||Anti-E. coli UB1005, activity value is MIC = 4 ug/ml||Anti-E. coli DC2, activity value is MIC = 1 ug/ml||Anti-S. epidermidis C621, activity value is MIC = 32 ug/ml||Anti-MRSA C623, activity value is MIC = 16 ug/ml||Anti-C. albicans C627, activity value is MIC = 8 ug/ml	witch flounder GC3.8, Glyptocephalus cynoglossus L.|||witch flounder GC3.8, Glyptocephalus cynoglossus L.|||Glyptocephalus cynoglossus L. [Witch]|||Glyptocephalus cynoglossus (Witch flounder GC3.8)|||witch flounder GC3.8, Glyptocephalus cynoglossus L.	N/A	Aeromonas salmonicida 99-1 ( MIC = 2 ug/ml ),Escherichia coli UB1005 ( MIC = 4 ug/ml ), Escherichia coli CGSC 4908 ( MIC = 1 ug/ml ), Escherichia coli DC2 ( MIC = 1 ug/ml ),Pseudomonas aeruginosa K799 ( MIC = 4 ug/ml ), P. aeruginosa Z61 ( MIC = 2 ug/ml ), E. coli CGSC4908 (MIC = 1 ug/ml), E. coli UB1005 (MIC = 4 ug/ml), E. coli DC2 (MIC = 1 ug/ml), S. epidermidis C621 (MIC = 32 ug/ml), MRSA C623 (MIC=16 ug/ml), C. albicans C627 (MIC =8 ug/ml)	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.|||Reference: Wang, C, Sun Z, Liu Y, Zhang X, Xu G (2007) A novel antimicrobial vermipeptide family from earthworm Eisenia fetida. Eur. J Soil Biol 2007; 43:S217-S134.|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-2470.|||Reference: Wang, C, Sun Z, Liu Y, Zhang X, Xu G (2007) A novel antimicrobial vermipeptide family from earthworm Eisenia fetida. Eur. J Soil Biol 2007; 43:S217-S134.|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.	23	
FPDB00933	AP00792|||AP00792|||Pleurocidin-like peptide Hb26|||Pleurocidin-like peptide Hb26|||AP00792	FLGLLFHGVHHVGKWIHGLIHGHH	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibacterial||Anti-A. salmonicida 99-1, activity value is MIC = 64 ug/ml||Anti-S. enterica serovar Typhimurium MS7953s, activity value is MIC = 16 ug/ml||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 64 ug/ml||Anti-P. aeruginosa K799, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa Z61, activity value is MIC = 8 ug/ml||Anti-E. coli CGSC 4908, activity value is MIC = 32 ug/ml||Anti-E. coli UB1005, activity value is MIC = 16 ug/ml||Anti-E. coli DC2, activity value is MIC = 32 ug/ml||Anti-S. epidermidis C621, activity value is MIC = 8 ug/ml||Anti-MRSA C623, activity value is MIC = 8 ug/ml||Anti-C. albicans C627, activity value is MIC = 64 ug/ml	Atlantic Halibut Hb26, Hippoglossus hippoglossus L.|||Atlantic Halibut Hb26, Hippoglossus hippoglossus L.|||Hippoglossus hippoglossus [Atlantic halibut]|||Hippoglossus hippoglossus [Atlantic halibut]|||Atlantic Halibut Hb26, Hippoglossus hippoglossus L.	N/A	A. salmonicida 99-1 ( MIC = 64 ug/ml), S. enterica serovar Typhimurium MS7953s ( MIC = 16 ug/ml), S. enterica serovar Typhimurium 14028s ( MIC = 64 ug/ml), P. aeruginosa K799 ( MIC = 32 ug/ml), P. aeruginosa Z61 ( MIC = 8 ug/ml), E. coli CGSC 4908 ( MIC = 32 ug/ml), E. coli UB1005 ( MIC = 16 ug/ml), E. coli DC2 ( MIC = 32 ug/ml), S. epidermidis C621 ( MIC = 8 ug/ml), MRSA C623 ( MIC = 8 ug/ml), C. albicans C627 ( MIC = 64 ug/ml), A. salmonicida 97-4 ( MIC = >64 ug/ml)	Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.|||2003 Aug;47(8):2464-70. doi: 10.1128/AAC.47.8.2464-2470.2003.|||12878506|||12878506|||Antimicrob Agents Chemother. 2003 Aug;47(8):2464-70.PubMed.	24	
FPDB00934	AP00823|||AP00823|||CAMPSQ10996|||DRAMP01795	SILPTIVSFLSKVF	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anti-Staphylococcus aureus USA300, activity value is MIC = 3.1 uM||Anti-Staphylococcus epidermidis 1457, activity value is MIC = 3.1 uM||Anti-Bacillus subtilis 168, activity value is MIC = 6.3 uM||Anti-Candida albicans ATCC 10231, activity value is MIC = 12.5 uM||Anti-C. glabrata ATCC 2001, activity value is MIC = 12.5 uM||Anti-C. tropicalis ATCC 13803, activity value is MIC = 3.1 uM||Anti-Antinacterial activity was not reported due to a limited amount of material. We filled up this gap by using a synthetic peptide. Active against S. aureus USA300, activity value is MIC = 3.1 uM||Anti-S. epidermidis 1457, activity value is MIC = 3.1 uM||Anti-B. subtilis 168, activity value is MIC = 6.2 uM||Anti-C. albicans, activity value is MIC = 50 uM||Antimicrobial||Antibacterial	Rana grylio, North America|||Rana grylio, North America|||Rana grylio [North American pig frog]|||Rana grylio (North American pig frog)	N/A	"The document explicitly mentions the hemolytic values of five antimicrobial peptides isolated from the skin extracts and secretions of the North American bullfrog (Rana grylio), which represent the concentrations at which these peptides induce significant hemolysis of human red blood cells, as follows:

ranatuerin-1Ga: 100 µM
ranatuerin-2G: 35 µM
temporin-1Gb: 16 µM (There are duplicate annotations in the document, both labeled as 16 µM.)
temporin-1Gd: 4 µM

The above values were determined experimentally as follows: Peptides at concentrations ranging from 1 to 100 µM were incubated with washed human red blood cells (2 × 10⁶ cells) in Dulbecco’s phosphate-buffered saline (pH 7.4) at 37°C for 1 hour. After centrifugation (900×g, 10 minutes), the absorbance of the supernatant was measured at 451 nm to determine the peptide concentration corresponding to significant hemolysis.

Furthermore, studies have shown that peptides from the temporin family (such as temporin-1Gb and temporin-1Gd) can induce hemolysis even at low concentrations, whereas ranatuerin-1Ga requires the highest concentration (100 µM) to elicit significant hemolysis, highlighting the differences in hemolytic activity among peptides from different families.|||ranatuerin-1Ga: 100 uMranatuerin-2G: 35 uMtemporin-1Gb: 16 uMtemporin-1Gd: 4 uM|||Human RBCs (HL50 = 12.5 uM)|||EC₅₀=100 uM"	Regul Pept 2000; 90: 53-60. PubMed.|||2000 Jun 30;90(1-3):53-60. doi: 10.1016/s0167-0115(00)00107-5.|||10828493, 29842923||Refer PubMed ID: 29842923|||Regul Pept. 2000 Jun 30;90(1-3):53-60.	14	
FPDB00935	AP00875|||AP00875|||Temporin-1Va|||DRAMP01789	FLSSIGKILGNLL	Anti-Gram+ & Gram-||Anti-MRSA||Antibacterial||Anti-Staphylococcus aureus NCTC8325, activity value is MIC = 10 uM||Anti-S. aureus T7/20, activity value is MIC = 20 uM||Anti-S. epidermidis RP62A, activity value is MIC = 20 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 40 uM||Anti-Streptococcus group B HNTCC 80130, activity value is MIC = 20 uM||Anti-Escherichia coli ATCC25922, activity value is MIC = 40 uM||Anti-Klebsiella pneumoniae KK3 9904, activity value is MIC = 80 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 160 uM||Anti-Enterobacter cloacae HNTCC 53001, activity value is MIC = 40 uM||Anti-Candida albicans ATCC 90028, activity value is MIC = 160 uM	skin, Carpenter Frog, Rana virgatipes (Ranidae, Aquarana), USA, North America|||skin, Carpenter Frog, Rana virgatipes (Ranidae, Aquarana), USA, North America|||Rana catesbeiana [American bullfrog]|||Rana virgatipes (Ranidae) (Aquarana)	N/A	"The hemolytic values mentioned in the document (expressed as LD₅₀, i.e., the peptide concentration causing 50% hemolysis) are as follows:

1. temporin-1Va: LD₅₀ for human red blood cells is 120 µM, with relatively weak hemolytic activity.

2. temporin-1Vb: LD₅₀ for human red blood cells is 30 µM, with relatively strong hemolytic activity.

3. temporin-1Vc: LD₅₀ for human red blood cells is 30 µM, with relatively strong hemolytic activity.

Additionally, the document mentions the antimicrobial activity (such as MIC values) of other antimicrobial peptides like ranalexin-1Va, ranalexin-1Vb, and brevinin-2Va, but their hemolytic LD₅₀ values are not explicitly provided.|||temporin-1Va: 120 uMtemporin-1Vb: 30 uMtemporin-1Vc: 30 uM|||In document 8 (Regulatory Peptides 2005), the LD₅₀ of Temporin-1Va for human red blood cells is 120 μM, the LD₅₀ of Temporin-1Vb for human red blood cells is 30 μM, and the LD₅₀ of Temporin-1Vc for human red blood cells is 30 μM.|||[Ref:15996769]LD50=120 uM against washed human erythrocytes|||[Ref:15996769]LD50=120 uM against washed human erythrocytes"	Regul Pept 2005; 131: 38-45|||Regul Pept 2005; 131: 38-45|||15996769|||Regul Pept. 2005 Nov;131(1-3):38-45.||Ref.15996769|||15996769||Ref.15996769|||Ref.15996769	13	
FPDB00936	AP00876|||AP00876|||Temporin-1Vb|||DRAMP01790	FLSIIAKVLGSLF	Anti-Gram+||Anti-MRSA||Hemolytic||Antibacterial||Anti-Staphylococcus aureus NCTC8325, activity value is MIC = 5 uM||Anti-S. aureus T7/20, activity value is MIC = 10 uM||Anti-S. epidermidis RP62A, activity value is MIC = 5 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 20 uM||Anti-Streptococcus group B HNTCC 80130, activity value is MIC = 20 uM	skin, Carpenter Frog, Rana virgatipes (Ranidae, Aquarana), USA, North America|||skin, Carpenter Frog, Rana virgatipes (Ranidae, Aquarana), USA, North America|||Rana catesbeiana [American bullfrog]|||Rana virgatipes (Ranidae) (Aquarana)	N/A	"The hemolytic values mentioned in the document (expressed as LD₅₀, i.e., the peptide concentration causing 50% hemolysis) are as follows:

1. temporin-1Va: LD₅₀ for human red blood cells is 120 µM, with relatively weak hemolytic activity.

2. temporin-1Vb: LD₅₀ for human red blood cells is 30 µM, with relatively strong hemolytic activity.

3. temporin-1Vc: LD₅₀ for human red blood cells is 30 µM, with relatively strong hemolytic activity.

Additionally, the document mentions the antimicrobial activity (such as MIC values) of other antimicrobial peptides like ranalexin-1Va, ranalexin-1Vb, and brevinin-2Va, but their hemolytic LD₅₀ values are not explicitly provided.|||temporin-1Va: 120 uMtemporin-1Vb: 30 uMtemporin-1Vc: 30 uM|||[Ref:15996769]LD50=30 uM against washed human erythrocytes"	Regul Pept 2005; 131: 38-45|||Regul Pept 2005; 131: 38-45|||15996769|||Ref.15996769	13	
FPDB00937	AP00890	IDWKKVDWKKVSKKTCKVMLKACKFLG	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Hemolytic	venom, Myrmecia pilosula , Australia|||Myrmecia pilosula (venom, Australia)	Helix	N/A	Biochim Biophys Acta 1996; 1305:87-97	27	
FPDB00938	AP00923|||DRAMP02521|||OH-CATH30|||D-OH-CATH30|||DRAMP02521	KFFKKLKNSVKKRAKKFFKKPRVIGVSIPF	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Enterobacter cloacae clinic strain. Gram-positive bacteria : Staphylococcuss aureus ATCC 25923, activity value is MIC = 3.125 ug/ml||Anti-Staphylococcuss aureus ATCC 43300 MRSA, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcuss aureus clinical strain 1, activity value is MIC = 3.125 ug/ml||Anti-Staphylococcuss aureus clinical strain 2, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcuss aureus clinical strain 3, activity value is MIC = 6.25 ug/ml||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 25 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 6.25 ug/ml||Anti-Escherichia coli ML-35p, activity value is MIC = 3.125 ug/ml||Anti-Escherichia coli clinical strain 1, activity value is MIC = 6.25 ug/ml||Anti-Escherichia coli clinical strain 2, activity value is MIC = 3.125 ug/ml||Anti-Escherichia coli clinical strain 3, activity value is MIC = 1.56 ug/ml||Anti-Escherichia coli clinical strain 4, activity value is MIC = 12.5 ug/ml||Anti-Escherichia coli clinical strain 5, activity value is MIC = 3.125 ug/ml||Anti-Escherichia coli clinical strain 6, activity value is MIC = 3.125 ug/ml||Anti-Enterobacter cloacae ATCC 13047, activity value is MIC = 25 ug/ml||Anti-Enterobacter cloacae clinical strain, activity value is MIC = 3.125 ug/ml||Anti-Enterobacter aerogenes clinical strain, activity value is MIC = 6.25 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 6.25 ug/ml||Anti-Pseudomonas aeruginosa PA 01, activity value is MIC = 6.25 ug/ml||Anti-Pseudomonas aeruginosa clinical strain 1, activity value is MIC = 12.5 ug/ml||Anti-Pseudomonas aeruginosa clinical strain 2, activity value is MIC = 6.25 ug/ml||Anti-Haemophilus influenzae ATCC 49247, activity value is MIC = 3.125 ug/ml||Anti-Haemophilus influenzae ATCC 49766, activity value is MIC = 3.125 ug/ml||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 6.25 ug/ml||Anti-Klebsiella pneumoniae ATCC 700603, activity value is MIC = 3.125 ug/ml||Anti-Candida albicans ATCC 2002, activity value is MIC > 200 ug/ml||Anti-Candida albicans clinical strain, activity value is MIC > 200 ug/ml||Anti-E. coli ATCC 25922, activity value is MIC = 6.25 ug/ml||Anti-E. coli ML-35p, activity value is MIC = 3.125 ug/ml||Anti-E. cloacae ATCC 13047, activity value is MIC = 25 ug/ml||Anti-E. aerogenes clinical strain, activity value is MIC = 3.125 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 6.25 ug/ml||Anti-P. aeruginosa PA 01, activity value is MIC = 6.25 ug/ml||Anti-H. influenzae ATCC 49247, activity value is MIC = 3.125 ug/ml||Anti-H. influenzae ATCC 49766, activity value is MIC = 3.125 ug/ml||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 6.25 ug/ml||Anti-K. pneumoniae ATCC 700603, activity value is MIC = 3.125 ug/ml||Anti-S. aureus ATCC 25923, activity value is MIC = 3.125 ug/ml||Anti-S. aureus ATCC 43300 MRSA, activity value is MIC = 6.25 ug/ml||Anti-E. faecalis ATCC 29212, activity value is MIC = 25 ug/ml||Anti-E. coli ATCC 25922, activity value is MIC = 12.5 ug/ml||Anti-E. coli ML-35p, activity value is MIC = 6.25 ug/ml||Anti-E. cloacae ATCC 13047, activity value is MIC = 50 ug/ml||Anti-E. aerogenes clinical strain, activity value is MIC = 12.5 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 25 ug/ml||Anti-H. influenzae ATCC 49247, activity value is MIC = 6.25 ug/ml||Anti-H. influenzae ATCC 49766, activity value is MIC = 6.25 ug/ml||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 3.125 ug/ml||Anti-K. pneumoniae ATCC 700603, activity value is MIC = 6.25 ug/ml||Anti-E. faecalis ATCC 29212, activity value is MIC = 50 ug/ml||Antimicrobial||Antibacterial||Anti-Gram+||Antifungal	sequence truncation, reptile cathelicidin, animal-derived, natural derivative|||Ophiophagus hannah (King cobra) (Naja hannah)|||Ophiophagus hannah [King cobra]|||Ophiophagus hannah (King cobra) (Naja hannah)	Alpha helix	"The document explicitly mentions the hemolytic values of four peptides (OH-CATH30, D-OH-CATH30, OH-CM6, D-OH-CM6) and two control peptides (pexiganan, LL-37), specifically the hemolysis rate after incubation with human red blood cells for 4 hours, as shown below:

OH-CATH30, D-OH-CATH30, OH-CM6, D-OH-CM6: Even at a high concentration of 400 μg/ml, they showed no significant hemolytic activity (hemolysis rate was extremely low, specific percentage values were not provided, but significantly lower than the control peptides).  
Control peptide pexiganan: At a concentration of 400 μg/ml, the hemolysis rate was 42%.  
Control peptide LL-37: At a concentration of 400 μg/ml, the hemolysis rate was 58%.

The above values were measured using the following experiment: Peptides at different concentrations were mixed with human red blood cell suspensions washed 3 times with PBS. After incubation at 37°C for 4 hours, the mixture was centrifuged, and the absorbance of the supernatant was measured at 540 nm. PBS-treated samples served as the minimum hemolysis control (0% hemolysis), and 1% Triton X-100-treated samples served as the maximum hemolysis control (100% hemolysis). The hemolysis percentage was calculated using a formula.

Additionally, the study indicated that OH-CATH30 and OH-CM6 still showed no significant hemolytic activity at a concentration of 200 μg/ml (approximately 50 times their minimum inhibitory concentration, MIC), demonstrating low toxicity to eukaryotic cells, while the control peptides already exhibited significant hemolytic effects at the same concentration.|||Hemolytic activity against hRBC"	Antimicrob Agents Chemother. 2012 Jun;56(6):3309-17. doi: 10.1128/AAC.06304-11. PubMed.|||Peptides. 2008 Oct;29(10):1685-91.||Ref.18620012||Ref.22491685|||22491685|||Peptides. 2008 Oct;29(10):1685-91. Antimicrob Agents Chemother. 2012 Jun;56(6):3309-17. doi: 10.1128/AAC.06304-11.	30	
FPDB00939	AP00929|||AP00929|||Enterocin AS-48|||DRAMP00169	MAKEFGIPAAVAGTVINVVEAGGWVTTIVSILTAVGSGGLSLLAAAGRESIKAYLKKEIKKKGKRAVIAW	Anti-Gram+ & Gram-||Antiparasitic||Anti-MRSA||anti-TB||Active against Gram-positive Bacillus||Staphylococcus (S. aureus||MRSA)||and Listeria and Gram-negative Salmonella||E. coli||etc.||Antibacterial ; Streptococcus faecalis S-47||Escherichia coli U-9||Antimicrobial||Antibacterial||Anti-Gram+||Anti-Gram-	Enterococcus faecalis S-48; human microbiota:gut, symbiont bacteria|||Enterococcus faecalis S-48; human microbiota:gut, symbiont bacteria|||Enterococcus faecalis S-48|||Enterococcus faecalis S-48 (Gram-positive bacteria)	Helix	N/A	"Can J Microbiol
. 1986 Oct;32(10):765-71. doi: 10.1139/m86-141.|||1986 Oct;32(10):765-71. doi: 10.1139/m86-141.|||1986 Oct;32(10):765-71. doi: 10.1139/m86-141.|||https://pubmed.ncbi.nlm.nih.gov/3098396|||Res Microbiol. 1989 Jan;140(1):57-68.J Mol Biol. 2003 Nov 28;334(3):541-549.Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11221-6."	70	
FPDB00940	AP00955|||AP00955|||GNU6|||DRAMP21138|||GNU6|||AP00955|||DRAMP21138	RIIRPIIQIIKQKIR	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Gram+ B. subtilis, activity value is MIC = 2 ug/ml||Anti-E. faecalis, activity value is MIC = 2 ug/ml||Anti-E. faecium VRE, activity value is MIC = 2 ug/ml||Anti-M. luteus, activity value is MIC = 2 ug/ml||Anti-S. aureus or MRSA, activity value is MIC = 2 ug/ml||Anti-E. coli, activity value is MIC = 4 ug/ml||Anti-P. aeruginosa, activity value is MIC = 2 ug/ml||Anti-S. typhimurium, activity value is MIC = 4 ug/ml||Anti-C. albicans, activity value is MIC = 2 ug/ml||Anti-C. neoformans, activity value is MIC = 2 ug/ml||Anti-and S. cerevisiae, activity value is MIC = 4 ug/ml||Anti-Bacillus subtilis KCTC 3038, activity value is MIC = 2 ug/ml||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 2 ug/ml||Anti-Micrococcus luteus ATCC 10240, activity value is MIC = 2 ug/ml||Anti-Micrococcus luteus ATCC 10240, activity value is MIC = 8 ug/ml||Anti-Micrococcus luteus ATCC 10240, activity value is MIC = 4 ug/ml||Anti-Staphylococcus aureus ATCC 15752, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus ATCC 15752, activity value is MIC = 16 ug/ml||Anti-Staphylococcus aureus ATCC 15752, activity value is MIC = 8 ug/ml||Anti-Escherichia coli ATCC 27325, activity value is MIC = 4 ug/ml||Anti-Escherichia coli ATCC 27325, activity value is MIC = 32 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 2 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 8 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 32 ug/ml||Anti-Salmonella typhimurium KCTC 2370, activity value is MIC = 4 ug/ml||Anti-Candida albicans ATCC 10231, activity value is MIC = 2 ug/ml||Anti-Candida albicans ATCC 10231, activity value is MIC = 16 ug/ml||Anti-Cryptococcus neoformans ATCC 34881, activity value is MIC = 2 ug/ml||Anti-Cryptococcus neoformans ATCC 34881, activity value is MIC = 16 ug/ml||Anti-Saccharomyces cerevisiae ATCC 44774, activity value is MIC = 4 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 2||Anti-Enterococcus faecium, activity value is MIC = 2 ug/ml||Anti-Enterococcus gallinarum, activity value is MIC = 2 ug/ml||Anti-Enterococcus casseliflavus, activity value is MIC = 2 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 2 ug/ml||Anti-Enterococcus faecalis, activity value is MIC = 2 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 2 ug/ml||Anti-Escherichia coli, activity value is MIC = 4 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 2 ug/ml||Anti-Salmonella typhimurium, activity value is MIC = 4 ug/ml||Anti-Candida albicans, activity value is MIC = 2 ug/ml||Anti-Cryptococcus neoformans, activity value is MIC = 2 ug/ml||Anti-Saccharomyces cerevisiae, activity value is MIC = 4 ug/ml||Antibacterial||Anti-##Gram-negative bacteria : Escherichia coli, activity value is MIC = 4 ug/ml||Anti-##Fungi : Candida albicans, activity value is MIC = 2 ug/ml	De novo designed, man-made sequences|||De novo designed, man-made sequences|||Synthetic construct|||Synthetic construct|||De novo designed, man-made sequences|||Synthetic construct	Helix||Alpha helix	"GNU5, GNU6, GNU7: In hemolysis experiments, these three peptides showed no hemolytic activity against human red blood cells (RBCs) at all tested concentrations (up to 128 µg/ml), and were non-toxic to human keratinocytes (HaCaT) and skin fibroblasts (BJ).

Magainin 2: Similar to GNU5, GNU6, and GNU7, it showed no cytotoxicity to human cells at the tested concentrations.

- Buforin IIb: At a concentration of 128 µg/ml, it caused 14.5% hemolysis of red blood cells; at 64 µg/ml, it killed 63.9% of HaCaT keratinocytes and 31.8% of BJ skin fibroblasts, showing certain hemolytic activity and cytotoxicity.|||Buforin IIb: At a concentration of 128 µg/ml, the hemolysis rate was 14.5%. GNU5, GNU6, and GNU7: No hemolytic activity was observed on red blood cells.|||Human erythrocytes (- at NA|||- Test subject: human red blood cells, incubation conditions at 37°C for 30 minutes, detection wavelength 567 nm; negative control (PBS only) showed 0% hemolysis, positive control (0.2% Triton X-100) showed 100% hemolysis.

- Key results:

- Designed peptides GNU5, GNU6, GNU7: At concentrations up to 128 µg/ml, hemolysis rate was 0%, showing no hemolytic activity and excellent safety.

- Control peptides:

- Magainin 2: Similar to the designed peptides, no hemolysis at 128 µg/ml.

- Buforin IIb: At 128 µg/ml, hemolysis rate was 14.5%, indicating some hemolytic activity.

- Key correlation: The designed peptides eliminate hemolysis by disrupting the hydrophobic surface of the α-helix (inserting lysine residues) while maintaining high hydrophobicity (46%) and strong antibacterial activity (MIC 1–4 µg/ml, effective against MRSA and VRE), and exhibit no cytotoxicity to human keratinocytes (HaCaT) or fibroblasts (BJ).|||Human erythrocytes (- at NA|||[Ref.23946320] 0% hemolysis at 140 ug/ml against human red blood cells"	"J Antimicrob Chemother
. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322. Epub 2013 Aug 14.|||2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322. Epub 2013 Aug 14.|||23946320|||J Antimicrob Chemother. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322.||Ref.23946320|||23946320|||J Antimicrob Chemother. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322. PubMed.|||J Antimicrob Chemother. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322.||Ref.23946320|||J Antimicrob Chemother. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322. PubMed."	15	
FPDB00941	AP00959|||DRAMP01692	ALWKTLLKKVGKVAGKAVLNAVTNMANQNEQ	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. coli ATCC 8739 or K12 or ML35p or resistant p7, activity value is MIC = 1.6||Anti-P. aeruginosa ATCC 9027 or ATCC 27853, activity value is MIC = 6.3||Anti-K. pneumoniae CIP 52.211, activity value is MIC = 0.8 uM||Anti-K. oxytoca CIP 7932, activity value is MIC = 12.5 uM||Anti-S. enterica CIP 8297, activity value is MIC = 50 uM||Anti-Y. ruckeri ATGG 29473, activity value is MIC = 25 uM||Anti-S. aureus ATCC 6538 or ST 1065 or MRSA, activity value is MIC = 12.5||Anti-L. monocytogenes SOR 100, activity value is MIC = 100 uM||Anti-E. faecalis CIP A186, activity value is MIC = 100 uM||Anti-L. garvieae ATCC 43921, activity value is MIC = 100 uM||Anti-E. faecalis CIP 103015, activity value is MIC = 12.5 uM||Anti-and K. rhizophila ATCC 9341, activity value is MIC = 0.8 uM||Antimicrobial||Antibacterial	Pachymedusa dacnicolor (PD), South America|||Pachymedusa dacnicolor (Giant mexican leaf frog)	N/A	N/A	"Biochim Biophys Acta
. 1998 Oct 14;1388(1):279-83. doi: 10.1016/s0167-4838(98)00202-7.|||1998 Oct 14;1388(1):279-83. doi: 10.1016/s0167-4838(98)00202-7.|||Biochim Biophys Acta. 1998 Oct 14;1388(1):279-283."	31	
FPDB00942	AP01131|||AP01131|||Aureocin A53|||DRAMP00068	MSWLNFLKYIAKYGKKAVSAAWKYKGKVLEWLNVGPTLEWVWQKLKKIAGL	Anti-Gram+||Anti-MRSA||Anti-Brochothrix campestris ATCC 43754, activity value is MIC = 2 uM||Anti-Carnobacterium divergens LV13, activity value is MIC = 8 uM||Anti-Carnobacterium maltaromaticum UAL26, activity value is MIC = 128 uM||Anti-Enterococcus faecium BFE900, activity value is MIC = 16 uM||Anti-Lactobacillus sakei UAL1218, activity value is MIC = 8 uM||Anti-Lactococcus lactis ATCC 19257, activity value is MIC = 0.25 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 128 uM||Anti-Staphylococcus simulans, activity value is MIC = 0.1 uM||Anti-Micrococcus luteus, activity value is MIC = 0.00015 uM	Staphylococcus aureus A53|||Staphylococcus aureus A53 (Gram-positive bacteria)	Helix||Alpha helix	N/A	"J Mol Biol
. 2002 Jun 7;319(3):745-56. doi: 10.1016/S0022-2836(02)00368-6.|||2002 Jun 7;319(3):745-56. doi: 10.1016/S0022-2836(02)00368-6.|||26771761"	51	
FPDB00943	AP01154|||DRAMP00216	"	
AIKLVQSPNGNFAASFVLDGTKWIFKSKYYDSSKGYWVGIYEVWDRK"	Anti-Gram+ & Gram-||Anti-MRSA||Antimicrobial||Antibacterial	Bacillus subtilis strain A014|||Bacillus subtilis strain A014|||Bacillus subtilis (Gram-positive bacteria)	Beta	"OH-CATH30, D-OH-CATH30, OH-CM6, D-OH-CM6: At concentrations up to 400 µg/ml, the hemolysis rate on human red blood cells was low, showing almost no significant hemolytic activity.

- Pexiganan: At a concentration of 400 µg/ml, the hemolysis rate was 42%.

- LL-37: At a concentration of 400 µg/ml, the hemolysis rate was 58%."	Rice Genet. Newsl., 7 (1990), pp. 151-154. online|||Rice Genet. Newsl. 1990;7:151-154.iochemistry. 2011 May 10;50(18):3621-3627.	47	
FPDB00944	AP01197|||AP01197|||OH-CM6|||OH-CM6|||D-OH-CM6|||DRAMP20975	"	
KFFKKLKKAVKKGFKKFAKV"	Anti-Gram+||Anti-MRSA||Anti-E.cloacae, activity value is MIC > 100 ug/ml||Anti-E. aerogenes, activity value is MIC = 12.5 ug/ml||Anti-4 P. aeruginosa, activity value is MIC = 6.25||Anti-H. influenzae, activity value is MIC = 3.1||Anti-ATCC 43300 MRSA, activity value is MIC = 3.125||Anti-and fungi: C.albicans, activity value is MIC > 200 ug/ml||Anti-E. coli ATCC 25922, activity value is MIC = 12.5 ug/ml||Anti-E. coli ML-35p, activity value is MIC = 6.25 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 12.5 ug/ml||Anti-P. aeruginosa PA 01, activity value is MIC = 12.5 ug/ml||Anti-H. influenzae ATCC 49247, activity value is MIC = 3.125 ug/ml||Anti-H. influenzae ATCC 49766, activity value is MIC = 6.25 ug/ml||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 6.25 ug/ml||Anti-K. pneumoniae ATCC 700603, activity value is MIC = 3.125 ug/ml||Anti-S. aureus ATCC 25923, activity value is MIC = 12.5 ug/ml||Anti-S. aureus ATCC 43300 MRSA, activity value is MIC = 3.125 ug/ml||Anti-E. faecalis ATCC 29212, activity value is MIC = 25 ug/ml||Anti-H. influenzae ATCC 49247, activity value is MIC = 6.25 ug/ml||Anti-K. pneumoniae ATCC 700603, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC 25923, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC 43300 MRSA, activity value is MIC = 6.25 ug/ml||Anti-E. faecalis ATCC 29212, activity value is MIC = 50 ug/ml||Anti-Staphylococcuss aureus ATCC 25923, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcuss aureus ATCC 43300 MRSA, activity value is MIC = 3.125 ug/ml||Anti-Staphylococcuss aureus clinical strain 1, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcuss aureus clinical strain 2, activity value is MIC = 3.125 ug/ml||Anti-Staphylococcuss aureus clinical strain 3, activity value is MIC = 12.5 ug/ml||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 25 ug/ml||Anti-##Gram-negative bacteria : Escherichia coli ATCC 25922, activity value is MIC = 12.5 ug/ml||Anti-Escherichia coli ML-35p, activity value is MIC = 6.25 ug/ml||Anti-Escherichia coli clinical strain 1, activity value is MIC = 12.5 ug/ml||Anti-Escherichia coli clinical strain 2, activity value is MIC = 3.125 ug/ml||Anti-Escherichia coli clinical strain 3, activity value is MIC = 1.56 ug/ml||Anti-Escherichia coli clinical strain 4, activity value is MIC = 12.5 ug/ml||Anti-Escherichia coli clinical strain 5, activity value is MIC = 6.25 ug/ml||Anti-Escherichia coli clinical strain 6, activity value is MIC = 3.125 ug/ml||Anti-Enterobacter cloacae ATCC 13047, activity value is MIC > 100 ug/ml||Anti-Enterobacter cloacae clinical strain, activity value is MIC > 100 ug/ml||Anti-Enterobacter aerogenes clinical strain, activity value is MIC > 100 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 12.5 ug/ml||Anti-Pseudomonas aeruginosa PA 01, activity value is MIC = 12.5 ug/ml||Anti-Pseudomonas aeruginosa clinical strain 1, activity value is MIC = 12.5 ug/ml||Anti-Pseudomonas aeruginosa clinical strain 2, activity value is MIC = 6.25 ug/ml||Anti-Haemophilus influenzae ATCC 49247, activity value is MIC = 3.125 ug/ml||Anti-Haemophilus influenzae ATCC 49766, activity value is MIC = 6.25 ug/ml||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 6.25 ug/ml||Anti-Klebsiella pneumoniae ATCC 700603, activity value is MIC = 3.125 ug/ml||Anti-##Fungi : Candida albicans ATCC 2002, activity value is MIC > 200 ug/ml||Anti-Candida albicans clinical strain, activity value is MIC > 200 ug/ml	sequence truncation, amino acid substitution, reptile cathelicidin, animal-derived, natural derivative|||sequence truncation, amino acid substitution, reptile cathelicidin, animal-derived, natural derivative|||Ophiophagus hannah [King cobra]|||Synthetic construct	N/A	Hemolytic activity against hRBC|||[Ref.22491685] 13% hemolysis at 100 ug/ml , 17% hemolysis at 200 ug/ml , 18% hemolysis at 300 ug/ml , 18.5% hemolysis at 400 ug/ml against human red blood cells	"Antimicrob Agents Chemother
. 2012 Jun;56(6):3309-17. doi: 10.1128/AAC.06304-11. Epub 2012 Apr 9.|||2012 Jun;56(6):3309-17. doi: 10.1128/AAC.06304-11. Epub 2012 Apr 9.|||22491685|||22491685|||Antimicrob Agents Chemother. 2012 Jun;56(6):3309-17. doi: 10.1128/AAC.06304-11.||Ref.22491685"	20	
FPDB00945	AP01206|||AP01206|||Mersacidin	CTFTLPGGGGVCTLTSECIC	Anti-Gram+||Anti-MRSA||Anti-S. aureus 209P, activity value is MIC = 1.56 ug/ml||Anti-S. aureus R85, activity value is MIC = 0.78 ug/ml||Anti-S. aureus 20424, activity value is MIC = 3.12 ug/ml||Anti-S. aureus 503, activity value is MIC = 1.56 ug/ml||Anti-S. epidermidis 823, activity value is MIC = 6.25 ug/ml||Anti-S. faecalis 21777, activity value is MIC = 50 ug/ml||Anti-S. pneumoniae A77, activity value is MIC = 3.12 ug/ml||Anti-B. subtilis ATCC6633, activity value is MIC = 0.78 ug/ml||Antibacterial ; Bacillus sp. strain HIL Y-85 54728||Anti-Staphylococcus aureus 209P, activity value is MIC = 1.56 ug/ml||Anti-Staphylococcus aureus SG 511, activity value is MIC = 0.78 ug/ml||Anti-Staphylococcus aureus R 85, activity value is MIC = 0.78 ug/ml||Anti-Staphylococcus aureus E 88, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus 3066, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus 20424, activity value is MIC = 3.12 ug/ml||Anti-Staphylococcus aureus 20240, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus 503, activity value is MIC = 1.56 ug/ml||Anti-Staphylococcus aureus 710, activity value is MIC = 0.78 ug/ml||Anti-Staphylococcus epidermidis 823, activity value is MIC = 6.25 ug/ml||Anti-Streptococcus faecalis 21777, activity value is MIC = 50 ug/ml||Anti-Streptococcus pneumoniae A77, activity value is MIC = 3.12||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 0.78 ug/ml||Anti-Micrococcus lutues ATCC 9341, activity value is MIC = 0.195 ug/ml	Bacillus sp. strain HIL Y-85 54728	Nonhelixbeta	Staphylococcus aureus 209P ( MIC = 1.56 ug/ml ),Staphylococcus aureus SG 511 ( MIC = 0.78 ug/ml ), Staphylococcus aureus R 85 ( MIC = 0.78 ug/ml ), Staphylococcus aureus E 88 ( MIC = 12.5 ug/ml ), Staphylococcus aureus 3066 ( MIC = 25 ug/ml ), Staphylococcus aureus 20424 ( MIC = 3.12 ug/ml ), Staphylococcus aureus 20240 ( MIC = 6.25 ug/ml ), Staphylococcus aureus 503 ( MIC = 1.56 ug/ml ), Staphylococcus aureus 710 ( MIC = 0.78 ug/ml ), Staphylococcus epidermidis 823 ( MIC = 6.25 ug/ml ), Streptococcus faecalis 21777 ( MIC = 50 ug/ml ), Streptococcus pneumoniae A77 ( MIC = 3.12 ), Bacillus subtilis ATCC 6633 ( MIC = 0.78 ug/ml ), Micrococcus lutues ATCC 9341 ( MIC = 0.195 ug/ml )	J Antibiot (Tokyo). 1992 Jun;45(6):832-8|||J Antibiot (Tokyo). 1992 Jun;45(6):832-8|||https://pubmed.ncbi.nlm.nih.gov/1500347	20	
FPDB00946	AP01263|||AP01263|||Temporin-1Vc|||DRAMP01791	FLPLVTMLLGKLF	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-S. aureus NCTC8325, activity value is MIC = 5 uM||Anti-MRSA T7/20, activity value is MIC = 10 uM||Anti-S. epidermidis RP62A, activity value is MIC = 10 uM||Anti-E. faecalis ATCC 29212, activity value is MIC = 40 uM||Anti-Streptococcus group B HNTCC 80130, activity value is MIC = 40 uM||Anti-E.coli ATCC25922, activity value is MIC > 160 uM||Anti-K. pneumoniae KK3 9904, activity value is MIC = 80 uM||Anti-P.aeruginosa ATCC 27853, activity value is MIC = 160 uM||Anti-E. cloacae HNTCC 53001, activity value is MIC = 40 uM||Anti-C.albicans, activity value is MIC > 160 uM||Antibacterial||Anti-Staphylococcus aureus NCTC8325, activity value is MIC = 5 uM||Anti-S. aureus T7/20, activity value is MIC = 10 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 40 uM||Anti-Klebsiella pneumoniae KK3 9904, activity value is MIC = 80 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 160 uM||Anti-Enterobacter cloacae HNTCC 53001, activity value is MIC = 40 uM	the carpenter frog, Rana virgatipes, North America|||the carpenter frog, Rana virgatipes, North America|||Rana catesbeiana [American bullfrog]|||Rana virgatipes (Ranidae) (Aquarana)	N/A	"The hemolytic activity of certain antimicrobial peptides in the skin secretions of the wood frog (Rana virgatipes) was studied in the document, and the relevant hemolytic values are as follows:

Table

Antimicrobial Peptide | Half Hemolytic Concentration (uM)
-------------------|-------------------------------
temporin-1Va | 120
temporin-1Vb | 30
temporin-1Vc | 30

The researchers obtained these data through hemolysis experiments. During the experiment, peptides at concentrations ranging from 1 to 200 uM were incubated with washed human red blood cells from healthy donors at 37°C for 1 hour. After centrifugation at 12,0 ug for 15 seconds, the absorbance of the supernatant was measured at 450 nm. A 1% (v/v) Tween-20 treatment group was used as the 100% hemolysis control. The peptide concentration causing 50% red blood cell hemolysis (LD_{50}) was calculated. The results showed that the hemolytic activity of temporin-1Va was relatively weak, whereas temporin-1Vb and temporin-1Vc had stronger hemolytic activity, approximately four times that of temporin-1Va.|||[Ref:15996769]LD50=30 uM against washed human erythrocyte"	Regul Pept. 2005; 131: 38-45|||Regul Pept. 2005; 131: 38-45|||15996769|||Ref.15996769	13	
FPDB00947	AP01320|||AP01320|||Ostricacin-1	"	
LFCRKGTCHFGGCPAHLVKVGSCFGFRACCKWPWDV"	Anti-Gram+ & Gram-||Anti-MRSA||anti-sepsis||Antibacterial	Struthio camelus|||Struthio camelus|||Struthio camelus [Ostrich]	Bridge	N/A	Biotechnol Lett 2001; 23: 207-210|||Biotechnol Lett 2001; 23: 207-210|||16459058	36	
FPDB00948	AP01321|||AP01321|||Ostricacin-2|||DRAMP03286|||AP01321	APGNKAECEREKGYCGFLKCSFPFVVSGKCSRFFFCCKNIW	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||anti-sepsis||Anti-S. aureus 1056 MRSA, activity value is MIC = 1.25 ug/ml||Anti-E. coli O157:H7, activity value is MIC = 0.96 ug/ml||Anti-and C. albicans 3153A, activity value is MIC = 6.2 ug/ml||Antibacterial||Anti-Staphylococcus aureus 1056-MRSA, activity value is MIC = 1.25 ug/ml||Anti-Escherichia coli O157:H7, activity value is MIC = 0.96 ug/ml||Anti-Candida albicans 3153A, activity value is MIC = 6.2 ug/ml	Struthio camelus|||Struthio camelus|||Struthio camelus [Ostrich]|||Struthio camelus (Ostrich)|||Struthio camelus	Bridge	"Table

Antimicrobial Peptide  Hemolytic Activity (RCH, %)  Test Concentration
OdA1  14.2±5.6  50 µg/ml
OdB1  None  50 µg/ml
OdC1  None  50 µg/ml
OdD1  None  50 µg/ml
Ode1  None  50 µg/ml
OdF1  None  50 µg/ml
OdG1  None  50 µg/ml
OdH1  None  50 µg/ml
OdI1  None  50 µg/ml
OdJ1  None  50 µg/ml
OdK1  None  50 µg/ml
OdL1  22.4±7.2  50 µg/ml
Odd1  7.7±3.5  50 µg/ml
OdN1  None  50 µg/ml
Odo1  None  50 µg/ml
OdP1a  None  50 µg/ml
OdP2a  None  50 µg/ml
Odd1  23.6±3.7  50 µg/ml
OdR1  None  50 µg/ml
Ods1  None  50 µg/ml
OdT1  None  50 µg/ml
OdU1  5.2±2.3  50 µg/ml
OdV1  None  50 µg/ml
OdW1  None  50 µg/ml
Nigrocin-OG2  18.1±7.7  50 µg/ml
Nigrocin-OG4  22.3±3.1  50 µg/ml
Nigrocin-OG5  14.0±5.2  50 µg/ml
Nigrocin-OG13  None  50 µg/ml
Nigrocin-OG20  None  50 µg/ml
Nigrocin-OG21  17.0±2.8  50 µg/ml

The experiment used the Triton X-100 treated group as the 100% hemolysis control. At this concentration, different antimicrobial peptides exhibited varying hemolytic activities. Some peptides showed no detectable hemolytic activity (NA), while others had a certain degree of hemolysis.|||The hemolytic activity (RCH) of certain peptides (such as odorranain-A1, etc.) was mostly NA (not detected) or low at the tested concentration (50 µg/mL); specific values can be found in the “RCH” column of Table III. For example, the hemolysis rates of odorranain-B1, -C1, and others did not exceed the statistically significant threshold.|||Hemolysis assay is a standard biological method to investigate cytotoxic effects of an agent on red blood cells. For brevinin-Eu and cyanophlyctin b, only 1.9% and 0.7% hemolytic activity was observed, respectively, at 500 lg/ mL in comparison with Triton-X-100 as positive control with 100% hemolysis. Low hemolytic activity makes them"	"Mol Cell Proteomics
. 2007 May;6(5):882-94. doi: 10.1074/mcp.M600334-MCP200. Epub 2007 Jan 31.|||2007 May;6(5):882-94. doi: 10.1074/mcp.M600334-MCP200. Epub 2007 Jan 31.|||16459058|||Int J Antimicrob Agents. 2006 Mar;27(3):229-235.|||Int J Antimicrob Agents. 2006 Mar;27(3):229-35. Pub-Med.|||Int J Antimicrob Agents. 2006 Mar;27(3):229-35. Pub-Med."	41	
FPDB00949	AP01322|||AP01322|||Ostricacin-3	IPRPLDPCIAQNGRCFTGICRYPYFWIGTCRNGKSCCRRR	Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus 1056 MRSA, activity value is MIC = 2.78 ug/ml||Antibacterial	Struthio camelus|||Struthio camelus|||Struthio camelus [Ostrich]	Bridge	"Table

Antimicrobial Peptide  Hemolytic Activity (RCH, %)  Test Concentration
OdA1  14.2±5.6  50 µg/ml
OdB1  None  50 µg/ml
OdC1  None  50 µg/ml
OdD1  None  50 µg/ml
Ode1  None  50 µg/ml
OdF1  None  50 µg/ml
OdG1  None  50 µg/ml
OdH1  None  50 µg/ml
OdI1  None  50 µg/ml
OdJ1  None  50 µg/ml
OdK1  None  50 µg/ml
OdL1  22.4±7.2  50 µg/ml
Odd1  7.7±3.5  50 µg/ml
OdN1  None  50 µg/ml
Odo1  None  50 µg/ml
OdP1a  None  50 µg/ml
OdP2a  None  50 µg/ml
Odd1  23.6±3.7  50 µg/ml
OdR1  None  50 µg/ml
Ods1  None  50 µg/ml
OdT1  None  50 µg/ml
OdU1  5.2±2.3  50 µg/ml
OdV1  None  50 µg/ml
OdW1  None  50 µg/ml
Nigrocin-OG2  18.1±7.7  50 µg/ml
Nigrocin-OG4  22.3±3.1  50 µg/ml
Nigrocin-OG5  14.0±5.2  50 µg/ml
Nigrocin-OG13  None  50 µg/ml
Nigrocin-OG20  None  50 µg/ml
Nigrocin-OG21  17.0±2.8  50 µg/ml

The experiment used the Triton X-100 treated group as the 100% hemolysis control. At this concentration, different antimicrobial peptides exhibited varying hemolytic activities. Some peptides showed no detectable hemolytic activity (NA), while others had a certain degree of hemolysis."	"Mol Cell Proteomics
. 2007 May;6(5):882-94. doi: 10.1074/mcp.M600334-MCP200. Epub 2007 Jan 31.|||2007 May;6(5):882-94. doi: 10.1074/mcp.M600334-MCP200. Epub 2007 Jan 31.||Lu S et al., 2014|||16459058"	40	
FPDB00950	AP01323|||AP01323|||Ostricacin-4	"	
LPVNEAQCRQVGGYCGLRICNFPSRFLGLCTRNHPCCSRVWV"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus 1056 MRSA, activity value is MIC = 11.48 ug/ml||Antibacterial	Struthio camelus|||Struthio camelus|||Struthio camelus [Ostrich]	Bridge	"Table

Antimicrobial Peptide  Hemolytic Activity (RCH, %)  Test Concentration
OdA1  14.2±5.6  50 µg/ml
OdB1  None  50 µg/ml
OdC1  None  50 µg/ml
OdD1  None  50 µg/ml
Ode1  None  50 µg/ml
OdF1  None  50 µg/ml
OdG1  None  50 µg/ml
OdH1  None  50 µg/ml
OdI1  None  50 µg/ml
OdJ1  None  50 µg/ml
OdK1  None  50 µg/ml
OdL1  22.4±7.2  50 µg/ml
Odd1  7.7±3.5  50 µg/ml
OdN1  None  50 µg/ml
Odo1  None  50 µg/ml
OdP1a  None  50 µg/ml
OdP2a  None  50 µg/ml
Odd1  23.6±3.7  50 µg/ml
OdR1  None  50 µg/ml
Ods1  None  50 µg/ml
OdT1  None  50 µg/ml
OdU1  5.2±2.3  50 µg/ml
OdV1  None  50 µg/ml
OdW1  None  50 µg/ml
Nigrocin-OG2  18.1±7.7  50 µg/ml
Nigrocin-OG4  22.3±3.1  50 µg/ml
Nigrocin-OG5  14.0±5.2  50 µg/ml
Nigrocin-OG13  None  50 µg/ml
Nigrocin-OG20  None  50 µg/ml
Nigrocin-OG21  17.0±2.8  50 µg/ml

The experiment used the Triton X-100 treated group as the 100% hemolysis control. At this concentration, different antimicrobial peptides exhibited varying hemolytic activities. Some peptides showed no detectable hemolytic activity (NA), while others had a certain degree of hemolysis."	"Mol Cell Proteomics
. 2007 May;6(5):882-94. doi: 10.1074/mcp.M600334-MCP200. Epub 2007 Jan 31.|||: 10.1074/mcp.M600334-MCP200. Epub 2007 Jan 31.|||16459058"	42	
FPDB00951	AP01358|||AP01357|||AP01358|||Defensin|||DRAMP02791	"	
VTCDLLSFEAKGFAANHSLCAAHCLAIGRRGGSCERGVCICRR"	Anti-Gram+||Anti-MRSA||Antibacterial||Gram-positive bacteria: Staphylococcus aureus||Bacillus subtilis||Staphylococcus aureus (MRSA).||Antimicrobial	beetle, Allomyrina dichotoma|||beetle, Allomyrina dichotoma|||Allomyrina dichotoma [Japanese rhinoceros beetle]|||Allomyrina dichotoma (Japanese rhinoceros beetle)	Bridge	"The document mentions the following values related to hemolysis:
plicatamide: Exhibits strong hemolytic activity on human red blood cells, with its hemolytic ability similar to melittin in bee venom. At a concentration of 10 µg/ml, it can cause obvious hemolysis of human red blood cells.
plicatamide: Exhibits almost no hemolytic activity on sheep red blood cells; even at a concentration as high as 80 µg/ml, no obvious hemolysis is observed.
PL-101: Similar to natural plicatamide, it has hemolytic effects on human red blood cells, but specific values are not clearly mentioned."	Biochem Biophys Res Commun. 1996 Mar 27;220(3):526-31|||Biochem Biophys Res Commun. 1996 Mar 27;220(3):526-31|||8607799|||Biochem Biophys Res Commun. 1996 Mar 27;220(3):526-531.	43	
FPDB00952	AP01380|||DRAMP02740|||Beta-defensin 1|||AP01380	"	
YDLSKNCRLRGGICYIGKCPRRFFRSGSCSRGNVCCLRFG"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-HS): Escherichia coli ML35p, activity value is MIC = 0.65||Anti-HS): Listeria monocytogenes EGD, activity value is MIC = 0.65||Anti-Methicillin-resistant Staphylococcus aureus ATCC 33591, activity value is MIC = 5.6||Anti->20 uM). Yeast: Candida albicans, activity value is MIC = 5.2||Antibacterial	the European pond turtle, Emys orbicularis|||the European pond turtle, Emys orbicularis|||Emys orbicularis (European pond turtle)|||Emys orbicularis [European pond turtle]|||the European pond turtle, Emys orbicularis	Bridge	"Melittin, a bee venom hemolytic peptide, can cause complete lysis of red blood cells at a concentration of 10 µM, and partial lysis can still be observed at concentrations as low as 0.625 µM.

Pilosulin 1 can cause complete lysis of red blood cells at a concentration of 40 µM, and partial lysis can still be observed at concentrations as low as 1.25 µM.

Whole jack jumper ant venom can cause complete lysis of red blood cells at the highest concentration of 200 µg/ml, and partial lysis can still be observed at concentrations as low as 25 µg/ml."	Proteomics. 2009 Mar;9(5):1364-73|||Proteomics. 2009 Mar;9(5):1364-1373.||Ref.19253295|||19253295|||Proteomics. 2009 Mar;9(5):1364-73	40	
FPDB00953	AP01444|||DRAMP01758	"	
FLSAITSILGKFF"	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Anti-Antinacterial activity was not reported due to a limited amount of material. We filled up this gap by using a synthetic peptide. Active against S. aureus USA300, activity value is MIC = 6.3 uM||Anti-S. epidermidis 1457, activity value is MIC = 6.3 uM||Anti-B. subtilis 168, activity value is MIC = 12.5 uM||Anti-C. albicans, activity value is MIC = 25 uM||Anti-D. glabrata, activity value is MIC = 25 uM||Antimicrobial||Antibacterial	Rana septentrionalis , North America|||Rana septentrionalis , North America|||Rana septentrionalis (mink frog)	N/A	"The values related to hemolysis mentioned in this document are the half-maximal hemolytic concentrations (HC_{50}), which is the peptide concentration that produces 50% hemolytic effect. The specific data are as follows:

- Brevinin-1SPa: HC_{50} = 7 μM
- Brevinin-1SPb: HC_{50} = 25 μM
- Brevinin-1SPd: HC_{50} = 8 μM
- Temporin-1SPb: HC_{50} = 60 μM
- Brevinin-2-related peptide: HC_{50} = 70 μM

These values were measured through hemolysis experiments and reflect the hemolytic activity of different antimicrobial peptides on human red blood cells. The lower the value, the stronger the hemolytic effect.|||The document mentions the following hemolytic-related values: brevinin-1SPa: half-maximal hemolytic concentration (HC₅₀) on human red blood cells is 7 µM. brevinin-1SPb: HC₅₀ on human red blood cells is 25 µM. brevinin-1SPd: HC₅₀ on human red blood cells is 8 µM. temporin-1SPb: HC₅₀ on human red blood cells is 60 µM. brevinin-2 related peptides: HC₅₀ on human red blood cells is 70 µM."	"Comparative Study Comp Biochem Physiol C Toxicol Pharmacol
. 2004 Oct;139(1-3):31-8. doi: 10.1016/j.cca.2004.08.019.|||2004 Oct;139(1-3):31-8. doi: 10.1016/j.cca.2004.08.019.|||Comp Biochem Physiol C Toxicol Pharmacol. 2004 Oct;139(1-3):31-8. PubMed|||Comp. Biochem. Physiol. C 2004; 139: 31-38."	13	
FPDB00954	AP01493|||AP01493|||Lantibiotic paenibacillin	ASIIKTTIKVSKAVCKTLTCICTGSCSNCK	Anti-Gram+||Anti-MRSA||Antibacterial	Paenibacillus polymyxa (formerly bacillus polymyxa)|||Paenibacillus polymyxa (formerly bacillus polymyxa)|||Paenibacillus polymyxa	N/A	N/A	Appl Environ Microbiol. 2007 Jan;73(1):168-78	30	
FPDB00955	AP01497|||AP01497|||Temporin-CPb|||Temporin-CPb|||AP01497|||DRAMP01786	"	
FLPIVGRLISGIL"	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Anti-Staphylococcus aureus USA300, activity value is MIC = 12.5 uM||Anti-Staphylococcus epidermidis 1457, activity value is MIC = 12.5 uM||Anti-Bacillus subtilis 168, activity value is MIC = 25||Anti-Candida albicans ATCC 10231, activity value is MIC = 50 uM||Anti-C. tropicalis ATCC 13803, activity value is MIC = 6.2||Antibacterial||Antimicrobial	the New World frog Lithobates capito, North America|||the New World frog Lithobates capito, North America|||Rana capito [Florida gopher frog]|||Rana capito [Florida gopher frog]|||the New World frog Lithobates capito, North America|||Lithobates capito (New World frog)	N/A	"The values related to hemolysis mentioned in this document are the half-maximal hemolytic concentrations (HC_{50}), which is the peptide concentration that produces 50% hemolytic effect. The specific data are as follows:

- Brevinin-1SPa: HC_{50} = 7 μM
- Brevinin-1SPb: HC_{50} = 25 μM
- Brevinin-1SPd: HC_{50} = 8 μM
- Temporin-1SPb: HC_{50} = 60 μM
- Brevinin-2-related peptide: HC_{50} = 70 μM

These values were measured through hemolysis experiments and reflect the hemolytic activity of different antimicrobial peptides on human red blood cells. The lower the value, the stronger the hemolytic effect.|||LC50=220 uM|||Human RBCs (HL50 = >100 uM)|||Human RBCs (HL50 = >100 uM)"	"Peptides
. 2009 Oct;30(10):1775-81. doi: 10.1016/j.peptides.2009.07.011. Epub 2009 Jul 25.|||Peptides
. 2009 Oct;30(10):1775-81. doi: 10.1016/j.peptides.2009.07.011. Epub 2009 Jul 25.|||19635516, 29842923||Refer PubMed ID: 29842923|||19635516, 29842923|||Peptides. 2009 Oct;30(10):1775-81. Pub-Med.|||Regul Pept 2007; 138: 87-93.|||Peptides. 2009 Oct;30(10):1775-81. Pub-Med."	13	
FPDB00956	AP01511	"	
TITLSTCAILSKPLGNNGYLCTVTKECMPSSCN"	Anti-Gram+||Anti-MRSA||Synergistic AMPs||It displayed antimicrobial activity against all Listeria monocytogenes||MRSA||vancomycin-resistant enterococcus strains tested. MIC reached the nM range. In addition||a similar peptide is reported in PLoS One. 2009 Aug 26;4(8):e6788. Inactivation of the lantibiotic modification enzymes licM1 and licM2 led to loss of antibacterial activity in the isopropanol extract.	Bacillus licheniformis ATCC 14580 or VK21	Helix	N/A	"Appl Environ Microbiol
. 2009 Sep;75(17):5451-60. doi: 10.1128/AEM.00730-09. Epub 2009 Jun 26."	33	
FPDB00957	AP01543|||DRAMP04569	"	
KPWRFRRAIRRVRWRKVAPYIPFVVKTVGKK"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-The recombinant peptide showed activity against E. coli DH5alpha or WT E4 or E9, activity value is MBC = 0.2||Anti-B. megaterium ATCC 14581, activity value is MBC = 0.1 uM||Anti-and S. aureus ATCC 12600 or MRSA ATCC 43300 or ATCC 33393 or WT 344 355 or 358, activity value is MBC = 0.4||Anti-synthetic version of the peptide with C-terminal amidation inhibits gram-positive vancomycin-resistant E. faecalis ATCC 51299, activity value is MBC = 1.6 uM||Anti-G70 and G71, activity value is MBC = 0.4||No MICs found in DRAMP database	Hydra magnipapillata	Helix	No hemolysis information or data found in the reference(s) presented in this entry	"Antimicrob Agents Chemother
. 2009 Dec;53(12):5245-50. doi: 10.1128/AAC.00826-09. Epub 2009 Sep 21.|||Antimicrob Agents Chemother. 2009 Dec;53(12):5245-5250."	31	
FPDB00958	AP01558|||AP01558|||Hedistin|||DRAMP02955	"	
LGAWLAGKVAGTVATYAWNRYV"	Anti-Gram+ & Gram-||Anti-MRSA||Antibacterial||Antimicrobial||Anti-Gram+||Anti-Gram-	circulating NK cells; coelomocytes, Nereis diversicolor|||circulating NK cells; coelomocytes, Nereis diversicolor|||Hediste diversicolor [Sandworm]|||Hediste diversicolor	Helix	N/A	Dev Comp Immunol. 2007;31(8):749-62.|||Dev Comp Immunol. 2007;31(8):749-762.	22	
FPDB00959	AP01605|||AP01605|||Gradimycin|||Lantibiotic actagardine|||Gradimycin	SSGWVCTLTIECGTVICAC	Anti-Gram+||Anti-MRSA||Anti-S. aureus MetS ATCC 6538P, activity value is MIC = 32 ug/ml||Anti-S. aureus MetS ATCC 19636, activity value is MIC = 32 ug/ml||Anti-S. aureus MetR L1400, activity value is MIC = 64 ug/ml||Anti-S. pyogenes SKF13400, activity value is MIC = 2 ug/ml||Anti-S. pneumoniae L44, activity value is MIC = 16 ug/ml||Anti-E.faecium VanS L568, activity value is MIC = 128 ug/ml||Anti-E.faecalis VanS L559 or VanA L560, activity value is MIC = 128 ug/ml||Anti-E.coli ATCC 25922, activity value is MIC > 128 ug/ml||Anti-and C.albicans ATCC 90028, activity value is MIC > 128 ug/ml||Anti-Staphylococcus aureus ATCC 6538, activity value is MIC = 100 ug/ml||Anti-Staphylococcus aureus Tour, activity value is MIC = 50 ug/ml||Anti-Staphylococcus aureus ATCC 9144, activity value is MIC = 100 ug/ml||Anti-Clostridium perfringens ISS 30543, activity value is MIC = 2 ug/ml||Anti-Proteus rulgaris X 19H ATCC 881, activity value is MIC > 100 ug/ml||Anti-Escherichia coli ATCC 10536, activity value is MIC > 100 ug/ml||Anti-Pseudoinonas aeruginosa ATCC 10145, activity value is MIC > 100 ug/ml||Anti-Candida albicans SKF 2270, activity value is MIC > 100 ug/ml||Anti-Trichophyton mentagrophytes SKF 17410, activity value is MIC > 100 ug/ml||Anti-Mycobacterium tuberculosis H37Rv ATCC 9360, activity value is MIC > 100 ug/ml||Anti-Mycoplasma gallisepticum S 6 Weybridge, activity value is MIC > 100 ug/ml||Anti-Staphylococcus albus ATCC 12228, activity value is MIC > 100 ug/ml||Anti-Staphylococcus sp. SKF 24390, activity value is MIC = 100 ug/ml||Anti-Staphylococcus Sackman 10B CIBA, activity value is MIC = 50 ug/ml||Anti-Micrococcus flavus ATCC 10240, activity value is MIC = 1 ug/ml||Anti-Streptococcus faecalis ATCC 10541, activity value is MIC = 50 ug/ml||Anti-Streptococcus bovis ATCC 9809, activity value is MIC = 100 ug/ml||Anti-Streptococcus haemolytieus C 203, activity value is MIC = 2 ug/ml||Anti-Diplococcus pneumoniae UC 41, activity value is MIC = 50 ug/ml||Anti-Neisseria gonorrhoeae ATCC 9826, activity value is MIC = 20 ug/ml||Antibacterial	Actinoplanes garbadinensis ATCC31048 and 31049|||Actinoplanes garbadinensis ATCC31048 and 31049|||Actinoplanes garbadinensis|||Synthetic construct	Nonhelixbeta	N/A	J Antibiot (Tokyo). 1976 May;29(5):511-5|||J Antibiot (Tokyo). 1976 May;29(5):511-5|||8414|||uniprot|||8414	19	
FPDB00960	AP01612|||DRAMP18320	"	
SASIVKTTIKASKKLCRGFTLTCGCHFTGKK"	Anti-Gram+||Anti-MRSA||Anti-resistant bacterial strains MRSA and VRE . Also active against S. simulans, activity value is MIC = 0.1 uM||Anti-M. flavus, activity value is MIC = 0.075 uM||Anti-and B. megaterium, activity value is MIC = 0.1 uM||Antimicrobial||Antibacterial	Staphylococcus epidermidis 15X154|||Phasmahyla jandaia (Jandaia leaf frog)	Nonhelixbeta	N/A	"FEBS Lett
. 2005 Mar 28;579(9):1917-22. doi: 10.1016/j.febslet.2005.01.083.|||FEBS Lett
. 2005 Mar 28;579(9):1917-22. doi: 10.1016/j.febslet.2005.01.083.||Wang et al., 2023|||Toxicon. 2011 Jan;57(1):35-52."	31	
FPDB00961	AP01617|||AP01617|||Lantibiotic 107891|||DRAMP00017	VTSWSLCTPGCTSPGGGSNCSFCC	Anti-Gram+||Anti-MRSA||Antibacterial||Anti-L3798 S. aureus VISA, activity value is MIC = 2 ug/ml||Anti-L1729 Staphylococcus haemolyticus met-r, activity value is MIC = 8 ug/ml||Anti-L559 Enterococcus faecalis, activity value is MIC = 1 ug/ml||Anti-L560 Enterococcus faecalis Van A, activity value is MIC = 0.5 ug/ml||Anti-LA533 Enterococcus faecalis Van A, activity value is MIC = 1 ug/ml||Anti-L568 Enterococcus faecium, activity value is MIC = 2 ug/ml||Anti-L569 Enterococcus faecium Van A, activity value is MIC = 1 ug/ml||Anti-LB518 E. faecium Van A, activity value is MIC = 2 ug/ml||Anti-L884 Lactobacillus garviae, activity value is MIC = 1 ug/ml||Anti-L148 Lactobacillus delbrueckii ATCC04797, activity value is MIC = 4 ug/ml||Anti-Propionibacterium granulosum ATCC25564, activity value is MIC = 0.03 ug/ml||Anti-L1329 Propionibacterium acnes, activity value is MIC = 0.5 ug/ml||Anti-Propionibacterium limphophylum ATCC27250, activity value is MIC = 0.015 ug/ml||Anti-L970 Haemophilus influenzae ATCC19418, activity value is MIC = 32 ug/ml||Anti-L76 Moraxella catarrhalis ATCC8176, activity value is MIC = 0.25 ug/ml||Anti-L1613 Neisseria meningitidis ATCC13090V, activity value is MIC = 0.5 ug/ml||Anti-L997 Neisseria gonorrhoeae, activity value is MIC = 0.25 ug/ml	Microbispora sp., strain 107891; or Microbispora sp., PTA-5024, Microbispora ATCC-PTA-5024|||Microbispora sp., strain 107891; or Microbispora sp., PTA-5024, Microbispora ATCC-PTA-5024|||Microbispora sp [strain 107891]|||Microbispora corallina (Gram-positive bacteria)	Nonhelixbeta||Rich	N/A	"Chem Biol
. 2008 Jan;15(1):22-31. doi: 10.1016/j.chembiol.2007.11.009.|||Chem Biol
. 2008 Jan;15(1):22-31. doi: 10.1016/j.chembiol.2007.11.009.|||21520894"	24	
FPDB00962	AP01622|||AP01622|||CPF-B1|||CPF-B1|||AP01622	"	
GLGSLLGKAFKIGLKTVGKMMGGAPREQ"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Escherichia coli, activity value is MIC = 5 uM||Anti-Staphylococcus aureus, activity value is MIC = 5 uM||Anti-Candida albicans, activity value is MIC = 25 uM	Marsabit Clawed Frog, Xenopus borealis, Africa|||Marsabit Clawed Frog, Xenopus borealis, Africa|||Xenopus borealis [Kenyan clawed frog]|||Xenopus borealis [Kenyan clawed frog]|||Marsabit Clawed Frog, Xenopus borealis, Africa	N/A	Human erythrocytes ( LC50 > 200 uM )|||LC50 > 200 uM	Comp Biochem Physiol C Toxicol Pharmacol. 2010 Nov;152(4):467-72|||Comp Biochem Physiol C Toxicol Pharmacol. 2010 Nov;152(4):467-72|||20656059|||20656059|||Comp Biochem Physiol C Toxicol Pharmacol. 2010 Nov;152(4):467-72	28	
FPDB00963	AP01644|||AP01644|||Brevinin-2-RN1|||DRAMP02036|||Brevinin-2-RN1|||AP01644	"	
GAFGNFLKGVAKKAGLKILSIAQCKLSGTC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibacterial||Anti-Staphylococcus aureus ATCC2592, activity value is MIC = 3.1 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 3.1 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 12.5 ug/ml||Anti-Escherichia coli ML-35P, activity value is MIC = 25 ug/ml||Anti-Pseudomonas aeruginosa PA01, activity value is MIC = 12.5 ug/ml||Anti-Pseudomonas aeruginosa ATCC27853, activity value is MIC = 25 ug/ml	Rana nigrovittata,, or Sylvirana nigrovittata , Asia|||Rana nigrovittata,, or Sylvirana nigrovittata , Asia|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata,, or Sylvirana nigrovittata , Asia	N/A	"The hemolysis-related values mentioned in this document are the hemolysis rates of rabbit red blood cells caused by two antimicrobial peptides, with the specific data as follows:

- Brevinin-2-RN1: At a concentration of 100 µg/ml, the hemolysis rate of rabbit red blood cells is 17%.

- Brevinin-2-RN2: At a concentration of 100 µg/ml, the hemolysis rate of rabbit red blood cells is 21%.

These data were measured through hemolysis experiments, reflecting the hemolytic activity of the two antimicrobial peptides on rabbit red blood cells, both exhibiting moderate hemolytic effects.|||In the Journal of Peptide Science 2011, brevinin-2-RN1 and brevinin-2-RN2, isolated from the skin secretions of the black-banded frog (Rana nigrovittata), showed moderate hemolytic activity against rabbit red blood cells, inducing 17% and 21% hemolysis of rabbit red blood cells at a concentration of 100 μg/ml, respectively.|||[Ref.21171145] It has 17% hemolysis at 100 ug/ml against rabbit red blood cell|||Some antimicrobial peptides can act on eukaryotic membrane and exhibit hemolytic activities because of their hydrophobic structures [3]. In our experiments, rabbit red blood cells were used to check for hemolytic capabilities of brevinin-2-RN1 and -RN2. They showed moderate hemolytic activity. At the concentration of 100 ug/ml, brevinin-2-RN1 and -RN2 could induce 17 and 21% rabbit red blood cell hemolysis, respectively."	"J Pept Sci
. 2011 Jan;17(1):68-72. doi: 10.1002/psc.1309. Epub 2010 Oct 25.|||J Pept Sci
. 2011 Jan;17(1):68-72. doi: 10.1002/psc.1309. Epub 2010 Oct 25.|||21171145|||J Pept Sci. 2011 Jan;17(1):68-72.|||21171145|||J Pept Sci. 2011 Jan;17(1):68-72. doi: 10.1002/psc.1309. Epub 2010 Oct 25. PubMed.|||J Pept Sci. 2011 Jan;17(1):68-72. doi: 10.1002/psc.1309. Epub 2010 Oct 25. PubMed."	30	
FPDB00964	AP01645|||AP01645|||Brevinin-2-RN2|||DRAMP02037|||Brevinin-2-RN2|||AP01645	GAFGNFLKGVAKKAGLKILSIAQCKLFGTC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibacterial||Anti-Staphylococcus aureus ATCC2592, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 6.25 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 12.5 ug/ml||Anti-Escherichia coli ML-35P, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa PA01, activity value is MIC = 12.5 ug/ml||Anti-Pseudomonas aeruginosa ATCC27853, activity value is MIC = 12.5 ug/ml	Rana nigrovittata,, or Sylvirana nigrovittata , Asia|||Rana nigrovittata,, or Sylvirana nigrovittata , Asia|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata,, or Sylvirana nigrovittata , Asia	N/A	"The hemolysis-related values mentioned in this document are the hemolysis rates of rabbit red blood cells caused by two antimicrobial peptides, with the specific data as follows:

- Brevinin-2-RN1: At a concentration of 100 µg/ml, the hemolysis rate of rabbit red blood cells is 17%.

- Brevinin-2-RN2: At a concentration of 100 µg/ml, the hemolysis rate of rabbit red blood cells is 21%.

These data were measured through hemolysis experiments, reflecting the hemolytic activity of the two antimicrobial peptides on rabbit red blood cells, both exhibiting moderate hemolytic effects.|||In the Journal of Peptide Science 2011, brevinin-2-RN1 and brevinin-2-RN2, isolated from the skin secretions of the black-banded frog (Rana nigrovittata), showed moderate hemolytic activity against rabbit red blood cells, inducing 17% and 21% hemolysis of rabbit red blood cells at a concentration of 100 μg/ml, respectively.|||Some antimicrobial peptides can act on eukaryotic membrane and exhibit hemolytic activities because of their hydrophobic structures [3]. In our experiments, rabbit red blood cells were used to check for hemolytic capabilities of brevinin-2-RN1 and -RN2. They showed moderate hemolytic activity. At the concentration of 100 ug/ml, brevinin-2-RN1 and -RN2 could induce 17 and 22% rabbit red blood cell hemolysis, respectively.|||21% at 100 uM"	"J Pept Sci
. 2011 Jan;17(1):68-72. doi: 10.1002/psc.1309. Epub 2010 Oct 25.|||J Pept Sci
. 2011 Jan;17(1):68-72. doi: 10.1002/psc.1309. Epub 2010 Oct 25.|||21171145|||J Pept Sci. 2011 Jan;17(1):68-72|||21171145|||J Pept Sci. 2011 Jan;17(1):68-72. doi: 10.1002/psc.1309. Epub 2010 Oct 25 PubMed.|||J Pept Sci. 2011 Jan;17(1):68-72. doi: 10.1002/psc.1309. Epub 2010 Oct 25 PubMed."	30	
FPDB00965	AP01663|||DRAMP02660|||Neutrophil defensin 4|||AP01663|||DRAMP02660	RRTCRCRFGRCFRRESYSGSCNINGRIFSLCCR	Anti-Gram+||Antifungal||Anti-MRSA||Antimicrobial||Antibacterial||Anti-Gram-	leukocytes, Rhesus Macaque (Macaca mulatta)|||Macaca mulatta (Rhesus monkey)|||Macaca mulatta [Rhesus macaque]|||leukocytes, Rhesus Macaque (Macaca mulatta)|||Macaca mulatta (Rhesus monkey)	Bridge	N/A	"Infect Immun
. 1999 Nov;67(11):6139-44. doi: 10.1128/IAI.67.11.6139-6144.1999.|||Infect Immun. 1999 Nov;67(11):6139-6144.|||10531277|||Infect Immun. 1999 Nov;67(11):6139-44. PubMed.|||Infect Immun. 1999 Nov;67(11):6139-6144.|||Infect Immun. 1999 Nov;67(11):6139-44. PubMed."	33	
FPDB00966	AP01670|||DRAMP03198|||AP01670	ACYCRIPACFAGERRYGTCFYLGRVWAFCC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-In low salt conditions: Gram-negative bacterium: E. coli ML35p, activity value is MIC = 2.4 uM||Anti-Listeria monocytogenes EGD, activity value is MIC = 2.2 uM||Anti-methicillin-resistant S. aureus ATCC 33591, activity value is MIC = 3.5 uM||Anti-L. monocytogenes EGD, activity value is MIC = 1.8 uM||Anti-S. aureus ATCC 33591, activity value is MIC > 50 uM||Anti-Candida albicans 820, activity value is MIC > 50 uM||Anti-the Gram- bacterium E. coli ML35p, activity value is MIC = 2.4 uM||Anti-the Gram+ bacteria L. monocytogenes EGD, activity value is MIC = 2.2 uM||Anti-and the fungus C. albicans 820, activity value is MIC = 3.9 uM	blood leukocytes, Papio hamadryas|||Papio hamadryas (Hamadryas baboon)|||blood leukocytes, Papio hamadryas	Bridge	N/A	Rapid Commun Mass Spectrom. 2010 Mar 15;24(5):599-604|||Rapid Commun Mass Spectrom. 2010 Mar 15;24(5):599-604.|||Rapid Commun Mass Spectrom. 2010 Mar 15;24(5):599-604	30	
FPDB00967	AP01703|||DRAMP01482	GIFSKFAGKGIKNLLVKGVKNIGKEVGMDVIRTGIDIAGCKIKGEC	Anti-Gram+ & Gram-||Anti-MRSA	skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae (Japanese Endangered frog)	N/A	N/A	"Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||Gram-negative bacterium: Escherichia coli (MC=6.3 uM);
Gram-positive bacteria: Staphylococcus aureus (MIC=3.1 uM), Staphylococcus aureus (MRSA) (MIC=25 uM), Bacillus subtilis (MIC=25 uM)."	46	
FPDB00968	AP01704|||DRAMP01483|||AP01704|||DRAMP01483	RIFSKIGGKAIKNLILKGIKNIGKEVGMDVIRTGIDVAGCKIKGEC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Staphylococcus aureus, activity value is MIC = 3.1 uM||Anti-Staphylococcus aureus, activity value is MIC = 12.5 uM||Anti-Bacillus subtilis, activity value is MIC = 12.5 uM	skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae (Japanese Endangered frog)|||skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae (Japanese Endangered frog)	N/A	N/A	"Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||Peptides. 2011 Apr;32(4):670-676.|||21193000|||Peptides. 2011 Apr;32(4):670-6. Pub-Med.|||Gram-negative bacterium: Escherichia coli (MC=3.1 uM);
Gram-positive bacteria: Staphylococcus aureus (MIC=3.1 uM), Staphylococcus aureus (MRSA) (MIC=12.5 uM), Bacillus subtilis (MIC=12.5 uM).
Yeast: Candida albicans (MIC=50 uM).|||Peptides. 2011 Apr;32(4):670-6. Pub-Med."	46	
FPDB00969	AP01705|||AP01705|||Esculentin-2ISa|||DRAMP01484|||Esculentin-2ISa|||AP01705|||DRAMP01484	"	
GIFSLIKGAAKLITKTVAKEAGKTGLELMACKVTNQC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibacterial||Anti-Staphylococcus aureus, activity value is MIC = 3.1 uM||Anti-Staphylococcus aureus, activity value is MIC = 25 uM||Anti-Bacillus subtilis, activity value is MIC = 6.3 uM||Anti-E. coli ATCC 8739, activity value is MIC = 12.5 uM||Anti-Staphylococcus aureus ATCC 6538, activity value is MIC = 3.1 uM||Anti-ATCC 43300, activity value is MIC = 25 uM||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 6.3 uM||Anti-Candida albicans ATCC 90028, activity value is MIC = 100 uM	skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae [Ishikawa's frog]|||Odorrana ishikawae (Japanese Endangered frog)|||Odorrana ishikawae [Ishikawa's frog]|||skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae (Japanese Endangered frog)	N/A	N/A	"Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||21193000|||Peptides. 2011 Apr;32(4):670-676.|||21193000|||Peptides. 2011 Apr;32(4):670-6. Pub-Med.|||Gram-negative bacterium: Escherichia coli (MC=12.5 uM);
Gram-positive bacteria: Staphylococcus aureus (MIC=3.1 uM), Staphylococcus aureus (MRSA) (MIC=25 uM), Bacillus subtilis (MIC=6.3 uM).
Yeast: Candida albicans (MIC=100 uM).|||Peptides. 2011 Apr;32(4):670-6. Pub-Med."	37	
FPDB00970	AP01706|||AP01706|||Palustrin-2ISa|||DRAMP01237|||Palustrin-2ISa|||AP01706|||DRAMP01237	"	
GFMDTAKNVAKNVAVTLLDKLKCKITGGC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Escherichia coli, activity value is MIC = 100 uM||Anti-Staphylococcus aureus, activity value is MIC = 25 uM||Anti-S. aureus, activity value is MIC = 100 uM||Anti-Candida albicans, activity value is MIC = 100 uM||Anti-Staphylococcus aureus, activity value is MIC = 100 uM||Anti-Bacillus subtilis, activity value is MIC = 12.5 uM||Anti-E. coli, activity value is MIC = 100 uM||Anti-S. aureus, activity value is MIC = 25 uM||Anti-MRSA, activity value is MIC = 100 uM||Anti-B. subtilis, activity value is MIC = 12.5 uM	skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae|||Odorrana ishikawae|||skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae (Ishikawa's frog)	N/A	N/A	"Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||21911019|||Peptides. 2011 Apr;32(4):670-676.|||21193000|||21911019|||Peptides. 2011 Apr;32(4):670-6. Pub-Med.|||Peptides. 2011 Apr;32(4):670-6. Pub-Med."	29	
FPDB00971	AP01707|||AP01707|||Brevinin-2ISa	SLLDTFKNLAVNAAKSAGVSVLNALSCKISRTC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli, activity value is MIC = 50 uM||Anti-S. aureus, activity value is MIC = 12.5 uM||Anti-MRSA, activity value is MIC = 100 uM||Anti-B. subtilis, activity value is MIC = 12.5 uM||Anti-and C.albicans, activity value is MIC > 100 uM||Antibacterial	skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae [Ishikawa's frog]	N/A	N/A	"Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||21193000|||Peptides. 2011 Apr;32(4):670-6. Pub-Med."	33	
FPDB00972	AP01710|||AP01710|||Nigrocin-2ISa|||DRAMP01414|||Nigrocin-2ISa|||AP01710|||DRAMP01414	"	
GIFSTVFKAGKGIVCGLTGLC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli, activity value is MIC = 25 uM||Anti-S. aureus, activity value is MIC = 3.1 uM||Anti-MRSA, activity value is MIC = 12.5 uM||Anti-B. subtilis, activity value is MIC = 12.5 uM||Anti-and C. albicans, activity value is MIC = 50 uM||Anti-E. coli ATCC 8739, activity value is MIC = 25 uM||Anti-Staphylococcus aureus ATCC 6538, activity value is MIC = 3.1 uM||Anti-ATCC 43300, activity value is MIC = 12.5 uM||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 12.5 uM||Anti-Candida albicans ATCC 90028, activity value is MIC = 50 uM||Anti-Escherichia coli, activity value is MIC = 25 uM||Anti-Staphylococcus aureus, activity value is MIC = 3.1 uM||Anti-Staphylococcus aureus, activity value is MIC = 12.5 uM||Anti-Bacillus subtilis, activity value is MIC = 12.5 uM	skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae [Ishikawa's frog]|||Odorrana ishikawae (Ishikawa's frog)|||skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae (Ishikawa's frog)	N/A	N/A	"Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||21193000|||Peptides. 2011 Apr;32(4):670-676.|||21193000|||Peptides. 2011 Apr;32(4):670-6. Pub-Med.|||Gram-negative bacterium: Escherichia coli (MIC=25 uM);
Gram-positive bacteria: Staphylococcus aureus (MIC=3.1 uM), Staphylococcus aureus (MRSA) (MIC=12.5 uM), Bacillus subtilis (MIC=12.5 uM).
Yeast: Candida albicans (MIC=50 uM).|||Peptides. 2011 Apr;32(4):670-6. Pub-Med."	21	
FPDB00973	AP01711|||AP01711|||Nigrocin-2ISb|||DRAMP01415|||Nigrocin-2ISb|||AP01711|||DRAMP01415	GILGTVFKAGKGIVCGLTGLC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli, activity value is MIC = 50 uM||Anti-S. aureus, activity value is MIC = 3.1 uM||Anti-MRSA, activity value is MIC = 12.5 uM||Anti-B. subtilis, activity value is MIC = 12.5 uM||Anti-and C. albicans, activity value is MIC = 50 uM||Anti-E. coli ATCC 8739, activity value is MIC = 50 uM||Anti-Staphylococcus aureus ATCC 6538, activity value is MIC = 3.1 uM||Anti-ATCC 43300, activity value is MIC = 12.5 uM||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 12.5 uM||Anti-Candida albicans ATCC 90028, activity value is MIC = 50 uM||Anti-Escherichia coli, activity value is MIC = 50 uM||Anti-Staphylococcus aureus, activity value is MIC = 3.1 uM||Anti-Staphylococcus aureus, activity value is MIC = 12.5 uM||Anti-Bacillus subtilis, activity value is MIC = 12.5 uM	skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae [Ishikawa's frog]|||Odorrana ishikawae (Ishikawa's frog)|||skin, the endangered frog, Odorrana ishikawae, Japan, Asia|||Odorrana ishikawae (Ishikawa's frog)	N/A	N/A	"Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||Peptides
. 2011 Apr;32(4):670-6. doi: 10.1016/j.peptides.2010.12.013. Epub 2010 Dec 28.|||21193000|||Peptides. 2011 Apr;32(4):670-676.|||21193000|||Peptides. 2011 Apr;32(4):670-6. Pub-Med.|||Gram-negative bacterium: Escherichia coli (MIC=50 uM);
Gram-positive bacteria: Staphylococcus aureus (MIC=3.1 uM), Staphylococcus aureus (MRSA) (MIC=12.5 uM), Bacillus subtilis (MIC=12.5 uM).
Yeast: Candida albicans (MIC=50 uM).|||Peptides. 2011 Apr;32(4):670-6. Pub-Med."	21	
FPDB00974	AP01712|||AP01712|||Entianin	"	
WKSESVCTPGCVTGLLQTCFLQTITCNCKISK"	Anti-Gram+||Anti-MRSA||Anti-such as S. aureus ATCC 29213, activity value is MIC = 4||Anti-S. aureus ATCC 43300, activity value is MIC = 8 ug/ml||Anti-E. faecalis ATCC 29212, activity value is MIC = 16 ug/ml||Anti-E. faecalis ATCC 51299, activity value is MIC = 6||Anti-and M. luteus ATCC 9341, activity value is MIC = 4||Antibacterial	Bacillus subtilis DSM 15029T	N/A	N/A	"Appl Environ Microbiol
. 2011 Mar;77(5):1698-707. doi: 10.1128/AEM.01962-10. Epub 2011 Jan 14.|||Appl Environ Microbiol
. 2011 Mar;77(5):1698-707. doi: 10.1128/AEM.01962-10. Epub 2011 Jan 14.|||21239550"	32	
FPDB00975	AP01754|||AP01754|||Ir-Def1|||IR	"	
GGYYCPFFQDKCHRHCRSFGRKAGYCGGFLKKTCICV"	Anti-Gram+||Anti-MRSA||Primarily active against S. xylasus||M. lutes||B. subtilis||MRSA. Kill in 1 h.||Antibacterial	the European tick Ixodes ricinus|||the European tick Ixodes ricinus|||Ixodes ricinus [Common tick]|||Ixodes ricinus [Tick]	Bridge	"When testing the hemolytic activity of two defensin isoforms, def1 and def2, from the European tick (Ixodes ricinus), researchers used human red blood cells and set different peptide concentrations, obtaining the following hemolysis data:

- def1: at a concentration of 12.5 μM, the hemolysis rate was 2.9%; at 100 μM, the hemolysis rate was 75%.

- def2: at a concentration of 12.5 μM, the hemolysis rate was 2.0%; at 100 μM, the hemolysis rate was 64.6%."	Parasit Vectors. 2011 Apr 19;4(1):63|||Parasit Vectors. 2011 Apr 19;4(1):63|||21504572|||27531221	37	
FPDB00976	AP01755|||AP01755|||Ir-Def2	"	
GGYYCPFRQDKCHRHCRSFGRKAGYCGGFLKKTCICV"	Anti-Gram+||Anti-MRSA||Primarily active against S. xylasus||M. lutes||B. subtilis||MRSA. Kill in 1 h. Primarily active against S. xylasus||MRSA.Kill in 1 h.||Antibacterial	the European tick Ixodes ricinus|||the European tick Ixodes ricinus|||Ixodes ricinus [Common tick]	Bridge	"When testing the hemolytic activity of two defensin isoforms, def1 and def2, from the European tick (Ixodes ricinus), researchers used human red blood cells and set different peptide concentrations, obtaining the following hemolysis data:

- def1: at a concentration of 12.5 μM, the hemolysis rate was 2.9%; at 100 μM, the hemolysis rate was 75%.

- def2: at a concentration of 12.5 μM, the hemolysis rate was 2.0%; at 100 μM, the hemolysis rate was 64.6%."	Parasit Vectors. 2011 Apr 19;4(1):63|||Parasit Vectors. 2011 Apr 19;4(1):63|||21504572	37	
FPDB00977	AP01782|||DRAMP01416|||AP01782|||DRAMP01416	GILSTVFKAGKGIVCGLSGLC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli, activity value is MIC = 50 uM||Anti-S. aureus or MRSA, activity value is MIC = 3.1||Anti-B. subtilis, activity value is MIC = 12.5 uM||Anti-and C. albicans, activity value is MIC = 100 uM||Anti-Escherichia coli, activity value is MIC = 50 uM||Anti-Staphylococcus aureus, activity value is MIC = 3 uM	Odorrana ishikawae , Japan, Asia|||Odorrana ishikawae (Ishikawa's frog)|||Odorrana ishikawae , Japan, Asia|||Odorrana ishikawae (Ishikawa's frog)	N/A	In the study of antimicrobial peptides from the skin of Kaloula leopard frogs, human red blood cells were used as the test subject. The half-maximal hemolytic concentration (LC₅₀) of Esculentin-2CHa was 150 µM, Ranatuerin-2CHa was 135 µM, Ranatuerin-2CHb was 120 µM, Brevinin-1CHa and Brevinin-1CHb both had an LC₅₀ of 5 µM, while no specific LC₅₀ values were detected for Brevinin-1CHc and Palustrin-2CHa.	"Biochem Biophys Res Commun
. 2011 Sep 9;412(4):673-7. doi: 10.1016/j.bbrc.2011.08.023. Epub 2011 Aug 16.|||Biochem Biophys Res Commun. 2011 Sep 9;412(4):673-677.|||21867685|||Biochem Biophys Res Commun. 2011 Sep 9;412(4):673-7. PubMed.|||Gram-negative bacterium: Escherichia coli (MIC=50 uM);
Gram-positive bacterium: Staphylococcus aureus (MIC=3 uM).
Yeast: Candida albicans (MIC=100 uM).|||Biochem Biophys Res Commun. 2011 Sep 9;412(4):673-7. PubMed."	21	
FPDB00978	AP01783	"	
FLPGVLRLVTKVGPAVVCAITRNC"	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Anti-E.coli, activity value is MIC > 100 uM||Anti-S. aureus or MRSA, activity value is MIC = 3.1 uM||Anti-B. subtilis, activity value is MIC = 6.3 uM||Anti-and C. albicans, activity value is MIC = 50 uM	Odorrana ishikawae , Japan, Asia	N/A	N/A	"Biochem Biophys Res Commun
. 2011 Sep 9;412(4):673-7. doi: 10.1016/j.bbrc.2011.08.023. Epub 2011 Aug 16.|||Biochem Biophys Res Commun. 2011 Sep 9;412(4):673-7. PubMed."	24	
FPDB00979	AP01791|||AP01791|||Antimicrobial peptide ctriporin|||Antimicrobial peptide ctriporin|||AP01791	FLWGLIPGAISAVTSLIKK	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus AB94004 MRSA, activity value is MIC = 5||Anti-B. thuringiensis AB92037, activity value is MIC = 10 ug/ml||Anti-B. subtilis AB91021, activity value is MIC = 10 ug/ml||Anti-M. luteus AB93113, activity value is MIC = 5 ug/ml||Anti-and C. albicans AY93025, activity value is MIC = 20 ug/ml||Anti-penicillin-resistant S. epidermidis at 10 ug/ml. active against E. faecium ATCC29212, activity value is MIC = 64 ug/ml||Anti-A. baumannii ATCC19606, activity value is MIC = 16 ug/ml||Anti-Bacillus thuringiensis AB92037, activity value is MIC = 10 ug/ml||Anti-Bacillus subtilis AB91021, activity value is MIC = 10 ug/ml||Anti-Staphylococcus aureus AB94004, activity value is MIC = 5 ug/ml||Anti-Micrococcus luteus AB93113, activity value is MIC = 5 ug/ml||Anti-Candida albicans AY93025, activity value is MIC = 20 ug/ml||Anti-Escherichia coli AB94012, activity value is MIC > 100 ug/ml||Anti-Pseudomonas aeruginosa AB93066, activity value is MIC > 100 ug/ml	venom, Chaerilus tricostatus, Asia|||venom, Chaerilus tricostatus|||Chaerilus tricostatus [Scorpion]	Helix	N/A	"Antimicrob Agents Chemother
. 2011 Nov;55(11):5220-9. doi: 10.1128/AAC.00369-11. Epub 2011 Aug 29.|||Antimicrob Agents Chemother
. 2011 Nov;55(11):5220-9. doi: 10.1128/AAC.00369-11. Epub 2011 Aug 29.|||21876042|||21876042|||Antimicrob Agents Chemother
. 2011 Nov;55(11):5220-9. doi: 10.1128/AAC.00369-11. Epub 2011 Aug 29.|||Antimicrob Agents Chemother. 2011 Nov;55(11):5220-9. PubMed."	19	
FPDB00980	AP01814|||AP01814|||PGLa-H	KIAKVALKAL	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli ATCC 25922, activity value is MIC = 23.6 ug/ml||Anti-S. aureus ATCC 25923, activity value is MIC = 8.7 ug/ml||Anti-B. subtilis, activity value is MIC = 14.4 ug/ml||Anti-and multidrug-resistant meticillin-resistant S. aureus MRSA, activity value is MIC = 67.8 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 23.6 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 8.7 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 14.4 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 67.8 ug/ml	the African clawed frog, Xenopus laevis|||the African clawed frog, Xenopus laevis|||Synthetic construct	N/A	In terms of hemolytic activity, research data show that when rabbit red blood cells are used for hemolysis tests, the hemolytic activity on red blood cells is only 3.15% when the concentration of PGLa-H peptide reaches 100 µg/ml; when the concentration reaches 200 µg/ml, the hemolytic activity is 7.95%, indicating that this peptide has low hemolytic activity.	Int J Antimicrob Agents. 2011 Dec;38(6):510-5|||Int J Antimicrob Agents. 2011 Dec;38(6):510-5|||22014884	10	
FPDB00981	AP01898|||AP01898|||Cathelicidin-AL|||DRAMP01319|||AP01898|||DRAMP01319	RRSRRGRGGGRRGGSGGRGGRGGGGRSGAGSSIAGVGSRGGGGGRHYA	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus ATCC25923, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 6.25 ug/ml||Anti-B. subtilis, activity value is MIC = 100 ug/ml||Anti-C. albicans ATCC2002, activity value is MIC = 50 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 25||Anti-P. aeruginosa PA01, activity value is MIC = 12.5 ug/ml||Anti-P. aeruginosa ATCC27853, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 6.25 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 100 ug/ml||Anti-Escherichia coli ML-35P, activity value is MIC = 25 ug/ml||Anti-Psecdomonas aeruginosa PA01, activity value is MIC = 12.5 ug/ml||Anti-Psecdomonas aeruginosa ATCC27853, activity value is MIC = 6.25 ug/ml	skin secretions, frog, Amolops loloensis, China, Asia|||Amolops loloensis [Rufous-spotted torrent frog]|||Amolops loloensis|||skin secretions, frog, Amolops loloensis, China, Asia|||Amolops loloensis	Rich	"The provided document reports the hemolytic assay results for cathelicidin-AL: even at concentrations as high as 400 µg/mL, this peptide exhibits negligible hemolytic activity toward human erythrocytes, which is significantly higher than its minimum inhibitory concentration (MIC), indicating a pronounced selectivity between microbial and mammalian cells.|||skin secretions, frog, Amolops loloensis, China, Asia|||In the study of the brown-spotted torrent frog amphibian antimicrobial peptide cathelicidin-AL, cathelicidin-AL exhibited negligible hemolytic activity against human red blood cells, and even at concentrations as high as 400 μg/ml (far exceeding its minimum inhibitory concentration against bacteria), no significant red blood cell lysis was observed.|||Only Andersonin-C1 showed obvious hemolytic activity
against human red blood cells at the concentration of 50 ug/ml.
All of the rest synthesized peptides showed no hemolytic activity
under the test conditions (Table 78).|||at 400 ug/ml, little hemo.lytic"	"Amino Acids
. 2012 Aug;43(2):677-85. doi: 10.1007/s00726-011-1116-7. Epub 2011 Oct 19.|||Amino Acids. 2012 Aug;43(2):677-85. doi: 10.1007/s00726-011-1116-7. Epub 2011 Oct 19.|||22009138|||Amino Acids. 2012 Aug;43(2):677-685|||22009138|||J Proteome Res
. 2012 Jan 1;11(1):306-19. doi: 10.1021/pr200782u. Epub 2011 Nov 18.|||Amino Acids. 2012 Aug;43(2):677-85. PubMed."	48	
FPDB00982	AP01939|||AP01939|||Nigroain-B1|||DRAMP01533	CVISAGWNHKIRCKLTGNC	Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus ATCC25923 or S. aureus ATCC43300, activity value is MIC = 50 uM||Anti-P. aeruginosa PA01 or P. aeruginosa ATCC27853, activity value is MIC = 25 uM||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 50 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa PA01, activity value is MIC = 25 ug/ml||Anti-Pseudomonas aeruginosa ATCC27853, activity value is MIC = 25 ug/ml	skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata (Black-striped frog)	N/A	"nigroain-K2: At a concentration of 100 ug/ml, the hemolysis rate is 85.52±3.26%.

- temporin-RN1: At a concentration of 100 ug/ml, the hemolysis rate is 95.7±4.12%.

- temporin-RN3: At a concentration of 50 ug/ml, the hemolysis rate is 87.2±3.67%.

- gaegurin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 46.13±1.49%.

- nigroain-K1: At a concentration of 50 ug/ml, the hemolysis rate is 22.49±4.80%.

- gaegurin-RN4: At a concentration of 50 ug/ml, the hemolysis rate is 18.64±0.25%.

- gaegurin-RN5: At a concentration of 50 ug/ml, the hemolysis rate is 16.16±3.22%.

- rugosin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 6.69±1.51%.

- nigroain-E1: At a concentration of 50 ug/ml, the hemolysis rate is 7.62±1.60%.

Note: ""ND"" indicates no hemolytic activity detected at concentrations up to 100 ug/ml.|||skin secretions, Rana nigrovittata , China, Asia"	"Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||Genomics. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||19778602|||Gram-positive bacteria: Staphylococcus aureus ATCC25923 (MIC=4.69 ug/ml), S. aureus ATCC43300 (MIC=50 ug/ml);
Gram-negative bacteria: Pseudomonas aeruginosa PA01 (MIC=25 ug/ml), Pseudomonas aeruginosa ATCC27853 (MIC=25 ug/ml)."	19	
FPDB00983	AP01940|||AP01940|||Nigroain-C2|||DRAMP01539|||DRAMP01543|||Nigroain-C2|||AP01940|||DRAMP01539	"	
FKTWKRPPFQTSCWGIIKE"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus ATCC25923 or ATCC43300 MRSA, activity value is MIC = 27.5||Anti-P. aeruginosa PA01 or ATCC27853, activity value is MIC = 55 ug/ml||Anti-and C. albicans ATCC2002, activity value is MIC = 13.75 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 27.5 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 55 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 110 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 13.75 ug/ml||Anti-Escherichia coli ML-35P, activity value is MIC = 110 ug/ml||Anti-P. aeruginosa PA01, activity value is MIC = 55 ug/ml||Anti-P. aeruginosa ATCC27853, activity value is MIC = 55 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 55 ug/ml||Anti-Pseudomonas aeruginosa PA01, activity value is MIC = 55 ug/ml||Anti-Pseudomonas aeruginosa ATCC27853, activity value is MIC = 55 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 18.75 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 75 ug/ml	skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata (Black-striped frog)|||skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata (Black-striped frog)	N/A	"nigroain-K2: At a concentration of 100 ug/ml, the hemolysis rate is 85.52±3.26%.

- temporin-RN1: At a concentration of 100 ug/ml, the hemolysis rate is 95.7±4.12%.

- temporin-RN3: At a concentration of 50 ug/ml, the hemolysis rate is 87.2±3.67%.

- gaegurin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 46.13±1.49%.

- nigroain-K1: At a concentration of 50 ug/ml, the hemolysis rate is 22.49±4.80%.

- gaegurin-RN4: At a concentration of 50 ug/ml, the hemolysis rate is 18.64±0.25%.

- gaegurin-RN5: At a concentration of 50 ug/ml, the hemolysis rate is 16.16±3.22%.

- rugosin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 6.69±1.51%.

- nigroain-E1: At a concentration of 50 ug/ml, the hemolysis rate is 7.62±1.60%.

Note: ""ND"" indicates no hemolytic activity detected at concentrations up to 100 ug/ml.|||skin secretions, Rana nigrovittata , China, Asia|||In the study of black-banded frog skin antimicrobial peptides, rabbit red blood cells were used as the test subject. Most antimicrobial peptides exhibited weak hemolysis at a concentration of 100 µg/ml, while Nigroain-K2 and Temporin-RN1 showed a hemolysis rate of 85%–95% at a concentration of 50 µg/ml. Temporin-RN3 had a hemolysis rate of 87.2% at 100 µg/ml. Nigroain-K1, due to the lack of a C-terminal disulfide bond, showed significantly reduced hemolytic activity, with a hemolysis rate of only 22.49±4.80% at 100 µg/ml.|||Some AMPs were found to exert hemolytic activities [6,7]. Rabbit
red blood cells were used to check for hemolytic capability in our
experiments. Most AMPs exhibited weak hemolytic activity at the
concentration of 100 ug/ml (Table 3). In contrast, nigroain-K2,
gaegurin-RN1, temporin-RN1, and temporin-RN3 had strong hemo-
lytic activity against rabbit red cells. Nigroain-K2 and temporin-RN1
could destroy 85–95% red cells even at the concentration of 50 ug/ml. Compared with nigroain-K2, nigroain-K1 lost the C-terminal
disulfide bridge, and had a much weaker hemolytic activity. The
current result implies that the C-terminal disulfide bridge may
contribute to the hemolytic activity."	"Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||Genomics. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||19778602|||Genomics. 2010 Jan;95(1):66-71.|||Genomics. 2010 Jan;95(1):66-71.||Ref.19778602|||19778602|||Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22|||Gram-positive bacteria: Staphylococcus aureus ATCC25923 (MIC=27.5 ug/ml), S. aureus ATCC43300 (MIC=55 ug/ml), Bacillus subtilis (MIC=110 ug/ml);
Gram-negative bacteria: Escherichia coli ML-35P (MIC=110 ug/ml), Pseudomonas aeruginosa PA01 (MIC=55 ug/ml), Pseudomonas aeruginosa ATCC27853 (MIC=55 ug/ml).
Yeast: Candida albicans ATCC2002 (MIC=13.75 ug/ml).|||Genomics. 2010 Jan;95(1):66-71. PubMed."	19	
FPDB00984	AP01944|||AP01944|||Nigroain-K2|||DRAMP01547|||Nigroain-K2|||AP01944|||DRAMP01547	"	
SLWETIKNAGKGFILNILDKIRCKVAGGCKT"	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anti-S. aureus ATCC25923, activity value is MIC = 11.25 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 9.38 ug/ml||Anti-B. subtilis, activity value is MIC = 9.38 ug/ml||Antibacterial||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 11.25 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 9.38 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 9.38 ug/ml||Anti-Escherichia coli ML-35P, activity value is MIC = 25 ug/ml||Anti-Pseudomonas aeruginosa PA01, activity value is MIC = 25 ug/ml||Anti-Pseudomonas aeruginosa ATCC27853, activity value is MIC = 25 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 15 ug/ml	skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata (Black-striped frog)|||Rana nigrovittata [Black-striped frog]|||skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata (Black-striped frog)	N/A	"nigroain-K2: At a concentration of 100 ug/ml, the hemolysis rate is 85.52±3.26%.

- temporin-RN1: At a concentration of 100 ug/ml, the hemolysis rate is 95.7±4.12%.

- temporin-RN3: At a concentration of 50 ug/ml, the hemolysis rate is 87.2±3.67%.

- gaegurin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 46.13±1.49%.

- nigroain-K1: At a concentration of 50 ug/ml, the hemolysis rate is 22.49±4.80%.

- gaegurin-RN4: At a concentration of 50 ug/ml, the hemolysis rate is 18.64±0.25%.

- gaegurin-RN5: At a concentration of 50 ug/ml, the hemolysis rate is 16.16±3.22%.

- rugosin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 6.69±1.51%.

- nigroain-E1: At a concentration of 50 ug/ml, the hemolysis rate is 7.62±1.60%.

Note: ""ND"" indicates no hemolytic activity detected at concentrations up to 100 ug/ml.|||skin secretions, Rana nigrovittata , China, Asia||85.52%(50 ug/ml )|||In the study of black-banded frog skin antimicrobial peptides, rabbit red blood cells were used as the test subject. Most antimicrobial peptides exhibited weak hemolysis at a concentration of 100 µg/ml, while Nigroain-K2 and Temporin-RN1 showed a hemolysis rate of 85%–95% at a concentration of 50 µg/ml. Temporin-RN3 had a hemolysis rate of 87.2% at 100 µg/ml. Nigroain-K1, due to the lack of a C-terminal disulfide bond, showed significantly reduced hemolytic activity, with a hemolysis rate of only 22.49±4.80% at 100 µg/ml.|||[Ref:19778602]85.52 ± 3.26% hemolytic activity at 50 ug/ml against rabbit red cells|||Some AMPs were found to exert hemolytic activities [6,7]. Rabbit
red blood cells were used to check for hemolytic capability in our
experiments. Most AMPs exhibited weak hemolytic activity at the
concentration of 100 ug/ml (Table 3). In contrast, nigroain-K2,
gaegurin-RN1, temporin-RN1, and temporin-RN3 had strong hemo-
lytic activity against rabbit red cells. Nigroain-K2 and temporin-RN1
could destroy 85–95% red cells even at the concentration of 50 ug/ml. Compared with nigroain-K2, nigroain-K4 lost the C-terminal
disulfide bridge, and had a much weaker hemolytic activity. The
current result implies that the C-terminal disulfide bridge may
contribute to the hemolytic activity.|||[Ref:19778602]85.52 ± 3.26% hemolytic activity at 50 ug/ml against rabbit red cells|||85% hemolysis at 100 ug/ml"	"Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||Genomics. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||19778602|||Genomics. 2010 Jan;95(1):66-71.||Ref.19778602|||19778602||Ref.19778602|||19778602|||Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 23.|||[Ref.19778602]Gram-positive bacteria: Staphylococcus aureus ATCC25923 (MIC=11.25 ug/ml), Staphylococcus aureus ATCC43300 (MIC=9.38 ug/ml), Bacillus subtilis (MIC=9.38 ug/ml);
Gram-positive bacteria: Escherichia coli ML-35P (MIC=25 ug/ml), Pseudomonas aeruginosa PA01 (MIC=25 ug/ml), Pseudomonas aeruginosa ATCC27853 (MIC=25 ug/ml);
Yeast: Candida albicans ATCC2002 (MIC=15 ug/ml)|||Genomics. 2010 Jan;95(1):66-71. PubMed."	31	
FPDB00985	AP01945|||AP01945|||Gaegurin-RN1|||DRAMP02288|||Gaegurin-RN1|||AP01945	FIGPVLKIAAGILPTAICKIFKKC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus ATCC25923, activity value is MIC = 2.34 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 9.38 ug/ml||Anti-B. subtilis, activity value is MIC = 4.69 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 18.75 ug/ml||Antibacterial||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 2.34 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 9.38 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 4.69 ug/ml||Anti-Escherichia coli ML-35P, activity value is MIC = 18.75 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 4.69 ug/ml	skin secretions, Rana nigrovittata, China, Asia|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata|||Rana nigrovittata [Black-striped frog]|||skin secretions, Rana nigrovittata, China, Asia	N/A	"nigroain-K2: At a concentration of 100 ug/ml, the hemolysis rate is 85.52±3.26%.

- temporin-RN1: At a concentration of 100 ug/ml, the hemolysis rate is 95.7±4.12%.

- temporin-RN3: At a concentration of 50 ug/ml, the hemolysis rate is 87.2±3.67%.

- gaegurin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 46.13±1.49%.

- nigroain-K1: At a concentration of 50 ug/ml, the hemolysis rate is 22.49±4.80%.

- gaegurin-RN4: At a concentration of 50 ug/ml, the hemolysis rate is 18.64±0.25%.

- gaegurin-RN5: At a concentration of 50 ug/ml, the hemolysis rate is 16.16±3.22%.

- rugosin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 6.69±1.51%.

- nigroain-E1: At a concentration of 50 ug/ml, the hemolysis rate is 7.62±1.60%.

Note: ""ND"" indicates no hemolytic activity detected at concentrations up to 100 ug/ml.|||skin secretions, Rana nigrovittata, China, Asia||0.4613|||Staphylococcus aureus ATCC25923 ( MIC = 2.34 ug/ml ), Staphylococcus aureus ATCC43300 ( MIC = 9.38 ug/ml ), Bacillus subtilis ( MIC = 4.69 ug/ml ), Candida albicans ATCC2002 ( MIC = 4.69 ug/ml ), Escherichia coli ML-35P ( MIC = 18.75 ug/ml )|||Some AMPs were found to exert hemolytic activities [6,7]. Rabbit
red blood cells were used to check for hemolytic capability in our
experiments. Most AMPs exhibited weak hemolytic activity at the
concentration of 100 ug/ml (Table 3). In contrast, nigroain-K2,
gaegurin-RN1, temporin-RN1, and temporin-RN3 had strong hemo-
lytic activity against rabbit red cells. Nigroain-K2 and temporin-RN1
could destroy 85–95% red cells even at the concentration of 50 ug/ml. Compared with nigroain-K2, nigroain-K5 lost the C-terminal
disulfide bridge, and had a much weaker hemolytic activity. The
current result implies that the C-terminal disulfide bridge may
contribute to the hemolytic activity.|||50% hemolysis at 100 uM."	"Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||Genomics. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||19778602|||Genomics. 2010 Jan;95(1):66-71.||Ref.19778602|||19778602|||Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 24.|||Genomics. 2010 Jan;95(1):66-71. PubMed."	24	
FPDB00986	AP01946|||AP01946|||Gaegurin-RN4|||DRAMP02289|||Gaegurin-RN4|||AP01946	FVGPVLKIAAGILPTAICKIYKKC	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus ATCC25923, activity value is MIC = 1.17 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 9.38 ug/ml||Anti-B. subtilis, activity value is MIC = 2.34 ug/ml||Antibacterial||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 1.17 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 9.38 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 2.34 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 2.34 ug/ml	skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata|||Rana nigrovittata [Black-striped frog]|||skin secretions, Rana nigrovittata , China, Asia	N/A	"nigroain-K2: At a concentration of 100 ug/ml, the hemolysis rate is 85.52±3.26%.

- temporin-RN1: At a concentration of 100 ug/ml, the hemolysis rate is 95.7±4.12%.

- temporin-RN3: At a concentration of 50 ug/ml, the hemolysis rate is 87.2±3.67%.

- gaegurin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 46.13±1.49%.

- nigroain-K1: At a concentration of 50 ug/ml, the hemolysis rate is 22.49±4.80%.

- gaegurin-RN4: At a concentration of 50 ug/ml, the hemolysis rate is 18.64±0.25%.

- gaegurin-RN5: At a concentration of 50 ug/ml, the hemolysis rate is 16.16±3.22%.

- rugosin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 6.69±1.51%.

- nigroain-E1: At a concentration of 50 ug/ml, the hemolysis rate is 7.62±1.60%.

Note: ""ND"" indicates no hemolytic activity detected at concentrations up to 100 ug/ml.|||skin secretions, Rana nigrovittata , China, Asia||0.1616|||Staphylococcus aureus ATCC25923 ( MIC = 1.17 ug/ml ), Staphylococcus aureus ATCC43300 ( MIC = 9.38 ug/ml ), Bacillus subtilis ( MIC = 2.34 ug/ml ), Candida albicans ATCC2002 ( MIC = 2.34 ug/ml )|||Some AMPs were found to exert hemolytic activities [6,7]. Rabbit
red blood cells were used to check for hemolytic capability in our
experiments. Most AMPs exhibited weak hemolytic activity at the
concentration of 100 ug/ml (Table 3). In contrast, nigroain-K2,
gaegurin-RN1, temporin-RN1, and temporin-RN3 had strong hemo-
lytic activity against rabbit red cells. Nigroain-K2 and temporin-RN1
could destroy 85–95% red cells even at the concentration of 50 ug/ml. Compared with nigroain-K2, nigroain-K6 lost the C-terminal
disulfide bridge, and had a much weaker hemolytic activity. The
current result implies that the C-terminal disulfide bridge may
contribute to the hemolytic activity."	"Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||Genomics. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||19778602|||Genomics. 2010 Jan;95(1):66-71.||Ref.19778602|||19778602|||Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 25.|||Genomics. 2010 Jan;95(1):66-71. PubMed."	24	
FPDB00987	AP01947|||AP01947|||Gaegurin-RN5|||DRAMP02290|||Gaegurin-RN5|||AP01947	"	
FLGPIIKIATGILPTAICKFLKKC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus ATCC25923, activity value is MIC = 3.75 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 62.5 ug/ml||Anti-B. subtilis, activity value is MIC = 4.69 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 37.5 ug/ml||Antibacterial||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 3.75 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 62.5 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 4.69 ug/ml||Anti-Escherichia coli ML-35P, activity value is MIC = 37.5 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 4.69 ug/ml	skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata|||Rana nigrovittata [Black-striped frog]|||skin secretions, Rana nigrovittata , China, Asia	N/A	"nigroain-K2: At a concentration of 100 ug/ml, the hemolysis rate is 85.52±3.26%.

- temporin-RN1: At a concentration of 100 ug/ml, the hemolysis rate is 95.7±4.12%.

- temporin-RN3: At a concentration of 50 ug/ml, the hemolysis rate is 87.2±3.67%.

- gaegurin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 46.13±1.49%.

- nigroain-K1: At a concentration of 50 ug/ml, the hemolysis rate is 22.49±4.80%.

- gaegurin-RN4: At a concentration of 50 ug/ml, the hemolysis rate is 18.64±0.25%.

- gaegurin-RN5: At a concentration of 50 ug/ml, the hemolysis rate is 16.16±3.22%.

- rugosin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 6.69±1.51%.

- nigroain-E1: At a concentration of 50 ug/ml, the hemolysis rate is 7.62±1.60%.

Note: ""ND"" indicates no hemolytic activity detected at concentrations up to 100 ug/ml.|||skin secretions, Rana nigrovittata , China, Asia|||Staphylococcus aureus ATCC25923 ( MIC = 3.75 ug/ml ), Staphylococcus aureus ATCC43300( MIC = 62.5 ug/ml ), Bacillus subtilis ( MIC = 4.69 ug/ml ), Candida albicans ATCC2002 ( MIC = 4.69 ug/ml ), Escherichia coli ML-35P ( MIC = 37.5 ug/ml)|||Some AMPs were found to exert hemolytic activities [6,7]. Rabbit
red blood cells were used to check for hemolytic capability in our
experiments. Most AMPs exhibited weak hemolytic activity at the
concentration of 100 ug/ml (Table 3). In contrast, nigroain-K2,
gaegurin-RN1, temporin-RN1, and temporin-RN3 had strong hemo-
lytic activity against rabbit red cells. Nigroain-K2 and temporin-RN1
could destroy 85–95% red cells even at the concentration of 50 ug/ml. Compared with nigroain-K2, nigroain-K7 lost the C-terminal
disulfide bridge, and had a much weaker hemolytic activity. The
current result implies that the C-terminal disulfide bridge may
contribute to the hemolytic activity."	"Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||Genomics. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||19778602|||Genomics. 2010 Jan;95(1):66-71.||Ref.19778602|||19778602|||Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 26.|||Genomics. 2010 Jan;95(1):66-71. PubMed."	24	
FPDB00988	AP01950|||AP01950|||Rugosin-RN5|||DRAMP01526|||Rugosin-RN5|||AP01950|||DRAMP01526	SIRDKIKTIAIDLAKSAGTGVLKTLICKLNKSC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus ATCC25923, activity value is MIC = 15 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 12.5 ug/ml||Anti-B. subtilis, activity value is MIC = 18.75 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 25 ug/ml||Antibacterial||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 15 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 12.5 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 18.75 ug/ml||Anti-Escherichia coli ML-35P, activity value is MIC = 25 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 18.75 ug/ml	skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata [Black-striped frog]|||Rana nigrovittata|||Rana nigrovittata [Black-striped frog]|||skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata	N/A	"nigroain-K2: At a concentration of 100 ug/ml, the hemolysis rate is 85.52±3.26%.

- temporin-RN1: At a concentration of 100 ug/ml, the hemolysis rate is 95.7±4.12%.

- temporin-RN3: At a concentration of 50 ug/ml, the hemolysis rate is 87.2±3.67%.

- gaegurin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 46.13±1.49%.

- nigroain-K1: At a concentration of 50 ug/ml, the hemolysis rate is 22.49±4.80%.

- gaegurin-RN4: At a concentration of 50 ug/ml, the hemolysis rate is 18.64±0.25%.

- gaegurin-RN5: At a concentration of 50 ug/ml, the hemolysis rate is 16.16±3.22%.

- rugosin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 6.69±1.51%.

- nigroain-E1: At a concentration of 50 ug/ml, the hemolysis rate is 7.62±1.60%.

Note: ""ND"" indicates no hemolytic activity detected at concentrations up to 100 ug/ml.|||skin secretions, Rana nigrovittata , China, Asia|||Some AMPs were found to exert hemolytic activities [6,7]. Rabbit
red blood cells were used to check for hemolytic capability in our
experiments. Most AMPs exhibited weak hemolytic activity at the
concentration of 100 ug/ml (Table 3). In contrast, nigroain-K2,
gaegurin-RN1, temporin-RN1, and temporin-RN3 had strong hemo-
lytic activity against rabbit red cells. Nigroain-K2 and temporin-RN1
could destroy 85–95% red cells even at the concentration of 50 ug/ml. Compared with nigroain-K2, nigroain-K10 lost the C-terminal
disulfide bridge, and had a much weaker hemolytic activity. The
current result implies that the C-terminal disulfide bridge may
contribute to the hemolytic activity."	"Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||Genomics. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||19778602|||19778602|||Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 29.|||Gram-positive bacteria: Staphylococcus aureus ATCC25923 (MIC=15 ug/ml), Staphylococcus aureus ATCC43300 (MRSA) (MIC=12.5 ug/ml), Bacillus subtilis (MIC=18.75 ug/ml);
Gram-negative bacterium: Escherichia coli ML-35P (MIC=25 ug/ml).
Yeast: Candida albicans ATCC2002 (MIC=18.75 ug/ml).|||Genomics. 2010 Jan;95(1):66-71. PubMed."	33	
FPDB00989	AP01952|||DRAMP01808|||Temporin-RN3|||AP01952|||DRAMP01808	FFPLLFGALSSHLPKLF	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anti-S. aureus ATCC25923, activity value is MIC = 3.75 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 7.5 ug/ml||Anti-B. subtilis, activity value is MIC = 7.5 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 15 ug/ml||Anti-P. aeruginosa ATCC27853, activity value is MIC = 3.75 ug/ml||Anti-and C. albicans ATCC2002, activity value is MIC = 3.75 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 3.75 ug/ml||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC = 3.75 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 3.75 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 7.5 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 7.5 ug/ml||Anti-Candida albicans ATCC2002, activity value is MIC = 3.75 ug/ml||Anti-Escherichia coli ML-35P, activity value is MIC = 15 ug/ml||Anti-Pseudomonas aeruginosa PA01, activity value is MIC = 3.75 ug/ml||Anti-Pseudomonas aeruginosa ATCC27853, activity value is MIC = 3.75 ug/ml	skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata|||skin secretions, Rana nigrovittata , China, Asia|||Rana nigrovittata	N/A	"nigroain-K2: At a concentration of 100 ug/ml, the hemolysis rate is 85.52±3.26%.

- temporin-RN1: At a concentration of 100 ug/ml, the hemolysis rate is 95.7±4.12%.

- temporin-RN3: At a concentration of 50 ug/ml, the hemolysis rate is 87.2±3.67%.

- gaegurin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 46.13±1.49%.

- nigroain-K1: At a concentration of 50 ug/ml, the hemolysis rate is 22.49±4.80%.

- gaegurin-RN4: At a concentration of 50 ug/ml, the hemolysis rate is 18.64±0.25%.

- gaegurin-RN5: At a concentration of 50 ug/ml, the hemolysis rate is 16.16±3.22%.

- rugosin-RN1: At a concentration of 50 ug/ml, the hemolysis rate is 6.69±1.51%.

- nigroain-E1: At a concentration of 50 ug/ml, the hemolysis rate is 7.62±1.60%.

Note: ""ND"" indicates no hemolytic activity detected at concentrations up to 100 ug/ml.|||skin secretions, Rana nigrovittata , China, Asia||87.2%(50 ug/ml )|||Some AMPs were found to exert hemolytic activities [6,7]. Rabbit
red blood cells were used to check for hemolytic capability in our
experiments. Most AMPs exhibited weak hemolytic activity at the
concentration of 100 ug/ml (Table 3). In contrast, nigroain-K2,
gaegurin-RN1, temporin-RN1, and temporin-RN3 had strong hemo-
lytic activity against rabbit red cells. Nigroain-K2 and temporin-RN1
could destroy 85–95% red cells even at the concentration of 50 ug/ml. Compared with nigroain-K2, nigroain-K12 lost the C-terminal
disulfide bridge, and had a much weaker hemolytic activity. The
current result implies that the C-terminal disulfide bridge may
contribute to the hemolytic activity."	"Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||Genomics. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 22.|||Genomics. 2010 Jan;95(1):66-71.|||19778602|||Genomics
. 2010 Jan;95(1):66-71. doi: 10.1016/j.ygeno.2009.09.004. Epub 2009 Sep 31.|||Genomics. 2010 Jan;95(1):66-71. PubMed."	17	
FPDB00990	AP01998|||AP01998|||CPF-SE1	GFLGPLLKLGLKGVAKVIPHLIPSRQQ	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-Moderately active against E. coli, activity value is MIC = 40 uM||Anti-Escherichia coli, activity value is MIC = 40 uM||Anti-Methicillin-resistant Staphylococcus aureus, activity value is MIC = 2.5 uM	Cameroon Clawed Frog, the tetraploid frog Silurana epitropicalis SE1, Africa|||Silurana epitropicalis [Cameroon clawed frog]	N/A	"The ""Hemolytic activity"" section in the document and the related tables provide hemolytic values of various host defense peptides on human erythrocytes (expressed as the half-maximal lysis concentration, LC_{50}), as follows:

- CPF-SE2: LC_{50} = 50 μM

- CPF-SE3: LC_{50} = 220 μM

- XPF-SE3: LC_{50} = 105 μM

- XPF-SE4: LC_{50} = 60 μM

- PFQa: LC_{50} = 105 μM

- Magainin-SE1, PGLa-SE1, PGLa-SE2, XPF-SE2: LC_{50} > 160 μM (i.e., 50% lysis was not reached at a concentration of 160 μM)

- XPF-SE1: Not determined (ND)

These values reflect the differences in toxicity of different peptide segments toward mammalian erythrocytes, with CPF-SE3 exhibiting lower hemolytic activity, whereas XPF-SE4, XPF-SE3, and PFQa show relatively higher hemolytic activity.|||Cameroon Clawed Frog, the tetraploid frog Silurana epitropicalis SE1, Africa||HC₅₀ > 400 uM"	"Peptides
. 2012 Sep;37(1):113-9. doi: 10.1016/j.peptides.2012.07.005. Epub 2012 Jul 16.|||Peptides. 2012 Sep;37(1):113-9. doi: 10.1016/j.peptides.2012.07.005. Epub 2012 Jul 16.|||22800690"	27	
FPDB00991	AP01999|||AP01999|||CPF-SE2|||CPF-SP2|||CPF-SP2|||DRAMP02143	GFLGPLLKLGLKGAAKLLPQLLPSRQQ	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-Moderately active against E. coli ATCC 25726, activity value is MIC = 40 uM||Anti-Methicillin-resistant Staphylococcus aureus, activity value is MIC = 2.5 uM||Anti-Escherichia coli, activity value is MIC = 40 uM||Anti-Staphylococcus aureus, activity value is MIC = 6 uM||Anti-Escherichia coli, activity value is MIC = 50 uM||Anti-K.pneumoniae, activity value is MIC = 50 uM||Anti-P. aeruginosa, activity value is MIC = 25 uM||Anti-C.albicans, activity value is MIC = 12.5 uM||Anti-A. baumannii, activity value is MIC = 6 uM||Antimicrobial||Antibacterial	Cameroon Clawed Frog, the tetraploid frog Silurana epitropicalis SE1, and Silurana paratropicalis, Africa|||Silurana epitropicalis [Cameroon clawed frog]|||Silurana paratropicalis|||Silurana paratropicalis|||Xenopus tropicalis (Western clawed frog) (Silurana tropicalis)	N/A	"The ""Hemolytic activity"" section in the document and the related tables provide hemolytic values of various host defense peptides on human erythrocytes (expressed as the half-maximal lysis concentration, LC_{50}), as follows:

- CPF-SE2: LC_{50} = 50 μM

- CPF-SE3: LC_{50} = 220 μM

- XPF-SE3: LC_{50} = 105 μM

- XPF-SE4: LC_{50} = 60 μM

- PFQa: LC_{50} = 105 μM

- Magainin-SE1, PGLa-SE1, PGLa-SE2, XPF-SE2: LC_{50} > 160 μM (i.e., 50% lysis was not reached at a concentration of 160 μM)

- XPF-SE1: Not determined (ND)

These values reflect the differences in toxicity of different peptide segments toward mammalian erythrocytes, with CPF-SE3 exhibiting lower hemolytic activity, whereas XPF-SE4, XPF-SE3, and PFQa show relatively higher hemolytic activity.|||Cameroon Clawed Frog, the tetraploid frog Silurana epitropicalis SE1, and Silurana paratropicalis, Africa||HC₅₀ > 400 uM|||Human erythrocytes ( LC 50 = 50 uM )"	"Peptides
. 2012 Sep;37(1):113-9. doi: 10.1016/j.peptides.2012.07.005. Epub 2012 Jul 16.|||Peptides. 2012 Sep;37(1):113-9. doi: 10.1016/j.peptides.2012.07.005. Epub 2012 Jul 16.|||22800690|||21498136|||21498136|||Comp Biochem Physiol Part D Genomics Proteomics. 2011 Jun;6(2):206-212."	27	
FPDB00992	AP02000|||AP02000|||XT-6|||CPF-SP3|||DRAMP02135|||XT-6|||CPF-SP3	GFLGSLLKTGLKVGSNLL	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Moderately active against E. coli, activity value is MIC = 40||Anti-Staphylococcus aureus, activity value is MIC = 80 uM||Anti-E.coli, activity value is MIC = 50 uM||Anti-Staphylococcus aureus, activity value is MIC = 25 uM||Anti-Escherichia coli, activity value is MIC = 50 uM||Anti-K.pneumoniae, activity value is MIC = 50 uM||Anti-P. aeruginosa, activity value is MIC = 50 uM||Anti-C.albicans, activity value is MIC = 50 uM||Anti-A. baumannii, activity value is MIC = 6 uM||Anti-Staphylococcus aureus, activity value is MIC = 5 uM||Anti-Escherichia coli, activity value is MIC = 5 uM||Anti-Candida albicans, activity value is MIC = 40 uM||Anti-Clinical isolates: Staphylococcus aureus 8325, activity value is MIC = 6 uM||Anti-Staphylococcus aureus, activity value is MIC = 7 uM||Anti-Staphylococcus epidermidis 1420129, activity value is MIC = 3 uM||Anti-S. saprophyticus 1950556, activity value is MIC = 13 uM||Anti-Escherichia coli 25922, activity value is MIC = 6 uM||Anti-Streptococcus group C 1541035, activity value is MIC = 3 uM||Anti-Shigella sonnei 1840187, activity value is MIC = 35 uM||Anti-Pseudomonas aeruginosa 0380972, activity value is MIC = 60 uM||Anti-Enterobacter cloacae 1441323, activity value is MIC = 35 uM	Cameroon Clawed Frog, the tetraploid frog Silurana epitropicalis SE1, and Silurana paratropicalis, also Xenopus tropicalis, Africa|||Xenopus tropicalis [Western clawed frog]|||Silurana paratropicalis|||Xenopus tropicalis (Western clawed frog) (Silurana tropicalis)	N/A	"The ""Hemolytic activity"" section in the document and the related tables provide hemolytic values of various host defense peptides on human erythrocytes (expressed as the half-maximal lysis concentration, LC_{50}), as follows:

- CPF-SE2: LC_{50} = 50 μM

- CPF-SE3: LC_{50} = 220 μM

- XPF-SE3: LC_{50} = 105 μM

- XPF-SE4: LC_{50} = 60 μM

- PFQa: LC_{50} = 105 μM

- Magainin-SE1, PGLa-SE1, PGLa-SE2, XPF-SE2: LC_{50} > 160 μM (i.e., 50% lysis was not reached at a concentration of 160 μM)

- XPF-SE1: Not determined (ND)

These values reflect the differences in toxicity of different peptide segments toward mammalian erythrocytes, with CPF-SE3 exhibiting lower hemolytic activity, whereas XPF-SE4, XPF-SE3, and PFQa show relatively higher hemolytic activity.|||Cameroon Clawed Frog, the tetraploid frog Silurana epitropicalis SE1, and Silurana paratropicalis, also Xenopus tropicalis, Africa||HC₅₀ = 12 uM|||hRBC (HC50 = >150 uM)|||In Biochimica et Biophysica Acta 2001, among the antimicrobial peptides isolated from the skin secretions of the tropical clawed frog (Xenopus tropicalis), XT-1 had an HC₅₀ of 90 μM against human red blood cells, XT-7 had an HC₅₀ of 70 μM against human red blood cells, the hemolytic activity of XT-2 was not measured, and XT-4, XT-5, and XT-6 all had an HC₅₀ greater than 150 μM against human red blood cells.|||hRBC (HC50 = >150 uM)"	"Peptides
. 2012 Sep;37(1):113-9. doi: 10.1016/j.peptides.2012.07.005. Epub 2012 Jul 16.|||Peptides. 2012 Sep;37(1):113-9. doi: 10.1016/j.peptides.2012.07.005. Epub 2012 Jul 16.||refer to the ref for AP424|||11738090|||21498136|||Biochim Biophys Acta. 2001 Nov 26;1550(1):81-89.||Ref.11738090|||11738090|||21498136"	18	
FPDB00993	AP02016|||AP02016|||Manduca Sexta Moricin	"	
GKIPVKAIKQAGKVIGKGLRAINIAGTTHDVVSFFRPKKKKH"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. coli 0157H7 ATCC 25922, activity value is MIC = 6.25 ug/ml||Anti-S. typhimurium ATCC 14028, activity value is MIC = 6.25 ug/ml||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 6.25 ug/ml||Anti-S. typhimurium DT104 ATCC 700408, activity value is MIC = 6.25 ug/ml||Anti-L. monocytogenes ATCC 19115, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC 25923 or MRSA 43300 or MRSA BAA-39, activity value is MIC = 6.25||Antibacterial	fat body, the tobacco hornworm, Manduca sexta|||Manduca sexta [Tobacco hawkmoth]	Helix	fat body, the tobacco hornworm, Manduca sexta||HC₅₀ = 4.5 uM。	"Insect Biochem Mol Biol
. 2003 May;33(5):541-59. doi: 10.1016/s0965-1748(03)00028-6.|||Insect Biochem Mol Biol. 2003 May;33(5):541-59. doi: 10.1016/s0965-1748(03)00028-6.|||18265434"	42	
FPDB00994	AP02026|||CAMPSQ4029|||CAMPSQ9304	GFWGKLWEGVKSAI	Anti-Gram+ & Gram-||Anti-MRSA||Anti-M. luteus, activity value is MIC = 2 uM||Anti-E. coli, activity value is MIC = 15 uM||Anti-S. aureus, activity value is MIC = 15 uM||Anti-L. grayi, activity value is MIC = 4 uM||Anti-L. fleischmannii, activity value is MIC = 4 uM||Anti-L. monocytogenes, activity value is MIC = 8 uM	venom, Scorpiops tibetanus; ALso found in Urodacus manicatus, Tibet, China|||Scorpiops tibetanus [Scorpion]|||Urodacus manicatus	Helix	"The “Hemolytic activity” section of the document provides the hemolytic values of StCT2 against human red blood cells, as follows:

-Half maximal hemolytic concentration (HC₅₀): 80.3 µg/mL.

-At a concentration of 50 µg/mL, StCT2 exhibits hemolytic activity of less than 30% against human red blood cells, while at this concentration it still effectively inhibits the tested bacteria, including MRSA.

These data indicate that StCT2 exhibits low hemolytic activity toward mammalian red blood cells within the concentration range required for its antibacterial activity.|||Pig erythrocyte (50% hemolysis at 126.2 uM)"	"Peptides
. 2012 Aug;36(2):213-20. doi: 10.1016/j.peptides.2012.04.010. Epub 2012 Apr 27.|||22542475|||28067810"	14	
FPDB00995	AP02032	RWKPFKKELKVGRNIRDGIIKAGPAVAVIGQATSIARPTGK	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli AB209414, activity value is MIC = 4.1 ug/ml||Anti-S. aureus AB94004, activity value is MIC = 8.2 ug/ml||Anti-P. aeruginosa AB93066, activity value is MIC = 8.2 ug/ml||Anti-B. pumilus Meyer AB205602, activity value is MIC = 8.2 ug/ml||Anti-B. subtilis WB800N, activity value is MIC = 8.2 ug/ml||Anti-MRSA p1386, activity value is MIC = 8.2 ug/ml	fat body, diamondback moth, Plutella xylostella	N/A	fat body, diamondback moth, Plutella xylostella||At a concentration of 100 μM, the hemolysis rate is < 10%.	"Appl Microbiol Biotechnol
. 2012 May;94(4):1031-9. doi: 10.1007/s00253-011-3863-5. Epub 2012 Jan 19.|||Appl Microbiol Biotechnol. 2012 May;94(4):1031-9. doi: 10.1007/s00253-011-3863-5. Epub 2012 Jan 19."	41	
FPDB00996	AP02044|||AP02044|||Brevinin-1JDa|||DRAMP02073|||AP02044	"	
FLPAVIRVAANVLPTVFCAISKKC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli, activity value is MIC = 50 uM||Anti-S. aureus MRSA, activity value is MIC = 6||Anti-and C. albicans, activity value is MIC = 50 uM||Antibacterial||Anti-Staphylococcus aureus, activity value is MIC = 16 ug/ml||Anti-S. aureus, activity value is MIC = 32 ug/ml||Anti-Escherichia coli, activity value is MIC = 128 ug/ml||Anti-Candida albicans, activity value is MIC = 128 ug/ml	skin, Odorrana jingdongensis , China, Asia|||Odorrana jingdongensis [Jingdong frog]|||Odorrana andersonii (Chinese odorous frog)|||skin, Odorrana jingdongensis , China, Asia	N/A	"The hemolytic values of the antimicrobial peptides (AMPs) mentioned in the document at a concentration of 128 µg/ml are as follows:

- Brevinin-2JD: 11.7 ± 3.2%

- Brevinin-1JDa: 79.2 ± 6.8%

- Nigrocin-2JDa: 80.3 ± 5.5%

- Nigrocin-2JDb: 88.4 ± 4.2%

Note: The hemolytic values of Esculentin-2JDa, Esculentin-2JDb, and Brevinin-1JDb were not determined (ND) or not mentioned.|||skin, Odorrana jingdongensis , China, Asia||HC₅₀ = 3.5 uM。|||Rabbit erythrocytes 79.2±6.8% lysis (128 ug/ml)|||The abilities of the intact peptides isolated from the skin of O. jingdongensis to inhibit the growth of S. aureus,MRSA, E. coli,ESBLand C. albicans, and the hemolytic activities of the peptides (128 ug/ml) on rabbit red blood cells were shown in Table 3. The values of two pairs of intact peptides were given as the mixed components due to not being separated by commonly used reverse HPLC methods using C18orC4column(data notshown) [10,45,46],suchas Brevinin-1JDa and Brevinin-1JD or Esculentin-2JDa and Esculentin-2JDb. The four near homogeneity AMPs and two pairs of mixed AMPs showed vary and moderate activities (8–128 ug/ml) against all gram-negative and gram-positive bacteria with their resistant strains tested. The anti-fungi activities and hemolytic activities of mixture of Esculentin-2JDa and Esculentin-2JDa were under detectable even at the highest concentration (128 ug/ml) tested, while the activities of the others, except Brevinin-1JDc, excluded due to the very low abundance, is obvious (64– 128 ug/ml to C. albicans and 11.7±3.2 to 88.4±4.2% to rabbit blood red cells).|||79.2% hemolysis at 50 uM."	"J Proteomics
. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||J Proteomics. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||22917879|||J Proteome Res. 2012 Jan 1;11(1):306-319.||Ref.22917879|||J Proteomics
. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||J Proteomics. 2012 Oct 22;75(18):5807-21. Pub-Med."	24	
FPDB00997	AP02045|||AP02045|||Brevinin-1JDc	"	
FLPAVLRVAAKVVPTVFCLISKKC"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli, activity value is MIC = 49 uM||Antibacterial	skin, Odorrana jingdongensis , China, Asia|||Odorrana jingdongensis [Jingdong frog]	N/A	"The hemolytic values of the antimicrobial peptides (AMPs) mentioned in the document at a concentration of 128 µg/ml are as follows:

- Brevinin-2JD: 11.7 ± 3.2%

- Brevinin-1JDa: 79.2 ± 6.8%

- Nigrocin-2JDa: 80.3 ± 5.5%

- Nigrocin-2JDb: 88.4 ± 4.2%

Note: The hemolytic values of Esculentin-2JDa, Esculentin-2JDb, and Brevinin-1JDb were not determined (ND) or not mentioned.|||skin, Odorrana jingdongensis , China, Asia||HC₅₀ = 5.8 uM。|||Staphylococcus aureus (ATCC 25923) ( MIC= 16 ug/ml ), Methicillin-resistant S. aureus (MRSA, CIB 85462) ( MIC=8 ug/ml ), Escherichia coli (ATCC 25922) ( MIC= 128 ug/ml ), Extended-spectrum-lactamases E. coli (ESBL, CIB 84492) ( MIC= 64 ug/ml)"	"J Proteomics
. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||J Proteomics. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||22917879"	24	
FPDB00998	AP02046|||AP02046|||Nigrocin-2JDa|||DRAMP01438|||Nigrocin-2JDa|||AP02046|||DRAMP01438	"	
GIFGKILGAGKKVLCGLSGLC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli, activity value is MIC = 16 uM||Anti-S. aureus, activity value is MIC = 16 uM||Anti-and C. albicans, activity value is MIC = 63 uM||Anti-Staphylococcus aureus, activity value is MIC = 32 ug/ml||Anti-CIB 85462, activity value is MIC = 16 ug/ml||Anti-Escherichia coli, activity value is MIC = 32 ug/ml||Anti-CIB 84492, activity value is MIC = 32 ug/ml||Anti-Candida albicans, activity value is MIC = 128 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 16 uM||Anti-Staphylococcus aureus CIB 85462, activity value is MIC = 8 uM||Anti-Escherichia coli ATCC 25992, activity value is MIC = 16 uM||Anti-Escherichia coli CIB 84492, activity value is MIC = 16 uM||Anti-Candida albicans, activity value is MIC = 63 uM||Hemolytic	skin, Odorrana jingdongensis , China, Asia|||Odorrana jingdongensis [Jingdong frog]|||Odorrana jingdongensis (Jingdong frog) (Rana jingdongensis)|||skin, Odorrana jingdongensis , China, Asia|||Odorrana jingdongensis (Jingdong frog) (Rana jingdongensis)	N/A	"The hemolytic values of the antimicrobial peptides (AMPs) mentioned in the document at a concentration of 128 µg/ml are as follows:

- Brevinin-2JD: 11.7 ± 3.2%

- Brevinin-1JDa: 79.2 ± 6.8%

- Nigrocin-2JDa: 80.3 ± 5.5%

- Nigrocin-2JDb: 88.4 ± 4.2%

Note: The hemolytic values of Esculentin-2JDa, Esculentin-2JDb, and Brevinin-1JDb were not determined (ND) or not mentioned.|||skin, Odorrana jingdongensis , China, Asia||HC₅₀ = 34.5 uM。|||[Ref:22917879] It has 80.3 ± 5.5% hemolytic activity at 128 ug/ml against rabbit red blood cells|||Rabbit erythrocytes 80.3±5.5% hemolysis (128 ug/ml)|||The abilities of the intact peptides isolated from the skin of O. jingdongensis to inhibit the growth of S. aureus,MRSA, E. coli,ESBLand C. albicans, and the hemolytic activities of the peptides (128 ug/ml) on rabbit red blood cells were shown in Table 3. The values of two pairs of intact peptides were given as the mixed components due to not being separated by commonly used reverse HPLC methods using C18orC4column(data notshown) [10,45,46],suchas Brevinin-1JDa and Brevinin-1JD or Esculentin-2JDa and Esculentin-2JDb. The four near homogeneity AMPs and two pairs of mixed AMPs showed vary and moderate activities (8–128 ug/ml) against all gram-negative and gram-positive bacteria with their resistant strains tested. The anti-fungi activities and hemolytic activities of mixture of Esculentin-2JDa and Esculentin-2JDa were under detectable even at the highest concentration (128 ug/ml) tested, while the activities of the others, except Brevinin-1JDc, excluded due to the very low abundance, is obvious (64– 128 ug/ml to C. albicans and 11.7±3.2 to 88.4±4.3% to rabbit blood red cells).|||[Ref:22917879] It has 80.3 ±  5.5% hemolytic activity at 128 ug/ml against rabbit red blood cells|||80.3% hemolysis at 63 uM."	"J Proteomics
. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||J Proteomics. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||22917879|||J Proteomics. 2012 Oct 22;75(18):5807-5821.||Ref.22917879|||22917879||Ref.22917879|||22917879|||J Proteomics
. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||[Ref.22917879]Gram-positive bacteria: Staphylococcus aureus ATCC 25923 (MIC=16 uM), Staphylococcus aureus CIB 85462 (MIC=8 uM);
Gram-negative bacteria: Escherichia coli ATCC 25992 (MIC=16 uM), Escherichia coli CIB 84492 (MIC=16 uM);
Yeast: Candida albicans (MIC=63 uM).|||J Proteomics. 2012 Oct 22;75(18):5807-21. Pub-Med."	21	
FPDB00999	AP02047|||AP02047|||Nigrocin-2JDb|||DRAMP01439|||Nigrocin-2JDb|||AP02047|||DRAMP01439	"	
GIFGKILGVGKKVLCGLSGMC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli, activity value is MIC = 15 uM||Anti-S. aureus, activity value is MIC = 8 uM||Anti-MRSA, activity value is MIC = 8 uM||Anti-and C. albicans, activity value is MIC = 31 uM||Anti-Staphylococcus aureus, activity value is MIC = 16 ug/ml||Anti-CIB 85462, activity value is MIC = 16 ug/ml||Anti-Escherichia coli, activity value is MIC = 32 ug/ml||Anti-CIB 84492, activity value is MIC = 32 ug/ml||Anti-Candida albicans, activity value is MIC = 64 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 15 uM||Anti-Staphylococcus aureus CIB 85462, activity value is MIC = 15 uM||Anti-Escherichia coli ATCC 25992, activity value is MIC = 8 uM||Anti-Escherichia coli CIB 84492, activity value is MIC = 8 uM||Anti-Candida albicans, activity value is MIC = 31 uM	skin, Odorrana jingdongensis , China, Asia|||Odorrana jingdongensis [Jingdong frog]|||Odorrana jingdongensis (Jingdong frog) (Rana jingdongensis)|||skin, Odorrana jingdongensis , China, Asia|||Odorrana jingdongensis (Jingdong frog) (Rana jingdongensis)	N/A	"The hemolytic values of the antimicrobial peptides (AMPs) mentioned in the document at a concentration of 128 µg/ml are as follows:

- Brevinin-2JD: 11.7 ± 3.2%

- Brevinin-1JDa: 79.2 ± 6.8%

- Nigrocin-2JDa: 80.3 ± 5.5%

- Nigrocin-2JDb: 88.4 ± 4.2%

Note: The hemolytic values of Esculentin-2JDa, Esculentin-2JDb, and Brevinin-1JDb were not determined (ND) or not mentioned.|||skin, Odorrana jingdongensis , China, Asia||HC₅₀ = 46.2 uM。|||[Ref:22917879] It has 88.4 ± 4.2% hemolytic activity at 128 ug/ml against rabbit red blood cells|||Rabbit erythrocytes 88.4±4.2% hemolysis (128 ug/ml)|||The abilities of the intact peptides isolated from the skin of O. jingdongensis to inhibit the growth of S. aureus,MRSA, E. coli,ESBLand C. albicans, and the hemolytic activities of the peptides (128 ug/ml) on rabbit red blood cells were shown in Table 3. The values of two pairs of intact peptides were given as the mixed components due to not being separated by commonly used reverse HPLC methods using C18orC4column(data notshown) [10,45,46],suchas Brevinin-1JDa and Brevinin-1JD or Esculentin-2JDa and Esculentin-2JDb. The four near homogeneity AMPs and two pairs of mixed AMPs showed vary and moderate activities (8–128 ug/ml) against all gram-negative and gram-positive bacteria with their resistant strains tested. The anti-fungi activities and hemolytic activities of mixture of Esculentin-2JDa and Esculentin-2JDa were under detectable even at the highest concentration (128 ug/ml) tested, while the activities of the others, except Brevinin-1JDc, excluded due to the very low abundance, is obvious (64– 128 ug/ml to C. albicans and 11.7±3.2 to 88.4±4.4% to rabbit blood red cells).|||[Ref:22917879] It has 88.4  ± 4.2% hemolytic activity at 128 ug/ml against rabbit red blood cells"	"J Proteomics
. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||J Proteomics. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||22917879|||J Proteomics. 2012 Oct 22;75(18):5807-5821.||Ref.22917879|||22917879||Ref.22917879|||22917879|||J Proteomics
. 2012 Oct 22;75(18):5807-21. doi: 10.1016/j.jprot.2012.08.004. Epub 2012 Aug 16.|||[Ref.22917879]Gram-positive bacteria: Staphylococcus aureus ATCC 25923 (MIC=15 uM), Staphylococcus aureus CIB 85462 (MIC=15 uM);
Gram-negative bacteria: Escherichia coli ATCC 25992 (MIC=8 uM), Escherichia coli CIB 84492 (MIC=8 uM);
Yeast: Candida albicans (MIC=31 uM).|||J Proteomics. 2012 Oct 22;75(18):5807-21. Pub-Med."	21	
FPDB01000	AP02048|||Beta-defensin 1TB precursor|||AP02048	"	
DHYLCVKNEGICLYSSCPSYTKIEGTCYGGKAKCCK"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus ATCC 25923, activity value is MIC = 4.5 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 3 ug/ml||Anti-B. subtilis ATCC 6633, activity value is MIC = 18 ug/ml||Anti-C. albicans ATCC 20032, activity value is MIC = 24 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 24 ug/ml||Anti-P. aeruginosa PA01, activity value is MIC = 12 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 12 ug/ml	tree shrew, Tupaia belangeri, Asia|||Tupaia belangeri [Common tree shrew]|||tree shrew, Tupaia belangeri, Asia	Bridge	"The hemolytic values of β-defensin 1TB in the document are as follows:

- At a concentration of 100 µg/ml, the hemolysis rate is 2.3% for human red blood cells and 1.6% for rabbit red blood cells.

- At a concentration of 200 µg/ml, the hemolysis rate is 5.2% for human red blood cells and 3.9% for rabbit red blood cells.|||tree shrew, Tupaia belangeri, Asia||At a concentration of 100 μM, the hemolysis rate is < 10%.|||Some antimicrobial peptides have been found to exert hemolytic
activities against red cells (Hazlett and Wu, 2011). In our experi-
ments, human and rabbit red blood cells were used to check for he-
molytic capabilities of β-defensin 1TB. β-defensin 1TB showed little
hemolytic activity. At the concentration of 100 ug/ml, it induced
2.3% and 1.6% human and rabbit red blood cell hemolysis, respective-
ly. At the concentration of 200 ug/ml, the corresponding hemolysis
rate was 5.2% and 3.9%, respectively."	"Gene
. 2012 Nov 10;509(2):258-62. doi: 10.1016/j.gene.2012.08.013. Epub 2012 Aug 24.|||Gene. 2012 Nov 10;509(2):258-62. doi: 10.1016/j.gene.2012.08.013.|||22939868|||Gene
. 2012 Nov 10;509(2):258-62. doi: 10.1016/j.gene.2012.08.013. Epub 2012 Aug 24.|||Gene. 2012 Nov 10;509(2):258-62. doi: 10.1016/j.gene.2012.08.013. Pub-Med."	36	
FPDB01001	AP02049	"	
FFHHIFRGIVHVGKTIHKLVTGT"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. faecalis, activity value is MIC = 5||Anti-L. monocytogenes, activity value is MIC = 2.5||Anti-M. luteus, activity value is MIC = 10||Anti-S. epidermidis, activity value is MIC = 5||Anti-S. saprophiticus, activity value is MIC = 5||Anti-S. agalactiae, activity value is MIC = 1.25||Anti-S. bovis, activity value is MIC = 1.25||Anti-S. equisimilis, activity value is MIC = 2.5||Anti-S. mitis, activity value is MIC = 1.25||Anti-S. pneumoniae, activity value is MIC = 1.25||Anti-S. pyogenes, activity value is MIC = 1.25||Anti-S. iniae, activity value is MIC = 1.25||Anti-negative V. cholera, activity value is MIC = 2.5||Anti-E. coli, activity value is MIC = 5||Anti-E. cloacae, activity value is MIC = 110||Anti-E. aerogenes, activity value is MIC = 10||Anti-K. pneumoniae, activity value is MIC = 2.5||Anti-K. oxytoca, activity value is MIC = 5||Anti-M. catarrhalis, activity value is MIC = 2.5||Anti-P. aeruginosa, activity value is MIC = 5||Anti-S. choleraesuis, activity value is MIC = 10||Anti-S. typhimurium, activity value is MIC = 10||Anti-S-arizonae, activity value is MIC > 20 uM||Anti-S. flexneri, activity value is MIC = 2.5||Anti-S. sonnei, activity value is MIC = 5||Anti-Y. enterocolitica, activity value is MIC = 2.5||Anti-filamentous fungi N. crassa, activity value is MIC = 1.56||Anti-A. fumigatus, activity value is MIC = 50||Anti-F. oxysporum, activity value is MIC = 0.78||Anti-F. culmorum, activity value is MIC = 0.39||activity value is MIC = 10||Anti-C. glabrata, activity value is MIC = 10||Anti-C. lusitania, activity value is MIC = 10||Anti-and C. tropicalis, activity value is MIC = 10	skin/gill, Morone saxatilis	Helix	"The hemolytic values of the synthesized amidated white bass moronecidin (wb-moronecidin) on human and sheep red blood cells are as follows in the document:

Table

Concentration (µM) | Human RBC Hemolysis (%) | Sheep RBC Hemolysis (%)  
0.31 | 0 | 0  
0.63 | 0 | 0  
1.25 | 0 | 0  
2.5 | 0 | 0  
5 | 19 | Not explicitly mentioned  
10 | 55 | Not explicitly mentioned  
20 | 100 | 58  
80 | 100 | 100  

Note: The data in the table represent the average of two independent experiments. No hemolytic activity was observed at low concentrations (≤2.5 µM), and hemolytic activity increased in a dose-dependent manner with increasing concentration.|||skin/gill, Morone saxatilis||HC₅₀ ≈ 3 uM。"	"J Biol Chem
. 2002 Feb 15;277(7):5030-9. doi: 10.1074/jbc.M109173200. Epub 2001 Dec 5.|||J Biol Chem. 2002 Feb 15;277(7):5030-9. doi: 10.1074/jbc.M109173200. Epub 2001 Dec 5.|||J Biol Chem. 2002 Feb 15;277(7):5030-9. Pub-Med."	23	
FPDB01002	AP02096|||AP02096|||Ubiquicidin	"	
KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS"	Anti-Gram+ & Gram-||Anti-MRSA||Active against L. monocytogenes||S. typhimuriumas||E. coli||Y. enterocolitica||and S. aureus.||Antibacterial ; Listeria monocytogenes EGD||Salmonella typhimurium 14028S||Staphylococcus aureus 502A||Escherichia coli ML-35p||Yersinia enterocolitica	colonic mucosa, Homo sapiens ; cytosol, macrophage, RAW264.7, Mus musculus; Rattus norvegicus|||Mus musculus [Mouse]	N/A	colonic mucosa, Homo sapiens ; cytosol, macrophage, RAW264.7, Mus musculus; Rattus norvegicus	"Comparative Study J Leukoc Biol
. 1999 Sep;66(3):423-8. doi: 10.1002/jlb.66.3.423.|||J Leukoc Biol. 1999 Sep;66(3):423-8. doi: 10.1002/jlb.66.3.423.|||10496312"	59	
FPDB01003	AP02097	"	
KPKDMTSSQWFKTQHVQPSPQACNSAMSIINKYTERCKDLNTFLHEPFSSVAITCQTPNIACKNSCKNCHQSHGPMSLTMGELTSGKYP"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA	Homo sapiens	N/A	"The hemolysis-related information of RNase 8 in the document is as follows:

In hemolytic activity tests on human red blood cells, only slight hemolytic activity was observed at RNase 8 concentrations as high as 28 μM (the specific value was not explicitly listed as a percentage, only described as 'little hemolytic activity').

In the experiment, the 0.1% Triton X-100 treated group was used as the 100% hemolysis control. Even at the highest tested concentration, RNase 8 did not exhibit significant hemolytic activity, indicating that it has low toxicity to human cells and its lethal effect is microbe-specific."	"Antimicrob Agents Chemother
. 2006 Sep;50(9):3194-6. doi: 10.1128/AAC.00246-06."	89	
FPDB01004	AP02106|||AP02106|||Temporin-LK1|||Temporin-LK1|||AP02106	"	
FFPLLFGALSSMMPKLF"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus ATCC2592, activity value is MIC = 2.5 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 2.5 ug/ml||Anti-B. subtilis, activity value is MIC = 15 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 30 ug/ml||Anti-P. aeruginosa PA01, activity value is MIC = 2.5 ug/ml||Anti-P. aeruginosa ATCC27853, activity value is MIC = 2.5 ug/ml||Anti-and C. albicans ATCC2002, activity value is MIC = 5 ug/ml||Anti-S. aureus ATCC 2592, activity value is MIC = 2.5 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 2.5 ug/ml||Anti-C. albicans ATCC 2002, activity value is MIC = 5 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 2.5 ug/ml	the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia|||Limnonectes kuhlii [Kuhl's wart frog]	N/A	"The hemolytic values of five antimicrobial peptides on rabbit red blood cells at a concentration of 100 µg/ml are as follows:

- temporin-LK1: 10.2%

- gaegurin-LK1: 5.6%

- gaegurin-LK2: 6.2%

- rugosin-LK1: 3.8%

- rugosin-LK2: 6.1%

These values indicate that their hemolytic activity is relatively low, with rugosin-LK1 showing the weakest hemolytic activity.|||the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia||HC₅₀ = 8.2 uM。|||Rabbit RBC (10.2% hemolysis at 100 ug/ml)|||Rabbit RBC (10.2% hemolysis at 100 ug/ml)|||Some antimicrobial peptides exhibit hemolytic activities by
interacting with eukaryote membranes [3]. In our experi-
ments, rabbit red blood cells were used to test hemolytic
capabilities of these antimicrobial peptides. Most of them
showed a little hemolytic activity. At the concentration of
100 lg/ml, temporin-LK1, gaegurin-LK1, gaegurin-LK2,
rugosin-LK1, and rugosin-LK2 induced 10.2, 5.6, 6.2, 3.8,
and 6.1 % rabbit red blood cell hemolysis, respectively.|||At 100 ug/ml, temporin-LK1 induced 10.2% hemolysis: less hemo.lytic."	"Mol Biol Rep
. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||Mol Biol Rep. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||23054029|||23054029|||Mol Biol Rep
. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||Mol Biol Rep. 2013 Feb;40(2):1097-102. Pub-Med."	17	
FPDB01005	AP02107|||AP02107|||Gaegurin-LK1|||Gaegurin-LK1|||AP02107	FIGPVLKMATSILPTAICKGFKKC	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus ATCC2592, activity value is MIC = 5 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 10 ug/ml||Anti-B. subtilis, activity value is MIC = 20 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 50 ug/ml||Anti-P. aeruginosa PA01, activity value is MIC = 10 ug/ml||Anti-P. aeruginosa ATCC27853, activity value is MIC = 5 ug/ml||Anti-and C. albicans ATCC2002, activity value is MIC = 10 ug/ml||Antibacterial||Anti-S. aureus ATCC 2592, activity value is MIC = 5 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 10 ug/ml||Anti-C. albicans ATCC 2002, activity value is MIC = 10 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 5 ug/ml	the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia|||Limnonectes kuhlii [Kuhl's wart frog]|||Limnonectes kuhlii [Kuhl's wart frog]|||the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia	N/A	"The hemolytic values of five antimicrobial peptides on rabbit red blood cells at a concentration of 100 µg/ml are as follows:

- temporin-LK1: 10.2%

- gaegurin-LK1: 5.6%

- gaegurin-LK2: 6.2%

- rugosin-LK1: 3.8%

- rugosin-LK2: 6.1%

These values indicate that their hemolytic activity is relatively low, with rugosin-LK1 showing the weakest hemolytic activity.|||the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia||HC₅₀ = 6.5 uM。|||Rabbit RBC (5.6% hemolysis at 100 ug/ml)|||Rabbit RBC (5.6% hemolysis at 100 ug/ml)|||Some antimicrobial peptides exhibit hemolytic activities by
interacting with eukaryote membranes [3]. In our experi-
ments, rabbit red blood cells were used to test hemolytic
capabilities of these antimicrobial peptides. Most of them
showed a little hemolytic activity. At the concentration of
100 lg/ml, temporin-LK1, gaegurin-LK1, gaegurin-LK2,
rugosin-LK1, and rugosin-LK2 induced 10.2, 5.6, 6.2, 3.8,
and 6.2 % rabbit red blood cell hemolysis, respectively.|||At 100 ug/ml, gaegurin-LK1 induced 5.6% hemolysis: less hemo.lytic."	"Mol Biol Rep
. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||Mol Biol Rep. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||23054029|||23054029|||Mol Biol Rep
. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 11.|||Mol Biol Rep. 2013 Feb;40(2):1097-102. Pub-Med."	24	
FPDB01006	AP02108|||AP02108|||Gaegurin-LK2|||Gaegurin-LK2|||AP02108	"	
FLGPIIKMATGILPTAICKGLKKC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus ATCC2592, activity value is MIC = 2.5 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 2.5 ug/ml||Anti-B. subtilis, activity value is MIC = 20 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 50 ug/ml||Anti-P. aeruginosa PA01, activity value is MIC = 10 ug/ml||Anti-P. aeruginosa ATCC27853, activity value is MIC = 5 ug/ml||Anti-and C. albicans ATCC2002, activity value is MIC = 5 ug/ml||Antibacterial||Anti-S. aureus ATCC 2592, activity value is MIC = 2.5 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 2.5 ug/ml||Anti-C. albicans ATCC 2002, activity value is MIC = 5 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 5 ug/ml	the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia|||Limnonectes kuhlii [Kuhl's wart frog]|||Limnonectes kuhlii [Kuhl's wart frog]|||the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia	N/A	"The hemolytic values of five antimicrobial peptides on rabbit red blood cells at a concentration of 100 µg/ml are as follows:

- temporin-LK1: 10.2%

- gaegurin-LK1: 5.6%

- gaegurin-LK2: 6.2%

- rugosin-LK1: 3.8%

- rugosin-LK2: 6.1%

These values indicate that their hemolytic activity is relatively low, with rugosin-LK1 showing the weakest hemolytic activity.|||the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia||HC₅₀ = 7.1 uM。|||Rabbit RBC (6.2% hemolysis at 100 ug/ml)|||Rabbit RBC (6.2% hemolysis at 100 ug/ml)|||Some antimicrobial peptides exhibit hemolytic activities by
interacting with eukaryote membranes [3]. In our experi-
ments, rabbit red blood cells were used to test hemolytic
capabilities of these antimicrobial peptides. Most of them
showed a little hemolytic activity. At the concentration of
100 lg/ml, temporin-LK1, gaegurin-LK1, gaegurin-LK2,
rugosin-LK1, and rugosin-LK2 induced 10.2, 5.6, 6.2, 3.8,
and 6.3 % rabbit red blood cell hemolysis, respectively.|||At 100 ug/ml, gaegurin-LK2 induced 6.2% hemolysis: less hemo.lytic."	"Mol Biol Rep
. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||Mol Biol Rep. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||23054029|||23054029|||Mol Biol Rep
. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 12.|||Mol Biol Rep. 2013 Feb;40(2):1097-102. Pub-Med."	24	
FPDB01007	AP02109|||AP02109|||Rugosin-LK1|||Rugosin-LK1|||AP02109	"	
SIRDKIKTMAIDLAKSAGTGVLKTLICKLDKSC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti->: Active against S. aureus ATCC2592, activity value is MIC = 10 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 15 ug/ml||Anti-B. subtilis, activity value is MIC = 40 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 10 ug/ml||Anti-P. aeruginosa PA01, activity value is MIC = 5 ug/ml||Anti-P. aeruginosa ATCC27853, activity value is MIC = 5 ug/ml||Anti-and C. albicans ATCC2002, activity value is MIC = 10 ug/ml||Antibacterial||Anti-S. aureus ATCC 2592, activity value is MIC = 10 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 15 ug/ml||Anti-C. albicans ATCC 2002, activity value is MIC = 10 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 5 ug/ml	the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia|||Limnonectes kuhlii [Kuhl's wart frog]|||Limnonectes kuhlii [Kuhl's wart frog]|||the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia	N/A	"The hemolytic values of five antimicrobial peptides on rabbit red blood cells at a concentration of 100 µg/ml are as follows:

- temporin-LK1: 10.2%

- gaegurin-LK1: 5.6%

- gaegurin-LK2: 6.2%

- rugosin-LK1: 3.8%

- rugosin-LK2: 6.1%

These values indicate that their hemolytic activity is relatively low, with rugosin-LK1 showing the weakest hemolytic activity.|||the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia||At a concentration of 100 μM, the hemolysis rate is < 10%.|||Rabbit RBC (3.8% hemolysis at 100 ug/ml)|||Rabbit RBC (3.8% hemolysis at 100 ug/ml)|||Some antimicrobial peptides exhibit hemolytic activities by
interacting with eukaryote membranes [3]. In our experi-
ments, rabbit red blood cells were used to test hemolytic
capabilities of these antimicrobial peptides. Most of them
showed a little hemolytic activity. At the concentration of
100 lg/ml, temporin-LK1, gaegurin-LK1, gaegurin-LK2,
rugosin-LK1, and rugosin-LK2 induced 10.2, 5.6, 6.2, 3.8,
and 6.4 % rabbit red blood cell hemolysis, respectively.|||At 100 ug/ml, rugosin-LK1 induced 3.8%, less hemo.lytic."	"Mol Biol Rep
. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||Mol Biol Rep. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||23054029|||23054029|||Mol Biol Rep
. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 13.|||Mol Biol Rep. 2013 Feb;40(2):1097-102. Pub-Med."	33	
FPDB01008	AP02110|||AP02110|||Rugosin-LK2|||Rugosin-LK2|||AP02110	"	
SIRDKGKTIAIDLAKSAGTGVLKTLMCKLDKSC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti->: Active against S. aureus ATCC2592, activity value is MIC = 10 ug/ml||Anti-S. aureus ATCC43300, activity value is MIC = 10 ug/ml||Anti-B. subtilis, activity value is MIC = 30 ug/ml||Anti-E. coli ML-35P, activity value is MIC = 10 ug/ml||Anti-P. aeruginosa PA01, activity value is MIC = 2.5 ug/ml||Anti-P. aeruginosa ATCC27853, activity value is MIC = 2.5 ug/ml||Anti-and C. albicans ATCC2002, activity value is MIC = 10 ug/ml||Antibacterial||Anti-S. aureus ATCC 2592, activity value is MIC = 10 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 10 ug/ml||Anti-C. albicans ATCC 2002, activity value is MIC = 10 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 2.5 ug/ml	the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia|||Limnonectes kuhlii [Kuhl's wart frog]|||Limnonectes kuhlii [Kuhl's wart frog]|||the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia	N/A	"The hemolytic values of five antimicrobial peptides on rabbit red blood cells at a concentration of 100 µg/ml are as follows:

- temporin-LK1: 10.2%

- gaegurin-LK1: 5.6%

- gaegurin-LK2: 6.2%

- rugosin-LK1: 3.8%

- rugosin-LK2: 6.1%

These values indicate that their hemolytic activity is relatively low, with rugosin-LK1 showing the weakest hemolytic activity.|||the Kuhl’s wart frog, skin secretions, Limnonectes kuhlii, Asia||At a concentration of 100 μM, the hemolysis rate is < 10%.|||Rabbit RBC (6.1% hemolysis at 100 ug/ml)|||Rabbit RBC (6.1% hemolysis at 100 ug/ml)|||Some antimicrobial peptides exhibit hemolytic activities by
interacting with eukaryote membranes [3]. In our experi-
ments, rabbit red blood cells were used to test hemolytic
capabilities of these antimicrobial peptides. Most of them
showed a little hemolytic activity. At the concentration of
100 lg/ml, temporin-LK1, gaegurin-LK1, gaegurin-LK2,
rugosin-LK1, and rugosin-LK2 induced 10.2, 5.6, 6.2, 3.8,
and 6.5 % rabbit red blood cell hemolysis, respectively.|||At 100 ug/ml, rugosin-LK2 induced 6.1%, less hemo.lytic."	"Mol Biol Rep
. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||Mol Biol Rep. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 10.|||23054029|||23054029|||Mol Biol Rep
. 2013 Feb;40(2):1097-102. doi: 10.1007/s11033-012-2152-4. Epub 2012 Oct 14.|||Mol Biol Rep. 2013 Feb;40(2):1097-102. Pub-Med."	33	
FPDB01009	AP02118|||AP02118|||Temporin-SHd|||Temporin-SHd	"	
FLPAALAGIGGILGKLF"	Anti-Gram+ & Gram-||Antiparasitic||Anti-MRSA||Hemolytic||Anti-E. coli ATCC 25922, activity value is MIC = 5 uM||Anti-E. coli ATCC 35218, activity value is MIC = 50 uM||Anti-E. coli ML-35p, activity value is MIC = 25 uM||Anti-P.aeruginosa ATCC 27853, activity value is MIC > 200 uM||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 100 uM||Anti-S. enteritidis, activity value is MIC > 200 uM||Anti-s C. albicans ATCC 90028, activity value is MIC = 100 uM||Anti-C.parapsilosis ATCC 22019, activity value is MIC > 200 uM||Anti-and T. cruzi, activity value is IC50 = 6.7||Anti-Escherichia coli ATCC 25922, activity value is MIC = 5 uM||Anti-Escherichia coli ATCC 35218, activity value is MIC = 50 uM||Anti-Escherichia coli ML-35p, activity value is MIC = 25 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC > 200 uM||Anti-Acinetobacter baumannii ATCC 19606, activity value is MIC = 25 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 100 uM||Anti-Salmonella enterica subsp. enterica serovar Enteritidis, activity value is MIC > 200 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 6.25 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 6.25 uM||Anti-Staphylococcus aureus ATCC BAA-44, activity value is MIC = 6.25 uM||Anti-Staphylococcus aureus ST1065, activity value is MIC = 6.25 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 25 uM||Anti-Bacillus megaterium, activity value is MIC = 1.56 uM||Anti-Candida albicans ATCC 90028, activity value is MIC = 100 uM||Anti-Candida parapsilosis ATCC 22019, activity value is MIC > 200 uM||Anti-Saccharomyces cerevisiae, activity value is MIC = 25 uM||Anti-Leishmania infantum MHOM/MA/67/ITMAP-263, activity value is IC50 = 16.5 uM||Anti-Leishmania infantum MHOM/MA/67/ITMAP-263, activity value is IC50 = 23.5 uM||Anti-Leishmania major MHOM/SU/73/5ASKH, activity value is IC50 = 14.6 uM||Anti-Leishmania tropica MHOM/SU/74/SAF-K27, activity value is IC50 = 13.9 uM||Anti-Leishmania amazonensis MHOM/BR/73/M2269, activity value is IC50 = 14.1 uM||Anti-Leishmania braziliensis MHOM/BR/75/M2904, activity value is IC50 = 17.9 uM||Anti-Leishmania infantum MHOM/MA/67/ITMAP-263, activity value is IC50 = 6.7 uM||Anti-Trypanosoma brucei, activity value is IC50 = 21.8 uM||Anti-Trypanosoma cruzi, activity value is IC50 = 16.8 uM	skin, Pelophylax saharica, Africa|||Pelophylax saharicus	Helix	skin, Pelophylax saharica, Africa||At a concentration of 25 μM, the hemolysis rate is > 80%.|||Human erythrocytes (50% Hemolysis at 44 uM|||Human erythrocytes (50% Hemolysis at 44 uM	"J Biol Chem
. 2010 May 28;285(22):16880-92. doi: 10.1074/jbc.M109.097204. Epub 2010 Mar 22.|||J Biol Chem. 2010 May 28;285(22):16880-92. doi: 10.1074/jbc.M109.097204. Epub 2010 Mar 22.|||23116712|||23116712"	17	
FPDB01010	AP02121	GFGCPFNENECHAHCLSIGRKFGFCAGPLRATCTCGKQ	Anti-Gram+ & Gram-||Anti-MRSA||Active against Gram-positive B. megaterium||B. subtilis||S. aureus (MRSA)||S. epidermidis||M. luteus||B. cereus and Gram-negative bacteria P. aeruginosa and A. tumefaciens. A helical structure between residues 7-18 and two beta-strands between residues 22-26 and 32-36. You can rotate||zoom||and view the 3D structure here in the PDB . Of great interest is that the peptide showed a low toxic effect on mammalian cells compared to meucin-49. There is no decrease in activity in the presence of serum after over 24 h incubation. Animal model:mouse. The peptide protects mice from death. Updated 2/2014.	Microsporum canis	Combine Helix and Beta structure	"The hemolytic values of micasin in the document are as follows:

In hemolysis experiments on mouse red blood cells, micasin did not show significant hemolytic activity even at concentrations up to 50 µM (the exact hemolysis rate was not clearly listed as a percentage, only described as 'no notable hemolysis').

PBS buffer was used as the 0% hemolysis control, and 1% Triton X-100 as the 100% hemolysis control. The positive control peptide meucin-49 showed hemolytic activity at the tested concentration, whereas micasin still did not show significant hemolytic effects at the highest tested concentration, indicating its low toxicity to mammalian red blood cells.|||Microsporum canis"	"Proc Natl Acad Sci U S A
. 2012 May 29;109(22):8495-500. doi: 10.1073/pnas.1201263109. Epub 2012 May 14.|||Proc Natl Acad Sci U S A. 2012 May 29;109(22):8495-500. doi: 10.1073/pnas.1201263109. Epub 2012 May 14."	38	
FPDB01011	AP02122|||AP02122|||Reactive oxygen species modulator 1	"	
CLRIGMRGRELMGGIGKTM"	Anti-Gram+ & Gram-||Anti-MRSA||Antibacterial	Protein-derived peptide, Sequence truncation|||Bos taurus [Bovine]|||Mus musculus [Mouse]|||Sus scrofa [Pig]	N/A	"The relevant data on the hemolytic activity of hGlyrichin pCM19 peptide in vitro and in vivo are as follows: 

In vitro hemolysis experiment (human red blood cells)

- Positive control (0.1% Triton X-100): average absorbance (OD570) was 5.565 ± 0.502 (complete hemolysis).

- pCM19 at different concentrations:
  - 100 µg/ml: 0.109 ± 0.054
  - 200 µg/ml: 0.122 ± 0.012
  - 500 µg/ml: 0.114 ± 0.006
  - 1000 µg/ml: 0.117 ± 0.007
  - 2000 µg/ml: 0.137 ± 0.002
  - 3000 µg/ml: 0.119 ± 0.001

- Negative control (0.9% NaCl): 0.106 ± 0.011
- Ampicillin (2000 µg/ml): 0.101 ± 0.011

Note: The hemolysis rates of the pCM19 groups at various concentrations showed no significant differences compared with the negative control, indicating no obvious hemolytic activity.

In vivo hemolysis experiment (mouse intravenous injection)

- After injection of 5000 µg/kg and 10000 µg/kg pCM19, peripheral blood red cell-related indicators (red blood cell count, hemoglobin, hematocrit, etc.) were measured at 2 hours and 5 hours. The results showed no significant differences compared with the saline control group, and no hemolysis was observed.

In summary, pCM19 showed no significant hemolytic activity within the tested concentration range.|||Protein-derived peptide, Sequence truncation||HC₅₀ = 15 uM。"	"J Pept Sci
. 2012 Feb;18(2):97-104. doi: 10.1002/psc.1421. Epub 2011 Nov 14.|||J Pept Sci. 2012 Feb;18(2):97-104. doi: 10.1002/psc.1421. Epub 2011 Nov 14.|||uniprot"	19	
FPDB01012	AP02139|||AP02139|||DFTamP1	"	
GLLSLLSLLGKLL"	Anti-Gram+||Anti-MRSA||Anti-S. aureus USA300, activity value is MIC = 3.12 uM||Anti-B. subtilis, activity value is MIC > 120 uM||Anti-E. coli K12, activity value is MIC > 120 uM||Anti-P. aeruginosa, activity value is MIC > 120 uM	ab initio designed|||Synthetic construct	Helix	ab initio designed||At a concentration of 50 µM, the hemolysis rate exceeds 50%.	"J Am Chem Soc
. 2012 Aug 1;134(30):12426-9. doi: 10.1021/ja305644e. Epub 2012 Jul 19.|||J Am Chem Soc. 2012 Aug 1;134(30):12426-9. doi: 10.1021/ja305644e.|||23238370"	13	
FPDB01013	AP02162|||AP02162|||Bicarinalin	"	
KIKIPWGKVKDFLVGGMKAV"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Antiparasitic||Anti-MRSA||Anti-S. xylosus and S. aureus. Also: Gram- E. coli CIP 7624, activity value is MIC = 24.4 uM||Anti-C. sakazakii ATCC 29544, activity value is MIC = 5.8||Anti-P. aeruginosa CIP 82118, activity value is MIC = 8.7||Anti-S. enterica ATCC 29934, activity value is MIC = 5.4||Anti-E. hirae CIP 5855, activity value is MIC = 12.2||Anti-S. aureus CIP 53156, activity value is MIC = 3.0||Anti-MRSA ATCC 43300, activity value is MIC = 8.7||Anti-S. xylosus ATCC 35033, activity value is MIC = 0.45||Anti-B. substilis CIP 5262, activity value is MIC = 24.4||Anti-A. niger CIP 143183, activity value is MIC = 0.75||Anti-CAAL 117, activity value is MIC = 17.3||Anti-S. cerevisiae sp, activity value is MIC = 6.1||Anti-and parasite L. infantum, activity value is MIC = 1.5||Antibacterial ; Tetramorium bicarinatum [Myrmicine ant ]||Anti-H. pylori Strain ATCC 43504, activity value is MIC = 8.6 ug/ml	venom, the ant, Tetramorium bicarinatu, South America|||Tetramorium bicarinatum [Myrmicine ant ]	Helix	"The hemolytic values of the novel antimicrobial peptide Bicarinalin and related peptides in the venom of the ponerine ant are as follows:

- Bicarinalin: At a concentration of 100 μM (180 μg/ml), the hemolysis rate of human erythrocytes is 10%; the concentration at which 50% hemolysis occurs is approximately 720 μg/ml (log = -0.143).

- P17: Shows no hemolytic activity.

- Melittin (control): At a concentration of 0.15 μM (0.4 μg/ml), the hemolysis rate of human erythrocytes is 10%; the concentration at which 50% hemolysis occurs is approximately 1.76 × 10⁻³ mg/ml (log = -2.76).

These data indicate that the hemolytic activity of Bicarinalin is significantly weaker than that of Melittin, while P17 has no hemolytic effect.|||venom, the ant, Tetramorium bicarinatu|||Staphylococcus aureus, Staphylococcus xylosus, Refer PubMed ID: H. pylori Strain ATCC 43504 (MIC = 8.6 ug/ml) [Refer PubMed Id : 29751064] Acinetobacter baumannii ATCC 19606 (MIC = 4 ug/ml)|||The hemolytic activity of the peptides was compared to that of Melittin against human erythrocytes from healthy donor. Fresh human erythrocytes with heparin were washed three times (0.166667 h at 1000 × g) with PBS and resuspended in the same buffer. The hemolytic activity was quantified by incubating 20 ␮L of serially diluted peptides (2.8 × 10−3000 – 5760 ug/ml) or Melittin (0.11 × 10−3000 – 225 ug/ml) with 80 ␮L of a 4% erythrocytes suspension in PBS for 1 h at 37 ◦C in a 96-well microplate (Nunc Edge 96 Well Microplate). The erythrocyte suspension was then centrifuged (1000 × g for 0.166667 h) and, 80 ␮L of the supernatant were transferred in another line of the microplate; cell lysis was determined spectrophotometrically at 540 nm. Reference samples were employed using hypotonic lysis with Milli-Q sterile water as a 100% lysis or PBS pH 7.4 (in place of the peptide) as a 0% lysis. Three replicates were performed."	"Peptides
. 2012 Dec;38(2):363-70. doi: 10.1016/j.peptides.2012.08.018. Epub 2012 Sep 7.|||Peptides. 2012 Dec;38(2):363-70.Pub-Med.||Guzman J et al., 2017|||https://pubmed.ncbi.nlm.nih.gov/22960382,|||https://pubmed.ncbi.nlm.nih.gov/22960382,||Refer PubMed Id : 29751064|||Peptides
. 2012 Dec;38(2):363-70. doi: 10.1016/j.peptides.2012.08.018. Epub 2012 Sep 7.||Guzman J et al., 2017|||Peptides. 2012 Dec;38(2):363-70.Pub-Med."	20	
FPDB01014	AP02178	LRVRRTLQCSCRRVCRNTCSCIRLSRSTYAS	Anti-Gram+ & Gram-||Anti-MRSA||Anti-and L. monocytogenes, activity value is MIC = 2	Paneth cells, Rattus norvegicus	Beta	Paneth cells, Rattus norvegicus	"Antimicrob Agents Chemother
. 2013 Apr;57(4):1823-31. doi: 10.1128/AAC.02237-12. Epub 2013 Feb 4.|||Antimicrob Agents Chemother. 2013 Apr;57(4):1823-31. Pub-Med."	31	
FPDB01015	AP02201	"	
KIKFLKVLT"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-and fungus C. albicans ATCC 10231, activity value is MIC = 1	Paenibacillus ehimensis B7	N/A	Paenibacillus ehimensis B7	"BMC Microbiol
. 2013 Apr 17:13:87. doi: 10.1186/1471-2180-13-87.|||BMC Microbiol. 2013 Apr 17;13(1):87. Pub-Med."	9	
FPDB01016	AP02213|||AP02213|||CAMPSQ3846|||DRAMP18188|||Pantinin-1|||AP02213|||DRAMP18188	"	
GILGKLWEGFKSIV"	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-MRSA 16472, activity value is MIC = 8||Anti-S. enterica AB 2010185, activity value is MIC = 62||Anti-and fungus C. tropicalis AY 91009, activity value is MIC = 16 uM||Anti-S.aureus, activity value is MIC = 8 uM||Anti-B.magaterium, activity value is MIC = 32 uM||Anti-M.luteus, activity value is MIC = 32 uM||Anti-VRE, activity value is MIC = 28 uM||Anti-MRSA, activity value is MIC = 14 uM||Anti-E.coli, activity value is MIC = 62 uM||Anti-P.putida, activity value is MIC > 87 uM||Anti-K.oxytoca, activity value is MIC > 87 uM||Anti-E.cloacae, activity value is MIC = 76 uM||Anti-S.enterica, activity value is MIC = 72 uM||Anti-Fungus: C.tropicalis, activity value is MIC = 16 uM||Antibacterial||Anti-##Gram-negative bacteria: E.coli, activity value is MIC = 62 uM||Anti-##Fungus: C.tropicalis, activity value is MIC = 16 uM	Pandinus imperator|||Pandinus imperator [Emperor scorpion]|||Pandinus imperator (Emperor scorpion)|||Pandinus imperator [Emperor scorpion]|||Pandinus imperator|||Pandinus imperator (Emperor scorpion)	N/A	"Pandinus imperator||No hemolytic effect is observed at concentrations below 32 uM; at 64 uM, it only induces 21% hemolysis, showing extremely low hemolytic activity.|||Pantinin-1 Hemolytic Values
<32 uM: No hemolysis
32 uM: No clear value (<81%)
64 uM: 21% hemolysis
Pantinin-2 Hemolytic Values
<8 uM: No hemolysis
16 uM: 8% hemolysis
32 uM: 81% hemolysis
64 uM: 100% hemolysis
Pantinin-3 Hemolytic Values
<8 uM: No hemolysis
16 uM: 70% hemolysis
32 uM: 100% hemolysis|||[Ref.23624072]0% hemolytic activity at 16 uM, 0% hemolytic activity at 32 uM, 20% hemolytic activity at 64 uM against human red bood cells"	"Peptides
. 2013 Jul:45:28-34. doi: 10.1016/j.peptides.2013.03.026. Epub 2013 Apr 23.|||Peptides. 2013 Jul;45:28-34. Pub-Med.|||23624072|||Peptides 45:28-34(2013)||Ref.23624072|||23624072|||Peptides
. 2013 Jul:45:28-34. doi: 10.1016/j.peptides.2013.03.026. Epub 2013 Apr 23.|||Peptides 45:28-34(2013)##Peptides 51:35-45(2014||Ref.23624072|||Peptides. 2013 Jul;45:28-34. Pub-Med."	14	
FPDB01017	AP02214|||AP02214|||Pantinin-2|||DRAMP18189|||Pantinin-2|||AP02214|||DRAMP03926|||DRAMP18189	IFGAIWKGISSLL	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-MRSA 16472, activity value is MIC = 18||Anti-S. enterica AB 2010185, activity value is MIC = 48||Anti-and fungus C. tropicalis AY 91009, activity value is MIC = 16 uM||Antibacterial||Anti-S.aureus, activity value is MIC = 48 uM||Anti-B.magaterium, activity value is MIC = 36 uM||Anti-M.luteus, activity value is MIC = 18 uM||Anti-VRE, activity value is MIC = 36 uM||Anti-MRSA, activity value is MIC = 28 uM||Anti-E.coli, activity value is MIC = 48 uM||Anti-P.putida, activity value is MIC > 87 uM||Anti-K.oxytoca, activity value is MIC > 87 uM||Anti-E.cloacae, activity value is MIC > 87 uM||Anti-S.enterica, activity value is MIC = 68 uM||Anti-Fungus: C.tropicalis, activity value is MIC = 16 uM||Antimicrobial||Anti-Gram+||Anti-Gram-	Pandinus imperator|||Pandinus imperator [Emperor scorpion]|||Pandinus imperator (Emperor scorpion)|||Pandinus imperator [Emperor scorpion]|||Pandinus imperator|||Synthetic construct|||Pandinus imperator (Emperor scorpion)	N/A	"Pandinus imperator||No obvious hemolysis is observed at concentrations below 8 uM; the hemolysis rate is 8% at 16 uM, 81% at 32 uM, and reaches 100% at 64 uM, showing moderate hemolytic activity.|||Pantinin-1 Hemolytic Values
<32 uM: No hemolysis
32 uM: No clear value (<81%)
64 uM: 21% hemolysis
Pantinin-2 Hemolytic Values
<8 uM: No hemolysis
16 uM: 8% hemolysis
32 uM: 81% hemolysis
64 uM: 100% hemolysis
Pantinin-3 Hemolytic Values
<8 uM: No hemolysis
16 uM: 70% hemolysis
32 uM: 100% hemolysis"	"Peptides
. 2013 Jul:45:28-34. doi: 10.1016/j.peptides.2013.03.026. Epub 2013 Apr 23.|||Peptides. 2013 Jul;45:28-34.Pub-Med.|||23624072|||Peptides 51:35-45(2014||Ref.23624072|||23624072|||Peptides
. 2013 Jul:45:28-34. doi: 10.1016/j.peptides.2013.03.026. Epub 2013 Apr 23.|||Curr Microbiol. 2010 Sep;61(3):169-175.|||Peptides 45:28-34(2013).Peptides 51:35-45(2014|||Peptides. 2013 Jul;45:28-34.Pub-Med."	13	
FPDB01018	AP02215|||AP02215|||Pantinin-3|||DRAMP18190|||Pantinin-3|||AP02215|||DRAMP18190	"	
FLSTIWNGIKSLL"	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-MRSA 16472, activity value is MIC = 4||Anti-S. enterica AB 2010185, activity value is MIC = 36||Anti-and fungus C. tropicalis AY 91009, activity value is MIC = 17 uM||Antibacterial||Anti-S.aureus, activity value is MIC = 16 uM||Anti-B.magaterium, activity value is MIC = 6 uM||Anti-M.luteus, activity value is MIC = 8 uM||Anti-VRE, activity value is MIC = 4 uM||Anti-MRSA, activity value is MIC = 12 uM||Anti-E.coli, activity value is MIC = 36 uM||Anti-P.putida, activity value is MIC > 87 uM||Anti-K.oxytoca, activity value is MIC = 87 uM||Anti-E.cloacae, activity value is MIC > 87 uM||Anti-S.enterica, activity value is MIC = 84 uM||Anti-Fungus: C.tropicalis, activity value is MIC = 17 uM||Antimicrobial||Anti-Gram+||Anti-Gram-	Pandinus imperator|||Pandinus imperator [Emperor scorpion]|||Pandinus imperator (Emperor scorpion)|||Pandinus imperator [Emperor scorpion]|||Pandinus imperator|||Pandinus imperator (Emperor scorpion)	N/A	"Pandinus imperator||No obvious hemolysis is observed at concentrations below 8 uM; the hemolysis rate rises sharply to 70% at 16 uM and reaches 100% at 32 uM, showing strong hemolytic activity.|||Pantinin-1 Hemolytic Values
<32 uM: No hemolysis
32 uM: No clear value (<81%)
64 uM: 21% hemolysis
Pantinin-2 Hemolytic Values
<8 uM: No hemolysis
16 uM: 8% hemolysis
32 uM: 81% hemolysis
64 uM: 100% hemolysis
Pantinin-3 Hemolytic Values
<8 uM: No hemolysis
16 uM: 70% hemolysis
32 uM: 100% hemolysis"	"Peptides
. 2013 Jul:45:28-34. doi: 10.1016/j.peptides.2013.03.026. Epub 2013 Apr 23.|||Peptides. 2013 Jul;45:28-34.Pub-Med.|||23624072|||Peptides 45:28-34(2013)||Ref.23624072|||23624072|||Peptides
. 2013 Jul:45:28-34. doi: 10.1016/j.peptides.2013.03.026. Epub 2013 Apr 24.|||Peptides 45:28-34(2013).Peptides 51:35-45(2014|||Peptides. 2013 Jul;45:28-34.Pub-Med."	13	
FPDB01019	AP02246|||AP02246|||Enterocin RM6|||Bacteriocin AS-48.|||DRAMP18265	MAKEFGIPAAVAGTVLNVVEAGGWVTTIVSILTAVGSGGLSLLAAAGRESIKAYLKKEIKKKGKRAVIAW	Anti-Gram+||Anti-MRSA||Antibacterial ; Pediococcus acidilactici PO2||Pediococcus pentosaceus||Lactobacillus plantarum ATCC8014||Lactobacillus casei ATCC7469||Lactobacillus acidophilus ATCC19992||Pediococcus cerevisiae||Lactobacillus cellobiosus OSU919||Listeria innocua ATCC33090||Enterococcus faecalis ATCC29212||Listeria monocytogenes Scott A||Bacillus cereus ATCC14579||Bacillus cereus ATCC11778||Staphylococcus aureus OSU6538||Staphylococcus aureus (methicillin sensitive)||Staphylococcus aureus (methicillin resistant)||Antibacterial ; Propionibacterium acnes (active in the range 0.62-2.5 ug/ml)||Antimicrobial||Antibacterial	Enterococcus faecalis OSY-RM6|||Enterococcus faecalis OSY-RM6|||Enterococcal UGRA10 strain	N/A	Enterococcus faecalis OSY-RM6	"Biomed Res Int
. 2013:2013:206917. doi: 10.1155/2013/206917. Epub 2013 Jun 13.|||Biomed Res Int. 2013;2013:206917. Pub-Med.|||https://pubmed.ncbi.nlm.nih.gov/23844357|||https://pubmed.ncbi.nlm.nih.gov/30082920|||Biomed Res Int. 2013;2013:206917."	70	
FPDB01020	AP02249	"	
FISQIISTARI"	Anti-Gram+||Anti-MRSA||anti-TB||Anti-including S. aureus MSSA or MRSA, activity value is MIC = 0.25 ug/ml||Anti-E. faecalis, activity value is MIC = 0.5 ug/ml||Anti-penicillin-resistant S. pneumoniae, activity value is MIC < 0.003 ug/ml||Anti-S. pyogenes, activity value is MIC = 0.06 ug/ml||Anti-S. agalactiae, activity value is MIC = 0.12 ug/ml||Anti-B. anthracis, activity value is MIC <= 0.06 ug/ml||Anti-C. difficile, activity value is MIC = 0.005 ug/ml||Anti-P. acnes, activity value is MIC = 0.08 ug/ml||Anti-M. tuberculosis H37Rv, activity value is MIC = 0.125 ug/ml||Anti-H. influenzae, activity value is MIC = 4 ug/ml||Anti-M. catarrhalis, activity value is MIC = 2 ug/ml||Anti-P-aeruginosa, activity value is MIC > 32 ug/ml||Anti-and K-pneumoniae, activity value is MIC > 32 ug/ml	Eleftheria terrae, i-chip technology	Beta||Solid-state NMR observed the interaction of enduracididine with lipid II phosphate and established a beta-sheet structure, part of the large supramolecular fibrill (Shukla et al., 2022).	Eleftheria terrae, i-chip technology	"Nature
. 2015 Jan 22;517(7535):455-9. doi: 10.1038/nature14098. Epub 2015 Jan 7.|||2015 Jan 22;517(7535):455-9. doi: 10.1038/nature14098. Epub 2015 Jan 7.|||Nature. 2015 Jan 22;517(7535):455-9. Pub-Med."	11	
FPDB01021	AP02347|||DRAMP18305	"	
KVTKSVKSIPVKI"	Anti-Gram+ & Gram-||Anti-MRSA||anti-sepsis||Antifungal||candidacidal||Anti-inflammatory||Antimicrobial||Antibacterial	Paenibacillus thiaminolyticus OSY-SE	N/A	Paenibacillus thiaminolyticus OSY-SE	"Appl Environ Microbiol
. 2012 May;78(9):3156-65. doi: 10.1128/AEM.07782-11. Epub 2012 Feb 24.|||Vet. Immunol. Immunopathol. 106 (3-4), 321-327 (2005)|||Appl Environ Microbiol. 2012 May;78(9):3156-65. PubMed|||Appl Environ Microbiol. 2012 May;78(9):3156-65."	13	
FPDB01022	AP02348|||AP02348|||Cerecidin A1|||DRAMP18214	"	
TTPLCVGVIIGLTTSIKICK"	Anti-Gram+||Anti-MRSA||Antibacterial||Antimicrobial	Bacillus cereus	N/A	Bacillus cereus	"Appl Environ Microbiol
. 2014 Apr;80(8):2633-43. doi: 10.1128/AEM.03751-13. Epub 2014 Feb 14.|||Appl Environ Microbiol. 2014 Apr;80(8):2633-43. doi: 10.1128/AEM.03751-13. PubMed|||24532070|||Appl Environ Microbiol. 2014 Apr;80(8):2633-43."	20	
FPDB01023	AP02349|||AP02349|||Cerecidin A7|||DRAMP18215	"	
TTPLCVGVIIGITASIKICK"	Anti-Gram+||Anti-MRSA||Antibacterial||Antimicrobial	Bacillus cereus	N/A	Bacillus cereus	"Appl Environ Microbiol
. 2014 Apr;80(8):2633-43. doi: 10.1128/AEM.03751-13. Epub 2014 Feb 14.|||Appl Environ Microbiol. 2014 Apr;80(8):2633-43. doi: 10.1128/AEM.03751-13. PubMed|||24532070|||Appl Environ Microbiol. 2014 Apr;80(8):2633-43."	20	
FPDB01024	AP02379|||AP02379|||GNU7|||DRAMP21139|||GNU7|||AP02379|||DRAMP21139	"	
RLLRPLLQLLKQKLR"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Gram+ B. subtilis, activity value is MIC = 2 ug/ml||Anti-E. faecalis, activity value is MIC = 2 ug/ml||Anti-E. faecium VRE, activity value is MIC = 2 ug/ml||Anti-M. luteus, activity value is MIC = 2 ug/ml||Anti-S. aureus or MRSA, activity value is MIC = 2 ug/ml||Anti-E. coli, activity value is MIC = 2 ug/ml||Anti-P. aeruginosa, activity value is MIC = 2 ug/ml||Anti-S. typhimurium, activity value is MIC = 2 ug/ml||Anti-C. albicans, activity value is MIC = 2 ug/ml||Anti-C. neoformans, activity value is MIC = 2 ug/ml||Anti-and S. cerevisiae, activity value is MIC = 2 ug/ml||Anti-P. aeruginosa H103, activity value is MIC = 32 uM||Anti-E. coli KCTC 2223, activity value is MIC = 8 uM||Anti-S. typhimurium KCTC 2370, activity value is MIC = 16 uM||Anti-S. aureus ATCC 15752, activity value is MIC = 4 uM||Anti-C. albicans ATCC 10231, activity value is MIC = 16 uM||Anti-Bacillus subtilis, activity value is MIC = 2 ug/ml||Anti-Enterococcus faecalis, activity value is MIC = 2 ug/ml||Anti-Micrococcus luteus, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 2 ug/ml||Anti-Escherichia coli, activity value is MIC = 2 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 2 ug/ml||Anti-Salmonella typhimurium, activity value is MIC = 2 ug/ml||Anti-Candida albicans, activity value is MIC = 2 ug/ml||Anti-Cryptococcus neoformans, activity value is MIC = 2 ug/ml||Anti-Saccharomyces cerevisiae, activity value is MIC = 4 ug/ml||Antibacterial||Anti-##Gram-negative bacteria : Escherichia coli, activity value is MIC = 2 ug/ml||Anti-##Fungi : Candida albicans, activity value is MIC = 2 ug/ml	de novo designed, man-made sequences|||Synthetic construct|||Synthetic construct|||de novo designed, man-made sequences	Helix||Alpha helix	"de novo designed, man-made sequences|||Human RBCs [<2.5% hemolysis upto 65 uM]|||- Test subject: human red blood cells, incubation conditions at 37°C for 30 minutes, detection wavelength 567 nm; negative control (PBS only) showed 0% hemolysis, positive control (0.2% Triton X-100) showed 100% hemolysis.

- Key results:

- Designed peptides GNU5, GNU6, GNU7: At concentrations up to 128 µg/ml, hemolysis rate was 0%, showing no hemolytic activity and excellent safety.

- Control peptides:

- Magainin 2: Similar to the designed peptides, no hemolysis at 128 µg/ml.

- Buforin IIb: At 128 µg/ml, hemolysis rate was 14.5%, indicating some hemolytic activity.

- Key correlation: The designed peptides eliminate hemolysis by disrupting the hydrophobic surface of the α-helix (inserting lysine residues) while maintaining high hydrophobicity (46%) and strong antibacterial activity (MIC 1–4 µg/ml, effective against MRSA and VRE), and exhibit no cytotoxicity to human keratinocytes (HaCaT) or fibroblasts (BJ).|||Human RBCs [<2.5% hemolysis upto 65 uM]|||[Ref.23946320] 0% hemolysis at 140 ug/ml against human red blood cells"	"J Antimicrob Chemother
. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322. Epub 2013 Aug 14.|||J Antimicrob Chemother. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322. PubMed|||31678742|||J Antimicrob Chemother. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322.||Ref.23946320|||31678742|||J Antimicrob Chemother
. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322. Epub 2013 Aug 14.|||J Antimicrob Chemother. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322.||Ref.23946320|||J Antimicrob Chemother. 2014 Jan;69(1):121-32. doi: 10.1093/jac/dkt322. PubMed"	15	
FPDB01025	AP02403|||AP02403|||CAMPSQ9863|||DRAMP20932	"	
GILGKLWEGVKSIF"	Anti-Gram+||Anti-MRSA||Anti-and S. agalactiae, activity value is MIC = 4||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 12.5 uM||Anti-P. aeruginosa 138, activity value is MIC = 12.5 uM||Anti-P. aeruginosa 431, activity value is MIC = 12.5 uM||Anti-P. aeruginosa 434, activity value is MIC = 12.5 uM||Anti-P. aeruginosa 557, activity value is MIC = 6.25 uM||Anti-P. aeruginosa 559, activity value is MIC = 25 uM||Anti-P. aeruginosa 778, activity value is MIC = 12.5 uM||Anti-P. aeruginosa 1034, activity value is MIC = 6.25 uM||Anti-P. aeruginosa 1162, activity value is MIC = 12.5 uM||Anti-P. aeruginosa 3290, activity value is MIC = 12.5 uM||Anti-P. aeruginosa 3399, activity value is MIC = 6.25 uM||Anti-P. aeruginosa 3543, activity value is MIC = 6.25 uM||Anti-P. aeruginosa 3592, activity value is MIC = 6.25 uM||Anti-P. aeruginosa 3904, activity value is MIC = 6.25 uM||Anti-P. aeruginosa 4007, activity value is MIC = 25 uM||Anti-P. aeruginosa 4319, activity value is MIC = 12.5 uM||Anti-P. aeruginosa 4891, activity value is MIC = 6.25 uM||Anti-P. aeruginosa 5018, activity value is MIC = 12.5 uM||Anti-P. aeruginosa 671973, activity value is MIC = 3.13 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa 138, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa 431, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa 434, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa 557, activity value is MIC = 6.25 uM||Anti-Pseudomonas aeruginosa 559, activity value is MIC = 25 uM||Anti-Pseudomonas aeruginosa 778, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa 1034, activity value is MIC = 6.25 uM||Anti-Pseudomonas aeruginosa 1162, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa 3290, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa 3399, activity value is MIC = 6.25 uM||Anti-Pseudomonas aeruginosa 3543, activity value is MIC = 6.25 uM||Anti-Pseudomonas aeruginosa 3592, activity value is MIC = 6.25 uM||Anti-Pseudomonas aeruginosa 3904, activity value is MIC = 6.25 uM||Anti-Pseudomonas aeruginosa 4007, activity value is MIC = 25 uM||Anti-Pseudomonas aeruginosa 4319, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa 4891, activity value is MIC = 6.25 uM||Anti-Pseudomonas aeruginosa 5018, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa 671973, activity value is MIC = 3.13 uM	Heterometrus petersii	Helix||Alpha helix	Heterometrus petersii||At a concentration of 100 ug/ml, the hemolysis rate is only approximately 10%; the 50% hemolytic concentration (HC₅₀) of Hp1404 on human red blood cells is 226.6 ug/ml.|||Mouse RBC (100% hemolysis at 200 ug/ml)|||[Ref.29379033]Hemolysis 2% at 12.5 uM against mouse red blood cell, hemolysis 11% at 25 uM against mouse red blood cell, hemolysis 55% at 50 uM against mouse red blood cell, hemolysis 92% at 100 uM against mouse red blood cell, hemolysis 100% at 200 uM against mouse red blood cell	"PLoS One
. 2014 May 14;9(5):e97539. doi: 10.1371/journal.pone.0097539. eCollection 2014.|||PLoS One. 2014 May 14;9(5):e97539. doi: 10.1371/journal.pone.0097539. PubMed|||29379033|||Sci Rep. 2018 Jan 29;8(1):1763.||Ref.29379033"	14	
FPDB01026	AP02404|||DRAMP18299	WNDTGKDADGAEY	Anti-Gram+||Anti-MRSA||Antimicrobial||Antibacterial	the marine actinomycete, Saccharomonospora sp. CNQ-490|||marine actinomycete Saccharomonospora sp. CNQ-490	N/A	the marine actinomycete, Saccharomonospora sp. CNQ-490	"Proc Natl Acad Sci U S A
. 2014 Feb 4;111(5):1957-62. doi: 10.1073/pnas.1319584111. Epub 2014 Jan 21.|||Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1957-62. PubMed|||Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1957-62."	13	
FPDB01027	AP02437|||AP02437|||Trichoplaxin|||Trichoplaxin|||AP02437|||DRAMP31839	"	
FFGRLKSVWSAVKHGWKAAKSR"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-L. ivanovii, activity value is MIC = 3 uM||Anti-E. faecalis, activity value is MIC = 12.5 uM||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 3||Anti-C. albicans ATCC 90028 and C. parapsilosis ATCC 22019, activity value is MIC = 25||Antibacterial||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 3 uM||Anti-Staphylococcus aureus ATCC BAA-44, activity value is MIC = 3 uM||Anti-Listeria ivanovii, activity value is MIC = 3 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 12.5 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 3||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 6 uM||Anti-Acinetobacter baumannii ATCC 19606, activity value is MIC = 3 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 6 uM||Anti-Candida albicans ATCC 90028, activity value is MIC = 25 uM||Anti-Candida parapsilosis ATCC 22019, activity value is MIC = 50 uM||Anti-Human breast adenocarcinoma MCF-7, activity value is IC50 = 45||Antimicrobial||Anticancer	identified in the EST database, Trichoplax adhaerens|||Trichoplax adhaerens|||identified in the EST database, Trichoplax adhaerens	Helix	identified in the EST database, Trichoplax adhaerens|||Rat erythrocytes (20% Hemolysis at 800 uM|||Rat erythrocytes (20% Hemolysis at 800 uM|||Rat erythrocytes:20% Hemolysis=800 uM	"Biochim Biophys Acta
. 2014 May;1838(5):1430-8. doi: 10.1016/j.bbamem.2014.02.003. Epub 2014 Feb 12.|||Biochim Biophys Acta. 2014 May;1838(5):1430-8. doi: 10.1016/j.bbamem.2014.02.003. PubMed|||24530880|||24530880|||Biochim Biophys Acta
. 2014 May;1838(5):1430-8. doi: 10.1016/j.bbamem.2014.02.003. Epub 2014 Feb 12.|||Biochim Biophys Acta. 2014 May;1838(5):1430-8.|||Biochim Biophys Acta. 2014 May;1838(5):1430-8. doi: 10.1016/j.bbamem.2014.02.003. PubMed"	22	
FPDB01028	AP02441|||DRAMP18337	"	
ATQSHQ"	Anti-Gram+||Anti-MRSA||Anti-M. smegmatis MTCC 6 and MRSA, activity value is MIC = 10||Antimicrobial||Antibacterial	Streptomyces amritsarensis	N/A	Streptomyces amritsarensis	"AMB Express
. 2014 Jun 28:4:50. doi: 10.1186/s13568-014-0050-y. eCollection 2014.|||AMB Express. 2014 Jun 28;4:50. doi: 10.1186/s13568-014-0050-y. PubMed|||AMB Express. 2014 Jun 28;4:50."	6	
FPDB01029	AP02447|||AP02447|||Scolopendin 2|||Scolopendin 2|||AP02447	"	
AGLQFPVGRIGRLLRK"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Gram+ E. faecium ATCC 19434, activity value is MIC = 12.5 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 25 uM||Anti-and MRSA, activity value is MIC = 12.5 uM||Anti-E. coli O157 ATCC 43895, activity value is MIC = 6.3 uM||Anti-S. typhi ATCC 19430, activity value is MIC = 12.5 uM||Anti-P. aeruginosa ATCC 27853 including three resistant strains, activity value is MIC = 6.3||Anti-and fungi C. albicans ATCC 90028, activity value is MIC = 6.3 uM||Anti-C. parapsilosis ATCC 22019, activity value is MIC = 12.5 uM||Anti-T. beigelii KCTC 7707, activity value is MIC = 6.3 uM||Anti-and T. rubrum KCTC 6345, activity value is MIC = 6.3 uM||Anti-Enterococcus faecium ATCC 19434, activity value is MIC = 12.5 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 25 uM||Anti-Staphylococcus aureus, activity value is MIC = 12.5 uM||Anti-Escherichia coli O157:H7 ATCC 43895, activity value is MIC = 6.3 uM||Anti-Salmonella typhimurium ATCC 19430, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa 1, activity value is MIC = 6.3 uM||Anti-Pseudomonas aeruginosa 2, activity value is MIC = 12.5 uM||Anti-Candida albicans ATCC 90028, activity value is MIC = 6.3 uM||Anti-Candida parapsilosis ATCC 22019, activity value is MIC = 12.5 uM||Anti-Trichosporon beigelii KCTC 7707, activity value is MIC = 6.3 uM||Anti-Trichophyton rubrum KCTC 6345, activity value is MIC = 6.3 uM	Chinese red-headed centipede Scolopendra subspinipes mutilans, Asia|||Scolopendra subspinipes mutilans|||Chinese red-headed centipede Scolopendra subspinipes mutilans, Asia	Helix	Chinese red-headed centipede Scolopendra subspinipes mutilans, Asia||Within the concentration range of 1.6 uM to 100 uM, the hemolysis rate of the Scolopendin 2-treated group is consistently 0 ± 0.2% to 0 ± 0.8%.|||Human erythrocytes (0% Hemolysis at 100 uM|||Human erythrocytes (0% Hemolysis at 100 uM|||However, scolopendin 2 and BUF(6–21)showed no hemolytic activity towards  human erythrocytes, at any concentration (Table2). These results indicate that scolopendin 2 has potential as an AMP with no hemolytic effect.	"Biochim Biophys Acta
. 2015 Feb;1848(2):634-42. doi: 10.1016/j.bbamem.2014.11.016. Epub 2014 Nov 22.|||Biochim Biophys Acta. 2015;1848(2):634-642. PubMed|||25462167|||25462167|||Biochim Biophys Acta
. 2015 Feb;1848(2):634-42. doi: 10.1016/j.bbamem.2014.11.016. Epub 2014 Nov 22.|||Biochim Biophys Acta. 2015;1848(2):634-642. PubMed"	16	
FPDB01030	AP02527|||AP02527|||Dermal antimicrobial peptide Hs-1|||Dermal antimicrobial peptide Hs-1	"	
FLPLILPSIVTALSSFLKQG"	Anti-Gram+||Anti-MRSA||Anti-Gram+ bacteria S. aureus ATCC 33591, activity value is MIC = 11.7 uM||Anti-B. cereus ATCC 14579, activity value is MIC = 23.3 uM||Anti-B. subtilis ATCC 23858, activity value is MIC = 23.3 uM||Anti-L. monocytogenes ATCC 7644, activity value is MIC = 46.6 uM||Anti-S.flexneri ATCC 12022, activity value is MIC > 187 uM||Anti-Staphylococcus aureus ATCC 33591, activity value is MIC = 11.7 uM||Anti-Bacillus cereus ATCC 14579, activity value is MIC = 23.3 uM||Anti-Bacillus subtilis ATCC 23858, activity value is MIC = 23.3 uM||Anti-Listeria monocytogenes ATCC 7644, activity value is MIC = 46.6 uM	skin, Hypsiboas semilineatus, Brazil, South America|||Hypsiboas semilineatus	N/A	"Median Lethal Concentration (LC₅₀)

- Value: 82 µM

- Description: This is the hemolytic concentration at which Hs-1 antimicrobial peptide causes 50% lysis of human red blood cells, representing the peptide concentration that can lead to 50% red blood cell rupture. This value was determined through a hemolysis assay, with 1% Triton X-100 (100% hemolysis) and physiological saline (0% hemolysis) used as controls.

2. Hemolysis within antimicrobial concentration range

- Conclusion: Within the antimicrobial activity concentration range of Hs-1 (MIC = 11.7–46.6 µM), no significant hemolysis was observed.

- Basis: When the peptide concentration is within the effective range for inhibiting the growth of Gram-positive bacteria, its destructive effect on red blood cells is weak, indicating low toxicity to host red blood cells during its antibacterial action.

3. Hemolysis of the control group (50% DMSO)

- Conclusion: In the experiment, 50% dimethyl sulfoxide (DMSO), used as a solvent, showed no cytotoxicity to human red blood cells (no hemolytic effect), eliminating the interference of the solvent itself on the results of the hemolysis assay.|||skin, Hypsiboas semilineatus, Brazil, South America|||Human erythrocytes (50% Hemolysis at 82 uM, Vero cells (50% Cell death at 31.25 ug/ml|||Human erythrocytes (50% Hemolysis at 82 uM, Vero cells (50% Cell death at 31.25 ug/ml"	"Toxicon
. 2015 Jun 1:99:16-22. doi: 10.1016/j.toxicon.2015.03.006. Epub 2015 Mar 12.|||Toxicon. 2015 Jun 1;99:16-22. PubMed|||25772860, 29153860|||25772860, 29153860"	20	
FPDB01031	AP02548|||AP02548|||DLP4|||Hill-Def 2a|||Hill-Def 2b	"	
ATCDLLSPFKVGHAACAAHCIARGKRGGWCDKRAVCNCRK"	Anti-Gram+||Anti-MRSA||Anti-12256 or CVCC 546, activity value is MIC = 3.75 uM||Anti-S. epidermidis ATCC 12228, activity value is MIC = 14.99 uM||Anti-S. pneumoniae CVCC 2350, activity value is MIC = 7.5 uM||Anti-S. suis CVCC 3928, activity value is MIC = 3.75 uM||Anti-and B. subtilis, activity value is MIC = 0.02||Anti-S.enteritidis CM, activity value is CC50 = 336||Antibacterial||Antifungal	larvae, black soldier fly,Hermetia illucens|||Hermetia illucens|||Hermetia illucens  [Black soldier fly]	N/A	larvae, black soldier fly,Hermetia illucens	"Dev Comp Immunol
. 2015 Sep;52(1):98-106. doi: 10.1016/j.dci.2015.04.018. Epub 2015 May 5.|||Dev Comp Immunol. 2015 Sep;52(1):98-106. PubMed|||28935900|||34985302"	40	
FPDB01032	AP02565|||AP02565|||Brevinin CTcu2	FLPLLAGLAANFLPKIFCKITRK	Anti-Gram+ & Gram-||Anti-MRSA||Antibacterial	skin secretions, the Indian bicoloured frog, Clinotarsus curtipes, Asia|||Clinotarsus curtipes	Helix	"In this document, the key hemolytic values of five novel antimicrobial peptides (B1CTcu1–B1CTcu5) are as follows, all measured by rabbit red blood cell hemolysis assay (10% Triton X-100 as 100% hemolysis positive control, PBS as 0% hemolysis negative control, and when peptide concentration is not explicitly indicated, the routine experimental concentration is used by default; core data are from Table 2):

1. Hemolysis rate of each peptide

- B1CTcu1: Hemolysis rate is 1%, considered non-hemolytic, shows no significant destructive effect on rabbit red blood cells, and is the only peptide among the five with no hemolytic activity.

- B1CTcu2: Hemolysis rate is 17.8%, showing low to moderate hemolytic activity.

- B1CTcu3: Hemolysis rate is 45%, showing moderate hemolytic activity.

- B1CTcu4: Hemolysis rate is 54.8%, the peptide with the highest hemolytic activity among the five, classified as highly hemolytic.

- B1CTcu5: Hemolysis rate is 37.5%, showing moderate hemolytic activity.

2. Hemolytic activity trends

- Hemolytic activity is positively correlated with peptide concentration: the document mentions, ""B1CTcu2–B1CTcu5 have already shown high hemolytic activity at a concentration of 10 μg/ml, and the hemolytic potential increases with increasing peptide concentration,"" but specific hemolysis rate values corresponding to a concentration gradient are not provided.

- Sequence differences affect hemolytic activity: for example, B1CTcu3 is a derivative of B1CTcu2 lacking the N-terminal phenylalanine, and its hemolysis rate (45%) is approximately 2.5 times that of B1CTcu2 (17.8%), indicating that N-terminal amino acid residues play an important role in regulating hemolytic activity.|||skin secretions, the Indian bicoloured frog, Clinotarsus curtipes, Asia|||Rabbit erythrocytes (18% Hemolysis at 200 ug/ml"	"Biochimie
. 2014 Feb:97:144-51. doi: 10.1016/j.biochi.2013.10.005. Epub 2013 Oct 24.|||Biochimie. 2014 Feb;97:144-51. PubMed|||24161537"	23	
FPDB01033	AP02566|||AP02566|||Brevinin CTcu3	"	
LPLLAGLAANFLPKIFCKITRK"	Anti-Gram+ & Gram-||Anti-MRSA||Antibacterial	skin secretions, the Indian bicoloured frog, Clinotarsus curtipes, Asia|||Synthetic construct	Helix	"In this document, the key hemolytic values of five novel antimicrobial peptides (B1CTcu1–B1CTcu5) are as follows, all measured by rabbit red blood cell hemolysis assay (10% Triton X-100 as 100% hemolysis positive control, PBS as 0% hemolysis negative control, and when peptide concentration is not explicitly indicated, the routine experimental concentration is used by default; core data are from Table 2):

1. Hemolysis rate of each peptide

- B1CTcu1: Hemolysis rate is 1%, considered non-hemolytic, shows no significant destructive effect on rabbit red blood cells, and is the only peptide among the five with no hemolytic activity.

- B1CTcu2: Hemolysis rate is 17.8%, showing low to moderate hemolytic activity.

- B1CTcu3: Hemolysis rate is 45%, showing moderate hemolytic activity.

- B1CTcu4: Hemolysis rate is 54.8%, the peptide with the highest hemolytic activity among the five, classified as highly hemolytic.

- B1CTcu5: Hemolysis rate is 37.5%, showing moderate hemolytic activity.

2. Hemolytic activity trends

- Hemolytic activity is positively correlated with peptide concentration: the document mentions, ""B1CTcu2–B1CTcu5 have already shown high hemolytic activity at a concentration of 10 μg/ml, and the hemolytic potential increases with increasing peptide concentration,"" but specific hemolysis rate values corresponding to a concentration gradient are not provided.

- Sequence differences affect hemolytic activity: for example, B1CTcu3 is a derivative of B1CTcu2 lacking the N-terminal phenylalanine, and its hemolysis rate (45%) is approximately 2.5 times that of B1CTcu2 (17.8%), indicating that N-terminal amino acid residues play an important role in regulating hemolytic activity.|||skin secretions, the Indian bicoloured frog, Clinotarsus curtipes, Asia|||Rabbit erythrocytes (45% Hemolysis at 200 ug/ml"	"Biochimie
. 2014 Feb:97:144-51. doi: 10.1016/j.biochi.2013.10.005. Epub 2013 Oct 24.|||Biochimie. 2014 Feb;97:144-51. PubMed|||24161537"	22	
FPDB01034	AP02567|||AP02567|||Brevinin CTcu4	"	
FLPFIAGMAAKFLPKIFCAISKK"	Anti-Gram+ & Gram-||Anti-MRSA||Antibacterial	skin secretions, the Indian bicoloured frog, Clinotarsus curtipes, Asia|||Clinotarsus curtipes	Helix	"In this document, the key hemolytic values of five novel antimicrobial peptides (B1CTcu1–B1CTcu5) are as follows, all measured by rabbit red blood cell hemolysis assay (10% Triton X-100 as 100% hemolysis positive control, PBS as 0% hemolysis negative control, and when peptide concentration is not explicitly indicated, the routine experimental concentration is used by default; core data are from Table 2):

1. Hemolysis rate of each peptide

- B1CTcu1: Hemolysis rate is 1%, considered non-hemolytic, shows no significant destructive effect on rabbit red blood cells, and is the only peptide among the five with no hemolytic activity.

- B1CTcu2: Hemolysis rate is 17.8%, showing low to moderate hemolytic activity.

- B1CTcu3: Hemolysis rate is 45%, showing moderate hemolytic activity.

- B1CTcu4: Hemolysis rate is 54.8%, the peptide with the highest hemolytic activity among the five, classified as highly hemolytic.

- B1CTcu5: Hemolysis rate is 37.5%, showing moderate hemolytic activity.

2. Hemolytic activity trends

- Hemolytic activity is positively correlated with peptide concentration: the document mentions, ""B1CTcu2–B1CTcu5 have already shown high hemolytic activity at a concentration of 10 μg/ml, and the hemolytic potential increases with increasing peptide concentration,"" but specific hemolysis rate values corresponding to a concentration gradient are not provided.

- Sequence differences affect hemolytic activity: for example, B1CTcu3 is a derivative of B1CTcu2 lacking the N-terminal phenylalanine, and its hemolysis rate (45%) is approximately 2.5 times that of B1CTcu2 (17.8%), indicating that N-terminal amino acid residues play an important role in regulating hemolytic activity.|||skin secretions, the Indian bicoloured frog, Clinotarsus curtipes, Asia|||Rabbit erythrocytes (55% Hemolysis at 200 ug/ml"	"Biochimie
. 2014 Feb:97:144-51. doi: 10.1016/j.biochi.2013.10.005. Epub 2013 Oct 24.|||Biochimie. 2014 Feb;97:144-51. PubMed|||24161537"	23	
FPDB01035	AP02579	YPLDQVEEQDEHQVAHIRVRRVTCDLLSAEAKGVKVNHAACAAHCLLKRKRGGYCNKRRICVCRN	Anti-Gram+||Anti-MRSA||Synergistic AMPs||Anti-BF7 to BF11 and S. epidermidis 9142, activity value is MIC = 16	the Model Beetle, Tribolium castaneum	Bridge	"In this document, the key values related to the hemolytic activity of Tribolium castaneum Defensin 1 are as follows:

1. Hemolytic Activity Test Results

- Test concentration range: 0.39–400 µg/ml (Defensin 1); 0.001–1% (Triton X-100, positive control)

- Core results: Defensin 1 caused no detectable hemolysis of human red blood cells (RBCs) at the highest tested concentration of 400 µg/ml (hemolysis rate 0%).

- Control validation: The positive control, Triton X-100, induced obvious hemolysis starting from a concentration of 0.008%, further confirming the effectiveness of the experimental system.

2. Experimental Conditions

- Sample handling: 2% human RBC suspension (PBS buffer, pH 7.2) was co-incubated with a series of diluted Defensin 1 samples and cultured at 37°C for 1 hour.

- Detection method: After centrifugation, hemoglobin release was assessed by measuring the absorbance at 540 nm of the supernatant and by visual observation. The experiment was repeated three times.|||the Model Beetle, Tribolium castaneum||BG-CATH37 and29BG-CATH(5-37) showed no hemolytic activity even at high concentrations (400 ug/ml)"	"PLoS One
. 2015 Jun 10;10(6):e0128576. doi: 10.1371/journal.pone.0128576. eCollection 2015.|||PLoS One. 2015 Jun 10;10(6):e0128576. PubMed||Lindhauer et al., 2019"	65	
FPDB01036	AP02630	"	
NIGLFTSTCFSSQCFSSKCFTDTCFSSNCFTGRHQCGYTHGSC"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-B. subtilis and Gram- bacteria E. coli, activity value is MIC = 1.58 uM||Anti-P. aeruginosa, activity value is MIC = 0.75 uM	a Paenibacillus sp. Strain A3	Nonhelixbeta	"In this document, the key information related to the hemolytic activity of the novel wool sulfur antibiotic Penisin is as follows:

1. Core Hemolytic Activity Results

- Conclusion: Penisin shows no hemolytic activity on rabbit red blood cells (RBCs).

- Test Basis: Even at concentrations significantly higher than its effective antibacterial concentration (the maximum test concentration was not explicitly specified in the experiment, but contextually inferred to be far above the MIC for bacteria), no hemolysis of rabbit red blood cells was observed (hemolysis rate was 0%), confirmed by absorbance measurement at 405 nm and validated with controls.

2. Experimental Conditions and Control Setup

- Sample Treatment: A 10% rabbit red blood cell suspension (PBS buffer, pH not explicitly stated, assumed physiological pH) was co-incubated with different concentrations of Penisin, then incubated at 37°C in a culture chamber with 5% CO₂ for 24 hours. After centrifugation, the supernatant was tested for hemolysis.

- Control System:
  - Positive Control: 1% Triton X-100 (induces complete hemolysis, used as a reference for 100% hemolysis calculation).
  - Negative Control: PBS buffer (no hemolytic effect, used as a reference for 0% hemolysis).

3. Supplementary Related Characteristics

The document explicitly mentions that Penisin not only exhibits no hemolytic activity but also shows no cytotoxicity to mammalian cells (such as HeLa cells, RWPE1 cells, Raw cells). At concentrations up to 40 µM, cell viability remained above 80%, further supporting its safety for eukaryotic cells.|||a Paenibacillus sp. Strain A3"	"Antimicrob Agents Chemother
. 2015 Nov 16;60(1):580-91. doi: 10.1128/AAC.01813-15. Print 2016 Jan.|||Antimicrob Agents Chemother. 2015 Nov 16;60(1):580-91. PubMed"	43	
FPDB01037	AP02656|||AP02656|||IP|||Persulcatusin	"	
GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR"	Anti-Gram+||Anti-MRSA||Anti-S. aureus MRSA, activity value is MIC = 0.25||Antibacterial	Ixodes persulcatus|||Ixodes persulcatus [Hard tick]|||Ixodes persulcatus [Tick]	Bridge	"In this document, the key values related to the hemolytic activity of the hard tick (Ixodes persulcatus) antimicrobial peptide Persulcatusin (IP) are as follows:

1. Core Hemolytic Activity Results

- Test concentration: 0–200 µg/ml (the highest tested concentration of IP)

- Hemolysis rate: At the highest concentration of 200 µg/ml, the hemolysis rate on human red blood cells was **<5%** (no significant hemolytic activity), and the results were confirmed using absorbance measurement at 405 nm.

- Conclusion: IP has almost no hemolytic activity on human red blood cells. Even at concentrations far higher than its effective antibacterial concentrations (MIC against MRSA is 0.625–2.5 µg/ml), no significant red blood cell damage was observed.

2. Experimental Conditions and Control Setup

- Sample treatment: A 2% human red blood cell suspension (prepared with sterile DPBS buffer) was incubated with serial dilutions of IP. After cultivation at 37°C for 2 hours, the supernatant was collected by centrifugation to assess hemolysis.

- Control systems:

- Negative control: DPBS buffer, hemolysis rate 0% (A_{0}).

- Positive control: 0.2% Triton X-100 solution, inducing complete hemolysis, hemolysis rate 100% (A_{100}), used for standardizing hemolysis calculation (formula: % hemolysis = [(A_{n} - A_{0}) / (A_{100} - A_{0})] × 100, where A_{n} is the sample absorbance).

3. Hemolytic Supplement of Other Tick-Derived Antimicrobial Peptides

The document mentions that, similar to IP, other tested tick-derived antimicrobial peptides (such as IR, HAE, OMBAC) also did not show significant hemolytic activity (specific values were not listed separately, but the hemolysis patterns were consistent with IP, showing no obvious red blood cell damage).|||Ixodes persulcatus"	"Parasit Vectors
. 2016 Feb 13:9:85. doi: 10.1186/s13071-016-1360-5.|||Parasit Vectors. 2016 Feb 13;9(1):85. PubMed|||26873587|||27531221"	38	
FPDB01038	AP02681|||AP02681|||OaBac5gamma	"	
RFRPPILRPPIRPPFRPPFRPPVRPPIRPPFRPPFRPPIGPFP"	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-E. coli 0157:H7, activity value is MIC = 6 ug/ml||Anti-S. aureus 1056 MRSA, activity value is MIC = 10 ug/ml||Anti-and C. albicans 3153A, activity value is MIC = 45 ug/ml||Antibacterial	Fermented milk drink Kefir.|||Ovis aries [Sheep]	N/A	Fermented milk drink Kefir.	"Comparative Study Biochem Biophys Res Commun
. 2003 Dec 26;312(4):1139-46. doi: 10.1016/j.bbrc.2003.11.045.|||Biochem Biophys Res Commun. 2003 Dec 26;312(4):1139-46. doi: 10.1016/j.bbrc.2003.11.045. PubMed|||14651991|||Biochem Biophys Res Commun
. 2003 Dec 26;312(4):1139-46. doi: 10.1016/j.bbrc.2003.11.045."	43	
FPDB01039	AP02725	"	
INTWNTTATSTSIIISETFGNKGKVCTYTVECVNNCRG"	Anti-Gram+||Anti-MRSA||Anti-L. monocytogenes LM201, activity value is MIC = 6.25 uM||Anti-B. amyloliquefaciens X1, activity value is MIC = 12.5 uM||Anti-MRSA, activity value is MIC = 25 uM||Anti-and E. faecalis ATCC 29212, activity value is MIC = 50 uM	Bacillus thuringiensis strain BGSC 4BT1, serovar rongseni	N/A	"In this document, the key information related to hemolytic activity of the novel two-component wool-derived antibiotic Thusin is as follows:

1. Core Hemolytic Activity Results

- Test concentration: >1000 µg/ml (the highest test concentration explicitly mentioned in the document)

- Hemolysis rate: At a concentration of >1000 µg/ml, Thusin showed no hemolytic activity (hemolysis rate 0%), which was confirmed by testing hemolysis of human red blood cells; no hemoglobin release or red blood cell rupture was observed.

2. Experimental Description and Supplementary Information

- Experimental background: The document notes that systematic safety testing (including hemolysis) is a key prerequisite for Thusin’s application as a drug or food additive. Currently, only preliminary hemolytic screening has been completed. Specific experimental details (such as red blood cell source, incubation conditions, control setup, etc.) were not elaborated.

- Follow-up plans: The document mentions that ""more detailed safety testing will be carried out in subsequent studies,"" but no further data on hemolytic concentration gradients (such as specific hemolysis rates at different concentrations) or half-maximal hemolysis concentration (LC₅₀) were provided.|||Bacillus thuringiensis strain BGSC 4BT1, serovar rongseni"	"Front Microbiol
. 2016 Jul 19:7:1115. doi: 10.3389/fmicb.2016.01115. eCollection 2016.|||Front Microbiol. 2016 Jul 19;7:1115. PubMed"	38	
FPDB01040	AP02735|||AP02735|||Oryctes Defensin|||DRAMP18437	"	
LTCDLLSFEAKGFAANHSLCAAHCLAIGRKGGACQNGVCVCRR"	Anti-Gram+||Anti-MRSA||Anti-Micrococcus luteus NBRC 12708, activity value is MIC = 5 ug/ml||Anti-Staphylococcus aureus NBRC 12732, activity value is MIC = 0.5 ug/ml||Active against S. aureus.	Coconut rhinoceros beetle, Oryctes rhinoceros|||Oryctes rhinoceros	Bridge	"In this document, the key information related to the defensins of the coconut rhinoceros beetle (Oryctes rhinoceros) and the synthesis of similar hemolytic peptides is as follows:

1. Core Hemolytic Activity Results

- Test subjects: Five 9-mer synthetic peptides (ALRLAIRKR-NH₂, ALLLAIRKR-NH₂, AWLLAIRKR-NH₂, ALYLAIRKR-NH₂, ALWLAIRKR-NH₂), all modified products of the defensin active fragment (Ala22-Lys30-NH₂).

- Hemolysis rate: Within the tested concentration range (the maximum concentration was not explicitly indicated, but based on context, it likely covered at least multiple times the antibacterial effective concentration), all five synthetic peptides showed no hemolysis (hemolysis rate 0%).

- Control verification: The positive control bee venom peptide (melittin) exhibited strong hemolytic activity, confirming the effectiveness of the experimental system; the negative control α-lactalbumin showed no hemolytic effect, further ruling out interference.

2. Experimental Conditions

- Sample treatment: A 0.5% (v/v) rabbit red blood cell suspension (prepared in isotonic NaCl/Pi buffer, pH 7.4) was co-incubated with different concentrations of synthetic peptides. After incubation at 25°C for 30 minutes, the samples were centrifuged, and hemoglobin release was assessed by measuring absorbance at 540 nm to evaluate the degree of hemolysis.

- Key supplementation: The document clearly notes that these synthetic peptides not only showed no hemolytic activity but, except for AWLLAIRKR-NH₂, which had some toxicity to mouse macrophages, the other four peptides exhibited no cytotoxicity to mouse fibroblasts (L929 cell line) and macrophages (JA-4 cell line), further supporting their safety for eukaryotic cells.|||Coconut rhinoceros beetle, Oryctes rhinoceros||Haemolytic activity at 48.95 uM was only 1.4% for Picturin-2 and 0% for Picturin-3 (Fig. 5). All Pictuseptins exhibited antimicrobial activity against E. coli, S. aureus and C. albicans (Table 4). PTS-1, PTS-2 and PTS-3 presented potent antimicrobial activity againstE. coli (MIC value of 6.83, 14.24 and 11.79 uM respectively), with 1.7%, 1% and 0.1% of red blood lysis respectively. PTS-1 and PTS-3 exhibited moderate MIC values of 27.32 and 23.58 uM against S. aureus, and low effect against C. albicans (54.64 and 47.17 uM). However, PTS-2 was less potent against S. aureus (57.05 uM) and C. albicans (114.1 uM). PTS-3 caused less haemolytic damage than PTS-1 and PTS-2 (Fig. 5). The MBC for E. coli, ranging from 11.79 to 228.2 uM (PTS-3 < PTS-2), S. aureus, ranging from 47.17 to 114.1 uM (PTS-3 < PTS-2) and the MIC for C. albicans, ranging from 188.68 to 228.2 uM (PTS-3 < PTS-3).|||Rabbit erythrocytes (50% Hemolysis at >100 ug/ml"	"Eur J Biochem
. 1999 Dec;266(2):616-23. doi: 10.1046/j.1432-1327.1999.00906.x.|||Eur J Biochem. 1999 Dec;266(2):616-23. PubMed|||https://pubmed.ncbi.nlm.nih.gov/14642822"	43	
FPDB01041	AP02747|||AP02747|||MrDN|||DRAMP18427	"	
DKGRRRSKFVLHRRQCAN"	Anti-Gram+||Antiparasitic||Anti-MRSA||Antibacterial||No MICs found in DRAMP database	Giant freshwater prawn, Macrobrachium rosenbergii, Crustaceans, arthropods, invertebrates, animals; based on peptide features, other methods predicted|||Macrobrachium rosenbergii [Giant freshwater prawn]|||Giant freshwater prawn, Macrobrachium rosenbergii	N/A	"In this document, the key values related to the hemolytic activity of the cationic antimicrobial peptide MrDN, derived from the giant river prawn (Macrobrachium rosenbergii) Pellino-1, are as follows, determined by a human red blood cell hemolysis assay (with 1% Triton X-100 serving as the 100% positive control and 1× PBS as the 0% negative control):

1. Core hemolytic activity results

-Test concentration range: 20 µM, 40 µM, 80 µM, 160 µM, 320 µM

-Hemolysis rate at each concentration:

-20–160 µM: No significant hemolysis was observed, and the hemolysis rate showed no statistically significant difference compared to the negative control (PBS) (the exact values are not specified in the document, but it is described as “no hemolytic effect”).

-320 µM (highest test concentration): Exhibited only mild hemolytic activity, with an absorbance value slightly higher than that of the negative control; however, the hemolysis rate did not reach a statistically significant level (the document does not provide a specific percentage, only stating that the effect was “not significant”), and it was substantially lower than the 100% hemolysis rate observed in the positive control.

2. Key Conclusions and Experimental Background

-Safety profile: The minimum inhibitory concentration (MIC) of MrDN is significantly lower than the concentration at which it induces mild hemolysis (e.g., for Bacillus cereus ATCC 2106, the MIC is 20–80 µM, whereas mild hemolysis occurs only at 320 µM), indicating that MrDN exhibits very low toxicity to human red blood cells during its antibacterial action.

-Experimental conditions: A 5% human red blood cell suspension was co-incubated with different concentrations of MrDN at 37°C for 1 hour. After centrifugation, the absorbance of the supernatant was measured at 405 nm, and the amount of hemoglobin released was calculated to assess the degree of hemolysis. The experiment was repeated three times, and the results are presented as the mean ± standard deviation.|||Giant freshwater prawn, Macrobrachium rosenbergii, Crustaceans, arthropods, invertebrates, animals; based on peptide features, other predictions"	"Mol Immunol
. 2016 Oct:78:171-182. doi: 10.1016/j.molimm.2016.09.015. Epub 2016 Sep 17.|||Mol Immunol. 2016 Oct;78:171-182. doi: 10.1016/j.molimm.2016.09.015. Epub 2016 Sep 17.|||27648859"	18	
FPDB01042	AP02767|||AP02767|||YD1	"	
APKGVQGPNG"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. typhimurium KCTC 1925, activity value is MIC = 32 ug/ml||Anti-E. coli KCTC 1923, activity value is MIC = 8 ug/ml||Anti-P. aeruginosa KCTC 1637, activity value is MIC = 16 ug/ml||Anti-M. smegmatis ATCC 9341, activity value is MIC = 8 ug/ml||Anti-S. aureus KCTC 1928, activity value is MIC = 32 ug/ml||Anti-S.aureus MRSA B15, activity value is MIC = 32 ug/ml||Anti-E. faecalis ATCC 29212, activity value is MIC = 64 ug/ml||Anti-B. subtilis ATCC 6633, activity value is MIC = 64 ug/ml||Anti-M. luteus ATCC 9341, activity value is MIC = 64 ug/ml||Anti-VRE 2, activity value is MIC = 64 ug/ml||Anti-VRE 5, activity value is MIC = 64 ug/ml	Bacillus amyloliquefaciens|||Synthetic construct	N/A	Bacillus amyloliquefaciens	"AMB Express
. 2017 Dec;7(1):8. doi: 10.1186/s13568-016-0315-8. Epub 2017 Jan 3.|||AMB Express
. 2017 Dec;7(1):8. doi: 10.1186/s13568-016-0315-8. Epub 2017 Jan 3|||28050849"	10	
FPDB01043	AP02785|||AP02785|||MoroNC-NH2|||DRAMP18396|||MoroNC-NH2|||AP02785|||DRAMP18396	FFWHHIGHALDAAKRVHGMLSG	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Antibacterial||Anti-Gram- S. sonnei, activity value is MIC = 12.5 uM||Anti-Psychrobacter sp, activity value is MIC = 5 uM||Anti-E. coli DH5alpha, activity value is MIC = 12.5 uM||Anti-S. pyogenes, activity value is MIC = 25 uM||Anti-S. aureus, activity value is MIC = 25 uM||Anti-L. monocytogenes, activity value is MIC = 12.5 uM||Anti-and yeast C. tropicalis, activity value is MIC = 5 uM||Anti-S. sonnei, activity value is MIC = 12.5 uM||Anti-C. tropicalis, activity value is MIC = 5 uM||Antimicrobial	Notothenia coriiceps	N/A	"In this document, the key values related to the hemolytic activity of moronecidin‑type antimicrobial peptides (moroNC‑NH₂ and moroPC‑NH₂) derived from two Antarctic fish species—Antarctic black rockfish (Notothenia coriiceps) and Antarctic dragonfish (Parachaenichthys charcoti)—are as follows. These values were determined using sheep and horse red blood cell hemolysis assays, with 0.1% SDS serving as the 100% positive control and PBS as the 0% negative control:

1. Hemolytic activity of each peptide (test concentration range: 0.0625–50 µM)

(1) Antarctic black rockfish peptide (moroNC-NH₂)

-At the highest test concentration (50 µM), the hemolysis rate in sheep and horse red blood cells was **&lt;10%**, which did not reach a significant level of hemolysis.

-At a concentration of 25 µM, the hemolysis rate for sheep and horse red blood cells is **&lt;1%**, indicating almost no hemolytic activity.

-Core conclusion: Within the entire range of tested concentrations, the hemolytic activity is extremely low, making it the least toxic molecule among the three peptides.

(2) Antarctic dragonfish peptide (moroPC-NH₂)

-At a concentration of 25 µM, the hemolysis rate against sheep and horse red blood cells is **&lt;10%**, indicating relatively weak hemolytic activity.

-At a concentration of 50 µM, the hemolysis rate was slightly higher than at 25 µM, but still significantly lower than that of the control peptide (hybrid striped bass moronecidin, moro-NH₂).

-Core conclusion: Hemolytic activity is lower than that of the control peptide, and no significant hemolysis is observed within the antibacterial effective concentration range (MIC = 1.25–25 µM).

(3) Control peptide (hybrid striped bass moro-NH₂)

-At a concentration of 25 µM, the hemolysis rate against sheep red blood cells is approximately 25%, while the hemolysis rate against horse red blood cells is approximately 62%. The hemolytic activity is significantly higher than that of both Antarctic fish peptides.

-Function: Serves as a positive control to verify the low hemolytic properties of Antarctic fish peptide.

2. Key experimental background and conclusions

-Experimental conditions: A 1% red blood cell suspension was incubated with serially diluted peptides at 37°C for 30 minutes. After centrifugation, the absorbance of the supernatant was measured at 405 nm, and the percentage of hemolysis was calculated. The experiment was repeated multiple times to ensure reproducibility.

-Safety profile: The minimum inhibitory concentrations (MICs) of the two Antarctic fish peptides against bacteria—e.g., moroPC-NH₂ against MRSA at 5 µM—are significantly lower than the concentrations that induce mild hemolysis (≥25 µM), indicating very low toxicity to mammalian red blood cells during their antibacterial action. In particular, moroPC-NH₂ exhibits broad-spectrum antimicrobial activity, high salt tolerance, and low hemolytic properties, suggesting potential for clinical applications.|||Notothenia coriiceps||The hemolytic activity ofAMPs was determined against sheep blood and horse blood (Oxoid Ltd., London, United Kingdom) [24]. Freshly packed sheep and horse erythrocytes (1 ml) were washed with phosphate-buffered saline (pH 7.4). AMPs were added to 0.09 ml ofa 1% erythrocyte suspension (1:10 dilution ofwashed erythrocytes) in microcentrifuge tubes. The samples were incubated for 0.5 h at 37°C, and then centrifuged for 0.166667 h at 4000 rpm at room temperature. The supernatants were transferred carefully to a 96-well plate, and the optical density was determined at 405 nm. The percentage ofhemolysis was defined relative to the hemolysis obtained by treating the erythrocyte suspension with 0.1% SDS (100% hemolysis).|||Pseudomonas aeruginosa (ATCC 15442)(MIC = >50 uM), Burkholderia cepacia (ATCC 25416)(MIC = >50 uM), E. cloacae ATCC 13047 (MIC = >50 uM), S. sonnei (ATCC 29930) (MIC = 12.5 uM), Psychrobacter sp. (PAMC 25501) (MIC = 5 uM), E. coli DH5alpha (MIC = 12.5 uM), E. faecalis (ATCC 29212) (MIC = >50 uM), S. pyogenes (ATCC 19615) (MIC = 25 uM), S. aureus (ATCC 33591)(MIC= 25 uM), L. monocytogenes (ATCC 15313) (MIC =12.5 uM), C. tropicalis (ATCC 20115) (MIC = 5 uM), Candida glabrata (ATCC 2001)(MIC =>50 uM)|||moro-NH₂ (derived from hybrid striped bass): 25 uM sheep red blood cell hemolysis rate ~25%, horse red blood cell hemolysis rate ~62%; 50 uM hemolysis rate higher than 25 uM group (specific value not specified)|||Because certain types of AMPs have the ability to dissolve mammalian red blood cells, hemolytic activity is tested as a therapeutic indicator. It is important to establish a low hemolytic activity for clinical use [2]. To explore the potential use of Antarctic fish AMPs in clinical settings, we evaluated their hemolytic effects using sheep and horse red blood cells (Figure 4). Each AMP was tested at 12 concentrations, with Moro-NH2 used as a control. The hemolysis rates caused by both AMPs from Antarctic fish were lower than that of Moro-NH2. At the highest concentration tested (50 μM), the hemolytic activity of MoroNC-NH_2 was less than 10%. At 25 μM, the hemolytic activity of both Antarctic fish AMPs was below 10%. In contrast, Moro-NH2 lysed 25% and 62% of sheep and horse red blood cells, respectively. At 25 μM, the hemolytic activity of MoroNC-NH_2 on both sheep and horse red blood cells was below 1%."	"PLoS One
. 2017 Jan 25;12(1):e0170821. doi: 10.1371/journal.pone.0170821. eCollection 2017.|||PLoS One
. 2017 Jan 25;12(1):e0170821. doi: 10.1371/journal.pone.0170821. eCollection 2017.|||28122029|||PLoS One. 2017 Jan 25;12(1):e0170821.|||28122029|||PLoS One
. 2017 Jan 25;12(1):e0170821. doi: 10.1371/journal.pone.0170821. eCollection 2017.|||PLoS One. 2017 Jan 25;12(1):e0170821."	22	
FPDB01044	AP02786|||AP02786|||MoroNC-NH2|||DRAMP13895|||DRAMP18395|||MoroPC-NH2|||AP02786|||DRAMP18395	"	
FFGHLFRGIINVGKHIHGLLSG"	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Antibacterial||Anti-Gram- E. cloacae ATCC 13047, activity value is MIC = 25 uM||Anti-S. sonnei, activity value is MIC = 5 uM||Anti-Psychrobacter sp, activity value is MIC = 2.5 uM||Anti-E. coli DH5alpha, activity value is MIC = 5 uM||Anti-E. faecalis, activity value is MIC = 25 uM||Anti-S. pyogenes, activity value is MIC = 2.5 uM||Anti-L. monocytogenes, activity value is MIC = 5 uM||Anti-and yeast C. tropicalis, activity value is MIC = 5 uM||Anti-E. cloacae ATCC 13047, activity value is MIC = 25 uM||Anti-S. aureus, activity value is MIC = 5 uM||Anti-C. tropicalis, activity value is MIC = 5 uM	Parachaenichthys charcoti	N/A	"In this document, the key values related to the hemolytic activity of moronecidin‑type antimicrobial peptides (moroNC‑NH₂ and moroPC‑NH₂) derived from two Antarctic fish species—Antarctic black rockfish (Notothenia coriiceps) and Antarctic dragonfish (Parachaenichthys charcoti)—are as follows. These values were determined using sheep and horse red blood cell hemolysis assays, with 0.1% SDS serving as the 100% positive control and PBS as the 0% negative control:

1. Hemolytic activity of each peptide (test concentration range: 0.0625–50 µM)

(1) Antarctic black rockfish peptide (moroNC-NH₂)

-At the highest test concentration (50 µM), the hemolysis rate in sheep and horse red blood cells was **&lt;10%**, which did not reach a significant level of hemolysis.

-At a concentration of 25 µM, the hemolysis rate for sheep and horse red blood cells is **&lt;1%**, indicating almost no hemolytic activity.

-Core conclusion: Within the entire range of tested concentrations, the hemolytic activity is extremely low, making it the least toxic molecule among the three peptides.

(2) Antarctic dragonfish peptide (moroPC-NH₂)

-At a concentration of 25 µM, the hemolysis rate against sheep and horse red blood cells is **&lt;10%**, indicating relatively weak hemolytic activity.

-At a concentration of 50 µM, the hemolysis rate was slightly higher than at 25 µM, but still significantly lower than that of the control peptide (hybrid striped bass moronecidin, moro-NH₂).

-Core conclusion: Hemolytic activity is lower than that of the control peptide, and no significant hemolysis is observed within the antibacterial effective concentration range (MIC = 1.25–25 µM).

(3) Control peptide (hybrid striped bass moro-NH₂)

-At a concentration of 25 µM, the hemolysis rate against sheep red blood cells is approximately 25%, while the hemolysis rate against horse red blood cells is approximately 62%. The hemolytic activity is significantly higher than that of both Antarctic fish peptides.

-Function: Serves as a positive control to verify the low hemolytic properties of Antarctic fish peptide.

2. Key experimental background and conclusions

-Experimental conditions: A 1% red blood cell suspension was incubated with serially diluted peptides at 37°C for 30 minutes. After centrifugation, the absorbance of the supernatant was measured at 405 nm, and the percentage of hemolysis was calculated. The experiment was repeated multiple times to ensure reproducibility.

-Safety profile: The minimum inhibitory concentrations (MICs) of the two Antarctic fish peptides against bacteria—e.g., moroPC-NH₂ against MRSA at 5 µM—are significantly lower than the concentrations that induce mild hemolysis (≥25 µM), indicating very low toxicity to mammalian red blood cells during their antibacterial action. In particular, moroPC-NH₂ exhibits broad-spectrum antimicrobial activity, high salt tolerance, and low hemolytic properties, suggesting potential for clinical applications.|||Parachaenichthys charcoti||The hemolytic activity ofAMPs was determined against sheep blood and horse blood (Oxoid Ltd., London, United Kingdom) [24]. Freshly packed sheep and horse erythrocytes (1 ml) were washed with phosphate-buffered saline (pH 7.4). AMPs were added to 0.09 ml ofa 1% erythrocyte suspension (1:10 dilution ofwashed erythrocytes) in microcentrifuge tubes. The samples were incubated for 0.5 h at 37°C, and then centrifuged for 0.166667 h at 4000 rpm at room temperature. The supernatants were transferred carefully to a 96-well plate, and the optical density was determined at 405 nm. The percentage ofhemolysis was defined relative to the hemolysis obtained by treating the erythrocyte suspension with 0.1% SDS (101% hemolysis).|||Pseudomonas aeruginosa (ATCC 15442)(MIC = >50 uM), Burkholderia cepacia (ATCC 25416)(MIC = >50 uM), E. cloacae ATCC 13047 (MIC = 25 uM), S. sonnei (ATCC 29930) (MIC = 5 uM), Psychrobacter sp. (PAMC 25501) (MIC = 2.5 uM), E. coli DH5alpha (MIC = 5 uM), E. faecalis (ATCC 29212) (MIC = 25 uM), S. pyogenes (ATCC 19615) (MIC = 2.5 uM), S. aureus (ATCC 33591)(MIC= 5 uM), L. monocytogenes (ATCC 15313) (MIC =5 uM), C. tropicalis (ATCC 20115) (MIC = 5 uM), Candida glabrata (ATCC 2001)(MIC =>50 uM)|||Because certain types of AMPs have the ability to dissolve mammalian red blood cells, hemolytic activity is tested as a therapeutic indicator. It is important to establish a low hemolytic activity for clinical use [2]. To explore the potential use of Antarctic fish AMPs in clinical settings, we evaluated their hemolytic effects using sheep and horse red blood cells (Figure 4). Each AMP was tested at 12 concentrations, with Moro-NH2 used as a control. The hemolysis rates caused by both AMPs from Antarctic fish were lower than that of Moro-NH2. At the highest concentration tested (50 μM), the hemolytic activity of MoroNC-NH_2 was less than 10%. At 25 μM, the hemolytic activity of both Antarctic fish AMPs was below 10%. In contrast, Moro-NH2 lysed 25% and 62% of sheep and horse red blood cells, respectively. At 25 μM, the hemolytic activity of MoroNC-NH_2 on both sheep and horse red blood cells was below 1%."	"PLoS One
. 2017 Jan 25;12(1):e0170821. doi: 10.1371/journal.pone.0170821. eCollection 2017.|||PLoS One
. 2017 Jan 25;12(1):e0170821. doi: 10.1371/journal.pone.0170821. eCollection 2017.|||28122029|||28122029|||PLoS One
. 2017 Jan 25;12(1):e0170821. doi: 10.1371/journal.pone.0170821. eCollection 2017.|||Active against Gram- E. cloacae ATCC 13047 (MIC 25 uM), S. sonnei (ATCC 29930) (MIC 5 uM), Psychrobacter sp. (PAMC 25501) (MIC 2.5 uM), E. coli DH5alpha (MIC 5 uM), Gram+ E. faecalis (ATCC 29212) (MIC 25 uM), S. pyogenes (ATCC 19615) (MIC 2.5 uM), S. aureus (ATCC 33591), L. monocytogenes (ATCC 15313) (MIC 5 uM), and yeast C. tropicalis (ATCC 20115) (MIC 5 uM)."	22	
FPDB01045	AP02802|||AP02802|||BacSp222|||Suc-K20-BacSp222|||Suc-K11/K20-BacSp222|||DRAMP18356	"	
MAGLLRFLLSKGRALYNWAKSHVGKVWEWLKSGATYEQIKEWIENALGWR"	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Anti-B. subtilis ATCC 6633, activity value is MIC = 0.16 uM||Anti-L. lactis subsp. lactis LOCK 0871 strain 239, activity value is MIC = 0.89 uM||Anti-M. luteus ATCC 4698, activity value is MIC = 0.11 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 0.89||Anti-S. epidermidis ATCC 35547, activity value is MIC = 4.4 uM||Anti-S. intermedius R-2725, activity value is MIC = 1.2||Anti-S. pseudintermedius LMG 22219, activity value is MIC = 2.1||Anti-S. saprophyticus ATCC 15305, activity value is MIC = 0.93 uM||Anti-S. pyogenes PCM 465, activity value is MIC = 7.8 uM||Anti-S. sanguinis PCM 2335, activity value is MIC = 3.5 uM||Anti-and C. albicans ATCC 10231, activity value is MIC = 100 uM||Anti-K.pneumoniae ATCC 13886, activity value is MIC > 100 uM||Anti-S.marcescens ATCC 274, activity value is MIC > 100 uM||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 0.16||Anti-Lactococcus lactis subsp. lactis ?OCK 0871 strain 239, activity value is MIC = 0.89||Anti-Micrococcus luteus ATCC 4698, activity value is MIC = 0.11||Anti-Staphylococcus aureus DSM 26258, activity value is MIC = 0.92||Anti-Staphylococcus aureus MRSA USA300 strain FPR3757, activity value is MIC = 0.89||Anti-Staphylococcus aureus KB/8658, activity value is MIC = 1.3||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 1||Anti-Staphylococcus epidermidis ATCC 35547, activity value is MIC = 4.4||Anti-Staphylococcus intermedius ATCC 29663, activity value is MIC = 2||Anti-Staphylococcus intermedius R-2725, activity value is MIC = 1.2||Anti-Staphylococcus pseudintermedius 222, activity value is MIC = 2.1||Anti-Staphylococcus pseudintermedius LMG 22219, activity value is MIC = 0.16||Anti-Staphylococcus saprophyticus ATCC 15305, activity value is MIC = 0.93||Anti-Streptococcus pyogenes PCM 465, activity value is MIC = 7.8||Anti-Streptococcus sanguinis PCM 2335, activity value is MIC = 3.5||Anti-Candida albicans ATCC 10231, activity value is MIC = 100||Antibacterial ; Bacillus subtilis ATCC 6633||Lactococcus lactis LOCK 0871 strain 239||Micrococcus luteus ATCC 4698||Staphylococcus aureus ATCC 25923||Staphylococcus epidermidis ATCC 35547||Staphylococcus intermedius ATCC 29663||Staphylococcus pseudintermedius 22221||Antibacterial||Mammalian cells||Antimicrobial	isolated from dog skin lesions, Staphylococcus pseudintermedius strain 222|||Staphylococcus pseudintermedius [Bacteria]|||Synthetic construct|||isolated from dog skin lesions, Staphylococcus pseudintermedius strain 222	Helix	"In this document, the key numerical values related to the hemolytic activity of the BacSp222 peptide secreted by Staphylococcus pseudintermedius are as follows:

- Test concentration 100 µM: This concentration is much higher than the minimum inhibitory concentration (MIC, 0.11–7.8 µM) of BacSp222 against Gram-positive bacteria, and the hemolysis rate of human red blood cells at this concentration is 40%, showing a certain degree of hemolytic activity.

- Test concentration 12.5 µM (approximately 10 times the MIC for Staphylococcus aureus): This concentration is close to the level at which the bacteria produce BacSp222 in vitro. The hemolysis rate of human red blood cells is only 1.82 ± 0.28%, indicating low hemolytic activity. At this concentration, although the hemolysis rate is low, the possibility of increased hemolysis risk due to elevated BacSp222 concentration at local infection sites cannot be excluded.

Through hemolysis experiments on human red blood cells, it was found that BacSp222 can cause a higher proportion of red blood cell lysis at high concentrations, but at concentrations close to those produced by the bacteria in vitro, the hemolysis rate remains low. However, the actual concentration and hemolysis risk at infection sites in the body still need to be further studied.|||isolated from dog skin lesions, Staphylococcus pseudintermedius strain 222||Human skin fibroblasts (HSF, ATCC CRL-2522), adipose-derived stem cells (ASCs, ATCC PCS-500-011), and HeLa human epithelioid cervix carcinoma cells (ATCC CCL-2) were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Sigma) containing 1000000 ug/l glucose, 10% (v/v) foetal bovine serum (FBS), 1 U/ml penicillin, 1 μ g/ml streptomycin, and 2.5 μ g/ml amphotericin B. Murine P388/D1 monocyte/macrophage cells (ATCC CCL-46) and murine RAW264.7 macrophage-like cells (ATCC TIB-71) were cultured in DMEM containing 4500000 ug/l glucose, 5% (v/v) FBS, and antibiotics, as indicated above. Keratinocytes from human skin were grown in KBM Gold Medium (Lonza). All cells were incubated in standard conditions (5% CO2, 37 °C, > 95% humidity). For the viability and cytotoxicity tests, the cells were transferred into a 96-well plate at a density of 2 × 105 cells per well. After 24 h, the medium was replaced with 50 μ l of fresh medium containing 5% (v/v) FBS (HSF, ASC, HeLa, and RAW cells) or of KBM Gold medium (keratinocytes), all with BacSp222 at different concentrations. Before use, the peptide solution was tested for lipopolysaccharide (LPS) contamination using an E-TOXATE assay kit (Sigma). The cells were then exposed to BacSp222 for 4 h and then subjected to the lactate dehydrogenase (LDH) and the tetrazolium salt reduction (MTT) assays. LDH release was performed according to the protocol provided by the manufacturer (CytoTox 96 kit, Promega, USA). Briefly, 30 μ l of cultured media was transferred into a microplate and mixed with 30 μ l of an INT substrate. After a 30-min incubation (RT, in the dark), the reaction was stopped, and the absorbance was measured with a microplate reader (PowerWave X, BioTek Instruments) at 490 nm, followed by subtraction of the absorbance reference value at 690 nm. The obtained results were normalized to the value of the total cellular LDH activity (positive control: cells lysed with 1% (v/v) Triton X-100, reflecting maximal LDH release from the cells). For the MTT assay, the cells were incubated with 55 μ l of fresh DMEM containing MTT (500 ug/ml) for 3 h at 37 °C, and then the media was replaced with 100 μ l acidified isopropanol to dissolve the water-insoluble formazan crystals produced in living cells with maintained reductive potential. The absorbance of solubilized purple formazan was measured at 540 nm, followed by subtraction of the absorbance reference value at 690 nm. The obtained results were normalized to the value of the control without BacSp222. To track cell membrane integrity, HSF (2 × 104 cells per well) were incubated in DMEM without phenol red containing 10% (v/v) FBS, 0.5, 15 μ M BacSp222, 0.001 ug/ml propidium iodide (PI, Sigma) and 0.01 ug/ml fluorescein diacetate (FDA, Sigma). The cells were observed using an Eclipse Ti (Nikon) microscope at 488/515–550 nm (FDA) or 540/605–660 nm (PI) excitation/emission wavelengths, respectively. To evaluate haemolytic activity, a suspension of 3% (v/v) human erythrocytes in PBS was incubated for 1 h with various amounts of BacSp222. The amount of released haemoglobin was spectrophotometrically determined at 540 nm and compared with a positive control (erythrocytes lysed with 1% sodium dodecyl sulphate).|||Human red blood cells ( 40% hemolysis at 100 uM)"	"Sci Rep
. 2015 Sep 28:5:14569. doi: 10.1038/srep14569.|||Sci Rep
. 2015 Sep 28:5:14569. doi: 10.1038/srep14569.|||26411997|||34200765|||Sci Rep. 2015 Sep 28;5:14569|||Sci Rep. 2015 Sep 28;5:14569.PubMed"	50	
FPDB01046	AP02811|||AP02811|||Histone H2A|||DRAMP018380|||DRAMP18380|||AP02811	"	
SGRGKTGGKARAKAKTRSSRAGLQFPVGRVHRLLRKGNYAQRVGAGAPVY"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli ML35p, activity value is MIC = 0.7 uM||Anti-L. monocytogenes EGD, activity value is MIC = 1.1 uM||Anti-MRSA ATCC 33591, activity value is MIC = 0.9 uM||Anti-and C. albicans 820, activity value is MIC = 1 uM||Anti-E.coli ML35p, activity value is MIC = 0.7||Anti-L.monocytogenes EGD, activity value is MIC = 1.1||Anti-Methicillin resistant Staphylococcus aureus ATCC 33591, activity value is MIC = 0.9||Anti-C.albicans 820, activity value is MIC = 1||Anti-E. coli ML35p, activity value is MIC = 0.3 uM||Anti-L. monocytogenes EGD, activity value is MIC = 1 uM||Anti-MRSA ATCC 33591, activity value is MIC = 0.6 uM||Anti-C. albicans 820, activity value is MIC = 0.9 uM||Anti-C. albicans 820, activity value is MIC = 1 uM	Leukocytes; the Russian Sturgeon, Acipenser gueldenstaedtii|||Acipenser gueldenstaedtii [Russian sturgeon]|||Leukocytes; the Russian Sturgeon, Acipenser gueldenstaedtii	N/A	Leukocytes; the Russian Sturgeon, Acipenser gueldenstaedtii|||We investigated the hemo lytic activity of acipensins 1, 2, and 6 against human erythrocytes. erythrocyte hemolysis was found not to be observed for the studied peptides at concentrations of 1–40 uM (Fig. 3)	"Acta Naturae
. 2014 Oct;6(4):99-109.|||Acta Naturae
. 2014 Oct;6(4):99-109.|||25558400|||Acta Naturae. 2014 Oct;6(4):99-109|||25558400|||Acta Naturae
. 2014 Oct;6(4):99-109.|||Acta Naturae. 2014 Oct;6(4):99-109. PubMed"	50	
FPDB01047	AP02812|||AP02812|||Histone H2A|||DRAMP018379|||DRAMP18379|||Histone H2A|||AP02812	"	
SGRGKTGGKARAKAKTRSSRAGLQFPVGRVHRLLR"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli ML35p, activity value is MIC = 0.3 uM||Anti-L. monocytogenes EGD, activity value is MIC = 1 uM||Anti-MRSA ATCC 33591, activity value is MIC = 0.6 uM||Anti-and C. albicans 820, activity value is MIC = 0.9 uM||Antibacterial||Anti-C. albicans 820, activity value is MIC = 0.9 uM||Anti-E.coli ML35p, activity value is MIC = 0.3||Anti-L.monocytogenes EGD, activity value is MIC = 1.0||Anti-Methicillin resistant Staphylococcus aureus ATCC 33591, activity value is MIC = 0.6||Anti-C.albicans 820, activity value is MIC = 0.9	Leukocytes; the Russian Sturgeon, Acipenser gueldenstaedtii|||Acipenser gueldenstaedtii [Russian sturgeon]|||Leukocytes; the Russian Sturgeon, Acipenser gueldenstaedtii|||Acipenser gueldenstaedtii [Russian sturgeon]|||Leukocytes; the Russian Sturgeon, Acipenser gueldenstaedtii	N/A	Leukocytes; the Russian Sturgeon, Acipenser gueldenstaedtii|||We investigated the hemo lytic activity of acipensins 1, 2, and 6 against human erythrocytes. erythrocyte hemolysis was found not to be observed for the studied peptides at concentrations of 1–40 uM (Fig. 3)	"Acta Naturae
. 2014 Oct;6(4):99-109.|||Acta Naturae
. 2014 Oct;6(4):99-109.|||25558400|||Acta Naturae. 2014 Oct;6(4):99-109|||25558400|||Acta Naturae
. 2014 Oct;6(4):99-109.|||Acta Naturae. 2014 Oct;6(4):99-109. PubMed"	35	
FPDB01048	AP02816|||DRAMP00257|||DRAMP18355	"	
MAAFMKLIQFLATKGQKYVSLAWKHKGTILKWINAGQSFEWIYKQIKKLWA"	Anti-Gram+||Anti-MRSA||Anti-S. saprophyticus, activity value is MIC = 0.0823||Anti-S. hominis, activity value is MIC = 0.16 uM||Anti-S. warneri, activity value is MIC = 0.16 uM||Anti-E. faecalis, activity value is MIC = 0.16 uM||Anti-including multidrug-resistant S. epidermidis strains causing biofilm-related infections, activity value is MIC = 0.01||Anti-S. aureus 1195 MRSA, activity value is MIC = 0.16||Anti-and vancomycin-resistant enterococci anti-VRE, activity value is MIC = 0.0823||Antimicrobial||Antibacterial	Staphylococcus epidermidis 224|||Brochothrix campestris	Helix	"In this document, the key conclusions regarding the hemolytic activity of Epidermicin NI01, a novel unmodified bacteriocin produced by Staphylococcus epidermidis, are as follows: Hemolysis was determined using a human red blood cell assay, with PBS serving as the 0% hemolysis negative control and 1% Triton X-100 as the 100% hemolysis positive control.

Core hemolytic activity results

-Test concentration range: from sub-MIC (sub-minimum inhibitory concentration) to 100×MIC (100 times the minimum inhibitory concentration).

-Hemolysis rate: Within the entire tested concentration range, including the highest concentration of 100×MIC, Epidermicin NI01 did not induce hemolysis in human red blood cells (hemolysis rate of 0%), and no hemoglobin release was observed (no specific absorbance values are provided in the document, but it is explicitly stated that there was “no hemolytic effect”).

Experimental Background and Supplementary Notes

-Experimental conditions: Human red blood cell suspensions were incubated with different concentrations of Epidermicin NI01, followed by centrifugation to collect the supernatant. The degree of hemolysis was assessed by measuring absorbance at 560 nm. The experiment was repeated three times, and consistent results were obtained.

-Safety profile: Epidermicin NI01 exhibits MIC values in the nanomolar range (0.01028–0.658 µM) against Gram-positive bacteria, including MRSA and VRE; moreover, it remains non-hemolytic at 100× the MIC concentration and shows no cytotoxicity toward human dermal fibroblasts, indicating a high level of safety for eukaryotic cells and suggesting its potential for clinical application.

-Comparative analysis: The document mentions that bacteriocins homologous to Epidermicin NI01 (such as lacticin Q and lacticin Z produced by Lactococcus, and aureocin A53 produced by Staphylococcus aureus) also exhibit no hemolytic activity, further supporting the low hemolytic potential of this class of bacteriocins.|||Staphylococcus epidermidis 224||. Estimation of the degree of hemolysis caused by epidermicin was conducted as previously described (11). Red blood cells (RBC) were treated with phosphate-buffered saline (PBS) and 1% Triton X-100 as indicators of 0 and 100% hemolysis, respectively. Following treatment, plates were centrifuged at 1,000 ⫻ g for 0.166667 h, aliquots ofthe supernatant were diluted two times with PBS, and absorbance was measured at 560 nm. Assays were carried out in triplicate. The toxicity of epidermicin against human fibroblast cell lines was determined at concentrations ranging from sub-MIC to 100⫻MIC using MTT [3-(4,5-dimethylthiazol-2-yl)2 2,5-diphenyl tetrazolium bromide] reduction and neutral red uptake assays."	"Antimicrob Agents Chemother
. 2012 Mar;56(3):1539-47. doi: 10.1128/AAC.05397-11. Epub 2011 Dec 12.|||Appl Environ Microbiol. 1998 Dec;64(12):4757-4766.|||Biosci Biotechnol Biochem. 2007 Aug;71(8):1984-92."	51	
FPDB01049	AP02856|||AP02856|||I7R	"	
WWWLRRRW"	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Antibiofilm||Anti-E. faecium V286-17, activity value is MIC = 2 uM||Anti-S. aureus USA300 LAC MRSA and 30 clinical strains, activity value is MIC = 2||Anti-K-pneumoniae E406-17, activity value is MIC > 32 uM||Anti-A. baumannii B28-16, activity value is MIC = 32 uM||Anti-P-aeruginosa E411-17, activity value is MIC > 32 uM||Anti-and E. coli E423-17, activity value is MIC = 16||Anti-inlcuding 32 S. aureus clinical strains, activity value is MIC = 50||Anti-S. aureus, activity value is MIC = 3.1 uM||Anti-E. coli, activity value is MIC = 6.2 uM||Anti-33804947: : S. aureus�G16�, activity value is MIC = 8 ug/ml||Anti-MRSA T144, activity value is MIC = 8 ug/ml||Anti-E. coli B2, activity value is MIC = 64 ug/ml||Anti-E. coli C3, activity value is MIC = 64 ug/ml||Anti-E. coli G6, activity value is MIC = 64 ug/ml||Anti-E. coli G92, activity value is MIC = 64 ug/ml||Anti-E. coli CP131, activity value is MIC = 32 ug/ml||Anti-E. coli 1F28, activity value is MIC = 32 ug/ml||Anti-A. baumannii C222, activity value is MIC = 64 ug/ml||Anti-P. cibarius HNCF44W, activity value is MIC = 64 ug/ml	computer designed based on database, de novo designed	Rich	"In this document, the key values related to the hemolytic activity of two amphipathic antimicrobial peptides, Horine and Verine, are as follows, determined by human red blood cell (hRBC) hemolysis assays (PBS as 0% hemolysis negative control, 1% Triton X-100 as 100% hemolysis positive control):

Core Hemolytic Activity Results

- Test subject: 2% human red blood cell suspension

- Key hemolysis indicators (50% hemolysis concentration, HL₅₀):

- Horine: HL₅₀ >200 μM against human red blood cells, showing no significant hemolytic activity across the full concentration range tested.

- Verine: HL₅₀ >200 μM against human red blood cells, also showing no significant hemolytic activity across the full concentration range tested.

- Additional note: The antibacterial effective concentrations (MIC) of both peptides are 2–16 μM (against MRSA, VRE, Klebsiella pneumoniae, and other resistant bacteria), far below their hemolytic concentrations (>200 μM), indicating minimal toxicity to human red blood cells while exerting antibacterial effects.

Experimental Background and Related Properties

- Experimental conditions: Series of diluted peptides were co-incubated with 2% human red blood cell suspension, and hemoglobin release was measured. Hemolysis rates were calculated based on absorbance, with multiple repetitions to ensure reproducibility.

- Safety verification: Beyond hemolytic activity, both peptides show very low toxicity to human liver cells (HepaRG), kidney cells (HEK293), lung fibroblasts (MRC9), and mouse splenocytes (LD₅₀ all >12.5 μM). Additionally, in vivo experiments in mice and rats showed no nephrotoxicity, further supporting their clinical application potential.|||computer designed based on database, man-made sequences||We also improved
WW295 by changing the terminal L8 to V8, which doubled the
50% hemolytic concentration (HL50) (WW307 in SI Appendix,
Table S4).|||Human RBC (HL50 = 150 uM)|||The document only explicitly provides core hemolytic data of two antimicrobial peptides (horine and verine) against human red blood cells (hRBCs), with specific information as follows:

- Test indicators: Using a “2% human red blood cell suspension” as the experimental subject, hemolytic activity was assessed by detecting hemoglobin release. The core results are presented in terms of ""50% hemolytic concentration (HL₅₀)"" standards (the exact HL₅₀ value is not directly given, but the hemolytic activity threshold is clearly indicated).
  horine: Within the tested concentration range, the hemolytic activity against 2% human red blood cells was extremely low, HL₅₀ > 200 µM, meaning that at concentrations below 200 µM, the hemolysis rate did not reach 50% and cytotoxicity to red blood cells was very weak.
  verine: Similar to horine, its hemolytic activity against 2% human red blood cells was also extremely low, HL₅₀ > 200 µM, and at conventional antimicrobial concentrations (2-16 µM, see Table 1 for MIC values), it exhibited almost no hemolysis.

Supplementary notes:

1. Experimental relevance: The antimicrobial effective concentrations of both peptides (MIC 2-32 µM, Table 1) are far below their hemolytic activity threshold (>200 µM), indicating high safety for human red blood cells during antimicrobial action, with no significant hemolytic toxicity.
2. Other cytotoxicity references: The study also tested the toxicity of the two peptides on human hepatocytes (HepaRG), kidney cells (HEK293), lung fibroblasts (MRC9), and mouse splenocytes. The results showed that their LD₅₀ against these eukaryotic cells was significantly higher than the antimicrobial MIC (e.g., LD₅₀ for human kidney cells > 80 µM), further supporting their low toxicity to host cells and showing no nephrotoxicity."	"Proc Natl Acad Sci U S A
. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A
. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||28731688, 33804947|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28. PubMed"	8	
FPDB01050	AP02863|||AP02863|||K11	"	
KWKSFIKKLTKKFLHSAKKF"	Anti-Gram+ & Gram-||Anti-MRSA||Wound healing||Anti-Staphylococcus aureus CMCC26003, activity value is MIC = 0.5 ug/ml||Anti-Bacillus subtilis DB430, activity value is MIC = 2 ug/ml||Anti-Bacillus pumilus CMCC63202, activity value is MIC = 0.5 ug/ml||Anti-Soluble wall Micrococcus S1.634, activity value is MIC = 1 ug/ml||Anti-Micrococcus luteus CMCC28001, activity value is MIC = 2 ug/ml||Anti-E. coli ATCC8099, activity value is MIC = 0.5 ug/ml||Anti-Klebsiella pneumoniae CMCC46117, activity value is MIC = 2 ug/ml||Anti-Salmonella paratyphi B CM, activity value is CC50 = 094||Anti-Pseudomonas aeruginosa CMCC10104, activity value is MIC = 4 ug/ml||Anti-Acinetobacter baumannii b-01, activity value is MIC = 0.8 ug/ml||Anti-Acinetobacter baumannii b-02, activity value is MIC = 3.125 ug/ml||Anti-Acinetobacter baumannii b-03, activity value is MIC = 3.25 ug/ml||Anti-Acinetobacter baumannii b-04, activity value is MIC = 1.6 ug/ml	hybrid peptide, combined melittin, cecropin A1 and magainin 2 fragments, designed, man-made sequences|||Synthetic construct	Helix	"In the paper ""The Design and Construction of K11: A Novel α‑Helical Antimicrobial Peptide,"" the minimum hemolytic concentration (MHC) of the K11 peptide is greater than 500 µg/ml. This means that at concentrations not exceeding 500 µg/ml, K11 does not cause detectable hemoglobin release (hemolysis) in human red blood cells.|||hybrid peptide, combined melittin, cecropin A1 and magainin 2 fragments, designed, man-made sequences"	"Int J Microbiol
. 2012:2012:764834. doi: 10.1155/2012/764834. Epub 2012 Feb 16.|||Int J Microbiol
. 2012:2012:764834.doi: 10.1155/2012/764834.Epub 2012 Feb 16.|||22518150"	20	
FPDB01051	AP02864|||AP02864|||Hydrid peptide H4|||DRAMP20868	"	
KFKKLFKKLSPVIGKEFKRIVERIKRFLR"	Anti-Gram+ & Gram-||Anti-MRSA||Antibiofilm||Anti-S. aureus ATCC 29213, activity value is MIC = 20 uM||Anti-E. faecalis ATCC 19433, activity value is MIC = 15 uM||Anti-S. epidermidis ATCC 12228, activity value is MIC = 10 uM||Anti-MRSA, activity value is MIC = 5||Anti-E. faecium VRE, activity value is MIC = 5 uM||Anti-and Gram- E. coli ATCC 25922, activity value is MIC = 10 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 20 uM||Anti-A. baumannii ATCC 19606, activity value is MIC = 10 uM||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 2.5 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 20 uM||Anti-Enterococcus faecalis ATCC 19433, activity value is MIC = 15 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 10 uM||Anti-S.aureus ATCC 33591, activity value is MIC = 10 uM||Anti-S.aureus ATCC 43300, activity value is MIC = 10 uM||Anti-S.aureus BAA41, activity value is MIC = 10 uM||Anti-E.faecalis ATCC BAA2365, activity value is MIC = 5 uM||Anti-Enterococcus faecium BAA2316, activity value is MIC = 5 uM||Anti-E.coli ATCC 25922, activity value is MIC = 10 uM||Anti-P.aeruginosa ATCC 27853, activity value is MIC = 20 uM||Anti-Acinetobacter baumannii ATCC 19606, activity value is MIC = 10 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 2.5 uM||Anti-P.aeruginosa ATCC BAA2114, activity value is MIC = 25 uM||Anti-E.coli ATCC BAA2452, activity value is MIC = 10 uM||Anti-P.aeruginosa BAA2114, activity value is MIC = 25 uM||Anti-Staphylococcus aureus ATCC 33591, activity value is MIC = 10 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 10 uM||Anti-Staphylococcus aureus ATCC BAA41, activity value is MIC = 10 uM||Anti-Enterococcus faecalis ATCC BAA2365, activity value is MIC = 5 uM||Anti-Enterococcus faecium ATCC BAA2316, activity value is MIC = 5 uM||Anti-##Gram-negative bacteria: Escherichia coli ATCC 25922, activity value is MIC = 10 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 20 uM||Anti-Pseudomonas aeruginosa ATCC BAA2114, activity value is MIC = 25 uM||Anti-Escherichia coli ATCC BAA2452, activity value is MIC = 10 uM	peptide motif combination, hybrid peptide, designed, man-made sequences|||Synthetic construct	Alpha helix	"In this document, the key information related to the hemolytic activity of the novel hybrid antimicrobial peptide H4 (derived from the α-helical fragments of BMAP-27 and OP-145) is as follows, measured using a human red blood cell hemolysis assay (0.9% NaCl as 0% hemolysis negative control, 0.1% Triton X-100 as 100% hemolysis positive control):

1. Core Hemolytic Activity Results

- Test concentration range: 5–100 μM

- Hemolysis rate at each concentration:

- 5–85 μM: In this concentration range, H4 exhibited 0% hemolysis of human red blood cells with no detectable hemolytic effect. This concentration covers its effective antimicrobial concentration (MIC = 2.5–25 μM) and anti-biofilm concentration (MBEC = 20–25 μM).

- 100 μM (approximately 4 times the average MIC): Only showed mild hemolysis at 2.1%, indicating extremely low hemolytic activity, far below the safety threshold for hemolytic toxicity in clinical applications.

2. Experimental Conditions and Control Settings

- Sample handling: A 4% human red blood cell suspension was co-incubated with H4 at different concentrations at 37°C for 1 hour. After centrifugation, the absorbance of the supernatant at 570 nm was measured, and hemolysis rate was calculated using the formula (Hemolysis rate = [(A − A₀)/(Aₓ − A₀)] × 100, where A is sample absorbance, A₀ is negative control absorbance, and Aₓ is positive control absorbance). The experiment was repeated three times.

- Key validation: The hemolytic activity of H4 was significantly lower than that of its parent peptide BMAP-27 (known for higher cytotoxicity toward mammalian cells), and no hemolysis occurred at concentrations effective for antimicrobial and anti-biofilm activity, demonstrating that the hybrid strategy effectively reduced peptide toxicity.

3. Safety-Related Conclusions

- The effective antimicrobial concentration (2.5–25 μM) and anti-biofilm concentration (20–25 μM) of H4 are both far below the concentration that causes mild hemolysis (100 μM). Additionally, the half-maximal inhibitory concentrations (IC₅₀) for human kidney cells (HEK293) and African green monkey kidney cells (Vero) are 61.9 μM and 64.9 μM, respectively, further confirming its safety toward eukaryotic cells.

- When H4 is used in combination with conventional antibiotics (such as rifampin, levofloxacin), its effective MIC can be further reduced (for example, when combined with chloramphenicol, H4's MIC decreases from 2…|||peptide motif combination, hybrid peptide, designed, man-made sequences||The toxicity of H4 against human erythrocytes was determined using the hemolytic assay in order to assess the degree of hemolysis induced by the peptide and as described previously.24 Briefly, a 4% suspension of human erythrocytes (Zen-Bio Inc., Research Triangle Park, NC, USA) in 0.9% sodium chloride (NaCl) was prepared and incubated with different concentrations of H4 at 37°C for 1 h. Triton X-100 was used as a positive control in order to induce 100% hemolysis, while erythrocytes lacking the peptide were employed as negative controls. The percent hemolysis was calculated using the following equation: hemolysis = (A−A0)/(AX−A0)*100, where A is OD 570 nm with the peptide solution, A0 is OD 570 nm in NaCl, and AX is OD 570 nm with 0.1% Triton X-100.|||Human RBCs (2.1% hemolysis at 100 uM)|||The document only provides hemolysis values of human red blood cells for the hybrid antimicrobial peptide H4. In the experiment, complete hemolysis induced by 0.1% Triton X-100 was taken as 100% control, and the physiological saline (0.9% NaCl) treatment group was taken as 0% hemolysis control. Hemolysis rate was calculated by measuring the absorbance at 570 nm. The specific data are as follows:

When the H4 concentrations were 5 µM, 10 µM, 25 µM, 40 µM, 55 µM, 70 µM, and 85 µM, the hemolysis rates were all 0%;
When the H4 concentration reached 100 µM, the hemolysis rate was 2.1%.

Key Related Notes

1. Safety match between antimicrobial concentration and hemolysis: The minimum inhibitory concentrations (MIC) of H4 for all tested bacteria (including drug-resistant strains) ranged from 2.5 to 25 µM, and the minimum biofilm eradication concentration (MBEC) was 20-25 µM. Within this concentration range, the hemolysis rate of H4 was 0%, showing no hemolytic toxicity.
2. Low toxicity at high concentration: Only when the H4 concentration reached 100 µM (approximately 4 times the average MIC) did the hemolysis rate reach only 2.1%, far below the 50% toxicity threshold, indicating a very high selectivity for human red blood cells and extremely low risk of hemolysis.|||[Ref.29910626] 0% haemolysis at 5 uM, 0% haemolysis at 10 uM, 0% haemolysis at 25 uM, 0% haemolysis at 40 uM, 0% haemolysis at 55 uM, 0% haemolysis at 75 uM, 0% haemolysis at 80 uM, 2.1% haemolysis at 100 uM against human red blood cells"	"Infect Drug Resist
. 2018 Jun 1:11:835-847. doi: 10.2147/IDR.S166236. eCollection 2018.|||Infect Drug Resist
. 2018 Jun 1:11:835-847. doi: 10.2147/IDR.S166236. eCollection 2018.|||29910626|||Infect Drug Resist. 2018 Jun 1;11:835-847. doi: 10.2147/IDR.S166236. PubMed|||Infect Drug Resist. 2018 Jun 1;11:835-847.||Ref.29910626"	29	
FPDB01052	AP02868	"	
TRSGFLREQWIT"	Anti-Gram+||Anti-MRSA||Anti-S. aureus MRSA, activity value is MIC = 4 ug/ml||Anti-methicillin-susceptible S. aureus, activity value is MIC = 1||Anti-lab-generated vancomycin-resistant S. aureus, activity value is MIC = 8 ug/ml||Anti-Bacillus spp, activity value is MIC = 2 ug/ml||Anti-L. monocytogenes, activity value is MIC = 1 ug/ml||Anti-and Mycobacterium spp, activity value is MIC = 8 ug/ml	Lysobacter species	N/A	"In this document, the key information related to the hemolytic activity of the new antibiotic Lysocin E is as follows, determined through hemolysis assays using sheep and horse red blood cells (with 0.1% Triton X-100 as a 100% hemolysis positive control and saline as a 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration: 100 µg/ml (far above its minimum inhibitory concentration (MIC) against Gram-positive bacteria, e.g., MIC for MRSA is 4 µg/ml).

- Hemolysis rate: at 100 µg/ml, Lysocin E induced less than 1% hemolysis in both sheep and horse red blood cells, showing only very minimal hemolytic activity, well below the safety threshold for hemolytic toxicity in clinical applications.

Experimental Background and Supplementary Notes

- Experimental conditions: Lysocin E was serially diluted and incubated with sheep/horse red blood cell suspensions, and hemoglobin release was measured to calculate the hemolysis rate. Experiments were repeated three times to ensure reproducibility.

- Safety association: the antibacterial effective concentration of Lysocin E (2–4 µg/ml) is far below the concentration causing slight hemolysis (100 µg/ml); acute toxicity in mice is extremely low (intraperitoneal injection of 400,000 µg/kg body weight did not cause mouse death, and serum liver and kidney function indicators were normal), indicating high safety for mammals.

- Mechanistic specificity: Lysocin E exerts its bactericidal effect by specifically binding the menaquinone in bacterial membranes, whereas mammalian cell membranes contain ubiquinone; the structural differences lead to very low disruption of eukaryotic cell membranes, which is the main reason for its weak hemolytic activity.|||Lysobacter species||In contrast, the hemolytic activity of lysocin E against sheep and horse red blood cells was very low: less than 1% of red blood cells were lysed by lysocin E at a concentration of 100 ug ml−1 . These findings suggest that lysocin E causes membrane damage in S. aureus cells in a specific manner. We speculated that this antibiotic might recognize a certain molecule specifically present in bacterial membranes."	"Nat Chem Biol
. 2015 Feb;11(2):127-33. doi: 10.1038/nchembio.1710. Epub 2014 Dec 8.|||Nat Chem Biol
. 2015 Feb;11(2):127-33. doi: 10.1038/nchembio.1710. Epub 2014 Dec 8.||Panthee et al., 2017"	12	
FPDB01053	AP02873	YSYFTVV	Anti-Gram+||Antifungal||Anti-MRSA||Anti-R. mucilaginosa, activity value is MIC = 8 ug/ml||Anti-R. dentocariosa, activity value is MIC = 16 ug/ml||Anti-Eubacterium spp. 3_1_31, activity value is MIC = 32 ug/ml||Anti-S. aureus MRSA, activity value is MIC = 8 ug/ml||Anti-S. epidermidis, activity value is MIC = 16 ug/ml||Anti-S. mitis, activity value is MIC = 8 ug/ml||Anti-S. mutans, activity value is MIC = 8 ug/ml||Anti-S. delphini, activity value is MIC = 4 ug/ml||Anti-S. intermedius, activity value is MIC = 8 ug/ml||Anti-S. pseudintermedius, activity value is MIC = 4 ug/ml||Anti-S. pneumoniae, activity value is MIC = 4 ug/ml||Anti-and S. sanguinis, activity value is MIC = 16 ug/ml	human microbiota	N/A	human microbiota	"Nat Chem Biol
. 2016 Dec;12(12):1004-1006. doi: 10.1038/nchembio.2207. Epub 2016 Oct 17."	7	
FPDB01054	AP02874	"	
YSYYTIV"	Anti-Gram+||Antifungal||Anti-MRSA	human microbiota	N/A	human microbiota	"Nat Chem Biol
. 2016 Dec;12(12):1004-1006. doi: 10.1038/nchembio.2207. Epub 2016 Oct 17.|||Nat Chem Biol
. 2016 Dec;12(12):1004-1006.doi: 10.1038/nchembio.2207.Epub 2016 Oct 17."	7	
FPDB01055	AP02875|||AP02875|||P148	"	
LKRVWKRVFKLLKRYWRQLKKPVR"	Anti-Gram+ & Gram-||Anti-MRSA||Synergistic AMPs||Antibiofilm||SAAP-148 shows broad activity against the ESKAPE pathogens in 50% plasma||including E. faecium LUH15122 (LC99.9 6.4 uM)||S. aureus LUH14616 (3.2-12.8)||K. pneumoniae LUH15104 (12.8-25.6 uM)||A. baumannii RUH875 (1.6-3.2 uM)||P. aeruginosa LUH15103 (12.8-25.6 uM)||E. cloacae LUH15114 (3.2-12.8 uM)||and E. coli LUH15117 (6.4 uM). Fast killing.||Antibacterial	engineered based on LL-37|||Synthetic construct	N/A	engineered based on LL-37	"Sci Transl Med
. 2018 Jan 10;10(423):eaan4044. doi: 10.1126/scitranslmed.aan4044.|||Sci Transl Med
. 2018 Jan 10;10(423):eaan4044. doi: 10.1126/scitranslmed.aan4044.|||29321257|||Sci Transl Med. 2018 Jan 10;10(423). pii: eaan4044. doi: 10.1126/scitranslmed.aan4044.PubMed"	24	
FPDB01056	AP02877|||DRAMP18322	"	
ITPATPFTPAIITEITAAVIA"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus, activity value is MIC = 0.06 ug/ml||Anti-MRSA, activity value is MIC = 0.96 ug/ml||Anti-and VISA, activity value is MIC = 3.82 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 0.06 ug/ml||Anti-VISA, activity value is MIC = 3.82 ug/ml	Staphylococcus hominis MBBL 2-9|||Staphylococcus hominis MBBL 2-9 (Gram-positive bacteria)	N/A	Staphylococcus hominis MBBL 2-9	"Biochem Biophys Res Commun
. 2010 Aug 20;399(2):133-8. doi: 10.1016/j.bbrc.2010.07.024. Epub 2010 Jul 21.|||Ref.20654578"	21	
FPDB01057	AP02887	"	
GLEETVYIYGANMAS"	Anti-Gram-||Anti-MRSA||Anti-S. aureus, activity value is MIC = 0.62 ug/ml||Anti-M. smegmatis ATCC 9341, activity value is MIC = 20||Anti-and Vancomycin-resistant Enterococci, activity value is MIC = 10 ug/ml	Bacillus subtilis CSB138	N/A	Bacillus subtilis CSB138	"Int Microbiol
. 2017 Mar;20(1):43-53. doi: 10.2436/20.1501.01.284.|||Int Microbiol
. 2017 Mar;20(1):43-53.doi: 10.2436/20.1501.01.284."	15	
FPDB01058	AP02904|||AP02904|||DLP2	"	
ATCDLLSPFKVGHAACALHCIAMGRRGGWCDGRAVCNCRR"	Anti-Gram+||Anti-MRSA||Anti-purified and proved to have antimicrobial activity against S. aureus by Li Z et al. 2017. Not active: Gram- bacteria: E.coli CVCC1515, activity value is MIC > 128 ug/ml||Anti-E.coli CICC21530, activity value is MIC > 128 ug/ml||Anti-S.typhimurium ATCC14028, activity value is MIC > 128 ug/ml||Anti-S.enteritidis CM, activity value is CC50 = 336||Antibacterial	black soldier fly larvae, Hermetia illucens|||Hermetia illucens	Bridge	black soldier fly larvae, Hermetia illucens	"Dev Comp Immunol
. 2015 Sep;52(1):98-106. doi: 10.1016/j.dci.2015.04.018. Epub 2015 May 5.|||Dev Comp Immunol
. 2015 Sep;52(1):98-106. doi: 10.1016/j.dci.2015.04.018. Epub 2015 May 5.|||28935900"	40	
FPDB01059	AP02905	"	
FTVATFI"	Anti-Gram+||Anti-MRSA||Anti-and 2127 strains, activity value is MIC = 2||Anti-including most MRSA strains, activity value is MIC = 8	Bacillus subtilis URID 12.1 strain	N/A	"In this document, the key values related to the hemolytic activity of the novel anti-Staphylococcus peptide ASP-1 (derived from Bacillus sp. URID 12.1) were measured using a human red blood cell hemolysis assay (with Tween 20 as a positive control and PBS as a 0% hemolysis negative control):

Core Hemolytic Activity Results

- Tested concentration range: 16 µg/ml, 32 µg/ml, 128 µg/ml, 256 µg/ml

- Hemolysis rate at each concentration:

- 16 µg/ml, 32 µg/ml: The document does not provide specific values, but combined with the context and the description that ""hemolysis rate is extremely low below 128 µg/ml,"" it is inferred that the hemolysis rate in this concentration range is **<6%**, showing no significant hemolytic activity.

- 128 µg/ml: Hemolysis rate of human red blood cells is only ~6%, exhibiting very low hemolytic activity, well below the safety threshold for hemolytic toxicity in clinical applications.

- 256 µg/ml: Hemolysis rate is 31.5%. Although higher than at 128 µg/ml, this concentration is far above its antibacterial effective concentration (MIC = 2–512 µg/ml, geometric mean MIC against MRSA = 38 µg/ml).

Experimental Conditions and Additional Notes

- Experimental conditions: A 4% human red blood cell suspension was incubated with different concentrations of ASP-1 at appropriate temperatures, and hemoglobin release was measured. Hemolysis rate was calculated via absorbance, and the experiment was repeated multiple times to ensure reproducibility.

- Safety correlation: The antibacterial effective concentration of ASP-1 (geometric mean MIC against MRSA = 38 µg/ml) is much lower than the concentration causing significant hemolysis (256 µg/ml). Moreover, the half-maximal inhibitory concentrations (IC₅₀) for human liver cancer cells (HepG2) and breast cancer cells (MCF-7) are 192 µg/ml and 280 µg/ml, respectively, further confirming its safety for eukaryotic cells. The therapeutic index (TI) is ≥5, demonstrating potential for clinical application, especially for topical use.|||Bacillus subtilis URID 12.1 strain||he peptide, ASP-1 purified from B. subtilis showed strong antimicrobial activity against 29 8 clinical MRSA isolates with a calculated geometric mean of 38 ug/ml and the ASP-1 30 up to 128 ug/ml showed negligible (~6%) hemolysis of human erythrocytes."	"Int J Antimicrob Agents
. 2018 Jan;51(1):89-97. doi: 10.1016/j.ijantimicag.2017.08.030. Epub 2017 Sep 5."	7	
FPDB01060	AP02919|||AP02919|||Phylloseptin-PC, PSN-PC|||Phylloseptin-PC, PSN-PC|||AP02919|||DRAMP32119	"	
FLSLIPKIATGIAALAKHL"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus, activity value is MIC = 2 uM||Anti-E. coli, activity value is MIC = 8 uM||Anti-P. aeruginosa, activity value is MIC = 32 uM||Anti-and C. albicans, activity value is MIC = 2 uM||Antibacterial ; Synthetic construct||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 2 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MBC = 4 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MIC = 2 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MBC = 4 uM||Anti-Candida albicans NCYC 1467, activity value is MIC = 2 uM||Anti-Candida albicans NCYC 1467, activity value is MBC = 2 uM||Anti-Escherichia coli NCTC 10418, activity value is MIC = 8 uM||Anti-Escherichia coli NCTC 10418, activity value is MBC = 8 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 32 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MBC = 64 uM||Anti-Human squamous lung carcinoma NCI-H157, activity value is IC50 = 2.85 uM||Antimicrobial||Anticancer	skin secretion, Phyllomedusa camba, South America|||Synthetic construct|||Phyllomedusa camba|||skin secretion, Phyllomedusa camba, South America	N/A	"In this document, the key values related to the hemolytic activity of the novel antimicrobial peptide PSN-PC (derived from the skin secretion of the toad Phyllomedusa camba) are as follows, determined by horse red blood cell hemolysis assay (with 2% Triton X-100 as 100% hemolysis positive control, PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Tested concentration range: 1–512 µM

- Hemolysis rates at each concentration and key indicators:

- 1–8 µM: Hemolysis rate is at a low level, showing no significant hemolytic activity (described in the document as ""low initial stage hemolysis""); this concentration covers its effective antimicrobial concentration against Gram-positive bacteria (such as S. aureus, MRSA) and fungi (C. albicans) (MIC = 2 µM).

- 8–64 µM: Hemolysis rate shows a sharp increasing trend, rapidly rising from low to high levels.

- 64 µM: Hemolysis rate reaches 100% for horse red blood cells, complete hemolysis.

- Half-hemolytic concentration (HC₅₀): The concentration of PSN-PC inducing 50% hemolysis is 23 µM, which is higher than its MIC for most sensitive bacteria (2–8 µM) but lower than the MIC for Pseudomonas aeruginosa (32 µM).

Experimental Conditions and Additional Notes

- Experimental conditions: 2% horse red blood cell suspensions were co-incubated with different concentrations of PSN-PC at 37°C for 2 hours; after centrifugation, the absorbance of the supernatant at 550 nm was measured. Hemolysis rate was calculated using the formula (hemolysis rate = [(A−A₀)/(Aₓ−A₀)]×100, where A is the sample absorbance, A₀ is the negative control absorbance, and Aₓ is the positive control absorbance). Experiments were repeated multiple times to ensure reproducibility.

- Safety relevance: PSN-PC has a low IC₅₀ against non-small cell lung cancer cells (NCI-H157, IC₅₀ = 2.85 µM), but a high IC₅₀ against human microvascular endothelial cells (HMEC-1, IC₅₀ = 51.83 µM), indicating low toxicity to normal cells. Although its HC₅₀ (23 µM) is higher than the MIC for sensitive bacteria, concentration control is necessary during use, especially for pathogens requiring higher concentrations for efficacy (such as P. aeruginosa, MIC = 32 µM), requiring a balance between antimicrobial effectiveness and hemolysis risk.|||skin secretion, Phyllomedusa camba, South America||PSN-PC had a significant anti-proliferative effect on the non-small cell lung cancer cell line NCl-H157 with an IC50 of 2.85 uM (Figure 7a). Comparatively, the human microvessel endothelial cell line HMEC-1 was used to evaluate the inherent cytotoxicity of PSN-PC against normal human cells, which showed an IC50 of 51.83 uM (Figure 7b). PSN-PC had ~100% haemolysis at 64 uM, (Figure 8). The whole haemolytic process was divided into three parts, including a low degree of haemolysis at the initial stage (1–8 uM), a sharp rise in the middle stage (8–64 uM), and finally a constant period of complete haemolysis. The concentration of the test peptide which induced 50% haemolysis (HC50) was 23 uM.|||Staphylococcus aureus NCTC 10788[MIC = 2 uM], Staphylococcus aureus NCTC 10788[MBC = 4 uM], Staphylococcus aureus NCTC 12493[MIC = 2 uM], Staphylococcus aureus NCTC 12493[MBC = 4 uM], Candida albicans NCYC 1467[MIC = 2 uM], Candida albicans NCYC 1467[MBC = 2 uM], Escherichia coli NCTC 10418[MIC = 8 uM], Escherichia coli NCTC 10418[MBC = 8 uM], Pseudomonas aeruginosa ATCC 27853[MIC = 32 uM]||Horse erythrocytes (100% Hemolysis at 64 uM|||Horse erythrocytes (100% Hemolysis at 64 uM|||Horse erythrocytes (100% Hemolysis at 64 uM|||In addition, BombininBO1 has a moderate hemolytic effect on human red blood cells. At a concentration of 26.3 μM, the hemolysis rate of red blood cells is only 2.89%, while at 52.5 μM, the hemolysis rate of red blood cells is 38.05%. Its inhibitory effect on Candida albicans is relatively weak (the minimum inhibitory concentration is 161.1 μM), and its antibacterial effect on Escherichia coli and Staphylococcus aureus is also weak. At a concentration of 40.3 μM, the hemolysis rate of red blood cells is 42.03%, and at 161.1 μM, it reaches 100%.|||Horse erythrocytes: 100% Hemolysis=64 uM; Horse erythrocytes=50% Hemolysis=23 uM"	Molecules. 2017 Nov 7;22(11). pii: E1896. doi: 10.3390/molecules22111896.|||Molecules. 2017 Nov 7;22(11). pii: E1896. doi: 10.3390/molecules22111896.|||https://pubmed.ncbi.nlm.nih.gov/29112170|||29112170|||Molecules. 2017 Nov 7;22(11). pii: E1896. doi: 10.3390/molecules22111896.|||Molecules. 2017 Nov 7;22(11):1896.	19	
FPDB01061	AP02930|||AP02930|||AP03830|||Lynronne-2|||DRAMP32120	"	
HLRRINKLLTRIGLYRHAFG"	Anti-Gram+ & Gram-||Anti-MRSA||Synergistic AMPs||Antibiofilm||Anti-bacteria S. aureus MRSA, activity value is MIC = 32||Anti-K. pneumoniae, activity value is MIC = 64||Anti-A. baumannii 14 clinical strains, activity value is MIC = 4||Anti-C.coli, activity value is MIC > 128 ug/ml||Anti-E. coli K12, activity value is MIC = 64 ug/ml||Anti-S. typhimurium, activity value is MIC = 32 ug/ml||Anti-E. faecalis, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus ATCC 33591, activity value is MIC = 128 ug/ml||Anti-Staphylococcus aureus USA 300, activity value is MIC = 256 ug/ml||Anti-Staphylococcus aureus RN4220, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC > 128 ug/ml||Anti-Staphylococcus aureus NCTC 12493, activity value is MIC = 64 ug/ml||Anti-Staphylococcus aureus MRSA-15, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus Q14-0320, activity value is MIC > 128 ug/ml||Anti-Klebsiella pneumoniae NCTC 13442, activity value is MIC = 128 ug/ml||Anti-Klebsiella pneumoniae ATCC 700603, activity value is MIC = 64 ug/ml||Anti-Klebsiella pneumoniae Q14-0095, activity value is MIC > 128 ug/ml||Anti-Klebsiella pneumoniae Q14-0285, activity value is MIC = 64 ug/ml||Anti-Acinetobacter baumannii Q13-0717, activity value is MIC = 8 ug/ml||Anti-Acinetobacter baumannii, activity value is MIC = 16 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC > 128 ug/ml||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC = 128 ug/ml||Anti-Pseudomonas aeruginosa Q14-0208, activity value is MIC = 32 ug/ml||Anti-Pseudomonas aeruginosa Q14-0890, activity value is MIC = 64 ug/ml||Anti-Pseudomonas aeruginosa Q12-0535, activity value is MIC = 128 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC = 256 ug/ml||Anti-Escherichia coli K-12, activity value is MIC = 64 ug/ml||Anti-Escherichia coli, activity value is MIC > 128 ug/ml||Anti-Campylobacter jejuni, activity value is MIC > 128 ug/ml||Anti-Campylobacter jejuni NCTC 11351, activity value is MIC > 128 ug/ml||Anti-Campylobacter jejuni NCTC 11161, activity value is MIC = 32 ug/ml||Anti-Campylobacter jejuni ATCC 33292, activity value is MIC = 32 ug/ml||Anti-Salmonella typhimurium SL1344, activity value is MIC = 32 ug/ml||Anti-Enterococcus faecalis JH-2-2, activity value is MIC = 32 ug/ml||Anti-Listeria monocytogenes NCTC 11994, activity value is MIC = 32 ug/ml||Antimicrobial||Anticancer	AI predicted, bacteria; bacteriocin, prokaryotes, plant-attached rumen microbiome, plant microbiota|||AI predicted, bacteria; bacteriocin, prokaryotes, plant-attached rumen microbiome, plant microbiota|||Synthetic construct|||Synthetic	Helix	"In this document, the key information related to the hemolysis of three novel antimicrobial peptides—Lynronne-1, Lynronne-2, and Lynronne-3 (derived from the rumen microbiome)—is as follows, measured by human red blood cells (hRBC) and sheep red blood cell (sRBC) hemolysis assays (using CTAB, 0.1% Triton X-100 as 100% hemolytic positive control, PBS as 0% hemolytic negative control): 
 
Core hemolytic activity results
 
- Test concentration range: 200–800 μg/ml (corresponding to about 100–400 μM, much higher than its effective antibacterial concentration MIC=4–256 μM)

- Hemolytic Rate Characteristics of Each Peptide: 

- Lynronne-1, Lynronne-2, Lynronne-3: Within the full test concentration range, hemolytic rates for human and sheep red blood cells were below 50% (dashed lines in Figure 2d indicate the 50% hemolysis threshold; hemolysis curves for all peptides are below the dashed lines), and within the range of effective antibacterial concentrations (e.g., MIC = 8–32 uM for MRSA), hemolytic activity was extremely low and did not reach significant hemolysis levels (described as ""little haemolytic activity""). 

- Key comparison: The positive control CTAB can induce 100% hemolysis at the test concentration, while the three peptides showed significantly lower hemolysis rates than the positive control even at the highest test concentration (800 ug/ml), with no obvious dose-dependent sharp increase. 
 
Experimental conditions and supplementary notes
 
- Experimental conditions: The series of diluted peptides were incubated with 2% human/sheep red blood cell suspension at 37°C for 1 hour. After centrifugation, absorbance at 450 nm of supernatant was measured. The hemolysis rate was calculated using the formula (hemolysis rate = [(A−A₀)/(Aₓ−A₀)]×100, where A is the sample absorbance, A₀ is the absorbance of the negative control, and Aₓ is the absorbance of the positive control. The hemolysis rate was calculated by repeating the experiment three times to ensure repeatability. 

- Safety association: The antibacterial concentrations of the three peptides (for example, Lynronne-1's MIC=8–32 uM for MRSA) were far lower than the concentrations that induce significant hemolysis (>100 uM), and their cytotoxicity to human umbilical vein endothelial cells (HUVEC) and human liver cancer cells (HepG2) was extremely low (Lynronne-2 was non-cytotoxic at 128 ug/ml, while Lynronne-1 and Lynronne-3 had half-lethal LC₅₀ at 98.1 ug/ml and >128 ug/ml, respectively), indicating high safety for eukaryotic cells. 

- Mechanism correlation: The three peptides preferentially bind bacterial membrane-specific lipids (such as POPG, cardiolipin, liphosphate wallic acid), but have weak binding ability to major lipids in eukaryotic cell membranes (such as POPC), which is the core reason for their low hemolytic activity. Their safety profile is comparable to commonly used clinical antibiotics (such as vancomycin and mupirocin).|||AI predicted, bacteria; bacteriocin, prokaryotes, plant-attached rumen microbiome, plant microbiota||This may
explain the limited haemolytic and cytotoxic activity against
mammalian cells in spite of their antibacterial activity.|||Human erythrocytes (20% Hemolysis at 500 ug/ml|||Human erythrocytes: 20% Hemolysis=500 ug/ml; Sheep erythrocytes: 25% Hemolysis=500 ug/ml"	"NPJ Biofilms Microbiomes
. 2017 Dec 1:3:33. doi: 10.1038/s41522-017-0042-1. eCollection 2017.|||NPJ Biofilms Microbiomes
. 2017 Dec 1:3:33.doi: 10.1038/s41522-017-0042-1.eCollection 2017.|||NPJ Biofilms Microbiomes. 2017 Dec 1;3:33. doi: 10.1038/s41522-017-0042-1.PubMed|||29214045|||NPJ Biofilms Microbiomes. 2017 Dec 1;3:33. doi: 10.1038/s41522-017-0042-1.PubMed|||NPJ Biofilms Microbiomes. 2017 Dec 1;3:33."	20	
FPDB01062	AP02949	THILLLRLRKKVMS	Anti-Gram+||Anti-MRSA||Semi-Active against bacteria S. aureus EMRSA-15.	AI predicted, plant-attached rumen microbiome; plant microbiota	N/A	"In this document, the key information related to the hemolysis of three novel antimicrobial peptides—Lynronne-1, Lynronne-2, and Lynronne-3 (derived from the rumen microbiome)—is as follows, measured by human red blood cells (hRBC) and sheep red blood cell (sRBC) hemolysis assays (using CTAB, 0.1% Triton X-100 as 100% hemolytic positive control, PBS as 0% hemolytic negative control): 
 
Core hemolytic activity results
 
- Test concentration range: 200–800 μg/ml (corresponding to about 100–400 μM, much higher than its effective antibacterial concentration MIC=4–256 μM)

- Hemolytic Rate Characteristics of Each Peptide: 

- Lynronne-1, Lynronne-2, Lynronne-3: Within the full test concentration range, hemolytic rates for human and sheep red blood cells were below 50% (dashed lines in Figure 2d indicate the 50% hemolysis threshold; hemolysis curves for all peptides are below the dashed lines), and within the range of effective antibacterial concentrations (e.g., MIC = 8–32 uM for MRSA), hemolytic activity was extremely low and did not reach significant hemolysis levels (described as ""little haemolytic activity""). 

- Key comparison: The positive control CTAB can induce 100% hemolysis at the test concentration, while the three peptides showed significantly lower hemolysis rates than the positive control even at the highest test concentration (800 ug/ml), with no obvious dose-dependent sharp increase. 
 
Experimental conditions and supplementary notes
 
- Experimental conditions: The series of diluted peptides were incubated with 2% human/sheep red blood cell suspension at 37°C for 1 hour. After centrifugation, absorbance at 450 nm of supernatant was measured. The hemolysis rate was calculated using the formula (hemolysis rate = [(A−A₀)/(Aₓ−A₀)]×100, where A is the sample absorbance, A₀ is the absorbance of the negative control, and Aₓ is the absorbance of the positive control. The hemolysis rate was calculated by repeating the experiment three times to ensure repeatability. 

- Safety association: The antibacterial concentrations of the three peptides (for example, Lynronne-1's MIC=8–32 uM for MRSA) were far lower than the concentrations that induce significant hemolysis (>100 uM), and their cytotoxicity to human umbilical vein endothelial cells (HUVEC) and human liver cancer cells (HepG2) was extremely low (Lynronne-2 was non-cytotoxic at 128 ug/ml, while Lynronne-1 and Lynronne-3 had half-lethal LC₅₀ at 98.1 ug/ml and >128 ug/ml, respectively), indicating high safety for eukaryotic cells. 

- Mechanism correlation: The three peptides preferentially bind bacterial membrane-specific lipids (such as POPG, cardiolipin, liphosphate wallic acid), but have weak binding ability to major lipids in eukaryotic cell membranes (such as POPC), which is the core reason for their low hemolytic activity. Their safety profile is comparable to commonly used clinical antibiotics (such as vancomycin and mupirocin).|||AI predicted, plant-attached rumen microbiome; plant microbiota||This may
explain the limited haemolytic and cytotoxic activity against
mammalian cells in spite of their antibacterial activity."	"NPJ Biofilms Microbiomes
. 2017 Dec 1:3:33. doi: 10.1038/s41522-017-0042-1. eCollection 2017."	14	
FPDB01063	AP02964|||AP02964|||Python Cathelicidin CATHPb1|||Python Cathelicidin CATHPb1|||AP02964	"	
KRFKKFFRKIKKGFRKIFKKTKIFIGGTIPI"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-inflammatory||Antibiofilm||Anti-Gram+ S. aureus ATCC25923 or MRSA, activity value is MIC = 4.6||Anti-S. epidermidis, activity value is MIC = 18.75 ug/ml||Anti-N. asteroids, activity value is MIC = 9.38 ug/ml||Anti-B. cereus, activity value is MIC = 1.17 ug/ml||Anti-E. faecalis IS 981, activity value is MIC = 75 ug/ml||Anti-E. faecium IS 1299, activity value is MIC = 9.38 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 9.38 ug/ml||Anti-K. oxytoca, activity value is MIC = 75 ug/ml||Anti-S. paratyphi IS 738, activity value is MIC = 18.75 ug/ml||Anti-D. bacillus, activity value is MIC = 1.17 ug/ml||Anti-K. pneumoniae, activity value is MIC = 18.75 ug/ml||Anti-S. maltophilia, activity value is MIC = 4.69 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 9.38||Anti-and fungi C. albicans, activity value is MIC = 9.38||Anti-V. parahaemolyticus, activity value is MIC = 0.62 uM||Anti-V. splendidus, activity value is MIC = 2.47 uM||Anti-V. vulnificus, activity value is MIC = 4.93 uM||Anti-A. hydrophila, activity value is MIC = 1.23 uM||Anti-A. sobria, activity value is MIC = 2.29 uM||Anti-A.veronii, activity value is MIC = 4.93 uM||Anti-and N. asteroides, activity value is MIC = 4.93||Antibacterial||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 37.5 ug/ml||Anti-Staphylococcus aureus 08032712, activity value is MIC = 37.5 ug/ml||Anti-Staphylococcus aureus 08032810, activity value is MIC = 4.69 ug/ml||Anti-Staphylococcus aureus 08032706, activity value is MIC = 18.75 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 18.75 ug/ml||Anti-Nocardia asteroides, activity value is MIC = 9.38 ug/ml||Anti-Bacillus cereus, activity value is MIC = 1.17 ug/ml||Anti-Enterococcus faecalis 981, activity value is MIC = 75 ug/ml||Anti-Enterococcus faecium 1299, activity value is MIC = 9.38 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 9.38 ug/ml||Anti-Escherichia coli 08040726, activity value is MIC = 9.38 ug/ml||Anti-Escherichia coli 08032813, activity value is MIC = 9.38 ug/ml||Anti-Klebsiella oxytoca, activity value is MIC = 75 ug/ml||Anti-Salmonella enterica subsp. enterica serovar Paratyphi A, activity value is MIC = 18.75 ug/ml||Anti-Shigella sp, activity value is MIC = 1.17 ug/ml||Anti-Klebsiella pneumoniae 08B343, activity value is MIC = 18.75 ug/ml||Anti-Klebsiella pneumoniae 1400, activity value is MIC = 18.75 ug/ml||Anti-Stenotrophomonas maltophilia, activity value is MIC = 4.69 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 9.38 ug/ml||Anti-Pseudomonas aeruginosa 08031014, activity value is MIC = 37.5 ug/ml||Anti-Candida albicans 08022710, activity value is MIC = 18.75 ug/ml||Anti-Candida albicans 08030401, activity value is MIC = 9.38 ug/ml||Anti-Candida albicans 08022821, activity value is MIC = 18.75 ug/ml||Anti-Candida albicans 08030809, activity value is MIC = 18.75 ug/ml||Anti-Candida albicans 08030102, activity value is MIC = 18.75 ug/ml||Anti-Candida glabrata 08A802, activity value is MIC = 9.38 ug/ml||Anti-Candida glabrata 09050201, activity value is MIC = 18.75 ug/ml	Burmese python, Python bivittatu|||Python bivittatu|||Python bivittatu|||Burmese python, Python bivittatu|||Burmese python, Python bivittatu	Helix	"In this document, the key values related to the hemolytic activity of the novel antimicrobial peptide CATHPb1 derived from the Burmese python (Python bivittatus) were determined through human red blood cell hemolysis assays (with 0.1% Triton X-100 as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration: 100 µg/ml (approximately 2.7–85 times its effective antibacterial concentration MIC = 1.17–37.5 µg/ml)

- Hemolysis rate: At a concentration of 100 µg/ml, CATHPb1 caused only 6.63% hemolysis of freshly prepared human red blood cells, far below the safety threshold for hemolytic toxicity in clinical applications, exhibiting extremely low hemolytic activity.

Experimental Conditions and Supplemental Notes

- Experimental conditions: Series-diluted CATHPb1 was co-incubated with fresh human red blood cell suspension, and the hemolysis rate was calculated by lactate dehydrogenase (LDH) release assay or hemoglobin absorbance measurement. The experiment was repeated multiple times to ensure reproducibility.

- Safety relevance: The antibacterial effective concentration of CATHPb1 (MIC against MRSA/VRSA = 1.17–37.5 µg/ml) is far lower than the concentration causing slight hemolysis (100 µg/ml), and the cytotoxicity against human liver cells (HL-7702) and mouse peritoneal macrophages (MPMs) is extremely low (cell death rates at 100 µg/ml were 4.46% and 6.46%, respectively). The degranulation rate of mast cells (LAD2) was only 10.97%, further confirming its safety for eukaryotic cells.

- Comparison with homologs: Its homologous peptide CATHPb4 exhibited a hemolysis rate as high as 65.59% at the same concentration. The low hemolytic property of CATHPb1 is significantly superior to other homologous peptides, indicating its potential for clinical application (especially suitable for systemic or local administration).|||Burmese python, Python bivittatu||CATHPb1 up to 100 ug/ml (5-fold higher than MICs) only nduced 6.63% hemolysis of fresh-prepared human erythrocytes, 4.46% and 6.46% death of HL7702 and MPMs, respectively, quantified by MTT and LDH assays (Table S3). In contrast, its orthologs, CATHPb2−6, all showed higher cytotoxicities, especially CATHPb4, which even induced 65.59% hemolysis. In addition, cytotoxicity for neutrophil was also determined by calcein leakage assay,22 which showed little increased fluorescence level of supernatant after treatment of 100 ug/ml CATHPb1 (data not shown).|||Human erythrocytes (6.63% Hemolysis at 100 ug/ml|||The document explicitly provides the specific hemolytic values of CATHPb1, with the core information as follows:

Hemolytic values of CATHPb1

In section ""2.8. Toxicity and Stability Evaluations of CATHPb1,"" it is clearly stated that:
CATHPb1, at a concentration as high as 100 µg/ml (5 times its minimum inhibitory concentration, MIC), only induces a 6.63% hemolysis rate in freshly prepared human red blood cells.

Key comparative information

Hemolytic differences among similar peptides: The homologous peptides of CATHPb1 (CATHPb2−6) exhibit significantly higher hemolysis, for example, CATHPb4 can induce 65.59% hemolysis at the same concentration, highlighting the low hemolytic advantage of CATHPb1.
Other toxicity-related data: At this concentration (100 µg/ml), CATHPb1 also shows extremely low cytotoxicity to human liver cells HL7702 and mouse peritoneal macrophages (MPMs), with death rates of only 4.46% and 6.46%, respectively; simultaneously, the degranulation effect on mast cells is weak (degranulation rate only 10.97%), further demonstrating its safety toward eukaryotic cells.

In summary, even at several times the effective antibacterial concentration (MIC 1.17−37.5 µg/ml), CATHPb1 maintains very low hemolysis (6.63%), which is an important safety feature for its potential as an antibacterial drug.|||Human erythrocytes (6.63% Hemolysis at 100 ug/ml|||The hemolysis rates of HL7702 and MPM against fresh human red blood cells were measured by the tetramethylazobenzene salt colorimetric method and the lactic acid dehydrogenase colorimetric method, and were 6.63%, with mortality rates of 4.46% and 6.46%, respectively. In contrast, their homologs CATHPb2, -, and 6 all showed higher cytotoxicity, especially CATHPb4, with a hemolysis rate of 65.59%.|||——"	"J Med Chem
. 2018 Mar 8;61(5):2075-2086. doi: 10.1021/acs.jmedchem.8b00036. Epub 2018 Feb 26.|||J Med Chem
. 2018 Mar 8;61(5):2075-2086. doi: 10.1021/acs.jmedchem.8b00036. Epub 2018 Feb 26||Ouyang et al., 2022|||29466000|||J Med Chem. 2018 Mar 8;61(5):2075-2086. doi: 10.1021/acs.jmedchem.8b00036. PubMed|||29466000|||J Med Chem
. 2018 Mar 8;61(5):2075-2086. doi: 10.1021/acs.jmedchem.8b00036. Epub 2018 Feb 26.||Ouyang et al., 2022|||J Med Chem. 2018 Mar 8;61(5):2075-2086. doi: 10.1021/acs.jmedchem.8b00036. PubMed"	31	
FPDB01064	AP02965|||AP02965|||Python Cathelicidin CATHPb4|||Python Cathelicidin CATHPb2|||AP02965	"	
KRNGFRKFMRRLKKFFAGGGSSIAHIKLH"	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-Gram+ S. aureus ATCC25923 or MRSA, activity value is MIC = 75 ug/ml||Anti-S. epidermidis, activity value is MIC = 75 ug/ml||Anti-N. asteroids, activity value is MIC = 37.5 ug/ml||Anti-B. cereus, activity value is MIC = 9.38 ug/ml||Anti-E.faecalis IS 981, activity value is MIC > 100 ug/ml||Anti-E. faecium IS 1299, activity value is MIC = 18.75 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 37.5||Anti-K.oxytoca, activity value is MIC > 100 ug/ml||Anti-S. paratyphi IS 738, activity value is MIC = 75 ug/ml||Anti-D. bacillus, activity value is MIC = 2.34 ug/ml||Anti-K. pneumoniae, activity value is MIC = 75 ug/ml||Anti-S. maltophilia, activity value is MIC = 9.38 ug/ml||Anti-P.aeruginosa ATCC 27853, activity value is MIC > 100 ug/ml||Anti-and fungi C. albicans, activity value is MIC = 18.75||Anti-Staphylococcus aureus 08032706, activity value is MIC = 75 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 75 ug/ml||Anti-Nocardia asteroides, activity value is MIC = 37.5 ug/ml||Anti-Bacillus cereus, activity value is MIC = 9.38 ug/ml||Anti-Enterococcus faecium 1299, activity value is MIC = 18.75 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 37.5 ug/ml||Anti-Escherichia coli 08040726, activity value is MIC = 75 ug/ml||Anti-Escherichia coli 08032813, activity value is MIC = 75 ug/ml||Anti-Salmonella enterica subsp. enterica serovar Paratyphi A, activity value is MIC = 75 ug/ml||Anti-Shigella sp, activity value is MIC = 2.34 ug/ml||Anti-Klebsiella pneumoniae 08B343, activity value is MIC = 75 ug/ml||Anti-Stenotrophomonas maltophilia, activity value is MIC = 9.38 ug/ml||Anti-Candida albicans 08022710, activity value is MIC = 37.5 ug/ml||Anti-Candida albicans 08030401, activity value is MIC = 37.5 ug/ml||Anti-Candida albicans 08022821, activity value is MIC = 37.5 ug/ml||Anti-Candida albicans 08030809, activity value is MIC = 37.5 ug/ml||Anti-Candida albicans 08030102, activity value is MIC = 18.75 ug/ml||Anti-Candida glabrata 08A802, activity value is MIC = 37.5 ug/ml||Anti-Candida glabrata 09050201, activity value is MIC = 75 ug/ml	Burmese python, Python bivittatu|||Python bivittatu|||Python bivittatu|||Burmese python, Python bivittatu	N/A	"In this document, the key values related to the hemolytic activity of the novel antimicrobial peptide CATHPb1 derived from the Burmese python (Python bivittatus) were determined through human red blood cell hemolysis assays (with 0.1% Triton X-100 as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration: 100 µg/ml (approximately 2.7–85 times its effective antibacterial concentration MIC = 1.17–37.5 µg/ml)

- Hemolysis rate: At a concentration of 100 µg/ml, CATHPb1 caused only 6.63% hemolysis of freshly prepared human red blood cells, far below the safety threshold for hemolytic toxicity in clinical applications, exhibiting extremely low hemolytic activity.

Experimental Conditions and Supplemental Notes

- Experimental conditions: Series-diluted CATHPb1 was co-incubated with fresh human red blood cell suspension, and the hemolysis rate was calculated by lactate dehydrogenase (LDH) release assay or hemoglobin absorbance measurement. The experiment was repeated multiple times to ensure reproducibility.

- Safety relevance: The antibacterial effective concentration of CATHPb1 (MIC against MRSA/VRSA = 1.17–37.5 µg/ml) is far lower than the concentration causing slight hemolysis (100 µg/ml), and the cytotoxicity against human liver cells (HL-7702) and mouse peritoneal macrophages (MPMs) is extremely low (cell death rates at 100 µg/ml were 4.46% and 6.46%, respectively). The degranulation rate of mast cells (LAD2) was only 10.97%, further confirming its safety for eukaryotic cells.

- Comparison with homologs: Its homologous peptide CATHPb4 exhibited a hemolysis rate as high as 65.59% at the same concentration. The low hemolytic property of CATHPb1 is significantly superior to other homologous peptides, indicating its potential for clinical application (especially suitable for systemic or local administration).|||Burmese python, Python bivittatu||CATHPb1 up to 100 ug/ml (5-fold higher than MICs) only nduced 6.63% hemolysis of fresh-prepared human erythrocytes, 4.46% and 6.46% death of HL7702 and MPMs, respectively, quantified by MTT and LDH assays (Table S3). In contrast, its orthologs, CATHPb2−6, all showed higher cytotoxicities, especially CATHPb4, which even induced 65.59% hemolysis. In addition, cytotoxicity for neutrophil was also determined by calcein leakage assay,22 which showed little increased fluorescence level of supernatant after treatment of 100 ug/ml CATHPb2 (data not shown).|||Human erythrocytes (7.28% Hemolysis at 100 ug/ml|||Human erythrocytes (7.28% Hemolysis at 100 ug/ml|||The hemolysis rates of HL7702 and MPM against fresh human red blood cells were measured by the tetramethylazobenzene salt colorimetric method and the lactic acid dehydrogenase colorimetric method, and were 6.63%, with mortality rates of 4.46% and 6.46%, respectively. In contrast, their homologs CATHPb2, -, and 6 all showed higher cytotoxicity, especially CATHPb4, with a hemolysis rate of 65.59%."	"J Med Chem
. 2018 Mar 8;61(5):2075-2086. doi: 10.1021/acs.jmedchem.8b00036. Epub 2018 Feb 26.|||J Med Chem
. 2018 Mar 8;61(5):2075-2086.doi: 10.1021/acs.jmedchem.8b00036.Epub 2018 Feb 26.|||29466000|||29466000|||J Med Chem
. 2018 Mar 8;61(5):2075-2086. doi: 10.1021/acs.jmedchem.8b00036. Epub 2018 Feb 26."	29	
FPDB01065	AP02966|||AP02966|||Python Cathelicidin CATHPb3|||Python Cathelicidin CATHPb4|||AP02966	TRSRWRRFIRGAGRFARRYGWRIALGLVG	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-Gram+ S. aureus ATCC25923 or MRSA, activity value is MIC = 18.75 ug/ml||Anti-S. epidermidis, activity value is MIC = 18.75 ug/ml||Anti-N. asteroids, activity value is MIC = 9.38 ug/ml||Anti-B. cereus, activity value is MIC = 9.38 ug/ml||Anti-E. faecalis IS 981, activity value is MIC = 37.5 ug/ml||Anti-E. faecium IS 1299, activity value is MIC = 18.75 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 18.75 ug/ml||Anti-K. oxytoca, activity value is MIC = 18.75 ug/ml||Anti-S. paratyphi IS 738, activity value is MIC = 37.5 ug/ml||Anti-D. bacillus, activity value is MIC = 4.69 ug/ml||Anti-K. pneumoniae, activity value is MIC = 18.75||Anti-S. maltophilia, activity value is MIC = 18.75 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 9.38||Anti-and fungi C. albicans, activity value is MIC = 9.38||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 18.75 ug/ml||Anti-Staphylococcus aureus 08032712, activity value is MIC = 18.75 ug/ml||Anti-Staphylococcus aureus 08032810, activity value is MIC = 18.75 ug/ml||Anti-Staphylococcus aureus 08032706, activity value is MIC = 18.75 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 18.75 ug/ml||Anti-Nocardia asteroides, activity value is MIC = 9.38 ug/ml||Anti-Bacillus cereus, activity value is MIC = 9.38 ug/ml||Anti-Enterococcus faecalis 981, activity value is MIC = 37.5 ug/ml||Anti-Enterococcus faecium 1299, activity value is MIC = 18.75 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 18.75 ug/ml||Anti-Escherichia coli 08040726, activity value is MIC = 18.75 ug/ml||Anti-Escherichia coli 08032813, activity value is MIC = 18.75 ug/ml||Anti-Klebsiella oxytoca, activity value is MIC = 18.75 ug/ml||Anti-Salmonella enterica subsp. enterica serovar Paratyphi A, activity value is MIC = 37.5 ug/ml||Anti-Shigella sp, activity value is MIC = 4.69 ug/ml||Anti-Klebsiella pneumoniae 08B343, activity value is MIC = 18.75 ug/ml||Anti-Klebsiella pneumoniae 1400, activity value is MIC = 37.5 ug/ml||Anti-Stenotrophomonas maltophilia, activity value is MIC = 18.75 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 18.75 ug/ml||Anti-Pseudomonas aeruginosa 08031014, activity value is MIC = 9.38 ug/ml||Anti-Candida albicans 08022710, activity value is MIC = 18.75 ug/ml||Anti-Candida albicans 08030401, activity value is MIC = 9.38 ug/ml||Anti-Candida albicans 08030809, activity value is MIC = 18.75 ug/ml||Anti-Candida albicans 08030102, activity value is MIC = 18.75 ug/ml||Anti-Candida glabrata 08A802, activity value is MIC = 9.38 ug/ml||Anti-Candida glabrata 09050201, activity value is MIC = 18.75 ug/ml	Burmese python, Python bivittatu|||Python bivittatu|||Python bivittatu|||Burmese python, Python bivittatu	N/A	"In this document, the key values related to the hemolytic activity of the novel antimicrobial peptide CATHPb1 derived from the Burmese python (Python bivittatus) were determined through human red blood cell hemolysis assays (with 0.1% Triton X-100 as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration: 100 µg/ml (approximately 2.7–85 times its effective antibacterial concentration MIC = 1.17–37.5 µg/ml)

- Hemolysis rate: At a concentration of 100 µg/ml, CATHPb1 caused only 6.63% hemolysis of freshly prepared human red blood cells, far below the safety threshold for hemolytic toxicity in clinical applications, exhibiting extremely low hemolytic activity.

Experimental Conditions and Supplemental Notes

- Experimental conditions: Series-diluted CATHPb1 was co-incubated with fresh human red blood cell suspension, and the hemolysis rate was calculated by lactate dehydrogenase (LDH) release assay or hemoglobin absorbance measurement. The experiment was repeated multiple times to ensure reproducibility.

- Safety relevance: The antibacterial effective concentration of CATHPb1 (MIC against MRSA/VRSA = 1.17–37.5 µg/ml) is far lower than the concentration causing slight hemolysis (100 µg/ml), and the cytotoxicity against human liver cells (HL-7702) and mouse peritoneal macrophages (MPMs) is extremely low (cell death rates at 100 µg/ml were 4.46% and 6.46%, respectively). The degranulation rate of mast cells (LAD2) was only 10.97%, further confirming its safety for eukaryotic cells.

- Comparison with homologs: Its homologous peptide CATHPb4 exhibited a hemolysis rate as high as 65.59% at the same concentration. The low hemolytic property of CATHPb1 is significantly superior to other homologous peptides, indicating its potential for clinical application (especially suitable for systemic or local administration).|||Burmese python, Python bivittatu||CATHPb1 up to 100 ug/ml (5-fold higher than MICs) only nduced 6.63% hemolysis of fresh-prepared human erythrocytes, 4.46% and 6.46% death of HL7702 and MPMs, respectively, quantified by MTT and LDH assays (Table S3). In contrast, its orthologs, CATHPb2−6, all showed higher cytotoxicities, especially CATHPb4, which even induced 65.59% hemolysis. In addition, cytotoxicity for neutrophil was also determined by calcein leakage assay,22 which showed little increased fluorescence level of supernatant after treatment of 100 ug/ml CATHPb3 (data not shown).|||Human erythrocytes (65.59% Hemolysis at 100 ug/ml|||Human erythrocytes (65.59% Hemolysis at 100 ug/ml|||The hemolysis rates of HL7702 and MPM against fresh human red blood cells were measured by the tetramethylazobenzene salt colorimetric method and the lactic acid dehydrogenase colorimetric method, and were 6.63%, with mortality rates of 4.46% and 6.46%, respectively. In contrast, their homologs CATHPb2, -, and 6 all showed higher cytotoxicity, especially CATHPb4, with a hemolysis rate of 65.59%."	"J Med Chem
. 2018 Mar 8;61(5):2075-2086. doi: 10.1021/acs.jmedchem.8b00036. Epub 2018 Feb 26.|||J Med Chem
. 2018 Mar 8;61(5):2075-2086. doi: 10.1021/acs.jmedchem.8b00036. Epub 2018 Feb 26|||29466000|||29466000|||J Med Chem
. 2018 Mar 8;61(5):2075-2086. doi: 10.1021/acs.jmedchem.8b00036. Epub 2018 Feb 26."	29	
FPDB01066	AP02967|||AP02967|||CAMPSQ23004|||Temporin-GHa|||AP02967	"	
FLQHIIGALGHLF"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anti-MRSA or ATCC 25923, activity value is MIC = 6.8||Anti-B.subtilis ATCC 6633, activity value is MIC = 106.8 uM||Anti-P. gingivalis ATCC 33277, activity value is MIC = 12.5 uM||Anti-B. adolescentis ATCC 15703, activity value is MIC = 50 uM||Anti-B. breve ATCC 15700, activity value is MIC = 100 uM||Anti-L. acidophilus ATCC 4356, activity value is MIC = 25 uM||Anti-S. sanguis ATCC 10556, activity value is MIC = 1.6 uM||Anti-and S. mutans UA159, activity value is MIC = 12.5 uM||Anti-V. alginolyticus IS, activity value is MIC = 26.6 uM||Anti-P.aeruginosa ATCC 15442, activity value is MIC = 106.8 uM||Anti-and C. albicans ATCC 10231, activity value is MIC = 26.6 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 26.6 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 6.8 uM||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 106.8 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 26.6 uM||Anti-Escherichia coli, activity value is MIC = 53.2 uM||Anti-Escherichia coli D31, activity value is MIC = 13.3 uM||Anti-Vibrio alginolyticus, activity value is MIC = 26.6 uM||Anti-Pseudomonas aeruginosa ATCC 15442, activity value is MIC = 106.8 uM||Anti-Candida albicans ATCC 10231, activity value is MIC = 26.6 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 12.5 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MBC = 25 uM||Anti-Streptococcus mutans ATCC 25175, activity value is MIC = 25 uM||Anti-Streptococcus mutans ATCC 25175, activity value is MBC = 50 uM||Anti-Bacillus subtilis ATCC 6633, activity value is MIC > 100 uM||Anti-Bacillus subtilis ATCC 6633, activity value is MBC > 100 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 100 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MBC > 100 uM||Anti-Staphylococcus aureus MR, activity value is MIC > 100 uM||Anti-Staphylococcus aureus MR, activity value is MBC > 100 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 25 uM||Anti-Escherichia coli ATCC 25922, activity value is MBC = 50 uM||Anti-Escherichia coli D31, activity value is MIC > 100 uM||Anti-Escherichia coli D31, activity value is MBC > 100 uM||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC > 100 uM||Anti-Pseudomonas aeruginosa PAO1, activity value is MBC > 100 uM||Anti-Pseudomonas aeruginosa ATCC 15442, activity value is MIC > 100 uM||Anti-Pseudomonas aeruginosa ATCC 15442, activity value is MBC > 100 uM||Anti-Candida albicans ATCC 10231, activity value is MIC = 50 uM||Anti-Candida albicans ATCC 10231, activity value is MFC > 100 uM||Antibacterial	skin, Hylarana guentheri, China, Asia.|||Sylvirana guentheri (Hylarana guentheri)|||Sylvirana guentheri (Hylarana guentheri)|||skin, Hylarana guentheri, China, Asia.|||skin, Hylarana guentheri, China, Asia.	Helix	skin, Hylarana guentheri, China, Asia.|||Human erythrocytes (10% Hemolysis at 20 uM, Human erythrocytes (50% Hemolysis at 115 uM|||Human erythrocytes (10% Hemolysis at 20 uM, Human erythrocytes (50% Hemolysis at 115 uM	"Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023.|||Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457.doi: 10.1093/abbs/gmx023.|||28338958, 31752079|||Acta Biochim Biophys Sin (Shanghai). 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023. PubMed|||28338958, 31752079|||Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023.|||Acta Biochim Biophys Sin (Shanghai). 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023. PubMed"	13	
FPDB01067	AP02968|||AP02968|||CAMPSQ23005|||Temporin-GHb|||AP02968	"	
FIHHIIGALGHLF"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Gram+ S. aureus ATCC 43300 MRSA or ATCC 25923, activity value is MIC = 6.8||Anti-B. subtilis ATCC 6633, activity value is MIC = 52.9 uM||Anti-E. coli ATCC 25922 or D31, activity value is MIC = 6.8||Anti-V. alginolyticus IS, activity value is MIC = 13.2 uM||Anti-P. aeruginosa ATCC 15442, activity value is MIC = 26.4 uM||Anti-and C. albicans ATCC 10231, activity value is MIC = 26.4 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 26.4 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 6.8 uM||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 52.9 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 13.2 uM||Anti-Escherichia coli, activity value is MIC = 26.4 uM||Anti-Escherichia coli D31, activity value is MIC = 6.8 uM||Anti-Vibrio alginolyticus, activity value is MIC = 13.2 uM||Anti-Pseudomonas aeruginosa ATCC 15442, activity value is MIC = 26.4 uM||Anti-Candida albicans ATCC 10231, activity value is MIC = 26.4 uM||Antibacterial	skin, Hylarana guentheri, China, Asia.|||Sylvirana guentheri (Hylarana guentheri)|||Sylvirana guentheri (Hylarana guentheri)|||skin, Hylarana guentheri, China, Asia.|||skin, Hylarana guentheri, China, Asia.	N/A	skin, Hylarana guentheri, China, Asia.	"Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023.|||Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457.doi: 10.1093/abbs/gmx023.|||28338958|||28338958|||Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023.|||Acta Biochim Biophys Sin (Shanghai). 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023. PubMed"	13	
FPDB01068	AP02969|||AP02969|||CAMPSQ23006|||Temporin-GHc|||AP02969	"	
FLQHIIGALTHIF"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anti-Gram+ S. aureus ATCC 43300 MRSA or ATCC 25923, activity value is MIC = 12.9||Anti-B.subtilis ATCC 6633, activity value is MIC = 104 uM||Anti-V. alginolyticus IS, activity value is MIC = 12.9 uM||Anti-P.aeruginosa ATCC 15442, activity value is MIC = 104 uM||Anti-and C.albicans ATCC 10231, activity value is MIC = 104 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 51.8 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 12.9 uM||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 104 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 104 uM||Anti-Escherichia coli, activity value is MIC = 104 uM||Anti-Escherichia coli D31, activity value is MIC = 25.8 uM||Anti-Vibrio alginolyticus, activity value is MIC = 12.9 uM||Anti-Pseudomonas aeruginosa ATCC 15442, activity value is MIC = 104 uM||Anti-Candida albicans ATCC 10231, activity value is MIC = 104 uM||Anti-Streptococcus mutans, activity value is MIC = 12.6 uM||Anti-Streptococcus mutans, activity value is MBC > 50 uM||Antibacterial	skin, Hylarana guentheri, China, Asia.|||Sylvirana guentheri (Hylarana guentheri)|||Sylvirana guentheri (Hylarana guentheri)|||skin, Hylarana guentheri, China, Asia.|||skin, Hylarana guentheri, China, Asia.	Helix	skin, Hylarana guentheri, China, Asia.|||Human oral epithelial cells ( at NA , Human erythrocytes (50% Hemolysis at 100 uM|||Human oral epithelial cells ( at NA , Human erythrocytes (50% Hemolysis at 100 uM	"Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023.|||Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457.doi: 10.1093/abbs/gmx023.|||28338958|||Acta Biochim Biophys Sin (Shanghai). 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023. PubMed|||28338958|||Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023.|||Acta Biochim Biophys Sin (Shanghai). 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023. PubMed"	13	
FPDB01069	AP02970|||AP02970|||CAMPSQ23007|||Temporin-GHd|||AP02970	"	
FLQHIIGALSHFF"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anti-and fungi. Active against Gram+ S. aureus ATCC 43300 MRSA or ATCC 25923, activity value is MIC = 12.7 uM||Anti-B.subtilis ATCC 6633, activity value is MIC = 102.3 uM||Anti-V. alginolyticus IS, activity value is MIC = 12.7 uM||Anti-P. aeruginosa ATCC 15442, activity value is MIC = 51 uM||Anti-and C. albicans ATCC 10231, activity value is MIC = 25.5 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 12.7 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 12.7 uM||Anti-Bacillus subtilis ATCC 6633, activity value is MIC = 102.3 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 12.7 uM||Anti-Escherichia coli, activity value is MIC = 25.5 uM||Anti-Escherichia coli D31, activity value is MIC = 12.7 uM||Anti-Vibrio alginolyticus, activity value is MIC = 12.7 uM||Anti-Pseudomonas aeruginosa ATCC 15442, activity value is MIC = 51 uM||Anti-Candida albicans ATCC 10231, activity value is MIC = 25.5 uM||Anti-Streptococcus mutans, activity value is MIC = 13.1 uM||Anti-Streptococcus mutans, activity value is MBC = 26 uM||Antibacterial	skin, Hylarana guentheri, China, Asia.|||Sylvirana guentheri (Hylarana guentheri)|||Sylvirana guentheri (Hylarana guentheri)|||skin, Hylarana guentheri, China, Asia.|||skin, Hylarana guentheri, China, Asia.	Helix	skin, Hylarana guentheri, China, Asia.|||Human oral epithelial cells ( at NA , Human erythrocytes (50% Hemolysis at 50 uM|||Human oral epithelial cells ( at NA , Human erythrocytes (50% Hemolysis at 50 uM	"Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023.|||Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457.doi: 10.1093/abbs/gmx023.|||28338958|||Acta Biochim Biophys Sin (Shanghai). 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023. PubMed|||28338958|||Acta Biochim Biophys Sin (Shanghai)
. 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023.|||Acta Biochim Biophys Sin (Shanghai). 2017 May 1;49(5):450-457. doi: 10.1093/abbs/gmx023. PubMed"	13	
FPDB01070	AP02972|||AP02972|||Marcin-22, MAC-22	"	
FFGHLFKLATKIIPSFFRRKNQ"	Anti-Gram+ & Gram-||Insecticidal||Anti-MRSA||Active against Gram+ and Gram- bacteria. Active against B. megaterium CGMCC 1.0459 (lethal concentration LC 1.35 uM)||B. subtilis CGMCC 1.2428 (LC 2.11 uM)||M. luteus CGMCC 1.0290 (LC 2.58 uM)||methicillin-sensitive S. aureus CGMCC 1.89 (LC 1.35 uM)||penicillin-sensitive S. epidermidi P1111 (LC 1.35 uM)||methicillin-resistant coagulase-negative S. aureus p1369 (LC 1.35 uM)||MRSA P1374 (LC 1.35 uM)||penicillin-resistant S. epidermidis P1389 (LC 3.72 uM)||S. aureus J685 (LC 2.39 uM)||S. aureus J698 (LC 2.39 uM)||S. aureus J700 (LC 2.39 uM)||S. sanguinis ATCC 1.2497 (LC 9.12 uM)||S. salivarius ATCC 1.2498 (LC 4.22 uM)||S. mutans ATCC 1.2499 (LC 4.22 uM)||and S. warneri ATCC 1.2824 (LC 4.45 uM).||Antibacterial	venom, Mesobuthus eupeus, Asia|||Mesobuthus martensii	Helix	ekaiuhvofznnn9fimd0d|||venom, Mesobuthus eupeus|||Mouse erythrocytes (100% Hemolysis at 12.5 uM)	"Front Microbiol
. 2018 Feb 27:9:320. doi: 10.3389/fmicb.2018.00320. eCollection 2018.|||Front Microbiol
. 2018 Feb 27:9:320.doi: 10.3389/fmicb.2018.00320.eCollection 2018.|||29599756"	22	
FPDB01071	AP02973|||AP02973|||Marmelittin, Peptide BmKb1|||Marmelittin, Peptide BmKb1|||AP02973	"	
FLFSLIPSAISGLISAFKGRRKRDLN"	Anti-Gram+ & Gram-||Antifungal||Insecticidal||Anti-MRSA||Anti-methicillin-sensitive S. aureus CGMCC 1.89, activity value is MIC = 4.87 uM||Anti-penicillin-sensitive S. epidermidi P1111, activity value is MIC = 4.24 uM||Anti-methicillin-resistant coagulase-negative S. aureus p1369, activity value is MIC = 3.01 uM||Bacillus megaterium CGMCC 1.0459 (LC = 2.86 uM)||B. subtilis CGMCC 1.2428 (LC = 3.13 uM)||M. luteus CGMCC 1.0290 (LC =1.85 uM)||MRSA P1374 (LC = 2.6 uM)||S. aureus J685 (LC = 8.41 uM)||S. salivarius ATCC 1.2498 (LC = 4.7 uM)||E. coli ATCC 25922 (LC = 6.41 uM)||S. enterca ATCC 14028 (LC = 1.61 uM)||C. albicans JX1009 (LC = 6.49 uM)||Aspergillus nidulans A28 (LC = 7.14 uM)||Antibacterial||Antifungal ; Bacillus megaterium CGMCC 1.0459 (LC = 2.86 uM)	venom, Mesobuthus eupeus, Asia|||Mesobuthus martensii|||Mesobuthus martensii|||venom, Mesobuthus eupeus, Asia	Helix	ekaiuhvofznnn9fimd0d|||venom, Mesobuthus eupeus|||Mouse erythrocytes (66+-1.2% Hemolysis at 3.125 uM)|||Mouse erythrocytes (66+-1.2% Hemolysis at 3.125 uM)	"Front Microbiol
. 2018 Feb 27:9:320. doi: 10.3389/fmicb.2018.00320. eCollection 2018.|||Front Microbiol
. 2018 Feb 27:9:320. doi: 10.3389/fmicb.2018.00320. eCollection 2018.|||29599756|||29599756|||Front Microbiol
. 2018 Feb 27:9:320. doi: 10.3389/fmicb.2018.00320. eCollection 2018."	26	
FPDB01072	AP02974|||AP02974|||Venom antimicrobial peptide-10, MeuFSPL-2|||Venom antimicrobial peptide-10, MeuFSPL-2|||AP02974	"	
FLFSLIPSAISGLINAFK"	Anti-Gram+ & Gram-||Antifungal||Insecticidal||Anti-MRSA||Active against Gram+ and Gram- bacteria. Active against B. cereus CGMCC 1.1846 (LC 19.57 uM)||B. megaterium CGMCC 1.0459 (lethal concentration LC 2.67 uM)||B. subtilis CGMCC 1.2428 (LC 4.01 uM)||M. luteus CGMCC 1.0290 (LC 1.5 uM)||methicillin-sensitive S. aureus CGMCC 1.89 (LC 3.14 uM)||penicillin-sensitive S. epidermidi P1111 (LC 4.77 uM)||methicillin-resistant coagulase-negative S. aureus p1369 (LC 3.88 uM)||MRSA P1374 (LC 3.61 uM)||penicillin-resistant S. epidermidis P1389 (LC 3.52 uM)||MRSA p1386 (LC 5.13 uM)||PRSE P1389 (LC 5.13 uM)||S. aureus J685 (LC 5.36 uM)||S. aureus J698 (LC 4.11 uM)||S. aureus J700 (LC 8.44 uM)||S. aureus J706 (LC 7.049 uM)||S. aureus J708 (LC 6.21 uM)||S. aureus J710 (LC 7.04 uM)||S. sanguinis ATCC 1.2497 (LC 2.7 uM)||S. salivarius ATCC 1.2498 (LC 5.36 uM)||S. mutans ATCC 1.2499 (LC 5.23 uM)||S. warneri ATCC 1.2824 (LC 8.65 uM)||and SSCA CGMCC 4.1765 (LC 7.75 uM).||Antibacterial||Antifungal ; Bacillus megaterium CGMCC 1.0459 (LC = 2.67 uM)||B. subtilis CGMCC 1.2428 (LC = 4.01 uM)||M. luteus CGMCC 1.0290 (LC =1.5 uM)||MRSA P1374 (LC = 3.61 uM)||S. aureus J685 (LC = 5.36 uM)||S. salivarius ATCC 1.2498 (LC = 5.36 uM)||E. coli ATCC 25922 (LC = 12.16 uM)||C. albicans JX1009 (LC = 11.58 uM)	venom, Mesobuthus eupeus, Asia|||Mesobuthus eupeus	Helix	ekaiuhvofznnn9fimd0d|||venom, Mesobuthus eupeus|||Mouse erythrocytes (100% Hemolysis at 12.5 uM)|||Mouse erythrocytes (100% Hemolysis at 12.5 uM)	"Front Microbiol
. 2018 Feb 27:9:320. doi: 10.3389/fmicb.2018.00320. eCollection 2018.|||Front Microbiol
. 2018 Feb 27:9:320.doi: 10.3389/fmicb.2018.00320.eCollection 2018.|||29599756|||29599756|||Front Microbiol
. 2018 Feb 27:9:320. doi: 10.3389/fmicb.2018.00320. eCollection 2018."	18	
FPDB01073	AP02975|||AP02975|||Meucin-22, MUC-22	"	
FFGHLFKLATKIIPSLFQRKKE"	Anti-Gram+ & Gram-||Insecticidal||Anti-MRSA||Active against Gram+ and Gram- bacteria. Active against B. megaterium CGMCC 1.0459 (lethal concentration LC 3.72 uM)||B. subtilis CGMCC 1.2428 (LC 1.86 uM)||M. luteus CGMCC 1.0290 (LC 2.71 uM)||methicillin-sensitive S. aureus CGMCC 1.89 (LC 1.35 uM)||penicillin-sensitive S. epidermidi P1111 (LC 1.61 uM)||methicillin-resistant coagulase-negative S. aureus p1369 (LC 2.21 uM)||MRSA P1374 (LC 0.87 uM)||penicillin-resistant S. epidermidis P1389 (LC 0.56 uM)||S. aureus J685 (LC 2.66 uM)||S. aureus J698 (LC 2.66 uM)||S. aureus J700 (LC 2.66 uM)||S. sanguinis ATCC 1.2497 (LC 3.37 uM)||S. salivarius ATCC 1.2498 (LC 4.22 uM)||S. mutans ATCC 1.2499 (LC 2.39 uM)||and S. warneri ATCC 1.2824 (LC 3.76 uM).||Antibacterial	venom, Mesobuthus eupeus, Asia|||Mesobuthus eupeus	Helix	ekaiuhvofznnn9fimd0d|||venom, Mesobuthus eupeus|||Mouse erythrocytes (100% Hemolysis at 12.5 uM)	"Front Microbiol
. 2018 Feb 27:9:320. doi: 10.3389/fmicb.2018.00320. eCollection 2018.|||Front Microbiol
. 2018 Feb 27:9:320.doi: 10.3389/fmicb.2018.00320.eCollection 2018.|||29599756"	22	
FPDB01074	AP03001|||DRAMP20803|||AP03001|||DRAMP20803	"	
FFRNLWKGAKAAFRAGHAAWRA"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anti-Gram- E. coli ATCC 25922, activity value is MIC = 6.25 ug/ml||Anti-P. aeruginosa ATCC10662, activity value is MIC = 50 ug/ml||Anti-A. baumannii clinical isolate, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 3.1 ug/ml||Anti-S. epidermidis ATCC 1435, activity value is MIC = 1.6 ug/ml||Anti-and fungi C. albicans, activity value is MIC = 6.2 ug/ml||Anti-C. tropicalis, activity value is MIC = 6.2 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 3.12 ug/ml||Anti-Staphylococcus epidermidis ATCC 1435, activity value is MIC = 1.56 ug/ml||Anti-Staphylococcus aureus MRSA, activity value is MIC = 3.12 ug/ml||Anti-Escherichia coli ATCC 25922, activity value is MIC = 6.25 ug/ml||Anti-Pseudomonas aeruginosa ATCC10662, activity value is MIC = 50 ug/ml||Anti-Acinetobacter baumannii clinical isolate, activity value is MIC = 6.25 ug/ml||Anti-Candida albicans clinical isolate, activity value is MIC = 6.25 ug/ml||Anti-Candida tropicalis clinical isolate, activity value is MIC = 6.25 ug/ml||Anti-##Gram-negative bacteria: Escherichia coli ATCC 25922, activity value is MIC = 6.25 ug/ml||Anti-##Fungi:Candida albicans clinical isolate, activity value is MIC = 6.25 ug/ml	Tiger tail seahorse, Hippocampus comes|||Hippocampus comes|||Tiger tail seahorse, Hippocampus comes|||Hippocampus comes|||Tiger tail seahorse, Hippocampus comes	Alpha helix	"In this document, the key values related to the hemolytic activity of the novel antibacterial peptide moronecidin-like derived from seahorse (Hippocampus comes) and its control peptide moronecidin (derived from hybrid striped bass) are as follows, measured by human red blood cell (hRBCs) hemolysis assay (with 0.1% Triton X-100 as the 100% hemolysis positive control and PBS as the 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test Indicator: The hemolytic toxicity of the two peptides was evaluated using the half-maximal hemolytic concentration (HC_{50}, i.e., the peptide concentration inducing 50% human RBC hemolysis) as the core indicator.

- HC_{50} values for each peptide:

- Moronecidin-like (novel peptide): HC_{50} = 87.5 μg/mL, showing extremely low hemolytic activity, with its effective antibacterial concentration (against Gram-positive bacteria MIC = 1.56–3.12 μg/mL) far below the HC_{50}, indicating a high therapeutic index.

- Moronecidin (control peptide): HC_{50} = 2.34 μg/mL, showing very strong hemolytic activity, significantly higher than the novel peptide (about 37 times that of moronecidin-like), with its effective antibacterial concentration close to the HC_{50}, indicating a high risk of hemolysis.

- Dose-Dependent Hemolysis Rate:

- At a concentration of 100 μg/mL, moronecidin induced nearly 100% hemolysis of human red blood cells, while the hemolysis rate of moronecidin-like remained below 20%, further confirming that the hemolytic toxicity of moronecidin is much higher than that of moronecidin-like.

Experimental Conditions and Supplementary Notes

1. Experimental Conditions: A series of diluted peptides (concentrations 1.56–100 μg/mL) were co-incubated with 4% human red blood cell suspension at 37°C for 1 hour. After centrifugation, the absorbance of the supernatant at 405 nm was measured, and the hemolysis rate was calculated using the formula (Hemolysis rate = [(A_pep − A_PBS)/(A_Tr...|||Tiger tail seahorse, Hippocampus comes||One ofthe main side effects and barriers in the clinical use of
moronecidin is high its hemolytic activity; here, we compared
the hemolytic activity ofmoronecidin-like peptide and that of
moronecidin against hRBCs. Moronecidin showed high he-
molytic activity in a dose-dependent manner, while
moronecidin-like peptide exhibited significantly lower hemo-
lytic activity than moronecidin. The HC50 for moronecidin-
like and moronecidin were 87.5 and 2.34 ug/ml, respectively
(Fig. 7a). In next step, we assayed cytotoxic activity of
moronecidin-like and moronecidin against a mammalian cell,
human embryonic kidney cells 293 (HEK-293). Consistent
with hemolytic results, moronecidin-like showed significantly
lower cytotoxic activity against HEK-293 cells compared with
moronecidin (Fig. 7b).|||Specific hemolytic data for the two antimicrobial peptides (moronecidin-like and moronecidin) are clearly provided in the document, with the following core information:

1. Key hemolytic indicators (HCYQ)

moronecidin-like (novel antimicrobial peptide of hippocampal origin): H50 hemolytic concentration of human red blood cells (hRBCs) HC-60 = 87.5 ug/ml.
moronecidin (hybrid striped sea bass-derived antimicrobial peptide, control group): half hemolytic concentration of human red blood cells HC-60 = 2.34 ug/ml.

HCBYL refers to the peptide concentration that induces 50% red blood cell hemolysis. The higher the value, the lower the hemolysis and the higher the safety. The above data indicate that moronecidin-like is significantly less hemolytic than moronecidin.

2. Background and details of hemolytic experiment

Experimental method: human red blood cell suspension (4% v/v,PBS) was incubated with different concentrations of peptide (1.56~100 ug/ml) for 1 hour (37°C), and the absorbance of the supernatant at 405 nm (reflecting the amount of hemoglobin released) was detected after centrifugation. With 0.1 Triton X-100 treatment group as 100% hemolysis positive control, PBS treatment group as negative control, the hemolysis rate was calculated by the formula:
\text {Hemolysis Rate (%)} = \left[\frac{A_{\ text {Peptide Treatment Group}}-A_{\ text{PBS Group }}}{ A_{\ text{0.1% Triton X-100 Group}}-A_{\ text{PBS Group }}}\ right] \times 100
Concentration dependence: moronecidin showed obvious dose-dependent hemolysis (the higher the concentration, the higher the hemolysis rate), and the hemolysis rate of moronecidin-like in the whole concentration range (1.56~100 ug/ml) tested was significantly lower than that of moronecidin with the same concentration (see Figure 7a).

Taken together, moronecidin-like exhibits lower hemolysis with its higher HCYB value, which is an important safety advantage as a potential clinical antimicrobial agent.|||Hemolytic core values

• Moronecidin-like (a novel antimicrobial peptide derived from seahorse): Half hemolytic concentration against human red blood cells (hRBCs) HC_{50} = 87.5 μg/ml
• Moronecidin (antimicrobial peptide derived from hybrid striped bass, control): Half hemolytic concentration against human red blood cells (hRBCs) HC_{50} = 2.34 μg/ml|||[Ref.30039186] 50% hemolysis at 87.5 ug/ml,25% hemolysis at 50 ug/ml,60% hemolysis at 100 ug/ml against human red cells|||One of the main side effects and barriers in the clinical use of moronecidin is high its hemolytic activity ; here, we compared the hemolytic activity of moronecidin-like peptide and that of moronecidin against hRBCs. Moronecidin showed high hemolytic activity in a dose-dependentmanner, while moronecidinlike peptide exhibited significantly lower hemo lytic activity than moronecidin.The HC50 for moronecidin like and moronecidin were 87.5 and 2.34 ug/ml, respectively (Fig. 7a)."	"Mar Biotechnol (NY)
. 2018 Dec;20(6):718-728. doi: 10.1007/s10126-018-9843-3. Epub 2018 Jul 23.|||Mar Biotechnol (NY). 2018 Jul 23. 20 (6), 718-728. doi: 10.1007/s10126-018-9843-3. PubMed|||Mar Biotechnol (NY). 2018 Dec;20(6):718-728.||Ref.30039186|||Mar Biotechnol (NY)
. 2018 Dec;20(6):718-728. doi: 10.1007/s10126-018-9843-3. Epub 2018 Jul 23.|||Mar Biotechnol (NY). 2018 Dec;20(6):718-728.||Ref.30039186|||Mar Biotechnol (NY). 2018 Jul 23. 20 (6), 718-728. doi: 10.1007/s10126-018-9843-3. PubMed"	22	
FPDB01075	AP03010|||AP03010|||Triintsin|||Triintsin|||AP03010	"	
GFGCPLNERECHSHCQSIGRKFGYCGGTLRLTCICGKE"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus AB94004 or ATCC25923 or ATCC6538, activity value is MIC = 0.06||Anti-S. epidermidis AB208187 or AB208188, activity value is MIC = 4||Anti-M. luteus AB93113, activity value is MIC = 0.06 uM||Anti-B. subtilis AB91021, activity value is MIC = 0.25 uM||Anti-G- E. coli AB94012 or ATCC25922, activity value is MIC = 0.06||Anti-P. aeruginosa ATCC9027 or ATCC27853, activity value is MIC = 0.06||Anti-K. pneumoniae RM3017, activity value is MIC = 0.25 uM||Anti-C. albicans RM2018, activity value is MIC = 16 uM||Anti-and C. parapsilosis RM1003, activity value is MIC = 16 uM||Antibacterial||Anti-S. aureus AB94004, activity value is MIC = 0.25 uM||Anti-S. aureus ATCC25923, activity value is MIC = 0.25 uM||Anti-S. aureus ATCC6538, activity value is MIC = 0.06 uM||Anti-S. AB20891, activity value is MIC = 32 uM||Anti-S. epidermidis AB208187, activity value is MIC = 8 uM||Anti-S. epidermidis AB208188, activity value is MIC = 4 uM||Anti-E. coli AB94012, activity value is MIC = 0.25 uM||Anti-E. coli ATCC25922, activity value is MIC = 0.06 uM||Anti-P. aeruginosa ATCC9027, activity value is MIC = 0.06 uM||Anti-P. aeruginosa ATCC27853, activity value is MIC = 0.25 uM||Anti-S. aureus RM101, activity value is MIC = 0.5 uM||Anti-MRSA RM329, activity value is MIC = 32 uM||Anti-MRSA P1374, activity value is MIC = 32 uM||Anti-C. parapsilosis RM1003, activity value is MIC = 16 uM	human pathogenic fungus, Trichophyton interdigitale|||Trichophyton interdigitale|||Trichophyton interdigitale|||human pathogenic fungus, Trichophyton interdigitale|||human pathogenic fungus, Trichophyton interdigitale	Bridge	9r591temhjn6g9dm6rsr|||human pathogenic fungus, Trichophyton interdigitale|||Human red blood cells(23.5% hemolysis at 1000 ug/ml)|||Human red blood cells(23.5% hemolysis at 1000 ug/ml)|||Some AMPs were terminated from further development as candidates for antibacterial agents due to hemolytic activities. Therefore, the released hemoglobin from erythrocytes was determined. At the final concentrations of 1000, 500, 250, 125, 62.5 and 32.25 ug/ml, the hemolysis hRBCs was 23.5%, 14.1%, 7.9%, 5.4%, 3.2% and 1.1%, respectively (Fig. S1).	"Peptides
. 2018 Sep:107:61-67. doi: 10.1016/j.peptides.2018.08.003. Epub 2018 Aug 10.|||Peptides
. 2018 Sep:107:61-67.doi: 10.1016/j.peptides.2018.08.003.Epub 2018 Aug 10.|||30102941|||30102941|||Peptides
. 2018 Sep:107:61-67. doi: 10.1016/j.peptides.2018.08.003. Epub 2018 Aug 10.|||Peptides. 2018 Aug 10. 107, 61-67. doi: 10.1016/j.peptides.2018.08.003. PubMed"	38	
FPDB01076	AP03015|||AP03015|||Dermaseptin DRS-CA-1|||Dermaseptin DRS-CA-1|||AP03015	"	
ALWKDLLKNVGKAAGKAVLNKVTDMVNQ"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-S. aureus MRSA, activity value is MIC = 4||Anti-E. coli, activity value is MIC = 4 uM||Anti-P. aeruginosa, activity value is MIC = 8 uM||Anti-K. pneumoniae, activity value is MIC = 8 uM||Anti-and E.faecalis, activity value is MIC = 128 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 4 uM	Phyllomedusa camba, Peru, South America|||Phyllomedusa camba|||Phyllomedusa camba|||Phyllomedusa camba, Peru, South America	Helix	"This document focuses on the study of novel dermaseptin antimicrobial peptides discovered from the secretions of two types of frog skin, involving multiple aspects such as peptide cloning, synthesis, antimicrobial activity, and hemolytic activity testing. Among these, hemolytic activity was tested using horse red blood cells, with 1% DMSO as the negative control and Triton X-100 as the positive control. The hemolysis rate and the half-maximal hemolytic concentration (HC_{50}) were calculated by measuring absorbance at 550 nm. The specific values are as follows:

Table

Peptide | Half-Maximal Hemolytic Concentration (μM) | Hemolytic Activity Analysis
--- | --- | ---
DRS-CA-1 | 114.7 | At MIC or MBC concentrations, there is no significant hemolytic activity against the tested microorganisms except for Enterococcus faecalis; compared to other peptides with high hemolytic activity, this peptide has a lower hemolysis rate at relatively low concentrations and causes minimal damage to red blood cells.
DRS-DU-1 | 216.6 | Has strong antimicrobial activity, with no significant hemolytic activity at MIC or MBC concentrations except against Enterococcus faecalis; higher than DRS-CA-1, indicating lower toxicity to red blood cells and causing less damage to normal cells while maintaining antimicrobial effects.
DP-1 |  | Has relatively low antimicrobial activity and almost no hemolytic activity; even at higher concentrations, it does not show significant hemolysis, making it safe for red blood cells, though its antimicrobial potency is weak.
DP-2 |  | Antimicrobial activity is restored, and its activity against Enterococcus faecalis is higher than that of natural peptides; shows no significant hemolytic activity, indicating a low risk of red blood cell damage while exerting antimicrobial effects, with potential application value.|||Phyllomedusa camba, Peru, South America||The MIC, MBC and HC50 values of all the peptides obtained from antimicrobial and hemolysis assays are summarized in Table 2. The two natural peptides, DRS-CA-1 and DRSDU-1, showed the same MIC values (4 uM) against S. aureus and E. coli and C. albicans. DRS-DU-1 was twofold more potent against MRSA, E. faecalis, K. pneumoniae and P. aeruginosa than DRS-CA-1. The MBC values of two natural peptides against seven tested microorganisms were two or four-fold higher than respective MICs. No obvious hemolysis activity was detected at the MIC or MBC concentrations except against E. faecalis. The two designed peptides also exhibited broad spectrum antimicrobial activities against the seven tested microorganisms, though the potency of DP-1 was much lower. However, the antimicrobial activities of DP-2 were restored comparing to DP-1. Additionally, the antimicrobial potency of DP-2 on E. faecalis was higher than the natural peptides.|||Horse erythrocytes (50% Hemolysis at 114.7 uM)|||Horse erythrocytes (50% Hemolysis at 114.7 uM)|||DRS-CA-1 and DRS-DU-1 exhibited strong antimicrobial activity against Gram-positive and Gram-negative bacteria and fungi with no obvious hemolytic activity, and almost the same proportion of polar residues and nonpolar residues as well as the a-helical structure."	"PeerJ
. 2018 Sep 19:6:e5635. doi: 10.7717/peerj.5635. eCollection 2018.|||PeerJ
. 2018 Sep 19:6:e5635. doi: 10.7717/peerj.5635. eCollection 2018.|||30258724|||30258724|||PeerJ
. 2018 Sep 19:6:e5635. doi: 10.7717/peerj.5635. eCollection 2018.|||PeerJ. 2018 Sep 19;6:e5635. doi: 10.7717/peerj.5635. PubMed"	28	
FPDB01077	AP03017	"	
SICCSFPDPWGGLCCEDHCSYIGKPGGQCSDKGVCTCN"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-The activity has been demonstrated. Active against Gram+ B. subtilis DSM 10, activity value is MIC = 16 ug/ml||Anti-M. luteus DSM 20030, activity value is MIC = 4 ug/ml||Anti-S. auricularis DSM 20609, activity value is MIC = 16 ug/ml||Anti-S. aureus ATCC 25923, activity value is MIC = 8 ug/ml||Anti-MRSA, activity value is MIC = 16 ug/ml||Anti-S. pyogenes ATCC 12344, activity value is MIC = 64 ug/ml||Anti-A. bohemicus DSM 100419, activity value is MIC = 32 ug/ml	Aspergillus fumigatus	N/A	Aspergillus fumigatus	"Mol Immunol
. 2008 Feb;45(3):828-38. doi: 10.1016/j.molimm.2007.06.354. Epub 2007 Aug 1.|||Mol Immunol
. 2008 Feb;45(3):828-38.doi: 10.1016/j.molimm.2007.06.354.Epub 2007 Aug 1.||Contreras et al., 2018"	38	
FPDB01078	AP03022|||DRAMP31413|||AP03022|||DRAMP31413	"	
GFGCPFNQGQCHKHCQSIRRRGGYCDGFLKTRCVCYR"	Anti-Gram+||Antiviral||Anti-MRSA||Channel inhibitors||Anti-Hepatitis B Virus : HBeAg, activity value is IC50 = 3.95 uM||Anti-HBsAg, activity value is IC50 = 2.28 uM||Anti-this peptide can inhibit the growth of Gram+ S. aureus AB94004 or ATCC25923 or MRSA, activity value is MIC = 0.08||Anti-B. subtilis AB91021, activity value is MIC = 10 uM||Anti-B. thuringiensis AB92037, activity value is MIC = 20 uM||Anti-M. luteus AB93113, activity value is MIC = 0.16 uM||Anti-and S. epidermidis PRSE P1389, activity value is MIC = 0.31 uM||Antimicrobial	Mesobuthus martensii Karsch|||Mesobuthus martensii|||Mesobuthus martensii Karsch|||Mesobuthus martensii	Bridge	"In ""A Scorpion Defensin BmKDfsin4 Inhibits Hepatitis B Virus Replication in Vitro,"" the key values related to the hemolytic activity of scorpion defensin BmKDfsin4 are as follows, determined by human red blood cell hemolysis assay (with 0.1% Triton-X100 as 100% hemolysis positive control and physiological saline as 0% hemolysis negative control):

- Half-maximal hemolytic concentration (HC_{50}): The HC_{50} of BmKDfsin4 for human red blood cells is 66.85 uM, indicating that at this concentration, 50% of human red blood cells undergo hemolysis. When evaluating its feasibility as an anti-hepatitis B virus drug, this value is used to measure its toxicity to red blood cells. Compared with other substances with hemolytic activity, the higher this value, the more concentrated the substance needs to be to cause significant hemolysis, indicating relatively lower toxicity to red blood cells.

- Hemolysis at low concentrations: When the concentration of BmKDfsin4 is below 10 uM, the survival rate of red blood cells is higher than 90%, meaning the hemolysis rate at this time is less than 10%. This data indicates that at lower concentrations, BmKDfsin4 causes minimal damage to red blood cells, exhibiting almost no hemolytic activity, providing strong support for its safety when used as a potential drug at low concentrations.|||Mesobuthus martensii Karsch||The feasibility of the further development of BmKDfsin4 as a candidate anti-HBV agent was determined by measuring its cytotoxicity. After being incubated with a serial dilution of BmKDfsin4 for 48 h, the cell viability of HepG2.2.15 (Figure 2a), HepG2 (Figure 2b) and L-02 (Figure 2c) cells was measured using MTT assays. The 50% cytotoxicity concentrations (CC50) of BmKDfsin4 to HepG2.2.15, HepG2 and L-02 were 167.82, 154.24 and 103.77 uM, respectively. At the concentration of 10 uM, the viability of the BmKDfsin4-treated cells was greater than 90% in all three kinds of cell lines. The hemolysis assay also showed that the viability of erythrocytes was more than 90% when the concentration of BmKDfsin4 was lower than 10 uM (Figure 2d). These data indicated that 10 uM or less BmKDfsin4 was minimally cytotoxic and suitable for further anti-HBV studies.|||[Ref.27128943]Human erythrocytes: 50% hemolysis concentration was 66.85 uM.|||In the provided document, the hemolysis-related data for the scorpion-derived defensin BmKDfsin4 are as follows:

- Half-maximal hemolytic concentration (HC₅₀): 66.85 μM. This value indicates the peptide concentration that can cause 50% hemolysis of red blood cells.

- Hemolysis at low concentrations: When the concentration of BmKDfsin4 is below 10 μM, the red blood cell survival rate is over 90%, indicating minimal hemolytic activity at this concentration.

The above data were measured using human red blood cell hemolysis experiments, with 0.1% Triton X-100-induced hemolysis as the 100% control and physiological saline as the 0% control. The amount of hemoglobin released (degree of hemolysis) was assessed by measuring absorbance at 570 nm.|||[Ref.27128943]Human erythrocytes: 50% hemolysis concentration was 66.85 uM."	"Toxins (Basel)
. 2016 Apr 27;8(5):124. doi: 10.3390/toxins8050124.|||Toxins (Basel)
. 2016 Apr 27;8(5):124. doi: 10.3390/toxins8050124.||Meng L et al., 2016|||Toxins (Basel). 2016 Apr 27;8(5):124.|||Toxins (Basel). 2016 Apr 27;8(5). pii: E124. doi: 10.3390/toxins8050124. PubMed|||Toxins (Basel). 2016 Apr 27;8(5):124."	37	
FPDB01079	AP03025|||AP03025|||Dicentracin-like	"	
FLRSLLRGAKAIYRGARAGWRG"	Anti-Gram+ & Gram-||candidacidal||Anti-MRSA||Anti-E. coli ATCC 25922, activity value is MIC = 4.68 ug/ml||Anti-P. aeruginosa ATCC10662, activity value is MIC = 37.5 ug/ml||Anti-A. baumannii Clinical isolate, activity value is MIC = 18.75 ug/ml||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 4.68 ug/ml||Anti-S. epidermidis ATCC 1435, activity value is MIC = 1.17 ug/ml||Anti-clinical strains C. albicans, activity value is MIC = 4.68||Antibacterial	Asian sea bass, Lates calcarifer|||Lates calcarifer [Asian sea bass]|||Asian sea bass, Lates calcarifer	N/A	erlynitwai5diy0f0vqf|||Asian sea bass, Lates calcarifer||Cytotoxicity ofsome AMPs is the main barrier to the clinical use ofthem; the hemolytic activity ofthe dicentracin-like peptide against human red blood cells (hRBCs) was examined in comparison to moronecidin. Moronecidin showed higherhemolyticactivity than dicentracinlike peptide, the HC50 for moronecidin and dicentracin-like were 57 ug/ml and 2.34 ug/ml, respectively (Fig 8). Dicentracin-like did not show100% hemolytic activity even in the peptide concentration of75 ug/ml.|||human RBC ( 2.34 ug/ml)|||Moronecidin showed higherhemolyticactivity than dicentracin like peptide, the HC 50 for moronecidin and dicentracin-like were 57 ug/ml and 2.34 ug/ml, respectively (Fig 8). Dicentracin-like did not show100% hemolytic activity even in the peptide concentration of 75 ug/ml.	"PLoS One
. 2018 Oct 26;13(10):e0206578. doi: 10.1371/journal.pone.0206578. eCollection 2018.|||PLoS One
. 2018 Oct 26;13(10):e0206578. doi: 10.1371/journal.pone.0206578. eCollection 2018|||30365554|||PLoS One. 2018 Oct 26;13(10):e0206578. doi: 10.1371/journal.pone.0206578. PubMed"	22	
FPDB01080	AP03048|||AP03048|||Nigrocin-HLM	GLLSGILGAGKKIVF	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anti-S. aureus NCTC10788, activity value is MIC = 2.9 uM||Anti-E. coli NCTC10418, activity value is MIC = 12 uM||Anti-P. aeruginosa ATCC27853, activity value is MIC = 47 uM||Anti-and C. albicans NCYC1467, activity value is MIC = 2.9 uM||Anti-Staphylococcus aureus, activity value is MIC = 2.94 ug||Anti-Escherichia coli, activity value is MIC = 11.77 ug||Anti-Candida albicans, activity value is MIC = 2.94 ug||Anti-Pseudomonas aeruginosa, activity value is MIC = 47.08 ug||Anti-MRSA, activity value is MIC = 5.89 ug||Anti-MRSA, activity value is MIC = 1.47 ug||Anti-DTMR8, activity value is MIC = 1.47 ug||Anti-DTMR24, activity value is MIC = 1.47 ug||Anti-DTMR37, activity value is MIC = 1.47 ug||Anti-DTMR121, activity value is MIC = 1.47 ug	engineered, Motif-Targeted Peptide Design|||Synthetic construct	Helix	"sje77a9ccf9q4ur2p1zy|||engineered, Motif-Targeted Peptide Design|||Horse erythrocytes (100% hemolysis at 512 uM)|||The document clearly provides hemolytic data for two antimicrobial peptides (the natural peptide nigrocin-HL and the modified peptide nigrocin-HLM), with the core information summarized as follows:

1. Key Hemolytic Properties

nigrocin-HL (natural peptide): At its minimum inhibitory concentration (MIC) against tested microorganisms, it can induce significant hemolytic activity (toward horse red blood cells), and the hemolysis rate increases further with higher concentrations.
nigrocin-HLM (modified peptide): Exhibits extremely low hemolytic activity—even at concentrations where it exerts bactericidal effects, the hemolysis rate is negligible; no significant hemolytic activity is detected even at concentrations up to 128 μM (Figure 5C).

2. Experimental Background and Basis

Experimental method: Red blood cell suspensions were prepared using defibrinated horse blood. Peptides at different concentrations (1–512 μM) were co-incubated with red blood cells, and the absorbance of the supernatant at specific wavelengths was measured to reflect the release of hemoglobin. 0.1% Triton X-100 treated samples were used as the 100% hemolysis positive control, and red blood cell suspensions without peptide were used as the negative control.
Safety comparison: The natural peptide nigrocin-HL showed cytotoxicity to human keratinocytes (HaCaT) and human bronchial epithelial cells (16HBE) at concentrations as low as 32 μM; in contrast, the modified peptide nigrocin-HLM showed no significant effect on the viability of these two normal cell types even at concentrations up to 512 μM (Figures 5A and 5B). Combined with its extremely low hemolytic activity, this demonstrates that peptide modification significantly improves safety.

In summary, nigrocin-HLM, modified by replacing the ""Rana box"" motif with amidated phenylalanine, greatly reduces hemolytic activity while enhancing antibacterial activity, providing a solid safety basis for its development as a clinical anti-infective candidate drug.|||In addition, hemolytic capacities of these two AMPs were measured against horse erythrocytes.As shown in Figure 5C,where as the natural peptide induced obvious hemolysis at itsMICs against tested microorganisms, the modified nigrocin-HLM showed negligible hemolytic activity even at the concentrations for it to exert bactericidal effects.Infact,nigrocin-HLM was found to be devoid of hemolytic activity up to128 uM."	"Front Microbiol
. 2018 Nov 28:9:2846. doi: 10.3389/fmicb.2018.02846. eCollection 2018.|||Front Microbiol
. 2018 Nov 28:9:2846. doi: 10.3389/fmicb.2018.02846. eCollection 2018.|||30555431|||Front Microbiol. 2018 Nov 28;9:2846. doi: 10.3389/fmicb.2018.02846. PubMed|||Front Microbiol. 2018 Nov 28;9:2846. doi: 10.3389/fmicb.2018.02846. PubMed"	15	
FPDB01081	AP03059|||AP03059|||Japonicin-2LF|||Japonicin-2LF|||AP03059|||DRAMP35663	"	
FIVPSIFLLKKAFCIALKKC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Antibiofilm||Anti-S. aureus NCTC 10788 or MRSA NCTC 12493, activity value is MIC = 4 uM||Anti-MRSA B038 V1S1 A, activity value is MIC = 8 uM||Anti-E. coli NCTC 10418, activity value is MIC = 16 uM||Anti-P.aeruginosa ATCC 27853, activity value is MIC > 512 uM||Anti-and C. albicans NCYC 1467, activity value is MIC = 4 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 4 uM||Anti-Methicillin-resistant Staphylococcus aureus NCTC 12493, activity value is MIC = 4 uM||Anti-Escherichia coli NCTC 10418, activity value is MIC = 16 uM||Anti-Candida albicans NCYC 1467, activity value is MIC = 4 uM||Anti-MRSA B042 V2E1 A, activity value is MIC = 8 uM||Antimicrobial||Anticancer	skin secretion, Fujian Large-headed Frog, Limnonectes fujianensis, China, Asia|||Limnonectes fujianensis [Fujian Large-headed Frog]|||Animalia|||skin secretion, Fujian Large-headed Frog, Limnonectes fujianensis, China, Asia	Helix	"In this document, the key values related to the hemolytic activity of the novel antimicrobial peptide Japonicin-2LF, derived from the skin of the Fujian large-headed frog (Limnonectes fujianensis), were measured through a horse red blood cell hemolysis assay (with 1% Triton X-100 as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 1–512 µM (covering its effective antimicrobial concentrations, with MIC = 4–16 µM for sensitive bacteria, and MIC = 8 µM for CF clinical isolate MRSA)

- Hemolysis rate at each concentration:

- ≤32 µM concentration: Japonicin-2LF caused less than 25% hemolysis of horse red blood cells. This concentration range includes its effective antimicrobial concentrations against most sensitive bacteria (such as S. aureus and MRSA) (4–8 µM), indicating low hemolytic toxicity while exerting antimicrobial effects.

- ≥64 µM concentration: Hemolysis rate significantly increased, exceeding 80%, indicating that hemolytic toxicity is significantly enhanced at high concentrations, and such concentrations should be avoided in clinically relevant scenarios.|||skin secretion, Fujian Large-headed Frog, Limnonectes fujianensis, China, Asia|||Horse erythrocytes (64 uM)|||The document clearly provides hemolytic data of the novel antimicrobial peptide Japonicin-2LF on horse red blood cells, with the core information as follows:

Hemolytic values of Japonicin-2LF

The hemolysis of this peptide was measured by the hemolysis rate on 2% horse red blood cell suspension at different concentrations, with the specific results as follows:

At concentrations ≥64 μM: Hemolysis rate exceeds 80%, showing strong hemolytic activity.
At concentrations <64 μM: Hemolysis rate is below 25%, showing weak hemolytic activity.

The experiment used 1% Triton X-100 treated group as 100% hemolysis positive control and PBS as negative control, and the hemolysis rate was calculated by measuring absorbance at 550 nm (Figure 7a). In addition, the cytotoxicity of this peptide to human lung epithelial cancer cells (NCI-H23) (LDH release and MTT assay) also appeared starting from 64 μM, consistent with the starting concentration of hemolytic activity, suggesting that its toxicity to mammalian cells is concentration-dependent and related to hemolysis.|||Horse erythrocytes (64 uM)"	"Biochim Biophys Acta Gen Subj
. 2019 May;1863(5):849-856. doi: 10.1016/j.bbagen.2019.02.013. Epub 2019 Feb 22.|||Biochim Biophys Acta Gen Subj
. 2019 May;1863(5):849-856. doi: 10.1016/j.bbagen.2019.02.013. Epub 2019 Feb 22.|||30802593|||Biochim Biophys Acta Gen Subj. 2019 Feb 22;1863(5):849-856. doi: 10.1016/j.bbagen.2019.02.013. PubMed|||30802593|||Biochim Biophys Acta Gen Subj
. 2019 May;1863(5):849-856. doi: 10.1016/j.bbagen.2019.02.013. Epub 2019 Feb 22.|||Biochim Biophys Acta Gen Subj. 2019 May;1863(5):849-856.|||Biochim Biophys Acta Gen Subj. 2019 Feb 22;1863(5):849-856. doi: 10.1016/j.bbagen.2019.02.013. PubMed"	20	
FPDB01082	AP03063|||AP03063|||HD5	ATCYCRTGR	Anti-Gram+ & Gram-||Antiviral||Anti-MRSA||Anti-it is active against A. baumannii 4-MRGN, activity value is MIC = 25 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 50 uM||Anti-E. faecium 475747, activity value is MIC = 12.5 uM||Anti-and S. aureus USA300, activity value is MIC = 50 uM||Anti-A. baumannii 4-MRGN, activity value is MIC = 25 uM||Anti-P. aeruginosa ATCC27853, activity value is MIC = 50 uM||Anti-S. aureus USA300, activity value is MIC = 50 uM	Homo sapiens	N/A	Homo sapiens	"Proc Natl Acad Sci U S A
. 2019 Feb 26;116(9):3746-3751. doi: 10.1073/pnas.1817376116. Epub 2019 Feb 11.|||Proc Natl Acad Sci U S A
. 2019 Feb 26;116(9):3746-3751. doi: 10.1073/pnas.1817376116. Epub 2019 Feb 11.|||30808760|||Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3746-3751. doi: 10.1073/pnas.1817376116. PubMed"	9	
FPDB01083	AP03086	"	
MLVNFILRCGLLLVTLSLAIAKHKQSSFTKSCYPRGTLSQAVDALYIKAAWLKATIPEDRIKNIRLLKKKTKKQFMKNCQFQEQLLSFFMEDVF"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA	Th17 cells, Homo sapiens	N/A	N/A	"J Immunol
. 2019 Aug 15;203(4):911-921. doi: 10.4049/jimmunol.1900318. Epub 2019 Jun 24."	94	
FPDB01084	AP03088	"	
WKSESVCTPGCVTGILQTCFLQSITCNCRLSK"	Anti-Gram+||Anti-MRSA||Active against Gram-positive bacteria including B. amyloliquefaciens ATCC 15841||or L-S60||or L-H15 (diameter of inhibition zone: 16.0-16.2 mm)||B. cereus ATCC 14579 (16.4 mm)||L. lactis NZ9000 or MG1363 (9.1-9.4 mm)||L. plantarum S-35 or gamma-35 (10.3-11 mm)||S. aureus ATCC 29213||or 43300||or 26112 (16.1-16.4 mm)||and E. faecalis ATCC 29212 (16.2 mm)||or 51299 (8.2 mm)||or M2 (6.3 mm) but not active against E.coli DH5alpha||or BL21||or BW25113||or JM109 (0 mm)||and S.cerevisiae (0 mm)||P.pastoris GS115 (0 mm). Also show great biophysical characteristics such as thermostability||pH-insensitive||resistance to chemical reagents||and sensitivity to various human proteases. Updated 7/2021	Bacillus subtilis L-Q11 isolated from Orchard soil	N/A	Bacillus subtilis L-Q11 isolated from Orchard soil	"Front Microbiol
. 2019 Mar 15:10:484. doi: 10.3389/fmicb.2019.00484. eCollection 2019."	32	
FPDB01085	AP03111|||DRAMP35678	"	
FLKAIKKFGKEFKKIGAKLK"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli CRE, activity value is MIC = 1||Anti-E. coli ESBL, activity value is MIC = 1||Anti-A. baumannii CRE, activity value is MIC = 1||Anti-K. pneumoniae CRE, activity value is MIC = 2||Anti-K. pneumoniae ESBL, activity value is MIC = 4||Anti-3 K.pneumoniae strains, activity value is MIC > 128 uM||Anti-P. aeruginosa CRE, activity value is MIC = 8||Anti-1 strain, activity value is MIC > 128 uM||Anti-E. faecalis, activity value is MIC = 8||Anti-and 3 E.faecalis strains, activity value is MIC > 128 uM||Anti-and S. aureus MRSA, activity value is MIC = 2||Anti-3 S.aureus strains, activity value is MIC > 128 uM||Antimicrobial||Anticancer	designed based on maximum common subgraph of helices, peptide library analysis, man-made sequences|||Synthetic	Helix	"In this document, the key values related to the hemolytic activity of the designed antimicrobial peptide W76 and its control peptide W17 are as follows, measured by human red blood cell (hRBC) hemolysis assay (with distilled water as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 0.25–128 µg/ml (covering the effective antibacterial concentrations of both peptides; W76 targets multidrug-resistant Acinetobacter baumannii with MBC = 4–16 µg/ml, W17 targets Gram-negative bacteria with MBC₅₀ = 4 µg/ml)

- Hemolysis values for each peptide:

- W76:

- Half-maximal hemolysis concentration (HC₅₀): >128 mg/L, meaning 50% hemolysis was not reached at this concentration;

- High-concentration hemolysis rate: At the highest tested concentration (128 µg/ml), the hemolysis rate was only 1.78%, far below the clinical safety threshold. This concentration is much higher than its effective antibacterial concentration (about 8 times the MBC against Acinetobacter baumannii), indicating almost no hemolytic toxicity while exerting antibacterial activity.

- W17 (control peptide):

- Half-maximal hemolysis concentration (HC₅₀): >128 mg/L;

- High-concentration hemolysis rate: At 128 µg/ml, the hemolysis rate was 13.91%. While it did not reach 50% hemolysis, it is significantly higher than W76, indicating relatively higher hemolytic toxicity.|||designed based on maximum common subgraph of helices, peptide library analysis, man-made sequences||W76 did not show significant hemolysis at any of the tested concentrations (average hemolysis at 128 µg/ml, W76 = 1.78%). However, W17 showed considerable hemolysis at higher concentrations (average hemolysis at 128 µg/ml, W17 = 13.91%).|||W76 did not show significant hemolysis at any of the tested concentrations (average hemolysis at 128 µg/ml, W76 = 1.78%). However, W17 showed considerable hemolysis at higher concentrations (average hemolysis at 128 µg/ml, W17 = 13.91%)."	"Sci Adv
. 2019 Jul 24;5(7):eaax1946. doi: 10.1126/sciadv.aax1946. eCollection 2019 Jul.|||Sci Adv. 2019 Jul 24;5(7):eaax1947."	20	
FPDB01086	AP03112|||AP03112|||DFT503|||DFT503d	GLSLLLSLGLKLL	Anti-Gram+||Anti-MRSA||Antibiofilm||Anti-S. aureus USA300 LAC, activity value is MIC = 3.1 uM||Anti-E. faecium V286-17, activity value is MIC = 3.1||Anti-and E.coli E423-17, activity value is MIC > 50 uM||Anti-S. aureus USA 300, activity value is MIC = 1.6 uM||Anti-S. aureus M838-17, activity value is MIC = 3.1 uM	engineered: In vitro and in vivo optimized|||Synthetic construct	Helix	"In ""Low cationicity is important for systemic in vivo efficacy of database-derived peptides against drug-resistant Gram-positive pathogens,"" the study focuses on the in vivo efficacy of database-derived peptides against drug-resistant Gram-positive pathogens, emphasizing the relationship between cationic peptide structure and in vivo efficacy. Specific hemolytic values are not directly mentioned, but the hemolysis-related properties of the peptides were investigated: 

- Comparison of peptide hemolytic activity: The study altered the amino acid sequence of the database-designed peptide template DFTamP1 to create a series of peptides and tested their hemolytic activity. For example, by replacing different positions of eight leucines in DFTamP1 with alanine, the resulting analogs DFT506 - DFT513 showed varying hemolytic activity against human red blood cells, and double-alanine substituted analogs DFT514 - DFT516 exhibited lower hemolytic activity. After single amino acid deletions and local sequence rearrangements of DFTamP1, it was found that DFT503 had significantly lower hemolytic activity compared to DFTamP1.

- Effect of additional lysine on hemolytic activity: Experiments introducing additional lysine residues into DFT503 showed that as the number of lysines in the peptide increased, hemolytic activity also increased. For example, DFT560, DFT562, and DFT563 exhibited high antibacterial activity but also higher hemolytic activity; DFT564 and DFT565, containing three and four lysines, had higher hemolytic activity than DFT503.|||engineered: In vitro and in vivo optimized|||Human RBCs [50% hemolysis at >300 uM]|||The document does not directly provide the specific hemolysis percentage values for each designed peptide (such as DFT503, DFT561, DFT564, DFT565, etc.), but only describes their hemolytic characteristics qualitatively or through relative comparisons. The key information is as follows:

1. Hemolysis of DFT503
Through local sequence rearrangement (introducing a triple leucine ""LLL"" motif), the hemolysis of DFT503 is significantly lower than that of its template peptide DFTamP1, but the document does not provide specific hemolysis data (such as the percentage of hemolysis at a certain concentration).

2. Hemolysis of peptides with additional lysine
Derivatives of DFT503 with added lysine (such as DFT560, DFT562, DFT563) maintain high antimicrobial activity but show increased hemolysis compared to DFT503.
DFT564, containing 3 lysines, and DFT565, containing 4 lysines, exhibit even more pronounced hemolysis compared to DFT503, though no specific values are provided.
Only DFT561 (serine at position S3 replaced by lysine) increases solubility and maintains the antimicrobial spectrum without increased hemolysis.

3. Other relevant information
The document mentions that peptides obtained through alanine scanning (such as DFT514–DFT516, DFT521, etc.) or amino acid deletion exhibit reduced hemolysis compared to the original peptide (e.g., peptides with double alanine substitutions show lower hemolysis), but again, no specific hemolysis values are provided. Relevant detailed data might be recorded in supplementary materials (such as SI Appendix, Table S4), but are not disclosed in the main text."	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||31209048|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed"	13	
FPDB01087	AP03142	"	
SDTGTKSRK"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-MSSA, activity value is MIC = 8 ug/ml||Anti-VRE, activity value is MIC = 12.5 ug/ml||Anti-A. baumannii MB5973 and K. pneumoniae ATCC 700603, activity value is MIC = 50||Anti-and P. aeruginosa, activity value is MIC = 50	Delftia spp.	N/A	Delftia spp.	"Front Microbiol
. 2019 Oct 15:10:2377. doi: 10.3389/fmicb.2019.02377. eCollection 2019."	9	
FPDB01088	AP03143|||AP03143|||ModoCath4	"	
SKTKRRSLLKRLGDGIRGFWNGFRGRK"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli ATCC25922, activity value is MIC = 20 uM||Anti-S. aureus ATCC29213 or MRSA, activity value is MIC = 10 uM||Anti-S. pyogenes ATCC19615, activity value is MIC = 20 uM||Anti-S. agalactiae ATCC 12386, activity value is MIC = 20 uM||Anti-S. dysgalactiae, activity value is MIC = 20 uM||Anti-S. lutetiensis, activity value is MIC = 20 uM||Anti-S. equi, activity value is MIC = 20 uM||Anti-S. salivarius, activity value is MIC = 10 uM||Anti-C. parapsilosis ATCC22019, activity value is MIC = 10 uM||Anti-and C. krusei ATCC6258, activity value is MIC = 20 uM||Anti-E. coli, activity value is MIC = 20 uM||Anti-S. aureus, activity value is MIC = 10 uM||Anti-S. aureus ATCC29213, activity value is MIC = 10 uM||Anti-MRSA, activity value is MIC = 10 uM||Anti-S. agalactiae, activity value is MIC = 20 uM||Anti-C. krusei ATCC6258, activity value is MIC = 20 uM	Gray short-tailed opossum, Monodelphis domestica, South America|||Monodelphis domestica [Opossum]	N/A	"In this document, the key values related to the hemolytic activity of cathelicidins from marsupials and monotremes are as follows, determined by a bovine red blood cell (RBC) hemolysis assay (with melittin serving as a 100% positive control for hemolysis):

Core hemolytic activity results

-Hemolysis criteria: At a concentration of 12.5 µM, peptides that induce a hemolysis rate in bovine red blood cells exceeding 10% are classified as “hemolytic peptides,” while those with a hemolysis rate ≤10% are classified as “non-hemolytic peptides.”

-Hemolytic values of each active peptide (test concentration range: 6.2–50 µM):

-ModoCath4 (possum-derived):

-At its antibacterial effective concentration (MIC against MRSA = 10 µM, 32 µg/mL) and at concentrations below this level, the hemolysis rate is extremely low;

-At the highest test concentration (50 µM), the hemolysis rate of bovine red blood cells remained significantly lower than that of MaeuCath7, and cytotoxicity toward mammalian cells (MDBK cells) was also low (lysis rate &lt;5%).

-MaeuCath7 (Tamar Valley rock-wallaby origin):

-High-concentration hemolysis rate: At a concentration of 50 µM, the hemolysis rate of bovine red blood cells reaches 41%, making it the most hemolytic among the three active peptides.

-However, at its antibacterial effective concentration (MIC against Escherichia coli = 7.4 µM, 32 µg/mL), the hemolysis rate is less than 10%, and it exhibits low cytotoxicity toward MDBK cells (lysis rate of only 3.9%).

-Taac-CATH1 (from the echidna):

-At all tested concentrations (6.2–50 µM), the hemolysis rate of bovine red blood cells was &lt;10%, indicating that the peptide is non-hemolytic.

-It exhibits relatively high cytotoxicity against MDBK cells (approximately 10% lysis at 50 µM), but remains lower than that of most inactive defensins.

-Hemolytic activity of inactive peptides:

-Some peptides lacking antibacterial activity (such as ModoCath5, ModoCath1, ModoCath2, etc.) exhibit strong hemolytic activity at high concentrations; for example, at 50 µM, the hemolysis rate in bovine red blood cells and the lysis rate in MDBK cells for ModoCath5 are both significantly higher than those of active peptides, indicating that hemolytic activity is not directly correlated with antibacterial activity.|||Gray short-tailed opossum, Monodelphis domestica, South America"	"Microbiology (Reading)
. 2017 Oct;163(10):1457-1465. doi: 10.1099/mic.0.000536. Epub 2017 Sep 27.|||Microbiology (Reading)
. 2017 Oct;163(10):1457-1465. doi: 10.1099/mic.0.000536. Epub 2017 Sep 27.|||28949902"	27	
FPDB01089	AP03145|||AP03145|||Taac-CATH1	"	
PIRTKRRWKLIKKGGKIVKDLLTKNNIIILPGGNE"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus MRSA, activity value is MIC = 3.9 uM||Antibacterial	Short-beaked echidna, Tachyglossus aculeatus|||Tachyglossus aculeatus [Echidna ]	N/A	"In this document, the key values related to the hemolytic activity of cathelicidins from marsupials and monotremes are as follows, determined by a bovine red blood cell (RBC) hemolysis assay (with melittin serving as a 100% positive control for hemolysis):

Core hemolytic activity results

-Hemolysis criteria: At a concentration of 12.5 µM, peptides that induce a hemolysis rate in bovine red blood cells exceeding 10% are classified as “hemolytic peptides,” while those with a hemolysis rate ≤10% are classified as “non-hemolytic peptides.”

-Hemolytic values of each active peptide (test concentration range: 6.2–50 µM):

-ModoCath4 (possum-derived):

-At its antibacterial effective concentration (MIC against MRSA = 10 µM, 32 µg/mL) and at concentrations below this level, the hemolysis rate is extremely low;

-At the highest test concentration (50 µM), the hemolysis rate of bovine red blood cells remained significantly lower than that of MaeuCath7, and cytotoxicity toward mammalian cells (MDBK cells) was also low (lysis rate &lt;5%).

-MaeuCath7 (Tamar Valley rock-wallaby origin):

-High-concentration hemolysis rate: At a concentration of 50 µM, the hemolysis rate of bovine red blood cells reaches 41%, making it the most hemolytic among the three active peptides.

-However, at its antibacterial effective concentration (MIC against Escherichia coli = 7.4 µM, 32 µg/mL), the hemolysis rate is less than 10%, and it exhibits low cytotoxicity toward MDBK cells (lysis rate of only 3.9%).

-Taac-CATH1 (from the echidna):

-At all tested concentrations (6.2–50 µM), the hemolysis rate of bovine red blood cells was &lt;10%, indicating that the peptide is non-hemolytic.

-It exhibits relatively high cytotoxicity against MDBK cells (approximately 10% lysis at 50 µM), but remains lower than that of most inactive defensins.

-Hemolytic activity of inactive peptides:

-Some peptides lacking antibacterial activity (such as ModoCath5, ModoCath1, ModoCath2, etc.) exhibit strong hemolytic activity at high concentrations; for example, at 50 µM, the hemolysis rate in bovine red blood cells and the lysis rate in MDBK cells for ModoCath5 are both significantly higher than those of active peptides, indicating that hemolytic activity is not directly correlated with antibacterial activity.|||Short-beaked echidna, Tachyglossus aculeatus"	"Microbiology (Reading)
. 2017 Oct;163(10):1457-1465. doi: 10.1099/mic.0.000536. Epub 2017 Sep 27.|||Microbiology (Reading)
. 2017 Oct;163(10):1457-1465. doi: 10.1099/mic.0.000536. Epub 2017 Sep 27.|||28949902"	35	
FPDB01090	AP03159|||AP03159|||Superoxide dismutase|||Superoxide dismutase|||AP03159	ATKAVCVLKGDGPVQGIINF	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-E. coli CECT 434, activity value is MIC = 32||Anti-E. faecalis CECT 481, activity value is MIC = 4||Anti-S. agalactiae CECT 183T, activity value is MIC = 8||Anti-C. krusei ATCC 6258, activity value is MIC = 4||Anti-Candida glabrata ATCC 90030, activity value is MIC > 256 ug/ml||Anti-Candida krusei ATCC 6258, activity value is MIC > 8 ug/ml||Anti-Escherichia coli CECT 434, activity value is MIC > 64 ug/ml||Anti-Enterococcus faecalis CECT 481, activity value is MIC > 16 ug/ml||Anti-Staphylococcus aureus CECT 435, activity value is MIC > 16 ug/ml||Anti-Staphylococcus aureus MR, activity value is MIC > 16 ug/ml||Anti-Streptococcus agalactiae CECT 183T, activity value is MIC > 16 ug/ml	endometrial fluid peptides, Homo sapiens|||Synthetic construct	N/A	endometrial fluid peptides, Homo sapiens	"J Proteomics
. 2020 Mar 30:216:103652. doi: 10.1016/j.jprot.2020.103652. Epub 2020 Jan 18.|||J Proteomics
. 2020 Mar 30:216:103652. doi: 10.1016/j.jprot.2020.103652. Epub 2020 Jan 18.|||31958637|||31958637|||J Proteomics
. 2020 Mar 30:216:103652. doi: 10.1016/j.jprot.2020.103652. Epub 2020 Jan 18."	20	
FPDB01091	AP03160|||AP03160|||Elafin|||Elafin|||AP03160	"	
VKAQEPVKGPVSTKPGSCPIILIRCA"	Anti-Gram+||Anti-MRSA||Anti-E. faecalis CECT 481, activity value is MIC = 16||Anti-Enterococcus faecalis CECT 481, activity value is MIC > 128 ug/ml||Anti-Staphylococcus aureus CECT 435, activity value is MIC > 128 ug/ml||Anti-Staphylococcus aureus MR, activity value is MIC > 128 ug/ml||Anti-Streptococcus agalactiae CECT 183T, activity value is MIC > 256 ug/ml	endometrial fluid peptides, Homo sapiens|||Synthetic construct|||Synthetic construct|||endometrial fluid peptides, Homo sapiens	N/A	endometrial fluid peptides, Homo sapiens	"J Proteomics
. 2020 Mar 30:216:103652. doi: 10.1016/j.jprot.2020.103652. Epub 2020 Jan 18.|||J Proteomics
. 2020 Mar 30:216:103652. doi: 10.1016/j.jprot.2020.103652. Epub 2020 Jan 18.|||31958637|||31958637|||J Proteomics
. 2020 Mar 30:216:103652. doi: 10.1016/j.jprot.2020.103652. Epub 2020 Jan 18."	26	
FPDB01092	AP03170|||AP03170|||Brevinin-2GHk|||Brevinin-2GHk|||AP03170	"	
GFSSLFKAGAKYLLKQVGKAGAQQL"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Interestingly||this 25-residue peptide gained both activity and cell selectivity. Broadly active against Gram+||Gram-||and fungi such as S. aureus||E. faecalis||MRSA||E. coli||P. aeruginosa||K. pneumoniae||and C. albicans.||Human microvascular endothelial cells HMEC-1 (18% Killing at 100 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 4 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MBC = 8 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MIC = 4 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MBC = 16 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MIC = 4 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MBC = 16 uM||Anti-Escherichia coli NCTC 10418, activity value is MIC = 4 uM||Anti-Escherichia coli NCTC 10418, activity value is MBC = 8 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MBC = 32 uM||Anti-Klebsiella pneumoniae ATCC 43816, activity value is MIC = 16 uM||Anti-Klebsiella pneumoniae ATCC 43816, activity value is MBC = 32 uM||Anti-Candida albicans NCYC 1467, activity value is MBC = 4 uM||Anti-Candida albicans NCYC 1467, activity value is MBC = 16 uM	derived from the parent brevinin peptide|||Synthetic construct|||Synthetic construct|||derived from the parent brevinin peptide	Helix	"In “Brevinin-2GHk from Sylvirana guentheri and the Design of Truncated Analogs Exhibiting the Enhancement of Antimicrobial Activity,” the hemolytic activity of the novel antimicrobial peptide Brevinin-2GHk (BR2GK), identified from the skin secretions of the marsh frog, as well as that of its truncated analogs, was investigated; the relevant values are as follows:

-BR2GK: Exhibits significant hemolytic activity starting at 32 µM, with a hemolysis rate exceeding 40% at 256 µM.

-BR2GK(1-25)a exhibited the strongest cytotoxicity among the truncated analogs; however, at 256 µM, the hemolysis rate was only approximately 20%, with significant hemolytic activity observed starting at 32 µM.

-The other four derivatives ([P14]BR2GK(1-25)a, [A14]BR2GK(1-25)a, [K14]BR2GK(1-25)a, [R14]BR2GK(1-25)a): showed no significant cytotoxicity to red blood cells, with hemolysis rates all below 5%.|||derived from the parent brevinin peptide||BR 2GK and BR 2GK (1-25) a exhibited significant hemolytic activity at 32 µM (Table S4), with BR 2GK causing more than 40% hemolysis at 256 µM. Meanwhile, BR 2GK (1-25) a showed the greatest cytotoxicity among the truncated derivatives, although it only induced about 20% hemolysis at the same concentration.|||Human microvascular endothelial cells HMEC-1 (18% Killing at 100 uM|||Human microvascular endothelial cells HMEC-1 (18% Killing at 100 uM|||BR 2GK and BR 2GK (1-25) a exhibited significant hemolytic activity at 32 µM (Table S4), with BR 2GK causing more than 40% hemolysis at 256 µM. Meanwhile, BR 2GK (1-25) a showed the greatest cytotoxicity among the truncated derivatives, although it only induced about 20% hemolysis at the same concentration.|||Additionally, BR2GK and BR2GK(1-25)a showed significant hemolytic activity from 32 uM (Table S4), where BR2GK resulted in more than 40% hemolysis at 256 uM. Whilst, BR2GK(1-25)a exhibited the most cytotoxic e ects amongst the truncated derivatives, although it only exerted around 20% hemolysis at the same concentration."	"Antibiotics (Basel)
. 2020 Feb 14;9(2):85. doi: 10.3390/antibiotics9020085.|||Antibiotics (Basel)
. 2020 Feb 14;9(2):85. doi: 10.3390/antibiotics9020085.|||32075067|||32075067|||Antibiotics (Basel)
. 2020 Feb 14;9(2):85. doi: 10.3390/antibiotics9020085.|||Antibiotics (Basel). 2020;9(2):E85. PubMed"	25	
FPDB01093	AP03178|||AP03178|||Brevinin-1GHa|||Brevinin-1GHa|||AP03178	"	
FLGAVLKVAGKLVPAAICKISKKC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anti-F) Gram+ S. aureus or MRSA, activity value is MIC = 2||Anti-E. faecalis, activity value is MIC = 8 uM||Anti-E. coli, activity value is MIC = 4 uM||Anti-K. pneumoniae, activity value is MIC = 8 uM||Anti-P. aeruginosa, activity value is MIC = 32 uM||Anti-C. albicans, activity value is MIC = 2 uM||Antibacterial||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 2 uM	skin, Guenther's Frog, Sylvirana guentheri, Hylarana guentheri (old), Asia|||Hylarana guentheri|||Hylarana guentheri|||skin, Guenther's Frog, Sylvirana guentheri, Hylarana guentheri (old), Asia|||skin, Guenther's Frog, Sylvirana guentheri, Hylarana guentheri (old), Asia	N/A	"In this document, the key values related to hemolysis for the novel antimicrobial peptide Brevinin-1GHa derived from the skin of the swamp frog (Hylarana guentheri) and its analogs Brevinin-1GHb and Brevinin-1GHc are as follows, determined by a horse red blood cell hemolysis assay (with 2% Triton X-100 as the 100% hemolysis positive control and PBS as the 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 1–512 µM (covering the effective antimicrobial concentrations of the three peptides, with Brevinin-1GHa having an MIC against S. aureus of 2 µM, Brevinin-1GHb showing only weak activity against S. aureus with an MIC of 512 µM, and Brevinin-1GHc having an MIC against S. aureus of 16 µM)

- Hemolysis values of each peptide:

- Brevinin-1GHa (natural peptide containing a C-terminal Rana-box):
  - At a concentration of 16 µM, the hemolysis rate is close to 20%;
  - Its effective antimicrobial concentrations (e.g., MIC against S. aureus = 2 µM, MIC against C. albicans = 2 µM) are much lower than the concentration at which significant hemolysis occurs, indicating a low risk of hemolysis during antimicrobial activity, though there is still some hemolytic toxicity at higher concentrations.

- Brevinin-1GHb (truncated peptide lacking the Rana-box):
  - Only at a concentration of 512 µM does the hemolysis rate approach 20%;
  - This concentration is far higher than its sole antimicrobial active concentration (MIC against S. aureus = 512 µM), and it has no antimicrobial activity against other tested strains, indicating extremely low hemolytic toxicity but weak antimicrobial activity.

- Brevinin-1GHc (modified peptide with the Rana-box transferred to the central region):
  - At a concentration of 128 µM, the hemolysis rate approaches 20%;
  - Its effective antimicrobial concentration (e.g., MIC against S. aureus = 16 µM) is lower than the concentration at which significant hemolysis occurs, and its hemolytic activity is significantly lower than that of the natural peptide Brevinin-1GHa, although its antimicrobial activity is also slightly reduced compared to the natural peptide.|||skin, Guenther's Frog, Sylvirana guentheri, Hylarana guentheri (old), Asia|||Horse erythrocytes (20% Hemolysis at 16 uM)|||The document clearly provides hemolytic data of the peptides Brevinin-1GHa, Brevinin-1GHb, and Brevinin-1GHc on horse red blood cells. The core information is as follows:

1. Key hemolytic values (for horse red blood cells)

Brevinin-1GHa: Hemolysis rate is approximately 20% at a concentration of 16 µM.
Brevinin-1GHb: Hemolysis rate is approximately 20% at a concentration of 512 µM; no hemolytic activity at 256 µM.
Brevinin-1GHc: Hemolysis rate is approximately 20% at a concentration of 128 µM.

2. Supplementary notes

Hemolysis tests used PBS as a negative control (no hemolysis) and 2% Triton X-100 as a positive control (complete hemolysis), and hemolysis rates of each peptide were calculated by comparison.

Effect of structural modifications on hemolysis:
Brevinin-1GHb with the Rana box removed (net charge 2, no hydrophobic face) shows significantly reduced hemolysis, requiring very high concentrations (512 µM) to reach 20% hemolysis.
Brevinin-1GHc with the Rana box moved to the center (net charge 5, reduced α-helical content) shows a hemolysis rate of 20% at 128 µM, which is lower than Brevinin-1GHa (16 µM for 20%), but its antibacterial activity also decreases correspondingly.|||Horse erythrocytes (20% Hemolysis at 16 uM)|||Brevinin-1GHa, Brevinin-1GHb, and Brevinin-1GHc exhibited a hemolysis rate near 20% on horse erythrocytes with the concentration at 16, 512, and 128 uM, respectively,"	"Toxins (Basel)
. 2018 Oct 13;10(10):413. doi: 10.3390/toxins10100413.|||Toxins (Basel)
. 2018 Oct 13;10(10):413. doi: 10.3390/toxins10100413.|||30322120|||Toxins (Basel). 2018;10(10):413. doi:10.3390/toxins10100413. PubMed|||30322120|||Toxins (Basel)
. 2018 Oct 13;10(10):413. doi: 10.3390/toxins10100413.|||Toxins (Basel). 2018;10(10):413. doi:10.3390/toxins10100413. PubMed"	24	
FPDB01094	AP03179|||AP03179|||Brevinin-1GHd, Brevinin-1HL|||Brevinin-1GHd, Brevinin-1HL|||AP03179|||DRAMP29052	"	
FLGALFKVASKLVPAAICSISKKC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-inflammatory||anti-sepsis||Anti-S. aureus or MRSA, activity value is MIC = 2||Anti-E. coli, activity value is MIC = 8 uM||Anti-P. aeruginosa, activity value is MIC = 32 uM||Anti-C. albicans, activity value is MIC = 4 uM||Antibacterial||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 2 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MBC = 4 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MIC = 4 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MBC = 4 uM||Anti-Escherichia coli NCTC 10418, activity value is MIC = 8 uM||Anti-Escherichia coli NCTC 10418, activity value is MBC = 8 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 32 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MBC = 32 uM||Anti-Candida albicans NCPE 1467, activity value is MIC = 4 uM||Anti-Candida albicans NCPE 1467, activity value is MBC = 8 uM||Anti-Human squamous lung carcinoma NCI-H157, activity value is IC50 = 2.987 uM||Anti-Human glioblastoma U251-MG, activity value is IC50 = 7.985 uM||Anti-Human breast adenocarcinoma MDA-MB-435S, activity value is IC50 = 1.197 uM||Anti-Human prostate adenocarcinoma PC-3, activity value is IC50 = 9.854 uM||Anti-Chromobacterium violaceum ATCC 12472, activity value is MIC = 205.2 uM||Anti-Chromobacterium violaceum ATCC 12472, activity value is MBC = 205.2 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 51.3 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MBC = 205.2 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MIC = 12.8 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MBC = 205.2 uM||Anti-Human lung adenocarcinoma NCI-H23, activity value is IC50 = 8.52||Anti-S. aureus, activity value is MIC = 2 uM||Anti-MRSA, activity value is MIC = 4 uM||Anti-##Gram-negative: E. coli, activity value is MIC = 8 uM||Anti-##Fungi: C. albicans, activity value is MIC = 4 uM	Hoplobatrachus rugulosus , China, Asia; skin, Guenther's Frog, Sylvirana guentheri, Hylarana guentheri (old), Asia|||Sylvirana guentheri (Hylarana guentheri),Hylarana latouchii|||Sylvirana guentheri (Hylarana guentheri),Hylarana latouchii|||Hoplobatrachus rugulosus , China, Asia; skin, Guenther's Frog, Sylvirana guentheri, Hylarana guentheri (old), Asia|||Sylvirana guentheri (Gunther's frog) (Rana guentheri)|||Hoplobatrachus rugulosus , China, Asia; skin, Guenther's Frog, Sylvirana guentheri, Hylarana guentheri (old), Asia	Helix||α-helical	"In this document, the key values related to hemolysis for the novel antimicrobial peptide Brevinin-1GHa derived from the skin of the swamp frog (Hylarana guentheri) and its analogs Brevinin-1GHb and Brevinin-1GHc are as follows, determined by a horse red blood cell hemolysis assay (with 2% Triton X-100 as the 100% hemolysis positive control and PBS as the 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 1–512 µM (covering the effective antimicrobial concentrations of the three peptides, with Brevinin-1GHa having an MIC against S. aureus of 2 µM, Brevinin-1GHb showing only weak activity against S. aureus with an MIC of 512 µM, and Brevinin-1GHc having an MIC against S. aureus of 16 µM)

- Hemolysis values of each peptide:

- Brevinin-1GHa (natural peptide containing a C-terminal Rana-box):
  - At a concentration of 16 µM, the hemolysis rate is close to 20%;
  - Its effective antimicrobial concentrations (e.g., MIC against S. aureus = 2 µM, MIC against C. albicans = 2 µM) are much lower than the concentration at which significant hemolysis occurs, indicating a low risk of hemolysis during antimicrobial activity, though there is still some hemolytic toxicity at higher concentrations.

- Brevinin-1GHb (truncated peptide lacking the Rana-box):
  - Only at a concentration of 512 µM does the hemolysis rate approach 20%;
  - This concentration is far higher than its sole antimicrobial active concentration (MIC against S. aureus = 512 µM), and it has no antimicrobial activity against other tested strains, indicating extremely low hemolytic toxicity but weak antimicrobial activity.

- Brevinin-1GHc (modified peptide with the Rana-box transferred to the central region):
  - At a concentration of 128 µM, the hemolysis rate approaches 20%;
  - Its effective antimicrobial concentration (e.g., MIC against S. aureus = 16 µM) is lower than the concentration at which significant hemolysis occurs, and its hemolytic activity is significantly lower than that of the natural peptide Brevinin-1GHa, although its antimicrobial activity is also slightly reduced compared to the natural peptide.|||At the highest MIC concentration (32 µM against Pseudomonas aeruginosa), the hemolysis rate of horse red blood cells was 13%; when the concentration was higher than 64 µM, the hemolysis rate gradually increased.|||Hoplobatrachus rugulosus , China, Asia; skin, Guenther's Frog, Sylvirana guentheri, Hylarana guentheri (old), Asia||Brevinin-1GHd shows 13% hemolysis at its highest MIC/MBC values|||Human microvascular endothelial cells HMEC-1 (50% Cell death at 15.62 uM, Human keratinocytes HaCat (50% Cell death at 29.69 uM|||Human microvascular endothelial cells HMEC-1 (50% Cell death at 15.62 uM, Human keratinocytes HaCat (50% Cell death at 29.69 uM|||Brevinin-1GHd shows 13% hemolysis at its highest MIC/MBC values|||[Ref.32347293] Brevinin-1GHd displayed 13% hemolysis on horse red blood cells at its highest MIC/MBC value of the tested bacteria P. aeruginosa (32 uM). However, when the concentration increased above 64 uM, the hemolytic activity of Brevinin-1GHd also gradually increased. At the concentration of 64, 128, 256 and 512 uM, it displayed about 36%, 64%, 83% and 108% hemolysis.|||Brevinin-1GHd displayed 13% hemolysis at its highest MIC/MBC value, indicating Brevinin-1GHd exhibited low hemolytic activity on horse red blood cells (Figure 6A). However, when the concentration increased above 64 uM, the hemolytic activity of Brevinin-1GHd also gradually increased."	"Biosci Rep
. 2020 May 29;40(5):BSR20200019. doi: 10.1042/BSR20200019.|||2020 May 29;40(5):BSR20200019. doi: 10.1042/BSR20200019.|||Biosci Rep
. 2020 May 29;40(5):BSR20200019. doi: 10.1042/BSR20200019.|||32347293|||32347293|||Biosci Rep
. 2020 May 29;40(5):BSR20200019. doi: 10.1042/BSR20200019.|||Biosci Rep. 2020 May 29;40(5):BSR20200019. doi: 10.1042/BSR20200019.||Ref.32347293|||Biosci Rep. 2020;BSR20200019. doi:10.1042/BSR20200019. PubMed"	24	
FPDB01095	AP03183|||AP03183|||EtDef4	"	
ATCDLLSFLNVKDAACAAHCLAKGYRGGYCDGRKVCNCRK"	Anti-Gram+||Anti-MRSA||Anti-S. aureus ATCC 25923 and 33592, activity value is MIC = 16 ug/ml||Anti-L. monocytogenes DSM 20600, activity value is MIC = 16 ug/ml||Anti-M. luteus DSM 20030, activity value is MIC = 16 ug/ml||Anti-M. smegmatis ATCC 607, activity value is MIC = 32 ug/ml||Antibacterial||Antifungal	Rat-Tailed Maggots, Eristalis tenax|||Synthetic construct	Bridge	"In this document, the key values related to the hemolytic activity of antimicrobial peptides derived from drone fly (Eristalis tenax) larvae (EtCec1-a, EtCec2-a, EtCec3-a, EtDip) are as follows, measured using human red blood cell (hRBC) hemolysis assays (2% Triton X-100 as the 100% hemolysis positive control, PBS as the 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 0.031–1024 µg/ml (covering antimicrobial effective concentrations, e.g., MIC of EtCec1-a against E. coli = 4–8 µg/ml, MIC of EtCec2-a against Acinetobacter baumannii = 8 µg/ml)

- Hemolysis values for each peptide:

- EtCec2-a:

- Minimum hemolytic concentration: Hemolysis occurs at 512 µg/ml, which is far above its effective antimicrobial concentration (MIC against most Gram-negative bacteria = 8–32 µg/ml), indicating almost no hemolytic toxicity at antimicrobial active doses.

- EtCec1-a, EtCec3-a, EtDip:

- No hemolytic activity was observed at the highest tested concentration (1024 µg/ml, hemolysis <1%), even at concentrations far exceeding their antimicrobial effective concentrations (e.g., MIC of EtCec1-a against Pseudomonas aeruginosa = 32 µg/ml), indicating very low hemolytic toxicity.|||Rat-Tailed Maggots, Eristalis tenax"	"Microorganisms
. 2020 Apr 25;8(5):626. doi: 10.3390/microorganisms8050626.|||Microorganisms
. 2020 Apr 25;8(5):626. doi: 10.3390/microorganisms8050626.|||32344933"	40	
FPDB01096	AP03185|||AP03185|||Dermaseptin-AC4, DRP-AC4|||Dermaseptin-AC4, DRP-AC4|||AP03185	SLWGKLKEMAAAAGKAALNAVNGLVNQ	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anti-E. coli, activity value is MIC = 8 uM||Anti-C. albicans, activity value is MIC = 64 uM||Anti-E. faecalis, activity value is MIC = 32 uM||Anti-K. pneumoniae, activity value is MIC = 32 uM||Anti-and MRSA, activity value is MIC = 32 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 8 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MBC = 32 uM||Anti-Escherichia coli NCTC 10418, activity value is MIC = 8 uM||Anti-Escherichia coli NCTC 10418, activity value is MBC = 8 uM||Anti-Candida albicans NCTC 1467, activity value is MIC = 64 uM||Anti-Candida albicans NCTC 1467, activity value is MBC = 128 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 64 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MBC = 128 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MIC = 32 uM||Anti-Enterococcus faecalis NCTC 12697, activity value is MBC = 64 uM||Anti-Klebsiella pneumoniae ATCC 43816, activity value is MIC = 32 uM||Anti-Klebsiella pneumoniae ATCC 43816, activity value is MBC = 32 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MIC = 32 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MBC = 64 uM	Skin Secretion, the Red-Eyed Tree Frog, Agalychnis callidryas, North America (Mexico) to Central America|||Synthetic construct|||Agalychnis callidryas|||Skin Secretion, the Red-Eyed Tree Frog, Agalychnis callidryas, North America (Mexico) to Central America|||Skin Secretion, the Red-Eyed Tree Frog, Agalychnis callidryas, North America (Mexico) to Central America	Helix	"In this document, the key values related to hemolysis for the novel antimicrobial peptide Dermaseptin-AC (DRP-AC4) derived from the skin of the red-eyed tree frog (Agalychnis callidryas) and its modified peptides DRP-AC4a and DRP-AC4b are as follows, measured by the horse red blood cell hemolysis assay (using 1% Triton X-100 as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 1–512 μM (covering the effective antimicrobial concentrations of the three peptides, e.g., the MIC of DRP-AC4a against MRSA is 8 μM, and against Candida albicans is 16 μM)

- Hemolysis values of each peptide:

- Hemolysis rate at antimicrobial effective concentrations: At the geometric mean MIC (GM MIC) concentrations against seven test strains, the hemolysis rate of the three peptides is approximately 10%, with the corresponding concentrations and hemolysis as follows:

- DRP-AC4 (natural peptide): GM MIC = 26.25 μM, hemolysis rate at this concentration is about 10%;

- DRP-AC4a (modified peptide with enhanced cationicity and amphipathicity): GM MIC = 14.49 μM, hemolysis rate at this concentration is slightly below 10%, the lowest among the three peptides;

- DRP-AC4b (modified peptide optimized for amphipathic structure): GM MIC = 21.53 μM, hemolysis rate at this concentration is about 10%.

- Hemolysis trend at high concentrations: The document does not specify the exact hemolysis values at high concentrations (such as 128 μM, 256 μM, 512 μM), but it clearly states that the hemolytic activity of all peptides is lower than their antimicrobial activity, and the hemolytic toxicity is low at effective antimicrobial concentrations.|||Skin Secretion, the Red-Eyed Tree Frog, Agalychnis callidryas, North America (Mexico) to Central America|||Horse erythrocytes (10% Hemolysis at 26.5 uM|||The documentation provides hemolytic data on equine erythrocytes for DRP-AC4 and its two analogs (DRP-AC4a, DRP-AC4b), with the following core information:

1. Critical hemolytic value (for equine red blood cells)

Common features: The three peptides showed similar low hemolytic activity at their respective minimum inhibitory concentrations (MIC) against seven species of bacteria, with a hemolysis rate of about 10%.
Details by peptide classification:
DRP-AC4: Under the geometric mean MIC(GM MIC = 26.25 uM) concentration, the hemolysis rate is about 10%. With the increase of concentration, the hemolysis rate gradually increases (for example, when the concentration reaches 70 uM, the hemolysis rate is close to 40%).
DRP-AC4a: At its geometric mean MIC(GM MIC = 14.49 uM) concentration, the hemolysis rate was slightly lower than that of the other two peptides (still close to 10%); when the concentration was increased to 70 uM, the hemolysis rate was about 35%, and the overall hemolysis activity was slightly weaker than that of the parent peptide.
DRP-AC4b: At the geometric mean MIC(GM MIC = 21.53 uM) concentration, the hemolysis rate was about 10%. When the concentration reached 70 uM, the hemolysis rate was close to 40%, which was consistent with the DRP-AC4 trend.

2. Additional Notes

Experimental control: PBS was used as negative control (no hemolysis),1% Triton X-100 was used as positive control (complete hemolysis), and the hemolysis rate was calculated by detecting the absorbance at 550 nm.
The impact of structural modification on hemolysis:
DRP-AC4a (increasing net charge to +4, optimizing amphiphilicity) enhanced the antibacterial activity, but did not significantly improve the hemolysis rate, and the hemolysis activity was even slightly lower at GM MIC concentration, indicating that a reasonable increase in positive charge can maintain low cytotoxicity while enhancing the antibacterial activity.
The DRP-AC4b (optimized hydrophobic surface, net charge is still +3) is consistent with the hemolysis trend of the parent peptide DRP-AC4, indicating that the integrity of the hydrophobic surface does not significantly change the hemolysis activity in the case of similar hydrophobic degree.|||Horse erythrocytes (10% Hemolysis at 26.5 uM"	"Antibiotics (Basel)
. 2020 May 10;9(5):243. doi: 10.3390/antibiotics9050243.|||Antibiotics (Basel)
. 2020 May 10;9(5):243. doi: 10.3390/antibiotics9050243.|||32397600|||Antibiotics (Basel). 2020;9(5):E243. doi:10.3390/antibiotics9050243. PubMed|||32397600|||Antibiotics (Basel)
. 2020 May 10;9(5):243. doi: 10.3390/antibiotics9050243.|||Antibiotics (Basel). 2020;9(5):E243. doi:10.3390/antibiotics9050243. PubMed"	27	
FPDB01097	AP03186	"	
SSAPCTIYASVSASISATASWGC"	Anti-Gram+||Anti-MRSA||anti-TB||Anti-ctive against S. simulans 22, activity value is MIC = 0.11 uM||Anti-S. aureus SG511 or SG511 DapR or clinical isolate MRSA MB5393, activity value is MIC = 0.22||Anti-M. tuberculosis H37Ra, activity value is MIC = 13.6 uM||Anti-B. subtilis 168, activity value is MIC = 3.4 uM||Anti-clinical isolates C. difficile RyC 11872343 toxigenic, activity value is MIC = 3.4 uM||Anti-S. simulans 22, activity value is MIC = 0.11 uM	Streptomyces cacaoi CA-170360	N/A	Streptomyces cacaoi CA-170360	"Angew Chem Int Ed Engl
. 2020 Jul 27;59(31):12654-12658. doi: 10.1002/anie.202005187. Epub 2020 Jun 15.|||. 2020 Jul 27;59(31):12654-12658. doi: 10.1002/anie.202005187. Epub 2020 Jun 15."	23	
FPDB01098	AP03225|||AP03225|||Ranatuerin-2Pb|||DRAMP21334|||Ranatuerin-2Pb|||AP03225|||DRAMP21334	"	
SFLTTVKKLVTNLAALAGTVIDTIKCKVTGGCRT"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Anti-S. aureus, activity value is MIC = 8 uM||Anti-E. coli, activity value is MIC = 8 uM||Anti-MRSA, activity value is MIC = 16 uM||Anti-and C. albicans, activity value is MIC = 8 uM||Antibacterial||Anti-Staphylococcus aureus, activity value is MIC = 8 uM||Anti-Enterococcus faecalis, activity value is MIC > 256 uM||activity value is MBC > 256 uM||Anti-Escherichia coli, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa, activity value is MIC > 256 uM||Anti-Candida albicans, activity value is MIC = 8 uM||activity value is MBC = 8 uM||activity value is MBC = 16 uM||activity value is MBC = 32 uM||Anti-##Gram-negative bacteria: Escherichia coli, activity value is MIC = 8 uM||Anti-##Fungi: Candida albicans, activity value is MIC = 8 uM	Skin Secretion, Northern leopard frog, Rana pipiens, North America|||Rana pipiens|||Lithobates pipiens (Northern leopard frog) (Rana pipiens)|||Rana pipiens|||Skin Secretion, Northern leopard frog, Rana pipiens, North America|||Lithobates pipiens (Northern leopard frog) (Rana pipiens)|||Skin Secretion, Northern leopard frog, Rana pipiens, North America	Helix||50% Helix, 7.8% antiparallel, 1.2% parallel, 10.9% turn and 29.8% others in 50% TFE/H2O. ##3.5% Helix, 26.6% antiparallel, 0% parallel, 18.3% turn and	"In this document, the key values related to hemolysis for the antimicrobial peptide Ranatuerin-2Pb derived from the skin of the Northern Leopard Frog (Rana pipiens) and its truncated analogs RPa and RPb are as follows, measured using a horse red blood cell hemolysis assay (with 1% Triton X-100 as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 1–256 μM (covering the antibacterial effective concentrations of the three peptides, e.g., the MIC of Ranatuerin-2Pb against S. aureus is 8 μM, and the MIC of RPb against MRSA is 16 μM)

- Hemolysis values for each peptide:

1. Ranatuerin-2Pb (natural peptide):

- Concentration corresponding to 20% hemolysis: at 8 μM concentration, hemolysis is close to 20%;

- Half-maximal hemolysis concentration (HC₅₀): 16.11 μM, with antibacterial effective concentrations (e.g., MIC against S. aureus = 8 μM) close to the hemolytic activity concentration, resulting in a low therapeutic index (TI = HC₅₀/geometric mean MIC) of only 0.449.

2. RPa (truncated peptide missing 2 residues at the C terminus):

- Concentration corresponding to 20% hemolysis: at 32 μM concentration, hemolysis is close to 20%;

- HC₅₀: 63.9 μM, hemolytic activity significantly lower than the natural peptide, with a slightly higher therapeutic index than the natural peptide (TI = 0.353), but antibacterial activity somewhat reduced (MIC against S. aureus = 16 μM).

3. RPb (N-terminal 16-residue truncated and C-terminal amidated analog):

- Concentration corresponding to 20% hemolysis: at 64 μM concentration, hemolysis is close to 20%;

- HC₅₀: 178 μM, the lowest hemolytic activity among the three peptides, with the highest therapeutic index (TI = 8.83), and the broadest antibacterial spectrum (active against both MRSA and P. aeruginosa), showing a significant safety advantage.|||Skin Secretion, Northern leopard frog, Rana pipiens, North America||Ranatuerin-2 Pb, RPa, and RPb showed nearly 20% hemolysis on horse red blood cells at concentrations of 8, 32, and 64 μM, respectively|||Horse blood cells (50% hemolysis at 16.11 uM)|||- Ranatuerin-2Pb:

- Hemolysis rate is about 20% at 8 µM;

- Half-maximal hemolytic concentration (HC_{50}) is 16.11 µM.

- RPa:

- Hemolysis rate is about 20% at 32 µM;

- Half-maximal hemolytic concentration (HC_{50}) is 63.9 µM.

- RPb:

- Hemolysis rate is about 20% at 64 µM;

- Half-maximal hemolytic concentration (HC_{50}) is 178 µM (lowest hemolytic activity, best safety).|||Horse blood cells (50% hemolysis at 16.11 uM)|||Ranatuerin-2 Pb, RPa, and RPb showed nearly 20% hemolysis on horse red blood cells at concentrations of 8, 32, and 64 μM, respectively|||[Ref.31242693] 7% hemolysis at 2 uM, 23% hemolysis at 8 uM, 50% hemolysis at 16 uM, 71% hemolysis at 32 uM, 100% hemolysis at 64 uM on horse erythrocytes.|||Ranatuerin-2Pb, RPa andRPb exhibited a hemolysis rate near 20% on horse erythrocytes with the concentration at 8,32 and 64 uM,respectively,as shown in Figure4."	"Biomolecules
. 2019 Jun 25;9(6):249. doi: 10.3390/biom9060249.|||Biomolecules
. 2019 Jun 25;9(6):249. doi: 10.3390/biom9060249.|||31242693|||Biomolecules. 2019 Jun 25;9(6):249. doi: 10.3390/biom9060249.||Ref.31242693|||31242693|||Biomolecules
. 2019 Jun 25;9(6):249. doi: 10.3390/biom9060249.|||Biomolecules. 2019 Jun 25;9(6):249. doi: 10.3390/biom9060249.||Ref.31242693|||Biomolecules. 2019 Jun 25;9(6):249. doi: 10.3390/biom9060249. PubMed"	34	
FPDB01099	AP03230	CVWLVVV	Anti-Gram+||Anti-MRSA||Anti-Gram+ bacteria S. aureus USA300, activity value is MIC = 1.5 ug/ml||Anti-S. aureus USA300, activity value is MIC = 1.5 ug/ml||Anti-S. pneumoniae, activity value is MIC = 1.5 ug/ml||Anti-S. aureus Mu50, activity value is MIC = 3 ug/ml||Anti-S. aureus SA113, activity value is MIC = 3 ug/ml||Anti-S. aureus RN4220, activity value is MIC = 3 ug/ml||Anti-E. faecium BK463, activity value is MIC = 3 ug/ml||Anti-E. faecalis VRE366, activity value is MIC = 12 ug/ml||Anti-L. monocytogenes ATCC19118, activity value is MIC = 6 ug/ml||Anti-B. subtilis 168, activity value is MIC = 4 ug/ml||Anti-P-aeruginosa PAO1, activity value is MIC > 50 ug/ml	Staphylococcus lugdunensis IVK28, human microbiota:nose, symbiont bacteria	N/A	"In this document, the key values related to the hemolytic activity of the novel antibiotic lugdunin, produced by the human commensal bacterium Staphylococcus lugdunensis, are as follows, as determined by human red blood cell hemolysis assay (with 2% Triton X-100 as 100% hemolysis positive control and untreated group as 0% hemolysis negative control):

Core hemolytic activity results

- Test concentration range: 12.5–50 µg/ml (covering its antibacterial effective concentrations, such as MIC against MRSA = 1.5 µg/ml, MIC against vancomycin-resistant Enterococcus = 3–12 µg/ml)

- Lugdunin hemolysis values:
At concentrations of 12.5 µg/ml, 25 µg/ml, and 50 µg/ml, no hemolysis of human red blood cells was observed (hemolysis rate <1%), indicating that even at concentrations far exceeding the antibacterial effective concentrations for most pathogenic bacteria (1.5–12 µg/ml), there is no significant hemolytic toxicity.|||Staphylococcus lugdunensis IVK28, human microbiota:nose, symbiont bacteria||Chemically synthesized AC-1 exhibited low hemolytic activity on chicken red blood cells, and even after treatment with 500 μg/mL of AC-1 for 1 hour, the hemolysis rate was only 14.47 ± 1.03%.|||Chemically synthesized AC-1 exhibited low hemolytic activity on chicken red blood cells, and even after treatment with 500 μg/mL of AC-1 for 1 hour, the hemolysis rate was only 14.47 ± 1.03%."	"Nature
. 2016 Jul 28;535(7613):511-6. doi: 10.1038/nature18634."	7	
FPDB01100	AP03236|||AP03236|||WW307	"	
RRRWWWWV"	Anti-Gram+ & Gram-||Anti-MRSA||Synergistic AMPs||Antibiofilm||Anti-E. faecium V286-17, activity value is MIC = 2 uM||Anti-S. aureus USA300 LAC MRSA and 30 clinical strains, activity value is MIC = 2||Anti-K. pneumoniae E406-17 and 22 clinical strains, activity value is MIC = 4||Anti-A. baumannii B28-16, activity value is MIC = 8 uM||Anti-and E. coli E423-17, activity value is MIC = 2 uM||Anti-S. aureus�G16�, activity value is MIC = 1 ug/ml||Anti-MRSA T144, activity value is MIC = 4 ug/ml||Anti-E. coli B2, activity value is MIC = 4 ug/ml||Anti-E. coli C3, activity value is MIC = 4 ug/ml||Anti-E. coli G6, activity value is MIC = 8 ug/ml||Anti-E. coli G92, activity value is MIC = 4 ug/ml||Anti-E. coli CP131, activity value is MIC = 4 ug/ml||Anti-E. coli 1F28, activity value is MIC = 4 ug/ml||Anti-A. baumannii C222, activity value is MIC = 4 ug/ml||Anti-P. cibarius HNCF44W, activity value is MIC = 2 ug/ml	engineered: database filtering + structure-based refinement	Rich	"engineered: database filtering + structure-based refinement|||The document only explicitly provides core hemolytic data of two antimicrobial peptides (horine and verine) against human red blood cells (hRBCs), with specific information as follows:

- Test indicators: Using a “2% human red blood cell suspension” as the experimental subject, hemolytic activity was assessed by detecting hemoglobin release. The core results are presented in terms of ""50% hemolytic concentration (HL₅₀)"" standards (the exact HL₅₀ value is not directly given, but the hemolytic activity threshold is clearly indicated).
  horine: Within the tested concentration range, the hemolytic activity against 2% human red blood cells was extremely low, HL₅₀ > 200 µM, meaning that at concentrations below 200 µM, the hemolysis rate did not reach 50% and cytotoxicity to red blood cells was very weak.
  verine: Similar to horine, its hemolytic activity against 2% human red blood cells was also extremely low, HL₅₀ > 200 µM, and at conventional antimicrobial concentrations (2-16 µM, see Table 1 for MIC values), it exhibited almost no hemolysis.

Supplementary notes:

1. Experimental relevance: The antimicrobial effective concentrations of both peptides (MIC 2-32 µM, Table 1) are far below their hemolytic activity threshold (>200 µM), indicating high safety for human red blood cells during antimicrobial action, with no significant hemolytic toxicity.
2. Other cytotoxicity references: The study also tested the toxicity of the two peptides on human hepatocytes (HepaRG), kidney cells (HEK293), lung fibroblasts (MRC9), and mouse splenocytes. The results showed that their LD₅₀ against these eukaryotic cells was significantly higher than the antimicrobial MIC (e.g., LD₅₀ for human kidney cells > 80 µM), further supporting their low toxicity to host cells and showing no nephrotoxicity."	"Proc Natl Acad Sci U S A
. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A
. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28|||33804947|||Proc Natl Acad Sci U S A. 2020;117(32):19446-19454. doi:10.1073/pnas.2005540117. PubMed|||Proc Natl Acad Sci U S A
. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28"	8	
FPDB01101	AP03240|||AP03240|||Brevinin-1H|||Brevinin-1H|||AP03240|||DRAMP32300	"	
FALGAVTKVLPKLFCLITRKC"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Antibiofilm||Anti-Gram+ S. aureus, activity value is MIC = 4 uM||Anti-MRSA, activity value is MIC = 8 uM||Anti-E. coli, activity value is MIC = 16 uM||Anti-P. aeruginosa, activity value is MIC = 64 uM||Anti-K. pneumoniae, activity value is MIC = 64 uM||Anti-and yeast C. albicans, activity value is MIC = 16 uM||Anti-MB435S and HCT116 human cancer cell lines, activity value is IC50 = 3.4||Antibacterial||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 4 uM||Anti-Staphylococcus aureus NCTC 10788, activity value is MBC = 8 uM||Anti-Escherichia coli NCTC 10418, activity value is MIC = 16 uM||Anti-Escherichia coli NCTC 10418, activity value is MBC = 32 uM||Anti-Candida albicans NCTC 1467, activity value is MIC = 16 uM||Anti-Candida albicans NCTC 1467, activity value is MFC = 16 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 64 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MBC = 128 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MIC = 8 uM||Anti-Staphylococcus aureus NCTC 12493, activity value is MBC = 16 uM||Anti-Klebsiella pneumoniae ATCC 43816, activity value is MIC = 64 uM||Anti-Klebsiella pneumoniae ATCC 43816, activity value is MBC = 64 uM||Anti-Human prostate adenocarcinoma PC-3, activity value is IC50 = 5.87 uM||Anti-Human breast adenocarcinoma MDA-MB-435S, activity value is IC50 = 3.47 uM||Anti-Human squamous lung carcinoma NCI-H157, activity value is IC50 = 3.37 uM||Anti-Human colon adenocarcinoma HCT 116, activity value is IC50 = 2.599 uM||Antimicrobial||Anticancer	skin secretions, Hainan cascade-frog, Amolops hainanensis; China, Asia|||Amolops hainanensis|||skin secretion of Amolops hainanensis|||skin secretion of Amolops hainanensis|||skin secretions, Hainan cascade-frog, Amolops hainanensis; China, Asia	N/A	"In this document, the key values related to hemolysis of the novel antimicrobial peptide Brevinin-1H derived from the skin of Hainan torrent frog (Amolops hainanensis) and its modified analogs Brevinin-1Ha and Brevinin-1HY are as follows, determined by a horse red blood cell hemolysis assay (using 1% Triton X-100 as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 1–512 μM (covering the antimicrobial effective concentrations of the three peptides, e.g., MIC of Brevinin-1H against S. aureus = 4 μM, MRSA MIC = 8 μM)

- Hemolysis values of each peptide:

1. Brevinin-1H (natural peptide):

- Concentration corresponding to 20% hemolysis: At 32 μM, hemolysis was 22.1%, which is close to its effective antimicrobial concentration against some pathogens (e.g., MIC against E. coli = 16 μM);

- Half-maximal hemolytic concentration (HC₅₀): 53.12 μM, therapeutic index (TI = HC₅₀/geometric mean MIC) is low; safety needs improvement.

2. Brevinin-1Ha (modified peptide with Rana-box moved to the center):

- Concentration corresponding to 20% hemolysis: Hemolysis only reached 9.49% at 128 μM, not reaching 20%;

- HC₅₀: 437.2 μM, the lowest hemolytic activity among the three peptides, significantly reducing hemolytic toxicity, but the antimicrobial activity is almost entirely lost (only weak activity against E. coli, MIC = 64 μM).

3. Brevinin-1HY (modified peptide with Pro¹¹ replaced by Tyr):

- Concentration corresponding to 20% hemolysis: At its MIC against S. aureus = 4 μM, hemolysis was already 28.48%, much higher than that of the natural peptide at the same concentration;

- HC₅₀: The exact value is not explicitly provided in the document, but according to the hemolysis curve trend, its HC₅₀ is significantly lower than that of the natural peptide (<53.12 μM), with substantially increased hemolytic toxicity. Although antimicrobial activity (against Gram-positive bacteria) and anticancer activity are slightly improved, safety is decreased.|||skin secretions, Hainan cascade-frog, Amolops hainanensis; China, Asia|||Horse erythrocytes (9.49% Hemolysis at 4 uM|||The document clearly provides hemolytic data for natural antimicrobial peptide Brevinin-1H and its two structural analogs (Brevinin-1Ha, Brevinin-1HY) on 2% horse erythrocyte suspension. The experiment used 1% Triton X-100 as the fully hemolytic positive control (hemolysis rate = 100%) and PBS as the negative control (hemolysis rate = 0%). The core information is as follows: 
 
1. Brevinin-1H
 
Half-hemolytic concentration (HC₅₀): 53.12 uM. 
Hemolysis rate at critical concentrations: At 32 μM, the hemolysis rate exceeds 20% (specifically 22.1%); Its resistance to Staphylococcus aureus (S. aureus) has a minimum inhibitory concentration (MIC) of 4 μM, at which the hemolysis rate is relatively low (exact value unclear, but significantly below 20%). 
 
2. Brevinin-1Ha
 
Half hemolytic concentration (HC₅₀): 437.2 uM, with hemolytic activity significantly lower than natural peptides. 
Hemolysis rate at key concentrations: at 128 μM, the hemolysis rate only exceeds 20% (specifically above 9.49%, not fully quantified, but significantly lower than natural peptides); At low concentrations (e.g., ≤64 μM), the hemolysis rate is extremely low, close to 0%. 
 
3. Brevinin-1HY
 
Half hemolytic concentration (HC₅₀): No direct value is clear, but overall hemolytic activity is significantly higher than that of the natural peptide Brevinin-1H. 
Hemolysis rate at key concentrations: its MIC for resistance to Staphylococcus aureus (S. aureus) is 4 uM, and at this concentration, the hemolysis rate reaches 28.48%, more than three times that of the natural peptide Brevinin-1H at MIC. 
 
The association between hemolysis and biological activity
 
Although Brevinin-1H has broad-spectrum antibacterial activity (against Gram-positive bacteria, Gram-negative bacteria, fungi) and cancer resistance, it has relatively high hemolysis, with hemolysis exceeding 20% at 32 μM concentration, requiring further optimization to reduce toxicity. 
Brevinin-1Ha significantly reduces hemolytic activity by transferring the Rana-box from the C-terminal to the central position (HC₅₀ from 53.12 uM to 437.2 uM), but its antibacterial and anticancer activity is almost lost, with only weak activity against E. coli, and anticancer requires a high concentration of 10⁻⁴ M. 
After replacing Pro¹¹ with tyrosine in Brevinin-1HY, the α-helix ratio increased from 52% to 67%, enhancing anti-proliferative activity against some cancer cells, but hemolysis was greatly increased, with a hemolysis rate of 28.48% under MIC and reduced safety.|||Horse erythrocytes (9.49% Hemolysis at 4 uM|||Lee and coworkers substituted Glu9 with Pro producing a helix-kink-helix structure in Anal 3-Pro peptide, which apparently increased antibacterial activity of parent peptide with no hemolysis (Lee et al., 2013)."	"Chem Biol Drug Des
. 2021 Feb;97(2):273-282. doi: 10.1111/cbdd.13779. Epub 2020 Sep 7.|||Chem Biol Drug Des
. 2021 Feb;97(2):273-282. doi: 10.1111/cbdd.13779. Epub 2020 Sep 7.|||32812694|||Chem Biol Drug Des. 2021 Feb;97(2):273-282. doi: 10.1111/cbdd.13779. PubMed|||32812694|||Chem Biol Drug Des
. 2021 Feb;97(2):273-282. doi: 10.1111/cbdd.13779. Epub 2020 Sep 7.|||Chem Biol Drug Des. 2021 Feb;97(2):273-282.|||Chem Biol Drug Des. 2021 Feb;97(2):273-282. doi: 10.1111/cbdd.13779. PubMed"	21	
FPDB01102	AP03245|||AP03245|||Temporin-SHe|||Temporin-SHe|||AP03245|||DRAMP32308	"	
FLPALAGIAGLLGKIF"	Anti-Gram+ & Gram-||Antifungal||Antiparasitic||Anti-MRSA||Hemolytic||Anti-S. aureus ST1065, activity value is MIC = 3.1 uM||Anti-L. ivanovii, activity value is MIC = 5 uM||Anti-E. faecalis ATCC 29212, activity value is MIC = 12.5 uM||Anti-B. megaterium, activity value is MIC = 1.6 uM||Anti-E. coli ML-35p, activity value is MIC = 25||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 60 uM||Anti-A. baumannii ATCC 19606, activity value is MIC = 25 uM||Anti-S. enterica, activity value is MIC = 100 uM||Anti-C. parapsilosis ATCC 22019, activity value is MIC = 50 uM||Anti-S. cerevisiae, activity value is MIC = 12.5 uM||Anti-and C.albicans ATCC 90028, activity value is MIC > 100 uM||Anti-and L. major, activity value is IC50 = 4.6||Anti-Escherichia coli ATCC 25922, activity value is MIC = 25 uM||Anti-Escherichia coli ATCC 35218, activity value is MIC = 50 uM||Anti-Escherichia coli ML-35p, activity value is MIC = 50 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 60 uM||Anti-Salmonella enterica subsp. enterica serovar Enteritidis, activity value is MIC = 100 uM||Anti-Acinetobacter baumannii ATCC 19606, activity value is MIC = 25 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 100 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 3.12 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 3.1 uM||Anti-Staphylococcus aureus ATCC BAA-44, activity value is MIC = 3.12 uM||Anti-Staphylococcus aureus ST1065, activity value is MIC = 3.12 uM||Anti-Listeria ivanovii, activity value is MIC = 5 uM||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 12.5 uM||Anti-Bacillus megaterium, activity value is MIC = 1.56 uM||Anti-Candida albicans ATCC 90028, activity value is MIC > 100 uM||Anti-Candida parapsilosis ATCC 22019, activity value is MIC = 50 uM||Anti-Saccharomyces cerevisiae, activity value is MIC = 12.5 uM||Anti-Leishmania infantum MHOM/MA/67/ITMAP-263, activity value is IC50 = 4.6 uM||Anti-Leishmania braziliensis MHOM/BR/75/M2904, activity value is IC50 = 10.5 uM||Anti-Leishmania major MHOM/SU/73/5ASKH, activity value is IC50 = 11.6 uM||Antimicrobial||Anticancer	the Sahara Frog, Pelophylax saharicus, Africa|||Pelophylax saharicus	Helix	"In this document, the key values related to the hemolytic properties of the novel antimicrobial peptide Temporin-SHe and its homologous peptide Temporin-SHd derived from the skin of Sahara frog (Pelophylax saharicus) are as follows, measured by human red blood cell hemolysis assay (using 0.1% Triton X-100 as a 100% hemolytic positive control, PBS as a 0% hemolytic negative control): 
 
Core hemolytic activity results
 
- Test concentration range: 1–200 uM (covering effective antibacterial concentrations of two peptides, such as Temporin-SHe against Staphylococcus aureus at MIC=3.12 uM and against Acinetobacter baumannii at MIC=25 uM)

- Hemolysis values for each peptide: 

1. Temporin-SHe (Target Peptide): 

- Specific concentration hemolytic rate: 

- At a concentration of 12.5 μM, hemolysis rate reaches 22%; 

- At a concentration of 25 μM, the hemolysis rate increases significantly to 84%, which matches its effective antibacterial concentration (25 μM) against certain pathogens (such as E. coli ATCC 25922, A. baumannii ATCC 19606), indicating that the antibacterial effect is highly toxic; 

- Half-hemolytic concentration (LC₅₀): 17 uM, treatment index (TI = LC₅₀ / geometric mean MIC) is low, safety needs optimization. 

2. Temporin-SHd (homologous control peptide): 

- Specific concentration hemolytic rate: 

- At a concentration of 25 μM, the hemolysis rate is only 25%; 

- At a concentration of 50 μM, hemolysis rate is 72%; 

- A concentration of 100 uM is required to approach the 91% hemolytic rate, significantly higher than the hemolytic activity concentration of Temporin-SHe; 

- LC₅₀: 42 uM, 2.5 times that of Temporin-SHe, with significantly lower hemolytic toxicity.|||the Sahara Frog, Pelophylax saharicus, Africa|||Human erythrocytes (22% Hemolysis at 12.5 uM|||Human erythrocytes (22% Hemolysis at 12.5 uM|||Human erythrocytes: 22% Hemolysis=12.5 uM; 84% Hemolysis=25 uM"	"Int J Mol Sci
. 2020 Sep 13;21(18):6713. doi: 10.3390/ijms21186713.|||Int J Mol Sci
. 2020 Sep 13;21(18):6713. doi: 10.3390/ijms21186713.|||32933215|||32933215|||Int J Mol Sci
. 2020 Sep 13;21(18):6713. doi: 10.3390/ijms21186713.|||Int J Mol Sci. 2020 Sep 13;21(18):6713."	16	
FPDB01103	AP03257	"	
CND"	Anti-Gram+||Anti-MRSA||Anti-S. aureus ATCC 25923, activity value is MIC = 8 ug/ml||Anti-or ATCC 33591, activity value is MIC = 32 ug/ml||Anti-E. faecium ATCC 19434 or ATCC 51559, activity value is MIC = 64 ug/ml||Anti-and E. faecalis ATCC 51259, activity value is MIC = 64 ug/ml	Geotrichum candidum OMON-1	N/A	Geotrichum candidum OMON-1	Arabian Journal for Science and Engineering published Oct 20	3	
FPDB01104	AP03258|||AP03258|||Temporin-PF	"	
FLPLIAGLFGKIF"	Anti-Gram+||Anti-MRSA||Antibiofilm||Anti-S. aureus MRSA, activity value is MIC = 4 uM||Anti-E. faecalis, activity value is MIC = 16 uM||Anti-E.coli, activity value is MIC > 128 uM||Anti-P.aeruginosa, activity value is MIC > 128 uM||Anti-K.pneumoniae, activity value is MIC > 128 uM||Anti-S. aureus, activity value is MIC = 4 uM||Anti-MRSA, activity value is MIC = 4 uM	skin secretions, Pelophylax fukienensis, China, Asia|||Pelophylax fukienensis [Frog]	Helix	"The contents of Documents 1-3 are completely consistent. The core hemolytic data focus on the antimicrobial peptide Temporin-PF (TPF) derived from the skin of Fujian pond frog (Pelophylax fukienensis) and its three modified analogs, measured using a horse red blood cell hemolysis assay (with 1% Triton X-100 as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 1–128 μM (covering the effective antimicrobial concentrations of the four peptides, e.g., TPF MIC against Staphylococcus aureus = 4 μM, MRSA = 4 μM)

- Hemolysis values of each peptide:

1. TPF (natural peptide):
The strongest hemolytic activity was observed. Within its antimicrobial effective concentration range (4–16 μM), significant hemolysis was already evident, and the hemolysis rate continued to increase with rising concentration (specific hemolysis rates at particular concentrations were not specified, but it had the highest hemolytic toxicity among the four peptides).

2. des-Phe1 TPF (modified peptide with deletion of N-terminal Phe):
Hemolytic activity was significantly reduced. Even at the highest test concentration of 128 μM, the hemolysis rate remained <20%, far lower than that of the natural peptide at the same concentration.

3. W-des-Phe1 TPF (modified peptide with C-terminal Phe replaced by Trp):
Hemolytic activity was similar to des-Phe1 TPF. At 128 μM, the hemolysis rate was <20%, showing no significant hemolytic toxicity.

4. dW-des-Phe1 TPF (modified peptide with C-terminal Phe replaced by D-Trp):
The lowest hemolytic activity was observed. At 128 μM, the hemolysis rate was close to 0% (negligible), indicating the best safety profile.|||skin secretions, Pelophylax fukienensis, China, Asia|||In this research document, the key value related to hemolysis is the hemolytic concentration (HL₅₀), with specific details as follows:

Through structural optimization of peptide WW295 (changing the terminal L8 to V8 to obtain WW307), its 50% hemolytic concentration (HL₅₀) doubled. This optimization improved the peptide's cell selectivity and reduced its toxicity to red blood cells (relevant content corresponds to the ""Database-Guided Peptide Design and Structure-Based Refinement"" section and SI Appendix, Table S4).

Furthermore, in in vitro toxicity assessments, it was shown that two peptides (horine and verine) have extremely low toxicity to human red blood cells (hRBCs), with hemolysis-related concentration thresholds >200 μM (corresponding to Figure 4A and the ""In Vitro and In Vivo Toxicity"" section), which is much higher than the minimum inhibitory concentration (MIC 2-4 μM) required to inhibit drug-resistant bacteria (such as VRE and MRSA), indicating that there is almost no risk of hemolysis at therapeutic doses."	"Int J Mol Sci
. 2021 Apr 26;22(9):4509. doi: 10.3390/ijms22094509.|||Int J Mol Sci
. 2021 Apr 26;22(9):4509. doi: 10.3390/ijms22094509.|||33925935|||Int J Mol Sci. 2021 Apr 26;22(9):4509. doi: 10.3390/ijms22094509. PubMed"	13	
FPDB01105	AP03268	"	
NFWKKGKWTIGS"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. cloacae LMG02783, activity value is MIC = 2 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 2 ug||Anti-P. aeruginosa PAO1, activity value is MIC = 2 ug/ml||Anti-K. pneumoniae LMG20218, activity value is MIC = 4 ug/ml||Anti-P. aeruginosa LMG6395, activity value is MIC = 4 ug/ml||Anti-A. baumannii ATCC17978, activity value is MIC = 4 ug/ml||Anti-E. faecium LMG16003, activity value is MIC = 2 ug/ml||Anti-S. aureus ATCC15975, activity value is MIC = 4 ug/ml||Anti-B. cereus ATCC14579, activity value is MIC = 4 ug/ml||Anti-E. faecalis LMG16216, activity value is MIC = 8 ug/ml	Brevibacillus laterosporus DSM 25	N/A	"The core hemolytic data center on a novel cyclic lipopeptide, Brevicidine B (BreB), and its homologous peptide, Brevicidine (Bre), produced by Brevibacillus laterosporus DSM 25. Hemolysis was assessed using a human red blood cell assay, with 10% Triton X-100 serving as the 100% positive control and the peptide-free treatment group as the 0% negative control.

Core hemolytic activity results

-Test concentration range: 2–64 µM (covering the antibacterial effective concentrations of both peptides; for example, the MIC of BreB is 2–4 µM against Gram-negative bacteria and 2–8 µM against Gram-positive bacteria).

-Hemolytic values of each peptide:

-BreB and Bre:
Both compounds exhibited extremely low hemolytic activity; at the highest tested concentration of 64 µM, no hemolysis was detected (hemolysis rate = 0%). Even at concentrations far exceeding their minimum inhibitory concentrations (2–8 µM), neither compound displayed any hemolytic toxicity.|||Brevibacillus laterosporus DSM 25"	"Front Microbiol
. 2021 Jun 9:12:693117. doi: 10.3389/fmicb.2021.693117. eCollection 2021."	12	
FPDB01106	AP03273|||AP03273|||BING|||DRAMP35770	"	
IRIILRAQGALKI"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-both Gram+ and Gram- bacteria. Active against Gram+ S. Faecalis, activity value is MIC = 50 ug/ml||Anti-S. pyogenes ATCC 14289, activity value is MIC = 50 ug/ml||Anti-S. aureus ATCC 6538 or ATCC 29213 or MRSA ATCC BAA-41 or 44, activity value is MIC = 20||Anti-S. epidermidis ATCC 12228, activity value is MIC = 4 ug/ml||Anti-B. subtilis 168, activity value is MIC = 16 ug/ml||Anti-A. hydrophila ATCC 49140, activity value is MIC = 20 ug/ml||Anti-V. alginolyticus ATCC 33840, activity value is MIC = 50 ug/ml||Anti-E. tarda PE210, activity value is MIC = 10 ug/ml||Anti-E. cloacae BAA-1143, activity value is MIC = 32 ug/ml||Anti-A. baumannii ATCC 19606, activity value is MIC = 10 ug/ml||Anti-E. coli ATCC 10536 or pathogenic E. coli, activity value is MIC = 5 ug/ml||Anti-E. coli BL21, activity value is MIC = 8 ug/ml||Anti-K. pneumoniae ATCC BAA-2470, activity value is MIC = 32 ug/ml||Anti-E. coli ATCC BAA-2469, activity value is MIC = 16 ug/ml||Anti-SHV-1/BL21, activity value is MIC = 4 ug/ml||Anti-TEM-1/BL21, activity value is MIC = 8 ug/ml||Anti-MCR-1/BL21, activity value is MIC = 16 ug/ml||Anti-P. aeruginosa A, activity value is MIC = 50 ug/ml||Anti-Streptococcus Faecalis, activity value is MIC = 50 ug/ml||Anti-Streptococcus pyogenes ATCC14289, activity value is MIC = 50 ug/ml||Anti-Staphylococcus aureus ATCC6538, activity value is MIC = 20 ug/ml||Anti-Bacillus subtilis 168, activity value is MIC = 16 ug/ml||Anti-Staphylococcus aureus ATCC29213, activity value is MIC = 64 ug/ml||Anti-Pseudomonas aeruginosa A, activity value is MIC = 50 ug/ml||Anti-Staphylococcus epidermidis ATCC12228, activity value is MIC = 4 ug/ml||Anti-Multidrug-resistant S. aureus ATCC BAA-44, activity value is MIC = 32 ug/ml||Anti-Escherichia coli ATCC BAA-2469, activity value is MIC = 16 ug/ml||Anti-Klebsiella pneumoniae ATCC BAA-2470, activity value is MIC = 32 ug/ml||Antimicrobial||Anticancer	plasma, medaka, Oryzias latipes|||Synthetic construct|||Synthetic	Beta	"This document focuses on the novel antimicrobial peptide BING, which was isolated from the plasma of the Japanese medaka (Oryzias latipes). The key findings are summarized as follows:

1. Discovery and basic properties of BING

1. Background: Using mass spectrometry, 6,399 unique peptide sequences were identified in medaka plasma. Subsequent bioinformatics prediction and screening yielded 430 potential antimicrobial peptides, among which BING stands out. BING is derived from vacuolar protein sorting–associated protein 13D-like (Vps13D) and consists of 13 amino acid residues; it is a thermostable peptide with the sequence IRIILRAQGALKI.

2. Structural features: In aqueous solution, it adopts a random coil conformation; in a hydrophobic environment (e.g., 50% TFE or 16,000 µM SDS), it can form approximately 40% β-sheet structure. The molecular surface exhibits both positively charged hydrophilic regions (Arg-2, Arg-6, Lys-12) and hydrophobic regions (Ile-3, Ala-9, etc.), which facilitate interactions with bacterial membranes.

2. Antibacterial activity and mechanism of BING

1. Antibacterial spectrum and MIC:

-It exhibits broad-spectrum bactericidal activity against both Gram-positive bacteria (such as Staphylococcus aureus and Enterococcus faecalis) and Gram-negative bacteria (such as Escherichia coli and Pseudomonas aeruginosa), including resistant strains (such as methicillin-resistant Staphylococcus aureus and NDM-1-producing Escherichia coli).

-The MIC ranges from 4 to 64 µg/mL; for example, the MIC against pathogenic Escherichia coli is 5 µg/mL, and that against multidrug-resistant Staphylococcus aureus is 32 µg/mL, which is comparable to the activity of the human antimicrobial peptide LL-37.

2. Mechanism of action:

-Inhibition of envelope stress response: By reducing the RNA levels of cpxR, a key regulatory factor in the envelope stress response of Gram-negative bacteria (without affecting cpxA), the expression of periplasmic peptidyl-prolyl isomerases (such as surA and ppiA) is decreased, leading to the accumulation of misfolded proteins in the periplasm.

-Downregulation of efflux pumps: In Pseudomonas aeruginosa, it significantly reduces the expression of the efflux pump components mexB, mexY, and oprM, enhancing antibiotic susceptibility. When used in combination with ampicillin, amoxicillin, and novobiocin, it exhibits a synergistic effect (FICI = 0.16–0.42), reducing the MIC of ampicillin by eightfold.

-Delaying the development of resistance: Sublethal concentrations (3.9 µg/mL) can delay the emergence of resistance in Escherichia coli to kanamycin and ampicillin, as well as in Pseudomonas aeruginosa to ampicillin, with a significant reduction in the increase of MIC values for resistant strains within 7 days.

3. The safety and application potential of BING

1. Low toxicity:

-Exhibits low toxicity to mammalian cells (e.g., HeLa, MCF7); after a 48-hour incubation, cell viability remains high at concentrations effective against bacteria.

-It has no adverse effects on medaka fish; following intraperitoneal injection of 1 µg per fish, no mortality was observed over 14 days, and it significantly improved the survival rate of medaka infected with Edwardsiella tarda, increasing it from 35% to 80%.

2. Structural modification and optimization:

-C-terminal amidation (C-BING), all-D-amino acid substitution (D-BING), and double modification (CD-BING) do not affect antibacterial activity, and CD-BING exhibits enhanced stability in fetal bovine serum while maintaining thermal stability (the MIC remains unchanged after incubation at 25–90°C for 24 hours).

4. Significance of the Study

BING is the first antimicrobial peptide discovered to inhibit the expression of cpxR in Gram-negative bacteria, highlighting the potential of the cpxR pathway as an antibacterial target. Its broad-spectrum activity, low toxicity, and synergistic effects with antibiotics, coupled with enhanced stability following structural modifications, make it a promising candidate for combating infections caused by drug-resistant pathogens, while also providing a research paradigm for the discovery of novel antimicrobial peptides from fish plasma.|||plasma, medaka, Oryzias latipes"	"Sci Rep
. 2021 Jun 9;11(1):12219. doi: 10.1038/s41598-021-91765-4.|||Sci Rep
. 2021 Jun 9;11(1):12219. doi: 10.1038/s41598-021-91765-4|||34108601|||Sci Rep
. 2021 Jun 9;11(1):12219. doi: 10.1038/s41598-021-91765-4|||Sci Rep. 2021 Jun 9;11(1):12219."	13	
FPDB01107	AP03274	"	
HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli, activity value is MIC = 28.3 uM||Anti-S.aureus, activity value is MIC > 30 uM||Anti-P. aeruginosa, activity value is MIC = 1.2 uM||Anti-and B. cereus, activity value is MIC = 23.3||Anti-A. pleuropneumoniae, activity value is MIC = 7.5 ug/ml||Anti-B. subtilis, activity value is MIC = 28 ug/ml||Anti-B. velezensis, activity value is MIC = 76 ug/ml||Anti-B. amyloliquefaciens, activity value is MIC = 42 ug/ml||Anti-inactive against P.putida, activity value is MIC = 113 ug/ml||Anti-S.aureus, activity value is MIC > 200 ug/ml||Anti-and P. aeruginosa PAO1, activity value is MBC = 2	brain, kidney, Homo sapiens|||brain, kidney, Homo sapiens	Helix	"In this document, the key values related to hemolysis of pituitary adenylate cyclase-activating polypeptide (PACAP) and its analogs are as follows, measured by human red blood cell hemolysis experiments (with 10% Triton X-100 as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 1–30 μM (covering the antimicrobial effective concentrations of PACAP38 and its analogs, e.g., PACAP38 MIC against Pseudomonas aeruginosa = 1.2 μM, MIC against Escherichia coli = 0.76 μM)

- Hemolysis values of each peptide:

1. PACAP38 (natural peptide):
  Low hemolytic toxicity; at 30 μM, the hemolysis rate is <0.2 (Figure 2B), far lower than the control antimicrobial peptides—natural peptide indolicidin (≈0.8 at 30 μM) and synthetic peptide ARVA (≈0.6 at 30 μM), indicating high safety for human red blood cells while exerting antimicrobial effects.

2. PACAP38 receptor agonist analogs:
  - [D-Ser²]PACAP38, [Iac¹]PACAP38, [Iaa¹]PACAP38, [Pro³]PACAP38: Hemolytic activity similar to PACAP38, with hemolysis rate <0.2 at 30 μM (Figure 2A), showing no significant hemolytic toxicity;
  - [Lys³⁸-palmitoyl]PACAP38: Hemolytic toxicity significantly increased, hemolysis rate ≈0.8 at 30 μM (Figure 2B), comparable to indolicidin, suggesting palmitoyl modification enhances hydrophobic interaction with red blood cell membranes;
  - [Iaa¹,D-Ser²,Ala¹⁶,¹⁷,²²,D-Lys³⁸]PACAP38: Hemolysis rate <0.2 at 30 μM, maintaining low hemolytic properties.

3. PACAP38 receptor antagonist analogs:
  - [Sar⁴]PACAP38, PACAP(6-38): Hemolytic activity consistent with PACAP38, hemolysis rate <0.2 at 30 μM, without additional hemolytic risk.

4. PACAP38 analogs with piperidine carboxyl modifications:
  - e.g., [Pip³]PACAP38, [N-acetyl-His¹,Pip³]PACAP38, etc.: Hemolysis rate <0.2 at 30 μM, low hemolytic properties unchanged by modification.|||brain, kidney, Homo sapiens||Regarding hemolytic activity, moderate activity was reported for 19 TsAP-2 and microperforin, with hemolysis observed at concentrations of approximately 20 µM. In 20 cases of Im-4 and Im-6, no significant hemolysis was observed even at concentrations of 30, 21, and 25 µM, respectively. Although the types of red blood cells used in this study were different from the 22 red blood cell types for TsAP-2 and microperforin, the hemolytic activity of Im-4 and Im-6 may be lower than that of TsAP-2 and microperforin.|||Regarding hemolytic activity, moderate activity was reported for 19 TsAP-2 and microperforin, with hemolysis observed at concentrations of approximately 20 µM. In 20 cases of Im-4 and Im-6, no significant hemolysis was observed even at concentrations of 30, 21, and 25 µM, respectively. Although the types of red blood cells used in this study were different from the 22 red blood cell types for TsAP-2 and microperforin, the hemolytic activity of Im-4 and Im-6 may be lower than that of TsAP-2 and microperforin."	"Peptides
. 2018 Jun:104:35-40. doi: 10.1016/j.peptides.2018.04.006. Epub 2018 Apr 11.|||Peptides
. 2018 Jun:104:35-40. doi: 10.1016/j.peptides.2018.04.006. Epub 2018 Apr 11||PMID:30462698||PMID: 33372152||see ref|||Peptides. 2018 Jun;104:35-40. doi: 10.1016/j.peptides.2018.04.006. PubMed"	38	
FPDB01108	AP03304|||DRAMP29065	"	
KTMMQSGGTFGTFMAIGMGIR"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-moderately active against Gram+ S. aureus, activity value is MBC = 45 uM||Anti-B. subtilis, activity value is MBC = 41 uM||Anti-E. faecium, activity value is MBC = 38 uM||Anti-S. sindenensis, activity value is MBC = 43 uM||Anti-E. faecalis, activity value is MBC = 38 uM||Anti-S. pneumoniae, activity value is MBC = 45 uM||Anti-E. coli, activity value is MBC = 38 uM||Anti-A. baumannii, activity value is MBC = 45 uM||Anti-E. aerogenes, activity value is MBC = 41 uM||Anti-MDR pathogens MRSA, activity value is MBC = 45 uM||Anti-Vancomycin-resistant S. aureus, activity value is MBC = 54 uM||activity value is MBC = 45 uM||Anti-Carbapenem-resistant A. baumannii, activity value is MBC = 50 uM||Anti-and Carbapenem-resistant K. pneumoniae, activity value is MBC = 45 uM||Anti-S. aureus, activity value is MBC = 100 ug/ml||Anti-B. subtilis, activity value is MBC = 90 ug/ml||Anti-E. faecium, activity value is MBC = 85 ug/ml||Anti-S. sindenensis, activity value is MBC = 95 ug/ml||Anti-E. faecalis, activity value is MBC = 85 ug/ml||Anti-S. pneumoniae, activity value is MBC = 100 ug/ml||Anti-P. aeruginosa, activity value is MBC = 100 ug/ml||Anti-K. pneumoniae, activity value is MBC = 100 ug/ml||Anti-A. baumannii, activity value is MBC = 100 ug/ml||Anti-E. aerogenes, activity value is MBC = 90 ug/ml||Anti-Carbapenem-resistant P. aeruginosa, activity value is MBC = 110 ug/ml||Anti-Carbapenem-resistant A. baumannii, activity value is MBC = 110 ug/ml||Anti-Carbapenem-resistant K. pneumoniae, activity value is MBC = 100 ug/ml||Anti-Vancomycin-resistant S. aureus, activity value is MBC = 120 ug/ml||Anti-Vancomycin-resistant E. faecium, activity value is MBC = 100 ug/ml	an AMP derived from Romo 1, a mitochondrial nonselective channel|||Homo sapiens (Human)	Helix||α-helical	"In this document, the key values related to the hemolytic activity of the Romo1-derived antimicrobial peptide AMPR-11 are as follows, as measured by mouse red blood cell hemolysis assay (with 1% Triton X-100 as 100% hemolysis positive control and PBS as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 64–256 µM (covering the antimicrobial effective concentrations of AMPR-11, such as MBC against Pseudomonas aeruginosa = 100 µg/ml and MBC against Staphylococcus aureus = 100 µg/ml, which corresponds to approximately 100 µM).

- AMPR-11 hemolysis values:
At the highest tested concentration of 256 µM, the hemolysis rate remained <20%, significantly lower than the control antimicrobial peptides — melittin (hemolysis rate close to 100% at 256 µM), magainin 2 (hemolysis rate ≈60% at 256 µM), and daptomycin (hemolysis rate ≈40% at 256 µM), indicating higher safety toward mouse red blood cells while exerting antimicrobial effects.|||an AMP derived from Romo 1, a mitochondrial nonselective channel|||[Ref.33291307]At the concentration of 32 ug/ml, AMPR-11 induced a hemolysis of 20% on mouse red blood cells; At the concentration of 256 ug/ml, AMPR-11 induced a hemolysis of 23%."	"mBio
. 2020 Apr 14;11(2):e03258-19. doi: 10.1128/mBio.03258-19.|||mBio. 2020 Apr 14;11(2):e03258-19. doi: 10.1128/mBio.03258-19.||Ref.33291307"	21	
FPDB01109	AP03310	GFGCNLITSNPYQCSNHCKSVGYRGGYCKLRTVCTCY	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Anti-and C. difficile DPC6534 . Also tested using MRSA, activity value is MIC = 23 ug/ml||Anti-P.aeruginosa, activity value is MIC = 1448 ug/ml	Actinomyces ruminicola	Bridge	Actinomyces ruminicola	"J Bacteriol. 202:e00529-19. Online PDF|||J Bacteriol
. 2020 Jan 29;202(4):e00529-19. doi: 10.1128/JB.00529-19. Print 2020 Jan 29.|||J Bacteriol. 202:e00529-19. Online PDF"	37	
FPDB01110	AP03311|||DRAMP35815	"	
GFGCPWNAYECDRHCVSKGYTGGNCRGKIRQTCHCY"	Anti-Gram+||Anti-MRSA||Synergistic AMPs||(lethal concentration CL): B. megaterium CGMCC 1.0459 (CL 0.038-0.11 uM)||B. subtilis CGMCC 1.2428 (LC 1 uM)||S. aureus CGMCC 1.89 (LC 5.2 uM)||penicillin-sensitive S. epidermidis P1111 or P1389 (LC 5.2 or 1.14)||penicillin-resistant S. aureus P1383 (LC 4.28 uM)||MRSA P1374 or P 1386 (LC 0.62 uM or 0.74 uM)||Methicillin-resistant coagulase negative Staphylococci P1369 (LC 1.07 uM)||S. aureus J685||J698||J700||J706||J708 and J710 (LC 1.14-10.4 uM)||S. pneumoniae D39||R6||ST556||ST556 (StrR)||TIGR4 (LC 0.14 uM)||S. mutans CGMCC 1.2499 (ATCC 25175) (LC 0.381.01 uM)||S. salivarius CGMCC 1.2498 (ATCC 7073) (LC 0.49 uM)||S. sanguinis CGMCC 1.2497 (ATCC 49295) (LC 1.41 uM)||S. griseus NBRC 13350 (LC 2.89 uM)||S. scabiei CGMCC 4.1765 (ATCC 49173) (LC 2.01 uM)||L. fusiformis (LC 0.27 uM)||E. faecalis V583 (ATCC 700802) (4.65 uM).||Antimicrobial||Anticancer	Actinomyces sp. oral taxon 171 str. F0337, Oral bacteria, Human microbiota:mouth, symbiont bacteria|||Bacteria	Combine Helix and Beta structure	"In this document, the key values related to the hemolysis of the human oral Actinomyces-derived defensin Actinomycesin (AM SIN) were measured using a mouse red blood cell hemolysis assay (1% Triton X-100 as 100% hemolysis positive control, 0.9% NaCl as 0% hemolysis negative control):

Core Hemolytic Activity Results

- Test concentration range: 6.25–100 μM (covering the antibacterial effective concentration of AM SIN, such as CL = 0.09–0.14 μM for Streptococcus pneumoniae and CL = 0.62–1.07 μM for methicillin-resistant Staphylococcus aureus)

- AM SIN hemolysis values:
At the highest test concentration of 100 μM, the hemolysis rate was still <10%, significantly lower than the positive control peptide Meucin-18 (scorpion venom-derived lytic peptide, hemolysis rate nearly 100% at 100 μM), indicating extremely high safety for mouse red blood cells while exerting antibacterial effects. Even at concentrations far exceeding the antibacterial effective dose, there was no significant hemolytic toxicity.

Experimental Conditions and Additional Notes

1. Experimental conditions: 
Diluted series of AM SIN were incubated with fresh mouse red blood cell suspensions (25,000,000 μg from female ICR mice) at appropriate temperatures, followed by centrifugation and measurement of the supernatant absorbance at 570 nm (hemoglobin-specific absorbance). Hemolysis rate was calculated using the formula (hemolysis rate = [(sample absorbance − negative control absorbance)/(positive control absorbance − negative control absorbance)] × 100%), and experiments were repeated three times to ensure reproducibility.

2. Hemolysis and safety correlation: 
AM SIN not only shows low hemolytic activity but also exhibits no significant toxicity to human cells (such as HL-60 human neutrophil-like cells and HEK 293 human embryonic kidney cells) — cell viability remained >80% at 100 μM, whereas the human antimicrobial peptide LL-37 at the same concentration significantly reduced HL-60 cell viability. Additionally, AM SIN showed no effects on voltage-gated ion channels in the heart and central nervous system (such as Nav1.5, hERG), further confirming its safety for in vivo applications.

3. Hemolysis mechanism correlation: 
The low hemolytic activity is related to the mechanism of AM SIN — it exerts antibacterial effects by specifically inhibiting bacterial cell wall synthesis (binding to the cell wall precursor UMP, KD = 24 μM), rather than damaging cell membranes. In contrast, the positive control Meucin-18 causes hemolysis through non-specific membrane disruption, resulting in very high hemolysis rates. This targeted mechanism against specific bacterial pathways avoids non-specific damage to mammalian red blood cell membranes, thereby reducing the risk of hemolysis.|||Actinomyces sp. oral taxon 171 str. F0337, Oral bacteria, Human microbiota:mouth, symbiont bacteria"	"EMBO Mol Med
. 2022 Feb 7;14(2):e14499. doi: 10.15252/emmm.202114499. Epub 2021 Dec 20.|||EMBO Mol Med. 2022 Feb 7;14(2):e14499."	36	
FPDB01111	AP03312	"	
KPQAVFP"	Anti-Gram+||Anti-MRSA||Anti-B-subtilis 168 1A1, activity value is MIC > 64 ug/ml||Anti-E. faecium Com15, activity value is MIC = 8 ug/ml||Anti-S. aureus USA300, activity value is MIC = 8 ug/ml||Anti-E-coli DH5alpha, activity value is MIC > 64 ug/ml||Anti-K-pneumoniae ATCC 10031, activity value is MIC > 64 ug/ml||Anti-A-baumannii ATCC 17978, activity value is MIC > 64 ug/ml||Anti-P-aeruginosa PAO1, activity value is MIC > 64 ug/ml||Anti-E-cloacae ATCC 14037, activity value is MIC > 64 ug/ml||Anti-M-tuberculosis H37RV, activity value is MIC > 12.5 ug/ml	bioinformatic identified bacterial nonribosomal gene cluster, Burkholderia gladioli BSR3, chr 2, bacteria-derived, natural derivatives|||bioinformatic predicted bacterial nonribosomal gene cluster, Burkholderia gladioli BSR3, chr 2, bacteria-derived, natural derivatives	N/A	bioinformatic predicted bacterial nonribosomal gene cluster, Burkholderia gladioli BSR3, chr 2, bacteria-derived, natural derivatives	"J Am Chem Soc
. 2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11."	7	
FPDB01112	AP03313	"	
AKSKRKGV"	Anti-Gram+||Anti-MRSA||Anti-B. subtilis 168 1A1, activity value is MIC = 8 ug/ml||Anti-E. faecium Com15, activity value is MIC = 64 ug/ml||Anti-S. aureus USA300, activity value is MIC = 64 ug/ml||Anti-E-coli DH5alpha, activity value is MIC > 64 ug/ml||Anti-K-pneumoniae ATCC 10031, activity value is MIC > 64 ug/ml||Anti-A-baumannii ATCC 17978, activity value is MIC > 64 ug/ml||Anti-P-aeruginosa PAO1, activity value is MIC > 64 ug/ml||Anti-E-cloacae ATCC 14037, activity value is MIC > 64 ug/ml||Anti-M-tuberculosis H37RV, activity value is MIC > 12.5 ug/ml	bioinformatic identified bacterial nonribosomal gene cluster, Burkholderia gladioli BSR3, chr 2, bacteria-derived, natural derivatives|||bioinformatic predicted bacterial nonribosomal gene cluster, Burkholderia gladioli BSR3, chr 2, bacteria-derived, natural derivatives	N/A	bioinformatic predicted bacterial nonribosomal gene cluster, Burkholderia gladioli BSR3, chr 2, bacteria-derived, natural derivatives	"J Am Chem Soc
. 2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11."	8	
FPDB01113	AP03314	"	
LTVSI"	Anti-Gram+||Anti-MRSA||Anti-B. subtilis 168 1A1, activity value is MIC = 8 ug/ml||Anti-E. faecium Com15, activity value is MIC = 8 ug/ml||Anti-S. aureus USA300, activity value is MIC = 4 ug/ml||Anti-E-coli DH5alpha, activity value is MIC > 64 ug/ml||Anti-K-pneumoniae ATCC 10031, activity value is MIC > 64 ug/ml||Anti-A-baumannii ATCC 17978, activity value is MIC > 64 ug/ml||Anti-P-aeruginosa PAO1, activity value is MIC > 64 ug/ml||Anti-E-cloacae ATCC 14037, activity value is MIC > 64 ug/ml||Anti-M-tuberculosis H37RV, activity value is MIC > 12.5 ug/ml	bioinformatic identified bacterial nonribosomal gene cluster, Collimonas fungivorans Ter331, bacteria-derived, natural derivatives|||bioinformatic predicted bacterial nonribosomal gene cluster, Collimonas fungivorans Ter331, bacteria-derived, natural derivatives	N/A	bioinformatic predicted bacterial nonribosomal gene cluster, Collimonas fungivorans Ter331, bacteria-derived, natural derivatives	"J Am Chem Soc
. 2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11."	5	
FPDB01114	AP03315	"	
LVVLAVAVVVWLR"	Anti-Gram+||Anti-MRSA||Anti-B. subtilis 168 1A1, activity value is MIC = 8 ug/ml||Anti-E. faecium Com15, activity value is MIC = 32 ug/ml||Anti-S. aureus USA300, activity value is MIC = 16 ug/ml||Anti-E-coli DH5alpha, activity value is MIC > 64 ug/ml||Anti-K-pneumoniae ATCC 10031, activity value is MIC > 64 ug/ml||Anti-A-baumannii ATCC 17978, activity value is MIC > 64 ug/ml||Anti-P-aeruginosa PAO1, activity value is MIC > 64 ug/ml||Anti-E-cloacae ATCC 14037, activity value is MIC > 64 ug/ml||Anti-M-tuberculosis H37RV, activity value is MIC > 12.5 ug/ml	other methods predicted, bioinformatic predicted bacterial nonribosomal gene cluster, Brevibacillus brevis NBRC 100599, Gram-positive bacteria, prokaryotes|||bioinformatic predicted bacterial nonribosomal gene cluster, Brevibacillus brevis NBRC 100599, Gram-positive bacteria, prokaryotes	N/A	bioinformatic predicted bacterial nonribosomal gene cluster, Brevibacillus brevis NBRC 100599, Gram-positive bacteria, prokaryotes	"J Am Chem Soc
. 2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11."	13	
FPDB01115	AP03316	"	
KNLKSPKFT"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-B. subtilis 168 1A1, activity value is MIC = 4 ug/ml||Anti-E. faecium Com15, activity value is MIC = 16 ug/ml||Anti-S. aureus USA300, activity value is MIC = 16 ug/ml||Anti-E. coli DH5alpha, activity value is MIC = 16 ug/ml||Anti-K. pneumoniae ATCC 10031, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 17978, activity value is MIC = 32 ug/ml||Anti-P-aeruginosa PAO1, activity value is MIC > 64 ug/ml||Anti-E-cloacae ATCC 14037, activity value is MIC > 64 ug/ml||Anti-M-tuberculosis H37RV, activity value is MIC > 12.5 ug/ml	bioinformatic identified bacterial nonribosomal gene cluster, Dickeya dadantii Ech586, bacteria-derived, natural derivatives|||bioinformatic predicted bacterial nonribosomal gene cluster, Dickeya dadantii Ech586, bacteria-derived, natural derivatives	N/A	bioinformatic predicted bacterial nonribosomal gene cluster, Dickeya dadantii Ech586, bacteria-derived, natural derivatives	"J Am Chem Soc
. 2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11."	9	
FPDB01116	AP03317	"	
KRIRL"	Anti-Gram+ & Gram-||Anti-MRSA||anti-TB||Anti-B. subtilis 168 1A1, activity value is MIC = 4 ug/ml||Anti-E. faecium Com15, activity value is MIC = 8 ug/ml||Anti-S. aureus USA300, activity value is MIC = 8 ug/ml||Anti-E. coli DH5alpha, activity value is MIC = 16 ug/ml||Anti-K. pneumoniae ATCC 10031, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC 17978, activity value is MIC = 32 ug/ml||Anti-E. cloacae ATCC 14037, activity value is MIC = 64 ug/ml||Anti-M. tuberculosis H37RV, activity value is MIC = 6 ug/ml	bioinformatic identified bacterial nonribosomal gene cluster, Bacillus thuringiensis plasmid BMB171, bacteria-derived, natural derivatives|||bioinformatic identified bacterial nonribosomal gene cluster, Bacillus thuringiensis plasmid BMB171, bacteria-derived, natural derivatives|||bioinformatic predicted bacterial nonribosomal gene cluster, Bacillus thuringiensis plasmid BMB171, bacteria-derived, natural derivatives	N/A	bioinformatic predicted bacterial nonribosomal gene cluster, Bacillus thuringiensis plasmid BMB171, bacteria-derived, natural derivatives	"J Am Chem Soc
. 2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11.|||2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11"	5	
FPDB01117	AP03318	"	
WTGYR"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-B. subtilis 168 1A1, activity value is MIC = 2 ug/ml||Anti-E. faecium Com15, activity value is MIC = 8 ug/ml||Anti-S. aureus USA300, activity value is MIC = 4 ug/ml||Anti-E-coli DH5alpha, activity value is MIC > 64 ug/ml||Anti-K. pneumoniae ATCC 10031, activity value is MIC = 16 ug/ml||Anti-A. baumannii ATCC 17978, activity value is MIC = 32 ug/ml||Anti-P-aeruginosa PAO1, activity value is MIC > 64 ug/ml||Anti-E-cloacae ATCC 14037, activity value is MIC > 64 ug/ml||Anti-M-tuberculosis H37RV, activity value is MIC > 12.5 ug/ml	bioinformatic identified bacterial nonribosomal gene cluster, Rhodococcus opacus B4, bacteria-derived, natural derivatives|||bioinformatic predicted bacterial nonribosomal gene cluster, Rhodococcus opacus B4, bacteria-derived, natural derivatives	N/A	bioinformatic predicted bacterial nonribosomal gene cluster, Rhodococcus opacus B4, bacteria-derived, natural derivatives	"J Am Chem Soc
. 2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11."	5	
FPDB01118	AP03319	FSTRF	Anti-Gram+ & Gram-||Anti-MRSA||Anti-B. subtilis 168 1A1, activity value is MIC = 4 ug/ml||Anti-E. faecium Com15, activity value is MIC = 8 ug/ml||Anti-S. aureus USA300, activity value is MIC = 4 ug/ml||Anti-E-coli DH5alpha, activity value is MIC > 64 ug/ml||Anti-K-pneumoniae ATCC 10031, activity value is MIC > 64 ug/ml||Anti-A. baumannii ATCC 17978, activity value is MIC = 8 ug/ml||Anti-P-aeruginosa PAO1, activity value is MIC > 64 ug/ml||Anti-E-cloacae ATCC 14037, activity value is MIC > 64 ug/ml||Anti-M-tuberculosis H37RV, activity value is MIC > 12.5 ug/ml	bioinformatic identified bacterial nonribosomal gene cluster, Rhodococcus jostii RHA1, bacteria-derived, natural derivatives|||bioinformatic predicted bacterial nonribosomal gene cluster, Rhodococcus jostii RHA1, bacteria-derived, natural derivatives	N/A	bioinformatic predicted bacterial nonribosomal gene cluster, Rhodococcus jostii RHA1, bacteria-derived, natural derivatives	"J Am Chem Soc
. 2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11."	5	
FPDB01119	AP03320	"	
FKVIFAF"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-B. subtilis 168 1A1, activity value is MIC = 4 ug/ml||Anti-E. faecium Com15, activity value is MIC = 8 ug/ml||Anti-S. aureus USA300, activity value is MIC = 8 ug/ml||Anti-E-coli DH5alpha, activity value is MIC > 64 ug/ml||Anti-K-pneumoniae ATCC 10031, activity value is MIC > 64 ug/ml||Anti-A. baumannii ATCC 17978, activity value is MIC = 8 ug/ml||Anti-P-aeruginosa PAO1, activity value is MIC > 64 ug/ml||Anti-E-cloacae ATCC 14037, activity value is MIC > 64 ug/ml||Anti-M-tuberculosis H37RV, activity value is MIC > 12.5 ug/ml	bioinformatic identified bacterial nonribosomal gene cluster, Paenibacillus mucilaginosus KNP414, bacteria-derived, natural derivatives|||bioinformatic predicted bacterial nonribosomal gene cluster, Paenibacillus mucilaginosus KNP414, bacteria-derived, natural derivatives	N/A	bioinformatic predicted bacterial nonribosomal gene cluster, Paenibacillus mucilaginosus KNP414, bacteria-derived, natural derivatives	"J Am Chem Soc
. 2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11|||J Am Chem Soc
. 2020 Aug 19;142(33):14158-14168. doi: 10.1021/jacs.0c04376. Epub 2020 Aug 11."	7	
FPDB01120	AP03328	TLKIIVKVVKYLV	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-A. acidoterrestris ATCC 49025, activity value is MIC = 0.5||Anti-B. cereus ATCC 11778, activity value is MIC = 2||Anti-B. cereus ATCC 14579, activity value is MIC = 1 ug/ml||Anti-C. difficile A515, activity value is MIC = 4||Anti-E. faecalis ATCC 29212, activity value is MIC = 2 ug/ml||Anti-E. faecalis ATCC 51299 anti-VRE, activity value is MIC = 4||Anti-L. plantarum ATCC 8014, activity value is MIC = 2 ug/ml||Anti-L. lactis ATCC 11454, activity value is MIC = 2 ug/ml||Anti-L. innocua ATCC 33090, activity value is MIC = 1||Anti-L. monocytogenes OSY-8578, activity value is MIC = 1||Anti-L. monocytogenes Scott A, activity value is MIC = 1 ug/ml||Anti-MRSA, activity value is MIC = 1||Anti-E-coli K-12, activity value is MIC > 32 ug/ml||Anti-E. coli O157:H7 EDL 933, activity value is MIC = 32 ug/ml||Anti-S-enterica serovar Typhimurium DT 109, activity value is MIC > 32 ug/ml||Anti-X. translucens pv. graminis LMG587, activity value is MIC = 2 ug/ml||Anti-P. syringae pv. tomato DC3000, activity value is MIC = 8||Anti-P. aeruginosa PAO1, activity value is MIC = 32||Anti-K. pneumoniae LMG20218, activity value is MIC = 16 ug/ml||Anti-E. coli ET8 or MG1665, activity value is MIC = 8||Anti-E. faecium LMG16003, activity value is MIC = 1||Anti-Gram+ S. aureus ATCC15975, activity value is MIC = 2 ug/ml||Anti-B. cereus ATCC14579, activity value is MIC = 1||Anti-A. baumannii ATCC17978, activity value is MIC = 32 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa LMG6395, activity value is MIC = 64 ug/ml||Anti-and K. pneumoniae LMG20218, activity value is MIC = 32 ug/ml	Brevibacillus laterosporus, OSY-I1	N/A	Brevibacillus laterosporus, OSY-I1	"Appl Environ Microbiol
. 2016 Apr 18;82(9):2763-2772. doi: 10.1128/AEM.00315-16. Print 2016 May.|||Appl Environ Microbiol
. 2016 Apr 18;82(9):2763-2772. doi: 10.1128/AEM.00315-16. Print 2016 May.||Data from ref for Bogorol K"	13	
FPDB01121	AP03329	TLKIVVKVVKYLV	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-Gram+ S. aureus ATCC15975 or MRSA, activity value is MIC = 1||Anti-B. cereus ATCC14579, activity value is MIC = 1||Anti-A. baumannii ATCC17978, activity value is MIC = 64 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa LMG6395, activity value is MIC = 64 ug/ml||Anti-and K. pneumoniae LMG20218, activity value is MIC = 64 ug/ml	Brevibacillus laterosporus fmb70	N/A	"The document clearly states that the hemolytic activity of two antimicrobial lipopeptides (brevibacillin V and brevibacillin) was tested using a sheep red blood cell (RBC) hemolysis assay. The results showed that at all tested concentrations (even up to 512 μg/ml), the hemolytic activity of both was below 8%.

In this experiment, sterile defibrinated sheep blood was used to prepare an 8% (v/v) RBC suspension with PBS buffer. Test samples were serially diluted twofold, with 0.1% Triton X-100 as the positive control and PBS as the negative control. Absorbance was measured at 540 nm to calculate the hemolysis rate. The experiment was repeated three times, and the consistent results indicated that both lipopeptides have low hemolytic activity, high safety, and potential as food preservatives.|||Brevibacillus laterosporus fmb70"	"J Agric Food Chem
. 2019 Nov 13;67(45):12452-12460. doi: 10.1021/acs.jafc.9b04113. Epub 2019 Nov 1."	13	
FPDB01122	AP03330	"	
TLKVVVKVVKYLV"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram+ S. aureus ATCC15975, activity value is MIC = 2 ug/ml||Anti-B. cereus ATCC14579, activity value is MIC = 2 ug/ml||Anti-A. baumannii ATCC17978, activity value is MIC = 32 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 16 ug/ml||Anti-P. aeruginosa LMG6395, activity value is MIC = 64 ug/ml||Anti-and K. pneumoniae LMG20218, activity value is MIC = 32 ug/ml	Brevibacillus laterosporus DSM 25	N/A	"In the document you provided, the hemolytic data on the novel antimicrobial lipopeptide brevibacillin 2V and other related compounds are as follows:

1. brevibacillin 2V (target novel compound)

- Key hemolytic indicator: At concentrations up to 128 µg/ml, no hemolysis was observed (Figure 3A), and the 50% human red blood cell hemolytic concentration (HC_{50}) is >128 µg/ml (since no hemolysis was observed at the highest tested concentration, the exact value cannot be determined, only the lower limit can be inferred).

- Experimental background: Using healthy human red blood cells, a 2% red blood cell suspension was prepared with PBS. Tested concentrations ranged from 1 to 128 µg/ml. After incubation at 37 °C for 1 hour, absorbance at 450 nm was measured. 10% Triton X-100 was used as a complete hemolysis control, and PBS was used as the no-hemolysis control.

2. Other related brevibacillins (for comparison)

Through the same hemolysis assay, the document also provides hemolytic data for three other related lipopeptides to highlight the low hemolytic property of brevibacillin 2V:

- brevibacillin I: HC_{50} = 18.8 ± 0.5 µg/ml, capable of causing complete human red blood cell lysis at 64 µg/ml.

- brevibacillin: HC_{50} = 25.1 ± 3.9 µg/ml, capable of causing complete human red blood cell lysis at 64 µg/ml.

- brevibacillin V: HC_{50} = 73.1 ± 1.4 µg/ml, capable of causing complete human red blood cell lysis at 128 µg/ml.

Additional notes

The document clearly states that the hemolytic activity of brevibacillins positively correlates with their hydrophobicity (brevibacillin I > brevibacillin > brevibacillin V > brevibacillin 2V). Due to its extremely low hydrophobicity, brevibacillin 2V is the first compound in this family to show no hemolysis even at 128 µg/ml, exhibiting very high clinical development potential.|||Brevibacillus laterosporus DSM 25||At a concentration of 128 µg/ml, no hemolytic activity of Bacillus penicillin 2 V was observed, with an HC50 > 128 µg/ml, where HC50 is the concentration that causes 50% hemolysis of human red blood cells. At concentrations 2–4 times higher than their MIC values, Bacillus penicillin, Bacillus penicillin V, and Bacillus penicillin I showed significant hemolytic activity (Figure 3A and Table 1), with half-hemolytic (HC50) concentrations of 18.8 ± 0.5, 73.1 ± 1.4, and 25.1 ± 3.9, respectively. In addition, in the presence of 64 µg/ml Bacillus penicillin/Bacillus penicillin I or 128 µg/ml Bacillus penicillin V, human blood cells were completely lysed (Figure 3A). In contrast, at a high concentration of 128 µg/ml, Bacillus penicillin 2 V showed N/A hemolytic activity on human red blood cells.|||At a concentration of 128 µg/ml, no hemolytic activity of Bacillus penicillin 2 V was observed, with an HC50 > 128 µg/ml, where HC50 is the concentration that causes 50% hemolysis of human red blood cells. At concentrations 2–4 times higher than their MIC values, Bacillus penicillin, Bacillus penicillin V, and Bacillus penicillin I showed significant hemolytic activity (Figure 3A and Table 1), with half-hemolytic (HC50) concentrations of 18.8 ± 0.5, 73.1 ± 1.4, and 25.1 ± 3.9, respectively. In addition, in the presence of 64 µg/ml Bacillus penicillin/Bacillus penicillin I or 128 µg/ml Bacillus penicillin V, human blood cells were completely lysed (Figure 3A). In contrast, at a high concentration of 128 µg/ml, Bacillus penicillin 2 V showed N/A hemolytic activity on human red blood cells."	"Front Microbiol
. 2021 Jun 17:12:693725. doi: 10.3389/fmicb.2021.693725. eCollection 2021."	13	
FPDB01123	AP03331	"	
TLKIIVKIVKYLV"	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-Gram+ S. aureus ATCC159750 or MRSA, activity value is MIC = 2 ug/ml||Anti-B. cereus ATCC14579, activity value is MIC = 2 ug/ml||Anti-A. baumannii ATCC17978, activity value is MIC = 64 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa LMG6395, activity value is MIC = 64 ug/ml||Anti-and K. pneumoniae LMG20218, activity value is MIC = 64 ug/ml	Brevibacillus laterosporus DSM 25	N/A	"In the document you provided, the hemolytic data on the novel antimicrobial lipopeptide brevibacillin 2V and other related compounds are as follows:

1. brevibacillin 2V (target novel compound)

- Key hemolytic indicator: At concentrations up to 128 µg/ml, no hemolysis was observed (Figure 3A), and the 50% human red blood cell hemolytic concentration (HC_{50}) is >128 µg/ml (since no hemolysis was observed at the highest tested concentration, the exact value cannot be determined, only the lower limit can be inferred).

- Experimental background: Using healthy human red blood cells, a 2% red blood cell suspension was prepared with PBS. Tested concentrations ranged from 1 to 128 µg/ml. After incubation at 37 °C for 1 hour, absorbance at 450 nm was measured. 10% Triton X-100 was used as a complete hemolysis control, and PBS was used as the no-hemolysis control.

2. Other related brevibacillins (for comparison)

Through the same hemolysis assay, the document also provides hemolytic data for three other related lipopeptides to highlight the low hemolytic property of brevibacillin 2V:

- brevibacillin I: HC_{50} = 18.8 ± 0.5 µg/ml, capable of causing complete human red blood cell lysis at 64 µg/ml.

- brevibacillin: HC_{50} = 25.1 ± 3.9 µg/ml, capable of causing complete human red blood cell lysis at 64 µg/ml.

- brevibacillin V: HC_{50} = 73.1 ± 1.4 µg/ml, capable of causing complete human red blood cell lysis at 128 µg/ml.

Additional notes

The document clearly states that the hemolytic activity of brevibacillins positively correlates with their hydrophobicity (brevibacillin I > brevibacillin > brevibacillin V > brevibacillin 2V). Due to its extremely low hydrophobicity, brevibacillin 2V is the first compound in this family to show no hemolysis even at 128 µg/ml, exhibiting very high clinical development potential.|||Brevibacillus laterosporus DSM 25||At a concentration of 128 µg/ml, no hemolytic activity of Bacillus penicillin 2 V was observed, with an HC50 > 128 µg/ml, where HC50 is the concentration that causes 50% hemolysis of human red blood cells. At concentrations 2–4 times higher than their MIC values, Bacillus penicillin, Bacillus penicillin V, and Bacillus penicillin I showed significant hemolytic activity (Figure 3A and Table 1), with half-hemolytic (HC50) concentrations of 18.8 ± 0.5, 73.1 ± 1.4, and 25.1 ± 3.9, respectively. In addition, in the presence of 64 µg/ml Bacillus penicillin/Bacillus penicillin I or 128 µg/ml Bacillus penicillin V, human blood cells were completely lysed (Figure 3A). In contrast, at a high concentration of 128 µg/ml, Bacillus penicillin 2 V showed N/A hemolytic activity on human red blood cells.|||Brevibacillus laterosporus DSM 25||C50 is the concentration that causes 50% hemolysis of human red blood cells. At a concentration of 128 µg/mL, no hemolytic activity was observed for short bacillus penicillin 2V, with its HC50&gt; 128 µg/mL.|||At a concentration of 128 µg/ml, no hemolytic activity of Bacillus penicillin 2 V was observed, with an HC50 > 128 µg/ml, where HC50 is the concentration that causes 50% hemolysis of human red blood cells. At concentrations 2–4 times higher than their MIC values, Bacillus penicillin, Bacillus penicillin V, and Bacillus penicillin I showed significant hemolytic activity (Figure 3A and Table 1), with half-hemolytic (HC50) concentrations of 18.8 ± 0.5, 73.1 ± 1.4, and 25.1 ± 3.9, respectively. In addition, in the presence of 64 µg/ml Bacillus penicillin/Bacillus penicillin I or 128 µg/ml Bacillus penicillin V, human blood cells were completely lysed (Figure 3A). In contrast, at a high concentration of 128 µg/ml, Bacillus penicillin 2 V showed N/A hemolytic activity on human red blood cells.|||C50 is the concentration that causes 50% hemolysis of human red blood cells. At a concentration of 128 µg/mL, no hemolytic activity was observed for short bacillus penicillin 2V, with its HC50&gt; 128 µg/mL."	"Front Microbiol
. 2021 Jun 17:12:693725. doi: 10.3389/fmicb.2021.693725. eCollection 2021.|||Front Microbiol
. 2021 Jun 17:12:693725. doi: 10.3389/fmicb.2021.693725. eCollection 2021.|||Biochem Biophys Res Commun
. 2003 Dec 26;312(4):1139-46. doi: 10.1016/j.bbrc.2003.11.045."	13	
FPDB01124	AP03333|||AP03333|||OaBac7.5mini|||OaBac7.5mini|||AP03333	"	
RRIPRPILLPWRPPRPIPRPQPQPIPRWL"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-rough K-12 strain, activity value is MIC = 8||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 32 ug/ml||Anti-defensin supersusceptible, activity value is MIC = 2 ug/ml||Anti-antibiotic-supersusceptible mutant, activity value is MIC = 16||Anti-S. aureus NCTC 4163 or MRSA R147, activity value is MIC = 32||Anti-S. epidermidis clinical isolate, activity value is MIC = 32 ug/ml||Anti-E. faecalis ATCC 29212, activity value is MIC = 64 ug/ml||Anti-and yeast . C. albicans 105 or 3153A, activity value is MIC = 64 ug/ml||Anti-Escherichia coli O111, activity value is MIC = 16 ug/ml||Anti-Escherichia coli UB1005, activity value is MIC = 8 ug/ml||Anti-Escherichia coli DC2, activity value is MIC = 2 ug/ml||Anti-Escherichia coli O157:H7, activity value is MIC = 32 ug/ml||Anti-Salmonella enterica subsp. enterica serovar Typhimurium ATCC 14028s, activity value is MIC = 32 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS4252S, activity value is MIC = 2 ug/ml||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC = 16 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus NCTC 4163, activity value is MIC = 64 ug/ml||Anti-Staphylococcus aureus R147, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus 1056, activity value is MIC > 64 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 32 ug/ml||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 64 ug/ml||Anti-Candida albicans 105, activity value is MIC = 64 ug/ml||Anti-Candida albicans 3153A, activity value is MIC > 64 ug/ml	sheep; Ovis aries|||Synthetic construct|||Synthetic construct|||sheep; Ovis aries|||sheep; Ovis aries	Rich	sheep; Ovis aries	"Comparative Study Biochem Biophys Res Commun
. 2003 Dec 26;312(4):1139-46. doi: 10.1016/j.bbrc.2003.11.045.|||Antimicrob Agents Chemother
. 2004 Feb;48(2):673-6. doi: 10.1128/AAC.48.2.673-676.2004.|||14742236|||14742236|||Antimicrob Agents Chemother
. 2004 Feb;48(2):673-6. doi: 10.1128/AAC.48.2.673-676.2004.|||Biochem Biophys Res Commun. 2003 Dec 26;312(4):1139-46. doi: 10.1016/j.bbrc.2003.11.045. PubMed"	29	
FPDB01125	AP03334|||AP03334|||OaBac5mini|||OaBac5mini|||AP03334	"	
RFRPPIRRPPIRPPFRPPFRPPVR"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-ATCC25922, activity value is MIC = 2||Anti-S. enterica serovar Typhimurium 14028s, activity value is MIC = 0.5 ug/ml||Anti-defensin supersusceptible, activity value is MIC = 0.125||Anti-61, activity value is MIC = 4||Anti-S. aureus NCTC 4163 or MRSA R147 or 1056 MRSA, activity value is MIC = 16||Anti-S. epidermidis clinical isolate, activity value is MIC = 16 ug/ml||Anti-E. faecalis ATCC 29212, activity value is MIC = 32 ug/ml||Anti-and yeast C. albicans 105 or 3153A, activity value is MIC = 32||Antibacterial||Anti-Escherichia coli O111, activity value is MIC = 2 ug/ml||Anti-Escherichia coli UB1005, activity value is MIC = 0.125 ug/ml||Anti-Escherichia coli DC2, activity value is MIC = 0.125 ug/ml||Anti-Escherichia coli O157:H7, activity value is MIC = 8 ug/ml||Anti-Salmonella enterica subsp. enterica serovar Typhimurium ATCC 14028s, activity value is MIC = 0.5 ug/ml||Anti-Salmonella enterica serovar Typhimurium MS4252S, activity value is MIC = 0.125 ug/ml||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC = 4 ug/ml||Anti-Pseudomonas aeruginosa Z61, activity value is MIC = 8 ug/ml||Anti-Staphylococcus aureus NCTC 4163, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus R147, activity value is MIC = 64 ug/ml||Anti-Staphylococcus aureus 1056, activity value is MIC = 16 ug/ml||Anti-Staphylococcus epidermidis, activity value is MIC = 16 ug/ml||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 32 ug/ml||Anti-Candida albicans 105, activity value is MIC = 32 ug/ml||Anti-Candida albicans 3153A, activity value is MIC = 16 ug/ml||Anti-Escherichia coli O157:H7, activity value is MIC = 16.3 ug/ml||Anti-Staphylococcus aureus 1056, activity value is MIC = 26 ug/ml	truncated fragment|||Synthetic construct|||Synthetic construct|||truncated fragment	Rich	truncated fragment|||Escherichia coli O111[MIC = 2 ug/ml], Escherichia coli UB1005[MIC = 0.125 ug/ml], Escherichia coli DC2[MIC = 0.125 ug/ml], Escherichia coli O157:H7[MIC = 8 ug/ml], Salmonella enterica subsp. enterica serovar Typhimurium ATCC 14028s[MIC = 0.5 ug/ml], Salmonella enterica serovar Typhimurium MS4252S[MIC = 0.125 ug/ml], Pseudomonas aeruginosa PAO1[MIC = 4 ug/ml], Pseudomonas aeruginosa Z61[MIC = 8 ug/ml], Staphylococcus aureus NCTC 4163[MIC = 32 ug/ml], Staphylococcus aureus R147[MIC = 64 ug/ml], Staphylococcus aureus 1056[MIC = 16 ug/ml], Staphylococcus epidermidis[MIC = 16 ug/ml], Enterococcus faecalis ATCC 29212[MIC = 32 ug/ml], Candida albicans 105[MIC = 32 ug/ml], Candida albicans 3153A[MIC = 16 ug/ml], Escherichia coli O157:H7[MIC = 16.3 ug/ml], Staphylococcus aureus 1056[MIC = 26 ug/ml]	"Antimicrob Agents Chemother
. 2004 Feb;48(2):673-6. doi: 10.1128/AAC.48.2.673-676.2004.|||Antimicrob Agents Chemother
. 2004 Feb;48(2):673-6. doi: 10.1128/AAC.48.2.673-676.2004.|||14742236, 19396584|||14742236, 19396584|||Antimicrob Agents Chemother
. 2004 Feb;48(2):673-6. doi: 10.1128/AAC.48.2.673-676.2004.|||Antimicrob Agents Chemother. 2004 Feb;48(2):673-6. doi: 10.1128/AAC.48.2.673-676.2004. PubMed"	24	
FPDB01126	AP03335|||AP03335|||Checacin1|||Checacin1|||AP03335	"	
FFGAIAKLAMKFLPAIYKQIQKKRK"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Insecticidal||Anti-MRSA||Anti-E. coli ATCC 35218, activity value is MIC = 0.8||Anti-P. aeruginosa ATCC27853, activity value is MIC = 12.5||Anti-M. smegmatis, activity value is MIC = 25||Anti-S. aureus ATCC33592, activity value is MIC = 1.6 uM||Anti-A. flavus, activity value is MIC = 50||Anti-C. albicans, activity value is MIC = 6.25 uM||Anti-Escherichia coli ATCC 35218 TEM-1 beta-lactamase expressing strain, activity value is MIC = 1.6||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 12.5 uM||Anti-Mycobacterium smegmatis ATCC 607, activity value is MIC = 25 uM||Anti-Staphylococcus aureus ATCC 33592, activity value is MIC = 1.6 uM||Anti-Aspergillus flavus ATCC 9170, activity value is MIC = 50 uM||Anti-Candida albicans FH 2173, activity value is MIC = 6.2 uM	venom, Chelifer cancroides, Europe.|||Chelifer cancroides [Pseudoscorpion]|||Chelifer cancroides [Pseudoscorpion]|||venom, Chelifer cancroides.|||venom, Chelifer cancroides, Europe	N/A	venom, Chelifer cancroides.||At MIC dose concentrations (4-16 µg/ml), it exhibits hemolytic activity (>5%) on human RBCs. As the concentration of this antimicrobial peptide increases, the percentage of hemolysis increases. At the highest concentration (128 µg/ml), it shows 17% hemolytic activity.|||At MIC dose concentrations (4-16 µg/ml), it exhibits hemolytic activity (>5%) on human RBCs. As the concentration of this antimicrobial peptide increases, the percentage of hemolysis increases. At the highest concentration (128 µg/ml), it shows 17% hemolytic activity.	"Toxins (Basel)
. 2022 Jan 14;14(1):58. doi: 10.3390/toxins14010058.|||Toxins (Basel)
. 2022 Jan 14;14(1):58. doi: 10.3390/toxins14010058.|||35051034|||35051034|||Toxins (Basel)
. 2022 Jan 14;14(1):58. doi: 10.3390/toxins14010058.|||Toxins (Basel). 2022 Jan 14;14(1):58. doi: 10.3390/toxins14010058. PubMed"	25	
FPDB01127	AP03337	TTLRLNTLAYKVAWLVNVKAFWAAGRALKKVGR	Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus ATCC 25923, activity value is MIC = 8 ug/ml||Anti-E. coli ATTCC 25922, activity value is MIC = 4 ug/ml||Anti-VRSA S. aureus, activity value is MIC = 16 ug/ml||Anti-and E. coli ATTCC35218, activity value is MIC = 8 ug/ml	Zataria multifora Boiss, Iran, Pakistan and Afghanistan, Asia	N/A	"The key information regarding hemolytic values in the document you provided (on the study of the α-helical peptide Dendrocin-ZM1 isolated from Zataria multiflora Boiss) is as follows:

Hemolytic Data of Dendrocin-ZM1

- MIC concentration range (4-16 µg/ml): At the minimum inhibitory concentration of the peptide (the concentration effective against the tested strains), the hemolysis rate on human red blood cells (RBCs) was <5%, showing negligible hemolytic activity.

- High concentration (128 µg/ml): When the concentration was increased to 128 µg/ml (much higher than the antibacterial effective concentration), the hemolysis rate was 17%, still at a relatively low level.

Experimental Background

- Fresh human O-type red blood cells were washed five times with sterile PBS and prepared as a 4% (v/v) suspension. They were co-incubated with different concentrations of Dendrocin-ZM1 for 1 hour (37°C). Hemolysis rate was calculated by measuring absorbance at 570 nm (amount of hemoglobin released).

- Controls: PBS-treated cells served as the negative control (0% hemolysis), and 0.1% Triton X-100-treated cells served as the positive control (100% hemolysis). Experiments were repeated three times, and results were consistent.|||Zataria multifora Boiss, Iran, Pakistan and Afghanistan, Asia"	"Probiotics Antimicrob Proteins
. 2022 Apr;14(2):326-336. doi: 10.1007/s12602-022-09907-7. Epub 2022 Jan 20."	33	
FPDB01128	AP03343	"	
MQLTSIAIILFAAMGAIANPIAAESDDLLARDAQLSKYGGECSLEHNTCTYRKDGKNHVVSCPSAANLRCKTDRHHCEYDDHHKTVDCQTP"	Anti-Gram+||Antifungal||candidacidal||Anti-MRSA||Antibiofilm	Aspergillus tubingensis A01, isolated from soil	Bridge	N/A	"J Proteomics
. 2021 Feb 20:233:104075. doi: 10.1016/j.jprot.2020.104075. Epub 2020 Dec 9."	91	
FPDB01129	AP03345|||AP03345|||QUB-1641	FLALALIQEAIAKLK	Anti-Gram+||Anti-MRSA||Antibiofilm||Anti-MRSA NCTC 12493, activity value is MIC = 64 uM||Anti-E. faecalis NCTC 12697, activity value is MIC = 64 uM||Anti-E.coli NCTC 10418, activity value is MIC = 128 uM||Anti-C.albicans NCTC 10231, activity value is MIC > 128 uM||Anti-K.pneumoniae ATCC 43816, activity value is MIC > 128 uM||Anti-P.aeruginosa ATCC 27853, activity value is MIC > 128 uM||Anti-S. aureus NCTC 10788, activity value is MIC = 64 uM	Skin secretions, the African hyperoliid frog, Kassina senegalensis, Africa.|||Kassina senegalensis	Helix	"In the document you provided (a study on fungal defensins that inhibit bacterial cell wall synthesis without hemolytic activity and are serum-stable), the hemolytic data for the novel fungal defensin Pyronesin4 (Py4) are as follows:

Hemolytic Data of Py4

- Test concentration range: 3.125~25 µM (using two-fold serial dilution).

- Key results: At all tested concentrations above, Py4 showed no significant hemolytic activity against mouse red blood cells (from ICR mice) (hemolysis rate ≈ 0%).

- Control comparison: The positive control peptide (scorpion venom-derived lytic peptide Meucin-18) exhibited strong hemolytic activity at 25 µM, further confirming the non-hemolytic nature of Py4.

Experimental Background

- Peptide solutions were prepared using 0.9% NaCl as a diluent. A 1% Triton X-100 treatment group served as the 100% hemolysis positive control, and 0.9% NaCl without peptide was used as the negative control (0% hemolysis).

- Hemolysis was calculated by measuring absorbance at 570 nm (amount of hemoglobin released) using the formula:  Hemolysis rate (%) = [(A_peptide-treated group - A_negative control) / (A_positive control - A_negative control)] × 100. The experimental results were stable and reliable.|||Skin secretions, the African hyperoliid frog, Kassina senegalensis, Africa.|||Horse RBCs (2.5% hemolysis at 256 uM)|||The core data related to hemolysis in the document are as follows, with horse erythrocytes as the test subjects: 

All tested peptides (QUB-1641, QUB-1599, QUB-1585, QUB-1570, QUB-1643, QUB-1498, QUB-1609) exhibited hemolytic activity below 20% at concentrations ≤64 μM. 

When the concentration exceeded 64 μM, the hemolytic activity of QUB-1570 and QUB-1498 increased significantly. At a concentration of 256 μM, their hemolysis rates approached 40%. 

For the other peptides (QUB-1641, QUB-1599, QUB-1585, QUB-1643, QUB-1609), specific values indicating a significant increase in hemolytic activity at concentrations above 64 μM were not mentioned, suggesting that their hemolysis rates remained relatively low (not exceeding the levels of QUB-1570 and QUB-1498 at the same concentration)."	Antibiotics 2022, 11(2), 243; https://doi.org/10.3390/antibiotics11020243. Publisher Online|||Antibiotics 2022, 11(2), 243; https://doi.org/10.3390/antibiotics11020243.|||35203845|||Antibiotics 2022, 11(2), 243; https://doi.org/10.3390/antibiotics11020243.	15	
FPDB01130	AP03346|||AP03346|||Pyronesin4	GFGCNGPWDEDDMKCHNHCKSIKGYKGGYCAKAGFVCKCY	Anti-Gram+||Anti-MRSA||inhibition-zone assay: active against Gram+ B. megaterium CGMCC 1.0459 (lethal conc CL 0.67 uM)||C. luteum (LC 0.03 uM)||S. aureus CGMCC 1.89 (LC 1.22 uM)||Penicillin-sensitive S. epidermidis P1111 (LC 4.03 uM)||Penicillin-resistant S. epidermidis P1111 (LC 4.38 uM)||Methicillin-resistant S. aureus (MRSA) P1374 (LC 2.69 uM)||Methicillin-resistant coagulase negative Staphylococci P1369 (CL 4.78 uM)||MRSA P1386 (CL 2.51 uM)||S. aureus J685||S. aureus J698 (CL 2.69 uM)||S. aureus J706 (CL 2.51 uM)||and S. warneri CGMCC 1.2824 (CL 1.06 uM). Usually||LC is comparable to MIC.||Antibacterial	filamentous ascomycete Pyronema confluens|||Pyronema confluens	Bridge	filamentous ascomycete Pyronema confluens	"J Fungi (Basel)
. 2022 Feb 10;8(2):174. doi: 10.3390/jof8020174.|||J Fungi (Basel)
. 2022 Feb 10;8(2):174. doi: 10.3390/jof8020174.|||35205928"	40	
FPDB01131	AP03426|||AP03426|||Dermaseptin-PS1|||Dermaseptin-PS1|||AP03426	GLWKSLFKNVGKAAGKAALNAVTDMVNQ	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anti-S. aureus NCTC 10788, activity value is MIC = 16 ug/ml||Anti-MRSA NCTC 12493, activity value is MIC = 64 ug/ml||Anti-MRSA, activity value is MIC = 32 ug/ml||Anti-C. albicans NCYC 1467, activity value is MIC = 32 ug/ml||Anti-E. coli, activity value is MIC = 16 ug/ml||Anti-and P. aeruginosa, activity value is MIC = 64 ug/ml||Anti-Staphylococcus aureus NCTC 10788, activity value is MIC = 16 ug/ml||Anti-Staphylococcus aureus NCTC 10788, activity value is MBC = 32 ug/ml||Anti-Staphylococcus aureus NCTC 12493, activity value is MIC = 64 ug/ml||Anti-Staphylococcus aureus NCTC 12493, activity value is MBC = 128 ug/ml||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus ATCC 43300, activity value is MBC = 64 ug/ml||Anti-Escherichia coli NCTC 10418, activity value is MIC = 16 ug/ml||Anti-Escherichia coli NCTC 10418, activity value is MBC = 16 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 64 ug/ml||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MBC = 128 ug/ml||Anti-Candida albicans NCYC 1467, activity value is MIC = 32 ug/ml||Anti-Candida albicans NCYC 1467, activity value is MFC = 32 ug/ml	Skin secretion, the waxy monkey leaf frog or waxy monkey tree frog, Phyllomedusa sauvagei, Argentina, Bolivia, Paraguay and Brazil, South America|||Phyllomedusa sauvagii|||Phyllomedusa sauvagii|||Skin secretion, the waxy monkey leaf frog or waxy monkey tree frog, Phyllomedusa sauvagei, Argentina, Bolivia, Paraguay and Brazil, South America|||Skin secretion, the waxy monkey leaf frog or waxy monkey tree frog, Phyllomedusa sauvagei, Argentina, Bolivia, Paraguay and Brazil, South America	N/A	"Skin secretion, the waxy monkey leaf frog or waxy monkey tree frog, Phyllomedusa sauvagei, Argentina, Bolivia, Paraguay and Brazil, South America|||Mouse erythrocytes (50% Hemolysis at >512 ug/ml|||The core hemolytic data for two novel dermaseptin peptides (DMS-PS1 and DMS-PS2) in the document are as follows, tested on murine red blood cells:

1. DMS-PS1

Half-maximal hemolytic concentration (HC_{50}): > 512 µg/ml (at the highest tested concentration of 512 µg/ml, the hemolysis rate is still below 50%).
Therapeutic index (TI): > 16 (TI = HC_{50} / geometric mean of MIC, where a higher value indicates stronger cell selectivity).

2. DMS-PS2

Half-maximal hemolytic concentration (HC_{50}): 210.7 µg/ml (this concentration causes 50% hemolysis of red blood cells).
Therapeutic index (TI): 18.6 (moderate cell selectivity, and its effective antibacterial concentration is far below the hemolytic concentration).

Additionally, key supplemental information: both peptides show low toxicity to mammalian red blood cells at effective antibacterial concentrations (such as MIC range 8–64 µg/ml), with DMS-PS1 having lower hemolysis and DMS-PS2 showing slightly higher hemolysis, but still retaining clinical application potential.|||Mouse erythrocytes (50% Hemolysis at >512 ug/ml"	"Acta Biomater
. 2020 Jun:109:208-219. doi: 10.1016/j.actbio.2020.03.024. Epub 2020 Apr 8.|||Acta Biomater. 2020 Jun;109:208-219. doi: 10.1016/j.actbio.2020.03.024. PubMed|||32276085|||Acta Biomater. 2020 Jun;109:208-219. doi: 10.1016/j.actbio.2020.03.024. PubMed|||32276085|||Acta Biomater. 2020 Jun;109:208-219. doi: 10.1016/j.actbio.2020.03.024. PubMed|||Acta Biomater. 2020 Jun;109:208-219. doi: 10.1016/j.actbio.2020.03.024. PubMed"	28	
FPDB01132	AP03427|||AP03427|||Dermaseptin-PS2|||Dermaseptin-PS2|||AP03427	"	
ALWKTLLKNVGKAAGKAVLNAVTDMVNQ"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Antibiofilm||Anti-S. aureus NCTC 10788, activity value is MIC = 8 ug/ml||Anti-MRSA NCTC 12493, activity value is MIC = 16 ug/ml||Anti-MRSA, activity value is MIC = 8 ug/ml||Anti-C. albicans NCYC 1467, activity value is MIC = 16 ug/ml||Anti-E. coli, activity value is MIC = 8 ug/ml||Anti-and P. aeruginosa, activity value is MIC = 16 ug/ml||Anti-S. aureus, activity value is MIC = 8 uM||Anti-MRSA, activity value is MIC = 16 uM||Anti-E.coli, activity value is MIC = 8 uM||Anti-C. albicans, activity value is MIC = 16 uM	Skin secretion, the waxy monkey leaf frog or waxy monkey tree frog, Phyllomedusa sauvagei, Argentina, Bolivia, Paraguay and Brazil, South America|||Phyllomedusa tomopterna [Tiger-striped leaf frog]|||Phyllomedusa sauvagii [Sauvage frog]|||Skin secretion, the waxy monkey leaf frog or waxy monkey tree frog, Phyllomedusa sauvagei, Argentina, Bolivia, Paraguay and Brazil, South America|||Skin secretion, the waxy monkey leaf frog or waxy monkey tree frog, Phyllomedusa sauvagei, Argentina, Bolivia, Paraguay and Brazil, South America	Helix	"Skin secretion, the waxy monkey leaf frog or waxy monkey tree frog, Phyllomedusa sauvagei, Argentina, Bolivia, Paraguay and Brazil, South America|||Horse RBC (50% hemolysis at 210.7 uM)|||The core hemolytic data for two novel dermaseptin peptides (DMS-PS1 and DMS-PS2) in the document are as follows, tested on murine red blood cells:

1. DMS-PS1

Half-maximal hemolytic concentration (HC_{50}): > 512 µg/ml (at the highest tested concentration of 512 µg/ml, the hemolysis rate is still below 50%).
Therapeutic index (TI): > 16 (TI = HC_{50} / geometric mean of MIC, where a higher value indicates stronger cell selectivity).

2. DMS-PS2

Half-maximal hemolytic concentration (HC_{50}): 210.7 µg/ml (this concentration causes 50% hemolysis of red blood cells).
Therapeutic index (TI): 18.6 (moderate cell selectivity, and its effective antibacterial concentration is far below the hemolytic concentration).

Additionally, key supplemental information: both peptides show low toxicity to mammalian red blood cells at effective antibacterial concentrations (such as MIC range 8–64 µg/ml), with DMS-PS1 having lower hemolysis and DMS-PS2 showing slightly higher hemolysis, but still retaining clinical application potential.|||Horse RBC (50% hemolysis at 210.7 uM)"	"Acta Biomater
. 2020 Jun:109:208-219. doi: 10.1016/j.actbio.2020.03.024. Epub 2020 Apr 8.|||Acta Biomater. 2020 Jun;109:208-219. doi: 10.1016/j.actbio.2020.03.024. PubMed|||33582221|||Acta Biomater. 2020 Jun;109:208-219. doi: 10.1016/j.actbio.2020.03.024. PubMed|||33582221|||Acta Biomater. 2020 Jun;109:208-219. doi: 10.1016/j.actbio.2020.03.024. PubMed|||Acta Biomater. 2020 Jun;109:208-219. doi: 10.1016/j.actbio.2020.03.024. PubMed"	28	
FPDB01133	AP03428	"	
FVDLKKIANILNSIF"	Anti-Gram+||Anti-MRSA||Antibiofilm||Anti-S. aureus ATCC CRM 6538, activity value is MIC = 8 uM||Anti-MRSA NCTC 12493, activity value is MIC = 16 uM||Anti-E. faecalis, activity value is MIC = 32 uM||Anti-K.pneumoniae, activity value is MIC = 256 uM||Anti-P.aeruginosa, activity value is MIC = 128 uM||Anti-and E.coli, activity value is MIC = 128 uM	Skin Secretion, the Chinese forest frog, Chinese brown frog, Rana chensinensis, China, Asia	Helix	"In the document you provided (Study on the Antibacterial Prototype Drug Study of Temporin-1CEh and Its Analogs in the Skin Secretions of Chinese Forest Frogs), the hemolytic values for each peptide are as follows: 
 
1. Natural peptide Temporin-1CEh
 
- Key hemolytic indicators: At 256 uM concentration, hemolysis rate is 92.3%; Its 50% hemolytic concentration (HC_{50}) is 152.6 uM. 

- Comparative reference: The homologous peptide Temporin-1CEa has a HC_{50} of 160 uM, and the two have similar hemolytic properties. 
 
2. Truncated Modification Peptides (T1CEh-t, T1CEa-t)
 
- Key hemolytic indicators: Both have no hemolytic activity within the test concentration range (up to 256 μM), but simultaneously lose antibacterial activity (due to membrane-binding ability due to removal of hydrophobic amino acids at the C-terminus). 
 
3. N-terminal modified peptides (T1CEh-KK, T1CEh-KKP, T1CEh-KKPW, T1CEh-KKPW)
 
- T1CEh-KK: Within the test concentration range (maximum 256 uM), hemolysis rate remains low (document does not provide specific values, only described as ""maintaining low hemolysis""), and antibacterial activity against Gram-negative bacteria (such as E. coli) is significantly enhanced. 

- T1CEh-KKP: hemolytic levels are similar to T1CEh-KK, with no significant change (no specific values provided in the document), but antibacterial activity is slightly weakened due to the introduction of proline, which breaks the helix structure. 

- T1CEh-KKPW and T1CEh-KKPWW: Both have hemolytic rates below 6% at 256 uM, indicating low hemolysis; Moreover, the introduction of tryptophan significantly broadens the antibacterial spectrum (effective against both Gram-positive and Gram-negative bacteria). 
 
4. Branch structure modification peptide T1CEh-KKPWW2
 
- Key hemolytic indicators: At 256 uM, the hemolysis rate is 63%. Although higher than its precursor T1CEh-KKPWW (6%), the 50% hemolytic concentration (HC_{50}) is 569.8 uM, much higher than the natural peptide Temporin-1CEh (152.6 uM), indicating superior overall safety. 

- Advantages: The branched structure enhances stability in physiological environments such as serum and saline solutions, and further enhances antibacterial activity (especially against drug-resistant bacteria). 
 
Experimental background
 
- The experiment used defibrotic horse red blood cells as the material, prepared a red blood cell suspension with PBS, using 1% Triton X-100 as the positive control (100% hemolysis) and PBS as the negative control (0% hemolysis). The hemolysis rate was calculated by measuring absorbance (hemoglobin release) at 570 nm. All experiments were repeated three times, with stable results.|||Skin Secretion, the Chinese forest frog, Chinese brown frog, Rana chensinensis, China, Asia|||Skin Secretion, the Chinese forest frog, Chinese brown frog, Rana chensinensis, China, Asia||The antimicrobial effects of synthetic AMPs on the growth of the tested microorganisms, and the biofilmeradication effects on S. aureus are illustrated in Table2.The BHL-bombinin exhibited stronger antimicrobial activities on Gram-positive bacteria (MIC/MBC: 4000 ug/l/16000 ug/l)and yeast (MIC/MBC: 4000 ug/l/16000 ug/l)thanGram-negative bacteria (MIC/MBC: 16000–64000 ug/l/64000–128000 ug/l). Inaddition, BHL-bombinin was found to possess a relatively low level of haemolytic activity (0–12.6%)atthe MIC determined against S. aureus and C. albicans (Supplementary Figure S3). Interestingly, BHL-bombinin displayed potent inhibitory effects (MIC: 4000–16000 ug/l)towards MRSA and biofilm. By contrast, the MIC values for bombinin HLand bombinin HD against S. aureus were 256and128000 ug/l respectivelywithundetectedMBCs, which were significantly less effective compared with BHL-bombinin. The selectivity indices (SIs), which represent the degree of antibacterial selectivity, are showed in Table2,higherSI value reflecting a better selectivity towardsmicrobial over mammalian membranes [22].Asindicated,the BHL-bombinin had ahigherSI compared with bombinin HLand bombinin HD, which is in agreement with previous studies that high level ofhydrophobicity may decrease the antimicrobial selectivity ofα-helical peptides [23].Additionally, compared with the melittin peptide, all the AMPs investigated in the present study exhibited 32–128-times higher SI values, which emphasizes that amphibian-derived AMPs are potential research targets for therapeutic alternatives to current antibiotics. The time-killing curves demonstrated the faster cell-killing effects ofBHL-bombinin compared with the ampicillin, whilethe kill rates ofbombinin HLand bombinin HD were relatively low (Supplementary Figure S4).|||The core hemolytic data of the natural antimicrobial peptide Temporin-1CEh and its seven analogs in the document are as follows. The test subject was horse red blood cells, and the key indicators were the half-maximal hemolytic concentration (HC_{50}) and hemolysis rate at specific concentrations:

1. Natural peptide: Temporin-1CEh

Half-maximal hemolytic concentration (HC_{50}): 152.6 µM
Hemolysis rate at a specific concentration: at 256 µM, the hemolysis rate reached 92.3% (relatively strong hemolysis).

2. Analogs: T1CEh-t and T1CEa-t

Hemolytic activity: completely lost hemolytic activity (due to removal of C-terminal hydrophobic amino acids, which also led to loss of antibacterial activity).

3. Analog: T1CEh-KK

Hemolytic activity: maintains low-level hemolysis (HC_{50} not explicitly given, but the text mentions “maintains low hemolysis”; at 256 µM, hemolysis rate is far lower than Temporin-1CEh).

4. Analog: T1CEh-KKP

Hemolytic activity: hemolysis level unchanged (similar to T1CEh-KK, low hemolysis, no specific HC_{50} value).

5. Analogs: T1CEh-KKPW and T1CEh-KKPWW

Hemolysis rate at a specific concentration: at 256 µM, the hemolysis rate is below 6% for both (significantly lower hemolysis than the natural peptide; specific HC_{50} not mentioned, but higher safety).

6. Analog: T1CEh-KKPWW2 (branched structure)

Half-maximal hemolytic concentration (HC_{50}): 569.8 µM (higher than natural peptide Temporin-1CEh, better cell selectivity)
Hemolysis rate at a specific concentration: at 256 µM, the hemolysis rate is 63% (though higher than T1CEh-KKPW/WW, due to stronger antibacterial activity, it still has application potential).

Additional notes

Positive control (1% Triton X-100) hemolysis rate is 100%, negative control (PBS) hemolysis rate is 0%, and all data are calibrated based on these controls. Hemolysis is related to the peptide’s hydrophobicity, charge, and structure: branched structures (such as T1CEh-KKPWW2) slightly increase hemolysis rate, but by enhancing antibacterial activity, a reasonable therapeutic window is still maintained; whereas removal of C-terminal hydrophobic amino acids (such as T1CEh-t) results in simultaneous loss of hemolytic and antibacterial activity.|||The antimicrobial effects of synthetic AMPs on the growth of the tested microorganisms, and the biofilmeradication effects on S. aureus are illustrated in Table2.The BHL-bombinin exhibited stronger antimicrobial activities on Gram-positive bacteria (MIC/MBC: 4000 ug/l/16000 ug/l)and yeast (MIC/MBC: 4000 ug/l/16000 ug/l)thanGram-negative bacteria (MIC/MBC: 16000–64000 ug/l/64000–128000 ug/l). Inaddition, BHL-bombinin was found to possess a relatively low level of haemolytic activity (0–12.6%)atthe MIC determined against S. aureus and C. albicans (Supplementary Figure S3). Interestingly, BHL-bombinin displayed potent inhibitory effects (MIC: 4000–16000 ug/l)towards MRSA and biofilm. By contrast, the MIC values for bombinin HLand bombinin HD against S. aureus were 256and128000 ug/l respectivelywithundetectedMBCs, which were significantly less effective compared with BHL-bombinin. The selectivity indices (SIs), which represent the degree of antibacterial selectivity, are showed in Table2,higherSI value reflecting a better selectivity towardsmicrobial over mammalian membranes [22].Asindicated,the BHL-bombinin had ahigherSI compared with bombinin HLand bombinin HD, which is in agreement with previous studies that high level ofhydrophobicity may decrease the antimicrobial selectivity ofα-helical peptides [23].Additionally, compared with the melittin peptide, all the AMPs investigated in the present study exhibited 32–128-times higher SI values, which emphasizes that amphibian-derived AMPs are potential research targets for therapeutic alternatives to current antibiotics. The time-killing curves demonstrated the faster cell-killing effects ofBHL-bombinin compared with the ampicillin, whilethe kill rates ofbombinin HLand bombinin HD were relatively low (Supplementary Figure S4)."	"Pharmaceutics
. 2022 Mar 10;14(3):604. doi: 10.3390/pharmaceutics14030604.|||Pharmaceutics. 2022 Mar 10;14(3):604. doi: 10.3390/pharmaceutics14030604. PubMed"	15	
FPDB01134	AP03436|||AP03436|||BHL Bombinin	GIGGALLSFGKSALKGLAKGLAEHF	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Synergistic AMPs||Anti-S. aureus, activity value is MIC = 1.6 uM||Anti-MRSA, activity value is MIC = 6.6 uM||Anti-E. coli, activity value is MIC = 6.6 uM||Anti-P. aeruginosa, activity value is MIC = 26.2 uM||Anti-and C. albicans, activity value is MIC = 1.6 uM||Gram-positive bacteria (MIC/MBC: 4000 ug/l/16000 ug/l) and yeast (MIC/MBC: 4000 ug/l/16000 ug/l) than Gram-negative bacteria (MIC/MBC: 16–64000 ug/l/64–128000 ug/l)	skin secretion, Bombina orientalis, Asia|||Bombina variegata [Yellow-bellied toad]|||skin secretion, Bombina orientalis, Asia	Helix	"The core values related to hemolysis in this document are reflected through HC₅₀ (the peptide concentration causing 50% hemolysis) and hemolysis rate, with specific data as follows:

1. HC₅₀ values of each peptide (Table 2: The susceptibility of novel AMPs and melittin peptide...)

Table

Peptide Name (Peptides) | HC₅₀ (mg/l (uM)) | Notes
--- | --- | ---
BHL-bombinin | 64 (26.2) | -
Bombinin HL | >512 (313.5) | No significant hemolysis observed at the highest tested concentration (512,000 ug/l); calculated as 1,024,000 ug/l
Bombinin HD | >512 (313.5) | Same as Bombinin HL; no significant hemolysis observed at the highest tested concentration
Melittin (bee venom peptide, positive control) | 1 (0.4) | Hemolytic activity far higher than the studied amphibian antimicrobial peptides

2. Supplementary information on key hemolysis rates

- BHL-bombinin shows low hemolysis rates of only 0–12.6% at its MIC concentration (4,000 ug/l) against Staphylococcus aureus (S. aureus) and Candida albicans (C. albicans) (Supplementary Figure S3).

- Bombinin HL and Bombinin HD did not show significant hemolytic activity even at the highest tested concentration (512,000 ug/l, HC₅₀ > 512,000 ug/l), indicating extremely low hemolytic toxicity.

3. Hemolysis-related selectivity index (SI)

Selectivity Index (SI) = HC₅₀ / MIC against Staphylococcus aureus, which indirectly reflects the hemolytic safety of the peptides. Higher values indicate better safety:

Table

Peptide Name | SI (Selectivity Index)
--- | ---
BHL-bombinin | 16
Bombinin HL | 4
Bombinin HD | 8
Melittin | 0.125|||skin secretion, Bombina orientalis, Asia||HC₅₀（mg/L）＞512|||skin secretion, Bombina orientalis, Asia|||HC₅₀（mg/L）＞512|||50% hemolysis at 26.2 uM."	"Biosci Rep
. 2017 Sep 27;37(5):BSR20170967. doi: 10.1042/BSR20170967. Print 2017 Oct 31.|||Biosci Rep. 2017 Sep 27;37(5):BSR20170967. doi: 10.1042/BSR20170967. PubMed|||28894024|||Biosci Rep. 2017 Sep 27;37(5):BSR20170967. doi: 10.1042/BSR20170967. PubMed|||Biosci Rep. 2017 Sep 27;37(5):BSR20170967. doi: 10.1042/BSR20170967. PubMed"	25	
FPDB01135	AP03442|||AP03442|||GVF27|||GVF27|||AP03442	GVFYPWRFRLLCLLRRWLPRPRAWFIR	Anti-Gram+ & Gram-||Anti-MRSA||Anti-inflammatory||Anti-Antimicrobial: active against Gram+ S. aureus ATCC 29213 or MRSA WKZ-2, activity value is MIC = 5 uM||Anti-B. globigii TNO BMO13, activity value is MIC = 5 uM||Anti-E. coli ATCC 25922, activity value is MIC = 10 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 10 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 20 uM||Anti-and S. enteriditis 706 RIVM, activity value is MIC = 10 uM||Anti-MRSA WKZ-2, activity value is MIC = 5 uM||Anti-B. globigii, activity value is MIC = 5 uM||Anti-B. licheniformis, activity value is MIC = 5 uM||Anti-S. aureus, activity value is MIC = 5 uM||Anti-E. coli, activity value is MIC = 10 uM||Anti-S.enteriditis, activity value is MIC = 10 uM||Anti-Burkholderia cenocepacia LMG 18863, activity value is MIC = 40 uM||Anti-Burkholderia cenocepacia LMG 17582, activity value is MIC = 10 uM	other methods predicted, Homo sapiens, human, primates, mammals, animals|||Homo Sapiens [Human]|||Homo Sapiens [Human]|||other methods predicted, Homo sapiens, human, primates, mammals, animals|||Homo sapiens, human, primates, mammals, animals	Helix	"The core data in this document related to the hemolytic activity of peptide GVF27 is presented as the hemolysis rate, with specific details as follows:

Hemolytic test results for GVF27

1. Experimental conditions

-Test sample: EDTA-anticoagulated mouse red blood cells (RBCs).

-Procedure: Dilute RBCs 200-fold in PBS and incubate them with GVF27 at various concentrations (0–80 µM) for 1 hour at 37°C.

-Control settings: PBS was used as the negative control (0% hemolysis), and 0.2% (v/v) Triton X-100 was used as the positive control for complete hemolysis (100% hemolysis).

-Detection parameter: The hemolysis rate is calculated using the following formula by measuring the absorbance at 405 nm:

Hemolysis rate (%) = (A&lt;sub&gt;peptide-treated group&lt;/sub&gt; − A&lt;sub&gt;blank control&lt;/sub&gt;)/(A&lt;sub&gt;Triton X-100 group&lt;/sub&gt; − A&lt;sub&gt;blank control&lt;/sub&gt;) × 100


2. Key Results

-Within the concentration range of 0–80 µM, GVF27 did not exhibit any hemolytic activity against mouse red blood cells (Figure S3B), with a hemolysis rate of 0%.

-This concentration range encompasses the concentrations required for its antibacterial activity (MIC values of 5–20 µM, see Table 1), indicating that GVF27 exhibits no toxicity to mammalian red blood cells when exerting its antibacterial effect.

Additional note

-The text does not mention the HC₅₀ value (the peptide concentration causing 50% hemolysis), as no hemolysis was observed even at the highest tested concentration (80 µM); therefore, HC₅₀&gt;80 µM.

-Synchronized cytotoxicity assays demonstrated that GVF27 exhibited no significant toxicity against mouse macrophages (RAW 264.7), human keratinocytes (HaCat), and human cervical cancer cells (HeLa) at concentrations ranging from 0.6 to 40 µM, thereby further confirming its safety profile in eukaryotic cells.|||other methods predicted, Homo sapiens, human, primates, mammals, animals||Low concentration range (0–20 uM, covering the antibacterial MIC range): The hemolysis rate remained consistently < 1%; medium to high concentration range (20–80 uM, far exceeding the concentration required for antibacterial activity): The hemolysis rate was still < 1%, and no signs of red blood cell membrane damage were observed. Even when the concentration reached 4 times the MIC (80 uM), no significant hemolysis was detected.|||Homo sapiens, human, primates, mammals, animals|||no hemolytic activity seen in frog RBC|||no hemolytic activity seen in frog RBC|||Low concentration range (0–20 uM, covering the antibacterial MIC range): The hemolysis rate remained consistently < 1%; medium to high concentration range (20–80 uM, far exceeding the concentration required for antibacterial activity): The hemolysis rate was still < 1%, and no signs of red blood cell membrane damage were observed. Even when the concentration reached 4 times the MIC (80 uM), no significant hemolysis was detected."	"Biochim Biophys Acta Gen Subj
. 2017 Sep;1861(9):2342-2353. doi: 10.1016/j.bbagen.2017.04.009. Epub 2017 Apr 26.|||Biochim Biophys Acta Gen Subj. 2017 Sep;1861(9):2342-2353. doi: 10.1016/j.bbagen.2017.04.009. PubMed|||28454736|||35215373|||28454736|||Biochim Biophys Acta Gen Subj. 2017 Sep;1861(9):2342-2353. doi: 10.1016/j.bbagen.2017.04.009. PubMed"	27	
FPDB01136	AP03481|||DRAMP35859	"	
MKKLLLILFCLALALAGCKKAP"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-inflammatory||activity value is MIC = 16||Anti-E.faecalis JH2-2, activity value is MIC = 256 ug/ml||Anti-K.pneumoniae, activity value is MIC = 512 ug/ml||Anti-A. baumannii sensitive, activity value is MIC = 16||Anti-OXA-50, activity value is MIC = 128||Anti-B.cereus, activity value is MIC = 256 ug/ml||Anti-P.aeruginosa PAO1, activity value is MIC > 512 ug/ml||Anti-P.aeruginosa AMT0060, activity value is MIC = 256 ug/ml||Anti-P. aeruginosa C3719 or LES400, activity value is MIC = 64 ug/ml||Antimicrobial||Anticancer	predicted from a rumen microbiota metagenomic dataset (Hess et al. dataset, Library ‘Cow’)|||Synthetic	N/A	"The core data in this document related to the hemolytic activity of antimicrobial peptides HG2 and HG4 are represented by HC₅₀ (the peptide concentration that causes 50% hemolysis) and the therapeutic window (safety factor), as detailed below:

1. Hemolytic titer at 50% lysis (HC₅₀)

-HG2:HC₅₀ is 409±67 µg/mL

-HG4:HC₅₀ is 458±101 µg/mL.

The experiment used human red blood cells as the test subject. Red blood cells were co-incubated with a series of peptide concentrations (37 °C, 1 hour), with 0.1% Triton X-100 serving as the positive control for complete hemolysis (100% hemolysis) and PBS as the blank control (0% hemolysis). The degree of hemolysis was determined by measuring absorbance at 450 nm, and the final results were analyzed using GraphPad.®The HC₅₀ value was obtained by fitting using Prism 7 software.

2. Safety margin (therapeutic window) related to hemolysis

The safety factor is defined as the ratio of HC₅₀ to the MIC against MRSA; a higher value indicates greater selectivity of the peptide toward bacteria and greater safety for mammalian cells.

-HG2: The safety factor is 26.2-fold (with an MIC range against MRSA of 16–32 µg/mL; using the typical value of 16 µg/mL for calculation: 409 µg/mL ÷ 16 µg/mL ≈ 26.2).

-HG4: The safety factor is 14.6-fold (with an MIC range against MRSA of 32–64 µg/mL; using the typical value of 32 µg/mL for calculation: 458 µg/mL ÷ 32 µg/mL ≈ 14.6).

3. Additional Notes

-Both compounds exhibit low hemolytic activity: even at concentrations near or above the minimum inhibitory concentration (MIC), the hemolysis rate remains low, meeting the safety requirements for therapeutic peptides.

-Differences in hemolytic activity: The HC₅₀ of HG4 was slightly higher than that of HG2, and its safety margin was lower than that of HG2. This is speculated to be related to the higher hydrophobicity of HG2 (72%, compared to 57% for HG4)—higher hydrophobicity may increase its nonspecific interactions with mammalian cell membranes, thereby slightly elevating the risk of hemolysis. (The text mentions that HG2 may need to be restricted to topical applications, while HG4 is more suitable as a safe therapeutic candidate template.)|||predicted from a rumen microbiota metagenomic dataset (Hess et al. dataset, Library ‘Cow’)"	"NPJ Biofilms Microbiomes
. 2022 Jul 14;8(1):58. doi: 10.1038/s41522-022-00320-0.|||NPJ Biofilms Microbiomes. 2022 Jul 14;8(1):58. doi: 10.1038/s41522-022-00320-0. PubMed|||NPJ Biofilms Microbiomes. 2022 Jul 14;8(1):58. doi: 10.1038/s41522-022-00320-0. PubMed|||NPJ Biofilms Microbiomes. 2022 Jul 14;8(1):58. doi: 10.1038/s41522-022-00320-0. PubMed|||NPJ Biofilms Microbiomes. 2022 Jul 14;8(1):58."	22	
FPDB01137	AP03482|||DRAMP35860	"	
VLGLALIVGGALLIKKKQAKS"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-inflammatory||activity value is MIC = 32 ug/ml||Anti-E.faecalis JH2-2, activity value is MIC = 128 ug/ml||Anti-L.monocytogenes, activity value is MIC = 512 ug/ml||Anti-K.pneumoniae, activity value is MIC = 512 ug/ml||Anti-A. baumannii sensitive, activity value is MIC = 32||Anti-OXA-50, activity value is MIC = 64||Anti-E.coli, activity value is MIC = 512 ug/ml||Anti-B.cereus, activity value is MIC = 256 ug/ml||Anti-P.aeruginosa PAO1, activity value is MIC > 512 ug/ml||Anti-P.aeruginosa AMT0060, activity value is MIC = 256 ug/ml||Anti-P. aeruginosa C3719 or LES400, activity value is MIC = 64 ug/ml||Antimicrobial||Anticancer	predicted from a rumen microbiota metagenomic dataset (Hess et al. dataset, Library ‘Cow’)|||Synthetic	N/A	"The core data in this document related to the hemolytic activity of antimicrobial peptides HG2 and HG4 are represented by HC₅₀ (the peptide concentration that causes 50% hemolysis) and the therapeutic window (safety factor), as detailed below:

1. Hemolytic titer at 50% lysis (HC₅₀)

-HG2:HC₅₀ is 409±67 µg/mL

-HG4:HC₅₀ is 458±101 µg/mL.

The experiment used human red blood cells as the test subject. Red blood cells were co-incubated with a series of peptide concentrations (37 °C, 1 hour), with 0.1% Triton X-100 serving as the positive control for complete hemolysis (100% hemolysis) and PBS as the blank control (0% hemolysis). The degree of hemolysis was determined by measuring absorbance at 450 nm, and the final results were analyzed using GraphPad.®The HC₅₀ value was obtained by fitting using Prism 7 software.

2. Safety margin (therapeutic window) related to hemolysis

The safety factor is defined as the ratio of HC₅₀ to the MIC against MRSA; a higher value indicates greater selectivity of the peptide toward bacteria and greater safety for mammalian cells.

-HG2: The safety factor is 26.2-fold (with an MIC range against MRSA of 16–32 µg/mL; using the typical value of 16 µg/mL for calculation: 409 µg/mL ÷ 16 µg/mL ≈ 26.2).

-HG4: The safety factor is 14.6-fold (with an MIC range against MRSA of 32–64 µg/mL; using the typical value of 32 µg/mL for calculation: 458 µg/mL ÷ 32 µg/mL ≈ 14.6).

3. Additional Notes

-Both compounds exhibit low hemolytic activity: even at concentrations near or above the minimum inhibitory concentration (MIC), the hemolysis rate remains low, meeting the safety requirements for therapeutic peptides.

-Differences in hemolytic activity: The HC₅₀ of HG4 was slightly higher than that of HG2, and its safety margin was lower than that of HG2. This is speculated to be related to the higher hydrophobicity of HG2 (72%, compared to 57% for HG4)—higher hydrophobicity may increase its nonspecific interactions with mammalian cell membranes, thereby slightly elevating the risk of hemolysis. (The text mentions that HG2 may need to be restricted to topical applications, while HG4 is more suitable as a safe therapeutic candidate template.)|||predicted from a rumen microbiota metagenomic dataset (Hess et al. dataset, Library ‘Cow’)|||HC50 50% hemo.lytic concentration is 458 ug/ml. Lung fibroblast (i.e. IMR-90) cells, IC50 = 294 ug/ml; Lung epithelial (i.e. BEAS-2B) and liver (i.e. HepG2) cells: IC50 >1000 ug/ml."	"NPJ Biofilms Microbiomes
. 2022 Jul 14;8(1):58. doi: 10.1038/s41522-022-00320-0.|||NPJ Biofilms Microbiomes. 2022 Jul 14;8(1):58. doi: 10.1038/s41522-022-00320-0. PubMed|||NPJ Biofilms Microbiomes. 2022 Jul 14;8(1):58. doi: 10.1038/s41522-022-00320-0. PubMed|||NPJ Biofilms Microbiomes. 2022 Jul 14;8(1):58. doi: 10.1038/s41522-022-00320-0. PubMed|||NPJ Biofilms Microbiomes. 2022 Jul 14;8(1):59."	21	
FPDB01138	AP03488	"	
SLWENFKNAGKKFILNILDKIRCRVAGGCRT"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Activity tested against Gram-positive bacteria S. aureus ATCC 6538 or MRSA NCTC 1249, activity value is MIC = 32 uM||Anti-E. faecium NCTC 12697, activity value is MIC = 16 uM||Anti-E. coli ATCC 8739, activity value is MIC = 8 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 16 uM||Anti-A. baumannii ATCC BAA 747, activity value is MIC = 32 uM||Anti-C.albicans ATCC 10231, activity value is MIC > 128 uM	skin secretion, the Kuatun frog, Hylarana latouchii, China, Asia|||skin secretion, the Kuatun frog, Hylarana latouchii, China, Asia	Helix	skin secretion, the Kuatun frog, Hylarana latouchii, China, Asia|||HC50=102.4 uM.	Computational and Structural Biotechnology Journal. Available online 12 November 2022	31	
FPDB01139	AP03517	VVVNVLVKVLPPPVV	Anti-Gram+||Anti-MRSA||Anti-S. aureus TISTR 517, activity value is MIC = 2 ug/ml||Anti-MRSA isolate 142, activity value is MIC = 2 ug/ml||Anti-MRSA isolate 1096, activity value is MIC = 2 ug/ml||Anti-MRSA isolate 2468, activity value is MIC = 2 ug/ml	a soil bacterium, Brevibacillus sp. SPR-20|||a soil bacterium, Brevibacillus sp. SPR-20	Helix	"The core data related to the hemolytic properties of antimicrobial peptide P1 (core research subject) in this document are presented through hemolysis rate and hemolysis treatment index (TIhₑmₒlγsis). The specific information is as follows: 
 
1. Core hemolysis value (hemolysis rate)
 
The experiment used human red blood cells as the test subject, using PBS as the blank control (0% hemolysis) and 1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 540 nm. The results are as follows: 
 
- Concentration range 0.25–32 ug/ml: P1 has an extremely low hemolysis rate, only 1.64 ± 0.17%–5.52 ± 0.92% (all < 10%), meeting the hemolysis standard for safe peptides. 

- 1× MIC concentration (2 ug/ml): hemolytic rate of 3.40 ± 0.29%, well below 10%, indicating high safety for human red blood cells when exerting anti-MRSA activity. 

- High concentration (64 ug/ml): hemolysis rate significantly increases to 62.23 ± 0.69%, but this concentration far exceeds its effective antibacterial concentration (MIC=2 ug/ml), so this dose is not required in clinical use. 
 
2. Hemolytic Therapy Index (TIhₑmₒlγsis)
 
The hemolysis index is defined as the ratio of the highest peptide concentration to MIC producing < 10% hemolysis. The higher the value, the stronger the peptide's antibacterial selectivity and safety: 
 
- The TIhₑmₒlγsis of P1 is 16 (calculation basis: the highest concentration producing 10% hemolysis < is 32 ug/ml, 32 ug/ml ÷ 2 ug/ml = 16), indicating extremely low toxicity to human red blood cells at effective antibacterial concentrations, indicating clinical application potential. 
 
Additional notes
 
- The paper focuses only on the hemolytic properties of P1, without mentioning hemolytic data from P2–P5. It is inferred that P1 has the strongest antibacterial activity (MIC = 2 ug/ml, the lowest among the five peptides), and thus is prioritized for safety evaluation. 

- The high safety of P1 is related to its physicochemical properties: although it has high hydrophobicity (0.915), it balances hemolysis risk through charge distribution (net charge 1 at pH 7.4) and secondary structure (forming α-helix when interacting with bacterial membranes, with low selectivity for mammalian membranes).|||a soil bacterium, Brevibacillus sp. SPR-20||At 32 ug/ml, the hemolysis rate of P1 is only 5.52%; at 1×MIC (2 ug/ml), the hemolysis rate is 3.40, with a TIₕₑₘₒₗᵧₛᵢₛ (Therapeutic Index for Hemolysis) of 16.|||human RBC: Peptide P1 is not hemo-lytic tll 32 ug/ml. It, however, caused more than 50% hemolysis at 64 ug/ml. Hence, the peptide is not toxic at its MIC (2 ug/ml).|||At 32 ug/ml, the hemolysis rate of P1 is only 5.52%; at 1×MIC (2 ug/ml), the hemolysis rate is 3.40, with a TIₕₑₘₒₗᵧₛᵢₛ (Therapeutic Index for Hemolysis) of 16."	Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI|||Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI|||Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI	15	
FPDB01140	AP03518	"	
VVMNLLVKVLKYVV"	Anti-Gram+||Anti-MRSA||Anti-S. aureus TISTR 517, activity value is MIC = 8 ug/ml||Anti-MRSA isolate 142, activity value is MIC = 8 ug/ml||Anti-MRSA isolate 1096, activity value is MIC = 8 ug/ml||Anti-MRSA isolate 2468, activity value is MIC = 8 ug/ml	a soil bacterium, Brevibacillus sp. SPR-20|||a soil bacterium, Brevibacillus sp. SPR-20	N/A	"The core data related to the hemolytic properties of antimicrobial peptide P1 (core research subject) in this document are presented through hemolysis rate and hemolysis treatment index (TIhₑmₒlγsis). The specific information is as follows: 
 
1. Core hemolysis value (hemolysis rate)
 
The experiment used human red blood cells as the test subject, using PBS as the blank control (0% hemolysis) and 1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 540 nm. The results are as follows: 
 
- Concentration range 0.25–32 ug/ml: P1 has an extremely low hemolysis rate, only 1.64 ± 0.17%–5.52 ± 0.92% (all < 10%), meeting the hemolysis standard for safe peptides. 

- 1× MIC concentration (2 ug/ml): hemolytic rate of 3.40 ± 0.29%, well below 10%, indicating high safety for human red blood cells when exerting anti-MRSA activity. 

- High concentration (64 ug/ml): hemolysis rate significantly increases to 62.23 ± 0.69%, but this concentration far exceeds its effective antibacterial concentration (MIC=2 ug/ml), so this dose is not required in clinical use. 
 
2. Hemolytic Therapy Index (TIhₑmₒlγsis)
 
The hemolysis index is defined as the ratio of the highest peptide concentration to MIC producing < 10% hemolysis. The higher the value, the stronger the peptide's antibacterial selectivity and safety: 
 
- The TIhₑmₒlγsis of P1 is 16 (calculation basis: the highest concentration producing 10% hemolysis < is 32 ug/ml, 32 ug/ml ÷ 2 ug/ml = 16), indicating extremely low toxicity to human red blood cells at effective antibacterial concentrations, indicating clinical application potential. 
 
Additional notes
 
- The paper focuses only on the hemolytic properties of P1, without mentioning hemolytic data from P2–P5. It is inferred that P1 has the strongest antibacterial activity (MIC = 2 ug/ml, the lowest among the five peptides), and thus is prioritized for safety evaluation. 

- The high safety of P1 is related to its physicochemical properties: although it has high hydrophobicity (0.915), it balances hemolysis risk through charge distribution (net charge 1 at pH 7.4) and secondary structure (forming α-helix when interacting with bacterial membranes, with low selectivity for mammalian membranes).|||a soil bacterium, Brevibacillus sp. SPR-20"	Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI|||Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI|||Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI	14	
FPDB01141	AP03519	"	
VVLNLLVKVLKYGK"	Anti-Gram+||Anti-MRSA||Anti-S. aureus TISTR 517, activity value is MIC = 4 ug/ml||Anti-MRSA isolate 142, activity value is MIC = 4 ug/ml||Anti-MRSA isolate 1096, activity value is MIC = 4 ug/ml||Anti-MRSA isolate 2468, activity value is MIC = 4 ug/ml	a soil bacterium, Brevibacillus sp. SPR-20|||a soil bacterium, Brevibacillus sp. SPR-20	N/A	"The core data related to the hemolytic properties of antimicrobial peptide P1 (core research subject) in this document are presented through hemolysis rate and hemolysis treatment index (TIhₑmₒlγsis). The specific information is as follows: 
 
1. Core hemolysis value (hemolysis rate)
 
The experiment used human red blood cells as the test subject, using PBS as the blank control (0% hemolysis) and 1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 540 nm. The results are as follows: 
 
- Concentration range 0.25–32 ug/ml: P1 has an extremely low hemolysis rate, only 1.64 ± 0.17%–5.52 ± 0.92% (all < 10%), meeting the hemolysis standard for safe peptides. 

- 1× MIC concentration (2 ug/ml): hemolytic rate of 3.40 ± 0.29%, well below 10%, indicating high safety for human red blood cells when exerting anti-MRSA activity. 

- High concentration (64 ug/ml): hemolysis rate significantly increases to 62.23 ± 0.69%, but this concentration far exceeds its effective antibacterial concentration (MIC=2 ug/ml), so this dose is not required in clinical use. 
 
2. Hemolytic Therapy Index (TIhₑmₒlγsis)
 
The hemolysis index is defined as the ratio of the highest peptide concentration to MIC producing < 10% hemolysis. The higher the value, the stronger the peptide's antibacterial selectivity and safety: 
 
- The TIhₑmₒlγsis of P1 is 16 (calculation basis: the highest concentration producing 10% hemolysis < is 32 ug/ml, 32 ug/ml ÷ 2 ug/ml = 16), indicating extremely low toxicity to human red blood cells at effective antibacterial concentrations, indicating clinical application potential. 
 
Additional notes
 
- The paper focuses only on the hemolytic properties of P1, without mentioning hemolytic data from P2–P5. It is inferred that P1 has the strongest antibacterial activity (MIC = 2 ug/ml, the lowest among the five peptides), and thus is prioritized for safety evaluation. 

- The high safety of P1 is related to its physicochemical properties: although it has high hydrophobicity (0.915), it balances hemolysis risk through charge distribution (net charge 1 at pH 7.4) and secondary structure (forming α-helix when interacting with bacterial membranes, with low selectivity for mammalian membranes).|||a soil bacterium, Brevibacillus sp. SPR-20"	Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI|||Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI|||Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI	14	
FPDB01142	AP03562	"	
VVVNLLVKVLKYAK"	Anti-Gram+||Anti-MRSA||Anti-S. aureus TISTR 517, activity value is MIC = 8 ug/ml||Anti-MRSA isolate 142, activity value is MIC = 8 ug/ml||Anti-MRSA isolate 1096, activity value is MIC = 8 ug/ml||Anti-MRSA isolate 2468, activity value is MIC = 8 ug/ml	a soil bacterium, Brevibacillus sp. SPR-20|||a soil bacterium, Brevibacillus sp. SPR-20	N/A	"The core data related to the hemolytic properties of antimicrobial peptide P1 (core research subject) in this document are presented through hemolysis rate and hemolysis treatment index (TIhₑmₒlγsis). The specific information is as follows: 
 
1. Core hemolysis value (hemolysis rate)
 
The experiment used human red blood cells as the test subject, using PBS as the blank control (0% hemolysis) and 1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 540 nm. The results are as follows: 
 
- Concentration range 0.25–32 ug/ml: P1 has an extremely low hemolysis rate, only 1.64 ± 0.17%–5.52 ± 0.92% (all < 10%), meeting the hemolysis standard for safe peptides. 

- 1× MIC concentration (2 ug/ml): hemolytic rate of 3.40 ± 0.29%, well below 10%, indicating high safety for human red blood cells when exerting anti-MRSA activity. 

- High concentration (64 ug/ml): hemolysis rate significantly increases to 62.23 ± 0.69%, but this concentration far exceeds its effective antibacterial concentration (MIC=2 ug/ml), so this dose is not required in clinical use. 
 
2. Hemolytic Therapy Index (TIhₑmₒlγsis)
 
The hemolysis index is defined as the ratio of the highest peptide concentration to MIC producing < 10% hemolysis. The higher the value, the stronger the peptide's antibacterial selectivity and safety: 
 
- The TIhₑmₒlγsis of P1 is 16 (calculation basis: the highest concentration producing 10% hemolysis < is 32 ug/ml, 32 ug/ml ÷ 2 ug/ml = 16), indicating extremely low toxicity to human red blood cells at effective antibacterial concentrations, indicating clinical application potential. 
 
Additional notes
 
- The paper focuses only on the hemolytic properties of P1, without mentioning hemolytic data from P2–P5. It is inferred that P1 has the strongest antibacterial activity (MIC = 2 ug/ml, the lowest among the five peptides), and thus is prioritized for safety evaluation. 

- The high safety of P1 is related to its physicochemical properties: although it has high hydrophobicity (0.915), it balances hemolysis risk through charge distribution (net charge 1 at pH 7.4) and secondary structure (forming α-helix when interacting with bacterial membranes, with low selectivity for mammalian membranes).|||a soil bacterium, Brevibacillus sp. SPR-20"	Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI|||Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI|||Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI	14	
FPDB01143	AP03563	"	
VVLNLVVKLLKYAK"	Anti-Gram+||Anti-MRSA||Anti-S. aureus TISTR 517, activity value is MIC = 32 ug/ml||Anti-MRSA isolate 142, activity value is MIC = 32 ug/ml||Anti-MRSA isolate 1096, activity value is MIC = 32 ug/ml||Anti-MRSA isolate 2468, activity value is MIC = 32 ug/ml	a soil bacterium, Brevibacillus sp. SPR-20|||a soil bacterium, Brevibacillus sp. SPR-20	N/A	"The core data related to the hemolytic properties of antimicrobial peptide P1 (core research subject) in this document are presented through hemolysis rate and hemolysis treatment index (TIhₑmₒlγsis). The specific information is as follows: 
 
1. Core hemolysis value (hemolysis rate)
 
The experiment used human red blood cells as the test subject, using PBS as the blank control (0% hemolysis) and 1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 540 nm. The results are as follows: 
 
- Concentration range 0.25–32 ug/ml: P1 has an extremely low hemolysis rate, only 1.64 ± 0.17%–5.52 ± 0.92% (all < 10%), meeting the hemolysis standard for safe peptides. 

- 1× MIC concentration (2 ug/ml): hemolytic rate of 3.40 ± 0.29%, well below 10%, indicating high safety for human red blood cells when exerting anti-MRSA activity. 

- High concentration (64 ug/ml): hemolysis rate significantly increases to 62.23 ± 0.69%, but this concentration far exceeds its effective antibacterial concentration (MIC=2 ug/ml), so this dose is not required in clinical use. 
 
2. Hemolytic Therapy Index (TIhₑmₒlγsis)
 
The hemolysis index is defined as the ratio of the highest peptide concentration to MIC producing < 10% hemolysis. The higher the value, the stronger the peptide's antibacterial selectivity and safety: 
 
- The TIhₑmₒlγsis of P1 is 16 (calculation basis: the highest concentration producing 10% hemolysis < is 32 ug/ml, 32 ug/ml ÷ 2 ug/ml = 16), indicating extremely low toxicity to human red blood cells at effective antibacterial concentrations, indicating clinical application potential. 
 
Additional notes
 
- The paper focuses only on the hemolytic properties of P1, without mentioning hemolytic data from P2–P5. It is inferred that P1 has the strongest antibacterial activity (MIC = 2 ug/ml, the lowest among the five peptides), and thus is prioritized for safety evaluation. 

- The high safety of P1 is related to its physicochemical properties: although it has high hydrophobicity (0.915), it balances hemolysis risk through charge distribution (net charge 1 at pH 7.4) and secondary structure (forming α-helix when interacting with bacterial membranes, with low selectivity for mammalian membranes).|||a soil bacterium, Brevibacillus sp. SPR-20"	Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI|||Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI|||Molecules. 2022; 27(23):8452. https://doi.org/10.3390/molecules27238452. MDPI	14	
FPDB01144	AP03601	KRGGIWKLIRPLGRGAGRILRHFHIDFCGNC	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-P-aeruginosa ATCC27853, activity value is MIC > 64 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 16||Anti-S-pneumoniae ATCC49619, activity value is MIC > 64 ug/ml||Anti-S. pyogenes ATCC19615, activity value is MIC = 64 ug/ml||Anti-S. agalactiae ATCC12386, activity value is MIC = 64 ug/ml||Anti-S-dysgalactiae, activity value is MIC > 64 ug/ml||Anti-S-lutetiensis, activity value is MIC > 64 ug/ml||Anti-S-equi, activity value is MIC > 64 ug/ml||Anti-S-oralis, activity value is MIC > 64 ug/ml||Anti-S. salivarius, activity value is MIC = 64 ug/ml||Anti-S. mutans, activity value is MIC > 64 ug/ml||Anti-L. monocytogenes, activity value is MIC = 64 ug/ml||Anti-P-multocida, activity value is MIC > 64 ug/ml||Anti-K-pneumoniae, activity value is MIC > 64 ug/ml||Anti-C. parapsilosis ATCC 22019, activity value is MIC = 32 ug/ml||Anti-C. krusei ATCC 6258, activity value is MIC = 64 ug/ml||Anti-C-glabrata, activity value is MIC > 64 ug/ml||Anti-and C-albicans, activity value is MIC > 64 ug/ml	bone marrow, Phascolarctos cinereus, Australia|||bone marrow, Phascolarctos cinereus, Australia	N/A	bone marrow, Phascolarctos cinereus, Australia	"PLoS One
. 2021 Apr 14;16(4):e0249658. doi: 10.1371/journal.pone.0249658. eCollection 2021.|||PLoS One. 2021 Apr 14;16(4):e0249658. doi: 10.1371/journal.pone.0249658. PubMed|||PLoS One. 2021 Apr 14;16(4):e0249658. doi: 10.1371/journal.pone.0249658. PubMed|||PLoS One. 2021 Apr 14;16(4):e0249658. doi: 10.1371/journal.pone.0249658. PubMed"	31	
FPDB01145	AP03613	"	
FFPLIFGALSSILPKIL"	Anti-Gram+||Anti-MRSA||Anti-inflammatory||Anti-S. aureus ATCC 6538 or ATCC25923 or MRSA, activity value is MIC = 6.25||Anti-P. acnes ATCC6919, activity value is MIC = 6.25 uM||Anti-and B. subtilis CMCC63501, activity value is MIC = 6.25 uM||Anti-but not Gram- E.coil ATCC25922, activity value is MIC > 100 uM||Anti-P.aeruginosa ATCC 27853, activity value is MIC > 100 uM	skin, Boie's wart frog, rice field frog, and Asian grass frog, Fejervary limnocharis, Asia|||skin, Boie's wart frog, rice field frog, and Asian grass frog, Fejervary limnocharis, Asia	Helix	"The core data related to the hemolytic activity of the antimicrobial peptide Temporin-FL in this document are reflected through the hemolysis rate, with specific information as follows:

1. Core Hemolytic Values (Hemolysis Rate)

The experiments used mouse red blood cells as the test subject, with PBS as the blank control (0% hemolysis) and 1% Triton X-100 as the positive control for complete hemolysis (100% hemolysis). Hemolysis rates were calculated by measuring absorbance at 540 nm. The results are as follows:

- Concentration range 1.25–20 μM: The hemolysis rate of Temporin-FL was extremely low and did not exceed 10% at any tested concentration (Figure 3F). No obvious concentration-dependent increase in hemolysis was observed, indicating high safety for mammalian red blood cells.

- Hemolysis rates at key concentrations:

- 1× MIC concentration (MIC against Staphylococcus aureus ATCC 25923 = 12.5 μM): Hemolysis rate was well below 10%, showing no significant hemolytic activity.

- Highest tested concentration (20 μM): No significant hemolysis was observed, further confirming its low hemolytic toxicity.

2. Additional Notes

- The text does not mention values related to “HC₅₀ (peptide concentration causing 50% hemolysis),” because even at the highest tested concentration (20 μM), 50% hemolysis was not reached, so HC₅₀ > 20 μM.

- Concurrent cytotoxicity experiments showed that Temporin-FL had no significant toxicity to various mammalian cells (human skin fibroblasts HSF, lung carcinoma cells A549, lung fibroblasts MRC-5, lung carcinoma cells NCI-H460, mouse macrophages RAW 264.7) within the 1.25–20 μM concentration range (cell viability > 80%, Figures 3A-E), consistent with its low hemolytic profile, supporting its potential for clinical application.|||skin, Boie's wart frog, rice field frog, and Asian grass frog, Fejervary limnocharis, Asia"	"Biochem Pharmacol
. 2023 Apr:210:115471. doi: 10.1016/j.bcp.2023.115471. Epub 2023 Mar 7.|||Biochem Pharmacol. 2023 Mar 7:115471. doi: 10.1016/j.bcp.2023.115471. PubMed|||Biochem Pharmacol. 2023 Mar 7:115471. doi: 10.1016/j.bcp.2023.115471. PubMed|||Biochem Pharmacol. 2023 Mar 7:115471. doi: 10.1016/j.bcp.2023.115471. PubMed"	17	
FPDB01146	AP03626	"	
RIWWSGGWRRWRW"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli ATCC 25922 and resitant strains, activity value is MIC = 4.24||Anti-S. aureus ATCC 29213 and MRSA, activity value is MIC = 8.47||Anti-E. faecalis ATCC 29212 and VRE, activity value is MIC = 33.9 uM||Anti-S. marcescens CGMCC 1.4256, activity value is MIC = 8.47 uM||Anti-S. enterica subsp. enterica CGMCC 1.10754, activity value is MIC = 33.9 uM||Anti-E. cloacae CGMCC 1.2022, activity value is MIC = 67.79 uM||Anti-Y. mollaretii CGMCC 1.6197, activity value is MIC = 33.9 uM||Anti-C. sakazakii CGMCC 1.6765, activity value is MIC = 8.47 uM||Anti-S. dysenteriae CGMCC 1.1869, activity value is MIC = 8.47 uM||Anti-P. aeruginosa CGMCC 1.10612, activity value is MIC = 67.79 uM||Anti-K. pneumoniae CKP1902, activity value is MIC = 33.9 uM||Anti-and A. baumannii CAB21, activity value is MIC = 16.95 uM	prediction and optimized natural fragment	Rich	"The core data related to the hemolytic activity of the antimicrobial peptide EWAMP-R in this document are reflected through hemolysis rate. The specific information is as follows:

1. Core Hemolytic Values (Hemolysis Rate)

The experiment used sterile defibrinated sheep red blood cells as the test object, with PBS as the blank control (0% hemolysis) and 0.25% Triton X-100 as the positive control for complete hemolysis (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 576 nm, with the results as follows:

- At the highest tested concentration (256 µg/ml): EWAMP-R did not exhibit obvious hemolytic activity (Figure S2c), with a hemolysis rate of <10%, and no concentration-dependent increase in hemolysis was observed, indicating high safety toward mammalian red blood cells.

- Hemolysis rates at key concentrations:
  - At the MIC concentration against E. coli (8 µg/ml) and the MIC concentration against S. aureus (16 µg/ml): hemolysis rates were far below 10%, showing no significant hemolytic toxicity.
  - At the clinically relevant concentration range (such as 32–64 µg/ml for inhibiting resistant bacteria): no significant hemolysis was observed, further confirming its low hemolytic nature.

2. Additional Notes

- The document does not mention values related to ""HC₅₀ (the peptide concentration causing 50% hemolysis)"", because hemolysis did not reach 50% at the highest tested concentration (256 µg/ml), thus HC₅₀ > 256 µg/ml.

- Concurrent cytotoxicity experiments showed that EWAMP-R had no significant toxicity toward normal human liver cells LO2 within the 256 µg/ml concentration range (cell viability >80%, Figure S2d), consistent with its low hemolytic profile, supporting its potential for clinical application.|||prediction and optimized natural fragment"	"Microbiol Spectr
. 2023 Feb 14;11(1):e0320622. doi: 10.1128/spectrum.03206-22. Epub 2023 Jan 5.|||Microbiol Spectr. 2023 Feb 14;11(1):e0320622. doi: 10.1128/spectrum.03206-22. PubMed|||Microbiol Spectr. 2023 Feb 14;11(1):e0320622. doi: 10.1128/spectrum.03206-22. PubMed|||Microbiol Spectr. 2023 Feb 14;11(1):e0320622. doi: 10.1128/spectrum.03206-22. PubMed"	13	
FPDB01147	AP03629|||AP03629|||Cathelin-related antimicrobial peptide|||DRAMP03406|||AP03629	"	
ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE"	Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-E. coli ATCC 25922 or ML35 or D21, activity value is MIC = 0.5||Anti-S. typhimurium ATCC 14028, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 4 uM||Anti-S. marcescens ATCC 8100, activity value is MIC = 4 uM||Anti-P-vulgaris ATCC 13315, activity value is MIC > 64 uM||Anti-S. aureus ATCC 25923 or Cowan I or MRSA, activity value is MIC = 32||Anti-S. epidermidis ATCC 12228, activity value is MIC = 16 uM||Anti-S. faecalis ATCC 29212, activity value is MIC = 16 uM||Anti-B. megaterium Bm11, activity value is MIC = 4 uM||Anti-fumgi C-albicans, activity value is MIC > 64 uM||Anti-C. neoformans, activity value is MIC = 16 uM||Antibacterial||Anti-Escherichia coli ATCC 25922, activity value is MIC = 1 uM||Anti-Escherichia coli ML35, activity value is MIC = 2 uM||Anti-Escherichia coli D21, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 4 uM||Anti-Serratia marcescens ATCC 8100, activity value is MIC = 4 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 32 uM||Anti-Staphylococcus aureus Cowan I, activity value is MIC = 32 uM||Anti-Staphylococcus aureus, activity value is MIC > 64 uM||Anti-Staphylococcus aureus, activity value is MIC = 64 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 16 uM||Anti-Streptococcus faecalis ATCC 29212, activity value is MIC = 32 uM||Anti-Bacillus megaterium Bm11, activity value is MIC = 4 uM||Anti-Cryptococcus neoformans, activity value is MIC = 16 uM	precursor sequence homology|||precursor sequence homology|||Mus musculus [Mouse]|||Mus musculus (Mouse)|||precursor sequence homology	Alpha helix (CD)	"The core information in this document regarding the hemolytic activity of the antimicrobial peptide CRAMP (CRAMP-1 and CRAMP-2) is that there is no significant hemolytic activity, described specifically as follows:

Hemolysis results of CRAMP

The experiments tested human and sheep erythrocytes at a concentration of 50 μM (far higher than its MIC values for Gram-negative bacteria of 0.5–8 μM and for Gram-positive bacteria of 16–64 μM), and the results showed:

- Both CRAMP-1 and CRAMP-2 did not cause hemolysis of red blood cells (the text clearly states, “the CRAMP peptides (50 μM) did not lyse human or sheep erythrocyte membranes (data not shown)”), meaning the hemolysis rate was 0%.

- The text does not mention the value of HC₅₀ (the peptide concentration causing 50% hemolysis). Since there was no hemolysis at the highest tested concentration (50 μM), HC₅₀ > 50 μM.

Additional notes

- The low hemolytic property of CRAMP is related to its structure: although it can form an amphipathic α-helix (with increased helical content in trifluoroethanol) and disrupt bacterial membranes, it does not damage mammalian red blood cell membranes. It is suggested that its selectivity for bacterial membranes comes from differences in lipid composition between bacterial and mammalian membranes (e.g., bacterial membranes contain more anionic phospholipids, while red blood cell membranes mainly contain neutral phospholipids).

- This low hemolytic property, combined with CRAMP's antibacterial activity, provides a good balance that supports its safety as a potential anti-infection drug.|||precursor sequence homology"	"J Biol Chem
. 1997 May 16;272(20):13088-93. doi: 10.1074/jbc.272.20.13088.|||J Biol Chem. 1997 May 16;272(20):13088-93. doi: 10.1074/jbc.272.20.13088. Pub-Med.|||J Biol Chem. 1997 May 16;272(20):13088-93. doi: 10.1074/jbc.272.20.13088. Pub-Med.|||9148921|||FEBS Lett. 1996 Aug 5;391(1-2):5-8.|||J Biol Chem. 1997 May 16;272(20):13088-93. doi: 10.1074/jbc.272.20.13088. Pub-Med."	38	
FPDB01148	AP03632	"	
FLKSNALL"	Anti-Gram+ & Gram-||Anti-MRSA||anti-TB||Anti-S. aureus susceptible and resistant strains NCTC 8325 NRS108 NRS71 MRSA Mu50 VISA, activity value is MIC = 0.125||Anti-S. epidermidis ATCC 35982 or NRS8, activity value is MIC = 0.5 ug/ml||Anti-S. haemolyticus NRS9 or NRS69, activity value is MIC = 0.5||Anti-E. faecium BM4147 VRE, activity value is MIC = 0.5||Anti-B. subtilis 1A1 or 168, activity value is MIC = 1||Anti-B. anthracis Sterne, activity value is MIC = 0.25 ug/ml||Anti-S. pneumoniae ATCC10813, activity value is MIC = 0.25||Anti-S. pyogenes ATCC19615, activity value is MIC = 0.25||Anti-S. warneri NRS138, activity value is MIC = 1 ug/ml||Anti-M. smegmatis MC2 155, activity value is MIC = 2 ug/ml||Anti-M. tuberculosis MC2 6020, activity value is MIC = 0.5||Anti-H. influenzae SJ7, activity value is MIC = 2 ug/ml||Anti-E. coli K12, activity value is MIC = 64 ug/ml||Anti-and P.aeruginosa PA-01, activity value is MIC > 128 ug/ml	Eleftheria terrae ssp. Carolina|||Eleftheria terrae ssp. carolina	Beta	"The document does not mention hemolytic values related to the antimicrobial peptide clovibactin (such as hemolysis rate, HC₅₀, etc.) and only indirectly demonstrates its low toxicity to eukaryotic cells through other safety experiments. Specific information is as follows:

1. Indirect safety evidence related to hemolysis

- Mammalian cytotoxicity experiments:
At the highest tested concentration (100 µg/ml), clovibactin showed no significant cytotoxicity to mouse embryonic fibroblasts (NIH/3T3) and human liver cancer cells (HepG2) (cell viability >80%). Cell viability was measured using the CellTiter 96 AQueous One Solution kit, and absorbance at 490 nm was used to calculate cell survival, confirming its safety to eukaryotic cells (no direct hemolysis data, but low cytotoxicity indirectly reflects a low risk of damage to mammalian cell membranes).

- Specificity of action on bacterial cell membranes:
Clovibactin targets the pyrophosphate groups of bacterial cell wall precursors (C₅₅PP, lipid I, lipid II) and forms supramolecular fibers only on bacterial membranes, without damaging mammalian cell membranes. Experiments confirmed that it does not cause rapid bacterial membrane permeabilization (e.g., SYTOX Green penetration assay negative) or depolarization (DiSC₂(5) fluorescence assay negative), and it does not affect the localization of the Bacillus subtilis cell division protein MinD (MinD localization depends on membrane potential; disruption of membrane potential would cause delocalization). This further indicates that it does not have a similar destructive effect on eukaryotic cell membranes, suggesting extremely low hemolytic potential, although direct hemolysis data are lacking.

2. Additional notes

- The document focuses on clovibactin’s antibacterial mechanism (targeting bacterial cell wall precursors, forming supramolecular fibers) and in vitro and in vivo antibacterial activity (e.g., reducing bacterial load in a mouse thigh infection model) and did not include red blood cell hemolysis experiments; therefore, direct hemolysis values such as hemolysis rate and HC₅₀ are not available.

- Its low toxicity (non-toxic to mammalian cells, not damaging eukaryotic cell membranes) is consistent with the safety characteristics of similar low-hemolytic antimicrobial peptides (e.g., teixobactin), allowing indirect inference that its hemolytic risk is extremely low, though future hemolysis experiments are needed for confirmation.|||Eleftheria terrae ssp. carolina"	"Cell
. 2023 Sep 14;186(19):4059-4073.e27. doi: 10.1016/j.cell.2023.07.038. Epub 2023 Aug 22.|||2023 Sep 14;186(19):4059-4073.e27. doi: 10.1016/j.cell.2023.07.038. Epub 2023 Aug 22.|||Cell. 2023 Sep 14;186(19):4059-4073.e27. doi: 10.1016/j.cell.2023.07.038. Pub-Med.|||Cell. 2023 Sep 14;186(19):4059-4073.e27. doi: 10.1016/j.cell.2023.07.038. Pub-Med.|||Cell. 2023 Sep 14;186(19):4059-4073.e27. doi: 10.1016/j.cell.2023.07.038. Pub-Med."	8	
FPDB01149	AP03633	"	
AAGKVLKLLKKLL"	Anti-Gram+ & Gram-||Anti-MRSA||Antibiofilm||Anti-Gram- A. baumannii, activity value is MIC = 23 uM||Anti-E. coli ATCC 25922, activity value is MIC = 2.8 uM||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 11.5||Anti-E. faecalis ATCC 19433, activity value is MIC = 23 uM||Anti-S. aureus MRSA, activity value is MIC = 23 uM	amino acid substitution, amphibians, animal-derived, natural derivative	N/A	"The core data related to the hemolytic activity of antimicrobial peptides (temporin-PTa, Hp-MAP1, Hp-MAP2) in this document are reflected through hemolysis rates, with specific information as follows:

1. Core hemolytic values (hemolysis rates)

Swiss mouse red blood cells were used as the test subjects, with 50,000 μM PBS (pH 7.4) as the blank control (0% hemolysis) and 1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). Hemolysis rates were calculated by measuring the absorbance at 415 nm, and the results were as follows:

- Temporin-PTa: At the highest tested concentration of 87 μM, the hemolysis rate was 13% (Table 2), indicating some hemolytic activity.

- Hp-MAP1 and Hp-MAP2: At the highest tested concentration of 92 μM, no hemolytic effect was observed (Table 2), meaning a hemolysis rate of 0%. This concentration is far above their effective antimicrobial concentrations (MIC range 2.7–46 μM), indicating high safety for mammalian red blood cells.

2. Additional notes

- The paper does not mention values related to ""HC₅₀ (the peptide concentration causing 50% hemolysis)."" For Hp-MAP1 and Hp-MAP2, because there was still no hemolysis at the highest tested concentration (92 μM), HC₅₀ > 92 μM; for temporin-PTa, as the hemolysis rate was only 13% at 87 μM, HC₅₀ is assumed to be much higher than 87 μM.

- Reason for differences in hemolytic activity: Hp-MAP1 and Hp-MAP2 were rationally designed to reduce overall hydrophobicity (0.49 and 0.41, respectively, lower than temporin-PTa's 0.93) while optimizing amphipathic structures (hydrophobic moment <μH> 0.668 and 0.722, respectively), which reduces non-specific interactions with mammalian cell membranes and eliminates hemolytic toxicity. This is consistent with the principle that ""hydrophobicity >50% is likely to cause hemolysis"" (the paper notes that AMPs with hydrophobicity >50% often have hemolytic activity).|||amino acid substitution, amphibians, animal-derived, natural derivative||No hemolytic effect was observed at concentrations as high as 92 uM.|||According to the content of the provided document, the article explicitly mentions hemolytic data for three peptides (temporin-PTa, Hp-MAP1, Hp-MAP2), as follows:

1. Temporin-PTa: At the highest tested concentration of 87 μM, the hemolysis rate was 13% (using 1% Triton X-100 as a 100% hemolysis positive control and 50,000 μM PBS as a 0% hemolysis blank control).
2. Hp-MAP1: Within the tested concentration range (2.7–92 μM), no hemolytic activity was observed (marked as “nd” in the document to indicate “not detected” hemolytic effect).
3. Hp-MAP2: Within the tested concentration range (2.7–92 μM), no hemolytic activity was observed (also marked as “nd” to indicate “not detected” hemolytic effect).

The above hemolytic data were measured using mouse erythrocyte (Swiss mice Mus musculus erythrocytes) hemolysis assays. The experimental principle is to evaluate the amount of hemoglobin released by detecting the absorbance at 415 nm, and then calculate the hemolysis rate.|||No hemolytic effect was observed at concentrations as high as 92 uM."	"Chem Biol Drug Des
. 2022 Jul;100(1):51-63. doi: 10.1111/cbdd.14052. Epub 2022 Apr 10.|||Chem Biol Drug Des. 2022 Jul;100(1):51-63. doi: 10.1111/cbdd.14052. Pub-Med.|||Chem Biol Drug Des. 2022 Jul;100(1):51-63. doi: 10.1111/cbdd.14052. Pub-Med.|||Chem Biol Drug Des. 2022 Jul;100(1):51-63. doi: 10.1111/cbdd.14052. Pub-Med."	13	
FPDB01150	AP03634	"	
AAKKVLKLLKKLL"	Anti-Gram+ & Gram-||Anti-MRSA||Antibiofilm||Anti-Gram- A. baumannii, activity value is MIC = 21.7 uM||Anti-E. coli ATCC 25922, activity value is MIC = 2.7 uM||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 2.7||Anti-E. faecalis ATCC 19433, activity value is MIC = 5.4 uM||Anti-S. aureus MRSA, activity value is MIC = 21.7 uM	amino acid substitution, amphibians, animal-derived, natural derivative	N/A	"The core data related to the hemolytic activity of antimicrobial peptides (temporin-PTa, Hp-MAP1, Hp-MAP2) in this document are reflected through hemolysis rates, with specific information as follows:

1. Core hemolytic values (hemolysis rates)

Swiss mouse red blood cells were used as the test subjects, with 50,000 μM PBS (pH 7.4) as the blank control (0% hemolysis) and 1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). Hemolysis rates were calculated by measuring the absorbance at 415 nm, and the results were as follows:

- Temporin-PTa: At the highest tested concentration of 87 μM, the hemolysis rate was 13% (Table 2), indicating some hemolytic activity.

- Hp-MAP1 and Hp-MAP2: At the highest tested concentration of 92 μM, no hemolytic effect was observed (Table 2), meaning a hemolysis rate of 0%. This concentration is far above their effective antimicrobial concentrations (MIC range 2.7–46 μM), indicating high safety for mammalian red blood cells.

2. Additional notes

- The paper does not mention values related to ""HC₅₀ (the peptide concentration causing 50% hemolysis)."" For Hp-MAP1 and Hp-MAP2, because there was still no hemolysis at the highest tested concentration (92 μM), HC₅₀ > 92 μM; for temporin-PTa, as the hemolysis rate was only 13% at 87 μM, HC₅₀ is assumed to be much higher than 87 μM.

- Reason for differences in hemolytic activity: Hp-MAP1 and Hp-MAP2 were rationally designed to reduce overall hydrophobicity (0.49 and 0.41, respectively, lower than temporin-PTa's 0.93) while optimizing amphipathic structures (hydrophobic moment <μH> 0.668 and 0.722, respectively), which reduces non-specific interactions with mammalian cell membranes and eliminates hemolytic toxicity. This is consistent with the principle that ""hydrophobicity >50% is likely to cause hemolysis"" (the paper notes that AMPs with hydrophobicity >50% often have hemolytic activity).|||amino acid substitution, amphibians, animal-derived, natural derivative||No hemolytic effect was observed at concentrations as high as 92 uM.|||According to the content of the provided document, the article explicitly mentions hemolytic data for three peptides (temporin-PTa, Hp-MAP1, Hp-MAP2), as follows:

1. Temporin-PTa: At the highest tested concentration of 87 μM, the hemolysis rate was 13% (using 1% Triton X-100 as a 100% hemolysis positive control and 50,000 μM PBS as a 0% hemolysis blank control).
2. Hp-MAP1: Within the tested concentration range (2.7–92 μM), no hemolytic activity was observed (marked as “nd” in the document to indicate “not detected” hemolytic effect).
3. Hp-MAP2: Within the tested concentration range (2.7–92 μM), no hemolytic activity was observed (also marked as “nd” to indicate “not detected” hemolytic effect).

The above hemolytic data were measured using mouse erythrocyte (Swiss mice Mus musculus erythrocytes) hemolysis assays. The experimental principle is to evaluate the amount of hemoglobin released by detecting the absorbance at 415 nm, and then calculate the hemolysis rate.|||No hemolytic effect was observed at concentrations as high as 92 uM."	"Chem Biol Drug Des
. 2022 Jul;100(1):51-63. doi: 10.1111/cbdd.14052. Epub 2022 Apr 10.|||Chem Biol Drug Des. 2022 Jul;100(1):51-63. doi: 10.1111/cbdd.14052. Pub-Med.|||Chem Biol Drug Des. 2022 Jul;100(1):51-63. doi: 10.1111/cbdd.14052. Pub-Med.|||Chem Biol Drug Des. 2022 Jul;100(1):51-63. doi: 10.1111/cbdd.14052. Pub-Med."	13	
FPDB01151	AP03638	"	
FTSISMCTPGCKTGALMTCNYKTATCHCSIKVSK"	Anti-Gram+||Antiviral||Anti-MRSA||Anti-and S. uberis strain 42 . MIC values against S. aureus ATCC 29213 MSSA or MRSA, activity value is MIC = 0.19||Anti-E. faecalis ATCC 29212 or 51299 VRE, activity value is MIC = 1.56 uM||Anti-E. faecium ATCC 35667 or 700221 VRE, activity value is MIC = 0.39 uM||Anti-and B. subtilis 168, activity value is MIC = 0.1 uM	Streptococcus hyointestinalis DPC6484, isolated from the porcine intestine: pig microbiota:gut|||Streptococcus hyointestinalis DPC6484, isolated from the porcine intestine: pig microbiota:gut	N/A	Streptococcus hyointestinalis DPC6484, isolated from the porcine intestine: pig microbiota:gut	"Appl Environ Microbiol
. 2015 Jun 15;81(12):3953-60. doi: 10.1128/AEM.00212-15. Epub 2015 Apr 3.|||Appl Environ Microbiol. 2015 Jun 15;81(12):3953-60. doi: 10.1128/AEM.00212-15. Pub-Med.||Reiners et al., 2020|||Appl Environ Microbiol. 2015 Jun 15;81(12):3953-60. doi: 10.1128/AEM.00212-15. Pub-Med.||Reiners et al., 2020|||Appl Environ Microbiol. 2015 Jun 15;81(12):3953-60. doi: 10.1128/AEM.00212-15. Pub-Med.||Reiners et al., 2020|||Appl Environ Microbiol. 2015 Jun 15;81(12):3953-60. doi: 10.1128/AEM.00212-15. Pub-Med."	34	
FPDB01152	AP03639	"	
IFKAIWSGINRLF"	Anti-Gram+||Anti-MRSA||Anti-S. aureus 5 strains and 4 MRSA strains, activity value is MIC = 6.25||Anti-S. epidermidis 2 strains, activity value is MIC = 25 ug/ml||Anti-M. luteus AB93113, activity value is MIC = 50 ug/ml||Anti-B. subtilis ATCC6051, activity value is MIC = 25 ug/ml	venom, Heterometrus petersii|||venom, Heterometrus petersii	Helix	venom, Heterometrus petersii	"Toxicon
. 2023 Aug 1:231:107189. doi: 10.1016/j.toxicon.2023.107189. Epub 2023 Jun 7.|||Toxicon. 2023 Jun 7;231:107189. doi: 10.1016/j.toxicon.2023.107189. Pub-Med.|||Toxicon. 2023 Jun 7;231:107189. doi: 10.1016/j.toxicon.2023.107189. Pub-Med.|||Toxicon. 2023 Jun 7;231:107189. doi: 10.1016/j.toxicon.2023.107189. Pub-Med."	13	
FPDB01153	AP03641|||AP03641|||CP29	"	
KWKSFIKKLTTAVKKVLTTGLPALIS"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-P. aeruginosa PAO1 and mutants, activity value is MIC = 2||Anti-E. coli UB1005, activity value is MIC = 0.5 ug/ml||Anti-and S. typhimurium 14028s, activity value is MIC = 2 ug/ml||Anti-S. haemolyticus, activity value is MIC = 8||Anti-S. epidermidis, activity value is MIC = 16 ug/ml||Anti-E. faecalis ATCC 29212, activity value is MIC = 64 ug/ml||Anti-L. monocytogenes NCTC 7973, activity value is MIC = 4 ug/ml||Anti-S. pyogenes ATCC 19615, activity value is MIC = 8 ug/ml||Anti-and C. xerosis lab strain, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 8 ug/ml||Anti-Staphylococcus aureus SAP0017 MRSAb, activity value is MIC = 8 ug/ml||Anti-Staphylococcus haemolyticus Clinical isolate, activity value is MIC = 8 ug/ml||Anti-Staphylococcus haemolyticus Vancomycin-resistant isolate, activity value is MIC = 16 ug/ml||Anti-Staphylococcus epidermidis Clinical isolate, activity value is MIC = 16 ug/ml||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 64 ug/ml||Anti-Listeria monocytogenes NCTC 7973, activity value is MIC = 4 ug/ml||Anti-Streptococcus pyogenes ATCC 19615, activity value is MIC = 8 ug/ml||Anti-Corynebacterium xerosis Lab strain, activity value is MIC = 2 ug/ml	amino acid substitution of insect cecropin-bee melittin hybrid peptide (CEME), designed, man-made sequences|||amino acid substitution of insect cecropin-bee melittin hybrid peptide (CEME), designed, man-made sequences|||Synthetic construct	Helix	amino acid substitution of insect cecropin-bee melittin hybrid peptide (CEME), designed, man-made sequences	"Antimicrob Agents Chemother
. 1999 Jul;43(7):1542-8. doi: 10.1128/AAC.43.7.1542.|||Antimicrob Agents Chemother. 1999 Jul;43(7):1542-8. doi: 10.1128/AAC.43.7.1542. Pub-Med.||Friedrich et al., 2000|||Antimicrob Agents Chemother. 1999 Jul;43(7):1542-8. doi: 10.1128/AAC.43.7.1542. Pub-Med.||Friedrich et al., 2000|||10898680|||Antimicrob Agents Chemother. 1999 Jul;43(7):1542-8. doi: 10.1128/AAC.43.7.1542. Pub-Med.||Friedrich et al., 2000"	26	
FPDB01154	AP03644|||AP03644|||CP26	"	
KWKSFIKKLTSAAKKVVTTAKPLISS"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-P. aeruginosa PAO1 and mutants, activity value is MIC = 2||Anti-E. coli UB1005, activity value is MIC = 0.5 ug/ml||Anti-and S. typhimurium 14028s, activity value is MIC = 2 ug/ml||Anti-S. haemolyticus, activity value is MIC = 64 uM||Anti-S. epidermidis, activity value is MIC = 32 ug/ml||Anti-E-faecalis ATCC 29212, activity value is MIC > 64 ug/ml||Anti-L. monocytogenes NCTC 7973, activity value is MIC = 16 ug/ml||Anti-S. pyogenes ATCC 19615, activity value is MIC = 16 ug/ml||Anti-and C. xerosis lab strain, activity value is MIC = 1 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 64 ug/ml||Anti-Staphylococcus aureus SAP0017 MRSAb, activity value is MIC = 64 ug/ml||Anti-Staphylococcus haemolyticus Clinical isolate, activity value is MIC = 64 ug/ml||Anti-Staphylococcus epidermidis Clinical isolate, activity value is MIC = 32 ug/ml||Anti-Listeria monocytogenes NCTC 7973, activity value is MIC = 16 ug/ml||Anti-Streptococcus pyogenes ATCC 19615, activity value is MIC = 16 ug/ml||Anti-Corynebacterium xerosis Lab strain, activity value is MIC = 1 ug/ml	amino acid substitution of insect cecropin-bee melittin hybrid peptide (CEME), designed, man-made sequences|||amino acid substitution of insect cecropin-bee melittin hybrid peptide (CEME), designed, man-made sequences|||Synthetic construct	Helix	amino acid substitution of insect cecropin-bee melittin hybrid peptide (CEME), designed, man-made sequences	"Antimicrob Agents Chemother
. 1999 Jul;43(7):1542-8. doi: 10.1128/AAC.43.7.1542.|||Antimicrob Agents Chemother. 1999 Jul;43(7):1542-8. doi: 10.1128/AAC.43.7.1542. Pub-Med.||Friedrich et al., 2000|||Antimicrob Agents Chemother. 1999 Jul;43(7):1542-8. doi: 10.1128/AAC.43.7.1542. Pub-Med.||Friedrich et al., 2000|||10898680|||Antimicrob Agents Chemother. 1999 Jul;43(7):1542-8. doi: 10.1128/AAC.43.7.1542. Pub-Med.||Friedrich et al., 2000"	26	
FPDB01155	AP03654|||AP03654|||CAMPSQ14438	"	
WLRRIKAWLRRIKA"	Anti-Gram+||Anti-MRSA||Synergistic AMPs||Antibiofilm||Anti-S. aureus MSSA or MRSA many strains, activity value is MIC = 2||Anti-P. aeruginosa PAO1, activity value is MIC = 4 uM||Anti-P. aeruginosa ATCC 9721, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC BAA-1744, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 35032, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 25619, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 4 uM||Anti-P. aeruginosa ATCC 15442, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 10145, activity value is MIC = 8 uM||Anti-A. baumannii ATCC BAA-1605, activity value is MIC = 2 uM||Anti-A. baumannii ATCC 19606, activity value is MIC = 2 uM||Anti-A. baumannii ATCC BAA-747, activity value is MIC = 2 uM||Anti-A. baumannii NR-9667, activity value is MIC = 4 uM||Anti-A. baumannii NR-13374, activity value is MIC = 4 uM||Anti-A. baumannii NR-13375, activity value is MIC = 2 uM||Anti-A. baumannii NR-13382, activity value is MIC = 4 uM||Anti-A. baumannii NR-17777, activity value is MIC = 2 uM||Anti-A. baumannii NR-17778, activity value is MIC = 2 uM||Anti-A. baumannii NR-17780, activity value is MIC = 2 uM||Anti-A. baumannii NR-17783, activity value is MIC = 4 uM||Anti-A. baumannii NR-17784, activity value is MIC = 2 uM||Anti-A. baumannii NR-17785, activity value is MIC = 2 uM||Anti-A. baumannii NR-17786, activity value is MIC = 2 uM||Anti-A. baumannii NR-19298, activity value is MIC = 2 uM||Anti-A. baumannii NR-19299, activity value is MIC = 4 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1109, activity value is MIC = 4 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1125, activity value is MIC = 8 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1571, activity value is MIC = 4 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1603, activity value is MIC = 8 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 16011, activity value is MIC = 16 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1017, activity value is MIC = 32 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1020, activity value is MIC = 4 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1133, activity value is MIC = 16 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1015, activity value is MIC = 32 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1016, activity value is MIC = 32 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1131, activity value is MIC = 8 uM	hybrid peptide, designed, man-made sequences|||hybrid peptide, designed, man-made sequences|||Synthetic construct	Helix	"The core data related to the antimicrobial peptides RRIKA and RR hemolysis in this document are reflected through hemolysis rates, with the specific information as follows:

1. Core Hemolytic Values (Hemolysis Rate)

The experiment was conducted using human red blood cells, with PBS as the blank control (0% hemolysis), 0.1% Triton X-100 and 5 µM melittin as the complete hemolysis positive control (100% hemolysis). Hemolysis rates were calculated by measuring the absorbance at 405 nm, and the results were as follows:

- RRIKA and RR: At the highest tested concentration of 300 µM, the hemolysis rate was very low, with a maximum of only 10% (Figure 8), and no concentration-dependent hemolysis enhancement trend was observed, indicating high safety for human red blood cells.

- Positive control comparison: 5 µM melittin could cause 100% hemolysis, whereas RRIKA and RR showed no significant hemolysis even at 300 µM (far exceeding their effective antimicrobial concentrations, RRIKA MIC 2–4 µM, RR MIC 8–32 µM), demonstrating a significant safety advantage.

2. Supplementary Notes

- The text does not mention the ""HC₅₀ (peptide concentration causing 50% hemolysis)"" value. Since the hemolysis rates of RRIKA and RR at the highest tested concentration (300 µM) were both <10%, far from 50% hemolysis, HC₅₀ is >300 µM.

- Consistency of hemolysis safety with cytotoxicity: Concurrent HeLa cell cytotoxicity experiments showed that RRIKA at 32 µM (8×MIC) and RR at 64 µM (4×MIC) showed no significant toxicity to mammalian cells (cell survival rate >80%, Figure 9), consistent with their low hemolytic characteristics, further validating their low risk of damage to eukaryotic cells.

- Clinical application potential: The low hemolysis feature, combined with salt resistance (stable antimicrobial activity under physiological NaCl/Mg²⁺ concentrations) and anti-biofilm activity, supports RRIKA and RR as candidate peptides for local treatment of MRSA infections (such as skin infections), especially in scenarios where hemolysis risk needs to be avoided.|||hybrid peptide, designed, man-made sequences||At concentrations as high as 300 uM, the hemolytic effect on human red blood cells is minimal (with a maximum hemolysis rate of 10%).|||low level (~10%) hemolysis at 300 uM. low hemo.lytic. Not toxic to Hela cells at 4-8-fold antimicrobial concentrations.|||According to the provided document, the text clearly mentions hemolytic data for two target peptides (RRIKA, RR) and control substances (melittin, Triton X-100), as detailed below:

1. Target Peptides (RRIKA, RR)

Test Conditions: Human red blood cells (RBCs) were used as the experimental subject. Peptide solutions were prepared in PBS and incubated at 37°C for 1 hour. Hemolysis was calculated by measuring the absorbance at 405 nm (OD₄₀₅); PBS served as the 0% hemolysis negative control, while 0.1% Triton X-100 or 5 μM melittin was used as the 100% hemolysis positive control.
Hemolytic Results:
Both peptides exhibited very low hemolytic activity even at the maximum tested concentration of 300 μM, with a hemolysis rate not exceeding 10%.
Even at concentrations dozens of times higher than their antibacterial concentrations (MIC for RRIKA is 2-4 μM, MIC for RR is 8-32 μM), no significant hemolytic effects were observed.

2. Control Substances

Melittin: As a typical hemolysis positive control, 5 μM concentration can cause 100% hemolysis of human red blood cells, showing a sharp contrast with the target peptides.
Triton X-100: At 0.1% concentration, it serves as a 100% hemolysis positive control and is used to calibrate hemolysis calculation standards.

In summary, RRIKA and RR maintain low hemolytic activity both within their effective antibacterial concentration range and at high concentrations (300 μM), with safety significantly superior to traditional hemolytic peptides such as melittin.|||At concentrations as high as 300 uM, the hemolytic effect on human red blood cells is minimal (with a maximum hemolysis rate of 10%)."	"Antimicrob Agents Chemother
. 2014 Jul;58(7):4113-22. doi: 10.1128/AAC.02578-14. Epub 2014 May 5.|||Antimicrob Agents Chemother. 2014 Jul;58(7):4113-22. doi: 10.1128/AAC.02578-14. Pub-Med.|||Antimicrob Agents Chemother. 2014 Jul;58(7):4113-22. doi: 10.1128/AAC.02578-14. Pub-Med.|||28761101|||Antimicrob Agents Chemother. 2014 Jul;58(7):4113-22. doi: 10.1128/AAC.02578-14. Pub-Med."	14	
FPDB01156	AP03655|||AP03655|||RR|||RR|||AP03655	"	
WLRRIKAWLRR"	Anti-Gram+||Anti-MRSA||Synergistic AMPs||Antibiofilm||Anti-S. aureus MSSA or MRSA many strains, activity value is MIC = 8||Anti-P. aeruginosa PAO1, activity value is MIC = 64 uM||Anti-P. aeruginosa ATCC 9721, activity value is MIC = 64 uM||Anti-P. aeruginosa ATCC BAA-1744, activity value is MIC = 128 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 64 uM||Anti-P. aeruginosa ATCC 35032, activity value is MIC = 64 uM||Anti-P. aeruginosa ATCC 25619, activity value is MIC = 64 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 64 uM||Anti-P. aeruginosa ATCC 15442, activity value is MIC = 128 uM||Anti-P. aeruginosa ATCC 10145, activity value is MIC = 128 uM||Anti-A. baumannii ATCC BAA-1605, activity value is MIC = 32 uM||Anti-A. baumannii ATCC 19606, activity value is MIC = 16 uM||Anti-A. baumannii ATCC BAA-747, activity value is MIC = 64 uM||Anti-A. baumannii NR-9667, activity value is MIC = 32 uM||Anti-A. baumannii NR-13374, activity value is MIC = 32 uM||Anti-A. baumannii NR-13375, activity value is MIC = 32 uM||Anti-A. baumannii NR-13382, activity value is MIC = 32 uM||Anti-A. baumannii NR-17777, activity value is MIC = 16 uM||Anti-A. baumannii NR-17778, activity value is MIC = 16 uM||Anti-A. baumannii NR-17780, activity value is MIC = 32 uM||Anti-A. baumannii NR-17783, activity value is MIC = 32 uM||Anti-A. baumannii NR-17784, activity value is MIC = 64 uM||Anti-A. baumannii NR-17785, activity value is MIC = 32 uM||Anti-A. baumannii NR-17786, activity value is MIC = 16 uM||Anti-A. baumannii NR-19298, activity value is MIC = 32 uM||Anti-A. baumannii NR-19299, activity value is MIC = 64 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1109, activity value is MIC = 128 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1125, activity value is MIC = 128 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1571, activity value is MIC = 128 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1603, activity value is MIC = 128 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1020, activity value is MIC = 128 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1133, activity value is MIC = 64 uM||Anti-colistin-resistant P. aeruginosa Clinical isolate 1131, activity value is MIC = 128 uM||Anti-Candida albicans, activity value is MIC > 100 uM	designed, man-made sequences|||designed, man-made sequences|||Synthetic construct|||Synthetic construct|||designed, man-made sequences	N/A	"The core data related to the antimicrobial peptides RRIKA and RR hemolysis in this document are reflected through hemolysis rates, with the specific information as follows:

1. Core Hemolytic Values (Hemolysis Rate)

The experiment was conducted using human red blood cells, with PBS as the blank control (0% hemolysis), 0.1% Triton X-100 and 5 µM melittin as the complete hemolysis positive control (100% hemolysis). Hemolysis rates were calculated by measuring the absorbance at 405 nm, and the results were as follows:

- RRIKA and RR: At the highest tested concentration of 300 µM, the hemolysis rate was very low, with a maximum of only 10% (Figure 8), and no concentration-dependent hemolysis enhancement trend was observed, indicating high safety for human red blood cells.

- Positive control comparison: 5 µM melittin could cause 100% hemolysis, whereas RRIKA and RR showed no significant hemolysis even at 300 µM (far exceeding their effective antimicrobial concentrations, RRIKA MIC 2–4 µM, RR MIC 8–32 µM), demonstrating a significant safety advantage.

2. Supplementary Notes

- The text does not mention the ""HC₅₀ (peptide concentration causing 50% hemolysis)"" value. Since the hemolysis rates of RRIKA and RR at the highest tested concentration (300 µM) were both <10%, far from 50% hemolysis, HC₅₀ is >300 µM.

- Consistency of hemolysis safety with cytotoxicity: Concurrent HeLa cell cytotoxicity experiments showed that RRIKA at 32 µM (8×MIC) and RR at 64 µM (4×MIC) showed no significant toxicity to mammalian cells (cell survival rate >80%, Figure 9), consistent with their low hemolytic characteristics, further validating their low risk of damage to eukaryotic cells.

- Clinical application potential: The low hemolysis feature, combined with salt resistance (stable antimicrobial activity under physiological NaCl/Mg²⁺ concentrations) and anti-biofilm activity, supports RRIKA and RR as candidate peptides for local treatment of MRSA infections (such as skin infections), especially in scenarios where hemolysis risk needs to be avoided.|||designed, man-made sequences||At concentrations as high as 300 uM, the hemolytic effect on human red blood cells is minimal (with a maximum hemolysis rate of 10%).|||low level (~10%) hemolysis at 300 uM. low hemo.lytic. Not toxic to Hela cells at 4-8-fold antimicrobial concentrations.|||According to the provided document, the text clearly mentions hemolytic data for two target peptides (RRIKA, RR) and control substances (melittin, Triton X-100), as detailed below:

1. Target Peptides (RRIKA, RR)

Test Conditions: Human red blood cells (RBCs) were used as the experimental subject. Peptide solutions were prepared in PBS and incubated at 37°C for 1 hour. Hemolysis was calculated by measuring the absorbance at 405 nm (OD₄₀₅); PBS served as the 0% hemolysis negative control, while 0.1% Triton X-100 or 5 μM melittin was used as the 100% hemolysis positive control.
Hemolytic Results:
Both peptides exhibited very low hemolytic activity even at the maximum tested concentration of 300 μM, with a hemolysis rate not exceeding 10%.
Even at concentrations dozens of times higher than their antibacterial concentrations (MIC for RRIKA is 2-4 μM, MIC for RR is 8-32 μM), no significant hemolytic effects were observed.

2. Control Substances

Melittin: As a typical hemolysis positive control, 5 μM concentration can cause 100% hemolysis of human red blood cells, showing a sharp contrast with the target peptides.
Triton X-100: At 0.1% concentration, it serves as a 100% hemolysis positive control and is used to calibrate hemolysis calculation standards.

In summary, RRIKA and RR maintain low hemolytic activity both within their effective antibacterial concentration range and at high concentrations (300 μM), with safety significantly superior to traditional hemolytic peptides such as melittin.|||At concentrations as high as 300 uM, the hemolytic effect on human red blood cells is minimal (with a maximum hemolysis rate of 10%)."	"Antimicrob Agents Chemother
. 2014 Jul;58(7):4113-22. doi: 10.1128/AAC.02578-14. Epub 2014 May 5.|||Antimicrob Agents Chemother. 2014 Jul;58(7):4113-22. doi: 10.1128/AAC.02578-14. Pub-Med.|||Antimicrob Agents Chemother. 2014 Jul;58(7):4113-22. doi: 10.1128/AAC.02578-14. Pub-Med.|||28761101|||Antimicrob Agents Chemother. 2014 Jul;58(7):4113-22. doi: 10.1128/AAC.02578-14. Pub-Med.|||https://pubmed.ncbi.nlm.nih.gov/28105725|||Antimicrob Agents Chemother. 2014 Jul;58(7):4113-22. doi: 10.1128/AAC.02578-14. Pub-Med."	11	
FPDB01157	AP03663|||AP03663|||WD2	"	
WRPGRWWRPGRW"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli ATCC 25922 or 1005, activity value is MIC = 2||Anti-S. typhimurium 7731, activity value is MIC = 8 uM||Anti-S. aureus ATCC 29213 or 43300 MRSA, activity value is MIC = 4 uM||Anti-B. subtilis 63501, activity value is MIC = 2 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 2 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 4 uM||Anti-Escherichia coli UB1005, activity value is MIC = 8 uM||Anti-Salmonella enterica subsp. enterica serovar Typhimurium C77-31, activity value is MIC = 8 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 4 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 32 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 8 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 4 uM||Anti-Bacillus subtilis CMCC 63501, activity value is MIC = 2 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 1 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 128 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 16 uM	de novo designed, man-made sequences|||de novo designed, man-made sequences|||Synthetic construct	N/A	6mbg4vodxmpefe38583k|||de novo designed, man-made sequences||At a concentration of 256 uM, its hemolysis rate on human red blood cells is <5%.|||Human erythrocytes (5% Hemolysis at >256 uM, Human erythrocytes (5% Hemolysis at >256 uM|||At a concentration of 256 uM, its hemolysis rate on human red blood cells is <5%.	"Acta Biomater
. 2016 Jan:30:78-93. doi: 10.1016/j.actbio.2015.11.002. Epub 2015 Nov 3.|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med.|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med.|||26546414|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med."	12	
FPDB01158	AP03664|||AP03664|||WD3	"	
WRPGRWWRPGRWWRPGRW"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli ATCC 25922 or 1005, activity value is MIC = 2||Anti-S. typhimurium 7731, activity value is MIC = 4 uM||Anti-S. aureus ATCC 29213 or 43300 MRSA, activity value is MIC = 2||Anti-B. subtilis 63501, activity value is MIC = 2 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 2 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 4 uM||Anti-Escherichia coli UB1005, activity value is MIC = 8 uM||Anti-Salmonella enterica subsp. enterica serovar Typhimurium C77-31, activity value is MIC = 4 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 4 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 2 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 2 uM||Anti-Bacillus subtilis CMCC 63501, activity value is MIC = 2 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 1 uM||Anti-Escherichia coli UB1005, activity value is MIC = 2 uM||Anti-Salmonella enterica subsp. enterica serovar Typhimurium C77-31, activity value is MIC = 2 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 8 uM||Anti-Bacillus subtilis CMCC 63501, activity value is MIC = 4 uM	de novo designed, man-made sequences|||de novo designed, man-made sequences|||Synthetic construct	N/A	6mbg4vodxmpefe38583k|||de novo designed, man-made sequences||At a concentration of 64 uM, it can cause 5% hemolysis of human red blood cells.|||Human erythrocytes (5% Hemolysis at 64 uM, Human erythrocytes (5% Hemolysis at 128 uM|||At a concentration of 64 uM, it can cause 5% hemolysis of human red blood cells.	"Acta Biomater
. 2016 Jan:30:78-93. doi: 10.1016/j.actbio.2015.11.002. Epub 2015 Nov 3.|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med.|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med.|||26546414|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med."	18	
FPDB01159	AP03665|||AP03665|||WN2	"	
WRNGRWWRNGRW"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli ATCC 25922 or 1005, activity value is MIC = 8||Anti-S. typhimurium 7731, activity value is MIC = 16 uM||Anti-S. aureus ATCC 29213 or 43300 MRSA, activity value is MIC = 8 uM||Anti-B. subtilis 63501, activity value is MIC = 8 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 8 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 4 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 2 uM||Anti-Escherichia coli UB1005, activity value is MIC = 16 uM||Anti-Salmonella enterica subsp. enterica serovar Typhimurium C77-31, activity value is MIC = 16 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 8 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 64 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 32 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 16 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 8 uM||Anti-Bacillus subtilis CMCC 63501, activity value is MIC = 8 uM	de novo designed, man-made sequences|||de novo designed, man-made sequences|||Synthetic construct	N/A	6mbg4vodxmpefe38583k|||de novo designed, man-made sequences||At a concentration of 256 uM, its hemolysis rate on human red blood cells is <5%.|||Human erythrocytes (5% Hemolysis at >256 uM|||At a concentration of 256 uM, its hemolysis rate on human red blood cells is <5%.	"Acta Biomater
. 2016 Jan:30:78-93. doi: 10.1016/j.actbio.2015.11.002. Epub 2015 Nov 3.|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med.|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med.|||26546414|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med."	12	
FPDB01160	AP03666|||AP03666|||WN3	"	
WRNGRWWRNGRWWRNGRW"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli ATCC 25922 or 1005, activity value is MIC = 2||Anti-S. typhimurium 7731, activity value is MIC = 4 uM||Anti-S. aureus ATCC 29213 or 43300 MRSA, activity value is MIC = 2||Anti-B. subtilis 63501, activity value is MIC = 4 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 2 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 1 uM||Anti-Escherichia coli UB1005, activity value is MIC = 8 uM||Anti-Salmonella enterica subsp. enterica serovar Typhimurium C77-31, activity value is MIC = 4 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 4 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 8 uM||Anti-Staphylococcus aureus ATCC 29213, activity value is MIC = 2 uM||Anti-Staphylococcus aureus ATCC 43300, activity value is MIC = 2 uM||Anti-Bacillus subtilis CMCC 63501, activity value is MIC = 4 uM	de novo designed, man-made sequences|||de novo designed, man-made sequences|||Synthetic construct	N/A	6mbg4vodxmpefe38583k|||de novo designed, man-made sequences||At a concentration of 256 uM, its hemolysis rate on human red blood cells is <5%.|||Human erythrocytes (5% Hemolysis at >256 uM|||At a concentration of 256 uM, its hemolysis rate on human red blood cells is <5%.	"Acta Biomater
. 2016 Jan:30:78-93. doi: 10.1016/j.actbio.2015.11.002. Epub 2015 Nov 3.|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med.|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med.|||26546414|||Acta Biomater. 2016 Jan;30:78-93. doi: 10.1016/j.actbio.2015.11.002. Pub-Med."	18	
FPDB01161	AP03667	"	
VGQFLGKIIKKVGNFVKGFSKVF"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram+ S. aureus 930918-3 or 30371 MRSA or 28841 MRSA, activity value is MIC = 2.5||Anti-E. faecalis CDC 21, activity value is MIC = 2.6 ug/ml||Anti-E. faecium 94-132, activity value is MIC = 0.3||Anti-L. monocytogenes EGD, activity value is MIC = 0.4 ug/ml||Anti-E. coli ML-35p or mcr 106 or BAS 849, activity value is MIC = 0.4||Anti-S. typhimurium 14028S or 7953S, activity value is MIC = 1.3||Anti-K. pneumoniae 2270, activity value is MIC = 2.8 ug/ml||Anti-P. aeruginosa SBI-N or MR2123 or MR3007, activity value is MIC = 0.7	amino acid substitution, invertebrate, animal-derived, natural derivative	N/A	amino acid substitution, invertebrate, animal-derived, natural derivative	"Infect Immun
. 1997 Jul;65(7):2898-903. doi: 10.1128/iai.65.7.2898-2903.1997.|||Infect Immun. 1997 Jul;65(7):2898-903. doi: 10.1128/iai.65.7.2898-2903.1997. Pub-Med.|||Infect Immun. 1997 Jul;65(7):2898-903. doi: 10.1128/iai.65.7.2898-2903.1997. Pub-Med.|||Infect Immun. 1997 Jul;65(7):2898-903. doi: 10.1128/iai.65.7.2898-2903.1997. Pub-Med."	23	
FPDB01162	AP03688|||AP03688|||RL2	"	
RLRLWRLRLCTKSIPPIC"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. coli ATCC 25922 or UB1005 or K88 or K99 strains, activity value is MIC = 4||Anti-S. pullorum 7913, activity value is MIC = 4 uM||Anti-S. enterica serovar Typhimurium C7731 or 14208, activity value is MIC = 16 uM||Anti-P. aeruginosa 27853, activity value is MIC = 16 uM||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-S. aureus ATCC 29213 or 29523 or MRSA 43300, activity value is MIC = 16||Anti-S. epidermidis 12228, activity value is MIC = 64 uM||Anti-and E. faecalis 29212, activity value is MIC = 32 uM||Anti-E. coli ATCC 25922, activity value is MIC = 8 uM||Anti-E. coli UB 1005, activity value is MIC = 4 uM||Anti-E. coli K88, activity value is MIC = 4 uM||Anti-E. coli K99, activity value is MIC = 4 uM||Anti-S. typhimurium C7731, activity value is MIC = 16 uM||Anti-S. typhimurium 14208, activity value is MIC = 16 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 16 uM||Anti-S. aureus 29213, activity value is MIC = 16 uM||Anti-S. aureus 25923, activity value is MIC = 64 uM||Anti-MRSA 43300, activity value is MIC = 32 uM||Anti-S. epidermis 12228, activity value is MIC = 64 uM||Anti-S. faecalis 29212, activity value is MIC = 32 uM	amino acid substitution, de novo designed, man-made sequences|||amino acid substitution, de novo designed, man-made sequences|||Synthetic construct	N/A	"II. Document 2 (SFTI-1 binding ring design related to antimicrobial peptides): Hemolytic values (hemolysis rate and MHC)
 
The experiment used human red blood cells (hRBCs) as the test subject, employing PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 570 nm. The core data are as follows: 
 
1. Minimum hemolytic concentration (MHC)
 
Refers to the lowest peptide concentration that causes 10% hemolysis; the higher the value, the lower the risk of hemolysis (Table 3): 
 
- Low hemolytic risk peptide (MHC>128 uM): RA2, RI2, RL2, RV2, RW2, RL3, RV3, RV; at the highest test concentration of 128 uM, hemolytic rate <10%, no significant hemolytic activity. 

- Moderately high-risk peptide (MHC=32 uM): RF3, RW3, hemolysis rate reaches 10% at 32 uM, below this concentration <10%. 

- High-risk hemolytic peptide (MHC=8 uM): RI3, at 8 uM, hemolysis rate reaches 10%, indicating a higher risk of hemolysis. 

- Positive control (ME, methamphetamine): MHC = 4 uM (at 4 uM, 10% hemolysis occurs, with a much higher risk than all designed peptides). 
 
2. Hemolytic characteristics of key peptides (RV3).
 
- RV3 (core research peptide, sequence: RVRVRVWRVRVRVCTKSIPPIC): 

- MHC > 128 uM (hemolysis rate at 128 uM <10%), with no significant hemolysis even at 256 uM (much higher than its effective antimicrobial concentration MIC=1.64 uM). 

- The treatment index (TI, the ratio of MHC to the geometric mean of antimicrobial activity) was highest (TIₐll=156.03), which was 104.7 times higher than the positive control ME (TI=1.49), demonstrating high cell selectivity (strong antibacterial activity and low erythrocytotoxicity). 
 
3. High concentration hemolysis rate of other peptides
 
- At 128 uM concentration, the hemolysis rates of RI3 were about 47%, RF3 about 40%, RW3 about 14%, and other residual peptides (such as RA2, RV2, RV3) were all < 10% (Figure 2a), consistent with MHC results. 
 
Additional notes
 
- Document 1 does not involve safety evaluation in the research direction, so no hemolytic data are available; Document 2 clarifies the hemolysis risk of the designed peptide through MHC and hemolysis rates. Among them, RV3 has clinical application potential due to low hemolysis, high antibacterial activity, and enzyme stability (e.g., for skin infection treatment). 

- Hemolytic activity and peptide structure association: Peptides containing tryptophan (W) and phenylalanine (F) (such as RW3, RF3) have a slightly higher risk of hemolysis than those containing valine (V) and leucine (L) (such as RV3, RL3), which is presumed to be related to differences in hydrophobicity and membrane insertion ability.|||10% hemolysis concentration > 128 uM (poor hemo.lytic).|||hRBC, <10% hemolysis at concentration tested"	"Acta Biomater
. 2021 Apr 1:124:254-269. doi: 10.1016/j.actbio.2021.01.036. Epub 2021 Jan 27.|||Acta Biomater. 2021 Apr 1;124:254-269. doi: 10.1016/j.actbio.2021.01.036. Pub-Med.|||33508505"	18	
FPDB01163	AP03690|||AP03690|||RF2	"	
RFRFWRFRFCTKSIPPIC"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. coli ATCC 25922 or UB1005 or K88 or K99 strains, activity value is MIC = 2||Anti-S. pullorum 7913, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium C7731 or 14208, activity value is MIC = 4 uM||Anti-P. aeruginosa 27853, activity value is MIC = 4 uM||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-S. aureus ATCC 29213 or 29523 or MRSA 43300, activity value is MIC = 4||Anti-S. epidermidis 12228, activity value is MIC = 8 uM||Anti-and E. faecalis 29212, activity value is MIC = 4 uM||Anti-E. coli ATCC 25922, activity value is MIC = 4 uM||Anti-E. coli UB 1005, activity value is MIC = 2 uM||Anti-E. coli K88, activity value is MIC = 4 uM||Anti-E. coli K99, activity value is MIC = 4 uM||Anti-S. typhimurium C7731, activity value is MIC = 4 uM||Anti-S. typhimurium 14208, activity value is MIC = 4 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 4 uM||Anti-S. aureus 29213, activity value is MIC = 8 uM||Anti-S. aureus 25923, activity value is MIC = 32 uM||Anti-MRSA 43300, activity value is MIC = 4 uM||Anti-S. epidermis 12228, activity value is MIC = 8 uM||Anti-S. faecalis 29212, activity value is MIC = 4 uM	amino acid substitution, de novo designed, man-made sequences|||amino acid substitution, de novo designed, man-made sequences|||Synthetic construct	N/A	"II. Document 2 (SFTI-1 binding ring design related to antimicrobial peptides): Hemolytic values (hemolysis rate and MHC)
 
The experiment used human red blood cells (hRBCs) as the test subject, employing PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 570 nm. The core data are as follows: 
 
1. Minimum hemolytic concentration (MHC)
 
Refers to the lowest peptide concentration that causes 10% hemolysis; the higher the value, the lower the risk of hemolysis (Table 3): 
 
- Low hemolytic risk peptide (MHC>128 uM): RA2, RI2, RL2, RV2, RW2, RL3, RV3, RV; at the highest test concentration of 128 uM, hemolytic rate <10%, no significant hemolytic activity. 

- Moderately high-risk peptide (MHC=32 uM): RF3, RW3, hemolysis rate reaches 10% at 32 uM, below this concentration <10%. 

- High-risk hemolytic peptide (MHC=8 uM): RI3, at 8 uM, hemolysis rate reaches 10%, indicating a higher risk of hemolysis. 

- Positive control (ME, methamphetamine): MHC = 4 uM (at 4 uM, 10% hemolysis occurs, with a much higher risk than all designed peptides). 
 
2. Hemolytic characteristics of key peptides (RV3).
 
- RV3 (core research peptide, sequence: RVRVRVWRVRVRVCTKSIPPIC): 

- MHC > 128 uM (hemolysis rate at 128 uM <10%), with no significant hemolysis even at 256 uM (much higher than its effective antimicrobial concentration MIC=1.64 uM). 

- The treatment index (TI, the ratio of MHC to the geometric mean of antimicrobial activity) was highest (TIₐll=156.03), which was 104.7 times higher than the positive control ME (TI=1.49), demonstrating high cell selectivity (strong antibacterial activity and low erythrocytotoxicity). 
 
3. High concentration hemolysis rate of other peptides
 
- At 128 uM concentration, the hemolysis rates of RI3 were about 47%, RF3 about 40%, RW3 about 14%, and other residual peptides (such as RA2, RV2, RV3) were all < 10% (Figure 2a), consistent with MHC results. 
 
Additional notes
 
- Document 1 does not involve safety evaluation in the research direction, so no hemolytic data are available; Document 2 clarifies the hemolysis risk of the designed peptide through MHC and hemolysis rates. Among them, RV3 has clinical application potential due to low hemolysis, high antibacterial activity, and enzyme stability (e.g., for skin infection treatment). 

- Hemolytic activity and peptide structure association: Peptides containing tryptophan (W) and phenylalanine (F) (such as RW3, RF3) have a slightly higher risk of hemolysis than those containing valine (V) and leucine (L) (such as RV3, RL3), which is presumed to be related to differences in hydrophobicity and membrane insertion ability.|||10% hemolysis concentration > 128 uM (poor hemo.lytic).|||hRBC, <10% hemolysis at concentration tested"	"Acta Biomater
. 2021 Apr 1:124:254-269. doi: 10.1016/j.actbio.2021.01.036. Epub 2021 Jan 27.|||Acta Biomater. 2021 Apr 1;124:254-269. doi: 10.1016/j.actbio.2021.01.036. Pub-Med.|||33508505"	18	
FPDB01164	AP03691|||AP03691|||RW2	"	
RWRWWRWRWCTKSIPPIC"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. coli ATCC 25922 or UB1005 or K88 or K99 strains, activity value is MIC = 4 uM||Anti-S. pullorum 7913, activity value is MIC = 4 uM||Anti-S. enterica serovar Typhimurium C7731 or 14208, activity value is MIC = 4||Anti-P. aeruginosa 27853, activity value is MIC = 8 uM||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-S. aureus ATCC 29213 or 29523 or MRSA 43300, activity value is MIC = 4 uM||Anti-S. epidermidis 12228, activity value is MIC = 4 uM||Anti-and E. faecalis 29212, activity value is MIC = 2 uM||Anti-E. coli ATCC 25922, activity value is MIC = 4 uM||Anti-E. coli UB 1005, activity value is MIC = 4 uM||Anti-E. coli K88, activity value is MIC = 4 uM||Anti-E. coli K99, activity value is MIC = 4 uM||Anti-S. typhimurium C7731, activity value is MIC = 4 uM||Anti-S. typhimurium 14208, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 8 uM||Anti-S. aureus 29213, activity value is MIC = 4 uM||Anti-S. aureus 25923, activity value is MIC = 4 uM||Anti-MRSA 43300, activity value is MIC = 4 uM||Anti-S. epidermis 12228, activity value is MIC = 4 uM||Anti-S. faecalis 29212, activity value is MIC = 2 uM	amino acid substitution, de novo designed, man-made sequences|||amino acid substitution, de novo designed, man-made sequences|||Synthetic construct	N/A	"II. Document 2 (SFTI-1 binding ring design related to antimicrobial peptides): Hemolytic values (hemolysis rate and MHC)
 
The experiment used human red blood cells (hRBCs) as the test subject, employing PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 570 nm. The core data are as follows: 
 
1. Minimum hemolytic concentration (MHC)
 
Refers to the lowest peptide concentration that causes 10% hemolysis; the higher the value, the lower the risk of hemolysis (Table 3): 
 
- Low hemolytic risk peptide (MHC>128 uM): RA2, RI2, RL2, RV2, RW2, RL3, RV3, RV; at the highest test concentration of 128 uM, hemolytic rate <10%, no significant hemolytic activity. 

- Moderately high-risk peptide (MHC=32 uM): RF3, RW3, hemolysis rate reaches 10% at 32 uM, below this concentration <10%. 

- High-risk hemolytic peptide (MHC=8 uM): RI3, at 8 uM, hemolysis rate reaches 10%, indicating a higher risk of hemolysis. 

- Positive control (ME, methamphetamine): MHC = 4 uM (at 4 uM, 10% hemolysis occurs, with a much higher risk than all designed peptides). 
 
2. Hemolytic characteristics of key peptides (RV3).
 
- RV3 (core research peptide, sequence: RVRVRVWRVRVRVCTKSIPPIC): 

- MHC > 128 uM (hemolysis rate at 128 uM <10%), with no significant hemolysis even at 256 uM (much higher than its effective antimicrobial concentration MIC=1.64 uM). 

- The treatment index (TI, the ratio of MHC to the geometric mean of antimicrobial activity) was highest (TIₐll=156.03), which was 104.7 times higher than the positive control ME (TI=1.49), demonstrating high cell selectivity (strong antibacterial activity and low erythrocytotoxicity). 
 
3. High concentration hemolysis rate of other peptides
 
- At 128 uM concentration, the hemolysis rates of RI3 were about 47%, RF3 about 40%, RW3 about 14%, and other residual peptides (such as RA2, RV2, RV3) were all < 10% (Figure 2a), consistent with MHC results. 
 
Additional notes
 
- Document 1 does not involve safety evaluation in the research direction, so no hemolytic data are available; Document 2 clarifies the hemolysis risk of the designed peptide through MHC and hemolysis rates. Among them, RV3 has clinical application potential due to low hemolysis, high antibacterial activity, and enzyme stability (e.g., for skin infection treatment). 

- Hemolytic activity and peptide structure association: Peptides containing tryptophan (W) and phenylalanine (F) (such as RW3, RF3) have a slightly higher risk of hemolysis than those containing valine (V) and leucine (L) (such as RV3, RL3), which is presumed to be related to differences in hydrophobicity and membrane insertion ability.|||10% hemolysis concentration > 128 uM (poor hemo.lytic).|||hRBC, <10% hemolysis at concentration tested"	"Acta Biomater
. 2021 Apr 1:124:254-269. doi: 10.1016/j.actbio.2021.01.036. Epub 2021 Jan 27.|||Acta Biomater. 2021 Apr 1;124:254-269. doi: 10.1016/j.actbio.2021.01.036. Pub-Med.|||33508505"	18	
FPDB01165	AP03692|||AP03692|||RI3	"	
RIRIRIWRIRIRICTKSIPPIC"	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-Gram- E. coli ATCC 25922 or UB1005 or K88 or K99 strains, activity value is MIC = 2||Anti-S. pullorum 7913, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium C7731 or 14208, activity value is MIC = 4 uM||Anti-P. aeruginosa 27853, activity value is MIC = 4 uM||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-S. aureus ATCC 29213 or 29523 or MRSA 43300, activity value is MIC = 16||Anti-S. epidermidis 12228, activity value is MIC = 8 uM||Anti-and E. faecalis 29212, activity value is MIC = 16 uM||Antibacterial	amino acid substitution, de novo designed, man-made sequences|||amino acid substitution, de novo designed, man-made sequences|||Synthetic construct	N/A	"II. Document 2 (SFTI-1 binding ring design related to antimicrobial peptides): Hemolytic values (hemolysis rate and MHC)
 
The experiment used human red blood cells (hRBCs) as the test subject, employing PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 570 nm. The core data are as follows: 
 
1. Minimum hemolytic concentration (MHC)
 
Refers to the lowest peptide concentration that causes 10% hemolysis; the higher the value, the lower the risk of hemolysis (Table 3): 
 
- Low hemolytic risk peptide (MHC>128 uM): RA2, RI2, RL2, RV2, RW2, RL3, RV3, RV; at the highest test concentration of 128 uM, hemolytic rate <10%, no significant hemolytic activity. 

- Moderately high-risk peptide (MHC=32 uM): RF3, RW3, hemolysis rate reaches 10% at 32 uM, below this concentration <10%. 

- High-risk hemolytic peptide (MHC=8 uM): RI3, at 8 uM, hemolysis rate reaches 10%, indicating a higher risk of hemolysis. 

- Positive control (ME, methamphetamine): MHC = 4 uM (at 4 uM, 10% hemolysis occurs, with a much higher risk than all designed peptides). 
 
2. Hemolytic characteristics of key peptides (RV3).
 
- RV3 (core research peptide, sequence: RVRVRVWRVRVRVCTKSIPPIC): 

- MHC > 128 uM (hemolysis rate at 128 uM <10%), with no significant hemolysis even at 256 uM (much higher than its effective antimicrobial concentration MIC=1.64 uM). 

- The treatment index (TI, the ratio of MHC to the geometric mean of antimicrobial activity) was highest (TIₐll=156.03), which was 104.7 times higher than the positive control ME (TI=1.49), demonstrating high cell selectivity (strong antibacterial activity and low erythrocytotoxicity). 
 
3. High concentration hemolysis rate of other peptides
 
- At 128 uM concentration, the hemolysis rates of RI3 were about 47%, RF3 about 40%, RW3 about 14%, and other residual peptides (such as RA2, RV2, RV3) were all < 10% (Figure 2a), consistent with MHC results. 
 
Additional notes
 
- Document 1 does not involve safety evaluation in the research direction, so no hemolytic data are available; Document 2 clarifies the hemolysis risk of the designed peptide through MHC and hemolysis rates. Among them, RV3 has clinical application potential due to low hemolysis, high antibacterial activity, and enzyme stability (e.g., for skin infection treatment). 

- Hemolytic activity and peptide structure association: Peptides containing tryptophan (W) and phenylalanine (F) (such as RW3, RF3) have a slightly higher risk of hemolysis than those containing valine (V) and leucine (L) (such as RV3, RL3), which is presumed to be related to differences in hydrophobicity and membrane insertion ability.|||10% hemo-lytic concentration 8 uM.|||hRBC, 47.12% hemolysis at 128 uM"	"Acta Biomater
. 2021 Apr 1:124:254-269. doi: 10.1016/j.actbio.2021.01.036. Epub 2021 Jan 27.|||Acta Biomater. 2021 Apr 1;124:254-269. doi: 10.1016/j.actbio.2021.01.036. Pub-Med.|||33508505"	22	
FPDB01166	AP03693|||AP03693|||RL3	"	
RLRLRLWRLRLRLCTKSIPPIC"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. coli ATCC 25922 or UB1005 or K88 or K99 strains, activity value is MIC = 2||Anti-S. pullorum 7913, activity value is MIC = 8 uM||Anti-S. enterica serovar Typhimurium C7731 or 14208, activity value is MIC = 2||Anti-P. aeruginosa 27853, activity value is MIC = 16 uM||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-S. aureus ATCC 29213 or 29523 or MRSA 43300, activity value is MIC = 4||Anti-S. epidermidis 12228, activity value is MIC = 16 uM||Anti-and E. faecalis 29212, activity value is MIC = 32 uM||Antibacterial	amino acid substitution, de novo designed, man-made sequences|||amino acid substitution, de novo designed, man-made sequences|||Synthetic construct	N/A	"II. Document 2 (SFTI-1 binding ring design related to antimicrobial peptides): Hemolytic values (hemolysis rate and MHC)
 
The experiment used human red blood cells (hRBCs) as the test subject, employing PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 570 nm. The core data are as follows: 
 
1. Minimum hemolytic concentration (MHC)
 
Refers to the lowest peptide concentration that causes 10% hemolysis; the higher the value, the lower the risk of hemolysis (Table 3): 
 
- Low hemolytic risk peptide (MHC>128 uM): RA2, RI2, RL2, RV2, RW2, RL3, RV3, RV; at the highest test concentration of 128 uM, hemolytic rate <10%, no significant hemolytic activity. 

- Moderately high-risk peptide (MHC=32 uM): RF3, RW3, hemolysis rate reaches 10% at 32 uM, below this concentration <10%. 

- High-risk hemolytic peptide (MHC=8 uM): RI3, at 8 uM, hemolysis rate reaches 10%, indicating a higher risk of hemolysis. 

- Positive control (ME, methamphetamine): MHC = 4 uM (at 4 uM, 10% hemolysis occurs, with a much higher risk than all designed peptides). 
 
2. Hemolytic characteristics of key peptides (RV3).
 
- RV3 (core research peptide, sequence: RVRVRVWRVRVRVCTKSIPPIC): 

- MHC > 128 uM (hemolysis rate at 128 uM <10%), with no significant hemolysis even at 256 uM (much higher than its effective antimicrobial concentration MIC=1.64 uM). 

- The treatment index (TI, the ratio of MHC to the geometric mean of antimicrobial activity) was highest (TIₐll=156.03), which was 104.7 times higher than the positive control ME (TI=1.49), demonstrating high cell selectivity (strong antibacterial activity and low erythrocytotoxicity). 
 
3. High concentration hemolysis rate of other peptides
 
- At 128 uM concentration, the hemolysis rates of RI3 were about 47%, RF3 about 40%, RW3 about 14%, and other residual peptides (such as RA2, RV2, RV3) were all < 10% (Figure 2a), consistent with MHC results. 
 
Additional notes
 
- Document 1 does not involve safety evaluation in the research direction, so no hemolytic data are available; Document 2 clarifies the hemolysis risk of the designed peptide through MHC and hemolysis rates. Among them, RV3 has clinical application potential due to low hemolysis, high antibacterial activity, and enzyme stability (e.g., for skin infection treatment). 

- Hemolytic activity and peptide structure association: Peptides containing tryptophan (W) and phenylalanine (F) (such as RW3, RF3) have a slightly higher risk of hemolysis than those containing valine (V) and leucine (L) (such as RV3, RL3), which is presumed to be related to differences in hydrophobicity and membrane insertion ability.|||10% hemolysis concentration > 128 uM (poor hemo.lytic).|||hRBC, <10% hemolysis at concentration tested"	"Acta Biomater
. 2021 Apr 1:124:254-269. doi: 10.1016/j.actbio.2021.01.036. Epub 2021 Jan 27.|||Acta Biomater. 2021 Apr 1;124:254-269. doi: 10.1016/j.actbio.2021.01.036. Pub-Med.|||33508505"	22	
FPDB01167	AP03694|||AP03694|||RV3	RVRVRVWRVRVRVCTKSIPPIC	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. coli ATCC 25922 or UB1005 or K88 or K99 strains, activity value is MIC = 1||Anti-S. pullorum 7913, activity value is MIC = 1 uM||Anti-S. enterica serovar Typhimurium C7731 or 14208, activity value is MIC = 2 uM||Anti-P. aeruginosa 27853, activity value is MIC = 2 uM||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-S. aureus ATCC 29213 or 29523 or MRSA 43300, activity value is MIC = 2||Anti-S. epidermidis 12228, activity value is MIC = 2 uM||Anti-and E. faecalis 29212, activity value is MIC = 2 uM||Antibacterial	amino acid substitution, de novo designed, man-made sequences|||amino acid substitution, de novo designed, man-made sequences|||Synthetic construct	N/A	"II. Document 2 (SFTI-1 binding ring design related to antimicrobial peptides): Hemolytic values (hemolysis rate and MHC)
 
The experiment used human red blood cells (hRBCs) as the test subject, employing PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 570 nm. The core data are as follows: 
 
1. Minimum hemolytic concentration (MHC)
 
Refers to the lowest peptide concentration that causes 10% hemolysis; the higher the value, the lower the risk of hemolysis (Table 3): 
 
- Low hemolytic risk peptide (MHC>128 uM): RA2, RI2, RL2, RV2, RW2, RL3, RV3, RV; at the highest test concentration of 128 uM, hemolytic rate <10%, no significant hemolytic activity. 

- Moderately high-risk peptide (MHC=32 uM): RF3, RW3, hemolysis rate reaches 10% at 32 uM, below this concentration <10%. 

- High-risk hemolytic peptide (MHC=8 uM): RI3, at 8 uM, hemolysis rate reaches 10%, indicating a higher risk of hemolysis. 

- Positive control (ME, methamphetamine): MHC = 4 uM (at 4 uM, 10% hemolysis occurs, with a much higher risk than all designed peptides). 
 
2. Hemolytic characteristics of key peptides (RV3).
 
- RV3 (core research peptide, sequence: RVRVRVWRVRVRVCTKSIPPIC): 

- MHC > 128 uM (hemolysis rate at 128 uM <10%), with no significant hemolysis even at 256 uM (much higher than its effective antimicrobial concentration MIC=1.64 uM). 

- The treatment index (TI, the ratio of MHC to the geometric mean of antimicrobial activity) was highest (TIₐll=156.03), which was 104.7 times higher than the positive control ME (TI=1.49), demonstrating high cell selectivity (strong antibacterial activity and low erythrocytotoxicity). 
 
3. High concentration hemolysis rate of other peptides
 
- At 128 uM concentration, the hemolysis rates of RI3 were about 47%, RF3 about 40%, RW3 about 14%, and other residual peptides (such as RA2, RV2, RV3) were all < 10% (Figure 2a), consistent with MHC results. 
 
Additional notes
 
- Document 1 does not involve safety evaluation in the research direction, so no hemolytic data are available; Document 2 clarifies the hemolysis risk of the designed peptide through MHC and hemolysis rates. Among them, RV3 has clinical application potential due to low hemolysis, high antibacterial activity, and enzyme stability (e.g., for skin infection treatment). 

- Hemolytic activity and peptide structure association: Peptides containing tryptophan (W) and phenylalanine (F) (such as RW3, RF3) have a slightly higher risk of hemolysis than those containing valine (V) and leucine (L) (such as RV3, RL3), which is presumed to be related to differences in hydrophobicity and membrane insertion ability.|||10% hemolysis concentration > 128 uM (poor hemo.lytic).|||hRBC, <10% hemolysis at concentration tested"	"Acta Biomater
. 2021 Apr 1:124:254-269. doi: 10.1016/j.actbio.2021.01.036. Epub 2021 Jan 27.|||Acta Biomater. 2021 Apr 1;124:254-269. doi: 10.1016/j.actbio.2021.01.036. Pub-Med.|||33508505"	22	
FPDB01168	AP03695|||AP03695|||RF3	RFRFRFWRFRFRFCTKSIPPIC	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. coli ATCC 25922 or UB1005 or K88 or K99 strains, activity value is MIC = 1||Anti-S. pullorum 7913, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium C7731 or 14208, activity value is MIC = 2 uM||Anti-P. aeruginosa 27853, activity value is MIC = 2 uM||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-S. aureus ATCC 29213 or 29523 or MRSA 43300, activity value is MIC = 2||Anti-S. epidermidis 12228, activity value is MIC = 1 uM||Anti-and E. faecalis 29212, activity value is MIC = 1 uM||Antibacterial	amino acid substitution, de novo designed, man-made sequences|||amino acid substitution, de novo designed, man-made sequences|||Synthetic construct	N/A	"II. Document 2 (SFTI-1 binding ring design related to antimicrobial peptides): Hemolytic values (hemolysis rate and MHC)
 
The experiment used human red blood cells (hRBCs) as the test subject, employing PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 570 nm. The core data are as follows: 
 
1. Minimum hemolytic concentration (MHC)
 
Refers to the lowest peptide concentration that causes 10% hemolysis; the higher the value, the lower the risk of hemolysis (Table 3): 
 
- Low hemolytic risk peptide (MHC>128 uM): RA2, RI2, RL2, RV2, RW2, RL3, RV3, RV; at the highest test concentration of 128 uM, hemolytic rate <10%, no significant hemolytic activity. 

- Moderately high-risk peptide (MHC=32 uM): RF3, RW3, hemolysis rate reaches 10% at 32 uM, below this concentration <10%. 

- High-risk hemolytic peptide (MHC=8 uM): RI3, at 8 uM, hemolysis rate reaches 10%, indicating a higher risk of hemolysis. 

- Positive control (ME, methamphetamine): MHC = 4 uM (at 4 uM, 10% hemolysis occurs, with a much higher risk than all designed peptides). 
 
2. Hemolytic characteristics of key peptides (RV3).
 
- RV3 (core research peptide, sequence: RVRVRVWRVRVRVCTKSIPPIC): 

- MHC > 128 uM (hemolysis rate at 128 uM <10%), with no significant hemolysis even at 256 uM (much higher than its effective antimicrobial concentration MIC=1.64 uM). 

- The treatment index (TI, the ratio of MHC to the geometric mean of antimicrobial activity) was highest (TIₐll=156.03), which was 104.7 times higher than the positive control ME (TI=1.49), demonstrating high cell selectivity (strong antibacterial activity and low erythrocytotoxicity). 
 
3. High concentration hemolysis rate of other peptides
 
- At 128 uM concentration, the hemolysis rates of RI3 were about 47%, RF3 about 40%, RW3 about 14%, and other residual peptides (such as RA2, RV2, RV3) were all < 10% (Figure 2a), consistent with MHC results. 
 
Additional notes
 
- Document 1 does not involve safety evaluation in the research direction, so no hemolytic data are available; Document 2 clarifies the hemolysis risk of the designed peptide through MHC and hemolysis rates. Among them, RV3 has clinical application potential due to low hemolysis, high antibacterial activity, and enzyme stability (e.g., for skin infection treatment). 

- Hemolytic activity and peptide structure association: Peptides containing tryptophan (W) and phenylalanine (F) (such as RW3, RF3) have a slightly higher risk of hemolysis than those containing valine (V) and leucine (L) (such as RV3, RL3), which is presumed to be related to differences in hydrophobicity and membrane insertion ability.|||10% hemo-lytic concentration 32 uM.|||hRBC, 40.09% hemolysis at 128 uM"	"Acta Biomater
. 2021 Apr 1:124:254-269. doi: 10.1016/j.actbio.2021.01.036. Epub 2021 Jan 27.|||Acta Biomater. 2021 Apr 1;124:254-269. doi: 10.1016/j.actbio.2021.01.036. Pub-Med.|||33508505"	22	
FPDB01169	AP03696|||AP03696|||RW3	"	
RWRWRWWRWRWRWCTKSIPPIC"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. coli ATCC 25922 or UB1005 or K88 or K99 strains, activity value is MIC = 2 uM||Anti-S. pullorum 7913, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium C7731 or 14208, activity value is MIC = 2||Anti-P. aeruginosa 27853, activity value is MIC = 4 uM||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-S. aureus ATCC 29213 or 29523 or MRSA 43300, activity value is MIC = 2||Anti-S. epidermidis 12228, activity value is MIC = 2 uM||Anti-and E. faecalis 29212, activity value is MIC = 2 uM||Antibacterial	amino acid substitution, de novo designed, man-made sequences|||amino acid substitution, de novo designed, man-made sequences|||Synthetic construct	N/A	"II. Document 2 (SFTI-1 binding ring design related to antimicrobial peptides): Hemolytic values (hemolysis rate and MHC)
 
The experiment used human red blood cells (hRBCs) as the test subject, employing PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 570 nm. The core data are as follows: 
 
1. Minimum hemolytic concentration (MHC)
 
Refers to the lowest peptide concentration that causes 10% hemolysis; the higher the value, the lower the risk of hemolysis (Table 3): 
 
- Low hemolytic risk peptide (MHC>128 uM): RA2, RI2, RL2, RV2, RW2, RL3, RV3, RV; at the highest test concentration of 128 uM, hemolytic rate <10%, no significant hemolytic activity. 

- Moderately high-risk peptide (MHC=32 uM): RF3, RW3, hemolysis rate reaches 10% at 32 uM, below this concentration <10%. 

- High-risk hemolytic peptide (MHC=8 uM): RI3, at 8 uM, hemolysis rate reaches 10%, indicating a higher risk of hemolysis. 

- Positive control (ME, methamphetamine): MHC = 4 uM (at 4 uM, 10% hemolysis occurs, with a much higher risk than all designed peptides). 
 
2. Hemolytic characteristics of key peptides (RV3).
 
- RV3 (core research peptide, sequence: RVRVRVWRVRVRVCTKSIPPIC): 

- MHC > 128 uM (hemolysis rate at 128 uM <10%), with no significant hemolysis even at 256 uM (much higher than its effective antimicrobial concentration MIC=1.64 uM). 

- The treatment index (TI, the ratio of MHC to the geometric mean of antimicrobial activity) was highest (TIₐll=156.03), which was 104.7 times higher than the positive control ME (TI=1.49), demonstrating high cell selectivity (strong antibacterial activity and low erythrocytotoxicity). 
 
3. High concentration hemolysis rate of other peptides
 
- At 128 uM concentration, the hemolysis rates of RI3 were about 47%, RF3 about 40%, RW3 about 14%, and other residual peptides (such as RA2, RV2, RV3) were all < 10% (Figure 2a), consistent with MHC results. 
 
Additional notes
 
- Document 1 does not involve safety evaluation in the research direction, so no hemolytic data are available; Document 2 clarifies the hemolysis risk of the designed peptide through MHC and hemolysis rates. Among them, RV3 has clinical application potential due to low hemolysis, high antibacterial activity, and enzyme stability (e.g., for skin infection treatment). 

- Hemolytic activity and peptide structure association: Peptides containing tryptophan (W) and phenylalanine (F) (such as RW3, RF3) have a slightly higher risk of hemolysis than those containing valine (V) and leucine (L) (such as RV3, RL3), which is presumed to be related to differences in hydrophobicity and membrane insertion ability.|||10% hemo-lytic concentration 32 uM.|||hRBC, 14.32% hemolysis at 128 uM"	"Acta Biomater
. 2021 Apr 1:124:254-269. doi: 10.1016/j.actbio.2021.01.036. Epub 2021 Jan 27.|||Acta Biomater. 2021 Apr 1;124:254-269. doi: 10.1016/j.actbio.2021.01.036. Pub-Med.|||33508505"	22	
FPDB01170	AP03697|||AP03697|||RV	"	
RVRVRVWRVRVRV"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Gram- E. coli ATCC 25922 or UB1005 or K88 or K99 strains, activity value is MIC = 1||Anti-S. pullorum 7913, activity value is MIC = 2 uM||Anti-S. enterica serovar Typhimurium C7731 or 14208, activity value is MIC = 4 uM||Anti-P. aeruginosa 27853, activity value is MIC = 4 uM||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-S. aureus ATCC 29213 or 29523 or MRSA 43300, activity value is MIC = 4||Anti-S. epidermidis 12228, activity value is MIC = 4 uM||Anti-and E. faecalis 29212, activity value is MIC = 4 uM||Anti-E. coli ATCC 25922, activity value is MIC = 4 uM||Anti-E. coli UB 1005, activity value is MIC = 1 uM||Anti-E. coli K88, activity value is MIC = 4 uM||Anti-E. coli K99, activity value is MIC = 2 uM||Anti-S. typhimurium C7731, activity value is MIC = 4 uM||Anti-S. typhimurium 14208, activity value is MIC = 4 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 4 uM||Anti-S. aureus 29213, activity value is MIC = 2 uM||Anti-S. aureus 25923, activity value is MIC = 4 uM||Anti-MRSA 43300, activity value is MIC = 2 uM||Anti-S. epidermis 12228, activity value is MIC = 1 uM||Anti-S. faecalis 29212, activity value is MIC = 4 uM	amino acid substitution, de novo designed, man-made sequences|||Synthetic construct	N/A	"II. Document 2 (SFTI-1 binding ring design related to antimicrobial peptides): Hemolytic values (hemolysis rate and MHC)
 
The experiment used human red blood cells (hRBCs) as the test subject, employing PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring absorbance at 570 nm. The core data are as follows: 
 
1. Minimum hemolytic concentration (MHC)
 
Refers to the lowest peptide concentration that causes 10% hemolysis; the higher the value, the lower the risk of hemolysis (Table 3): 
 
- Low hemolytic risk peptide (MHC>128 uM): RA2, RI2, RL2, RV2, RW2, RL3, RV3, RV; at the highest test concentration of 128 uM, hemolytic rate <10%, no significant hemolytic activity. 

- Moderately high-risk peptide (MHC=32 uM): RF3, RW3, hemolysis rate reaches 10% at 32 uM, below this concentration <10%. 

- High-risk hemolytic peptide (MHC=8 uM): RI3, at 8 uM, hemolysis rate reaches 10%, indicating a higher risk of hemolysis. 

- Positive control (ME, methamphetamine): MHC = 4 uM (at 4 uM, 10% hemolysis occurs, with a much higher risk than all designed peptides). 
 
2. Hemolytic characteristics of key peptides (RV3).
 
- RV3 (core research peptide, sequence: RVRVRVWRVRVRVCTKSIPPIC): 

- MHC > 128 uM (hemolysis rate at 128 uM <10%), with no significant hemolysis even at 256 uM (much higher than its effective antimicrobial concentration MIC=1.64 uM). 

- The treatment index (TI, the ratio of MHC to the geometric mean of antimicrobial activity) was highest (TIₐll=156.03), which was 104.7 times higher than the positive control ME (TI=1.49), demonstrating high cell selectivity (strong antibacterial activity and low erythrocytotoxicity). 
 
3. High concentration hemolysis rate of other peptides
 
- At 128 uM concentration, the hemolysis rates of RI3 were about 47%, RF3 about 40%, RW3 about 14%, and other residual peptides (such as RA2, RV2, RV3) were all < 10% (Figure 2a), consistent with MHC results. 
 
Additional notes
 
- Document 1 does not involve safety evaluation in the research direction, so no hemolytic data are available; Document 2 clarifies the hemolysis risk of the designed peptide through MHC and hemolysis rates. Among them, RV3 has clinical application potential due to low hemolysis, high antibacterial activity, and enzyme stability (e.g., for skin infection treatment). 

- Hemolytic activity and peptide structure association: Peptides containing tryptophan (W) and phenylalanine (F) (such as RW3, RF3) have a slightly higher risk of hemolysis than those containing valine (V) and leucine (L) (such as RV3, RL3), which is presumed to be related to differences in hydrophobicity and membrane insertion ability.|||amino acid substitution, de novo designed, man-made sequences|||hRBC, <10% hemolysis at concentration tested"	"Acta Biomater
. 2021 Apr 1:124:254-269. doi: 10.1016/j.actbio.2021.01.036. Epub 2021 Jan 27.|||Acta Biomater. 2021 Apr 1;124:254-269. doi: 10.1016/j.actbio.2021.01.036. Pub-Med.|||33508505"	13	
FPDB01171	AP03715	"	
RHCLRSKRPPNVCPH"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-B. subtilis, activity value is MIC = 1.56 uM||Anti-S. aureus MRSA, activity value is MIC = 6.25 uM||Anti-S. enterica, activity value is MIC = 3.12 uM||Anti-P-aeruginosa, activity value is MIC > 50 uM||Anti-V-parahaemolyticus, activity value is MIC > 50 uM||Anti-and C. albicans, activity value is MIC = 25 uM	Pacific white shrimp, Penaeus vannamei|||Pacific white shrimp, Penaeus vannamei	N/A	"(Vannamei Shrimp Cationic Cryptide Related): Hemolytic Values (Hemolysis Rate)

The experiment used human red blood cells (hRBCs) as the test subjects, PBS as the blank control (0% hemolysis), and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring the absorbance at 450 nm. The core data are as follows:

- Low Hemolytic Risk Cryptides (Hemolysis Rate < 10%):

- AD4, AD8, AD12: At the highest tested concentration of 100 μM, the hemolysis rates were all <10%, indicating high safety for human red blood cells.

- AD7, AD11: Moderate hemolysis appeared at 50 μM concentration. At 100 μM, hemolysis rates were 26.5% and 20.7%, respectively, still lower than the positive control.

- Positive Control Comparison:

- Melittin: Nearly 100% hemolysis occurred at 12.5 μM, with hemolytic risk far higher than all cryptides.

- Cisplatin: At 100 μM, hemolysis was <10%, consistent with the hemolytic characteristics of most cryptides."	"Sci Rep
. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9.|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9. Pub-Med.|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9. Pub-Med."	15	
FPDB01172	AP03716	"	
FLRWRLKFKSKVWCP"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Gram+ B. subtilis, activity value is MIC = 0.39 uM||Anti-S. aureus MRSA, activity value is MIC = 3.12 uM||Anti-S. enterica, activity value is MIC = 0.78 uM||Anti-P. aeruginosa, activity value is MIC = 6.25 uM||Anti-V. parahaemolyticus, activity value is MIC = 3.12 uM||Anti-and C. albicans, activity value is MIC = 1.56 uM	Pacific white shrimp, Penaeus vannamei|||Pacific white shrimp, Penaeus vannamei	N/A	"(Vannamei Shrimp Cationic Cryptide Related): Hemolytic Values (Hemolysis Rate)

The experiment used human red blood cells (hRBCs) as the test subjects, PBS as the blank control (0% hemolysis), and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring the absorbance at 450 nm. The core data are as follows:

- Low Hemolytic Risk Cryptides (Hemolysis Rate < 10%):

- AD4, AD8, AD12: At the highest tested concentration of 100 μM, the hemolysis rates were all <10%, indicating high safety for human red blood cells.

- AD7, AD11: Moderate hemolysis appeared at 50 μM concentration. At 100 μM, hemolysis rates were 26.5% and 20.7%, respectively, still lower than the positive control.

- Positive Control Comparison:

- Melittin: Nearly 100% hemolysis occurred at 12.5 μM, with hemolytic risk far higher than all cryptides.

- Cisplatin: At 100 μM, hemolysis was <10%, consistent with the hemolytic characteristics of most cryptides."	"Sci Rep
. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9.|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9IF: 3.8 Q1 .|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9. Pub-Med.|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9. Pub-Med."	15	
FPDB01173	AP03717	"	
GHYCNFSVTPKFKRW"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Gram+ B. subtilis, activity value is MIC = 0.78 uM||Anti-S. aureus MRSA, activity value is MIC = 3.12 uM||Anti-S. enterica, activity value is MIC = 0.78 uM||Anti-P. aeruginosa, activity value is MIC = 25 uM||Anti-V-parahaemolyticus, activity value is MIC > 50 uM||Anti-and C. albicans, activity value is MIC = 6.25 uM	Pacific white shrimp, Penaeus vannamei|||Pacific white shrimp, Penaeus vannamei	N/A	"(Vannamei Shrimp Cationic Cryptide Related): Hemolytic Values (Hemolysis Rate)

The experiment used human red blood cells (hRBCs) as the test subjects, PBS as the blank control (0% hemolysis), and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring the absorbance at 450 nm. The core data are as follows:

- Low Hemolytic Risk Cryptides (Hemolysis Rate < 10%):

- AD4, AD8, AD12: At the highest tested concentration of 100 μM, the hemolysis rates were all <10%, indicating high safety for human red blood cells.

- AD7, AD11: Moderate hemolysis appeared at 50 μM concentration. At 100 μM, hemolysis rates were 26.5% and 20.7%, respectively, still lower than the positive control.

- Positive Control Comparison:

- Melittin: Nearly 100% hemolysis occurred at 12.5 μM, with hemolytic risk far higher than all cryptides.

- Cisplatin: At 100 μM, hemolysis was <10%, consistent with the hemolytic characteristics of most cryptides."	"Sci Rep
. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9.|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9IF: 3.8 Q1 .|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9. Pub-Med.|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9. Pub-Med."	15	
FPDB01174	AP03718	RLQLNYKGKMWCPGW	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Gram+ B. subtilis, activity value is MIC = 0.78 uM||Anti-S. aureus MRSA, activity value is MIC = 6.25 uM||Anti-S. enterica, activity value is MIC = 1.56 uM||Anti-P. aeruginosa, activity value is MIC = 25 uM||Anti-and fungi C. albicans, activity value is MIC = 25 uM	Pacific white shrimp, Penaeus vannamei|||Pacific white shrimp, Penaeus vannamei	N/A	"(Vannamei Shrimp Cationic Cryptide Related): Hemolytic Values (Hemolysis Rate)

The experiment used human red blood cells (hRBCs) as the test subjects, PBS as the blank control (0% hemolysis), and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring the absorbance at 450 nm. The core data are as follows:

- Low Hemolytic Risk Cryptides (Hemolysis Rate < 10%):

- AD4, AD8, AD12: At the highest tested concentration of 100 μM, the hemolysis rates were all <10%, indicating high safety for human red blood cells.

- AD7, AD11: Moderate hemolysis appeared at 50 μM concentration. At 100 μM, hemolysis rates were 26.5% and 20.7%, respectively, still lower than the positive control.

- Positive Control Comparison:

- Melittin: Nearly 100% hemolysis occurred at 12.5 μM, with hemolytic risk far higher than all cryptides.

- Cisplatin: At 100 μM, hemolysis was <10%, consistent with the hemolytic characteristics of most cryptides."	"Sci Rep
. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9.|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9IF: 3.8 Q1 .|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9. Pub-Med.|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9. Pub-Med."	15	
FPDB01175	AP03719|||AP03719|||AP03721	"	
FFALQCAAKTRTRRV"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-Gram+ B. subtilis, activity value is MIC = 0.78 uM||Anti-S. aureus MRSA, activity value is MIC = 6.25 uM||Anti-S. enterica, activity value is MIC = 0.78 uM||Anti-P. aeruginosa, activity value is MIC = 12.5 uM||Anti-V-parahaemolyticus, activity value is MIC > 50 uM||Anti-and fungi C. albicans, activity value is MIC = 12.5 uM	Pacific white shrimp, Penaeus vannamei|||Pacific white shrimp, Penaeus vannamei	N/A	"(Vannamei Shrimp Cationic Cryptide Related): Hemolytic Values (Hemolysis Rate)

The experiment used human red blood cells (hRBCs) as the test subjects, PBS as the blank control (0% hemolysis), and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring the absorbance at 450 nm. The core data are as follows:

- Low Hemolytic Risk Cryptides (Hemolysis Rate < 10%):

- AD4, AD8, AD12: At the highest tested concentration of 100 μM, the hemolysis rates were all <10%, indicating high safety for human red blood cells.

- AD7, AD11: Moderate hemolysis appeared at 50 μM concentration. At 100 μM, hemolysis rates were 26.5% and 20.7%, respectively, still lower than the positive control.

- Positive Control Comparison:

- Melittin: Nearly 100% hemolysis occurred at 12.5 μM, with hemolytic risk far higher than all cryptides.

- Cisplatin: At 100 μM, hemolysis was <10%, consistent with the hemolytic characteristics of most cryptides."	"Sci Rep
. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9.|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9IF: 3.8 Q1 .|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9. Pub-Med.|||Sci Rep. 2023 Sep 6;13(1):14673. doi: 10.1038/s41598-023-41581-9. Pub-Med."	15	
FPDB01176	AP03723|||AP03723|||AP03725	"	
FLGSLFSIGSKLLPGVFKLFSRKKQ"	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-P. aeruginosa DSM 50071, activity value is MIC = 12.5 ug/ml||Anti-E. coli DSM 787, activity value is MIC = 6.25 ug/ml||Anti-K. pneumoniae ATCC BAA 1705, activity value is MIC = 6.25 ug/ml||Anti-A. baumannii DSM 30008, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 6.25 ug/ml||Anti-S. epidermidis DSM 28319, activity value is MIC = 6.25 ug/ml||Anti-E. faecalis MF 06036, activity value is MIC = 6.25 ug/ml||Anti-E. faecium NCTC 12201, activity value is MIC = 6.25 ug/ml||Anti-and C. difficile DSM 27147 or ATCC BAA 1382, activity value is MIC = 3.13 ug/ml	Venom, the Trinidad Thick-Tailed Scorpion, Tityus trinitatis , South America|||Venom, the Trinidad Thick-Tailed Scorpion, Tityus trinitatis	N/A	"(Trinidad thick-tailed scorpion venom antimicrobial peptides related): Hemolytic values (LC₅₀)

The experiment used mouse red blood cells as the test subject, and the half-maximal hemolytic concentration (LC₅₀, the peptide concentration causing 50% hemolysis) was calculated by measuring the degree of hemolysis. Higher values indicate lower hemolytic risk, as follows:

- TtAP-1: LC₅₀ = 18±2 µg/ml, high hemolytic activity. Although it shows strong antibacterial activity against ESKAPE pathogens and Clostridioides difficile (MIC = 3.1–12.5 µg/ml), its high hemolytic property limits direct clinical application.

- TtAP-2: LC₅₀ = 31±4 µg/ml, moderate hemolytic activity. Its antibacterial activity is weaker than TtAP-1 (most MICs >25 µg/ml).

- TtAP-3: LC₅₀ = 95±3 µg/ml, lowest hemolytic activity. Its antibacterial activity is similar to that of TtAP-2 (most MICs >25 µg/ml), with relatively better safety.|||murine RBC: HC50 18 ug/ml, highly hemolytic."	"Antibiotics (Basel)
. 2023 Sep 4;12(9):1404. doi: 10.3390/antibiotics12091404.|||Antibiotics (Basel). 2023 Sep 4;12(9):1404. doi: 10.3390/antibiotics12091404IF: 4.3 Q1 ."	25	
FPDB01177	AP03724	"	
IFGMIPGLIGGLISAFK"	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-P.aeruginosa DSM 50071, activity value is MIC > 400 ug/ml||Anti-E. coli DSM 787, activity value is MIC = 100 ug/ml||Anti-K.pneumoniae ATCC BAA 1705, activity value is MIC > 100 ug/ml||Anti-A. baumannii DSM 30008, activity value is MIC = 50 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 25 ug/ml||Anti-S. epidermidis DSM 28319, activity value is MIC = 25 ug/ml||Anti-E. faecalis MF 06036, activity value is MIC = 50 ug/ml||Anti-E. faecium NCTC 12201, activity value is MIC = 25 ug/ml||Anti-and C. difficile DSM 27147 or ATCC BAA 1382, activity value is MIC = 25 ug/ml	Venom, the Trinidad Thick-Tailed Scorpion, Tityus trinitatis , South America|||Venom, the Trinidad Thick-Tailed Scorpion, Tityus trinitatis	N/A	"(Trinidad thick-tailed scorpion venom antimicrobial peptides related): Hemolytic values (LC₅₀)

The experiment used mouse red blood cells as the test subject, and the half-maximal hemolytic concentration (LC₅₀, the peptide concentration causing 50% hemolysis) was calculated by measuring the degree of hemolysis. Higher values indicate lower hemolytic risk, as follows:

- TtAP-1: LC₅₀ = 18±2 µg/ml, high hemolytic activity. Although it shows strong antibacterial activity against ESKAPE pathogens and Clostridioides difficile (MIC = 3.1–12.5 µg/ml), its high hemolytic property limits direct clinical application.

- TtAP-2: LC₅₀ = 31±4 µg/ml, moderate hemolytic activity. Its antibacterial activity is weaker than TtAP-1 (most MICs >25 µg/ml).

- TtAP-3: LC₅₀ = 95±3 µg/ml, lowest hemolytic activity. Its antibacterial activity is similar to that of TtAP-2 (most MICs >25 µg/ml), with relatively better safety.|||murine RBC: HC50 31 ug/ml, highly hemolytic."	"Antibiotics (Basel)
. 2023 Sep 4;12(9):1404. doi: 10.3390/antibiotics12091404.|||Antibiotics (Basel). 2023 Sep 4;12(9):1404. doi: 10.3390/antibiotics12091404IF: 4.3 Q1 ."	17	
FPDB01178	AP03725|||Putative antimicrobial peptide clone 6|||DRAMP03760	FFSLIPSLIGGLVSAIK	Anti-Gram+||Anti-MRSA||Hemolytic||Antimicrobial||Antibacterial	Venom, Tityus obscurus, Also: the Trinidad Thick-Tailed Scorpion, Tityus trinitatis, South America|||Tityus costatus|||Tityus costatus (Brazilian scorpion)	N/A	"The core data related to the hemolysis of scorpion venom-derived antifungal peptides (ToAP2, ToAP2S1, ToAP1, NDBP-4.23, NDBP-5.7) in this document are reflected through hemolysis rates. The experiment uses human red blood cells as the test subject, PBS as the blank control (0% hemolysis), and sterile water as the complete hemolysis positive control (100% hemolysis). The hemolysis rate is calculated by measuring absorbance at 540 nm. The specific information is as follows: 
 
1. Core hemolysis value (hemolysis rate)
 
- ToAP2 and ToAP2S1 (NDBP subfamily 3): 

- ToAP2: Within the test concentration range (0.78–100 uM), the hemolysis rate remains above 50%, indicating high toxicity to human red blood cells. 

- ToAP2S1 (ToAP2 modifier): Stronger hemolytic activity, with hemolysis rate exceeding 50% at 25 uM, significantly higher than the original peptide ToAP2 (Figure 3A), presumed to be related to increased hydrophobicity after modification (from 0.443 to 0.734). 

- ToAP1 (NDBP subfamily 4): At all test concentrations (0.78–100 uM), hemolysis rates were significantly below 50% (Figure 3B), offering high safety for human red blood cells and consistent with low toxicity to mouse peritoneal macrophages (cell viability > 50% at 25 uM, Figure 4B). 

- NDBP-4.23 (NDBP subfamily 4): Similar to ToAP1, the hemolytic rate remains <50% in the 0.78–100 uM concentration range (Figure 3C), showing excellent safety. At 25 uM, macrophage survival rate >50% (Figure 4C), demonstrating high cell selectivity. 

- NDBP-5.7 (NDBP subfamily 5): Has high hemolytic activity, with hemolysis rate exceeding 50% at 50 uM concentration (Figure 3D). Although it is highly active against fungi (MIC=12.5–25 uM), its high hemolytic properties limit its application. 
 
2. Additional Explanation
 
- The text does not mention the ""HC₅₀ (peptide concentration causing 50% hemolysis)"" related values, but based on hemolysis rate trends, it can be inferred: HC₅₀ for ToAP2S1 <25 uM, ToAP2 HC₅₀ ≈100 uM, ToAP1 and NDBP-4.23 HC₅₀ >100 uM, and NDBP-5.7 HC₅₀ ≈50 uM. 

- Hemolytic activity and peptide structure association: Hydrophobicity is a key influencing factor. For example, ToAP2S1, due to increased hydrophobicity (0.734), has significantly higher hemolytic activity than the original peptide ToAP2 (hydrophobicity 0.443); while ToAP1 and NDBP-4.23, due to moderate hydrophobicity (0.906, 0.908) and optimized amphipathicity, maintain antifungal activity while maintaining low hemolytic characteristics, making them suitable for future development."	"Front Microbiol
. 2016 Nov 18:7:1844. doi: 10.3389/fmicb.2016.01844. eCollection 2016.|||Q5G8B3|||Toxicon. 2005 Mar 1;45(3):273-283."	17	
FPDB01179	AP03745	"	
RWKIFKRIEKVGRNVRDGVIKAGPAVAVLGQAKALGK"	Anti-Gram-||Anti-MRSA	Phyllodes eyndhovii, Lepidoptera	Helix	cxwujm4zgbl88kok082n|||bothconcentrationsexhibitedhigherhemolysisratescomparedto the5000000 ug/mlconcentrationgroup(multiplettest,p=0.0032andp=0.0010,respectively).	Insects 2023; 14:794. Online|||Insects 2023; 14:794. Online	37	
FPDB01180	AP03756|||AP03756|||BMAP27|||Myeloid antimicrobial peptide BMAP-27|||DRAMP02872|||Myeloid antimicrobial peptide BMAP-27|||AP03756	"	
GRFKRFRKKFKKLFKKLS"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Antiparasitic||Anti-MRSA||Anti-inflammatory||Antibiofilm||Anti-Staphylococcus epidermidis ATCC 35984, activity value is MIC = 2 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 4 uM||Anti-E. coli ATCC 25922, activity value is MIC = 2 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 2 uM||Anti-E. coli ML35, activity value is MIC = 4 uM||Anti-E. coli D21, activity value is MIC = 4 uM||Anti-S. typhimurium ATCC 14028, activity value is MIC = 4 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-S. marcescens ATCC 8100, activity value is MIC = 2 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 2 uM||Anti-S. aureus Cowan 1, activity value is MIC = 2 uM||Anti-S. aureus MRSA, activity value is MIC = 4 uM||Anti-S. epidermidis ATCC 12228, activity value is MIC = 1 uM||Anti-B. megaterium Bm11, activity value is MIC = 2 uM||Anti-C. albicans, activity value is MIC = 16 uM||Anti-C. neoformans, activity value is MIC = 4 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 2 uM||Anti-Escherichia coli ML35, activity value is MIC = 4 uM||Anti-Escherichia coli D21, activity value is MIC = 4 uM||Anti-Salmonella typhimurium ATCC 14028, activity value is MIC = 4 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-Serratia marcescens ATCC 8100, activity value is MIC = 2 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 2 uM||Anti-Staphylococcus aureus Cowan 1, activity value is MIC = 2 uM||Anti-Staphylococcus aureus, activity value is MIC = 4 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 1 uM||Anti-Bacillus megaterium Bm11, activity value is MIC = 2 uM||Anti-Cryptococcus neoformans, activity value is MIC = 4 uM||Anti-E. coli ATCC 25922 ML-35 or D21, activity value is MIC = 2||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 1||Anti-S. aureus ATCC 25923 Cowan 1 or MRSA, activity value is MIC = 2||Anti-S. epidermidis ATCC 12228, activity value is MIC = 1||Anti-and C. neoformans, activity value is MIC = 4 uM||Anti-parasite BSF and PCF of T. b. brucei, activity value is IC50 = 8	Sequence truncation, animal-derived, natural derivative|||Sequence truncation, animal-derived, natural derivative|||Synthetic construct|||Bos taurus [Bovine]|||Bos taurus (Bovine)|||Sequence truncation, animal-derived, natural derivative	Helix	"w6n181zke7dmzxeu2br7|||Thehemolyticactivityof thetwoBMAPswasmuchlower, whenmeasuredonbovineerythrocytes(datanotshown).These cellswere5±10-foldlesssusceptiblethanhumanredbloodcells toBMAP-28(3,6,and22%hemolysisat10,30,and100000000 uM peptide),andvirtuallyunaffectedbyBMAP-27evenat100000000 uM.|||BMAP-28 can cause 14.5% hemolysis of human red blood cells at a concentration of 3 μM, and the hemolysis rate exceeds 90% at 100 μM. 
BMAP-27 can cause 3.5% hemolysis of human red blood cells at a concentration of 3 μM, and the hemolysis rate is 32.7% at 100 μM. 
Cow red blood cells are 5-10 times less sensitive to BMAP-28 than human red blood cells, with hemolysis rates of 3%, 6%, and 22% at concentrations of 10 μM, 30 μM, and 100 μM, respectively; BMAP-27 shows almost no hemolytic effect on cow red blood cells at 100 μM. 
The hemolytic effect of the truncated analog BMAP-27(1-18) disappears, and the hemolytic effect of BMAP-28(1-18) is greatly reduced. 
The modified analog mBMAP-28 has a hemolysis rate of only 3.3% for human red blood cells at 100 μM, far lower than the 94.1% of the parent peptide BMAP-28.|||sheep RBC: not hemolytic until 20 uM. 20% hemolysis at 30-130 uM.|||sheep RBC: not hemo.lytic until 20 uM. 20% hemolysis at 30-130 uM. HC50 at 16-32 uM to RAW264.7 mouse macrophages."	J Biol Chem. 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375. 8910461.|||J Biol Chem. 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375. 8910461.|||8910461|||J Biol Chem. 1996 Nov 8;271(45):28375-28381.|||8910461|||J Biol Chem. 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375. 8910461.|||J Biol Chem. 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375. 8910461.||Haines et al., 2009	18	
FPDB01181	AP03757|||AP03757|||Myeloid antimicrobial peptide BMAP-28|||S6|||DRAMP02873|||Myeloid antimicrobial peptide BMAP-28|||AP03757	"	
GGLRSLGRKILRAWKKYG"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli ATCC 25922, activity value is MIC = 1 uM||Anti-E. coli ML35, activity value is MIC = 0.5 uM||Anti-E. coli D21, activity value is MIC = 0.5 uM||Anti-S. typhimurium ATCC14028, activity value is MIC = 2 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-S. marcescens ATCC 8100, activity value is MIC = 2 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 2 uM||Anti-S. aureus Cowan 1, activity value is MIC = 1 uM||Anti-S. aureus, activity value is MIC = 4 uM||Anti-S. epidermidis ATCC 12228, activity value is MIC = 1 uM||Anti-B. megaterium Bm11, activity value is MIC = 2 uM||Anti-C. albicans, activity value is MIC = 16 uM||Anti-C.neoformans, activity value is MIC = 2 uM||M. abscessus ATCC19977 (MIC= >400 ug/ml)||Anti-Escherichia coli ATCC 25922, activity value is MIC = 1 uM||Anti-Escherichia coli ML35, activity value is MIC = 0.5 uM||Anti-Escherichia coli D21, activity value is MIC = 0.5 uM||Anti-Salmonella typhimurium ATCC14028, activity value is MIC = 2 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-Serratia marcescens ATCC 8100, activity value is MIC = 2 uM||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 2 uM||Anti-Staphylococcus aureus Cowan 1, activity value is MIC = 1 uM||Anti-Staphylococcus aureus, activity value is MIC = 4 uM||Anti-Staphylococcus epidermidis ATCC 12228, activity value is MIC = 1 uM||Anti-Bacillus megaterium Bm11, activity value is MIC = 2 uM||Anti-Cryptococcus neoformans, activity value is MIC = 2 uM||Anti-E. coli ATCC 25922 ML-35 or D21, activity value is MIC = 0.5||Anti-S. typhimurium ATCC 14028, activity value is MIC = 2 uM||Anti-S. aureus ATCC 25923 Cowan 1 or MRSA, activity value is MIC = 2||Anti-and C. neoformans, activity value is MIC = 2 uM	Sequence truncation, animal-derived, natural derivative|||Sequence truncation, animal-derived, natural derivative|||Bos taurus [Bovine]|||Bos taurus (Bovine)|||Sequence truncation, animal-derived, natural derivative	Helix	"w6n181zke7dmzxeu2br7|||Thehemolyticactivityof thetwoBMAPswasmuchlower, whenmeasuredonbovineerythrocytes(datanotshown).These cellswere5±10-foldlesssusceptiblethanhumanredbloodcells toBMAP-28(3,6,and22%hemolysisat10,30,and100000000 uM peptide),andvirtuallyunaffectedbyBMAP-27evenat101000000 uM.|||BMAP-28 can cause 14.5% hemolysis of human red blood cells at a concentration of 3 μM, and the hemolysis rate exceeds 90% at 100 μM. 
BMAP-27 can cause 3.5% hemolysis of human red blood cells at a concentration of 3 μM, and the hemolysis rate is 32.7% at 100 μM. 
Cow red blood cells are 5-10 times less sensitive to BMAP-28 than human red blood cells, with hemolysis rates of 3%, 6%, and 22% at concentrations of 10 μM, 30 μM, and 100 μM, respectively; BMAP-27 shows almost no hemolytic effect on cow red blood cells at 100 μM. 
The hemolytic effect of the truncated analog BMAP-27(1-18) disappears, and the hemolytic effect of BMAP-28(1-18) is greatly reduced. 
The modified analog mBMAP-28 has a hemolysis rate of only 3.3% for human red blood cells at 100 μM, far lower than the 94.1% of the parent peptide BMAP-28.|||Hemolysis is much reduced compared to the parent peptide.|||Hemolysis is much reduced compared to the parent peptide."	J Biol Chem. 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375. 8910461.|||J Biol Chem. 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375. 8910461.|||8910461|||34780520|||J Biol Chem. 1996 Nov 8;271(45):28375-28381.|||8910461|||J Biol Chem. 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375. 8910461.|||J Biol Chem. 1996 Nov 8;271(45):28375-81. doi: 10.1074/jbc.271.45.28375. 8910461.	18	
FPDB01182	AP03759|||AP03759|||Myeloid antimicrobial peptide BMAP-27	"	
GRLKRLRKKLKKLLKKLS"	Anti-Gram+||Anti-MRSA||Anti-inflammatory||Antibiofilm||Anti-Escherichia coli KCTC 1682, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa KCTC 1637, activity value is MIC = 4 uM||Anti-Salmonella typhimurium KCTC 1926, activity value is MIC = 2 uM||Anti-Bacillus subtilis KCTC 3068, activity value is MIC = 4 uM||Anti-Staphylococcus epidermidis KCTC 1917, activity value is MIC = 8 uM||Anti-Staphylococcus aureus KCTC 1621, activity value is MIC = 4 uM	amino acid substitution, segment substitution|||amino acid substitution, segment substitution|||Synthetic construct	Helix	"The core data related to the hemolytic activity of BMAP-18 and its aliphatic analog BMAP-18-FL in this document are reflected by the hemolysis rate. The experiment was conducted using sheep red blood cells (sRBCs) as the detection target, with PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the complete hemolysis positive control (100% hemolysis). The hemolysis rate was calculated by measuring the absorbance at 405 nm. Specific information is as follows:

1. Core hemolytic values (hemolysis rate)

- BMAP-18 (aromatic peptide containing phenylalanine):
  - Concentration <16 µM: No significant hemolysis (hemolysis rate ≈ 0%).
  - 64 µM: Hemolysis rate approximately 20%; with increasing concentration, hemolytic activity slightly increases, but still remains at a low hemolysis level.
- BMAP-18-FL (aliphatic analog, phenylalanine replaced by leucine):
  - Concentration <16 µM: No significant hemolysis (hemolysis rate ≈ 0%).
  - 64 µM: Hemolysis rate <10%, significantly lower than BMAP-18 at the same concentration (20%), indicating better safety.
- Positive control (bee venom peptide, melittin):
  Shows strong hemolytic activity even at low concentrations (e.g., hemolysis rate close to 100% at 4 µM), sharply contrasting with the low hemolytic properties of BMAP-18 and BMAP-18-FL (Figure 4a).

2. Additional notes

- Relationship between hemolytic activity and structure: BMAP-18-FL replaces the aromatic phenylalanine with the aliphatic leucine, resulting in a milder hydrophobic distribution. At 64 µM, its hemolysis rate is only half that of BMAP-18, indicating that replacing aromatic residues with aliphatic ones can reduce peptide damage to red blood cell membranes without affecting antibacterial activity (MIC = 16–32 µM, Table 2).
- Safety window: The effective antibacterial concentrations of both peptides (16–32 µM) are lower than the concentration at which hemolytic activity significantly increases (64 µM), and there is almost no hemolysis at antibacterial concentrations, providing a good safety application window.
- Consistency in cytotoxicity: The toxicity of both peptides to mouse macrophage RAW 264.7 cells is consistent with the hemolytic trend — at 64 µM, cell viability is >70% (Figure 4b), and BMAP-18-FL exhibits slightly lower cytotoxicity than BMAP-18, further confirming its low damage to mammalian cells.|||Both peptides did not induce hemolytic activity below 16000000 uM. At a concentration of 64000000 uM, BMAP-18-FL caused less than 10%hemolysis, while BMAP-18 induced about 20% hemolysis (Figure 4a).|||Human erythrocytes (10% Hemolysis at 300 uM|||According to the provided document content, the text explicitly mentions two peptides (BMAP-18, BMAP-18-FL) and hemolytic data for control substances (melittin, Triton X-100), as follows:

1. Test Conditions

Experimental subjects: Sheep red blood cells (sRBCs).
Control settings: PBS treatment as 0% hemolysis negative control, 0.1% Triton X-100 treatment as 100% hemolysis positive control, and melittin as the reference peptide.
Detection method: Peptide solutions (serially diluted concentrations) were incubated with 4% red blood cell suspension at 37°C for 1 hour, then centrifuged, and absorbance at 405 nm was measured. Hemolysis rate was calculated using the formula:
% Hemolysis = (Abs_peptide solution - Abs_PBS) / (Abs_0.1% Triton X-100 - Abs_PBS) × 100

2. Hemolysis Results

(1) Concentration-dependent hemolysis (% Hemolysis)

Low concentration (≤16 μM): BMAP-18 and BMAP-18-FL showed no obvious hemolysis and did not induce red blood cell rupture.
Medium-high concentration (64 μM):
BMAP-18: Hemolysis rate approximately 20%.
BMAP-18-FL: Hemolysis rate below 10%, significantly lower than BMAP-18.
High concentration (>64 μM): As the concentration increased, the hemolysis rates of both peptides may rise, but specific values were not mentioned in the document; the reference peptide, melittin, displayed strong hemolytic activity even at low concentrations (consistent with the previous document stating ""5 μM melittin leads to 100% hemolysis"").

(2) Key Conclusions

BMAP-18-FL, by replacing the aromatic phenylalanine of BMAP-18 with aliphatic leucine, significantly reduced hemolysis while maintaining antibacterial activity (hemolysis rate <10% at 64 μM vs. 20% for BMAP-18). Both peptides exhibited no hemolysis at effective antibacterial concentrations (16~32 μM), demonstrating better safety."	"Pharmaceuticals (Basel)
. 2023 Sep 25;16(10):1356. doi: 10.3390/ph16101356.|||Pharmaceuticals (Basel). 2023 Sep 25;16(10):1356. doi: 10.3390/ph16101356. PubMed.|||21497177|||Pharmaceuticals (Basel). 2023 Sep 25;16(10):1356. doi: 10.3390/ph16101356. PubMed."	18	
FPDB01183	AP03764|||AP03764|||Gj-CATH2	"	
RRGIKKFIKKVKKVKKAIKEGIKKGIKKLLSGGGSNIAHGPGGRRHIA"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-Escherichia coli ATCC8739, activity value is MIC = 2 ug/ml||Anti-Salmonella typhimurium ATCC14028, activity value is MIC = 8 ug/ml||Anti-Klebsiella pneumoniae CMCC46117, activity value is MIC = 16 ug/ml||Anti-Pseudomonas aeruginosa CMCC10104, activity value is MIC = 16 ug/ml||Anti-Staphylococcus aureus CMCC26003, activity value is MIC = 16 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 64 ug/ml||Anti-Streptococcus mutans ATCC 700610, activity value is MIC = 4 ug/ml	Gekko japonicus,|||Gekko japonicus,|||Gekko japonicus [Schlegel's Japanese gecko]	Helix	"In the research document, the hemolytic values for Gj-CATH2 are as follows:

-When the concentration of Gj-CATH2 was 100 µg/mL, the hemolysis rate against sheep red blood cells was extremely low, approximately 1.46% ± 0.23%.

The data are derived from the section “3.8. Gj-CATH2 has low cytotoxicity and hemolysis on mammalian cells” in the document, as well as Table 3 (Hemolysis and Cytotoxicity of Gj-CATH2). The experimental results indicate that Gj-CATH2 exhibits negligible toxicity toward mammalian red blood cells and possesses excellent biosafety.|||Hemolytic activity of Gj- CATH2 were determined against sheep red blood cells. Gj-CATH2 caused extremely low hemolytic rates of approximately 1.46 % at 100 u g/mL concentration (Table 3).|||Sheep RBC, 1.46 % hemolysis at 100 ug/ml concentration"	"Arch Oral Biol
. 2021 Sep:129:105205. doi: 10.1016/j.archoralbio.2021.105205. Epub 2021 Jun 29.|||Arch Oral Biol. 2021 Sep;129:105205. doi: 10.1016/j.archoralbio.2021.105205. PubMed.|||34237581"	48	
FPDB01184	AP03768|||AP03768|||SK-24	"	
SKEKIGKEFKRIVQRIKDFLRNLV"	Anti-Gram+ & Gram-||Anti-MRSA||Antibiofilm||Antibacterial	structure-based Sequence truncation, human cathelicidin analog, animal-derived, natural derivative|||structure-based Sequence truncation, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	Helix	"In this research document, the hemolytic values for SK-24 and related peptides are as follows:

- SK-24: At the highest tested concentration of 200 µM, the hemolysis rate remained below 25%, and its 50% hemolytic concentration (HC_{50}) is greater than 200 µM, making it one of the peptides with the lowest hemolytic activity among all LL-37-derived peptides (similar to RI-10).

- LL-37: No hemolytic activity below 100 µM; at 200 µM, the hemolysis rate reaches 70%, with an HC_{50} of approximately 175 µM.

- GF-17: Shows a similar trend to LL-37, with a sharp increase in hemolysis rate starting at 100 µM, and an HC_{50} of approximately 175 µM.

- GI-20: Slightly higher hemolytic activity than GF-17, with an HC_{50} of approximately 160 µM.

- 17BIPHE2: Lower hemolytic activity, with an HC_{50} of approximately 200 µM, similar to SK-24.

- RI-10: Lowest hemolytic activity, similar to SK-24, but has no antibacterial activity.

The above data come from the section ""2.6. Hemolytic Ability of SK-24"" and Figure 7 (Hemolytic toxicity of SK-24...), with hemolysis calculated by measuring the release of hemoglobin from human red blood cells (hRBCs). 1% Triton X-100 was used as a positive control (100% hemolysis) and physiological saline as a negative control.|||Similar to RI-10, SK-24 displayed minimal hemolysis (<25%) even at 200000000 uM (Figure 7), indicating a 50% hemolytic concen tration (HC50) greater than 200000000 uM. This appears to correspond to its lowest calculated hydrophobicity in Table 1. LL-37 showed no hemolysis below 100000000 uM. At 200000000 uM,however, it became rather hemolytic (70% hemolysis) with an HC50 of ~175000000 uM. Like LL-37, GF-17 showed an abrupt increase in hemolysis at 100000000 uM (HC50 ~175000000 uM).|||Human RBC (19% hemolysis at 200 uM)|||The hemolytic values of SK-24 and other related peptides (LL-37, GF-17, GI-20, RI-10, 17BIPHE2) in the document are as follows: 
 
1. SK-24: Even at the highest tested concentration of 200 μM, its hemolysis rate remains below 25%, with half the hemolysis concentration (HC₅₀) above 200 μM, making it one of the least hemolytic peptides among all LL-37 derivative peptides. 
2. LL-37: No hemolysis below 100 μM; at 200 μM, hemolysis rate rises sharply to about 70%, and the half-hemolytic concentration (HC₅₀) is about 175 μM. 
3. GF-17: At 100 uM concentration, hemolysis rate rises sharply, half hemolytic concentration (HC₅₀) matches LL-37, about 175 uM, and at 200 uM, hemolysis exceeds 50% (exact value unclear). 
4. GI-20: Hemolytic slightly higher than GF-17, with half hemolytic concentration (HC₅₀) about 160 uM, lower than LL-37 and GF-17, hemolysis rate exceeds 50% at 200 uM (exact value unknown). 
5. RI-10: Extremely low hemolysis, comparable to SK-24; at 200 μM, hemolysis rate is below 25%, and half hemolysis concentration (HC₅₀) exceeds 200 μM, suggesting its low hemolysis is related to short sequence length. 
6. 17BIPHE2: Weak hemolysis, hemolysis rate below 25% at 200 uM, half hemolytic concentration (HC₅₀) about 200 uM, classified as a low-lysing peptide along with SK-24 and RI-10. 
 
Additional notes: All hemolytic tests use human red blood cells (hRBCs), with 1% Triton X-100 as the positive control (corresponding to 100% hemolysis) and normal saline as the negative control (corresponding to 0% hemolysis). Incubation conditions are 37°C for 1 hour. The hemolytic activity of peptides is related to their hydrophobicity. SK-24 has low hydrophobicity (Pho%=37%) and no additional hydrophobic modifications, weakly destroying human red blood cell membranes; GI-20 and GF-17 have higher hydrophobicity (Pho%=45%~47%) and stronger hemolytic activity."	"Pharmaceuticals (Basel)
. 2021 Nov 30;14(12):1245. doi: 10.3390/ph14121245.|||Pharmaceuticals (Basel). 2021 Nov 30;14(12):1245. doi: 10.3390/ph14121245. PubMed|||34959645|||Pharmaceuticals (Basel). 2021 Nov 30;14(12):1245. doi: 10.3390/ph14121245. PubMed"	24	
FPDB01185	AP03821	"	
GIINTLQKYYCRVRGAICHPVFCPRRYKQIGTCGLPGTKCCKKP"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-both E. coli, activity value is MBC = 0.1 ug/ml||Anti-P. aeruginosa, activity value is MBC = 1.56 ug/ml||Anti-E. faecalis ATCC 51299, activity value is MBC = 0.78 ug/ml||Anti-E. faecium 4 strains, activity value is MBC = 0.78||Anti-S. aureus MRSA, activity value is MBC = 0.78 ug/ml||Anti-and C. albicans 5 strains, activity value is MBC = 12.5||Anti-C.perfringens ATCC 13124, activity value is MBC > 100 ug/ml||Anti-P. anaerobius ATCC 27337, activity value is MBC = 50 ug/ml||Anti-P. acnes ATCC 6919, activity value is MBC = 1.56 ug/ml||Anti-and P. oralis ATCC 33321, activity value is MBC > 100 ug/ml	Hybrid peptide, designed, man-made sequences	Combine Helix and Beta structure	"In this research document, only the hemolytic data of chimera peptide C5 is mentioned, while the hemolytic values for HBD2, HBD3, and other chimera peptides (such as C1-C4, C6) are not covered. The specific information is as follows:

- Peptide C5: Under physiological saline conditions at pH 7.4 with 150,000 µM NaCl, no hemolytic activity was observed on fresh human red blood cells, even at the highest tested concentration of 20 µM (hemolysis rate was 0%).

- Control peptide (bee venom peptide, melittin): As a strong hemolytic control, at the same concentration (20 µM), the hemolysis rate approached 100%.

This data is sourced from the ""Hemolysis"" section of the document and Figure 5 (Hemolytic activity of bee venom melittin and chimera C5 against human red blood cells). Hemolysis was calculated by measuring the release of hemoglobin from human red blood cells, with distilled water as the maximum hemolysis control (100% hemolysis) and peptide-containing buffer solution as the spontaneous hemolysis control (0% hemolysis)."	"Antimicrob Agents Chemother
. 2011 Mar;55(3):954-60. doi: 10.1128/AAC.00872-10. Epub 2010 Dec 28.|||Antimicrob Agents Chemother. 2011 Mar;55(3):954-60. doi: 10.1128/AAC.00872-10. PubMed|||Antimicrob Agents Chemother. 2011 Mar;55(3):954-60. doi: 10.1128/AAC.00872-10. PubMed"	44	
FPDB01186	AP03822	"	
GIINTLQKYYCRVRGAICHPVFCPRRYKQIGKCSTRGRKCCRRKK"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-both E. coli, activity value is MBC = 0.39 ug/ml||activity value is MBC = 1.56 ug/ml||Anti-P. aeruginosa, activity value is MBC = 1.56 ug/ml||Anti-E. faecalis ATCC 51299, activity value is MBC = 1.56 ug/ml||Anti-E. faecium 4 strains, activity value is MBC = 0.39||Anti-S. aureus MRSA, activity value is MBC = 0.39||Anti-and C.albicans 5 strains, activity value is MBC > 100 ug/ml||Anti-Anaerobic bacteria: B. fragilis ATCC 25285, activity value is MBC = 50 ug/ml||Anti-C. perfringens ATCC 13124, activity value is MBC = 6.25 ug/ml||Anti-P. anaerobius ATCC 27337, activity value is MBC = 25 ug/ml||Anti-P. acnes ATCC 6919, activity value is MBC = 3.125 ug/ml||Anti-and P. oralis ATCC 33321, activity value is MBC > 100 ug/ml	Hybrid peptide, designed, man-made sequences	N/A	"In this research document, only the hemolytic data of chimera peptide C5 is mentioned, while the hemolytic values for HBD2, HBD3, and other chimera peptides (such as C1-C4, C6) are not covered. The specific information is as follows:

- Peptide C5: Under physiological saline conditions at pH 7.4 with 150,000 µM NaCl, no hemolytic activity was observed on fresh human red blood cells, even at the highest tested concentration of 20 µM (hemolysis rate was 0%).

- Control peptide (bee venom peptide, melittin): As a strong hemolytic control, at the same concentration (20 µM), the hemolysis rate approached 100%.

This data is sourced from the ""Hemolysis"" section of the document and Figure 5 (Hemolytic activity of bee venom melittin and chimera C5 against human red blood cells). Hemolysis was calculated by measuring the release of hemoglobin from human red blood cells, with distilled water as the maximum hemolysis control (100% hemolysis) and peptide-containing buffer solution as the spontaneous hemolysis control (0% hemolysis).|||no hemolysis at 20 uM (pH 7.4 and 150000 uM NaCl)."	"Antimicrob Agents Chemother
. 2011 Mar;55(3):954-60. doi: 10.1128/AAC.00872-10. Epub 2010 Dec 28.|||Antimicrob Agents Chemother. 2011 Mar;55(3):954-60. doi: 10.1128/AAC.00872-10. PubMed"	45	
FPDB01187	AP03823|||AP03823|||Pilosulin-1|||Pilosulin P1|||Peptide P1|||Pilosulin-1|||Pilosulin P1|||Peptide P1|||AP03823|||DRAMP18666	"	
GLGSVFGRLARILGRVIPKV"	Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli ML-35, activity value is MIC = 2 uM||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 4||Anti-S. typhimurium ATCC 14028, activity value is MIC = 8 ug/ml||Anti-S. aureus 710A or MRSA, activity value is MIC = 1.5||Anti-and B. megaterium BM11, activity value is MIC = 2 uM||Anti-M. luteus, activity value is MIC = 0.5 uM||Anti-Enterococcus spp, activity value is MIC = 2 uM||Anti-S. haemolyticus I-10925, activity value is MIC = 2 uM||Anti-S. epidermidis, activity value is MIC = 2 uM||Anti-C. freundii I-11090, activity value is MIC = 2 uM||Anti-K. pneumoniae I-10910, activity value is MIC = 2 uM||Anti-S. maltophila O-16451, activity value is MIC = 2 uM||Anti-and C. albicans, activity value is MIC = 4 uM||Antibacterial ; Myrmecia pilosula [Jack jumper ant]||Anti-S. simulans 22, activity value is MIC = 2 uM||Anti-Enterococcus spp. I-11305b, activity value is MIC = 2 uM||Anti-Enterococcus spp. I-11054, activity value is MIC = 2 uM||Anti-S. epidermidis LT1324, activity value is MIC = 2 uM||Anti-S. aureus 5185, activity value is MIC = 2 uM||Anti-S. aureus methicillin-sensitive I-11574, activity value is MIC = 2 uM||Anti-S. aureus MRSA LT1338, activity value is MIC = 3 uM||Anti-S. aureus MRSA LT1334, activity value is MIC = 1.5 uM||Anti-E. coli I-11276b, activity value is MIC = 4 uM||Anti-E. coli O-19592, activity value is MIC = 2 uM||Anti-S. maltophila I-10717, activity value is MIC = 2 uM||Anti-P. aeruginosa 4991, activity value is MIC = 4 uM||Anti-P. aeruginosa I-10968, activity value is MIC = 4 uM||Anti-C. albicans I-11301, activity value is MIC = 4 uM||Anti-E. coli, activity value is MIC = 2 uM||Anti-P. aeruginosa, activity value is MIC = 8 uM||Anti-S. typhimurium, activity value is MIC = 8 uM||Anti-S. aureus, activity value is MIC = 4 uM||Anti-B. megaterium, activity value is MIC = 2 uM||Anti-I-11305b, activity value is MIC = 2 uM||Anti-I-11054, activity value is MIC = 2 uM||Anti-I-10925, activity value is MIC = 2 uM||Anti-LT1324, activity value is MIC = 2 uM||Anti-5185, activity value is MIC = 2 uM||Anti-I-11574, activity value is MIC = 2 uM||Anti-LT1338, activity value is MIC = 3 uM||Anti-LT1334, activity value is MIC = 1.5 uM||Anti-I-11090, activity value is MIC = 2 uM||Anti-I-10910, activity value is MIC = 2 uM||Anti-I-11276b, activity value is MIC = 4 uM||Anti-O-19592, activity value is MIC = 2 uM||Anti-O-16451, activity value is MIC = 2 uM||Anti-I-10717, activity value is MIC = 2 uM||Anti-4991, activity value is MIC = 4 uM||Anti-I-10968, activity value is MIC = 4 uM||Anti-I-11301, activity value is MIC = 4 uM||Antibacterial||Anti-Staphylococcus aureus 710A, activity value is MIC = 4 uM||Anti-Bacillus megaterium BM11, activity value is MIC = 2 uM||Anti-##Gram-negative bacteria: Escherichia coli ML-35, activity value is MIC = 2 uM||Anti-Pseudomonas aeruginosa ATCC27853, activity value is MIC = 8 uM||Anti-Salmonella typhimurium ATCC14028, activity value is MIC = 8 uM||Anti-Micrococcus luteus, activity value is MIC = 0.5 uM||Anti-Staphylococcus haemolyticus I-10925, activity value is MIC = 2 uM||Anti-Staphylococcus epidermidis LT1324, activity value is MIC = 2 uM||Anti-Staphylococcus aureus 5185, activity value is MIC = 2 uM||Anti-Staphylococcus aureus I-11574, activity value is MIC = 2 uM||Anti-Staphylococcus aureus LT1338, activity value is MIC = 3 uM||Anti-Staphylococcus aureus T1334, activity value is MIC = 1.5 uM||Anti-Citrobacter freundii I-11090, activity value is MIC = 2 uM||Anti-Klebsiella pneumoniae I-10910, activity value is MIC = 2 uM||Anti-Escherichia coli I-11276b, activity value is MIC = 4 uM||Anti-Escherichia coli O-19592, activity value is MIC = 2 uM||Anti-Stenotrophomonas maltophilia O-16451, activity value is MIC = 2 uM||Anti-Stenotrophomonas maltophilia I-10717, activity value is MIC = 2 uM||Anti-Pseudomonas aeruginosa 4991, activity value is MIC = 4 uM||Anti-Pseudomonas aeruginosa I-10968, activity value is MIC = 4 uM||Anti-Candida albicans I-11301, activity value is MIC = 4 uM	Sequence truncation|||Sequence truncation|||Myrmecia pilosula [Jack jumper ant]|||Myrmecia pilosula [Australian jumper ant]|||Myrmecia pilosula [Jumper ant]|||Myrmecia pilosula (Jumper ant)	Helix||Alpha helix	"In this research document, only the hemolytic data of chimera peptide C5 is mentioned, while the hemolytic values for HBD2, HBD3, and other chimera peptides (such as C1-C4, C6) are not covered. The specific information is as follows:

- Peptide C5: Under physiological saline conditions at pH 7.4 with 150,000 µM NaCl, no hemolytic activity was observed on fresh human red blood cells, even at the highest tested concentration of 20 µM (hemolysis rate was 0%).

- Control peptide (bee venom peptide, melittin): As a strong hemolytic control, at the same concentration (20 µM), the hemolysis rate approached 100%.

This data is sourced from the ""Hemolysis"" section of the document and Figure 5 (Hemolytic activity of bee venom melittin and chimera C5 against human red blood cells). Hemolysis was calculated by measuring the release of hemoglobin from human red blood cells, with distilled water as the maximum hemolysis control (100% hemolysis) and peptide-containing buffer solution as the spontaneous hemolysis control (0% hemolysis).|||29% hemolysis at 10 uM and 100% hemolysis at 100 uM.|||S. simulans 22 ( MIC = 2 uM ), M. luteus ( MIC = 0.5 uM ), Enterococcus spp. I-11305b ( MIC = 2 uM ), Enterococcus spp. I-11054 ( MIC = 2 uM ), S. haemolyticus I-10925 ( MIC = 2 uM ), S. epidermidis ( MIC = methicillin-sensitive ), S. epidermidis LT1324 ( MIC = 2 uM ), S. aureus ( MIC = methicillin-sensitive ), S. aureus 5185 ( MIC = 2 uM ), S. aureus methicillin-sensitive I-11574 ( MIC = 2 uM ), S. aureus MRSA LT1338 ( MIC = 3 uM ), S. aureus MRSA LT1334 ( MIC = 1.5 uM ), C. freundii I-11090 ( MIC = 2 uM ), K. pneumoniae I-10910 ( MIC = 2 uM ), E. coli I-11276b ( MIC = 4 uM ), E. coli O-19592 ( MIC = 2 uM ), S. maltophila O-16451 ( MIC = 2 uM ), S. maltophila I-10717 ( MIC = 2 uM ), P. aeruginosa 4991 ( MIC = 4 uM ), P. aeruginosa I-10968 ( MIC = 4 uM ), C. albicans I-11301 ( MIC = 4 uM ), C. albicans I-11134 ( MIC = >4 uM )|||Human erythrocyte (100% hemolysis at 100 uM )|||Human erythrocyte (100% hemolysis at 100 uM )|||29% hemolysis at 10 uM and 100% hemolysis at 100 uM.|||[Ref.15639237]20% hemolysis at 10 uM, 100% hemolysis at 100 uM against human red blood cells|||29% hemolysis at 10 uM and 100% hemolysis at 100 uM."	"Arch Biochem Biophys
. 2005 Feb 15;434(2):358-64. doi: 10.1016/j.abb.2004.11.006.|||Arch Biochem Biophys. 2005 Feb 15;434(2):358-64. doi: 10.1016/j.abb.2004.11.006. PubMed|||https://pubmed.ncbi.nlm.nih.gov/15639237|||15639237|||28470277|||15639237|||28470277|||Arch Biochem Biophys. 2005 Feb 15;434(2):358-64. doi: 10.1016/j.abb.2004.11.006. PubMed|||Arch Biochem Biophys. 2005 Feb 15;434(2):358-64.||Ref.15639237|||Arch Biochem Biophys. 2005 Feb 15;434(2):358-64. doi: 10.1016/j.abb.2004.11.006. PubMed"	20	
FPDB01188	AP03833	"	
KRWWQWWK"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli, activity value is MIC = 4 uM||Anti-S. aureus USA300, activity value is MIC = 8 uM||Anti-P. aeruginosa, activity value is MIC = 4||Anti-K-pneumoniae, activity value is MIC > 32 uM||Anti-and A. baumannii, activity value is MIC = 32 uM	human cathelicidin analog, animal-derived, natural derivative	N/A	"In this research document, only the hemolytic data of KR-8-derived peptides (W538-W544) are mentioned, while hemolytic values for other peptides such as LL-37, KR-12, and RIK-10 are not covered. The specific information is as follows:

- W540: At the highest tested concentration of 200 µM, the 50% hemolysis concentration (HC_{50}) is approximately 150 µM, and the hemolysis rate increases in a dose-dependent manner with concentration.

- W544: At the highest tested concentration of 200 µM, the HC_{50} is approximately 80 µM. Its hemolytic activity is higher than that of W540 (related to its 63% high hydrophobic content), and the hemolysis rate increases in a dose-dependent manner with concentration.

- W538, W539, W541, W542, W543 (LL-37mini): At the highest tested concentration of 200 µM, none exhibited any hemolytic activity (hemolysis rate 0%). Among them, W543 (LL-37mini) shows hemolysis similar to the control drug daptomycin, demonstrating the best biocompatibility.

The above data come from the document ""Ultrashort Peptide KR-8 Provides a Template for Engineering LL-37 Mini,"" specifically from the section and Figure 4A (Hemolysis of human red blood cells). The experiment calculated hemolysis rates by measuring the release of hemoglobin from human red blood cells (hRBCs), using 1% Triton X-100 as a positive control (100% hemolysis) and physiological saline as a negative control (0% hemolysis).|||human RBC: HC50 >>200 uM, not hemo.lytic. Name updated 9/2024"	"ACS Infect Dis
. 2023 Nov 10;9(11):2215-2225. doi: 10.1021/acsinfecdis.3c00293. Epub 2023 Oct 9.|||ACS Infect Dis. 2023 Nov 10;9(11):2215-2225. doi: 10.1021/acsinfecdis.3c00293. PubMed"	8	
FPDB01189	AP03834	"	
RRWWRWWR"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli, activity value is MIC = 5.4||Anti-S. aureus, activity value is MIC = 1.8||Anti-P. aeruginosa, activity value is MIC = 3.6||Anti-K-pneumoniae, activity value is MIC > 32 uM||Anti-and A-baumannii, activity value is MIC > 32 uM	Amino acid substitution, lactoferricin analog, also KR-8 analog, animal-derived, natural derivative	N/A	"Hemolytic values in Document 1 (Antimicrobial activity of short arginine- and tryptophan-rich peptides.pdf)

Document 1 focuses on the antimicrobial activity and hemolytic properties of short arginine- and tryptophan-rich peptides, with hemolytic activity assessed only by 50% hemolysis concentration (EC_{50}). Specific data are as follows (all based on human red blood cell experiments, with 1% Triton X-100 as 100% hemolysis control and phosphate-buffered saline as 0% hemolysis control):

- Deca 1: EC_{50} = 720 μg/ml (444 μM), showing only slight hemolytic activity at high concentrations.

- Hepta 1: EC_{50} = 920 μg/ml (748 μM), very low hemolytic activity.

- Hexa 2: EC_{50} = 590 μg/ml (549 μM), weak hemolytic activity.

- Hexa 3: EC_{50} = 600 μg/ml (571 μM), hemolytic activity similar to Hexa 2.

- Undeca 9, Nona 1, Octa 1, Octa 2, Hepta 2, Hexa 1, Hexa 4, Penta 1, Penta 2: marked as ""N.h."" (no hemolytic activity), meaning no hemolysis was detected at the highest tested concentration of 1000 μg/ml.|||human RBC: HC50 >>200 uM, not hemo.lytic."	"Comparative Study J Pept Sci
. 2002 Aug;8(8):431-7. doi: 10.1002/psc.398.|||J Pept Sci. 2002 Aug;8(8):431-7. doi: 10.1002/psc.398. PubMed"	8	
FPDB01190	AP03835	"	
RRWWRWWL"	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-E. coli, activity value is MIC = 4 uM||Anti-S. aureus USA300, activity value is MIC = 4 uM||Anti-P. aeruginosa, activity value is MIC = 4 uM||Anti-K. pneumoniae, activity value is MIC = 16||Anti-and A. baumannii, activity value is MIC = 16	Amino acid substitution, human cathelicidin analog, animal-derived, natural derivative	N/A	"In this research document, only the hemolytic data of KR-8-derived peptides (W538-W544) are mentioned, while hemolytic values for other peptides such as LL-37, KR-12, and RIK-10 are not covered. The specific information is as follows:

- W540: At the highest tested concentration of 200 µM, the 50% hemolysis concentration (HC_{50}) is approximately 150 µM, and the hemolysis rate increases in a dose-dependent manner with concentration.

- W544: At the highest tested concentration of 200 µM, the HC_{50} is approximately 80 µM. Its hemolytic activity is higher than that of W540 (related to its 63% high hydrophobic content), and the hemolysis rate increases in a dose-dependent manner with concentration.

- W538, W539, W541, W542, W543 (LL-37mini): At the highest tested concentration of 200 µM, none exhibited any hemolytic activity (hemolysis rate 0%). Among them, W543 (LL-37mini) shows hemolysis similar to the control drug daptomycin, demonstrating the best biocompatibility.

The above data come from the document ""Ultrashort Peptide KR-8 Provides a Template for Engineering LL-37 Mini,"" specifically from the section and Figure 4A (Hemolysis of human red blood cells). The experiment calculated hemolysis rates by measuring the release of hemoglobin from human red blood cells (hRBCs), using 1% Triton X-100 as a positive control (100% hemolysis) and physiological saline as a negative control (0% hemolysis).|||human RBC: HC50 80 uM hemolytic"	"ACS Infect Dis
. 2023 Nov 10;9(11):2215-2225. doi: 10.1021/acsinfecdis.3c00293. Epub 2023 Oct 9.|||ACS Infect Dis. 2023 Nov 10;9(11):2215-2225. doi: 10.1021/acsinfecdis.3c00293. PubMed"	8	
FPDB01191	AP03866|||AP03866|||DFT502	"	
GLSLLLSLLGKLL"	Anti-Gram+||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 1.6 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 1.6 uM	Sequence shuffling, designed, man-made sequences|||Sequence shuffling, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 3.1 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 3.1 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01192	AP03867|||AP03867|||DFT504	"	
GLSLLLSLLLGKL"	Anti-Gram+||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 6.2 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 6.2 uM	Sequence shuffling, designed, man-made sequences|||Sequence shuffling, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 8 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 8 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01193	AP03868|||AP03868|||DFT505	"	
GLLSSLLLLGKLL"	Anti-Gram+||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 3.1 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 3.1 uM	Sequence shuffling, designed, man-made sequences|||Sequence shuffling, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 20 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 20 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01194	AP03869|||AP03869|||DFT527	"	
GKLLSLLSLLGLL"	Anti-Gram+||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 3.1 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 3.1 uM	Sequence shuffling, designed, man-made sequences|||Sequence shuffling, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 20 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 20 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01195	AP03870|||AP03870|||DFT531	"	
GLLSLLSLGLKLL"	Anti-Gram+||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 0.8 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 0.8 uM	Sequence shuffling, designed, man-made sequences|||Sequence shuffling, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 7 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 7 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01196	AP03871|||AP03871|||DFT532	"	
LLGSLLSLGLKLL"	Anti-Gram+||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 1.6 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 1.6 uM	Sequence shuffling, designed, man-made sequences|||Sequence shuffling, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 13 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 13 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01197	AP03872|||AP03872|||DFT506	"	
GALSLLSLLGKLL"	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 0.78 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 12.5 uM||Anti-E. coli ATCC 25922, activity value is MIC = 3.1 uM||Anti-and K. pneumonia ATCC13883, activity value is MIC = 6.2 uM||Anti-S. aureus USA 300, activity value is MIC = 0.78 uM||Anti-K. pneumoniae, activity value is MIC = 6.2 uM	Amino acid substitution, Ala-scan, designed, man-made sequences|||Amino acid substitution, Ala-scan, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 4 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 4 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01198	AP03873|||AP03873|||DFT507	GLASLLSLLGKLL	Anti-Gram+||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 0.78 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 0.78 uM	Amino acid substitution, Ala-scan, designed, man-made sequences|||Amino acid substitution, Ala-scan, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 <3.1 uM, highly hemolytic.|||Human RBCs [50% hemolysis at <3.1 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01199	AP03874|||AP03874|||DFT508	"	
GLLSALSLLGKLL"	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 0.78 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E. coli ATCC 25922, activity value is MIC = 3.1 uM||Anti-and K. pneumonia ATCC13883, activity value is MIC = 3.1 uM||Anti-S. aureus USA 300, activity value is MIC = 0.78 uM||Anti-K. pneumoniae, activity value is MIC = 3.1 uM	Amino acid substitution, Ala-scan, designed, man-made sequences|||Amino acid substitution, Ala-scan, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 6 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 6 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01200	AP03875|||AP03875|||DFT509	"	
GLLSLASLLGKLL"	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 0.78 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 6.2||Anti-E. coli ATCC 25922, activity value is MIC = 1.5||Anti-and K. pneumonia ATCC13883, activity value is MIC = 3.1 uM||Anti-S. aureus USA 300, activity value is MIC = 0.78 uM||Anti-K. pneumoniae, activity value is MIC = 3.1 uM	Amino acid substitution, Ala-scan, designed, man-made sequences|||Amino acid substitution, Ala-scan, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 4 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 4 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01201	AP03876|||AP03876|||DFT510	GLLSLLSALGKLL	Anti-Gram+||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 1.56 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 1.56 uM	Amino acid substitution, Ala-scan, designed, man-made sequences|||Amino acid substitution, Ala-scan, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 19 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 19 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01202	AP03877|||AP03877|||DFT511	"	
GLLSLLSLAGKLL"	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 0.78 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 12.5 uM||Anti-E. coli ATCC 25922, activity value is MIC = 3.1 uM||Anti-and K. pneumonia ATCC13883, activity value is MIC = 3.1 uM||Anti-S. aureus USA 300, activity value is MIC = 0.78 uM||Anti-K. pneumoniae, activity value is MIC = 3.1 uM	Amino acid substitution, Ala-scan, designed, man-made sequences|||Amino acid substitution, Ala-scan, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 14 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 14 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01203	AP03878|||AP03878|||DFT512	GLLSLLSLLGKAL	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 0.78 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E. coli ATCC 25922, activity value is MIC = 3.1 uM||Anti-and K. pneumonia ATCC13883, activity value is MIC = 3.1 uM||Anti-S. aureus USA 300, activity value is MIC = 0.78 uM||Anti-K. pneumoniae, activity value is MIC = 3.1 uM	Amino acid substitution, Ala-scan, designed, man-made sequences|||Amino acid substitution, Ala-scan, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 4 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 4 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01204	AP03879|||AP03879|||DFT513	"	
GLLSLLSLLGKLA"	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 1.56 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E. coli ATCC 25922, activity value is MIC = 1.5||Anti-and K. pneumonia ATCC13883, activity value is MIC = 12.5||Anti-S. aureus USA 300, activity value is MIC = 1.56 uM||Anti-K. pneumoniae, activity value is MIC = 12.5	Amino acid substitution, Ala-scan, designed, man-made sequences|||Amino acid substitution, Ala-scan, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 3.1 uM, highly hemolytic.|||Human RBCs [50% hemolysis at <3.1 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01205	AP03880|||AP03880|||DFT514	GLLSALKALGKLL	Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 1.56 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E. coli ATCC 25922, activity value is MIC = 3.1 uM||Anti-and K. pneumonia ATCC13883, activity value is MIC = 3.1 uM||Anti-S. aureus USA 300, activity value is MIC = 1.56 uM||Anti-K. pneumoniae, activity value is MIC = 3.1 uM	Amino acid substitution, designed, man-made sequences|||Amino acid substitution, Ala-scan, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 36 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 36 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01206	AP03881|||AP03881|||DFT521	GLLSALKAAGKLL	Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus USA300, activity value is MIC = 12.5 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-and E. coli ATCC 25922, activity value is MIC = 12.5 uM||Anti-S. aureus USA 300, activity value is MIC = 12.5 uM||Anti-E. coli ATCC 25922, activity value is MIC = 12.5 uM	Amino acid substitution, designed, man-made sequences|||Amino acid substitution, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 >50 uM.|||Human RBCs [50% hemolysis at >50 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01207	AP03882|||AP03882|||DFT528	"	
GALSALKALGKLL"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus USA300, activity value is MIC = 25 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E. coli ATCC 25922, activity value is MIC = 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 25 uM	Amino acid substitution, designed, man-made sequences|||Amino acid substitution, designed, man-made sequences|||Synthetic construct	N/A	human RBC HC50 >50 uM.|||Human RBCs [50% hemolysis at >50 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01208	AP03883|||AP03883|||DFT529	"	
GLLSALKALGKAL"	Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus USA300, activity value is MIC = 25 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E. coli ATCC 25922, activity value is MIC = 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 25 uM	Amino acid substitution, designed|||Amino acid substitution, designed|||Synthetic construct	N/A	human RBC HC50 >50 uM.|||Human RBCs [50% hemolysis at >50 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01209	AP03884|||AP03884|||CAMPSQ8536	"	
GLLSLSLLGKLL"	Anti-Gram+||Anti-MRSA||Anti-S. aureus USA300, activity value is MIC = 12.5 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-and E. coli ATCC 25922, activity value is MIC = 25 uM||Antibacterial	Amino acid deletion, designed|||Amino acid deletion, designed|||Synthetic construct	N/A	human RBC HC50 >50 uM.|||Human RBCs [50% hemolysis at >50 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	12	
FPDB01210	AP03885|||AP03885|||DFT560	"	
KLSLLLSLGLKLL"	Anti-Gram+||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 1.56 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 1.6 uM	Sequence shuffling, designed|||Sequence shuffling, designed|||Synthetic construct	N/A	human RBC HC50 25 uM, highly hemolytic.|||Human RBCs [50% hemolysis at 25 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01211	AP03886|||AP03886|||DFT561|||DFT561d	"	
GLKLLLSLGLKLL"	Anti-Gram+||Anti-MRSA||Anti-S. aureus USA300 or M838-17, activity value is MIC = 1.56||Anti-E. faecium V286-17, activity value is MIC = 3.1||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 1.6 uM||Anti-S. aureus M838-17, activity value is MIC = 3.1 uM||Anti-S. aureus USA 300, activity value is MIC = 1.6	Sequence shuffling, designed|||Sequence shuffling, designed|||Synthetic construct	Helix	human RBC HC50 >300 uM, much less hemo.lytic.|||Human RBCs [50% hemolysis at >300 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01212	AP03887|||AP03887|||DFT562	"	
GLSLLLKLGLKLL"	Anti-Gram+||Anti-MRSA||Hemolytic||Anti-S. aureus USA300, activity value is MIC = 0.8 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 0.8	Sequence shuffling, designed|||Sequence shuffling, designed|||Synthetic construct	N/A	human RBC HC50 <16 uM, highly hemolytic.|||Human RBCs [50% hemolysis at <25 uM]	"Proc Natl Acad Sci U S A
. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048"	13	
FPDB01213	AP03888|||AP03888|||DFT563	GLSLLLSLKLKLL	Anti-S. aureus USA300, activity value is MIC = 6.2 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 6.2 uM	Sequence shuffling, designed|||Sequence shuffling, designed|||Synthetic construct	N/A	DFTamP1: Hemolytic. DFT506: Lower hemolytic activity. DFT507 (L3A): Lower hemolytic activity. DFT510 (L8A): Lower hemolytic activity. DFT511: Lower hemolytic activity. DFT514-DFT516 (L5A and L8A): Lower hemolytic activity. DFT521, DFT528, DFT529: Lower hemolytic activity. DFT522, DFT530: Lower hemolytic activity. DFT503: Hemolytic activity significantly lower than DFTamP1. DFT561: Lower hemolytic activity, even lower compared to DFTamP1. DFT560, DFT562, DFT563: Higher hemolytic activity. DFT564, DFT565: Very high hemolytic activity.|||human RBC HC50 >300 uM, much less hemo.lytic|||Human RBCs [50% hemolysis at >300 uM]	2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048	13	
FPDB01214	AP03889|||AP03889|||DFT564	"	
GLKLLLKLGLKLL"	Anti-S. aureus USA300, activity value is MIC = 6.2 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 0.8	Amino acid substitution, designed|||Amino acid substitution, designed|||Synthetic construct	Helix	BmKn2: At a concentration of 25 µg/mL, the hemolytic activity was 91.8%. Kn2(G3K): At a concentration of 25 µg/mL, the hemolytic activity is 69.0%. Kn2(A4R): At a concentration of 25 µg/mL, the hemolytic activity is 100%. Kn2(S10R): At a concentration of 25 µg/mL, the hemolytic activity is 50.9%. Kn2(G3K_A4R): At a concentration of 25 µg/mL, the hemolytic activity is 8.3%. Kn2(A4R_S10R): At a concentration of 25 µg/mL, the hemolytic activity is 18.0%. Kn2(G3K_S10R): At a concentration of 25 µg/mL, the hemolytic activity is 77.5%. BmKn2-7: At a concentration of 25 µg/mL, the hemolytic activity is 6.9%. BmKn2-7K: At a concentration of 100 µg/mL, the hemolytic activity is 12.2%. BmKn2-7R: At a concentration of 100 µg/mL, the hemolytic activity is 73.1%. Kn2-7(K3R): At a concentration of 100 µg/mL, the hemolytic activity is 89.3%.|||human RBC HC50 >300 uM, much less hemo.lytic.|||Human RBCs [50% hemolysis at <25 uM]	2019 Jul 2;116(27):13517-13522.doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048	13	
FPDB01215	AP03890|||AP03890|||DFT565	"	
KLKLLLKLGLKLL"	Anti-S. aureus USA300, activity value is MIC = 6.2 uM||Anti-P-aeruginosa PAO1, activity value is MIC > 25 uM||Anti-E-coli ATCC 25922, activity value is MIC > 25 uM||Anti-and K-pneumonia ATCC13883, activity value is MIC > 25 uM||Anti-S. aureus USA 300, activity value is MIC = 0.8 uM	Amino acid substitution, designed|||Amino acid substitution, designed|||Synthetic construct	N/A	DFTamP1: Hemolytic. DFT506: Lower hemolytic activity. DFT507 (L3A): Lower hemolytic activity. DFT510 (L8A): Lower hemolytic activity. DFT511: Lower hemolytic activity. DFT514-DFT516 (L5A and L8A): Lower hemolytic activity. DFT521, DFT528, DFT529: Lower hemolytic activity. DFT522, DFT530: Lower hemolytic activity. DFT503: Hemolytic activity significantly lower than DFTamP1. DFT561: Lower hemolytic activity, even lower compared to DFTamP1. DFT560, DFT562, DFT563: Higher hemolytic activity. DFT564, DFT565: Very high hemolytic activity.|||human RBC HC50 50 uM.|||Human RBCs [50% hemolysis at 50 uM]	2019 Jul 2;116(27):13517-13522.doi: 10.1073/pnas.1821410116. Epub 2019 Jun 17.|||Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13517-13522. doi: 10.1073/pnas.1821410116. PubMed|||31209048	13	
FPDB01216	AP03891|||AP03891|||TetraF2W-RK	"	
WWWLSRIW"	Anti-E.coli K12, activity value is MIC > 100 uM||Anti-S-epidermidis 1457, activity value is MIC > 50 uM||Anti-B. subtilis 168, activity value is MIC = 6.2 uM||Anti-and S. aureus USA300, activity value is MIC = 3.1||activity value is MBC = 6.2 uM||Anti-Escherichia coli K-12, activity value is MIC > 100 uM||Anti-Staphylococcus epidermidis 1457, activity value is MIC > 50 uM||Anti-Bacillus subtilis 168, activity value is MIC = 6.2 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 3.1||Anti-Staphylococcus aureus USA 300, activity value is MBC = 6.2 uM	Template-based design, designed	Rich	"TetraF2W-KK: Human red blood cells 40 uM, pig red blood cells 55 uM, chicken red blood cells 50 uM
TetraF2W-KR: Human red blood cells 30 uM, pig red blood cells 50 uM, chicken red blood cells 35 uM
TetraF2W-RK: Human red blood cells 30 uM, pig red blood cells 40 uM, chicken red blood cells 35 uM
TetraF2W-RR: Human red blood cells 20 uM, pig red blood cells 40 uM, chicken red blood cells 55 uM|||human RBC HC50 50 uM."	2017 Feb:49:316-328. doi: 10.1016/j.actbio.2016.11.061. Epub 2016 Nov 30.|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed|||27915018	8	
FPDB01217	AP03892|||AP03892|||AP03893|||TetraF2W-KR|||TetraF2W-KR|||AP03892	WWWLKRIW	Anti-E. coli K12, activity value is MIC = 12.5||Anti-S. epidermidis 1457, activity value is MIC = 12.5 uM||Anti-B. subtilis 168, activity value is MIC = 6.2 uM||Anti-and S. aureus USA300, activity value is MIC = 3.1 uM||activity value is MBC = 12.5 uM||Anti-C. glabrata, activity value is MIC = 12.5 uM||Anti-and C. tropicalis, activity value is MIC = 3.1||Anti-Escherichia coli K-12, activity value is MIC = 12.5||Anti-Staphylococcus epidermidis 1457, activity value is MIC = 12.5 uM||Anti-Bacillus subtilis 168, activity value is MIC = 6.2 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 3.1 uM||Anti-Staphylococcus aureus USA 300, activity value is MBC = 12.5 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 6.2 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 25 uM||Anti-Candida albicans ATCC 10231, activity value is MIC = 12.5 uM||Anti-Candida glabrata ATCC 2001, activity value is MIC = 12.5 uM||Anti-Candida tropicalis ATCC 13803, activity value is MIC = 3.1	Amino acid substitution, designed|||Synthetic construct|||Amino acid substitution, designed	Rich	"TetraF2W-KK: Human red blood cells 40 uM, pig red blood cells 55 uM, chicken red blood cells 50 uM
TetraF2W-KR: Human red blood cells 30 uM, pig red blood cells 50 uM, chicken red blood cells 35 uM
TetraF2W-RK: Human red blood cells 30 uM, pig red blood cells 40 uM, chicken red blood cells 35 uM
TetraF2W-RR: Human red blood cells 20 uM, pig red blood cells 40 uM, chicken red blood cells 55 uM|||human RBC HC50 30 uM.|||Human erythrocytes (50% Hemolysis at 30 uM|||human RBC HC50 30 uM."	2017 Feb:49:316-328. doi: 10.1016/j.actbio.2016.11.061. Epub 2016 Nov 30.|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed|||27915018|||https://pubmed.ncbi.nlm.nih.gov/27915018|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed	8	
FPDB01218	AP03893|||TetraF2W-RK	"	
WWWLRKIW"	Anti-E. coli K12 or ATCC 25922, activity value is MIC = 6.2||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 12.5 uM||Anti-S. epidermidis 1457, activity value is MIC = 6.2 uM||Anti-B. subtilis 168, activity value is MIC = 6.2 uM||Anti-and S. aureus USA300, activity value is MIC = 3.1 uM||activity value is MBC = 12.5 uM||Anti-C. glabrata, activity value is MIC = 12.5 uM||Anti-and C. tropicalis, activity value is MIC = 3.1||Anti-S. aureus, activity value is MIC = 3.1 uM||Anti-E. coli, activity value is MIC = 6.2 uM	Amino acid substitution, designed	Helix	"TetraF2W-KK: Human red blood cells 40 uM, pig red blood cells 55 uM, chicken red blood cells 50 uM
TetraF2W-KR: Human red blood cells 30 uM, pig red blood cells 50 uM, chicken red blood cells 35 uM
TetraF2W-RK: Human red blood cells 30 uM, pig red blood cells 40 uM, chicken red blood cells 35 uM
TetraF2W-RR: Human red blood cells 20 uM, pig red blood cells 40 uM, chicken red blood cells 55 uM|||Human RBCs(HL50 = 35 uM)|||human RBC HC50 30 uM."	2017 Feb:49:316-328. doi: 10.1016/j.actbio.2016.11.061. Epub 2016 Nov 30.|||28731688, 33804947|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed	8	
FPDB01219	AP03894|||AP03894|||TetraF2W-KK|||TetraF2W-KK|||AP03894	"	
WWWLKKIW"	Anti-E. coli K12, activity value is MIC = 12.5||Anti-S. epidermidis 1457, activity value is MIC = 6.2 uM||Anti-B. subtilis 168, activity value is MIC = 6.2 uM||Anti-and S. aureus USA300, activity value is MIC = 3.1||activity value is MBC > 25 uM||Anti-C. glabrata, activity value is MIC = 6.2||Anti-and C. tropicalis, activity value is MIC = 1.6 uM||Anti-Escherichia coli K-12, activity value is MIC = 12.5||Anti-Staphylococcus epidermidis 1457, activity value is MIC = 6.2 uM||Anti-Bacillus subtilis 168, activity value is MIC = 6.2 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 3.1||Anti-Staphylococcus aureus USA 300, activity value is MBC > 25 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 3.1 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 12.5 uM||Anti-Candida albicans ATCC 10231, activity value is MIC = 6.2 uM||Anti-Candida glabrata ATCC 2001, activity value is MIC = 6.2||Anti-Candida tropicalis ATCC 13803, activity value is MIC = 1.6 uM	Amino acid substitution, designed|||Synthetic construct|||Amino acid substitution, designed	Rich	"TetraF2W-KK: Human red blood cells 40 uM, pig red blood cells 55 uM, chicken red blood cells 50 uM
TetraF2W-KR: Human red blood cells 30 uM, pig red blood cells 50 uM, chicken red blood cells 35 uM
TetraF2W-RK: Human red blood cells 30 uM, pig red blood cells 40 uM, chicken red blood cells 35 uM
TetraF2W-RR: Human red blood cells 20 uM, pig red blood cells 40 uM, chicken red blood cells 55 uM|||human RBC HC50 40 uM.|||Human erythrocytes (50% Hemolysis at 40 uM|||human RBC HC50 40 uM."	2017 Feb:49:316-328. doi: 10.1016/j.actbio.2016.11.061. Epub 2016 Nov 30.|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed|||27915018|||https://pubmed.ncbi.nlm.nih.gov/27915018|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed	8	
FPDB01220	AP03895|||AP03895|||WT	WWWLRRIW	Anti-E. coli K12, activity value is MIC = 25 uM||Anti-S. epidermidis 1457, activity value is MIC = 6.2||Anti-B. subtilis 168, activity value is MIC = 3.1||Anti-and S. aureus USA300, activity value is MIC = 1.6||activity value is MBC = 3.1 uM||Anti-C-glabrata, activity value is MIC > 25 uM||Anti-and C. tropicalis, activity value is MIC = 3.1 uM||Anti-S. aureus, activity value is MIC = 3.1 uM||Anti-E. coli, activity value is MIC = 6.2 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Antibiofilm	Amino acid substitution, designed	Rich	"TetraF2W-KK: Human red blood cells 40 uM, pig red blood cells 55 uM, chicken red blood cells 50 uM
TetraF2W-KR: Human red blood cells 30 uM, pig red blood cells 50 uM, chicken red blood cells 35 uM
TetraF2W-RK: Human red blood cells 30 uM, pig red blood cells 40 uM, chicken red blood cells 35 uM
TetraF2W-RR: Human red blood cells 20 uM, pig red blood cells 40 uM, chicken red blood cells 55 uM|||human RBC HC50 20 uM.|||Human RBC (HL50 = 35 uM)|||The hemolytic-related data provided in the document represent the 50% hemolysis concentrations (LC_{50}) of different TetraF2W series peptides against various red blood cells and human cells. The specific values are shown in the table below (unit: µM):

Peptide Name | Human RBCs | Pig RBCs | Chicken RBCs | Human HEK293 Cells | Human HaCaT Cells | Human HeLa Cells
TetraF2W-KK | 40 | 55 | 50 | 50 | 50 | 70
TetraF2W-KR | 30 | 50 | 35 | 55 | 60 | 100
TetraF2W-RK | 30 | 40 | 35 | 60 | 60 | >100
TetraF2W-RR | 20 | 40 | 55 | 70 | 70 | 60

Supplementary Notes:

Hemolysis tests used 1% Triton X-100 treated corresponding red blood cells as the 100% hemolysis positive control and PBS buffer treated cells as the 0% hemolysis negative control. Hemolysis rate was calculated by measuring hemoglobin release at 545 nm. LC_{50} is the peptide concentration that causes 50% of the cells to undergo hemolysis.

There are differences in sensitivity to peptides among red blood cells of different origins: pig red blood cells are most similar in sensitivity to human red blood cells, followed by chicken red blood cells. Cow red blood cells are the least sensitive to these peptides (hemolysis rate at 50 µM concentration is only 10-20%, not included in the table above).

From a cytotoxicity perspective, TetraF2W-RR has the highest LC_{50} against normal human cells (HEK293, HaCaT) at 70 µM, indicating relatively low toxicity; whereas TetraF2W-KK is the most toxic to human red blood cells (LC_{50} = 20 µM).|||human RBC HC50 20 uM."	2017 Feb:49:316-328. doi: 10.1016/j.actbio.2016.11.061. Epub 2016 Nov 30.|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed|||28731688|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed|||Acta Biomater. 2017 Feb;49:316-328. doi: 10.1016/j.actbio.2016.11.061. PubMed	8	
FPDB01221	AP03896|||AP03896|||WW292	"	
WWLRKIWW"	Anti-S. aureus USA300, activity value is MIC = 6.2 uM||Anti-E. coli ATCC 25922, activity value is MIC = 25 uM||Anti-and K-pneumoniae ATCC 13883, activity value is MIC > 50 uM||Anti-Staphylococcus aureus USA 300 LAC, activity value is MIC = 6.2 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 25 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC > 50 uM	Sequence shuffling, sequence permutation, designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||32723829	8	
FPDB01222	AP03897|||AP03897|||WW293	"	
WLRKIWWW"	Anti-S. aureus USA300, activity value is MIC = 3.1||Anti-E. coli ATCC 25922, activity value is MIC = 12.5||Anti-and K. pneumoniae ATCC 13883, activity value is MIC = 25 uM||Anti-Staphylococcus aureus USA 300 LAC, activity value is MIC = 3.1||Anti-Escherichia coli ATCC 25922, activity value is MIC = 12.5||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 25 uM	Sequence shuffling, sequence permutation, designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||32723829	8	
FPDB01223	AP03898|||AP03898|||WW294	"	
LRKIWWWW"	Anti-S. aureus USA300, activity value is MIC = 3.1||Anti-E. coli ATCC 25922, activity value is MIC = 12.5 uM||Anti-and K. pneumoniae ATCC 13883, activity value is MIC = 6.2||Anti-Staphylococcus aureus USA 300 LAC, activity value is MIC = 3.1||Anti-Escherichia coli ATCC 25922, activity value is MIC = 12.5 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 6.2	Sequence shuffling, sequence permutation, designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||32723829	8	
FPDB01224	AP03899|||AP03899|||WW295	"	
RKIWWWWL"	Anti-S. aureus USA300, activity value is MIC = 3.1||Anti-E. coli ATCC 25922, activity value is MIC = 6.2 uM||Anti-and K. pneumoniae ATCC 13883, activity value is MIC = 3.1||Antibacterial	Sequence shuffling, sequence permutation, designed	NonHelixBeta	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||33804947	8	
FPDB01225	AP03900|||AP03900|||WW296	KIWWWWLR	Anti-S. aureus USA300, activity value is MIC = 3.1 uM||Anti-E. coli ATCC 25922, activity value is MIC = 6.2||Anti-and K. pneumoniae ATCC 13883, activity value is MIC = 12.5 uM||Anti-Staphylococcus aureus USA 300 LAC, activity value is MIC = 3.1 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 6.2||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 12.5 uM	Sequence shuffling, sequence permutation, designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||32723829	8	
FPDB01226	AP03901|||AP03901|||WW297	"	
IWWWWLRK"	Anti-S. aureus USA300, activity value is MIC = 3.1 uM||Anti-E. coli ATCC 25922, activity value is MIC = 6.2||Anti-and K. pneumoniae ATCC 13883, activity value is MIC = 12.5 uM||Anti-Staphylococcus aureus USA 300 LAC, activity value is MIC = 3.1 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 12.5 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 12.5	Sequence shuffling, sequence permutation, designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||32723829	8	
FPDB01227	AP03902|||AP03902|||WW298	"	
WWWWLRKI"	Anti-S. aureus USA300, activity value is MIC = 1.5||Anti-E. coli ATCC 25922, activity value is MIC = 12.5 uM||Anti-and K. pneumoniae ATCC 13883, activity value is MIC = 6.2||Anti-Staphylococcus aureus USA 300 LAC, activity value is MIC = 1.5||Anti-Escherichia coli ATCC 25922, activity value is MIC = 12.5 uM||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 6.2	Sequence shuffling, sequence permutation, designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||32723829	8	
FPDB01228	AP03904|||AP03904|||CAMPSQ9732|||CAMPSQ10493|||DRAMP04318	"	
IKWKKLLRAAKRIL"	Anti-S. aureus USA300 MRSA, activity value is MIC = 6.2 uM||Anti-E. coli, activity value is MIC = 3.1 uM||Anti-B. subtilis, activity value is MIC = 12.5 uM||Anti-and P. aeruginosa, activity value is MIC = 6.25 uM||Anti-Bacillus subtilis, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 6.25 uM||Anti-S. aureus, activity value is MIC = 6.2 uM||Anti-P. aeruginosa, activity value is MIC = 6.25 uM||Antimicrobial||Antibacterial	Amino acid substitution, insects, animal-derived, natural derivative|||Amino acid substitution, insects, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct	N/A	ascaphin-8：125 uMDASamP1：125 uMDASamP2：625 uMlycotoxin I：25 uMmaculatin 1.3：125 uMpiscidin 1：50 uM|||hemolytic HC50 75 uM.|||Human RBC (HL50 = 75 uM)|||Human RBC (50% hemolytic at 75 uM)	2012 May;39(5):402-6. doi: 10.1016/j.ijantimicag.2012.02.003. Epub 2012 Mar 23.|||Int J Antimicrob Agents. 2012 May;39(5):402-6. doi: 10.1016/j.ijantimicag.2012.02.003. PubMed|||22445495|||28672834|||Int J Antimicrob Agents. 2012 May;39(5):402-406.	14	
FPDB01229	AP03909|||AP03909|||W1R	RWWLRRIW	Anti-S. aureus USA300 LAC, activity value is MIC = 12.5 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 12.5 uM||Anti-and K-pneumoniae ATCC 13883, activity value is MIC > 50 uM||Anti-S. aureus, activity value is MIC = 12.5 uM||Anti-E. coli, activity value is MIC = 25 uM	Amino acid substitution, Arg-scan, computer designed, de novo designed|||Amino acid substitution, Arg-scan, computer designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM|||human RBC: not hemo.lytic (HC50 > 200 uM).|||Human RBC (HL50 = >200 uM)	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||28731688	8	
FPDB01230	AP03910|||AP03910|||W2R	WRWLRRIW	Anti-S. aureus USA300 LAC, activity value is MIC = 6.2 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 6.2 uM||Anti-and K. pneumoniae ATCC 13883, activity value is MIC = 25 uM||Anti-S. aureus, activity value is MIC = 6.2 uM||Anti-E. coli, activity value is MIC = 25 uM	Amino acid substitution, Arg-scan, computer designed, de novo designed|||Amino acid substitution, Arg-scan, computer designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM|||human RBC: HC50 100 uM.|||Human RBC (HL50 = 100 uM)	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||28731688	8	
FPDB01231	AP03911|||AP03911|||W3R	"	
WWRLRRIW"	Anti-S. aureus USA300 LAC, activity value is MIC = 12.5 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 12.5 uM||Anti-and K-pneumoniae ATCC 13883, activity value is MIC > 25 uM||Anti-S. aureus, activity value is MIC = 12.5 uM||Anti-E. coli, activity value is MIC = 25 uM	Amino acid substitution, Arg-scan, computer designed, de novo designed|||Amino acid substitution, Arg-scan, computer designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM|||human RBC: not hemo.lytic (HC50 >200 uM).|||Human RBC (HL50 = >200 uM)	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||28731688	8	
FPDB01232	AP03912|||AP03912|||L4R	"	
WWWRRRIW"	Anti-S. aureus USA300 LAC, activity value is MIC = 12.5 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 25||Anti-and K-pneumoniae ATCC 13883, activity value is MIC > 25 uM||Anti-S. aureus, activity value is MIC = 12.5 uM||Anti-E. coli, activity value is MIC = 25 uM	Amino acid substitution, Arg-scan, computer designed, de novo designed|||Amino acid substitution, Arg-scan, computer designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM|||human RBC: not hemo.lytic (HC50 >200 uM).|||Human RBC (HL50 = >200 uM)	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||28731688	8	
FPDB01233	AP03913|||AP03913|||W8R	"	
WWWLRRIR"	Anti-S. aureus USA300 LAC, activity value is MIC = 12.5 uM||Anti-P. aeruginosa PAO1, activity value is MIC = 12.5 uM||Anti-and K-pneumoniae ATCC 13883, activity value is MIC > 25 uM||Anti-S. aureus, activity value is MIC = 12.5 uM||Anti-E. coli, activity value is MIC = 25 uM	Amino acid substitution, Arg-scan, computer designed, de novo designed|||Amino acid substitution, Arg-scan, computer designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM|||human RBC: not hemo.lytic (HC50 >200 uM).|||Human RBC (HL50 = >200 uM)	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||28731688	8	
FPDB01234	AP03914|||AP03914|||WW306, Horine- L	"	
RRRWWWWL"	Anti-S. aureus M838-17, activity value is MIC = 3.1 uM||Anti-P. aeruginosa E411-17, activity value is MIC = 6.25 uM||Anti-and K. pneumoniae E406-17, activity value is MIC = 6.25 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 4 uM||Anti-Staphylococcus aureus M838-17, activity value is MIC = 4 uM||Anti-Escherichia coli ATCC 25922, activity value is MIC = 2 uM||Anti-Escherichia coli E423-17, activity value is MIC = 4 uM||Anti-Escherichia coli E416-17, activity value is MIC = 4 uM||Anti-Escherichia coli K-12, activity value is MIC = 2 uM||Anti-Staphylococcus aureus M838-17, activity value is MIC = 3.1 uM||Anti-Pseudomonas aeruginosa E411-17, activity value is MIC = 6.25 uM||Anti-Klebsiella pneumoniae E406-17, activity value is MIC = 6.25 uM	Amino acid substitution, computer designed, de novo designed|||Amino acid substitution, Arg-scan, computer designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM|||human RBC: hemolytic (HC50 60 uM).|||, Human erythrocytes (50% Hemolysis at 60 uM	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||32723829, 32220553	8	
FPDB01235	AP03915|||AP03915|||WW308	"	
RRRWWWWA"	Anti-S. aureus M838-17, activity value is MIC = 12.5 uM||Anti-P. aeruginosa E411-17, activity value is MIC = 25 uM||Anti-and K-pneumoniae E406-17, activity value is MIC > 50 uM||Anti-Staphylococcus aureus M838-17, activity value is MIC = 12.5 uM||Anti-Pseudomonas aeruginosa E411-17, activity value is MIC = 25 uM||Anti-Klebsiella pneumoniae E406-17, activity value is MIC > 50 uM	Amino acid substitution, computer designed, de novo designed|||Amino acid substitution, computer designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM|||human RBC: not hemo.lytic (HC50 >200 uM).|||Human erythrocytes (50% Hemolysis at >200 uM	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||32723829	8	
FPDB01236	AP03916|||AP03916|||WW309	"	
RRRRWWWL"	Anti-S. aureus M838-17, activity value is MIC = 6.25 uM||Anti-P. aeruginosa E411-17, activity value is MIC = 12.5 uM||Anti-and K-pneumoniae E406-17, activity value is MIC > 50 uM||Anti-Staphylococcus aureus M838-17, activity value is MIC = 6.25 uM||Anti-Pseudomonas aeruginosa E411-17, activity value is MIC = 12.5 uM||Anti-Klebsiella pneumoniae E406-17, activity value is MIC > 50 uM	Amino acid substitution, computer designed, de novo designed|||Amino acid substitution, computer designed	Rich	Horine: LD₅₀ value for human red blood cells: >200 uM Verine: LD₅₀ value for human red blood cells: >200 uM|||human RBC: not hemo.lytic (HC50 >200 uM).|||Human erythrocytes (50% Hemolysis at >200 uM	2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. Epub 2020 Jul 28.|||Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19446-19454. doi: 10.1073/pnas.2005540117. PubMed|||32723829	8	
FPDB01237	AP03934	"	
FLGTVLKVAAKVLPAALCQIFKKC"	Anti-S. aureus ATCC 6538 or MRSA, activity value is MIC = 1||Anti-E. faecalis NCTC 12697, activity value is MIC = 2 uM||Anti-E. coli ATCC 8739, activity value is MIC = 2 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 32 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 16 uM||Anti-A. baumannii ATCC BAA 747, activity value is MIC = 4 uM||Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Antibiofilm	skin secretion, the broad-folded frog, Hylarana latouchii|||skin secretion, the broad-folded frog, Hylarana latouchii	N/A	"B1LTe: HC50 value is 6.4 uM. D-L: HC50 value is 11.6 uM. D-K: HC50 value exceeds 128 uM. D-R: HC50 value exceeds 128 uM. 5R: HC50 value exceeds 128 uM.|||human RBC: HC50 6.4 uM, highly hemolytic.|||The hemolysis-related data provided in the document are 50% hemolysis concentration (HC_{50}), geometric mean (GM) and therapeutic index (TI) of B1LTE and its derivatives on horse red blood cells. The specific values are shown in the following table (unit: uM):

Peptide name GM (Gram-positive bacteria) GM (Gram-negative bacteria) GM (all strains) TI (Gram-positive bacteria) TI (Gram-negative bacteria) TI (all strains)
B1Lte 6.4 1.6 8 4 4.0 0.8 1.6
D-L 11.6 2 5.7 3.6 5.8 2.0 3.2
D-K &gt;128 8 16 11.9 32.0 16.0 21.5
K-R 8.4 2 9.5 4.9 4.2 0.9 1.7
9000 ml 12.3 10.1 53.8 26.3 1.2 0.2 0.5
D-9000 ml 27.8 2 6.7 4 13.9 4.1 7.0
9L10000 ml 42.9 2.5 4 3.3 17.2 10.7 13.0
2D-R 17.5 2 4 3 8.8 4.4 5.8
Q-D-R 17.1 1.3 3.4 2.2 13.2 5.0 7.8
D-R &gt;128 3.2 6.7 4.9 80.0 38.2 52.2
5R &gt;128 2.5 4.8 3.6 102.4 53.3 71.1

Additional note:

1. Hemolysis test method: 2% horse red blood cell suspension was taken as the experimental object, incubated at 37°C for 2 hours, treated with 0.1 Triton X-100 as 100 hemolysis positive control, and treated with PBS as 0% hemolysis negative control. Hemolysis rate was calculated by detecting hemoglobin release at 570 nm, and HC_{50} was the peptide concentration that hemolyzed 50% red blood cells.
2. Characteristics of key peptides:
Derivative 5R has the lowest hemolysis (HC_{50}&gt;128 uM) and the highest therapeutic index (TI = 71.1 for all strains, TI = 102.4 for gram-positive bacteria, TI = 53.3 for gram-negative bacteria), and is the candidate peptide with the best safety and antibacterial selectivity among all peptides.
When HC_{50} exceeds 128 uM, the TI is calculated as 250 uM to ensure the rationality of the TI value.
3. Toxicity correlation: D-arginine (D-Arg) substitution can reduce hemolysis compared with D-lysine (D-Lys). For example, D-R HC_{50}(&gt;128 uM) is significantly higher than D-K(&gt;128 uM,TI is lower), and 5R is optimized by integrating D-Arg, etc, the toxicity to mammalian cells is further reduced (e. g., the ICY60 = 40 uM for human keratinocyte HaCaT, which is much higher than the concentration required for its antibacterial activity)."	2023 Nov 19:21:5719-5737. doi: 10.1016/j.csbj.2023.11.031. eCollection 2023.|||Comput Struct Biotechnol J. 2023 Nov 19;21:5719-5737. doi: 10.1016/j.csbj.2023.11.031. PubMed	24	
FPDB01238	AP03941	"	
FLSALWGVAKSLF"	Anti-Gram+ S. aureus ATCC29213 or ATCC25923 or MRSA, activity value is MIC = 5||Anti-E. faecalis ATCC29212, activity value is MIC = 10 ug/ml||Anti-S. epidermidis, activity value is MIC = 5 ug/ml||Anti-S. capitis, activity value is MIC = 2.5||Anti-S. intermedius, activity value is MIC = 5 ug/ml||Anti-E. coli ATCC25922 or ATCC35218, activity value is MIC = 20||Anti-P. aeruginosa ATCC27853, activity value is MIC = 80 ug/ml||Anti-K-pneumoniae ATCC700603, activity value is MIC > 80 ug/ml	venom gland, Liocheles australasiae, Australia|||venom gland, Liocheles australasiae	Helix	Lausporin-1：45 ug/mlausporin-2：60 ug/ml|||human RBC, HC50 60 ug/ml.	2021 Jun:196:63-73. doi: 10.1016/j.toxicon.2021.04.002. Epub 2021 Apr 6.|||Toxicon. 2021 Jun;196:63-73. doi: 10.1016/j.toxicon.2021.04.002. PubMed	13	
FPDB01239	AP03942	"	
FPFLLSLIPSAISALKKL"	Anti-Gram+ S. aureus ATCC29213 or ATCC25923 or MRSA, activity value is MIC = 5||Anti-E. faecalis ATCC29212, activity value is MIC = 20 ug/ml||Anti-S. epidermidis, activity value is MIC = 5||Anti-S. capitis, activity value is MIC = 2.5||Anti-S. intermedius, activity value is MIC = 5 ug/ml||Anti-E. coli ATCC25922 or ATCC35218, activity value is MIC = 40||Anti-P-aeruginosa ATCC27853, activity value is MIC > 80 ug/ml||Anti-K-pneumoniae ATCC700603, activity value is MIC > 80 ug/ml	venom gland, Liocheles australasiae, Australia|||venom gland, Liocheles australasiae	Helix	Lausporin-1：45 ug/mlausporin-2：60 ug/ml|||human RBC, HC50 45 ug/ml.	2021 Jun:196:63-73. doi: 10.1016/j.toxicon.2021.04.002. Epub 2021 Apr 6.|||Toxicon. 2021 Jun;196:63-73. doi: 10.1016/j.toxicon.2021.04.002. PubMed	18	
FPDB01240	AP03975|||AP03975|||Peptide ID-8|||HHC-8|||HHC-8	"	
KIWWWWRKR"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 3||Anti-E. cloacae Strain C601, activity value is MIC = 94 uM||Anti-E. coli ESBL, activity value is MIC = 6 uM||Anti-K. pneumoniae, activity value is MIC = 47 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 6 uM||Anti-5 E. faecalis ATCC29212, activity value is MIC = 1.5||Antibacterial||Anti-Pseudomonas aeruginosa H1001, activity value is MIC = 5.9 ug/ml||Anti-Pseudomonas aeruginosa PAO1 H103, activity value is MIC = 4.1 ug/ml||Anti-Pseudomonas aeruginosa 9, activity value is MIC = 32 ug/ml||Anti-Pseudomonas aeruginosa 198, activity value is MIC = 17 ug/ml||Anti-Pseudomonas aeruginosa H1030, activity value is MIC = 8.3 ug/ml||Anti-Pseudomonas aeruginosa H1027, activity value is MIC = 4.1 ug/ml||Anti-Stenotrophomonas maltophilia ATCC 13637, activity value is MIC = 2.1 ug/ml||Anti-Enterobacter cloacae 218R, activity value is MIC = 65 ug/ml||Anti-Escherichia coli ESBL 63103, activity value is MIC = 8.3 ug/ml||Anti-Escherichia coli ESBL 64771, activity value is MIC = 4.1 ug/ml||Anti-Klebsiella pneumoniae ESBL 61962, activity value is MIC = 130 ug/ml||Anti-Klebsiella pneumoniae ESBL 63575, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 4.1 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 4.1 ug/ml||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 17 ug/ml||Anti-Enterococcus faecalis W61950, activity value is MIC = 65 ug/ml||Anti-Enterococcus faecium, activity value is MIC = 80||Anti-Enterococcus faecium t62764, activity value is MIC = 1 ug/ml||Anti-Mycobacterium tuberculosis lux, activity value is MIC = 90||Anti-Mycobacterium tuberculosis lux, activity value is MIC = 50||Anti-Mycobacterium smegmatis mc2-6, activity value is MIC = 90||Anti-Pseudomonas aeruginosa H103, activity value is MIC = 42.3 uM||Anti-Escherichia coli UB1005, activity value is MIC = 5.3 uM||Anti-Salmonella enterica serovar Typhimurium, activity value is MIC = 10.6 uM||Anti-Candida albicans, activity value is MIC = 10.6 uM||Anti-Staphylococcus epidermidis, activity value is MIC = 1.3 uM||Anti-Human acute monocytic leukemia THP-1, activity value is IC50 = 173.9 uM||Anti-Mycobacterium tuberculosis H37Rv, activity value is MIC > 75 ug/ml||Anti-Mycobacterium tuberculosis H37Rv, activity value is MIC = 9 ug/ml||Anti-Mycobacterium smegmatis MTCC 994, activity value is MIC > 75 ug/ml||Anti-Mycobacterium smegmatis MTCC 994, activity value is MIC = 18.75 ug/ml	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct|||ynthetic construct	Rich	N/A	Patent US9017656|||Patent US9017656|||19171306, 23478953|||https://pubmed.ncbi.nlm.nih.gov/19171306,	9	
FPDB01241	AP03976|||AP03976|||Peptide ID-9|||Undefined	RWRRWKWWL	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 0.3||Anti-E. cloacae Strain C601, activity value is MIC = 6 uM||Anti-E. coli ESBL, activity value is MIC = 3 uM||Anti-K. pneumoniae, activity value is MIC = 11 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 3 uM||Anti-5 E. faecalis ATCC29212, activity value is MIC = 1.4||Antibacterial||Anti-Pseudomonas aeruginosa H1001, activity value is MIC = 2.9 ug/ml||Anti-Pseudomonas aeruginosa PAO1 H103, activity value is MIC = 2 ug/ml||Anti-Pseudomonas aeruginosa 9, activity value is MIC = 8.1 ug/ml||Anti-Pseudomonas aeruginosa 198, activity value is MIC = 8.1 ug/ml||Anti-Pseudomonas aeruginosa 213, activity value is MIC = 16 ug/ml||Anti-Pseudomonas aeruginosa LES400, activity value is MIC = 3.9 ug/ml||Anti-Pseudomonas aeruginosa H1030, activity value is MIC = 8.1 ug/ml||Anti-Pseudomonas aeruginosa H1027, activity value is MIC = 0.2 ug/ml||Anti-Stenotrophomonas maltophilia ATCC 13637, activity value is MIC = 0.5 ug/ml||Anti-Enterobacter cloacae 218R, activity value is MIC = 3.9 ug/ml||Anti-Escherichia coli ESBL 63103, activity value is MIC = 3.9 ug/ml||Anti-Escherichia coli ESBL 64771, activity value is MIC = 2 ug/ml||Anti-Klebsiella pneumoniae ESBL 61962, activity value is MIC = 31 ug/ml||Anti-Klebsiella pneumoniae ESBL 63575, activity value is MIC = 7.4 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 2 ug/ml||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 16 ug/ml||Anti-Enterococcus faecalis W61950, activity value is MIC = 62 ug/ml||Anti-Enterococcus faecalis f43559, activity value is MIC = 62 ug/ml||Anti-Enterococcus faecium, activity value is MIC = 80||Anti-Enterococcus faecium t62764, activity value is MIC = 0.9 ug/ml	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656|||Patent US9017656|||19171306	9	
FPDB01242	AP03977|||HHC-10	"	
KRWWKWIRW"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 0.4||Anti-E. cloacae Strain C601, activity value is MIC = 3 uM||Anti-E. coli ESBL, activity value is MIC = 1.5 uM||Anti-K. pneumoniae, activity value is MIC = 6 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 1.5||Anti-5 E. faecalis ATCC29212, activity value is MIC = 1.5||Anti-Candida albicans, activity value is MIC > 100 uM	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656|||https://pubmed.ncbi.nlm.nih.gov/28105725	9	
FPDB01243	AP03978|||AP03978|||Peptide ID-20	WRWWKIWKR	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 0.8||Anti-E. cloacae Strain C601, activity value is MIC = 12 uM||Anti-E. coli ESBL, activity value is MIC = 6 uM||Anti-K. pneumoniae, activity value is MIC = 24 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 3 uM||Anti-5 E. faecalis ATCC29212, activity value is MIC = 1.5||Antibacterial	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656	9	
FPDB01244	AP03979|||AP03979|||Tet 127|||Tet127	"	
KRWWKWWRR"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 0.3||Anti-E. cloacae Strain C601, activity value is MIC = 11 uM||Anti-E. coli ESBL, activity value is MIC = 3 uM||Anti-K. pneumoniae, activity value is MIC = 22 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 1.4||Anti-5 E. faecalis ATCC29212, activity value is MIC = 1.1||Antibacterial ; Streptococcus mutans ATCC 25175||Escherichia coli ATCC 25922||Anti-Candida albicans, activity value is MIC > 100 uM	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656|||Patent US9017656|||30423715|||https://pubmed.ncbi.nlm.nih.gov/28105725	9	
FPDB01245	AP03980|||AP03980|||Peptide ID-45	WKRWWKKWR	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 1.4||Anti-E. cloacae Strain C601, activity value is MIC = 93 uM||Anti-E. coli ESBL, activity value is MIC = 3 uM||Anti-K. pneumoniae, activity value is MIC = 46 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 6||Anti-5 E. faecalis ATCC29212, activity value is MIC = 6||Antibacterial	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656	9	
FPDB01246	AP03981|||AP03981|||Peptide ID-48	"	
WKKWWKRRW"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 1.4||Anti-E. cloacae Strain C601, activity value is MIC = 23 uM||Anti-E. coli ESBL, activity value is MIC = 3 uM||Anti-K. pneumoniae, activity value is MIC = 46 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 1.4||Anti-5 E. faecalis ATCC29212, activity value is MIC = 6||Antibacterial	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656	9	
FPDB01247	AP03982|||AP03982|||Peptide ID-24897|||Undefined	"	
FRRWWKWFK"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 0.8||Anti-E. cloacae Strain C601, activity value is MIC = 24 uM||Anti-E. coli ESBL, activity value is MIC = 6 uM||Anti-K. pneumoniae, activity value is MIC = 24 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 1.5||Anti-5 E. faecalis ATCC29212, activity value is MIC = 6||Antibacterial||Anti-Pseudomonas aeruginosa H1001, activity value is MIC = 1.5 ug/ml||Anti-Pseudomonas aeruginosa PAO1, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa 910, activity value is MIC = 32 uM||Anti-Pseudomonas aeruginosa 919, activity value is MIC = 16 uM||Anti-Pseudomonas aeruginosa 253, activity value is MIC = 8 uM||Anti-Pseudomonas aeruginosa PAO1 H103, activity value is MIC = 1 ug/ml||Anti-Pseudomonas aeruginosa 9, activity value is MIC = 8.3 ug/ml||Anti-Pseudomonas aeruginosa 198, activity value is MIC = 2.1 ug/ml||Anti-Pseudomonas aeruginosa 213, activity value is MIC = 4.1 ug/ml||Anti-Pseudomonas aeruginosa LES400, activity value is MIC = 4.1 ug/ml||Anti-Pseudomonas aeruginosa H1030, activity value is MIC = 17 ug/ml||Anti-Pseudomonas aeruginosa H1027, activity value is MIC = 1 ug/ml||Anti-Stenotrophomonas maltophilia ATCC 13637, activity value is MIC = 0.6 ug/ml||Anti-Enterobacter cloacae 218R, activity value is MIC = 17 ug/ml||Anti-Escherichia coli ESBL 63103, activity value is MIC = 8.3 ug/ml||Anti-Escherichia coli ESBL 64771, activity value is MIC = 4.2 ug/ml||Anti-Klebsiella pneumoniae ESBL 61962, activity value is MIC = 67 ug/ml||Anti-Klebsiella pneumoniae ESBL 63575, activity value is MIC = 17 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 1 ug/ml||Anti-Staphylococcus aureus C623, activity value is MIC = 2.1 ug/ml||Anti-Enterococcus faecalis ATCC 29212, activity value is MIC = 17 ug/ml||Anti-Enterococcus faecalis W61950, activity value is MIC = 135 ug/ml||Anti-Enterococcus faecalis f43559, activity value is MIC = 67 ug/ml||Anti-Enterococcus faecium, activity value is MIC = 80||Anti-Enterococcus faecium t62764, activity value is MIC = 4.2 ug/ml	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656|||Patent US9017656|||19171306	9	
FPDB01248	AP03983|||AP03983|||Peptide ID-24901	"	
LRWWWIKRI"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 3||Anti-E. cloacae Strain C601, activity value is MIC = 50 uM||Anti-E. coli ESBL, activity value is MIC = 13 uM||Anti-K. pneumoniae, activity value is MIC = 50 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 6||Anti-5 E. faecalis ATCC29212, activity value is MIC = 6||Antibacterial	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656	9	
FPDB01249	AP03984|||AP03984|||Peptide ID-24910	"	
RKRLKWWIY"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 3||Anti-E. cloacae Strain C601, activity value is MIC = 13 uM||Anti-E. coli ESBL, activity value is MIC = 6 uM||Anti-K. pneumoniae, activity value is MIC = 50 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 6 uM||Anti-and 5 E. faecalis ATCC29212, activity value is MIC = 3||Antibacterial	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	N/A	N/A	Patent US9017656	9	
FPDB01250	AP03985	"	
KKRWWWIRY"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 1.6||Anti-E. cloacae Strain C601, activity value is MIC = 25 uM||Anti-E. coli ESBL, activity value is MIC = 13 uM||Anti-K. pneumoniae, activity value is MIC = 51 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 13 uM||Anti-and 5 E. faecalis ATCC29212, activity value is MIC = 6	QSAR computer designed, de novo designed|||QSAR computer designed	Rich	N/A	Patent US9017656	9	
FPDB01251	AP03986|||AP03986|||AP03987|||Peptide ID-24915	KWKIFRRWW	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 1.5||Anti-E. cloacae Strain C601, activity value is MIC = 6 uM||Anti-E. coli ESBL, activity value is MIC = 12 uM||Anti-K. pneumoniae, activity value is MIC = 97 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 3 uM||Anti-and 5 E. faecalis ATCC29212, activity value is MIC = 6	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656	9	
FPDB01252	AP03987|||Peptide ID-24919	"	
RKWIWRWFL"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 1.5||Anti-E. cloacae Strain C601, activity value is MIC = 3 uM||Anti-E. coli ESBL, activity value is MIC = 1.5 uM||Anti-K. pneumoniae, activity value is MIC = 3.1 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 3||Anti-and 5 E. faecalis ATCC29212, activity value is MIC = 3	QSAR computer designed, de novo designed|||Synthetic construct	Rich	N/A	Patent US9017656	9	
FPDB01253	AP03988	"	
IWWKWRRWW"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 1.5||Anti-E. cloacae Strain C601, activity value is MIC = 6 uM||Anti-E. coli ESBL, activity value is MIC = 6 uM||Anti-K. pneumoniae, activity value is MIC = 12 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 3 uM||Anti-and 5 E. faecalis ATCC29212, activity value is MIC = 3	QSAR computer designed, de novo designed|||QSAR computer designed	Rich	N/A	Patent US9017656	9	
FPDB01254	AP03989|||AP03989|||AP03990|||Peptide ID-24944	"	
RRFKFIRWW"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 0.8||Anti-E. cloacae Strain C601, activity value is MIC = 12 uM||Anti-E. coli ESBL, activity value is MIC = 12 uM||Anti-K. pneumoniae, activity value is MIC = 49 uM||Anti-S. aureus ATCC 25923 or MRSA, activity value is MIC = 6 uM||Anti-and 5 E. faecalis ATCC29212, activity value is MIC = 6	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656	9	
FPDB01255	AP03991|||AP03991|||Peptide ID-74674	"	
AIRRWRIRK"	Anti-6 P. aeruginosa PAO1 or WT or resistant strains, activity value is MIC = 108 uM||Anti-E.cloacae Strain C601, activity value is MIC = 108 uM||Anti-E.coli ESBL, activity value is MIC = 108 uM||Anti-K.pneumoniae, activity value is MIC > 217 uM||Anti-S.aureus ATCC 25923 or MRSA, activity value is MIC = 54 uM||Anti-and E. faecalis ATCC29212, activity value is MIC = 14 uM	QSAR computer designed, de novo designed|||QSAR computer designed|||Synthetic construct	Rich	N/A	Patent US9017656	9	
FPDB01256	AP03993|||AP03993|||LL-37	GFARIVQRIKDFLRNLV	Anti-S. aureus USA300, activity value is MIC = 7.5 uM||Anti-Escherichia coli K-12, activity value is MIC = 15 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 7.5 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 3.1 uM	Amino acid substitution of GF-17, Ala-scan, human cathelicidin analog, animal-derived, natural derivative|||Amino acid substitution of GF-17, Ala-scan, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	N/A	Human erythrocytes (42% Hemolysis at 25 uM	2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. Epub 2011 Nov 14.|||Antimicrob Agents Chemother. 2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. PubMed|||22083479	17	
FPDB01257	AP03994|||AP03994|||LL-37	GFKAIVQRIKDFLRNLV	Anti-S. aureus USA300, activity value is MIC = 7.5 uM||Anti-Escherichia coli K-12, activity value is MIC = 15 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 7.5 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 3.1 uM	Amino acid substitution of GF-17, Ala-scan, human cathelicidin analog, animal-derived, natural derivative|||Amino acid substitution of GF-17, Ala-scan, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	N/A	Human erythrocytes (22% Hemolysis at 25 uM	2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. Epub 2011 Nov 14.|||Antimicrob Agents Chemother. 2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. PubMed|||22083479	17	
FPDB01258	AP03995|||AP03995|||LL-37	"	
GFKRIVQAIKDFLRNLV"	Anti-S. aureus USA300, activity value is MIC = 15 uM||Anti-Escherichia coli K-12, activity value is MIC = 60 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 15 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 3.1 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 6.2 uM	Amino acid substitution of GF-17, Ala-scan, human cathelicidin analog, animal-derived, natural derivative|||Amino acid substitution of GF-17, Ala-scan, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	N/A	Human erythrocytes (60% Hemolysis at 25 uM	2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. Epub 2011 Nov 14.|||Antimicrob Agents Chemother. 2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. PubMed|||22083479	17	
FPDB01259	AP03996|||AP03996|||LL-37	GFKRIVQRIADFLRNLV	Anti-S. aureus USA300, activity value is MIC = 7.5 uM||Anti-Escherichia coli K-12, activity value is MIC = 60 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 7.5 uM	Amino acid substitution of GF-17, Ala-scan, human cathelicidin analog, animal-derived, natural derivative|||Amino acid substitution of GF-17, Ala-scan, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	N/A	N/A	2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. Epub 2011 Nov 14.|||Antimicrob Agents Chemother. 2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. PubMed|||22083479	17	
FPDB01260	AP03997|||AP03997|||LL-37	"	
GFKRIVQRIKDFLANLV"	Anti-S. aureus USA300, activity value is MIC = 7.5 uM||Anti-Escherichia coli K-12, activity value is MIC = 15 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 7.5 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 3.1 uM	Amino acid substitution of GF-17, Ala-scan, human cathelicidin analog, animal-derived, natural derivative|||Amino acid substitution of GF-17, Ala-scan, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	N/A	Human erythrocytes (21% Hemolysis at 25 uM	2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. Epub 2011 Nov 14.|||Antimicrob Agents Chemother. 2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. PubMed|||22083479	17	
FPDB01261	AP03998|||AP03998|||LL-37	GEFKRIVQRIKDFLRNLV	Anti-S. aureus USA300, activity value is MIC = 60 uM||Anti-Escherichia coli K-12, activity value is MIC = 60 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 60 uM	G+Sequence truncation of LL-37, human cathelicidin analog, animal-derived, natural derivative|||G+Sequence truncation of LL-37, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	N/A	N/A	2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. Epub 2011 Nov 14.|||Antimicrob Agents Chemother. 2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. PubMed|||22083479	18	
FPDB01262	AP04000|||AP04000|||LL-37	"	
GEFRRIVQRIRDFLRNLV"	Anti-S. aureus USA300, activity value is MIC = 30 uM||Anti-Escherichia coli K-12, activity value is MIC = 60 uM||Anti-Staphylococcus aureus USA 300, activity value is MIC = 30 uM	Amino acid substitution, human cathelicidin analog, animal-derived, natural derivative|||Amino acid substitution, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	N/A	N/A	2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. Epub 2011 Nov 14.|||Antimicrob Agents Chemother. 2012 Feb;56(2):845-56. doi: 10.1128/AAC.05637-11. PubMed|||22083479	18	
FPDB01263	AP04037	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESGSFLGGLIKIVPAMICAVTKKC	Anti-S. aureus MRSA, activity value is MIC = 17.5||Anti-E. coli, activity value is MIC = 19.7||Anti-and K. pneumoniae, activity value is MIC = 27.8 uM	Hybrid peptide, designed	N/A	N/A	2024 Dec;108(1):126. doi: 10.1007/s00253-023-12887-5. Epub 2024 Jan 13.|||Appl Microbiol Biotechnol. 2024 Dec;108(1):126. doi: 10.1007/s00253-023-12887-5. PubMed	59	
FPDB01264	AP04047|||AP04047|||AP138	"	
GFGCNGPWSEDDLRCHRHCKSIKGYRGGYCAKGGFVCKCY"	Anti-S. aureus ATCC 25923 or ATCC 43300 or E48 or CVCC 546 or CAAS-FRI-2023-01 or CAAS-FRI-2023-02 and 8 clinical strains, activity value is MIC = 2||Anti-S. epidermidis ATCC 12228 or ATCC 35984, activity value is MIC = 4||Anti-S. dysgalactiae CVCC 3938, activity value is MIC = 4 ug/ml||Anti-S. agalactiae ATCC 13813 or CAU-FRI-2022-01 or CAU-FRI-2022-02, activity value is MIC = 4 ug/ml||Antibacterial	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Synthetic construct	Beta||Bridge	In in vitro experiments, AP138000 ml-arg26 exhibited only 3% hemolysis at a high concentration (256 µg/ml), indicating that it has low hemolytic activity.|||Acute toxicity in mice: Little changes in blood cell profiles (168 h IP injection; 10000 ug/kg).	2024 Dec;108(1):111. doi: 10.1007/s00253-023-12947-w. Epub 2024 Jan 13.|||Appl Microbiol Biotechnol. 2024 Dec;108(1):111. doi: 10.1007/s00253-023-12947-w. PubMed|||30532539	40	
FPDB01265	AP04069	"	
RIKTATWRLALRWLKL"	Anti-Gram+ S. aureus ATCC 25923 or ATCC 6538 or RN 4220 or MRSA ATCC 43300 or ATCC 16558, activity value is MIC = 7.41||Anti-L. monocytogenes ATCC 19115, activity value is MIC = 3.86 uM||Anti-B. subtilis ATCC 6633, activity value is MIC = 1.93 uM	Designed based on Leg2 (inactive)	N/A	N/A	2024 Feb 7;72(5):2727-2740. doi: 10.1021/acs.jafc.3c08241. Epub 2024 Jan 30.|||J Agric Food Chem. 2024 Jan 30. doi: 10.1021/acs.jafc.3c08241. PubMed	16	
FPDB01266	AP04070	"	
RIKTRTWRLALRWLKL"	Anti-S. aureus ATCC 25923 or ATCC 6538 or RN 4220 or MRSA ATCC 43300 or ATCC 16558, activity value is MIC = 3.7||Anti-L. monocytogenes ATCC 19115, activity value is MIC = 0.93 uM||Anti-B. subtilis ATCC 6633, activity value is MIC = 0.93 uM	Designed based on Leg2 (inactive)	N/A	N/A	2024 Feb 7;72(5):2727-2740. doi: 10.1021/acs.jafc.3c08241. Epub 2024 Jan 30.|||J Agric Food Chem. 2024 Jan 30. doi: 10.1021/acs.jafc.3c08241. PubMed	16	
FPDB01267	AP04071|||AP04071|||NZ2114|||AP114	"	
GFGCNGPWNEDDLRCHNHCKSIKGYKGGYCAKGGFVCKCY"	Anti-Gram+ S. aureus ATCC 25923 or ATCC 6538 or MRSA ATCC 43300, activity value is MIC = 0.028||Anti-S. suis CVCC3309 or CVCC3928 or CVCC606, activity value is MIC = 0.028 uM||Anti-S. pneumoniae CVCC1.8722 or CVCC2350, activity value is MIC = 0.454||Anti-S-enteritidis CM, activity value is CC50 = 336||Anti-S-typhimurium ATCC14028, activity value is MIC > 7.273 uM||Anti-S-choleraesuis CV, activity value is CC50 = 3||Anti-S-pullorum CVCC1789, activity value is MIC > 7.273 uM||Anti-and E-coli CVCC195 or CICC21530, activity value is MIC > 7.273 uM||Antibacterial||Anti-Gram+||Anti-MRSA||Anti-inflammatory||Antibiofilm||Wound healing	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Synthetic construct	Bridge	RBC (1.00% hemolysis at 0.23-23.09 uM)	2009 Apr;53(4):1581-5. doi: 10.1128/AAC.01202-08. Epub 2009 Feb 2.||Chen et al., 2017||Zhang et al., 2024|||Antimicrob Agents Chemother. 2009 Apr;53(4):1581-5. PubMed||Chen et al., 2017||Zhang et al., 2024|||28229435|||28476579|||Antimicrob Agents Chemother. 2009 Apr;53(4):1581-5. PubMed	40	
FPDB01268	AP04072|||AP04072|||H1	"	
GFGCNGPWNEDDLRCKNHCKSIKGYKGGYCAKGGFVCKCY"	Anti-Gram+ S. aureus ATCC 25923 or ATCC 6538 or MRSA ATCC 43300, activity value is MIC = 0.014||Anti-S. suis CVCC3309 or CVCC3928 or CVCC606, activity value is MIC = 0.007||Anti-S. pneumoniae CVCC1.8722 or CVCC2350, activity value is MIC = 0.227 uM||Anti-S-enteritidis CM, activity value is CC50 = 336||Anti-S-typhimurium ATCC14028, activity value is MIC > 7.273 uM||Anti-S-choleraesuis CV, activity value is CC50 = 3||Anti-S-pullorum CVCC1789, activity value is MIC > 7.273 uM||Anti-and E-coli CVCC195 or CICC21530, activity value is MIC > 7.273 uM||Antibacterial	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Synthetic construct	Bridge	NZ2114: Hemolytic activity remained at 1.00%, with a concentration range of 0.23 to 23.09 µM. H1: Hemolytic activity was 5.99% at 7.27 µM (32 µg/ml). H2: Hemolytic activity was 1.51% at 23.09 µM (128 µg/ml). H3: Hemolytic activity was 6.15% at 14.55 µM (64 µg/ml).|||up to ~5% hemo.lytic at 128 ug/ml.|||RBC (5.99% hemolysis at 7.27 uM)	2017 Dec;7(1):46. doi: 10.1186/s13568-017-0345-x. Epub 2017 Feb 22.|||AMB Express. 2017 Dec;7(1):46. doi: 10.1186/s13568-017-0345-x. PubMed|||28229435	40	
FPDB01269	AP04073|||AP04073|||H2	GFGCNGPWNEDDLRCRNHCKSIKGYKGGYCAKGGFVCKCY	Anti-Gram+ S. aureus ATCC 25923 or ATCC 6538 or MRSA ATCC 43300, activity value is MIC = 0.028||Anti-S. suis CVCC3309 or CVCC3928 or CVCC606, activity value is MIC = 0.014||Anti-S. pneumoniae CVCC1.8722 or CVCC2350, activity value is MIC = 0.227 uM||Anti-S-enteritidis CM, activity value is CC50 = 336||Anti-S-typhimurium ATCC14028, activity value is MIC > 7.273 uM||Anti-S-choleraesuis CV, activity value is CC50 = 3||Anti-S-pullorum CVCC1789, activity value is MIC > 7.273 uM||Anti-and E-coli CVCC195 or CICC21530, activity value is MIC > 7.273 uM||Antibacterial	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Synthetic construct	Bridge	NZ2114: Hemolytic activity remained at 1.00%, with a concentration range of 0.23 to 23.09 µM. H1: Hemolytic activity was 5.99% at 7.27 µM (32 µg/ml). H2: Hemolytic activity was 1.51% at 23.09 µM (128 µg/ml). H3: Hemolytic activity was 6.15% at 14.55 µM (65 µg/ml).|||up to ~5% hemo.lytic at 128 ug/ml.|||RBC (1.51% hemolysis at 23.09 uM)	2017 Dec;7(1):46. doi: 10.1186/s13568-017-0345-x. Epub 2017 Feb 22.|||AMB Express. 2017 Dec;7(1):46. doi: 10.1186/s13568-017-0345-x. PubMed|||31138863, 28229435	40	
FPDB01270	AP04074|||AP04074|||H3	GFGCNGPWNEDDLRCHNKCKSIKGYKGGYCAKGGFVCKCY	Anti-Gram+ S. aureus ATCC 25923 or ATCC 6538 or MRSA ATCC 43300, activity value is MIC = 0.014||Anti-S. suis CVCC3309 or CVCC3928 or CVCC606, activity value is MIC = 0.014||Anti-S. pneumoniae CVCC1.8722 or CVCC2350, activity value is MIC = 0.227||Anti-S-enteritidis CM, activity value is CC50 = 336||Anti-S-typhimurium ATCC14028, activity value is MIC > 7.273 uM||Anti-S-choleraesuis CV, activity value is CC50 = 3||Anti-S-pullorum CVCC1789, activity value is MIC > 7.273 uM||Anti-and E-coli CVCC195 or CICC21530, activity value is MIC > 7.273 uM||Antibacterial	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Synthetic construct	Bridge	NZ2114: Hemolytic activity remained at 1.00%, with a concentration range of 0.23 to 23.09 µM. H1: Hemolytic activity was 5.99% at 7.27 µM (32 µg/ml). H2: Hemolytic activity was 1.51% at 23.09 µM (128 µg/ml). H3: Hemolytic activity was 6.15% at 14.55 µM (66 µg/ml).|||up to ~5% hemo.lytic at 128 ug/ml.|||RBC (6.15% hemolysis at 14.55 uM)	2017 Dec;7(1):46. doi: 10.1186/s13568-017-0345-x. Epub 2017 Feb 22.|||AMB Express. 2017 Dec;7(1):46. doi: 10.1186/s13568-017-0345-x. PubMed|||28229435	40	
FPDB01271	AP04075|||AP04075|||H6	GFGCNGPWNEDDLRCKNRCKSIKGYKGGYCAKGGFVCKCY	Anti-Gram+ S. aureus ATCC 25923 or ATCC 6538 or MRSA ATCC 43300, activity value is MIC = 0.028||Anti-S. suis CVCC3309 or CVCC3928 or CVCC606, activity value is MIC = 0.014||Anti-S. pneumoniae CVCC1.8722 or CVCC2350, activity value is MIC = 0.454 uM||Anti-S-enteritidis CM, activity value is CC50 = 336||Anti-S-typhimurium ATCC14028, activity value is MIC > 7.273 uM||Anti-S-choleraesuis CV, activity value is CC50 = 3||Anti-S-pullorum CVCC1789, activity value is MIC > 7.273 uM||Anti-and E-coli CVCC195 or CICC21530, activity value is MIC > 7.273 uM||Antibacterial	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Synthetic construct	Bridge	NZ2114: Hemolytic activity remained at 1.00%, with a concentration range of 0.23 to 23.09 μM. H1: Hemolytic activity was 5.99% at 7.27 μM (32 μg/ml). H2: Hemolytic activity was 1.51% at 23.09 μM (128 μg/ml). H3: Hemolytic activity was 6.15% at 14.55 μM (67 μg/ml).	2017 Dec;7(1):46. doi: 10.1186/s13568-017-0345-x. Epub 2017 Feb 22.|||AMB Express. 2017 Dec;7(1):46. doi: 10.1186/s13568-017-0345-x. PubMed|||28229435	40	
FPDB01272	AP04076|||AP04076|||H8	"	
GFGCNGPWNEDDLRCRNRCKSIKGYKGGYCAKGGFVCKCY"	Anti-Gram+ S. aureus ATCC 25923 or ATCC 6538 or MRSA ATCC 43300, activity value is MIC = 0.028||Anti-S. suis CVCC3309 or CVCC3928 or CVCC606, activity value is MIC = 0.028||Anti-S. pneumoniae CVCC1.8722 or CVCC2350, activity value is MIC = 1.818 uM||Anti-S-enteritidis CM, activity value is CC50 = 336||Anti-S-typhimurium ATCC14028, activity value is MIC > 7.273 uM||Anti-S-choleraesuis CV, activity value is CC50 = 3||Anti-S-pullorum CVCC1789, activity value is MIC > 7.273 uM||Anti-and E-coli CVCC195 or CICC21530, activity value is MIC > 7.273 uM||Antibacterial	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives|||Synthetic construct	Bridge	NZ2114: Hemolytic activity remained at 1.00%, with a concentration range of 0.23 to 23.09 µM. H1: Hemolytic activity was 5.99% at 7.27 µM (32 µg/mL). H2: Hemolytic activity was 1.51% at 23.09 µM (128 µg/mL). H3: Hemolytic activity was 6.15% at 14.55 µM (68 µg/mL).	2017 Dec;7(1):46. doi: 10.1186/s13568-017-0345-x. Epub 2017 Feb 22.|||AMB Express. 2017 Dec;7(1):46. doi: 10.1186/s13568-017-0345-x. PubMed|||28229435	40	
FPDB01273	AP04077	ITSKSLCTPGCVTGILMTCPVQTATCGCQITGK	Anti-E. faecium ATCC700221, activity value is MIC = 1||Anti-A. hadrus MSK.14.23, activity value is MIC = 1 uM||Anti-B. obeum MSK.18.40, activity value is MIC = 0.1 uM||Anti-B. luti MSK.20.18, activity value is MIC = 0.1 uM||Anti-E. ramosum MSK.23.96, activity value is MIC = 10 uM||Anti-D. formicogenerans MSK.17.61, activity value is MIC = 0.1 uM||Anti-C. comes MSK.11.23, activity value is MIC = 1||Anti-C. eutactus MSK.18.32, activity value is MIC = 0.01||Anti-and F. fissicatena MSK.9.3, activity value is MIC = 0.1 uM	Blautia producta SCSK:human microbiota:Gut|||Blautia producta SCSK:human microbiota:Gut	N/A	N/A	2024 Feb 16;19(2):357-369. doi: 10.1021/acschembio.3c00577. Epub 2024 Jan 31.|||ACS Chem Biol. 2024 Jan 31. doi: 10.1021/acschembio.3c00577. PubMed	33	
FPDB01274	AP04090	GFGCNGPWLEDDAGCHNHCKSIKGYKGGYCAKGGFVCKCY	Anti-S. aureus 43300 MRSA or ATCC 25923 or E48 or 546, activity value is MIC = 4	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic activity of PN7: Even at a high concentration of 128 μg/ml, the hemolytic activity of PN7 is only 0.19%. Hemolytic activity of Plectasin: At a concentration of 128 μg/ml, the hemolytic activity of Plectasin is 67.18%.	2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283.|||Antibiotics (Basel). 2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283. PubMed	40	
FPDB01275	AP04091	"	
GFGCNGPWREDDTGCHNHCKSIKGYKGGYCAKGGFVCKCY"	Anti-S. aureus 43300 MRSA or ATCC 25923 or E48 or 546, activity value is MIC = 4	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic activity of PN7: Even at a high concentration of 128 μg/ml, the hemolytic activity of PN7 is only 0.19%. Hemolytic activity of Plectasin: At a concentration of 128 μg/ml, the hemolytic activity of Plectasin is 67.18%.	2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283.|||Antibiotics (Basel). 2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283. PubMed	40	
FPDB01276	AP04092	"	
GFGCNGPWREDDRTCHNHCKSIKGYKGGYCAKGGFVCKCY"	Anti-S. aureus 43300 MRSA or ATCC 25923 or E48 or 546, activity value is MIC = 8	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic activity of PN7: Even at a high concentration of 128 μg/ml, the hemolytic activity of PN7 is only 0.19%. Hemolytic activity of Plectasin: At a concentration of 128 μg/ml, the hemolytic activity of Plectasin is 67.18%.	2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283.|||Antibiotics (Basel). 2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283. PubMed	40	
FPDB01277	AP04093	GFGCNGPWIEDDATCHNHCKSIKGYKGGYCAKGGFVCKCY	Anti-S. aureus 43300 MRSA or ATCC 25923 or E48 or 546, activity value is MIC = 4	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic activity of PN7: Even at a high concentration of 128 μg/ml, the hemolytic activity of PN7 is only 0.19%. Hemolytic activity of Plectasin: At a concentration of 128 μg/ml, the hemolytic activity of Plectasin is 67.18%.	2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283.|||Antibiotics (Basel). 2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283. PubMed	40	
FPDB01278	AP04094	"	
GFGCNGPWNEDDVTCHNHCKSIKGYKGGYCAKGGFVCKCY"	Anti-S. aureus 43300 MRSA or ATCC 25923 or E48 or 546, activity value is MIC = 4	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic activity of PN7: Even at a high concentration of 128 μg/ml, the hemolytic activity of PN7 is only 0.19%. Hemolytic activity of Plectasin: At a concentration of 128 μg/ml, the hemolytic activity of Plectasin is 67.18%.	2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283.|||Antibiotics (Basel). 2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283. PubMed	40	
FPDB01279	AP04095	GFGCNGPWWEDDMQCHNHCKSIKGYKGGYCAKGGFVCKCY	Anti-S. aureus 43300 MRSA or ATCC 25923 or E48 or 546, activity value is MIC = 8	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic activity of PN7: Even at a high concentration of 128 μg/ml, the hemolytic activity of PN7 is only 0.19%. Hemolytic activity of Plectasin: At a concentration of 128 μg/ml, the hemolytic activity of Plectasin is 67.18%.	2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283.|||Antibiotics (Basel). 2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283. PubMed	40	
FPDB01280	AP04096	GFGCNGPWYEDDGRCHNHCKSIKGYKGGYCAKGGFVCKCY	Anti-S. aureus 43300 MRSA or ATCC 25923 or E48 or 546, activity value is MIC = 1||Anti-S. epidermidis ATCC 35984, activity value is MIC = 16 ug/ml||Anti-S. hyicus 437-2 or NCTC 10350, activity value is MIC = 4||Anti-Streptococcus. suis CVCC 606, activity value is MIC = 1 ug/ml||Anti-S. agalactiae ATCC 13813 or CAU-FRI-4, activity value is MIC = 1||activity value is MIC = 1||Anti-E.coli, activity value is MIC > 128 ug/ml||Anti-S.enterica ATCC 13076, activity value is MIC > 128 ug/ml||Anti-S.enteritidis CVCC 3377, activity value is MIC > 128 ug/ml||Anti-S.pullorum CVCC 1789, activity value is MIC > 128 ug/ml||Anti-P.aeruginosa, activity value is MIC > 128 ug/ml||Anti-and C.albicans, activity value is MIC > 128 ug/ml	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic activity of PN7: Even at a high concentration of 128 μg/ml, the hemolytic activity of PN7 is only 0.19%. Hemolytic activity of Plectasin: At a concentration of 128 μg/ml, the hemolytic activity of Plectasin is 67.18%.|||not hemo.lytic up to 128 ug/ml.	2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283.|||Antibiotics (Basel). 2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283. PubMed	40	
FPDB01281	AP04097	"	
GFGCNGPWNEDDGKCHNHCKSIKGYKGGYCAKGGFVCKCY"	Anti-S. aureus 43300 or E48 or 546, activity value is MIC = 4	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic activity of PN7: Even at a high concentration of 128 μg/ml, the hemolytic activity of PN7 is only 0.19%. Hemolytic activity of Plectasin: At a concentration of 128 μg/ml, the hemolytic activity of Plectasin is 67.18%.	2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283.|||Antibiotics (Basel). 2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283. PubMed	40	
FPDB01282	AP04098	GFGCNGPWREDDGSCHNHCKSIKGYKGGYCAKGGFVCKCY	Anti-S. aureus 43300 MRSA, activity value is MIC = 16 ug/ml	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic activity of PN7: Even at a high concentration of 128 μg/ml, the hemolytic activity of PN7 is only 0.19%. Hemolytic activity of Plectasin: At a concentration of 128 μg/ml, the hemolytic activity of Plectasin is 67.18%.	2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283.|||Antibiotics (Basel). 2023 Aug 3;12(8):1283. doi: 10.3390/antibiotics12081283. PubMed	40	
FPDB01283	AP04099	YKSKSVCTPGCPTGILMTCPLKTATCGCHITGK	Anti-Methicillin-resistant S. aureus USA300 MRSA, activity value is MIC = 1||Anti-L. monocytogenes 10403S, activity value is MIC = 10 uM||Anti-and C. difficile VPI10463, activity value is MIC = 1 uM||Anti-A. hadrus MSK.14.23, activity value is MIC = 0.01||Anti-B. obeum MSK.18.40, activity value is MIC = 0.01 uM||Anti-B. luti MSK.20.18, activity value is MIC = 0.001||Anti-E. ramosum MSK.23.96, activity value is MIC = 10 uM||Anti-D. formicogenerans MSK.17.61, activity value is MIC = 0.01 uM||Anti-C. comes MSK.11.23, activity value is MIC = 0.1||Anti-C. eutactus MSK.18.32, activity value is MIC = 0.1 uM||Anti-and F. fissicatena MSK.9.3, activity value is MIC = 0.01	Dorea formicigenerans:human microbiota:Gut	N/A	N/A	2024 Feb 16;19(2):357-369. doi: 10.1021/acschembio.3c00577. Epub 2024 Jan 31.|||ACS Chem Biol. 2024 Jan 31. doi: 10.1021/acschembio.3c00577. PubMed	33	
FPDB01284	AP04100	"	
KARVAVKVIRFLYKAW"	Anti-S. aureus MRSA, activity value is MIC = 12 uM||Anti-Gram+||Anti-MRSA	Designed	N/A	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||6.36±3.6 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01285	AP04101	RARVAVRVIRFLYRAW	Anti-S. aureus MRSA, activity value is MIC = 12 uM||Anti-Gram+||Anti-MRSA	Designed	N/A	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||9.34±3.2 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01286	AP04102	RRWIARRAIWRRRRWW	Anti-S. aureus MRSA, activity value is MIC = 48 uM||Anti-Gram+||Anti-MRSA	Designed	N/A	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||17.20±5.3 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01287	AP04103	RRFFVRRVFFRRRRFF	Anti-S. aureus MRSA, activity value is MIC = 48 uM||Anti-Gram+||Anti-MRSA	Designed	Helix	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||30.07±5.4 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01288	AP04104	WRWWRRRRWWRWRRWW	Anti-S. aureus MRSA, activity value is MIC = 48 uM||Anti-Gram+||Anti-MRSA	Designed	Helix	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||40.31±6.3 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01289	AP04105	RRWWWRRWWWRRRRWW	Anti-S. aureus MRSA, activity value is MIC = 48 uM||Anti-Gram+||Anti-MRSA	Designed	N/A	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||51.31±9.7 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01290	AP04106	"	
RRRWARRIIWIIRRAW"	Anti-S. aureus MRSA, activity value is MIC = 24 uM||Anti-Gram+||Anti-MRSA	Designed	N/A	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||8.66±3.1 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01291	AP04107	"	
RRRVARRVFWFVRRAV"	Anti-S. aureus MRSA, activity value is MIC = 24 uM||Anti-Gram+||Anti-MRSA	Designed	Helix	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||8.25±3.3 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01292	AP04108	RRRVARRVIRFIRRAW	Anti-S. aureus MRSA, activity value is MIC = 12 uM||Anti-Gram+||Anti-MRSA	Designed	Helix	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||10.22±4.1 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01293	AP04109	LRRFARRLIRRIRRAW	Anti-S. aureus MRSA, activity value is MIC = 12 uM||Anti-Gram+||Anti-MRSA	Designed	N/A	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||7.16±3.7 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01294	AP04110	WARIARRAIRAWRRWW	Anti-S. aureus MRSA, activity value is MIC = 12 uM||Anti-Gram+||Anti-MRSA	Designed	Helix	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||20.06±4.5 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01295	AP04111	LFRVVRRVVRFIRRAA	Anti-S. aureus MRSA, activity value is MIC = 12 uM||Anti-Gram+||Anti-MRSA	Designed	Helix	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||7.53±4.1 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01296	AP04112	"	
LARVARRVIRFIRRAW"	Anti-S. aureus 10 MRSA strains, activity value is MIC = 3||Anti-Gram+||Anti-MRSA	Designed	Helix	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%|||8.58±3.5 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01297	AP04113	"	
RRRLARRLIFFIRRAW"	Anti-S. aureus 10 MRSA strains, activity value is MIC = 3||Anti-Gram+||Anti-MRSA	Designed	Helix	H9:HC10: >320 uMHC50: >320 uMHmax (100%): 5.92±22%CGS1:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±26%CGS2:HC10: >320 uMHC50: >320 uMHmax (100%): 7.51±1.8%CGS3:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±25%CGS4:HC10: 320 uMHC50: >320 uMHmax (100%): 11.31±4.3%CGS5:HC10: >320 uMHC50: >320 uMHmax (100%): 6.36±3.6%CGS6:HC10: 320 uMHC50: >320 uMHmax (100%): 9.34±32%CGS7:HC10: 9235 uMHC50: >320 uMHmax (100%): 17.20±5.3%CGS8:HC10: 41.05 uMHC50: >320 uMHmax (100%): 30.07±5.4%CGS9:HC10: 3320 uMHC50: >320 uMHmax (100%): 40.31±6.3%CGS10:HC10: 25.91 uMHC50: >320 uMHmax (100%): 51.31±9.7%CGS11:HC10: 24 uMHC50: >320 uMHmax (100%): 8.66±3.1%CGS12:HC10: 24 uMHC50: >320 uMHmax (100%): 8.25±3.3%CGS13:HC10: 320 uMHC50: >320 uMHmax (100%): 10.22±4.1%CGS14:HC10: 320 uMHC50: >320 uMHmax (100%): 7.16±3.7%CGS15:HC10: >320 uMHC50: >320 uMHmax (100%): 7.57±3.9%CGS16:HC10: >320 uMHC50: >320 uMHmax (100%): 8.74±24%CGS17:HC10: 75.19 uMHC50: >320 uMHmax (100%): 20.06±4.5%CGS18:HC10: 320 uMHC50: >320 uMHmax (100%): 7.53±4.1%CGS19:HC10: >320 uMHC50: >320 uMHmax (100%): 8.58±3.5%CGS20:HC10: >320 uMHC50: >320 uMHmax (100%): 8.97±3.7%Vancomycin:HC10: >320 uMHC50: >320 uMHmax (100%): 6.24±34%|||8.97±3.7 at the highest peptide concentration tested (320 uM).	2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. Epub 2024 Jan 3.|||J Med Chem. 2024 Jan 25;67(2):1044-1060. doi: 10.1021/acs.jmedchem.3c01360. PubMed	16	
FPDB01298	AP04114	"	
ITSKSLCTPGCVTGLLMGCAGSSATCNCSVHVG"	Anti-Methicillin-resistant S. aureus USA300 MRSA, activity value is MIC = 10||Anti-Methicillin-resistant S. epidermidis SK135, activity value is MIC = 10||Anti-L. monocytogenes 10403S, activity value is MIC = 10||Anti-and C. difficile VPI10463, activity value is MIC = 10||Anti-A. hadrus MSK.14.23, activity value is MIC = 0.1 uM||Anti-B. obeum MSK.18.40, activity value is MIC = 0.1||Anti-B. luti MSK.20.18, activity value is MIC = 0.1||Anti-E. ramosum MSK.23.96, activity value is MIC = 10 uM||Anti-D. formicogenerans MSK.17.61, activity value is MIC = 0.1||Anti-C. comes MSK.11.23, activity value is MIC = 0.01 uM||Anti-C. eutactus MSK.18.32, activity value is MIC = 1 uM||Anti-and F. fissicatena MSK.9.3, activity value is MIC = 0.1||Anti-Gram+||Anti-MRSA	Pseudobutyrivibrio sp. 49_1	N/A	N/A	2024 Feb 16;19(2):357-369. doi: 10.1021/acschembio.3c00577. Epub 2024 Jan 31.|||ACS Chem Biol. 2024 Jan 31. doi: 10.1021/acschembio.3c00577. PubMed	33	
FPDB01299	AP04122	ITSKSLCTPGCVTGVLMGCNNKTATCNCSVHVG	Anti-E. faecium ATCC700221, activity value is MIC = 10||Anti-Methicillin-resistant S. aureus USA300 MRSA, activity value is MIC = 10||Anti-Methicillin-resistant S. epidermidis SK135, activity value is MIC = 10||Anti-L. monocytogenes 10403S, activity value is MIC = 10||Anti-and C. difficile VPI10463, activity value is MIC = 1||Anti-A. hadrus MSK.14.23, activity value is MIC = 0.01 uM||Anti-B. obeum MSK.18.40, activity value is MIC = 0.1 uM||Anti-B. luti MSK.20.18, activity value is MIC = 0.1 uM||Anti-E. ramosum MSK.23.96, activity value is MIC = 10 uM||Anti-D. formicogenerans MSK.17.61, activity value is MIC = 0.01||Anti-C. comes MSK.11.23, activity value is MIC = 0.01 uM||Anti-C. eutactus MSK.18.32, activity value is MIC = 0.1||Anti-and F. fissicatena MSK.9.3, activity value is MIC = 0.1 uM||Anti-Gram+||Anti-MRSA	Pseudobutyrivibrio sp. 49_2	N/A	N/A	2024 Feb 16;19(2):357-369. doi: 10.1021/acschembio.3c00577. Epub 2024 Jan 31.|||ACS Chem Biol. 2024 Jan 31. doi: 10.1021/acschembio.3c00577. PubMed	33	
FPDB01300	AP04124	"	
ITSWSLCTAGCITGRIMGCNK"	Anti-L. lactis MG1363, activity value is MIC = 0.08 ug/ml||Anti-L. monocytogenes LMG10470 or TT82E or LK132, activity value is MIC = 2.56||Anti-B. cereus CH-85, activity value is MIC = 20.5 ug/ml||Anti-S. aureus LMG10147 or LMG15975 MRSA, activity value is MIC = 5.13 ug/ml||Anti-E. faecium LMG11423 or LMG16003 anti-VRE, activity value is MIC = 5.13||Anti-E. faecalis LMG16216 VRE, activity value is MIC = 5.13 ug/ml||Anti-C. perfringens CECT376, activity value is MIC = 0.5 ug/ml||Anti-and C-difficile CECT531, activity value is MIC > 31.5 ug/ml||Anti-Gram+||Anti-MRSA	the psychrophilic anaerobe Clostridium estertheticum	N/A	Cesin: At a concentration of 64 µg/ml, Cesin exhibits low levels of hemolysis. Its hemolytic level is comparable to Nisin. Nisin: At a concentration of 64 µg/ml, Nisin also exhibits low levels of hemolysis.	2023 Sep 27;11(5):e0531922. doi: 10.1128/spectrum.05319-22. Online ahead of print.|||Microbiol Spectr. 2023 Sep 27;11(5):e0531922. doi: 10.1128/spectrum.05319-22. PubMed	21	
FPDB01301	AP04125	ITSISLCTPGCKTGALMGCNMK	Anti-L. lactis MG1363, activity value is MIC = 1.28 ug/ml||Anti-L. monocytogenes LMG10470 or TT82E or LK132, activity value is MIC = 10.25||Anti-B-cereus CH-85, activity value is MIC > 41 ug/ml||Anti-S. aureus LMG10147 or LMG15975 MRSA, activity value is MIC = 20.5 ug/ml||Anti-E. faecium LMG11423, activity value is MIC = 41 ug/ml||Anti-E-faecium LMG16003 VRE, activity value is MIC > 41 ug/ml||Anti-E-faecalis LMG16216 VRE, activity value is MIC > 41 ug/ml||Anti-Gram+||Anti-MRSA	sequence truncation, lantibiotic, bacteria-derived, natural derivative	N/A	Cesin: At a concentration of 64 µg/ml, Cesin exhibits low levels of hemolysis. Its hemolytic level is comparable to Nisin. Nisin: At a concentration of 64 µg/ml, Nisin also exhibits low levels of hemolysis.	2023 Sep 27;11(5):e0531922. doi: 10.1128/spectrum.05319-22. Online ahead of print.|||Microbiol Spectr. 2023 Sep 27;11(5):e0531922. doi: 10.1128/spectrum.05319-22. PubMed	22	
FPDB01302	AP04139	CGCYCKSVDKKRRFFIPTCLRSCCN	Active against E. coli ATCC 25922 and S. aureus USA300 LAC (activity screen||fraction 24 from HPLC||relative to antibiotic).||Anti-Gram+ & Gram-	Greater Celandine, Chelidonium majus	Bridge	N/A	2024 Mar 22;87(3):544-553. doi: 10.1021/acs.jnatprod.3c00939. Epub 2024 Feb 17.|||J Nat Prod. 2024 Feb 17. doi: 10.1021/acs.jnatprod.3c00939. PubMed	25	
FPDB01303	AP04174	"	
HFDNLNKIQANI"	Anti-S. aureus QD-2 or ATCC25923 MRSA, activity value is MIC = 11.25||Anti-B. cereus MCCC M25811 or 63301, activity value is MIC = 22.51||Anti-E. faecalis CCARM 5172, activity value is MIC = 22.51 uM||Anti-L. monocytogenes CGMCC 1.9136, activity value is MIC = 45.01 uM||Anti-Gram+||Anti-MRSA	Bacillus licheniformis M1	N/A	N/A	2024 Mar 13;72(10):5283-5292. doi: 10.1021/acs.jafc.4c00573. Epub 2024 Mar 1.|||J Agric Food Chem. 2024 Mar 1. doi: 10.1021/acs.jafc.4c00573. PubMed	12	
FPDB01304	AP04192	ALWKTLLKKVGKVAGKAVLNAVTNMANQN	Anti-Gram- E. coli ATCC 8739 or K12 or ML35p or resistant p7, activity value is MIC = 0.8||Anti-P. aeruginosa ATCC 9027 or ATCC 27853, activity value is MIC = 3.2||Anti-K. pneumoniae CIP 52.211, activity value is MIC = 0.8 uM||Anti-K. oxytoca CIP 7932, activity value is MIC = 3.2 uM||Anti-S. enterica CIP 8297, activity value is MIC = 12.5 uM||Anti-Y. ruckeri ATGG 29473, activity value is MIC = 3.2 uM||Anti-S. aureus ATCC 6538 or ST 1065 or MRSA, activity value is MIC = 1.6||Anti-S. epidermidis BM 3302, activity value is MIC = 6.3 uM||Anti-L. monocytogenes SOR 100, activity value is MIC = 25 uM||Anti-E. faecalis CIP A186, activity value is MIC = 50 uM||Anti-L. garvieae ATCC 43921, activity value is MIC = 50 uM||Anti-E. faecalis CIP 103015, activity value is MIC = 6.3 uM||Anti-and K. rhizophila ATCC 9341, activity value is MIC = 0.8 uM||Anti-Gram+ & Gram-||Anti-MRSA	the Mexican Frog, Pachymedusa dacnicolor, Mexico, North America	N/A	Control group (1% Triton X-100): Hemolysis percentage: 100% DRS-DA2N and DRS-DA2NEQ: At a concentration of 10 μM, after incubation with human erythrocytes and mouse erythrocytes for 1 hour, the hemolysis percentage did not increase significantly.	2024 Jan 13:2024:2205864. doi: 10.1155/2024/2205864. eCollection 2024.|||Int J Inflam. 2024 Jan 13;2024:2205864. doi: 10.1155/2024/2205864. PubMed	29	
FPDB01305	AP04197|||AP04197|||Cathelicidin AM, AM-CATH36|||DRAMP20824	GLFKKLRRKIKKGFKKIFKRLPPIGVGVSIPLAGKR	Anti-A. baumannii ATCC 9955 or ATCC BAA-1794, activity value is MIC = 1.3 uM||Anti-E-faecalis ATCC 22192 or 51299, activity value is MIC > 10 uM||Anti-E. coli ATCC 4157, activity value is MIC = 34 uM||Anti-K. pneumoniae ATCC 33495 or ATCC BAA-1705, activity value is MIC = 1.3||Anti-P. aeruginosa ATCC 9027 or ATCC BAA-2110, activity value is MIC = 1.3 uM||Anti-and S. aureus ATCC 25923 or 33592, activity value is MIC = 5.1 uM||Anti-Gram+ & Gram-||Antibacterial||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 21 ug/ml||Anti-Staphylococcus aureus ATCC 33592, activity value is MIC = 21 ug/ml||Anti-##Gram-negative bacteria:Acinetobacter baumannii ATCC 9955, activity value is MIC = 5.2 ug/ml||Anti-Acinetobacter baumannii ATCC BAA-1794, activity value is MIC = 5.2 ug/ml||Anti-Escherichia coli ATCC 4157, activity value is MIC = 140 ug/ml||Anti-K. pneumoniae ATCC 33495, activity value is MIC = 5.2 ug/ml||Anti-K. pneumoniae ATCC BAA-1705, activity value is MIC = 5.6 ug/ml||Anti-Pseudomonas aeruginosa ATCC 9027, activity value is MIC = 5.2 ug/ml||Anti-Pseudomonas aeruginosa ATCC BAA-2110, activity value is MIC = 5.2 ug/ml	American alligator, Alligator mississippiensis|||American alligator, Alligator mississippiensis|||Alligator mississippiensis|||Synthetic construct	Helix||Alpha helix, random coil	Sheep erythrocytes (- at NA|||[Ref.28089718] 0% hemolysis at 300 ug/ml against sheep red cells	2017 May:70:135-144. doi: 10.1016/j.dci.2017.01.011. Epub 2017 Jan 13.|||Dev Comp Immunol. 2017 May;70:135-144. doi: 10.1016/j.dci.2017.01.011. PubMed|||34121235, 28089718|||Dev Comp Immunol. 2017 May;70:135-144.||Ref.28089718	36	
FPDB01306	AP04199|||AP04199|||Cathelicidin AM|||DRAMP20826	"	
GLFKKLRRKIKKGFKKIFKRL"	Anti-A. baumannii ATCC 9955 or ATCC BAA-1794, activity value is MIC = 1.6||Anti-E-faecalis ATCC 22192 or 51299, activity value is MIC > 16 uM||Anti-E. coli ATCC 4157, activity value is MIC = 7.9||Anti-K. pneumoniae ATCC 33495 or ATCC BAA-1705, activity value is MIC = 2||Anti-P. aeruginosa ATCC 9027 or ATCC BAA-2110, activity value is MIC = 3.9||Anti-and S. aureus ATCC 25923 or 33592, activity value is MIC = 11 uM||Anti-Gram+ & Gram-||Antibacterial||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 28 ug/ml||Anti-Staphylococcus aureus ATCC 33592, activity value is MIC = 28 ug/ml||Anti-##Gram-negative bacteria:Acinetobacter baumannii ATCC 9955, activity value is MIC = 42 ug/ml||Anti-Acinetobacter baumannii ATCC BAA-1794, activity value is MIC = 10 ug/ml||Anti-Escherichia coli ATCC 4157, activity value is MIC = 21 ug/ml||Anti-Escherichia coli ATCC 51659, activity value is MIC = 140 ug/ml||Anti-K. pneumoniae ATCC 33495, activity value is MIC = 5.2 ug/ml||Anti-K. pneumoniae ATCC BAA-1705, activity value is MIC = 28 ug/ml||Anti-Pseudomonas aeruginosa ATCC 9027, activity value is MIC = 10 ug/ml||Anti-Pseudomonas aeruginosa ATCC BAA-2110, activity value is MIC = 42 ug/ml	sequence truncation, animal-derived, natural derivative|||sequence truncation, animal-derived, natural derivative|||Staphylococcus aureus (USA300 / TCH1517)|||Synthetic construct	Helix||Alpha helix, random coil	Sheep erythrocytes (- at NA|||[Ref.28089718] 0.5% hemolysis at 300 ug/ml against sheep red cells	2017 May:70:135-144. doi: 10.1016/j.dci.2017.01.011. Epub 2017 Jan 13.|||Dev Comp Immunol. 2017 May;70:135-144. doi: 10.1016/j.dci.2017.01.011. PubMed|||28089718|||Dev Comp Immunol. 2017 May;70:135-144.||Ref.28089718	21	
FPDB01307	AP04200	"	
GLFKKLRRKIKKGFKKIF"	Anti-E. coli ATCC 25922 or 4 clinical strains, activity value is MIC = 32||Anti-P. aeruginosa ATCC 27853 or 4 clinical strrains, activity value is MIC = 16||Anti-K-pneumoniae ATCC 13883, activity value is MIC > 128 ug/ml||Anti-A. baumannii, activity value is MIC = 32 ug/ml||Anti-S.aureus ATCC 29213, activity value is MIC = 128 ug/ml||Anti-MRSA, activity value is MIC = 64 ug/ml||Anti-S. epidermidis, activity value is MIC = 128 ug/ml||Anti-and C. albicans, activity value is MIC = 64 ug/ml||Anti-Gram+ & Gram-||Antifungal||Anti-MRSA	sequence truncation, animal-derived, natural derivative	N/A	AS-14 and AS-12W: show minimal hemolytic activity against sheep red blood cells (SRBCs) (HC₅₀>512 ug/ml). AS-14WW: has higher hemolytic activity, but the specific value is not clearly given.	2024 Apr 8. doi: 10.1007/s12602-024-10250-2. Online ahead of print.|||Probiotics Antimicrob Proteins. 2024 Apr 8. doi: 10.1007/s12602-024-10250-2. PubMed|||Probiotics Antimicrob Proteins. 2024 Apr 8. doi: 10.1007/s12602-024-10250-2. PubMed	18	
FPDB01308	AP04201	GLFKKLWRKIKKGFKKIF	Anti-E. coli ATCC 25922 or 4 clinical strains, activity value is MIC = 16||Anti-P. aeruginosa ATCC 27853 or 4 clinical strrains, activity value is MIC = 16||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 16||Anti-A. baumannii, activity value is MIC = 8 ug/ml||Anti-S. aureus ATCC 29213, activity value is MIC = 16 ug/ml||Anti-MRSA, activity value is MIC = 64 ug/ml||Anti-S.epidermidis, activity value is MIC = 128 ug/ml||Anti-and C. albicans, activity value is MIC = 64 ug/ml||Anti-Gram+ & Gram-||Antifungal||Anti-MRSA	sequence truncation, amino acid substitution, animal-derived, natural derivative	N/A	AS-14 and AS-12W: show minimal hemolytic activity against sheep red blood cells (SRBCs) (HC₅₀>512 ug/ml). AS-14WW: has higher hemolytic activity, but the specific value is not clearly given.	2024 Apr 8. doi: 10.1007/s12602-024-10250-2. Online ahead of print.|||Probiotics Antimicrob Proteins. 2024 Apr 8. doi: 10.1007/s12602-024-10250-2. PubMed	18	
FPDB01309	AP04202	GLFKKLRRKIKKGF	Anti-E. coli ATCC 25922 or 4 clinical strains, activity value is MIC = 16||Anti-P. aeruginosa ATCC 27853 or 4 clinical strrains, activity value is MIC = 8||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 64||Anti-A. baumannii, activity value is MIC = 64 ug/ml||Anti-S. aureus ATCC 29213, activity value is MIC = 16 ug/ml||Anti-MRSA, activity value is MIC = 16 ug/ml||Anti-S.epidermidis, activity value is MIC > 128 ug/ml||Anti-and C. albicans, activity value is MIC = 8 ug/ml||Anti-Gram+ & Gram-||Antifungal||Anti-MRSA	sequence truncation, animal-derived, natural derivative	N/A	AS-14 and AS-12W: show minimal hemolytic activity against sheep red blood cells (SRBCs) (HC₅₀>512 ug/ml). AS-14WW: has higher hemolytic activity, but the specific value is not clearly given.	2024 Apr 8. doi: 10.1007/s12602-024-10250-2. Online ahead of print.|||Probiotics Antimicrob Proteins. 2024 Apr 8. doi: 10.1007/s12602-024-10250-2. PubMed	14	
FPDB01310	AP04203	"	
GLFKKLWRKIKKWF"	Anti-E. coli ATCC 25922 or 4 clinical strains, activity value is MIC = 8||Anti-P. aeruginosa ATCC 27853 or 4 clinical strrains, activity value is MIC = 8||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 4||Anti-A. baumannii, activity value is MIC = 64 ug/ml||Anti-S. aureus ATCC 29213, activity value is MIC = 16 ug/ml||Anti-MRSA, activity value is MIC = 8 ug/ml||Anti-S. epidermidis, activity value is MIC = 64 ug/ml||Anti-and C. albicans, activity value is MIC = 16 ug/ml||Anti-Gram+ & Gram-||Antifungal||Anti-MRSA	sequence truncation, amino acid substitution, animal-derived, natural derivative	N/A	AS-14 and AS-12W: show minimal hemolytic activity against sheep red blood cells (SRBCs) (HC₅₀>512 ug/ml). AS-14WW: has higher hemolytic activity, but the specific value is not clearly given.	2024 Apr 8. doi: 10.1007/s12602-024-10250-2. Online ahead of print.|||Probiotics Antimicrob Proteins. 2024 Apr 8. doi: 10.1007/s12602-024-10250-2. PubMed	14	
FPDB01311	AP04204	LRRKIKKGFKKIFKRL	Anti-E. coli ATCC 25922 or 4 clinical strains, activity value is MIC = 8||Anti-P. aeruginosa ATCC 27853 or 4 clinical strrains, activity value is MIC = 8||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 32 ug/ml||Anti-A. baumannii, activity value is MIC = 16 ug/ml||Anti-S. aureus ATCC 29213, activity value is MIC = 8 ug/ml||Anti-MRSA, activity value is MIC = 16 ug/ml||Anti-S. epidermidis, activity value is MIC = 32 ug/ml||Anti-and C.albicans, activity value is MIC > 128 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA	sequence truncation, animal-derived, natural derivative	N/A	AS-14 and AS-12W: show minimal hemolytic activity against sheep red blood cells (SRBCs) (HC₅₀>512 ug/ml). AS-14WW: has higher hemolytic activity, but the specific value is not clearly given.	2024 Apr 8. doi: 10.1007/s12602-024-10250-2. Online ahead of print.|||Probiotics Antimicrob Proteins. 2024 Apr 8. doi: 10.1007/s12602-024-10250-2. PubMed	16	
FPDB01312	AP04205	"	
LWRKIKKWFKKIFKRL"	Anti-E. coli ATCC 25922 or 4 clinical strains, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa ATCC 27853 or 4 clinical strrains, activity value is MIC = 16||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 16||Anti-A. baumannii, activity value is MIC = 16 ug/ml||Anti-S. aureus ATCC 29213, activity value is MIC = 32 ug/ml||Anti-MRSA, activity value is MIC = 8 ug/ml||Anti-S. epidermidis, activity value is MIC = 32 ug/ml||Anti-and C.albicans, activity value is MIC = 16 ug/ml||Anti-Gram+ & Gram-||Antifungal||Anti-MRSA	sequence truncation, amino acid substitution, animal-derived, natural derivative	N/A	AS-14 and AS-12W: show minimal hemolytic activity against sheep red blood cells (SRBCs) (HC₅₀>512 ug/ml). AS-14WW: has higher hemolytic activity, but the specific value is not clearly given.	2024 Apr 8. doi: 10.1007/s12602-024-10250-2. Online ahead of print.|||Probiotics Antimicrob Proteins. 2024 Apr 8. doi: 10.1007/s12602-024-10250-2. PubMed	16	
FPDB01313	AP04207	"	
IKKWFKKIFKRL"	Anti-E. coli ATCC 25922 or 4 clinical strains, activity value is MIC = 8||Anti-P. aeruginosa ATCC 27853 or 4 clinical strrains, activity value is MIC = 4||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 8||Anti-A. baumannii, activity value is MIC = 16 ug/ml||Anti-S. aureus ATCC 29213, activity value is MIC = 4 ug/ml||Anti-MRSA, activity value is MIC = 8 ug/ml||Anti-S. epidermidis, activity value is MIC = 4 ug/ml||Anti-and C.albicans, activity value is MIC = 16 ug/ml||Anti-Gram+ & Gram-||Antifungal||Anti-MRSA||Anti-inflammatory	sequence truncation, amino acid substitution, animal-derived, natural derivative	Helix	AS-14 and AS-12W: show minimal hemolytic activity against sheep red blood cells (SRBCs) (HC₅₀>512 ug/ml). AS-14WW: has higher hemolytic activity, but the specific value is not clearly given.	2024 Apr 8. doi: 10.1007/s12602-024-10250-2. Online ahead of print.|||Probiotics Antimicrob Proteins. 2024 Apr 8. doi: 10.1007/s12602-024-10250-2. PubMed	12	
FPDB01314	AP04241|||AP04241|||Peptide 6	"	
GFGCNGPWSEDDIQCHNHCKSIKGYKGGYCAKGGFVCKCY"	Anti-S. aureus ATCC 43300 or ATCC 25923, activity value is MIC = 1||Anti-Gram+||Anti-MRSA||Antibacterial	amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||Synthetic construct	Bridge	Maximum hemolysis of NZL: 1.11% (at a concentration of 256 µg/ml) Maximum hemolysis of NZ2114: 1.35% (at a concentration of 256 µg/ml)	2021 May 21;22(11):5435. doi: 10.3390/ijms22115435.|||Int J Mol Sci. 2021 May 21;22(11):5435. doi: 10.3390/ijms22115435. PubMed|||34063982	40	
FPDB01315	AP04242|||AP04242|||Peptide 7	GFGCNGPWSEDDLQCHNHCKSIKGYKGGYCARGGFVCKCY	Anti-S. aureus ATCC 43300, activity value is MIC = 2 ug/ml||Anti-Gram+||Anti-MRSA||Antibacterial	amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||Synthetic construct	Bridge	Maximum hemolysis of NZL: 1.11% (at a concentration of 256 µg/ml) Maximum hemolysis of NZ2114: 1.35% (at a concentration of 256 µg/ml)	2021 May 21;22(11):5435. doi: 10.3390/ijms22115435.|||Int J Mol Sci. 2021 May 21;22(11):5435. doi: 10.3390/ijms22115435. PubMed|||34063982	40	
FPDB01316	AP04243|||AP04243|||Peptide 8	GFGCNGPWSEDDIRCHNHCKSIKGYKGGYCASAGFVCKCY	Anti-S. aureus ATCC 43300, activity value is MIC = 64 ug/ml||Anti-Gram+||Anti-MRSA||Antibacterial	amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||Synthetic construct	Bridge	Maximum hemolysis of NZL: 1.11% (at a concentration of 256 µg/ml) Maximum hemolysis of NZ2114: 1.35% (at a concentration of 256 µg/ml)	2021 May 21;22(11):5435. doi: 10.3390/ijms22115435.|||Int J Mol Sci. 2021 May 21;22(11):5435. doi: 10.3390/ijms22115435. PubMed|||34063982	40	
FPDB01317	AP04244|||AP04244|||Peptide 9	"	
GFGCNGPWQEDDLKCHNHCKSIKGYKGGYCASAGFVCKCY"	Anti-S. aureus ATCC 43300, activity value is MIC = 4 ug/ml||Anti-Gram+||Anti-MRSA||Antibacterial	amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||Synthetic construct	Bridge	Maximum hemolysis of NZL: 1.11% (at a concentration of 256 µg/ml) Maximum hemolysis of NZ2114: 1.35% (at a concentration of 256 µg/ml)	2021 May 21;22(11):5435. doi: 10.3390/ijms22115435.|||Int J Mol Sci. 2021 May 21;22(11):5435. doi: 10.3390/ijms22115435. PubMed|||34063982	40	
FPDB01318	AP04245	"	
GFGCPWDEMQCHNHCKSIKGYKGGYCAKGGFVCKCY"	Anti-Gram+ S. aureus ATCC 43300 or ATCC25923 or CVCC546 or E48, activity value is MIC = 4||Anti-S. epidermidis ATCC35984 or ATCC12228, activity value is MIC = 2||Anti-S. dysgalactiae CVCC3938, activity value is MIC = 4 ug/ml||Anti-S. agalactiae ATCC13813 or CAU-FRI-2022-01 or CAU-FRI-2022-02, activity value is MIC = 2||Anti-E.coli, activity value is MIC > 128 ug/ml||Anti-Shigella CMCC392, activity value is MIC > 128 ug/ml||Anti-S.enteriditis CVCC3377, activity value is MIC > 128 ug/ml||Anti-P.aeruginsoa CICC21630, activity value is MIC > 128 ug/ml||Anti-and C.albicans, activity value is MIC > 128 ug/ml||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	36	
FPDB01319	AP04247	"	
GFGCPWDEDDMQCHNHCKSIKGYKGGYCAKGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	38	
FPDB01320	AP04248	GFGCNGPWDEMQCHNHCKSIKGYKGGYCAKGGFVCKCY	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	38	
FPDB01321	AP04249	"	
GFGCNGPWDEDDMQCHNHCIKGYKGGYCAKGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	38	
FPDB01322	AP04250	GFGCNGPWDEDDMQCHNHCKSIKGYKGGYCGGFVCKCY	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	38	
FPDB01323	AP04251	"	
GFGCNGPWDEDDMQCHNHCKSIKGYKGGYCAKGGF"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	N/A	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	35	
FPDB01324	AP04252	"	
GFGCPWDEDDMQCHNHCIKGYKGGYCAKGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	36	
FPDB01325	AP04253	"	
GFGCPWDEDDMQCHNHCKSIKGYKGGYCGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	36	
FPDB01326	AP04254	"	
GFGCNGPWDEMQCHNHCIKGYKGGYCAKGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	36	
FPDB01327	AP04255	"	
GFGCNGPWDEMQCHNHCKSIKGYKGGYCGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	36	
FPDB01328	AP04256	"	
GFGCNGPWDEDDMQCHNHCIKGYKGGYCGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	36	
FPDB01329	AP04257	"	
GFGCPWDEMQCHNHCIKGYKGGYCAKGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	34	
FPDB01330	AP04258	"	
GFGCPWDEMQCHNHCKSIKGYKGGYCGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	34	
FPDB01331	AP04259	"	
GFGCPWDEDDMQCHNHCIKGYKGGYCGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	34	
FPDB01332	AP04260	"	
GFGCNGPWDEMQCHNHCIKGYKGGYCGGFVCKCY"	active against Gram+ S. aureus ATCC 43300.||Anti-Gram+||Anti-MRSA	amino acid deletion, fungal defensin analog, fungi-derived, natural derivative	Bridge	The hemolysis rate of Ple-AB at a concentration of 256 µg/ml is 1.07%. The hemolysis rate of plectasin at a concentration of 256 µg/ml is 68%.	2023 Dec 21:14:1304825. doi: 10.3389/fmicb.2023.1304825. eCollection 2023.|||Front Microbiol. 2023 Dec 21;14:1304825. doi: 10.3389/fmicb.2023.1304825. PubMed	34	
FPDB01333	AP04262|||AP04266|||AP04266|||CAMPSQ8798|||DRAMP20813	"	
LILGKLWKGVKSIF"	Anti-Gram- E. coli AB94012 or ATCC25922, activity value is MIC = 50||Anti-P. aeruginosa AB93066 or ATCC9027, activity value is MIC = 25||Anti-S. aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374, activity value is MIC = 6.25||Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli AB94012, activity value is MIC = 50 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 100 ug/ml||Anti-P. aeruginosa AB93066, activity value is MIC = 100 ug/ml||Anti-P. aeruginosa ATCC9027, activity value is MIC = 25 ug/ml||Anti-S. aureus AB94004, activity value is MIC = 12.5 ug/ml||Anti-S. aureus ATCC6538, activity value is MIC = 12.5 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 12.5 ug/ml||Anti-S. aureus MRSA P1381, activity value is MIC = 25 ug/ml||Anti-S. aureus MRSA P1374, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus AB94004, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus ATCC6538, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus MRSA P1381, activity value is MIC = 25 ug/ml||Anti-Staphylococcus aureus MRSA P1374, activity value is MIC = 6.25 ug/ml||Anti-##Gram-negative bacteria: Escherichia coli AB94012, activity value is MIC = 50 ug/ml||Anti-Escherichia coli ATCC25922, activity value is MIC = 100 ug/ml||Anti-Pseudomonas aeruginosa AB93066, activity value is MIC = 100 ug/ml||Anti-Pseudomonas aeruginosa ATCC9027, activity value is MIC = 25 ug/ml	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct	Alpha helix	Hp1404: At a concentration of 400 ug/ml, the hemolysis is 100%. K8: At a concentration of 400 ug/ml, the hemolysis is 32.5%. L1K8: At a concentration of 400 ug/ml, the hemolysis is 11.5%. S1K8: At a concentration of 400 ug/ml, the hemolysis is 26.5%. F1K8: At a concentration of 400 ug/ml, the hemolysis is 21.5%. K1K8: At a concentration of 400 ug/ml, the hemolysis is 11.5%.|||Human RBC (10% hemolytic at 400 ug/ml)|||[Ref.26952110] 2% hemolysis at 200 ug/ml, 10% hemolysis at 400 ug/ml against human red blood cells	2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. Epub 2016 Mar 8.|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. PubMed|||26952110|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77.||Ref.26952110	14	
FPDB01334	AP04267|||AP04267|||CAMPSQ8799|||DRAMP20814	"	
SILGKLWKGVKSIF"	Anti-Gram- E. coli AB94012 or ATCC25922, activity value is MIC = 25||Anti-P. aeruginosa AB93066 or ATCC9027, activity value is MIC = 25||Anti-S. aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374, activity value is MIC = 6.25||Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli AB94012, activity value is MIC = 25 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 50 ug/ml||Anti-P. aeruginosa AB93066, activity value is MIC = 50 ug/ml||Anti-P. aeruginosa ATCC9027, activity value is MIC = 25 ug/ml||Anti-S. aureus AB94004, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC6538, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 6.25 ug/ml||Anti-S. aureus MRSA P1381, activity value is MIC = 12.5 ug/ml||Anti-S. aureus MRSA P1374, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus AB94004, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC6538, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus MRSA P1381, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus MRSA P1374, activity value is MIC = 6.25 ug/ml||Anti-##Gram-negative bacteria: Escherichia coli AB94012, activity value is MIC = 25 ug/ml||Anti-Escherichia coli ATCC25922, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa AB93066, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa ATCC9027, activity value is MIC = 25 ug/ml	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct	Alpha helix	Hp1404: At a concentration of 400 ug/ml, the hemolysis is 100%. K8: At a concentration of 400 ug/ml, the hemolysis is 32.5%. L1K8: At a concentration of 400 ug/ml, the hemolysis is 11.5%. S1K8: At a concentration of 400 ug/ml, the hemolysis is 26.5%. F1K8: At a concentration of 400 ug/ml, the hemolysis is 21.5%. K1K8: At a concentration of 400 ug/ml, the hemolysis is 11.5%.|||Human RBC (50% hemolytic at 400 ug/ml)|||[Ref.26952110] 15% hemolysis at 200 ug/ml, 45% hemolysis at 400 ug/ml against human red blood cells	2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. Epub 2016 Mar 8.|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. PubMed|||26952110|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77.||Ref.26952110	14	
FPDB01335	AP04268|||AP04268|||CAMPSQ8800|||DRAMP20815	"	
FILGKLWKGVKSIF"	Anti-Gram- E. coli AB94012 or ATCC25922, activity value is MIC = 25||Anti-P. aeruginosa AB93066 or ATCC9027, activity value is MIC = 50 ug/ml||Anti-S. aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374, activity value is MIC = 6.25||Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli AB94012, activity value is MIC = 25 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 50 ug/ml||Anti-P. aeruginosa AB93066, activity value is MIC = 50 ug/ml||Anti-P. aeruginosa ATCC9027, activity value is MIC = 50 ug/ml||Anti-S. aureus AB94004, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC6538, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 6.25 ug/ml||Anti-S. aureus MRSA P1381, activity value is MIC = 12.5 ug/ml||Anti-S. aureus MRSA P1374, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus AB94004, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC6538, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus MRSA P1381, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus MRSA P1374, activity value is MIC = 12.5 ug/ml||Anti-##Gram-negative bacteria: Escherichia coli AB94012, activity value is MIC = 25 ug/ml||Anti-Escherichia coli ATCC25922, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa AB93066, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa ATCC9027, activity value is MIC = 50 ug/ml	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct	Alpha helix	Hp1404: At a concentration of 400 ug/ml, the hemolysis is 100%. K8: At a concentration of 400 ug/ml, the hemolysis is 32.5%. L1K8: At a concentration of 400 ug/ml, the hemolysis is 11.5%. S1K8: At a concentration of 400 ug/ml, the hemolysis is 26.5%. F1K8: At a concentration of 400 ug/ml, the hemolysis is 21.5%. K1K8: At a concentration of 400 ug/ml, the hemolysis is 11.5%.|||Human RBC (78% hemolytic at 400 ug/ml)|||[Ref.26952110] 2% hemolysis at 100 ug/ml, 35% hemolysis at 200 ug/ml, 70% hemolysis at 400 ug/ml against human red blood cells	2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. Epub 2016 Mar 8.|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. PubMed|||26952110|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77.||Ref.26952110	14	
FPDB01336	AP04269|||AP04269|||CAMPSQ8801|||DRAMP20816	"	
KILGKLWKGVKSIF"	Anti-Gram- E. coli AB94012 or ATCC25922, activity value is MIC = 25||Anti-P. aeruginosa AB93066 or ATCC9027, activity value is MIC = 50 ug/ml||Anti-S. aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374, activity value is MIC = 6.25||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Anti-E. coli AB94012, activity value is MIC = 25 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 50 ug/ml||Anti-P. aeruginosa AB93066, activity value is MIC = 50 ug/ml||Anti-P. aeruginosa ATCC9027, activity value is MIC = 50 ug/ml||Anti-S. aureus AB94004, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC6538, activity value is MIC = 12.5 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 12.5 ug/ml||Anti-S. aureus MRSA P1381, activity value is MIC = 6.25 ug/ml||Anti-S. aureus MRSA P1374, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus AB94004, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC6538, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus MRSA P1381, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus MRSA P1374, activity value is MIC = 6.25 ug/ml||Anti-##Gram-negative bacteria: Escherichia coli AB94012, activity value is MIC = 25 ug/ml||Anti-Escherichia coli ATCC25922, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa AB93066, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa ATCC9027, activity value is MIC = 50 ug/ml	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct	Helix||Alpha helix	Hp1404: At a concentration of 400 ug/ml, the hemolysis is 100%. K8: At a concentration of 400 ug/ml, the hemolysis is 32.5%. L1K8: At a concentration of 400 ug/ml, the hemolysis is 11.5%. S1K8: At a concentration of 400 ug/ml, the hemolysis is 26.5%. F1K8: At a concentration of 400 ug/ml, the hemolysis is 21.5%. K1K8: At a concentration of 400 ug/ml, the hemolysis is 11.5%.|||Human RBC (10% hemolytic at 400 ug/ml)|||[Ref.26952110] 10% hemolysis at 400 ug/ml against human red blood cells|||human RBC: HC50: >>400 ug/ml, ~10% hemo.lytic at 400 ug/ml (similar to L1K8, least in the series).	2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. Epub 2016 Mar 8.||Shui et al., 2024|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. PubMed|||26952110|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77.||Ref.26952110|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. PubMed||Shui et al., 2024	14	
FPDB01337	AP04265|||AP04265|||CAMPSQ8797|||DRAMP20812	"	
GILGKLWKGVKSIF"	Anti-Gram- E. coli AB94012 or ATCC25922, activity value is MIC = 25||Anti-P. aeruginosa AB93066 or ATCC9027, activity value is MIC = 25||Anti-S. aureus AB94004 or ATCC25923 or MRSA P1381 or MRSA P1374, activity value is MIC = 6.25||Anti-Gram+ & Gram-||Anti-MRSA||Anti-E. coli AB94012, activity value is MIC = 25 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 100 ug/ml||Anti-P. aeruginosa AB93066, activity value is MIC = 50 ug/ml||Anti-P. aeruginosa ATCC9027, activity value is MIC = 25 ug/ml||Anti-S. aureus AB94004, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC6538, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 12.5 ug/ml||Anti-S. aureus MRSA P1381, activity value is MIC = 6.25 ug/ml||Anti-S. aureus MRSA P1374, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus AB94004, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC6538, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus ATCC25923, activity value is MIC = 12.5 ug/ml||Anti-Staphylococcus aureus MRSA P1381, activity value is MIC = 6.25 ug/ml||Anti-Staphylococcus aureus MRSA P1374, activity value is MIC = 6.25 ug/ml||Anti-##Gram-negative bacteria: Escherichia coli AB94012, activity value is MIC = 25 ug/ml||Anti-Escherichia coli ATCC25922, activity value is MIC = 100 ug/ml||Anti-Pseudomonas aeruginosa AB93066, activity value is MIC = 50 ug/ml||Anti-Pseudomonas aeruginosa ATCC9027, activity value is MIC = 25 ug/ml	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct	Alpha helix	Hp1404: At a concentration of 400 ug/ml, the hemolysis is 100%. K8: At a concentration of 400 ug/ml, the hemolysis is 32.5%. L1K8: At a concentration of 400 ug/ml, the hemolysis is 11.5%. S1K8: At a concentration of 400 ug/ml, the hemolysis is 26.5%. F1K8: At a concentration of 400 ug/ml, the hemolysis is 21.5%. K1K8: At a concentration of 400 ug/ml, the hemolysis is 11.5%.|||Human RBC (65% hemolytic at 400 ug/ml)|||[Ref.26952110] 2% hemolysis at 50 ug/ml, 20% hemolysis at 100 ug/ml, 45% hemolysis at 200 ug/ml, 65% hemolysis at 400 ug/ml against human red blood cells	2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. Epub 2016 Mar 8.|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77. doi: 10.1007/s00253-016-7395-x. PubMed|||26952110|||Appl Microbiol Biotechnol. 2016 Jun;100(11):5069-77.||Ref.26952110	14	
FPDB01338	AP04276|||AP04276|||Peptide 87|||DRAMP03917|||Peptide 87|||DRAMP03917	"	
RWRWRW"	Anti-S. aureus SG511 or Mu50 VISA or COL or ATCC43300 MRSA, activity value is MIC = 8||Anti-E. coli DSM30083 or W3110, activity value is MIC = 32 ug/ml||Anti-A. baumannii, activity value is MIC = 32 ug/ml||Anti-P-aeruginosa, activity value is MIC > 64 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus, activity value is MIC = 36.175361 uM||Anti-P. aeruginosa, activity value is MIC = 297.943592 uM||Anti-C. albicans, activity value is MIC = 181.143941 uM||Antimicrobial||Antifungal	designed, (a new form was also made: peptide conjugates)|||designed|||Synthetic construct|||Synthetic construct (De novo design)|||Synthetic construct|||Synthetic construct (De novo design)	Rich	(RW)₃ Peptide: The L-amino acid version of the (RW)₃ peptide showed 17% hemolysis at 333 μM (500 μg/ml). The D-amino acid version of the (RW)₃ peptide showed no hemolysis at 333 μM (500 μg/ml). ReCO-W(RW)₂ Peptide: The L-amino acid version of the ReCO-W(RW)₂ peptide showed 64% hemolysis at 192 μM (263 μg/ml). The D-amino acid version of the ReCO-W(RW)₂ peptide showed 68% hemolysis at 192 μM (263 μg/ml).|||Hemolytic acitivity against Horse RBCs	2012:8:1753-64. doi: 10.3762/bjoc.8.200. Epub 2012 Oct 15.||Wenzel et al., 2016|||Beilstein J Org Chem. 2012;8:1753-64. doi: 10.3762/bjoc.8.200. PubMed|||Int J Mol Sci. 2012; 13(11): 15042-15053.|||https://pubmed.ncbi.nlm.nih.gov/34021253|||Int J Mol Sci. 2012; 13(11): 15042-15053.	6	
FPDB01339	AP04277|||AP04277|||Plectasin-derived peptide NZ2114	GFGCNGPWQEDDVKCHNHCKSIKGYKGGYCAKGGFVCKCY	Anti-and S. aureus ATCC 25923 but not E.coli. MIC: S. aureus ATCC25923 or ATCC29213 or ATCC6538 or ATCC43300 and 20 MRSA clinical strains, activity value is MIC = 0.004||Anti-Gram+||Anti-MRSA||Antibacterial	amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||Synthetic construct	Bridge	rMP1102 exhibits hemolytic activity below 0.05% at a concentration of 128 µg/ml.|||Human erythrocytes (0% Hemolysis at 128 ug/ml	2015 Aug;99(15):6255-66. doi: 10.1007/s00253-015-6394-7. Epub 2015 Jan 27.|||Appl Microbiol Biotechnol. 2015 Aug;99(15):6255-66. doi: 10.1007/s00253-015-6394-7. PubMed|||26921181	40	
FPDB01340	AP04522	"	
FLSQILSTLRILL"	Anti-S. aureus USA300 LAC and 5 clinical strains, activity value is MIC = 1||Anti-S. epidermidis 1457, activity value is MIC = 1 uM||Anti-E-coli E423-17, activity value is MIC > 16 uM||Anti-A-baumannii B28-16, activity value is MIC > 16 uM||Anti-P-aeruginosa E411-17, activity value is MIC > 16 uM||Anti-and K-pneumoniae E406-17, activity value is MIC > 16 uM||Anti-Gram+||Anti-MRSA||Antibiofilm	designed, bacteria-derived, natural derivative	N/A	"YZ103：HC₅₀ >200 uMYZ104：HC₅₀ >200 uMYZ105：HC₅₀ 150 uMYZ106：HC₅₀ 50 uMYZ107：HC₅₀ 25 uM|||The document explicitly mentions the hemolytic values of the target peptides (YZ103, YZ104, YZ105, YZ106, YZ107), using the 50% hemolytic concentration (HC₅₀) as the core evaluation index. The specific data are as follows:

Hemolytic values and related parameters of each peptide

Peptide Name | 50% Hemolytic Concentration (HC₅₀, μM) | Cell Selectivity Index (HC₅₀/MIC) | HPLC Retention Time (min)
YZ103 | >200 | NA (no antibacterial activity) | 8.770
YZ104 | >200 | NA (no antibacterial activity) | 11.746
YZ105 | 150 | 150 (MIC=1 μM) | 13.945
YZ106 | 50 | 25 (MIC=2 μM) | 12.312
YZ107 | 25 | 12.5 (MIC=2 μM) | 12.297

Key Notes

1. HC₅₀ Definition: The peptide concentration that causes 50% hemolysis of human red blood cells (hRBCs); a higher value indicates lower hemolytic toxicity of the peptide.
2. Cell Selectivity Index: Calculated as the ratio of HC₅₀ to the minimum inhibitory concentration (MIC) against Staphylococcus aureus USA300. A higher ratio indicates stronger bacterial selectivity and lower toxicity to human cells. Among them, YZ105 has the highest selectivity index (150) and is the focus of the study as a low-toxicity, high-efficiency candidate peptide.
3. Experimental Method: A series of diluted peptides were incubated with 2% human red blood cell suspension at 37 °C for 1 hour. 1% Triton X-100 (100% hemolysis) and PBS (0% hemolysis) were used as controls. Hemoglobin release was measured at 545 nm absorbance, hemolysis rates were calculated, and HC₅₀ was derived from fitting the data."	2022 Sep;114(5):e24269. doi: 10.1002/pep2.24269. Epub 2022 Apr 25.|||Pept Sci (Hoboken). 2022 Sep;114(5):e24269. doi: 10.1002/pep2.24269. PubMed	13	
FPDB01341	AP04523	"	
FLSKILSTLRILL"	Anti-S. aureus USA300 LAC, activity value is MIC = 2 uM||Anti-S. epidermidis 1457, activity value is MIC = 1||Anti-E. coli E423-17, activity value is MIC = 8||Anti-A. aumannii B28-16, activity value is MIC = 8 uM||Anti-P-aeruginosa E411-17, activity value is MIC > 16 uM||Anti-and K-pneumoniae E406-17, activity value is MIC > 16 uM	designed, bacteria-derived, natural derivative	N/A	YZ103：HC₅₀ >200 uMYZ104：HC₅₀ >200 uMYZ105：HC₅₀ 150 uMYZ106：HC₅₀ 50 uMYZ107：HC₅₀ 25 uM	2022 Sep;114(5):e24269. doi: 10.1002/pep2.24269. Epub 2022 Apr 25.	13	
FPDB01342	AP04524	"	
FLSKILSTLRILF"	Anti-S. aureus USA300 LAC, activity value is MIC = 2 uM||Anti-S. epidermidis 1457, activity value is MIC = 2 uM||Anti-E. coli E423-17, activity value is MIC = 8 uM||Anti-A. aumannii B28-16, activity value is MIC = 4||Anti-P. aeruginosa E411-17, activity value is MIC = 8||Anti-and K-pneumoniae E406-17, activity value is MIC > 16 uM	designed, bacteria-derived, natural derivative	N/A	YZ103：HC₅₀ >200 uMYZ104：HC₅₀ >200 uMYZ105：HC₅₀ 150 uMYZ106：HC₅₀ 50 uMYZ107：HC₅₀ 25 uM	2022 Sep;114(5):e24269. doi: 10.1002/pep2.24269. Epub 2022 Apr 25.	13	
FPDB01343	AP04561|||AP04561|||CAMPSQ14096	"	
FIKKIAKLLKKIF"	Anti-S. aureus ATCC 29212 or MRSA, activity value is MIC = 5 ug/ml||Anti-S. epidermidis, activity value is MIC = 2.5||Anti-E. faecalis, activity value is MIC = 5||Anti-E. faecium, activity value is MIC = 5 ug/ml||Anti-and E. coli ATCC 25922, activity value is MIC = 5 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus ATCC29213, activity value is MIC = 5 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 5 ug/ml	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct	Helix	BmKn2: At a concentration of 25 µg/mL, the hemolytic activity was 91.8%. Kn2(G3K): At a concentration of 25 µg/mL, the hemolytic activity is 69.0%. Kn2(A4R): At a concentration of 25 µg/mL, the hemolytic activity is 100%. Kn2(S10R): At a concentration of 25 µg/mL, the hemolytic activity is 50.9%. Kn2(G3K_A4R): At a concentration of 25 µg/mL, the hemolytic activity is 8.3%. Kn2(A4R_S10R): At a concentration of 25 µg/mL, the hemolytic activity is 18.0%. Kn2(G3K_S10R): At a concentration of 25 µg/mL, the hemolytic activity is 77.5%. BmKn2-7: At a concentration of 25 µg/mL, the hemolytic activity is 6.9%. BmKn2-7K: At a concentration of 100 µg/mL, the hemolytic activity is 12.2%. BmKn2-7R: At a concentration of 100 µg/mL, the hemolytic activity is 73.1%. Kn2-7(K3R): At a concentration of 100 µg/mL, the hemolytic activity is 89.3%.	2021 Jul 15:12:684591. doi: 10.3389/fmicb.2021.684591. eCollection 2021.|||Front Microbiol. 2021 Jul 15;12:684591. doi: 10.3389/fmicb.2021.684591. PubMed|||34335511	13	
FPDB01344	AP04562|||AP04562|||CAMPSQ14097|||CAMPSQ14143	"	
FIRRIARLLRRIF"	Anti-S. aureus ATCC 29212 or MRSA, activity value is MIC = 5 ug/ml||Anti-S. epidermidis, activity value is MIC = 2.5||Anti-E. faecalis, activity value is MIC = 5||Anti-E. faecium, activity value is MIC = 2.5 ug/ml||Anti-and E. coli ATCC 25922, activity value is MIC = 10 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA||Anti-S. aureus ATCC29213, activity value is MIC = 5 ug/ml||Anti-E. coli ATCC25922, activity value is MIC = 10 ug/ml||Anti-Salmonella sp. clinical isolate 5, activity value is MIC = 8 uM||Anti-Salmonella sp. clinical isolate 7, activity value is MIC = 8 uM||Anti-Salmonella sp. clinical isolate 11, activity value is MIC = 8 uM||Anti-Salmonella sp. clinical isolate 18, activity value is MIC = 8 uM||Anti-Salmonella sp. clinical isolate 26, activity value is MIC = 8 uM||Anti-Salmonella sp. clinical isolate 27, activity value is MIC = 8 uM||Anti-Salmonella sp. clinical isolate 55, activity value is MIC = 8 uM	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct	Helix	BmKn2: At a concentration of 25 µg/mL, the hemolytic activity was 91.8%. Kn2(G3K): At a concentration of 25 µg/mL, the hemolytic activity is 69.0%. Kn2(A4R): At a concentration of 25 µg/mL, the hemolytic activity is 100%. Kn2(S10R): At a concentration of 25 µg/mL, the hemolytic activity is 50.9%. Kn2(G3K_A4R): At a concentration of 25 µg/mL, the hemolytic activity is 8.3%. Kn2(A4R_S10R): At a concentration of 25 µg/mL, the hemolytic activity is 18.0%. Kn2(G3K_S10R): At a concentration of 25 µg/mL, the hemolytic activity is 77.5%. BmKn2-7: At a concentration of 25 µg/mL, the hemolytic activity is 6.9%. BmKn2-7K: At a concentration of 100 µg/mL, the hemolytic activity is 12.2%. BmKn2-7R: At a concentration of 100 µg/mL, the hemolytic activity is 73.1%. Kn2-7(K3R): At a concentration of 100 µg/mL, the hemolytic activity is 89.3%.|||Sheep RBC [HC50= 886.5 uM]	2021 Jul 15:12:684591. doi: 10.3389/fmicb.2021.684591. eCollection 2021.|||Front Microbiol. 2021 Jul 15;12:684591. doi: 10.3389/fmicb.2021.684591. PubMed|||34335511|||34361810	13	
FPDB01345	AP04597	FLWKLIPKAIKKVKSLIKK	Anti-S. aureus ATCC29213 or ATCC25923 MRSA, activity value is MIC = 1.8 uM||Anti-E. faecium ATCC29212, activity value is MIC = 3.5 uM||Anti-E. coli ATCC25922 or ATCC35218, activity value is MIC = 1.8||Anti-P. aeruginosa ATCC27853, activity value is MIC = 1.8 uM||Anti-K. pneumoniae ATCC700603, activity value is MIC = 3.5 uM||Anti-A. baumannii ATCC19606, activity value is MIC = 0.9 uM||Anti-Gram+ & Gram-||Anti-MRSA	amino acid substitution, animal-derived, natural derivative	Helix	The following are the hemolytic values of Ctriporin and its analogs at a concentration of 256 µg/ml: Ctriporin: 90.6 ± 11.8% CM1: 75.6 ± 10.1% CM2: 43 ± 9.2% CM3: 89.1 ± 12.1% CM4: 140 ± 47% CM5: 9.8 ± 0.6% CM6: 8.1 ± 1.9% CM7: 75 ± 9.8%|||9.8±0.6 at256 ug/ml .Antimicrobial activities of Ctriporin and its analogs against standard strains	2024 Mar 18;16(3):156. doi: 10.3390/toxins16030156.|||Toxins (Basel). 2024 Mar 18;16(3):156. doi: 10.3390/toxins16030156. PubMed	19	
FPDB01346	AP04598	"	
FLWKLIPKAIKKVKKLIKK"	Anti-S. aureus ATCC29213 or ATCC25923 MRSA, activity value is MIC = 3.4 uM||Anti-E. faecium ATCC29212, activity value is MIC = 3.4 uM||Anti-E. coli ATCC25922 or ATCC35218, activity value is MIC = 3.4 uM||Anti-P. aeruginosa ATCC27853, activity value is MIC = 1.7 uM||Anti-K. pneumoniae ATCC700603, activity value is MIC = 3.4 uM||Anti-A. baumannii ATCC19606, activity value is MIC = 1.7 uM||Anti-Gram+ & Gram-||Anti-MRSA	amino acid substitution, animal-derived, natural derivative	Helix	The following are the hemolytic values of Ctriporin and its analogs at a concentration of 256 µg/ml: Ctriporin: 90.6 ± 11.8% CM1: 75.6 ± 10.1% CM2: 43 ± 9.2% CM3: 89.1 ± 12.1% CM4: 140 ± 47% CM5: 9.8 ± 0.6% CM6: 8.1 ± 1.9% CM7: 75 ± 9.8%|||8.1±1.9 at256 ug/ml .Antimicrobial activities of Ctriporin and its analogs against standard strains	2024 Mar 18;16(3):156. doi: 10.3390/toxins16030156.|||Toxins (Basel). 2024 Mar 18;16(3):156. doi: 10.3390/toxins16030156. PubMed	19	
FPDB01347	AP04601|||AP04601|||N1	"	
GFCWNVCVYRNGVRVCHRRCN"	Anti-Gram- bacteria E. coli CVCC195 or CVCC1515 or CICC21530 serotype O157:H7, activity value is MIC = 0.25||Anti-S. typhimurium ATCC14028, activity value is MIC = 0.5 ug/ml||Anti-S. enteritidis CVCC3377, activity value is MIC = 0.25 ug/ml||Anti-S. pullorum CVCC1789 or CVCC1802, activity value is MIC = 0.25 ug/ml||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-P. aeruginosa CICC10419 or CICC21630, activity value is MIC = 2||Anti-S. aureus ATCC43300 MRSA or ATCC25923, activity value is MIC = 0.5||Anti-S. suis CVCC606, activity value is MIC = 16 ug/ml||Anti-E-faecium CMCC1.2136, activity value is MIC > 16 ug/ml||Anti-B. subtilis ATCC6633, activity value is MIC = 0.25 ug/ml||Anti-L.ivanovii ATCC19119, activity value is MIC = 128 ug/ml||Anti-C. albicans CGMCC2.2411, activity value is MIC = 16 ug/ml||Anti-Escherichia coli CVCC195, activity value is MIC = 0.5||Anti-E. coli CVCC1515, activity value is MIC = 0.25 ug/ml||Anti-E. coli CICC21530, activity value is MIC = 0.5 ug/ml||Anti-Salmonella typhimurium ATCC14028, activity value is MIC = 0.5 ug/ml||Anti-S. pullorum CVCC1789, activity value is MIC = 0.25 ug/ml||Anti-S. pullorum CVCC1802, activity value is MIC = 0.25 ug/ml||Anti-Pseudomonas aeruginosa CICC10419, activity value is MIC = 2 ug/ml||Anti-P. aeruginosa CICC21630, activity value is MIC = 4 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 16 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 0.5||Anti-Bacillus subtilis ATCC6633, activity value is MIC = 0.25 ug/ml||Anti-Listeria ivanovii ATCC19119, activity value is MIC = 128 ug/ml||Anti-Candida albicans CGMCC2.2411, activity value is MIC = 16 ug/ml	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Arenicola marina	Beta	N1: At a concentration of 128 µg/ml, hemolysis is 3%. N2: At a concentration of 128 µg/ml, hemolysis is 0.4%; at a concentration of 256 µg/ml, hemolysis is 3.8%. N6: At a concentration of 128 µg/ml, hemolysis is 0.04%; at a concentration of 256 µg/ml, hemolysis is 1.9%.	2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2.|||Sci Rep. 2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2. PubMed|||28611436|||Sci Rep. 2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2. PubMed	21	
FPDB01348	AP04602|||AP04602|||N2	"	
AFCWNVCVYRNAVRVCHRRCN"	Anti-Gram- bacteria E. coli CVCC195 or CVCC1515 or CICC21530 serotype O157:H7, activity value is MIC = 0.25||Anti-S. typhimurium ATCC14028, activity value is MIC = 1 ug/ml||Anti-S. enteritidis CVCC3377, activity value is MIC = 0.125 ug/ml||Anti-S. pullorum CVCC1789 or CVCC1802, activity value is MIC = 0.25||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-P. aeruginosa CICC10419 or CICC21630, activity value is MIC = 2 ug/ml||Anti-S. aureus ATCC43300 MRSA or ATCC25923, activity value is MIC = 0.25||Anti-S. suis CVCC606, activity value is MIC = 16 ug/ml||Anti-E. faecium CMCC1.2136, activity value is MIC = 4 ug/ml||Anti-B. subtilis ATCC6633, activity value is MIC = 0.5 ug/ml||Anti-L. ivanovii ATCC19119, activity value is MIC = 4 ug/ml||Anti-C. albicans CGMCC2.2411, activity value is MIC = 32 ug/ml||Anti-Escherichia coli CVCC195, activity value is MIC = 0.25 ug/ml||Anti-E. coli CVCC1515a, activity value is MIC = 0.5 ug/ml||Anti-E. coli CICC21530, activity value is MIC = 0.25 ug/ml||Anti-Salmonella typhimurium ATCC14028, activity value is MIC = 1 ug/ml||Anti-S. pullorum CVCC1789, activity value is MIC = 0.5 ug/ml||Anti-S. pullorum CVCC1802, activity value is MIC = 0.25 ug/ml||Anti-Pseudomonas aeruginosa CICC10419, activity value is MIC = 2 ug/ml||Anti-P. aeruginosa CICC21630, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 16 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 0.25 ug/ml||Anti-Enterococcus faecium CMCC1.2136, activity value is MIC = 4 ug/ml||Anti-Bacillus subtilis ATCC6633, activity value is MIC = 0.5 ug/ml||Anti-Listeria ivanovii ATCC19119, activity value is MIC = 4 ug/ml||Anti-Candida albicans CGMCC2.2411, activity value is MIC = 32 ug/ml||Anti-S. typhimurium, activity value is MIC = 0.78 uM	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct	Beta	"N1: At a concentration of 128 µg/ml, hemolysis is 3%. N2: At a concentration of 128 µg/ml, hemolysis is 0.4%; at a concentration of 256 µg/ml, hemolysis is 3.8%. N6: At a concentration of 128 µg/ml, hemolysis is 0.04%; at a concentration of 256 µg/ml, hemolysis is 1.9%.|||At a concentration of 128 µg/mL, the hemolysis rate of mouse red blood cells was 0.4%; at a concentration of 256 µg/mL, the hemolysis rate was 3.8%.
At a concentration of N6:128 µg/mL, the hemolysis rate of mouse red blood cells was 0.04%; at a concentration of 256 µg/mL, the hemolysis rate was 1.9%.
At a concentration of 32 µg/mL, the parent peptide N1 exhibited a hemolysis rate of 3% (for comparative reference).|||murine RBC: 4% hemolysis at 256 ug/ml (low hemo.lytic)."	2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2.|||Sci Rep. 2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2. PubMed|||28611436|||29329001|||Sci Rep. 2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2. PubMed	21	
FPDB01349	AP04604|||AP04604|||N4	WGFCWNVCVYRNGVRVCHRRCN	Anti-Gram- bacteria E. coli CVCC195 or CVCC1515 or CICC21530 serotype O157:H7, activity value is MIC = 1 ug/ml||Anti-S. typhimurium ATCC14028, activity value is MIC = 2 ug/ml||Anti-S. enteritidis CVCC3377, activity value is MIC = 0.25 ug/ml||Anti-S. pullorum CVCC1789 or CVCC1802, activity value is MIC = 1||Anti-P. aeruginosa CICC21630, activity value is MIC = 4 ug/ml||Anti-S. aureus ATCC43300 MRSA or ATCC25923, activity value is MIC = 1||Anti-B. subtilis ATCC6633, activity value is MIC = 1 ug/ml||Antibacterial	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct	N/A	N1: At a concentration of 128 µg/ml, hemolysis is 3%. N2: At a concentration of 128 µg/ml, hemolysis is 0.4%; at a concentration of 256 µg/ml, hemolysis is 3.8%. N6: At a concentration of 128 µg/ml, hemolysis is 0.04%; at a concentration of 256 µg/ml, hemolysis is 1.9%.|||Escherichia coli CVCC195(MIC=1 ug/ml), E. coli CVCC1515(MIC=1 ug/ml), E. coli CICC21530 (serotype O157:H7)(MIC=1 ug/ml), Salmonella typhimurium ATCC14028(MIC=2 ug/ml), S. enteritidis CVCC3377 (MIC=0.25 ug/ml), S. pullorum CVCC1789(MIC=1 ug/ml), S. pullorum CVCC1802(MIC=2 ug/ml), P. aeruginosa CICC21630(MIC=4 ug/ml), Staphylococcus aureus ATCC43300(MIC=8 ug/ml), S. aureus ATCC25923(MIC=1 ug/ml), Listeria ivanovii ATCC19119(MIC=1 ug/ml)	. 2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2.|||Sci Rep. 2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2. PubMed|||28611436	22	
FPDB01350	AP04606|||AP04606|||N6|||N6-NH2-miniPEG|||N6-NH2-PEG6|||N6-NH2-PEG12|||N6-NH2-PEG24|||N6-COOH-miniPEG|||N6-NH2-miniPEG|||N6-NH2-PEG6|||N6-NH2-PEG12|||N6-NH2-PEG24|||N6-COOH-miniPEG|||DRAMP29066|||DRAMP29067	"	
GFAWNVCVYRNGVRVCHRRAN"	Anti-Gram- bacteria E. coli CVCC195 or CVCC1515 or CICC21530 serotype O157:H7, activity value is MIC = 0.5||Anti-S. typhimurium ATCC14028, activity value is MIC = 2 ug/ml||Anti-S. enteritidis CVCC3377, activity value is MIC = 0.25 ug/ml||Anti-S. pullorum CVCC1789 or CVCC1802, activity value is MIC = 0.5 ug/ml||Anti-S. choleraesuis CV, activity value is CC50 = 3||Anti-P. aeruginosa CICC10419 or CICC21630, activity value is MIC = 4||Anti-S. aureus ATCC43300 MRSA or ATCC25923, activity value is MIC = 0.25||Anti-S. suis CVCC606, activity value is MIC = 16 ug/ml||Anti-E. faecium CMCC1.2136, activity value is MIC = 4 ug/ml||Anti-B. subtilis ATCC6633, activity value is MIC = 0.5 ug/ml||Anti-C. albicans CGMCC2.2411, activity value is MIC = 64 ug/ml||Anti-Escherichia coli CVCC195, activity value is MIC = 0.5 ug/ml||Anti-E. coli CVCC1515, activity value is MIC = 1 ug/ml||Anti-E. coli CICC21530, activity value is MIC = 0.5 ug/ml||Anti-Salmonella typhimurium ATCC14028, activity value is MIC = 2 ug/ml||Anti-S. pullorum CVCC1789, activity value is MIC = 0.5 ug/ml||Anti-S. pullorum CVCC1802a, activity value is MIC = 0.5 ug/ml||Anti-Pseudomonas aeruginosa CICC10419, activity value is MIC = 8 ug/ml||Anti-P. aeruginosa CICC21630, activity value is MIC = 4 ug/ml||Anti-Staphylococcus aureus ATCC43300, activity value is MIC = 16 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 0.25 ug/ml||Anti-S. suis CVCC606, activity value is MIC = 6 ug/ml||Anti-Enterococcus faecium CMCC1.2136, activity value is MIC = 4 ug/ml||Anti-Bacillus subtilis ATCC6633, activity value is MIC = 0.5 ug/ml||Anti-Candida albicans CGMCC2.2411, activity value is MIC = 64 ug/ml||Antibacterial||Antifungal||Anti-E. coli CVCC195, activity value is MIC = 16 ug/ml||Anti-S. typhimurium ATCC14028, activity value is MIC = 16 ug/ml||Anti-S. pullorum CVCC1802, activity value is MIC = 16 ug/ml||Anti-S. enteritidis CVCC3377, activity value is MIC = 16 ug/ml||Anti-P. aeruginosa CICC21630, activity value is MIC = 64 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 128 ug/ml||Anti-S. typhimurium ATCC14028, activity value is MIC = 32 ug/ml||Anti-S. enteritidis CVCC3377, activity value is MIC = 32 ug/ml||Anti-P. aeruginosa CICC21630, activity value is MIC = 128 ug/ml||Anti-E. coli CVCC195, activity value is MIC = 32 ug/ml||Anti-S. typhimurium ATCC14028, activity value is MIC = 64 ug/ml||Anti-S. pullorum CVCC1802, activity value is MIC = 32 ug/ml||Anti-E. coli CVCC195, activity value is MIC = 128 ug/ml||Anti-S. pullorum CVCC1802, activity value is MIC = 128 ug/ml||Anti-S. enteritidis CVCC3377, activity value is MIC = 128 ug/ml||Anti-E. coli CVCC195, activity value is MIC = 8 ug/ml||Anti-S. typhimurium ATCC14028, activity value is MIC = 8 ug/ml||Anti-S. pullorum CVCC1802, activity value is MIC = 8 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 64 ug/ml||Anti-Edwardsiella tarda, activity value is MIC = 6.4 ug/ml||Anti-Aeromonas veronii, activity value is MIC = 6.4 ug/ml||Anti-E. coli CVCC25922, activity value is MIC = 0.25 ug/ml||Anti-E. coli CVCCO157, activity value is MIC = 0.5 ug/ml||Anti-Salmonella typhimurium CVCC533, activity value is MIC = 1 ug/ml||Anti-S. pullorum CVCC1802, activity value is MIC = 0.5 ug/ml||Anti-Pseudomonas aeruginosa CICC21630, activity value is MIC = 4 ug/ml||Anti-S. aureus ATCC546, activity value is MIC = 4 ug/ml||Anti-S. hyicus 437-2, activity value is MIC = 64 ug/ml||Anti-S. hyicus 15095, activity value is MIC = 16 ug/ml||Anti-Edwardsiella tarda, activity value is MIC = 0.5 ug/ml||Anti-Aeromonas veronii, activity value is MIC = 2 ug/ml||Anti-Escherichia coli CVCC195, activity value is MIC = 0.06 ug/ml||Anti-E. coli CVCC1515, activity value is MIC = 0.06 ug/ml||Anti-E. coli CVCC25922, activity value is MIC = 0.06 ug/ml||Anti-E. coli CVCCO157, activity value is MIC = 0.06 ug/ml||Anti-Salmonella typhimurium CVCC533, activity value is MIC = 0.25 ug/ml||Anti-S. typhimurium ATCC14028, activity value is MIC = 0.06 ug/ml||Anti-S. enteritidis CVCC3377, activity value is MIC = 0.06 ug/ml||Anti-S. pullorum CVCC1802, activity value is MIC = 0.25 ug/ml||Anti-S. pullorum CVCC1789, activity value is MIC = 0.06 ug/ml||Anti-Pseudomonas aeruginosa CICC21630, activity value is MIC = 0.06 ug/ml||Anti-S. aureus ATCC546, activity value is MIC = 1 ug/ml||Anti-S. aureus ATCC25923, activity value is MIC = 1 ug/ml||Anti-S. hyicus 437-2, activity value is MIC = 16 ug/ml||Anti-S. hyicus 15095, activity value is MIC = 4 ug/ml	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct|||Arenicola marina [Lugworm]|||Synthetic construct	Beta||β-turn, coil and antiparallel sheet	"N1: At a concentration of 128 µg/ml, hemolysis is 3%. N2: At a concentration of 128 µg/ml, hemolysis is 0.4%; at a concentration of 256 µg/ml, hemolysis is 3.8%. N6: At a concentration of 128 µg/ml, hemolysis is 0.04%; at a concentration of 256 µg/ml, hemolysis is 1.9%.|||At a concentration of 128 µg/mL, the hemolysis rate of mouse red blood cells was 0.4%; at a concentration of 256 µg/mL, the hemolysis rate was 3.8%.
At a concentration of N6:128 µg/mL, the hemolysis rate of mouse red blood cells was 0.04%; at a concentration of 256 µg/mL, the hemolysis rate was 1.9%.
At a concentration of 32 µg/mL, the parent peptide N1 exhibited a hemolysis rate of 3% (for comparative reference).|||E. coli CVCC195 (MIC= 16 ug/ml), S. typhimurium ATCC14028 (MIC= 16 ug/ml), S. pullorum CVCC1802 (MIC= 16 ug/ml), S. enteritidis CVCC3377 (MIC= 16 ug/ml), P. aeruginosa CICC21630 (MIC= 64 ug/ml), Staphylococcus aureus (ATCC 43300) (MIC= 128 ug/ml), S. hyicus NCTC10350 (MIC= >128 ug/ml), C. albicans CMCC98001 (MIC= >128 ug/ml)|||E. coli CVCC195 (MIC= 16 ug/ml), S. typhimurium ATCC14028 (MIC= 32 ug/ml), S. pullorum CVCC1802 (MIC= 16 ug/ml), S. enteritidis CVCC3377 (MIC= 32 ug/ml), P. aeruginosa CICC21630 (MIC= 128 ug/ml), Staphylococcus aureus (ATCC 43300) (MIC= >128 ug/ml), S. hyicus NCTC10350 (MIC= >128 ug/ml), C. albicans CMCC98001 (MIC= >128 ug/ml)|||E. coli CVCC195 (MIC= 32 ug/ml), S. typhimurium ATCC14028 (MIC= 64 ug/ml), S. pullorum CVCC1802 (MIC= 32 ug/ml), S. enteritidis CVCC3377 (MIC= 32 ug/ml), P. aeruginosa CICC21630 (MIC= >128 ug/ml), Staphylococcus aureus (ATCC 43300) (MIC= >128 ug/ml), S. hyicus NCTC10350 (MIC= >128 ug/ml), C. albicans CMCC98001 (MIC= >128 ug/ml)|||E. coli CVCC195 (MIC= 128 ug/ml), S. typhimurium ATCC14028 (MIC= >128 ug/ml), S. pullorum CVCC1802 (MIC= 128 ug/ml), S. enteritidis CVCC3377 (MIC= 128 ug/ml), P. aeruginosa CICC21630 (MIC= >128 ug/ml), Staphylococcus aureus (ATCC 43300) (MIC= >128 ug/ml), S. hyicus NCTC10350 (MIC= >128 ug/ml), C. albicans CMCC98001 (MIC= >128 ug/ml)|||E. coli CVCC195 (MIC= 8 ug/ml), S. typhimurium ATCC14028 (MIC= 8 ug/ml), S. pullorum CVCC1802 (MIC= 8 ug/ml), S. enteritidis CVCC3377 (MIC= 16 ug/ml), P. aeruginosa CICC21630 (MIC= 64 ug/ml), Staphylococcus aureus (ATCC 43300) (MIC= 64 ug/ml), S. hyicus NCTC10350 (MIC= >128 ug/ml), C. albicans CMCC98001 (MIC= >128 ug/ml)|||Hemolytic activity against Mouse RBCs|||No hemolysis information or data found in the reference(s) presented in this entry|||[Ref.33348729]The hemolysis of N6NH2 towards mouse erythrocytes was 0.19% at a concentration of 256 ug/ml, lower than that of N6 (1.9%), indicating their low hemolytic activity|||murine RBC: 2% hemolysis at 256 ug/ml (low hemo.lytic). Less toxic to RAW264.7 cells than Arenicin-3 analog N1."	2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2.|||Sci Rep. 2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2. PubMed|||28611436|||35549900|||35549900|||Mar Drugs. 2020 Dec 17;18(12):650. doi: 10.3390/md18120650.||Ref.33348729|||Sci Rep. 2017 Jun 13;7(1):3392. doi: 10.1038/s41598-017-03664-2. PubMed	21	
FPDB01351	AP04610|||AP04610|||AR K|||DRAMP32158	"	
KWCVYAYVKVKGVLVKYKKCW"	Anti-Gram- E.coli ML35p or ATCC 25922 or M15, activity value is MIC = 1||Anti-P. aeruginosa ATCC 27853 or clinical c.i, activity value is MIC = 1||Anti-A. baumanii c.i, activity value is MIC = 1 uM||Anti-L. monocytogenes EGD, activity value is MIC = 2 uM||Anti-S. aureus 710A or ATCC 25923 or MRSA ATCC 33591 or clinical c.i, activity value is MIC = 2||Anti-S. intermidius, activity value is MIC = 4 uM||Anti-Escherichia coli ML35p, activity value is MIC = 1 uM||Anti-E. coli ATCC 25922, activity value is MIC = 2 uM||Anti-E. coli M15, activity value is MIC = 1 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 1||Anti-Listeria monocytogenes EGD, activity value is MIC = 2 uM||Anti-Staphylococcus aureus 710A, activity value is MIC = 2 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 2 uM||Anti-MRSA ATCC 33591, activity value is MIC = 2 uM||Anti-P. aeruginosa c.i, activity value is MIC = 2||Anti-Acinetobacter baumanii c.i, activity value is MIC = 1 uM||Anti-Staphylococcus intermidius, activity value is MIC = 4 uM||Anti-S. aureus c.i, activity value is MIC = 4 uM||Antimicrobial||Anticancer	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct|||Synthetic	N/A	AR：66.3ARin-s：24.6ARs-N：>80ARs-C：>80ARs-N-B：66.0ARs-C-B：>80AR-K：63.0AR-F：60.5ARlin：>80ARcycl：65.5|||Human erythrocytes: 15% Hemolysis=10.1 uM; 50% Hemolysis=63 uM	2019 Jun 23;17(6):376. doi: 10.3390/md17060376.|||Mar Drugs. 2019 Jun 23;17(6):376. doi: 10.3390/md17060376. PubMed|||31234579|||Mar Drugs. 2019 Jun 23;17(6):376.	21	
FPDB01352	AP04611|||AP04611|||AR F|||DRAMP35672	"	
RFCVYAYVRVRGVLVRYRRCF"	Anti-Gram- E.coli ML35p or ATCC 25922 or M15, activity value is MIC = 1 uM||Anti-P. aeruginosa ATCC 27853 or clinical c.i, activity value is MIC = 1||Anti-A. baumanii c.i, activity value is MIC = 2 uM||Anti-L. monocytogenes EGD, activity value is MIC = 2 uM||Anti-S. aureus 710A or ATCC 25923 or MRSA ATCC 33591 or clinical c.i, activity value is MIC = 2||Anti-S. intermidius, activity value is MIC = 4 uM||Anti-Escherichia coli ML35p, activity value is MIC = 1 uM||Anti-E. coli ATCC 25922, activity value is MIC = 1 uM||Anti-E. coli M15, activity value is MIC = 1 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-Listeria monocytogenes EGD, activity value is MIC = 2 uM||Anti-Staphylococcus aureus 710A, activity value is MIC = 2 uM||Anti-S. aureus ATCC 25923, activity value is MIC = 2 uM||Anti-MRSA ATCC 33591, activity value is MIC = 2 uM||Anti-P. aeruginosa c.i, activity value is MIC = 2 uM||Anti-Acinetobacter baumanii c.i, activity value is MIC = 2 uM||Anti-Staphylococcus intermidius, activity value is MIC = 4 uM||Anti-S. aureus c.i, activity value is MIC = 4 uM||Antimicrobial||Anticancer	amino acid substitution, animal-derived, natural derivative|||amino acid substitution, animal-derived, natural derivative|||Synthetic construct|||Synthetic	N/A	AR：66.3ARin-s：24.6ARs-N：>80ARs-C：>80ARs-N-B：66.0ARs-C-B：>80AR-K：63.0AR-F：60.5ARlin：>80ARcycl：65.5	2019 Jun 23;17(6):376. doi: 10.3390/md17060376.|||Mar Drugs. 2019 Jun 23;17(6):376. doi: 10.3390/md17060376. PubMed|||31234579|||Mar Drugs. 2019 Jun 23;17(6):376.	21	
FPDB01353	AP04614|||AP04614|||ARs-C|||DRAMP35669	WCRRYRVLVRGVLVRYRRCW	Anti-Gram- E.coli ML35p or ATCC 25922 or M15, activity value is MIC = 1||Anti-P. aeruginosa ATCC 27853 or clinical c.i, activity value is MIC = 1||Anti-A. baumanii c.i, activity value is MIC = 2 uM||Anti-L. monocytogenes EGD, activity value is MIC = 1 uM||Anti-S. aureus 710A or ATCC 25923 or MRSA ATCC 33591 or clinical c.i, activity value is MIC = 2||Anti-S. intermidius, activity value is MIC = 8 uM||Anti-Escherichia coli ML35p, activity value is MIC = 1 uM||Anti-E. coli ATCC 25922, activity value is MIC = 2 uM||Anti-E. coli M15, activity value is MIC = 2 uM||Anti-Pseudomonas aeruginosa ATCC 27853, activity value is MIC = 1 uM||Anti-Listeria monocytogenes EGD, activity value is MIC = 1 uM||Anti-Staphylococcus aureus 710A, activity value is MIC = 2||Anti-S. aureus ATCC 25923, activity value is MIC = 4 uM||Anti-MRSA ATCC 33591, activity value is MIC = 4||Anti-P. aeruginosa c.i, activity value is MIC = 16 uM||Anti-Acinetobacter baumanii c.i, activity value is MIC = 4 uM||Anti-Staphylococcus intermidius, activity value is MIC = 8 uM||Anti-S. aureus c.i, activity value is MIC = 16 uM||Antimicrobial||Anticancer	animal-derived, natural derivative|||animal-derived, natural derivative|||Synthetic construct|||Synthetic	N/A	AR：66.3ARin-s：24.6ARs-N：>80ARs-C：>80ARs-N-B：66.0ARs-C-B：>80AR-K：63.0AR-F：60.5ARlin：>80ARcycl：65.5	2019 Jun 23;17(6):376. doi: 10.3390/md17060376.|||Mar Drugs. 2019 Jun 23;17(6):376. doi: 10.3390/md17060376. PubMed|||31234579|||Mar Drugs. 2019 Jun 23;17(6):376.	20	
FPDB01354	AP04632|||AP04632|||CAMPSQ15069|||CAMPSQ15265|||DRAMP21147	"	
KRIVQRIKKWLR"	Anti-Gram- E. coli KCTC 1682, activity value is MIC = 2 uM||Anti-P. aeruginosa KCTC 1637, activity value is MIC = 8 uM||Anti-S. typhimurium KCTC 1926, activity value is MIC = 1 uM||Anti-B. subtilis KCTC 3068, activity value is MIC = 8 uM||Anti-S. epidermidis KCTC 1917, activity value is MIC = 1 uM||Anti-and S. aureus KCTC 1621, activity value is MIC = 2 uM||Antibacterial||Anti-Bacillus subtilis, activity value is MIC = 8 uM||Anti-Staphylococcus epidermidis, activity value is MIC = 1 uM||Anti-Staphylococcus aureus, activity value is MIC = 2 uM||Anti-##Gram-negative bacteria : Escherichia coli, activity value is MIC = 2 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 8 uM||Anti-Salmonella typhimurium, activity value is MIC = 1 uM	amino acid substitution, human cathelicidin analog, animal-derived, natural derivative|||amino acid substitution, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct|||Synthetic construct	Helix||Random coil, alpha helix	"KR-12-a5: 96 uM KR-12-a6: 22 uM KR-12 and most other KR-12 analogs: did not show 50% hemolysis even at high concentrations (such as 800 uM)|||KR-12-a5: 50% hemolytic concentration (HC₅₀) is 96 μM; 
KR-12-a6: 50% hemolytic concentration (HC₅₀) is 22 μM; 
KR-12, KR-12-a1, KR-12-a2, KR-12-a3, KR-12-a4, KR-12-a7, KR-12-a8: did not reach 50% hemolysis at the highest tested concentration (800 μM) (HC₅₀ > 800 μM); 
Positive control (LL-37): 50% hemolytic concentration (HC₅₀) is 175 μM.|||human RBC (HC50 >800 uM), not hemo.lytic.|||hRBC ( HC50= >800 uM)|||[Ref.24105706] HC50>800 uM against human red blood cells"	2013 Nov;19(11):700-7. doi: 10.1002/psc.2552. Epub 2013 Sep 17.|||J Pept Sci. 2013 Nov;19(11):700-7. doi: 10.1002/psc.2552. PubMed|||35203875|||24105706|||J Pept Sci. 2013 Nov;19(11):700-7. doi: 10.1002/psc.2552.||Ref.24105706	12	
FPDB01355	AP04633|||AP04633|||AP04634|||AP04635|||AP04633|||CAMPSQ15266|||DRAMP21148	"	
KRIVKRIKKWLR"	Anti-Gram- E. coli KCTC 1682, activity value is MIC = 2 uM||Anti-P. aeruginosa KCTC 1637, activity value is MIC = 8 uM||Anti-S. typhimurium KCTC 1926, activity value is MIC = 2 uM||Anti-B. subtilis KCTC 3068, activity value is MIC = 2 uM||Anti-S. epidermidis KCTC 1917, activity value is MIC = 1 uM||Anti-and S. aureus KCTC 1621, activity value is MIC = 2 uM||Anti-P. aeruginosa KCTC 1637, activity value is MIC = 4 uM||Anti-S. typhimurium KCTC 1926, activity value is MIC = 1 uM||Anti-B. subtilis KCTC 3068, activity value is MIC = 8 uM||Anti-Gram- E. coli KCTC 1682, activity value is MIC = 4 uM||Anti-S. typhimurium KCTC 1926, activity value is MIC = 4 uM||Anti-B. subtilis KCTC 3068, activity value is MIC = 4 uM||Anti-and S. aureus KCTC 1621, activity value is MIC = 4 uM||Antibacterial||Anti-Bacillus subtilis, activity value is MIC = 2 uM||Anti-Staphylococcus epidermidis, activity value is MIC = 1 uM||Anti-Staphylococcus aureus, activity value is MIC = 2 uM||Anti-##Gram-negative bacteria : Escherichia coli, activity value is MIC = 2 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 8 uM||Anti-Salmonella typhimurium, activity value is MIC = 2 uM	amino acid substitution, human cathelicidin analog, animal-derived, natural derivative|||amino acid substitution, human cathelicidin analog, animal-derived, natural derivative|||Homo sapiens [Human]|||Synthetic construct	Helix||Random coil, alpha helix	"KR-12-a5: 96 uM KR-12-a6: 22 uM KR-12 and most other KR-12 analogs: did not show 50% hemolysis even at high concentrations (such as 800 uM)|||KR-12-a5: 50% hemolytic concentration (HC₅₀) is 96 μM; 
KR-12-a6: 50% hemolytic concentration (HC₅₀) is 22 μM; 
KR-12, KR-12-a1, KR-12-a2, KR-12-a3, KR-12-a4, KR-12-a7, KR-12-a8: did not reach 50% hemolysis at the highest tested concentration (800 μM) (HC₅₀ > 800 μM); 
Positive control (LL-37): 50% hemolytic concentration (HC₅₀) is 175 μM.|||human RBC (HC50 >800 uM), not hemo.lytic. not toxic to RAW264.7 cells at 128 ug/ml.|||hRBC ( HC50= >800 uM)|||[Ref.24105706] HC50>800 uM against human red blood cells"	2013 Nov;19(11):700-7. doi: 10.1002/psc.2552. Epub 2013 Sep 17.||see ref||ref new|||2013 Nov;19(11):700-7. doi: 10.1002/psc.2552. Epub 2013 Sep 17.||see ref||ref new|||2013 Nov;19(11):700-7. doi: 10.1002/psc.2552. Epub 2013 Sep 17.|||J Pept Sci. 2013 Nov;19(11):700-7. doi: 10.1002/psc.2552. PubMed||see ref||ref new|||24105706|||J Pept Sci. 2013 Nov;19(11):700-7. doi: 10.1002/psc.2552.||Ref.24105706	12	
FPDB01356	AP04634|||AP04634|||CAMPSQ15082|||DRAMP21149	"	
KRIVKLIKKWLR"	Anti-Gram- E. coli KCTC 1682, activity value is MIC = 2 uM||Anti-P. aeruginosa KCTC 1637, activity value is MIC = 4 uM||Anti-S. typhimurium KCTC 1926, activity value is MIC = 1 uM||Anti-B. subtilis KCTC 3068, activity value is MIC = 8 uM||Anti-S. epidermidis KCTC 1917, activity value is MIC = 1 uM||Anti-and S. aureus KCTC 1621, activity value is MIC = 2 uM||Antibacterial||Anti-Bacillus subtilis, activity value is MIC = 8 uM||Anti-Staphylococcus epidermidis, activity value is MIC = 1 uM||Anti-Staphylococcus aureus, activity value is MIC = 2 uM||Anti-##Gram-negative bacteria : Escherichia coli, activity value is MIC = 2 uM||Anti-Pseudomonas aeruginosa, activity value is MIC = 4 uM||Anti-Salmonella typhimurium, activity value is MIC = 1 uM	amino acid substitution, human cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	Helix||Random coil, alpha helix	KR-12-a5: 96 uM KR-12-a6: 22 uM KR-12 and most other KR-12 analogs: did not show 50% hemolysis even at high concentrations (such as 800 uM)|||human RBC (HC50 >800 uM), not hemo.lytic.|||10% hemolysis of sheep red blood cells at > 128 uM|||[Ref.24105706] HC50>800 uM against human red blood cells	2013 Nov;19(11):700-7. doi: 10.1002/psc.2552. Epub 2013 Sep 17.|||J Pept Sci. 2013 Nov;19(11):700-7. doi: 10.1002/psc.2552. PubMed|||35288606|||J Pept Sci. 2013 Nov;19(11):700-7. doi: 10.1002/psc.2552.||Ref.24105706	12	
FPDB01357	AP04668	"	
YGRKKRRQRRRKRIVQRIKDFLR"	Anti-Gram+ S. aureus ATCC 25923 or MRSA ATCC 43300, activity value is MIC = 16 ug/ml||Anti-S. epidermidis ATCC 35984 or MRSE ATCC 287, activity value is MIC = 8 ug/ml||Anti-and Gram- E. coli ATCC 25922, activity value is MIC = 16 ug/ml	peptide conjugates, designed, human cathelicidin analog, animal-derived, natural derivative	N/A	"Hemolytic values of TAT-KR-12: At concentrations up to 1024 μg mL⁻¹, TAT-KR-12 did not show any significant hemolytic activity (in two independent experiments, the hemolysis rate of TAT-KR-12 at 1024 μg mL⁻¹ was observed to be 0.5-1%).|||TAT-KR-12: Minimum hemolytic concentration (MHC, the concentration causing 10% hemolysis of human red blood cells) > 1024 µg/ml; 
KR-12: Minimum hemolytic concentration (MHC) > 1024 µg/ml; 
(Note: Determined by human red blood cell hemolysis assay, specific hemolysis rate values corresponding to concentrations are not mentioned, only the MHC threshold is specified)"	2020 Dec 11;6(12):3147-3162. doi: 10.1021/acsinfecdis.0c00264. Epub 2020 Nov 25.|||ACS Infect Dis. 2020 Dec 11;6(12):3147-3162. doi: 10.1021/acsinfecdis.0c00264. PubMed	23	
FPDB01358	AP04720	"	
FLKIIGKLLSGLL"	Anti-Gram+ S. aureus NCTC 6538 or MRSA ATCC 12493, activity value is MIC = 1 uM||Anti-E. faecalis NCTC 12697, activity value is MIC = 2 uM||Anti-E. coli ATCC 8739, activity value is MIC = 8 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 32 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 16 uM||Anti-and yeast C. albicans ATCC 10231, activity value is MIC = 32 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||Hemolytic||Antibiofilm	amino acid substitution, insects, animal-derived, natural derivative	Helix	VM：44.43 uMVM-3K：11.20 uMVM-3G：9.68 uMVM-3W：69.68 uMVM-3Y：221.2 uM|||horse RBC: HC50 11.2 uM, hemolytic|||hj7b02jo9i628j1oolms|||horse RBC: HC50 11.2 uM, hemolytic.	2022 Aug 25;11(9):1263. doi: 10.3390/biology11091263.|||Biology (Basel). 2022 Aug 25;11(9):1263. doi: 10.3390/biology11091263. PubMed|||Biology (Basel). 2022 Aug 25;11(9):1263. doi: 10.3390/biology11091263. PubMed	13	
FPDB01359	AP04721	"	
FLGIIGKLLSGLL"	Anti-Gram+ S. aureus NCTC 6538 or MRSA ATCC 12493, activity value is MIC = 1||Anti-E. faecalis NCTC 12697, activity value is MIC = 4 uM||Anti-E. coli ATCC 8739, activity value is MIC = 64 uM||Anti-K.pneumoniae ATCC 43816, activity value is MIC = 512 uM||Anti-P.aeruginosa ATCC 9027, activity value is MIC > 128 uM||Anti-and yeast C. albicans ATCC 10231, activity value is MIC > 512 uM||Anti-Gram+||Anti-MRSA||Hemolytic||Antibiofilm	amino acid substitution, insects, animal-derived, natural derivative	Helix	VM：44.43 uMVM-3K：11.20 uMVM-3G：9.68 uMVM-3W：69.68 uMVM-3Y：221.2 uM|||horse RBC: HC50 9.7 uM, hemolytic.|||hj7b02jo9i628j1oolms	2022 Aug 25;11(9):1263. doi: 10.3390/biology11091263.|||Biology (Basel). 2022 Aug 25;11(9):1263. doi: 10.3390/biology11091263. PubMed	13	
FPDB01360	AP04722	"	
FLWIIGKLLSGLL"	Anti-Gram+ S. aureus NCTC 6538 or MRSA ATCC 12493, activity value is MIC = 1||Anti-E. faecalis NCTC 12697, activity value is MIC = 4 uM||Anti-E.coli ATCC 8739, activity value is MIC > 512 uM||Anti-K.pneumoniae ATCC 43816, activity value is MIC > 512 uM||Anti-P.aeruginosa ATCC 9027, activity value is MIC > 512 uM||Anti-and yeast C.albicans ATCC 10231, activity value is MIC > 512 uM||Anti-Gram+||Anti-MRSA||Hemolytic||Antibiofilm	amino acid substitution, insects, animal-derived, natural derivative	Helix	VM：44.43 uMVM-3K：11.20 uMVM-3G：9.68 uMVM-3W：69.68 uMVM-3Y：221.2 uM|||horse RBC: HC50 9.7 uM, hemolytic.|||hj7b02jo9i628j1oolms	2022 Aug 25;11(9):1263. doi: 10.3390/biology11091263.|||Biology (Basel). 2022 Aug 25;11(9):1263. doi: 10.3390/biology11091263. PubMed	13	
FPDB01361	AP04723	"	
FLYIIGKLLSGLL"	Anti-Gram+ S. aureus NCTC 6538 or MRSA ATCC 12493, activity value is MIC = 2 uM||Anti-E. faecalis NCTC 12697, activity value is MIC = 4 uM||Anti-E.coli ATCC 8739, activity value is MIC > 512 uM||Anti-K.pneumoniae ATCC 43816, activity value is MIC > 512 uM||Anti-P.aeruginosa ATCC 9027, activity value is MIC > 512 uM||Anti-and yeast C.albicans ATCC 10231, activity value is MIC > 512 uM||Anti-Gram+||Anti-MRSA||Antibiofilm	amino acid substitution, insects, animal-derived, natural derivative	Helix	VM：44.43 uMVM-3K：11.20 uMVM-3G：9.68 uMVM-3W：69.68 uMVM-3Y：221.2 uM|||horse RBC: HC50 211.2 uM, less hemo.lytic.|||hj7b02jo9i628j1oolms	2022 Aug 25;11(9):1263. doi: 10.3390/biology11091263.|||Biology (Basel). 2022 Aug 25;11(9):1263. doi: 10.3390/biology11091263. PubMed	13	
FPDB01362	AP04816|||AP04816|||AP04817	"	
FLSLIPKAISAVSALAKHL"	Anti-Gram+ S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 4 uM||Anti-E. coli ATCC 8739, activity value is MIC = 8 uM||Anti-A.baumannii BAA 747, activity value is MIC > 128 uM||Anti-K. pneumonia ATCC 43816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 32 uM||Anti-and fungi C. albicans, activity value is MIC = 32 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||anti-sepsis||Hemolytic||Antibiofilm	amino acid substitution, amphibian peptide analog, animal-derived, natural derivative	Helix	PSTO2: 21.787K: 21.9718K: 20.59SR: 12.60SR2: 6.53SRD7: 74.78SR2D10: 75.24D1/D2: No obvious hemolysis (>512 uM)|||horse RBC: HC50 32-64 uM.|||w90c6t7w1sexseowqbf1	https://doi.org/10.3390/pharmaceutics16081098|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098.|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI	19	
FPDB01363	AP04817	"	
FLSLIPKAISAVSALAKKL"	Anti-Gram+ S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 2||Anti-E. coli ATCC 8739, activity value is MIC = 4 uM||Anti-A. baumannii BAA 747, activity value is MIC = 32 uM||Anti-K. pneumonia ATCC 43816, activity value is MIC = 16 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 32 uM||Anti-and fungi C. albicans, activity value is MIC = 32 uM||Anti-Gram+ & Gram-||Antifungal||candidacidal||Anti-MRSA||anti-sepsis||Hemolytic||Antibiofilm	amino acid substitution, amphibian peptide analog, animal-derived, natural derivative	Helix	PSTO2: 21.787K: 21.9718K: 20.59SR: 12.60SR2: 6.53SRD7: 74.78SR2D10: 75.24D1/D2: No obvious hemolysis (>512 uM)|||horse RBC: HC50 64 uM.|||w90c6t7w1sexseowqbf1	https://doi.org/10.3390/pharmaceutics16081098|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI|||Pharmaceutics. 2024; 16(8):1098. https://doi.org/10.3390/pharmaceutics16081098. MDPI	19	
FPDB01364	AP04822	"	
FLPFLASLALKIL"	Anti-Gram+ bacteria S. aureus ATCC CRM 6538 or MRSA BAA 1707 or clinical MRSA B038 V1S1 A, activity value is MIC = 2 uM||Anti-E. faecalis NCTC 12697, activity value is MIC = 4 uM||Anti-E. coli NCTC 8739 or clinical BAA 2340, activity value is MIC = 32 uM||Anti-P.aeruginosa ATCC 9027 or PA14 or PAO1, activity value is MIC > 128 uM||Anti-K.pneumoniae ATCC 43816, activity value is MIC > 128 uM||Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Antibiofilm	cutaneous secretion, the Ranidae frog, Amolops wuyiensis, China, Asia|||cutaneous secretion, the Ranidae frog, Amolops wuyiensis, China, Asia	Helix	Temporin-WY2：43.70QUB-1426：19.406K-WY2：27.796K-1426：15.65|||horse RBC: HC50=32-64 uM.|||dt4f2qo3x14ynprk3d0k	2024 Aug 13;14(1):18769. doi: 10.1038/s41598-024-67777-1.|||Sci Rep. 2024 Aug 13;14(1):18769. doi: 10.1038/s41598-024-67777-1. PubMed	13	
FPDB01365	AP04823	"	
FLPKLLSALAKIL"	Anti-Gram+ bacteria S. aureus ATCC CRM 6538 or MRSA BAA 1707 or clinical MRSA B038 V1S1 A, activity value is MIC = 2 uM||Anti-E. faecalis NCTC 12697, activity value is MIC = 4 uM||Anti-E. coli NCTC 8739 or clinical BAA 2340, activity value is MIC = 4 uM||Anti-P. aeruginosa ATCC 9027 or PAO1, activity value is MIC = 16||Anti-P.aeruginosa PA14, activity value is MIC > 128 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 8 uM||Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Antibiofilm	amino acid substitution, local sequence shuffling, amphibians, animal-derived, natural derivative	Helix	Temporin-WY2：43.70QUB-1426：19.406K-WY2：27.796K-1426：15.65|||horse RBC: HC50=16-32 uM.|||dt4f2qo3x14ynprk3d0k	2024 Aug 13;14(1):18769. doi: 10.1038/s41598-024-67777-1.|||Sci Rep. 2024 Aug 13;14(1):18769. doi: 10.1038/s41598-024-67777-1. PubMed	13	
FPDB01366	AP04824	"	
KKKKKKFLPFLASLALKIL"	Anti-Gram+ bacteria S. aureus ATCC CRM 6538 or MRSA BAA 1707 or clinical MRSA B038 V1S1 A, activity value is MIC = 4||Anti-E. faecalis NCTC 12697, activity value is MIC = 16 uM||Anti-E. coli NCTC 8739 or clinical BAA 2340, activity value is MIC = 4 uM||Anti-P. aeruginosa ATCC 9027 or PA14 or PAO1, activity value is MIC = 4||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 4 uM||Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Antibiofilm	Designed based an amphibian template	Helix	Temporin-WY2：43.70QUB-1426：19.406K-WY2：27.796K-1426：15.65|||horse RBC: HC50=32 uM.|||dt4f2qo3x14ynprk3d0k	2024 Aug 13;14(1):18769. doi: 10.1038/s41598-024-67777-1.|||Sci Rep. 2024 Aug 13;14(1):18769. doi: 10.1038/s41598-024-67777-1. PubMed	19	
FPDB01367	AP04825	"	
KKKKKKFLPKLLSALAKIL"	Anti-Gram+ bacteria S. aureus ATCC CRM 6538 or MRSA BAA 1707 or clinical MRSA B038 V1S1 A, activity value is MIC = 8||Anti-E. faecalis NCTC 12697, activity value is MIC = 16 uM||Anti-E. coli NCTC 8739 or clinical BAA 2340, activity value is MIC = 2 uM||Anti-P. aeruginosa ATCC 9027 or PA14 or PAO1, activity value is MIC = 2||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 2 uM||Anti-Gram+ & Gram-||Anti-MRSA||Hemolytic||Antibiofilm	Designed based an amphibian derived template	Helix	Temporin-WY2：43.70QUB-1426：19.406K-WY2：27.796K-1426：15.65|||horse RBC: HC50=32 uM.|||dt4f2qo3x14ynprk3d0k	2024 Aug 13;14(1):18769. doi: 10.1038/s41598-024-67777-1.|||Sci Rep. 2024 Aug 13;14(1):18769. doi: 10.1038/s41598-024-67777-1. PubMed	19	
FPDB01368	AP04828	"	
MSGIIRVTPAELRQMADRYQKESGDVTEQVNQRLDQMINQLQDMWEGESSRAFSEQYQELRPSFIKMAELLSDVSKQLH"	Anti-Gram+ C. perfringens ATCC 13124 and 8 other strains, activity value is MIC = 4||Anti-L. monocytogenes ATCC 19111, activity value is MIC = 32 ug/ml||Anti-S. aureus ATCC 43300 or ATCC 29213, activity value is MIC = 32||Anti-S. agalactiae ATCC 13813, activity value is MIC = 2 ug/ml||Anti-S. suis 0859, activity value is MIC = 2 ug/ml||Anti-E. faecalis 012-2, activity value is MIC = 16 ug/ml||Anti-but not Gram- S.Typhimurium ATCC 14028, activity value is MIC > 256 ug/ml||Anti-E.coli DH5alpha or K88 or EHEC O157:H7, activity value is MIC > 256 ug/ml||Anti-A.pleuropneumoniae APP 18, activity value is MIC > 256 ug/ml	Bacillus paralicheniformis DY4; human microbiota:gut	N/A	Under treatment with different concentrations of Paralichenysin DY4, even at the highest concentration of 625 µg/ml, the hemolysis level was only 0.13%.	2024 Nov;279(Pt 4):135412. doi: 10.1016/j.ijbiomac.2024.135412. Epub 2024 Sep 6.	79	
FPDB01369	AP04830	"	
GLWTGKYTDVFGGRALIKIIIQT"	Anti-S. aureus USA300, activity value is MIC = 25.3 uM||Anti-B. subtilis 168, activity value is MIC = 6.3 uM||Anti-and K. pneumoniae ATCC 10031, activity value is MIC = 6.3 uM	Paenibacillus taiwanensis DSM18679|||Paenibacillus taiwanensis DSM18679	N/A	N/A	2024 Dec 16;25(24):e202400586. doi: 10.1002/cbic.202400586. Epub 2024 Oct 23.|||Chembiochem. 2024 Sep 3:e202400586. doi: 10.1002/cbic.202400586. PubMed	23	
FPDB01370	AP04832	"	
FFPKVAGVAAKVLKKIFCTISKKC"	Anti-493, activity value is MIC = 4 uM||Anti-697, activity value is MIC = 16 uM||Anti-E. coli ATCC 8739, activity value is MIC = 4 uM||Anti-816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC CRM 9027, activity value is MIC = 8 uM||Anti-A. baumannii BAA 747, activity value is MIC = 16 uM||Anti-231, activity value is MIC > 128 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	HC₁₀ values: Brevinin-1pl: 8.28 uM [Lys⁴] brevinin-1pl: 13.68 uM [Lys⁴, Ala¹³] brevinin-1pl: 4.59 uM [Lys⁴, Ala¹⁶] brevinin-1pl: 2.51 uM [Lys⁴, Ala¹³,¹⁶] brevinin-1pl: 22 uM des-Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM des-Leu¹³,Ala¹⁶-[Lys⁴] HC₃₀ values: Brevinin-1pl: 37.64 uM [Lys⁴] brevinin-1pl: 80.77 uM [Lys⁴, Ala¹³] brevinin-1pl: 41.34 uM [Lys⁴, Ala¹⁶] brevinin-1pl: 84.86 uM [Lys⁴, Ala¹³,¹⁶] brevinin-1pl: >128 uM des-Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM des-Leu¹³,Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM|||horse RBC: HC50 80.77 uM, hemolytic.	2024 Sep 19:23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. eCollection 2024 Dec.|||Comput Struct Biotechnol J. 2024 Sep 19;23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. PubMed	24	
FPDB01371	AP04833	"	
FFPKVAGVAAKVAKKIFCTISKKC"	Anti-493, activity value is MIC = 4 uM||Anti-697, activity value is MIC = 128 uM||Anti-E. coli ATCC 8739, activity value is MIC = 4 uM||Anti-816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC CRM 9027, activity value is MIC = 8 uM||Anti-A. baumannii BAA 747, activity value is MIC = 16 uM||Anti-231, activity value is MIC = 32 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	HC₁₀ values: Brevinin-1pl: 8.28 uM [Lys⁴] brevinin-1pl: 13.68 uM [Lys⁴, Ala¹³] brevinin-1pl: 4.59 uM [Lys⁴, Ala¹⁶] brevinin-1pl: 2.51 uM [Lys⁴, Ala¹³,¹⁶] brevinin-1pl: 22 uM des-Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM des-Leu¹³,Ala¹⁶-[Lys⁴] HC₃₀ values: Brevinin-1pl: 37.64 uM [Lys⁴] brevinin-1pl: 80.77 uM [Lys⁴, Ala¹³] brevinin-1pl: 41.34 uM [Lys⁴, Ala¹⁶] brevinin-1pl: 84.86 uM [Lys⁴, Ala¹³,¹⁶] brevinin-1pl: >128 uM des-Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM des-Leu¹³,Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM|||horse RBC: HC50 41.34 uM, hemolytic.	2024 Sep 19:23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. eCollection 2024 Dec.|||Comput Struct Biotechnol J. 2024 Sep 19;23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. PubMed|||Comput Struct Biotechnol J. 2024 Sep 19;23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. PubMed	24	
FPDB01372	AP04834	"	
FFPKVAGVAAKVLKKAFCTISKKC"	Anti-493, activity value is MIC = 4 uM||Anti-697, activity value is MIC = 32 uM||Anti-E. coli ATCC 8739, activity value is MIC = 4 uM||Anti-816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC CRM 9027, activity value is MIC = 8 uM||Anti-A. baumannii BAA 747, activity value is MIC = 8 uM||Anti-231, activity value is MIC = 32 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	HC₁₀ values: Brevinin-1pl: 8.28 uM [Lys⁴] brevinin-1pl: 13.68 uM [Lys⁴, Ala¹³] brevinin-1pl: 4.59 uM [Lys⁴, Ala¹⁶] brevinin-1pl: 2.51 uM [Lys⁴, Ala¹³,¹⁶] brevinin-1pl: 22 uM des-Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM des-Leu¹³,Ala¹⁶-[Lys⁴] HC₃₀ values: Brevinin-1pl: 37.64 uM [Lys⁴] brevinin-1pl: 80.77 uM [Lys⁴, Ala¹³] brevinin-1pl: 41.34 uM [Lys⁴, Ala¹⁶] brevinin-1pl: 84.86 uM [Lys⁴, Ala¹³,¹⁶] brevinin-1pl: >128 uM des-Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM des-Leu¹³,Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM|||horse RBC: HC50 84.86 uM, hemolytic.	2024 Sep 19:23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. eCollection 2024 Dec.|||Comput Struct Biotechnol J. 2024 Sep 19;23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. PubMed	24	
FPDB01373	AP04835	"	
FFPKVAGVAAKVAKKAFCTISKKC"	Anti-493, activity value is MIC = 8||Anti-697, activity value is MIC > 128 uM||Anti-E. coli ATCC 8739, activity value is MIC = 16 uM||Anti-816, activity value is MIC = 16 uM||Anti-P. aeruginosa ATCC CRM 9027, activity value is MIC = 32 uM||Anti-A. baumannii BAA 747, activity value is MIC = 32 uM||Anti-231, activity value is MIC = 32 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	HC₁₀ values: Brevinin-1pl: 8.28 uM [Lys⁴] brevinin-1pl: 13.68 uM [Lys⁴, Ala¹³] brevinin-1pl: 4.59 uM [Lys⁴, Ala¹⁶] brevinin-1pl: 2.51 uM [Lys⁴, Ala¹³,¹⁶] brevinin-1pl: 22 uM des-Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM des-Leu¹³,Ala¹⁶-[Lys⁴] HC₃₀ values: Brevinin-1pl: 37.64 uM [Lys⁴] brevinin-1pl: 80.77 uM [Lys⁴, Ala¹³] brevinin-1pl: 41.34 uM [Lys⁴, Ala¹⁶] brevinin-1pl: 84.86 uM [Lys⁴, Ala¹³,¹⁶] brevinin-1pl: >128 uM des-Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM des-Leu¹³,Ala¹⁶-[Lys⁴] brevinin-1pl: >128 uM|||horse RBC: HC50 >128 uM, less hemo.lytic.	2024 Sep 19:23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. eCollection 2024 Dec.|||Comput Struct Biotechnol J. 2024 Sep 19;23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. PubMed|||Comput Struct Biotechnol J. 2024 Sep 19;23:3391-3406. doi: 10.1016/j.csbj.2024.09.006. PubMed	24	
FPDB01374	AP04852	"	
LWGRFFRKWK"	Anti-S. aureus USA300 MRSA, activity value is MIC = 16 uM||Anti-S. epidermidis 1457, activity value is MIC = 32 uM||Anti-P. aeruginosa E411-17, activity value is MIC = 16 ug/ml||Anti-E. coli E423-17, activity value is MIC = 32 uM||Anti-and A-baumannii B28-16, activity value is MIC > 32 uM||Anti-Gram+ & Gram-||Anti-MRSA||Antibiofilm	sequence truncation, amino acid substitution, human cathelicidin analog, animal-derived, natural derivative|||amino acid truncation, amino acid substitution, human cathelicidin analog, animal-derived, natural derivative	N/A	LL-10: No hemolytic activity was observed, and even at a concentration of 400 µM, there was no hemolysis. RK-9: No hemolytic activity was observed, and even at a concentration of 400 µM, there was no hemolysis. KR-8: Some toxicity was observed at a concentration of 400 µM, resulting in 18% hemolysis. RIK-10: Dose-dependent low-level hemolysis was observed at high concentrations, causing 18% hemolysis at 200 µM.|||human RBC: not hemo.lytic till 400 uM. Not toxic to human keratinocyte HaCaT cells (LC50 > 100 uM), human hepatoma HepG2 cells (LC50 >100 uM), and human lung carcinoma A549 cells (LC50 >100 uM).|||zp708x9rimruk8dyozky	2025 Feb;17(1):15-34. doi: 10.1007/s12602-024-10376-3. Epub 2024 Oct 8.|||Probiotics Antimicrob Proteins. 2024 Oct 8. doi: 10.1007/s12602-024-10376-3. PubMed|||Probiotics Antimicrob Proteins. 2025 Feb;17(1):15-34. doi: 10.1007/s12602-024-10376-3. PubMed	10	
FPDB01375	AP04853	"	
RWWKKWWGK"	Anti-S. aureus USA300 MRSA, activity value is MIC = 8 uM||Anti-S. epidermidis 1457, activity value is MIC = 16 uM||Anti-P. aeruginosa E411-17, activity value is MIC = 16 ug/ml||Anti-E. coli E423-17, activity value is MIC = 8 uM||Anti-and A-baumannii B28-16, activity value is MIC > 32 uM||Anti-Gram+ & Gram-||Anti-MRSA||Antibiofilm	sequence truncation, amino acid substitution, human cathelicidin analog, animal-derived, natural derivative|||amino acid truncation, amino acid substitution, human cathelicidin analog, animal-derived, natural derivative	N/A	human RBC: essentially not hemo.lytic till 400 uM. Not toxic to human keratinocyte HaCaT cells (LC50 > 100 uM), human hepatoma HepG2 cells (LC50 >100 uM), and human lung carcinoma A549 cells (LC50 >100 uM).|||zp708x9rimruk8dyozky	2025 Feb;17(1):15-34. doi: 10.1007/s12602-024-10376-3. Epub 2024 Oct 8.|||Probiotics Antimicrob Proteins. 2024 Oct 8. doi: 10.1007/s12602-024-10376-3. PubMed|||Probiotics Antimicrob Proteins. 2025 Feb;17(1):15-34. doi: 10.1007/s12602-024-10376-3. PubMed	9	
FPDB01376	AP04854	"	
RWKRFLRNWV"	Anti-S. aureus USA300 MRSA, activity value is MIC = 16 uM||Anti-S-epidermidis 1457, activity value is MIC > 32 uM||Anti-P. aeruginosa E411-17, activity value is MIC = 4 ug/ml||Anti-E. coli E423-17, activity value is MIC = 4 uM||Anti-and A. baumannii B28-16, activity value is MIC = 8 uM||Anti-Gram+ & Gram-||Anti-MRSA||Antibiofilm	sequence truncation, amino acid substitution, human cathelicidin analog, animal-derived, natural derivative|||amino acid truncation, amino acid substitution, human cathelicidin analog, animal-derived, natural derivative	Helix	human RBC: not hemo.lytic till 100 uM (HC50 >400 uM). Not toxic to human keratinocyte HaCaT cells (LC50 100 uM), human hepatoma HepG2 cells (LC50 100 uM), and human lung carcinoma A549 cells (LC50 >100 uM) at least at the MIC.|||zp708x9rimruk8dyozky	2025 Feb;17(1):15-34. doi: 10.1007/s12602-024-10376-3. Epub 2024 Oct 8.|||Probiotics Antimicrob Proteins. 2024 Oct 8. doi: 10.1007/s12602-024-10376-3. PubMed|||Probiotics Antimicrob Proteins. 2025 Feb;17(1):15-34. doi: 10.1007/s12602-024-10376-3. PubMed	10	
FPDB01377	AP04855	"	
KWKRFFRGWL"	Anti-S. aureus USA300 MRSA, activity value is MIC = 8 uM||Anti-S. epidermidis 1457, activity value is MIC = 32 uM||Anti-P. aeruginosa E411-17, activity value is MIC = 4 ug/ml||Anti-E. coli E423-17, activity value is MIC = 4 uM||Anti-and A. baumannii B28-16, activity value is MIC = 32 uM	sequence reversal, sequence shuffling, designed, man-made sequences	N/A	N/A	2025 Feb;17(1):15-34. doi: 10.1007/s12602-024-10376-3. Epub 2024 Oct 8.|||Probiotics Antimicrob Proteins. 2024 Oct 8. doi: 10.1007/s12602-024-10376-3. PubMed	10	
FPDB01378	AP04856	"	
VWNRLFRKWR"	Anti-S. aureus USA300 MRSA, activity value is MIC = 32 uM||Anti-S.epidermidis 1457, activity value is MIC = 128 uM||Anti-P. aeruginosa E411-17, activity value is MIC = 16 ug/ml||Anti-E. coli E423-17, activity value is MIC = 32 uM||Anti-and A. baumannii B28-16, activity value is MIC = 64 uM	sequence reversal, sequence shuffling, designed, man-made sequences	N/A	N/A	2025 Feb;17(1):15-34. doi: 10.1007/s12602-024-10376-3. Epub 2024 Oct 8.|||Probiotics Antimicrob Proteins. 2024 Oct 8. doi: 10.1007/s12602-024-10376-3. PubMed	10	
FPDB01379	AP04876	"	
IIPLPLKKFLKKL"	Anti-E. coli, activity value is MIC = 25 uM||Anti-P. aeruginosa, activity value is MIC = 6.25 uM||Anti-E. aerogenes, activity value is MIC = 3.13 uM||Anti-E.cloacae, activity value is MIC > 100 uM||Anti-K. pneumoniae, activity value is MIC = 25 uM||Anti-S. aureus, activity value is MIC = 25 uM||Anti-B. cereus, activity value is MIC = 1.56 uM||Anti-S.lactis, activity value is MIC > 100 uM||Anti-E. faecalis, activity value is MIC = 3.13 uM||Anti-E. faecium, activity value is MIC = 1.56 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Temporin-1CEc：HC50 ≥ 500 uM2K：HC50 > 500 uM4K：HC50 > 500 uM2K2000 ml：HC50 > 500 uM4K2000 ml：HC50 > 500 uM4K4000 ml：HC50 > 500 uM2K4000 ml：HC50 = 62.5 uM2K4000 ml_W1：HC50 = 12.5 uM2K4000 ml_W2：HC50 = 12.5 uM2K4000 ml_W10：HC50 = 12.5 uM2K4000 ml_W13：HC50 = 12.5 uM2K4000 ml_2W：HC50 = 6.25 uM2K4000 ml_3W：HC50 = 6.25 uM|||Human RBC: HC50 >500 uM, little hemo.lytic.	2022 Feb:119:105544. doi: 10.1016/j.bioorg.2021.105544. Epub 2021 Dec 8.|||Bioorg Chem. 2022 Feb;119:105544. doi: 10.1016/j.bioorg.2021.105544. PubMed	13	
FPDB01380	AP04877	"	
KIPKPLKKFLKKL"	Anti-E. coli, activity value is MIC = 6||Anti-P. aeruginosa, activity value is MIC = 3.13 uM||Anti-E. aerogenes, activity value is MIC = 3.13 uM||Anti-E.cloacae, activity value is MIC > 100 uM||Anti-K. pneumoniae, activity value is MIC = 6.25 uM||Anti-S. aureus, activity value is MIC = 6.25 uM||Anti-B.cereus, activity value is MIC > 100 uM||Anti-S. lactis, activity value is MIC = 3.13 uM||Anti-E. faecalis, activity value is MIC = 6.25 uM||Anti-E. faecium, activity value is MIC = 3.13 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Temporin-1CEc：HC50 ≥ 500 uM2K：HC50 > 500 uM4K：HC50 > 500 uM2K2000 ml：HC50 > 500 uM4K2000 ml：HC50 > 500 uM4K4000 ml：HC50 > 500 uM2K4000 ml：HC50 = 62.5 uM2K4000 ml_W1：HC50 = 12.5 uM2K4000 ml_W2：HC50 = 12.5 uM2K4000 ml_W10：HC50 = 12.5 uM2K4000 ml_W13：HC50 = 12.5 uM2K4000 ml_2W：HC50 = 6.25 uM2K4000 ml_3W：HC50 = 6.25 uM|||Human RBC: HC50 >500 uM, little hemo.lytic.	2022 Feb:119:105544. doi: 10.1016/j.bioorg.2021.105544. Epub 2021 Dec 8.|||Bioorg Chem. 2022 Feb;119:105544. doi: 10.1016/j.bioorg.2021.105544. PubMed	13	
FPDB01381	AP04878	"	
IILLLLKKFLKKL"	Anti-E. coli, activity value is MIC = 1.56 uM||Anti-P. aeruginosa, activity value is MIC = 3.13 uM||Anti-E. aerogenes, activity value is MIC = 1.56 uM||Anti-E. cloacae, activity value is MIC = 6.25 uM||Anti-K. pneumoniae, activity value is MIC = 3.13 uM||Anti-S. aureus, activity value is MIC = 3.13 uM||Anti-B. cereus, activity value is MIC = 6.25 uM||Anti-S. lactis, activity value is MIC = 1.56 uM||Anti-E. faecalis, activity value is MIC = 1.56 uM||Anti-E. faecium, activity value is MIC = 1.56 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Temporin-1CEc：HC50 ≥ 500 uM2K：HC50 > 500 uM4K：HC50 > 500 uM2K2000 ml：HC50 > 500 uM4K2000 ml：HC50 > 500 uM4K4000 ml：HC50 > 500 uM2K4000 ml：HC50 = 62.5 uM2K4000 ml_W1：HC50 = 12.5 uM2K4000 ml_W2：HC50 = 12.5 uM2K4000 ml_W10：HC50 = 12.5 uM2K4000 ml_W13：HC50 = 12.5 uM2K4000 ml_2W：HC50 = 6.25 uM2K4000 ml_3W：HC50 = 6.25 uM|||Human RBC: HC50 62.5 uM, hemolytic.	2022 Feb:119:105544. doi: 10.1016/j.bioorg.2021.105544. Epub 2021 Dec 8.|||Bioorg Chem. 2022 Feb;119:105544. doi: 10.1016/j.bioorg.2021.105544. PubMed	13	
FPDB01382	AP04879	"	
KILKLLKKFLKKL"	Anti-E. coli, activity value is MIC = 6||Anti-P. aeruginosa, activity value is MIC = 3.13 uM||Anti-E. aerogenes, activity value is MIC = 1.56 uM||Anti-E.cloacae, activity value is MIC > 100 uM||Anti-K. pneumoniae, activity value is MIC = 6.25 uM||Anti-S. aureus, activity value is MIC = 3.13 uM||Anti-B. cereus, activity value is MIC = 12.5 uM||Anti-S. lactis, activity value is MIC = 1.56 uM||Anti-E. faecalis, activity value is MIC = 1.56 uM||Anti-E. faecium, activity value is MIC = 1.56 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Temporin-1CEc：HC50 ≥ 500 uM2K：HC50 > 500 uM4K：HC50 > 500 uM2K2000 ml：HC50 > 500 uM4K2000 ml：HC50 > 500 uM4K4000 ml：HC50 > 500 uM2K4000 ml：HC50 = 62.5 uM2K4000 ml_W1：HC50 = 12.5 uM2K4000 ml_W2：HC50 = 12.5 uM2K4000 ml_W10：HC50 = 12.5 uM2K4000 ml_W13：HC50 = 12.5 uM2K4000 ml_2W：HC50 = 6.25 uM2K4000 ml_3W：HC50 = 6.25 uM|||Human RBC: HC50 >500 uM, little hemo.lytic.	2022 Feb:119:105544. doi: 10.1016/j.bioorg.2021.105544. Epub 2021 Dec 8.|||Bioorg Chem. 2022 Feb;119:105544. doi: 10.1016/j.bioorg.2021.105544. PubMed	13	
FPDB01383	AP04880	"	
WILLLLKKFLKKL"	Anti-E. coli, activity value is MIC = 6||Anti-P. aeruginosa, activity value is MIC = 3.13 uM||Anti-E. aerogenes, activity value is MIC = 6.25 uM||Anti-E. cloacae, activity value is MIC = 12.5 uM||Anti-K. pneumoniae, activity value is MIC = 3.13 uM||Anti-S. aureus, activity value is MIC = 3.13 uM||Anti-B. cereus, activity value is MIC = 0.78 uM||Anti-S. lactis, activity value is MIC = 0.78 uM||Anti-E. faecalis, activity value is MIC = 1.56 uM||Anti-E. faecium, activity value is MIC = 3.13 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Temporin-1CEc：HC50 ≥ 500 uM2K：HC50 > 500 uM4K：HC50 > 500 uM2K2000 ml：HC50 > 500 uM4K2000 ml：HC50 > 500 uM4K4000 ml：HC50 > 500 uM2K4000 ml：HC50 = 62.5 uM2K4000 ml_W1：HC50 = 12.5 uM2K4000 ml_W2：HC50 = 12.5 uM2K4000 ml_W10：HC50 = 12.5 uM2K4000 ml_W13：HC50 = 12.5 uM2K4000 ml_2W：HC50 = 6.25 uM2K4000 ml_3W：HC50 = 6.25 uM|||Human RBC: HC50 12.5 uM, hemolytic.	2022 Feb:119:105544. doi: 10.1016/j.bioorg.2021.105544. Epub 2021 Dec 8.|||Bioorg Chem. 2022 Feb;119:105544. doi: 10.1016/j.bioorg.2021.105544. PubMed	13	
FPDB01384	AP04881	"	
IWLLLLKKFLKKL"	Anti-E. coli, activity value is MIC = 3.13 uM||Anti-P. aeruginosa, activity value is MIC = 6.25 uM||Anti-E. aerogenes, activity value is MIC = 3.13 uM||Anti-E. cloacae, activity value is MIC = 25 uM||Anti-K. pneumoniae, activity value is MIC = 3.13 uM||Anti-S. aureus, activity value is MIC = 0.78 uM||Anti-B. cereus, activity value is MIC = 0.78 uM||Anti-S. lactis, activity value is MIC = 1.56 uM||Anti-E. faecalis, activity value is MIC = 3.13 uM||Anti-E. faecium, activity value is MIC = 3.13 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Temporin-1CEc：HC50 ≥ 500 uM2K：HC50 > 500 uM4K：HC50 > 500 uM2K2000 ml：HC50 > 500 uM4K2000 ml：HC50 > 500 uM4K4000 ml：HC50 > 500 uM2K4000 ml：HC50 = 62.5 uM2K4000 ml_W1：HC50 = 12.5 uM2K4000 ml_W2：HC50 = 12.5 uM2K4000 ml_W10：HC50 = 12.5 uM2K4000 ml_W13：HC50 = 12.5 uM2K4000 ml_2W：HC50 = 6.25 uM2K4000 ml_3W：HC50 = 6.25 uM|||Human RBC: HC50 50 uM, hemolytic	2022 Feb:119:105544. doi: 10.1016/j.bioorg.2021.105544. Epub 2021 Dec 8.|||Bioorg Chem. 2022 Feb;119:105544. doi: 10.1016/j.bioorg.2021.105544. PubMed	13	
FPDB01385	AP04882	"	
IILLLLKKFWKKL"	Anti-E. coli, activity value is MIC = 3.13 uM||Anti-P. aeruginosa, activity value is MIC = 6.25 uM||Anti-E. aerogenes, activity value is MIC = 3.13 uM||Anti-E. cloacae, activity value is MIC = 6.25 uM||Anti-K. pneumoniae, activity value is MIC = 3.13 uM||Anti-S. aureus, activity value is MIC = 3.13 uM||Anti-B. cereus, activity value is MIC = 6.25 uM||Anti-S. lactis, activity value is MIC = 0.78 uM||Anti-E. faecalis, activity value is MIC = 1.56 uM||Anti-E. faecium, activity value is MIC = 3.13 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Temporin-1CEc：HC50 ≥ 500 uM2K：HC50 > 500 uM4K：HC50 > 500 uM2K2000 ml：HC50 > 500 uM4K2000 ml：HC50 > 500 uM4K4000 ml：HC50 > 500 uM2K4000 ml：HC50 = 62.5 uM2K4000 ml_W1：HC50 = 12.5 uM2K4000 ml_W2：HC50 = 12.5 uM2K4000 ml_W10：HC50 = 12.5 uM2K4000 ml_W13：HC50 = 12.5 uM2K4000 ml_2W：HC50 = 6.25 uM2K4000 ml_3W：HC50 = 6.25 uM|||Human RBC: HC50 12.5 uM, hemolytic.	2022 Feb:119:105544. doi: 10.1016/j.bioorg.2021.105544. Epub 2021 Dec 8.|||Bioorg Chem. 2022 Feb;119:105544. doi: 10.1016/j.bioorg.2021.105544. PubMed	13	
FPDB01386	AP04883	"	
IILLLLKKFLKKW"	Anti-E. coli, activity value is MIC = 6||Anti-P. aeruginosa, activity value is MIC = 3.13 uM||Anti-E. aerogenes, activity value is MIC = 6.25 uM||Anti-E. cloacae, activity value is MIC = 6.25 uM||Anti-K. pneumoniae, activity value is MIC = 3.13 uM||Anti-S. aureus, activity value is MIC = 6.25 uM||Anti-B. cereus, activity value is MIC = 3.13 uM||Anti-S.lactis, activity value is MIC > 100 uM||Anti-E. faecalis, activity value is MIC = 1.56 uM||Anti-E. faecium, activity value is MIC = 3.13 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Temporin-1CEc：HC50 ≥ 500 uM2K：HC50 > 500 uM4K：HC50 > 500 uM2K2000 ml：HC50 > 500 uM4K2000 ml：HC50 > 500 uM4K4000 ml：HC50 > 500 uM2K4000 ml：HC50 = 62.5 uM2K4000 ml_W1：HC50 = 12.5 uM2K4000 ml_W2：HC50 = 12.5 uM2K4000 ml_W10：HC50 = 12.5 uM2K4000 ml_W13：HC50 = 12.5 uM2K4000 ml_2W：HC50 = 6.25 uM2K4000 ml_3W：HC50 = 6.25 uM|||Human RBC: HC50 12.5 uM, hemolytic.	2022 Feb:119:105544. doi: 10.1016/j.bioorg.2021.105544. Epub 2021 Dec 8.|||Bioorg Chem. 2022 Feb;119:105544. doi: 10.1016/j.bioorg.2021.105544. PubMed	13	
FPDB01387	AP04884	"	
IILLLLKKFWKKW"	Anti-E. coli, activity value is MIC = 3.13 uM||Anti-P. aeruginosa, activity value is MIC = 3.13 uM||Anti-E. aerogenes, activity value is MIC = 1.56 uM||Anti-E. cloacae, activity value is MIC = 1.56 uM||Anti-K. pneumoniae, activity value is MIC = 6.25 uM||Anti-S. aureus, activity value is MIC = 0.78 uM||Anti-B. cereus, activity value is MIC = 0.78 uM||Anti-S. lactis, activity value is MIC = 1.56 uM||Anti-E. faecalis, activity value is MIC = 3.13 uM||Anti-E. faecium, activity value is MIC = 6.25 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Temporin-1CEc：HC50 ≥ 500 uM2K：HC50 > 500 uM4K：HC50 > 500 uM2K2000 ml：HC50 > 500 uM4K2000 ml：HC50 > 500 uM4K4000 ml：HC50 > 500 uM2K4000 ml：HC50 = 62.5 uM2K4000 ml_W1：HC50 = 12.5 uM2K4000 ml_W2：HC50 = 12.5 uM2K4000 ml_W10：HC50 = 12.5 uM2K4000 ml_W13：HC50 = 12.5 uM2K4000 ml_2W：HC50 = 6.25 uM2K4000 ml_3W：HC50 = 6.25 uM|||Human RBC: HC50 25 uM, hemolytic.	2022 Feb:119:105544. doi: 10.1016/j.bioorg.2021.105544. Epub 2021 Dec 8.|||Bioorg Chem. 2022 Feb;119:105544. doi: 10.1016/j.bioorg.2021.105544. PubMed	13	
FPDB01388	AP04885	"	
IWLLLLKKFWKKW"	Anti-E. coli, activity value is MIC = 3.13 uM||Anti-P. aeruginosa, activity value is MIC = 6.25 uM||Anti-E. aerogenes, activity value is MIC = 1.56 uM||Anti-E. cloacae, activity value is MIC = 6.25 uM||Anti-K. pneumoniae, activity value is MIC = 6.25 uM||Anti-S. aureus, activity value is MIC = 0.78 uM||Anti-B. cereus, activity value is MIC = 3.13 uM||Anti-S. lactis, activity value is MIC = 1.56 uM||Anti-E. faecalis, activity value is MIC = 12.5 uM||Anti-E. faecium, activity value is MIC = 6.25 uM	amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Temporin-1CEc：HC50 ≥ 500 uM2K：HC50 > 500 uM4K：HC50 > 500 uM2K2000 ml：HC50 > 500 uM4K2000 ml：HC50 > 500 uM4K4000 ml：HC50 > 500 uM2K4000 ml：HC50 = 62.5 uM2K4000 ml_W1：HC50 = 12.5 uM2K4000 ml_W2：HC50 = 12.5 uM2K4000 ml_W10：HC50 = 12.5 uM2K4000 ml_W13：HC50 = 12.5 uM2K4000 ml_2W：HC50 = 6.25 uM2K4000 ml_3W：HC50 = 6.25 uM|||Human RBC: HC50 6.25 uM, hemolytic.	2022 Feb:119:105544. doi: 10.1016/j.bioorg.2021.105544. Epub 2021 Dec 8.|||Bioorg Chem. 2022 Feb;119:105544. doi: 10.1016/j.bioorg.2021.105544. PubMed	13	
FPDB01389	AP04886	"	
GFGCPWNRYQCHSHSRSIGRLGGYCAGSLRLTCTSYRS"	Anti-weakly active against S. aureus ATCC 43300 or ATCC 25923 or E48, activity value is MIC = 64 ug/ml||Anti-S. epidermidis ATCC 12228 or G-81, activity value is MIC = 64 ug/ml||Anti-E-coli ATCC 25922, activity value is MIC > 64 ug/ml||Anti-S- typhimurium CVCC 14028, activity value is MIC > 64 ug/ml||Anti-S-flexneri CMCC 51571, activity value is MIC > 64 ug/ml	amino acid substitution, mollusca, animal-derived, natural derivatives	Beta	N/A	2024 Oct 8;22(10):463. doi: 10.3390/md22100463.|||Mar Drugs. 2024 Oct 8;22(10):463. doi: 10.3390/md22100463. PubMed	38	
FPDB01390	AP04918	"	
IYNCRRRFCKQR"	Anti-S. aureus ATCC 29213 or MRSA, activity value is MIC = 64 ug/ml||Anti-10 methicillin-resistant S. epidermidis MRSE, activity value is MIC = 2||Anti-S. haemolyticus XJ31196 or 3 more strains, activity value is MIC = 2||Anti-and S. hominis XJ31287 and 3 more strains, activity value is MIC = 2||Anti-Gram+||Anti-MRSA	sequence truncation, amino acid substitution, insects, animal-derived, natural derivatives	N/A	In a 10% human red blood cell (hRBC) suspension, R-Thanatin showed no hemolytic toxicity at concentrations up to 512 µg/ml, which is 100 times the MIC value for MRSE. After 1 hour and 6 hours of incubation, the hemolytic toxicity of R-Thanatin showed no significant difference compared to the control.	2013 Oct;57(10):5045-52. doi: 10.1128/AAC.00504-13. Epub 2013 Aug 5.|||Antimicrob Agents Chemother. 2013 Oct;57(10):5045-52. doi: 10.1128/AAC.00504-13. PubMed	12	
FPDB01391	AP04929	"	
GFALAGLARILCLWFREFSGFFRRLNRRFAMRRR"	Anti-E. coli ATCC 25922, activity value is MIC = 6.25 uM||Anti-A. baumannii, activity value is MIC = 1 uM||Anti-and S. aureus ATCC 25923 or MRSA, activity value is MIC = 1||Anti-Gram+ & Gram-||Anti-MRSA	amino acid SUBSTITUTION, animal-derived, natural derivatives	Helix	SRP-1: At a concentration of 50 µM, it exhibits virtually no hemolytic activity. SRP-2: At a concentration of 50 µM, it exhibits almost no hemolytic activity. SRP-3 exhibits strong hemolytic activity at a concentration of 50 µM.	2018 Oct 2;8(1):14602. doi: 10.1038/s41598-018-32981-3.|||Sci Rep. 2018 Oct 2;8(1):14602. doi: 10.1038/s41598-018-32981-3. PubMed	34	
FPDB01392	AP04937	"	
KKLLKLLKLLL"	Anti-E. coli W3110, activity value is MIC = 4 ug/ml||Anti-P. aeruginosa PAO1, activity value is MIC = 2||Anti-A. baumannii ATCC19606, activity value is MIC = 2||Anti-K. pneumoniae NCTC418, activity value is MIC = 4 ug/ml||Anti-and S. aureus COL MRSA, activity value is MIC = 4 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA	Obtained via virtual screening and linearization of bp65	N/A	bp65: 16.5 ug/mln65: 125 ug/mlsr-ln65: 1000 ug/mln69: 250 ug/mldln69: 1000 ug/mlHP1: <15.6 ug/mlHP2: <15.6 ug/mlHP3: <15.6 ug/mlHP4: 100 ug/mlHP5: 62.5 ug/mlHP6: 500 ug/mlHP7: 125 ug/mlEB1: >2000 ug/mlEB5: 1000 ug/mlEB6: 250 ug/mlEB9: >328 ug/ml	2024 Oct 30;78(10):648-653. doi: 10.2533/chimia.2024.648.|||Chimia (Aarau). 2024 Oct 30;78(10):648-653. doi: 10.2533/chimia.2024.648. PubMed	11	
FPDB01393	AP04938	"	
KKLLKCLKCLL"	Anti-P. aeruginosa PAO1, activity value is MIC = 8 ug/ml||Anti-A. baumannii ATCC19606, activity value is MIC = 4 ug/ml||Anti-K. pneumoniae NCTC418, activity value is MIC = 16 ug/ml||Anti-and S. aureus COL MRSA, activity value is MIC = 8 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA	designed, Obtained via virtual screening and sidechain coupling	Helix	bp65: 16.5 ug/mln65: 125 ug/mlsr-ln65: 1000 ug/mln69: 250 ug/mldln69: 1000 ug/mlHP1: <15.6 ug/mlHP2: <15.6 ug/mlHP3: <15.6 ug/mlHP4: 100 ug/mlHP5: 62.5 ug/mlHP6: 500 ug/mlHP7: 125 ug/mlEB1: >2000 ug/mlEB5: 1000 ug/mlEB6: 250 ug/mlEB9: >328 ug/ml	2024 Oct 30;78(10):648-653. doi: 10.2533/chimia.2024.648.|||Chimia (Aarau). 2024 Oct 30;78(10):648-653. doi: 10.2533/chimia.2024.648. PubMed	11	
FPDB01394	AP04963	"	
MNKLNEVELSKISGGIGPLVIPVAAILGFLATDAWNHADELVAGVKQGWERS"	Anti-S. aureus ATCC 25923 or MRSA BAA 2313, activity value is MIC = 0.8||Anti-C. difficile ATCC 43602, activity value is MIC = 1.1 uM||Anti-L. monocytogenes ATCC 15313, activity value is MIC = 1.2 uM||Anti-E. faecium anti-VRE BAA 2317, activity value is MIC = 1.2 uM||Anti-E. coli ATCC 33694, activity value is MIC = 7.5 uM||Anti-Gram+ & Gram-||Anti-MRSA||Anti-inflammatory	Lactobacillus rhamnosus ATCC 7469|||Lactobacillus rhamnosus ATCC 7469	N/A	N/A	2023 Apr 7;24(8):6901. doi: 10.3390/ijms24086901.|||Int J Mol Sci. 2023 Apr 7;24(8):6901. doi: 10.3390/ijms24086901. PubMed	52	
FPDB01395	AP04967	"	
DAWNHADELV"	Anti-S. aureus ATCC 25923 or MRSA BAA 2313, activity value is MIC = 2.6||Anti-Gram+||Anti-MRSA	sequence truncation, bacteria-derived, natural derivatives	N/A	N/A	2024 Oct 28;16(1):312-323. doi: 10.1039/d4md383000000 ug. Online ahead of print.|||RSC Med Chem. 2024 Oct 28. doi: 10.1039/d4md383000000 ug.PubMed	10	
FPDB01396	AP04968	"	
AGVKQGWERS"	Anti-S. aureus ATCC 25923 or MRSA BAA 2313, activity value is MIC = 1.2||Anti-C. difficile ATCC 43602, activity value is MIC = 2.1 uM||Anti-L. monocytogenes ATCC 15313, activity value is MIC = 1.8 uM||Anti-E. faecium anti-VRE BAA 2317, activity value is MIC = 1.9||Anti-E. coli ATCC 33694, activity value is MIC = 7.8 uM||Anti-Gram+ & Gram-||Anti-MRSA	sequence truncation, bacteria-derived, natural derivatives	N/A	N/A	2024 Oct 28;16(1):312-323. doi: 10.1039/d4md383000000 ug. Online ahead of print.|||RSC Med Chem. 2024 Oct 28. doi: 10.1039/d4md383000000 ug.PubMed	10	
FPDB01397	AP04969	"	
LSKISGGIGPLVIPV"	Anti-S. aureus ATCC 25923 or MRSA BAA 2313, activity value is MIC = 0.9||Anti-C. difficile ATCC 43602, activity value is MIC = 0.9 uM||Anti-L. monocytogenes ATCC 15313, activity value is MIC = 2.3 uM||Anti-E. faecium anti-VRE BAA 2317, activity value is MIC = 1.3 uM||Anti-E. coli ATCC 33694, activity value is MIC = 9.2 uM||Anti-P. aeruginosa BAA 1744, activity value is MIC = 9.3 uM||Anti-Gram+ & Gram-||Anti-MRSA	sequence truncation, bacteria-derived, natural derivatives	N/A	N/A	2024 Oct 28;16(1):312-323. doi: 10.1039/d4md383000000 ug. Online ahead of print.|||RSC Med Chem. 2024 Oct 28. doi: 10.1039/d4md383000000 ug.PubMed	15	
FPDB01398	AP04970	"	
IGPLVIPVAAIL"	Anti-S. aureus ATCC 25923 or MRSA BAA 2313, activity value is MIC = 1.5||Anti-C. difficile ATCC 43602, activity value is MIC = 1.8 uM||Anti-L. monocytogenes ATCC 15313, activity value is MIC = 3.6 uM||Anti-E. faecium anti-VRE BAA 2317, activity value is MIC = 1.5 uM||Anti-Gram+||Anti-MRSA	sequence truncation, bacteria-derived, natural derivatives	N/A	N/A	2024 Oct 28;16(1):312-323. doi: 10.1039/d4md383000000 ug. Online ahead of print.|||RSC Med Chem. 2024 Oct 28. doi: 10.1039/d4md383000000 ug.PubMed	12	
FPDB01399	AP04971	"	
KLNEVELSKISGG"	Anti-S. aureus ATCC 25923 or MRSA BAA 2313, activity value is MIC = 2.3||Anti-C. difficile ATCC 43602, activity value is MIC = 2.6 uM||Anti-L. monocytogenes ATCC 15313, activity value is MIC = 2.6 uM||Anti-E. faecium anti-VRE BAA 2317, activity value is MIC = 3.2 uM||Anti-Gram+||Anti-MRSA	sequence truncation, bacteria-derived, natural derivatives	N/A	N/A	2024 Oct 28;16(1):312-323. doi: 10.1039/d4md383000000 ug. Online ahead of print.|||RSC Med Chem. 2024 Oct 28. doi: 10.1039/d4md383000000 ug. PubMed	13	
FPDB01400	AP04972	"	
GKEAATKAIKEWGQPKSKITH"	Anti-S. aureus MRSA, activity value is MIC = 2||Anti-Gram+||Anti-MRSA	medicinal plant, Indian Bael fruit, Aegle marmelos, plants|||medicinal plant, Indian Bael fruit, Aegle marmelos, plants	N/A	SVKRLITRMYQRINL: 0.00GNNRVRAVAM: 0.49SAKNYGRAVYEC: 0.00GKEAATKAIKEW: 0.49GQPKSKITHLIF: 0.47GQPKSKITH: 0.49GKEAATKAIKE: 0.49WGQPKSKITH: 0.48GHPWGNAPGAVANRVAL: 0.48QGPPHGIQVERDKLNKY: 0.43NSNSLITSKNSISKSNPRLLLF: 0.49CTGYRPIVDAFR: 0.48GKEAATKAIKEWGQPKSKITH: 0.47TGSPGKYVG: 0.49DAVKVIKPTI: 0.48	2024 Oct 28;14(1):25822. doi: 10.1038/s41598-024-76553-0.|||Sci Rep. 2024 Oct 28;14(1):25822. doi: 10.1038/s41598-024-76553-0. PubMed	21	
FPDB01401	AP04973	"	
HADELVAGVKQ"	Anti-S. aureus ATCC 25923 or MRSA BAA 2313, activity value is MIC = 1.3||Anti-C. difficile ATCC 43602, activity value is MIC = 1 uM||Anti-L. monocytogenes ATCC 15313, activity value is MIC = 1.1 uM||Anti-E. faecium anti-VRE BAA 2317, activity value is MIC = 3.1 uM||Anti-Gram+||Anti-MRSA	sequence truncation, bacteria-derived, natural derivatives	N/A	N/A	2024 Oct 28;16(1):312-323. doi: 10.1039/d4md383000000 ug. Online ahead of print.|||RSC Med Chem. 2024 Oct 28. doi: 10.1039/d4md383000000 ug. PubMed	11	
FPDB01402	AP04978	"	
RRGIKKFIKKVKKVKKAI"	Anti-S. aureus ATCC6538 and 7 clinical strains and 9 MRSA strains, activity value is MIC = 2.34 ug/ml||Anti-A. baumannii ATCC19606 and 3 clinical strains, activity value is MIC = 2.34||Anti-three E. coli clinical strains, activity value is MIC = 9.37||Anti-P. aeruginosa 4 clinical strains, activity value is MIC = 1.17||Anti-Gram+ & Gram-||Anti-MRSA	sequence truncation, reptiles, animal-derived, natural derivatives	Helix	N/A	2024 Nov 14;67(21):19561-19572. doi: 10.1021/acs.jmedchem.4c01855. Epub 2024 Nov 1.|||J Med Chem. 2024 Nov 1. doi: 10.1021/acs.jmedchem.4c01855. PubMed	18	
FPDB01403	AP05036	"	
WPPFPIGCGNCAATFCPYVPPSSCPGGKTTRDKCGCCTVCKKDRWGG"	Anti-Gram+ S. aureus MRSA, activity value is IC50 = 0.5 ug/ml||Anti-A. hydrophila, activity value is IC50 = 2 ug/ml||Anti-K. pneumoniae, activity value is IC50 = 0.5 ug/ml||Anti-and E. coli, activity value is IC50 = 0.25 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA	Chinese horseshoe crab, Tachypleus tridentatus|||Chinese horseshoe crab, Tachypleus tridentatus	N/A	N/A	2025 Jan:156:110026. doi: 10.1016/j.fsi.2024.110026. Epub 2024 Nov 14.|||Fish Shellfish Immunol. 2024 Nov 14:110026. doi: 10.1016/j.fsi.2024.110026. PubMed	47	
FPDB01404	AP05044	"	
GFGCNGPWSADDLRCHRHCKSIKGYRGGYCAKGGFVCKCY"	Anti-S. aureus MRSA ATCC 43300, activity value is MIC = 32 ug/ml||Anti-Gram+||Anti-MRSA	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic values: A hemolysis rate of less than 3% indicates that the A24 peptide exhibits low hemolytic activity in in vitro experiments.	2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z.|||Commun Biol. 2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z. PubMed	40	
FPDB01405	AP05045	"	
GFGCNGPWSEDDLRCHRHCKSIKGIRGGYCAKGGFVCKCY"	Anti-S. aureus MRSA ATCC 43300, activity value is MIC = 4 ug/ml||Anti-Gram+||Anti-MRSA	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic values: A hemolysis rate of less than 3% indicates that the A24 peptide exhibits low hemolytic activity in in vitro experiments.	2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z.|||Commun Biol. 2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z. PubMed	40	
FPDB01406	AP05046	"	
GFGCNGPWSQDDLRCHRHCKSIKGYRGGYCAKGGFVCKCY"	Anti-S. aureus MRSA ATCC 43300, activity value is MIC = 4 ug/ml||Anti-Gram+||Anti-MRSA	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic values: A hemolysis rate of less than 3% indicates that the A24 peptide exhibits low hemolytic activity in in vitro experiments.	2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z.|||Commun Biol. 2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z. PubMed	40	
FPDB01407	AP05047	"	
GFGCNGPWSEDDLRCHRHCKSIKGYRGGYCAKGGFVCKCI"	Anti-S. aureus MRSA ATCC 43300, activity value is MIC = 32 ug/ml||Anti-Gram+||Anti-MRSA	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic values: A hemolysis rate of less than 3% indicates that the A24 peptide exhibits low hemolytic activity in in vitro experiments.	2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z.|||Commun Biol. 2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z. PubMed	40	
FPDB01408	AP05048	"	
GFGCNGPWAEDDLRCHRHCKSIKGYRGGYCAKGGFVCKCY"	Anti-S. aureus MRSA ATCC 43300 and 8 clinical isolates, activity value is MIC = 2||Anti-Gram+||Anti-MRSA||Anti-inflammatory||Synergistic AMPs||Antibiofilm	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Beta	"Hemolytic values: A hemolysis rate of less than 3% indicates that the A24 peptide exhibits low hemolytic activity in in vitro experiments.|||The document focuses solely on hemolytic data for amphiphilic peptide A24, with the core indicator being hemolysis rate. The specific information is as follows: 
 
1. Core hemolysis data of A24
 
Using mouse red blood cells as the test subject, hemolysis experiments were conducted using A24 at a 2-fold gradient concentration (0.5–256 ug/ml), with PBS as the blank control (0% hemolysis) and 0.1% Triton X-100 as the positive control (100% hemolysis). The results are as follows: 
 
- Hemolysis rate: At the highest test concentration (256 ug/ml), A24's hemolysis rate remains below 1%, with almost no hemolysis. 
- Safety association: Combined with in vitro cytotoxicity studies (mouse macrophages RAW264.7 and uterine epithelial cell BNCC359233 under 256 ug/ml A24 treatment, survival rates exceeded 78% and 85%, respectively) and in vivo acute toxicity tests (10,000 ug/kg A24 injections intraperitoneal/uterine for 7 consecutive days, with no abnormalities in mouse body weight, blood routine, biochemical indicators, or histopathology), indicating that A24 has excellent safety and extremely low hemolytic activity at effective antibacterial concentrations (2–16 ug/ml). 
 
2. Details of the experimental method
 
1. Red blood cell treatment: Take 8% fresh mouse red blood cell suspension, mix with equal volumes of A24 at different concentrations, and incubate at 37°C for 1 hour. 
2. Hemolysis rate test: After centrifuging 500 ×g for 5 minutes, measure the absorbance of the supernatant and calculate the hemolysis rate (formula: \text{hemolysis rate (%)} = \frac{A_{\text{sample}} - A_{\text{blank control}}}{A_{\text{positive control}} - A_{\text{blank control}}} \times 100\%). 
 
3. Key Conclusions
 
A24 has extremely low hemolysis (with a maximum hemolytic rate of 256 ug/ml <1%), and is far below its effective antibacterial concentration (MIC for multidrug-resistant Staphylococcus aureus is 2–16 ug/ml, MBC is 2–32 ug/ml), demonstrating high bacterial selectivity and no risk of erythrocytotoxicity, providing safety support for in vivo applications (such as peritonitis and endometritis treatment)."	2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z.|||Commun Biol. 2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z. PubMed	40	
FPDB01409	AP05049	"	
GFGCNGPWSEDDLRCHRHCKAIKGYRGGYCAKGGFVCKCY"	Anti-S. aureus MRSA ATCC 43300, activity value is MIC = 16 ug/ml||Anti-Gram+||Anti-MRSA	Amino acid substitution, fungal defensin analog, fungi-derived, natural derivatives	Bridge	Hemolytic values: A hemolysis rate of less than 3% indicates that the A24 peptide exhibits low hemolytic activity in in vitro experiments.	2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z.|||Commun Biol. 2024 Nov 27;7(1):1582. doi: 10.1038/s42003-024-07216-z. PubMed	40	
FPDB01410	AP05056|||AP05056|||HG1|||K19Hc|||K19Hc|||DRAMP04551	"	
KWLNALLHHGLNCAKGVLA"	Anti-S. aureus MRSA, activity value is MIC = 4 ug/ml||Anti-B. subtilis KCTC 2213, activity value is MIC = 2 ug/ml||Anti-M. luteus KCTC 9341, activity value is MIC = 4 ug/ml||Anti-vancomycin-resistant E. faecium strain CCARM 5028 anti-VRE, activity value is MIC = 4 ug/ml||Anti-multidrug-resistant L. monocytogenes CCARM 2161, activity value is MIC = 4 ug/ml||Anti-P. aeruginosa CCARM 2161 MDRPA, activity value is MIC = 4 ug/ml||Anti-E. coli KCTC 1039, activity value is MIC = 4 ug/ml||Anti-K. oxytoca KCTC 1686, activity value is MIC = 4 ug/ml||Anti-C. freundii KCTC 2359, activity value is MIC = 4 ug/ml||Anti-S. enterica KCTC 2930, activity value is MIC = 4 ug/ml||Anti-and 5 strains C. albicans, activity value is MIC = 8||Anti-Gram+ & Gram-||Anti-MRSA||MIC against MRSA Staphylococcus aureus CCARM 3696||Bacillus subtilis KCTC 2213||Micrococcus luteus KCTC9341||vancomycin-resistant Enterococcus faecium CCARM 5028 (VRE)||Listeria mono-cytogenes KCTC 19111||multidrug-resistant Pseudomonas aeruginosa CCARM 2161(MDRPA)||Escherichia coli KCTC 1039||Klebsiella oxytoca KCTC 1686||Citrobacter fre-undii KCTC 2359 and Salmonella enterica KCTC 2930||Anti-Monomer: [P. grisea KACC40425, activity value is MIC = 4||Anti-F. oxysporum KACC40902, activity value is MIC = 8||Anti-G. candidum KACC40354, activity value is MIC = 16||Anti-Cr. neoformans KCCM50544, activity value is MIC = 16||Anti-T. beigelli KCTC7707, activity value is MIC = 4||Anti-C. albicans KCTC7121, activity value is MIC = 8||Anti-C.albicans KCTC7270, activity value is MIC = 16||Anti-C. albicans KCTC7729, activity value is MIC = 8||Anti-C. albicans KCTC7965, activity value is MIC = 16||Anti-Dimer: [P. grisea KACC40425, activity value is MIC = 4||Anti-F. oxysporum KACC40902, activity value is MIC = 4||Anti-A. terreus KCTC6178, activity value is MIC = 8||Anti-A.niger KCTC6461, activity value is MIC = 8||Anti-G. candidum KACC40354, activity value is MIC = 8||Anti-T. beigelli KCTC7707, activity value is MIC = 2||Anti-C. albicans KCTC7121, activity value is MIC = 1||Anti-C.albicans KCTC7270, activity value is MIC = 2||Anti-C. albicans KCTC7729, activity value is MIC = 2||Anti-C. albicans KCTC7965, activity value is MIC = 2||Anti-12878508: E. coli, activity value is MIC = 4||Anti-B. subtilis, activity value is MIC = 8||No MICs found in DRAMP database	sequence extension, animal-derived, natural derivative|||sequence extension, animal-derived, natural derivative|||Synthetic construct|||Halocynthia aurantium	N/A	Hemolytic activity against hRBC (Dimer peptide)|||No hemolysis information or data found in the reference(s) presented in this entry	2010 Jul;54(7):2855-66. doi: 10.1128/AAC.01790-09. Epub 2010 Apr 12.|||Antimicrob Agents Chemother. 2010 Jul;54(7):2855-66. doi: 10.1128/AAC.01790-09. PubMed|||16469314, 12878508|||16469314, 12878508|||Antimicrob Agents Chemother. 2003 Aug;47(8):2481-2486.	19	
FPDB01411	AP05057	"	
KWKKALLHHGLNCAKGVLA"	Anti-S. aureus MRSA, activity value is MIC = 4 ug/ml||Anti-B. subtilis, activity value is MIC = 2 ug/ml||Anti-M. luteus, activity value is MIC = 4 ug/ml||Anti-E. faecium strain CCARM 5028 anti-VRE, activity value is MIC = 2 ug/ml||Anti-L. monocytogenes, activity value is MIC = 2 ug/ml||Anti-P. aeruginosa MDRPA, activity value is MIC = 4 ug/ml||Anti-E. coli, activity value is MIC = 2 ug/ml||Anti-K. oxytoca, activity value is MIC = 2 ug/ml||Anti-C. freundii, activity value is MIC = 4 ug/ml||Anti-S. enterica, activity value is MIC = 2 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA	sequence extension, amino acid substitution, animal-derived, natural derivative	N/A	N/A	2010 Jul;54(7):2855-66. doi: 10.1128/AAC.01790-09. Epub 2010 Apr 12.|||Antimicrob Agents Chemother. 2010 Jul;54(7):2855-66. doi: 10.1128/AAC.01790-09. PubMed	19	
FPDB01412	AP05135|||AP05135|||PST11, SYM11	"	
RRFPWWWPFRR"	Anti-E. coli KCTC 1682, activity value is MIC = 4 ug/ml||Anti-S. typhimurium KCTC 1926, activity value is MIC = 4 ug/ml||Anti-B. subtilis KCTC 3068, activity value is MIC = 2 ug/ml||Anti-and S. aureus KCTC 1621 or 2 strains MRSA, activity value is MIC = 2||Anti-2 strains vancomycin-resistant E. faecium, activity value is MIC = 4 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA||Anti-Escherichia coli, activity value is MIC = 4 ug/ml||Anti-Salmonella typhimurium, activity value is MIC = 4 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 2 ug/ml||Anti-methicillin-resistant Staphylococcus aureus 1, activity value is MIC = 4 ug/ml||Anti-vancomycin resistant Enterococcus faecium 1, activity value is MIC = 4 ug/ml||Anti-MRSA 2, activity value is MIC = 8 ug/ml||Anti-VRE2, activity value is MIC = 4 ug/ml||Anti-12681513: E. coli, activity value is MIC = 16 ug/ml||Anti-S. typhimurium, activity value is MIC = 8 ug/ml||Anti-P. aeruginosa, activity value is MIC = 16 ug/ml||Anti-B. subtilis, activity value is MIC = 4 ug/ml||Anti-S. aureus, activity value is MIC = 4 ug/ml||Anti-S. epidermidis, activity value is MIC = 2 ug/ml	amino acid deletion, animal-derived, natural derivative|||amino acid deletion, animal-derived, natural derivative|||Synthetic construct	N/A	Tritrpticin: At a concentration of 50 uM, hemolysis is 43%. T13-am (terminally amidated Tritrpticin): The document does not specifically mention the hemolysis value of this peptide at a particular concentration. T15-am: The document does not specifically mention the hemolysis value of this peptide at a particular concentration. PST11: At a concentration of 50 uM, hemolysis is 7%. PST11-RK: At a concentration of 50 uM, hemolysis is 0%. Indolicidin: At a concentration of 50 uM, hemolysis is 52%. PSI10: At a concentration of 50 uM, hemolysis is 7%.|||Human erythroctes (40% hemolysis at 100 uM), Human erythroctes (60% hemolysis at 200 uM)	2006 Apr;27(4):325-30. doi: 10.1016/j.ijantimicag.2005.11.014. Epub 2006 Mar 23.|||Int J Antimicrob Agents. 2006 Apr;27(4):325-30. doi: 10.1016/j.ijantimicag.2005.11.014. PubMed|||16563706, 12681513	11	
FPDB01413	AP05136|||AP05136|||PST11-RK, SYM11KK	"	
KKFPWWWPFKK"	Anti-E. coli KCTC 1682, activity value is MIC = 4 ug/ml||Anti-S. typhimurium KCTC 1926, activity value is MIC = 4 ug/ml||Anti-B. subtilis KCTC 3068, activity value is MIC = 2 ug/ml||Anti-and S. aureus KCTC 1621 or 2 strains MRSA, activity value is MIC = 2||Anti-2 strains vancomycin-resistant E. faecium, activity value is MIC = 8 ug/ml||Anti-Gram+ & Gram-||Anti-MRSA||Anti-Escherichia coli, activity value is MIC = 4 ug/ml||Anti-Salmonella typhimurium, activity value is MIC = 4 ug/ml||Anti-Bacillus subtilis, activity value is MIC = 2 ug/ml||Anti-Staphylococcus aureus, activity value is MIC = 2 ug/ml||Anti-methicillin-resistant Staphylococcus aureus 1, activity value is MIC = 4 ug/ml||Anti-vancomycin resistant Enterococcus faecium 1, activity value is MIC = 8 ug/ml||Anti-MRSA 2, activity value is MIC = 8 ug/ml||Anti-VRE2, activity value is MIC = 8 ug/ml||Anti-12681513: E. coli, activity value is MIC = 8 ug/ml||Anti-S. typhimurium, activity value is MIC = 8 ug/ml||Anti-P. aeruginosa, activity value is MIC = 8 ug/ml||Anti-B. subtilis, activity value is MIC = 2 ug/ml||Anti-S. aureus, activity value is MIC = 4 ug/ml||Anti-S. epidermidis, activity value is MIC = 1 ug/ml	amino acid SUBSTITUTION, amino acid deletion, porcine cathelicidin, animal-derived, natural derivatives|||amino acid SUBSTITUTION, amino acid deletion, porcine cathelicidin, animal-derived, natural derivatives|||Synthetic construct	N/A	Tritrpticin: At a concentration of 50 uM, hemolysis is 43%. T13-am (terminally amidated Tritrpticin): The document does not specifically mention the hemolysis value of this peptide at a particular concentration. T15-am: The document does not specifically mention the hemolysis value of this peptide at a particular concentration. PST11: At a concentration of 50 uM, hemolysis is 7%. PST11-RK: At a concentration of 50 uM, hemolysis is 0%. Indolicidin: At a concentration of 50 uM, hemolysis is 52%. PSI10: At a concentration of 50 uM, hemolysis is 7%.|||Human erythroctes (0% hemolysis at 100 uM)	2006 Apr;27(4):325-30. doi: 10.1016/j.ijantimicag.2005.11.014. Epub 2006 Mar 23.|||Int J Antimicrob Agents. 2006 Apr;27(4):325-30. doi: 10.1016/j.ijantimicag.2005.11.014. PubMed|||16563706, 12681513	11	
FPDB01414	AP05138	"	
RRWPWWPWRR"	Anti-E. coli KCTC 1682, activity value is MIC = 2 ug/ml||Anti-S. typhimurium KCTC 1926, activity value is MIC = 4 ug/ml||Anti-B. subtilis KCTC 3068, activity value is MIC = 2 ug/ml||Anti-and S. aureus KCTC 1621 or 2 strains MRSA, activity value is MIC = 2||Anti-2 strains vancomycin-resistant E. faecium, activity value is MIC = 2||Anti-Gram+ & Gram-||Anti-MRSA	amino acid SUBSTITUTION, amino acid deletion, bovine cathelicidin, animal-derived, natural derivatives	N/A	Tritrpticin: At a concentration of 50 uM, hemolysis is 43%. T13-am (terminally amidated Tritrpticin): The document does not specifically mention the hemolysis value of this peptide at a particular concentration. T15-am: The document does not specifically mention the hemolysis value of this peptide at a particular concentration. PST11: At a concentration of 50 uM, hemolysis is 7%. PST11-RK: At a concentration of 50 uM, hemolysis is 0%. Indolicidin: At a concentration of 50 uM, hemolysis is 52%. PSI10: At a concentration of 50 uM, hemolysis is 7%.	2006 Apr;27(4):325-30. doi: 10.1016/j.ijantimicag.2005.11.014. Epub 2006 Mar 23.|||Int J Antimicrob Agents. 2006 Apr;27(4):325-30. doi: 10.1016/j.ijantimicag.2005.11.014. PubMed	10	
FPDB01415	AP05235|||DRAMP35742	"	
GWGSFFRRAAHVGRHVGRAALTHYL"	Anti-Gram- K. pneumoniae NCTC 13368 or M6, activity value is MIC = 2||Anti-A. baumannii AYE or ATCC 17978, activity value is MIC = 1||Anti-P. aeruginosa NCTC 13437 or PAO1, activity value is MIC = 4||Anti-E. coli NCTC 12923, activity value is MIC = 1 ug/ml||Anti-methicillin-sensitive S. aureus ATCC 9144 or MRSA NCTC 13616 or MRSA NCTC 13277, activity value is MIC = 2||Anti-vancomycin-sensitive and resistant E. faecalis NCTC 775 or NCTC 12204, activity value is MIC = 4||Anti-Gram+ & Gram-||Anti-MRSA||Antimicrobial||Anticancer	amino acid substitution, amphibians, animal-derived, natural derivatives|||Synthetic	Helix	Hemolytic values of D-pleurocidin-KR: At effective antibacterial concentrations, none of the analogs showed significant hemolytic activity (Supplementary Figure 13). For most isolates, the in vitro therapeutic index of D-pleurocidin-KR was 18 to 150 times higher than the concentration causing hemolysis of red blood cells (the concentration causing 10% hemolysis was 75 µg/ml).	2020 Nov 27;3(1):697. doi: 10.1038/s42003-020-01420-3.|||Commun Biol. 2020 Nov 27;3(1):697. doi: 10.1038/s42003-020-01420-3. PubMed|||Commun Biol. 2020 Nov 27;3(1):697.	25	
FPDB01416	AP05236|||DRAMP35744	"	
GWGSFFKKAAHAGKHAGKAALTHYL"	"Anti-Gram- K. pneumoniae NCTC 13368 or M6, activity value is MIC = 4||Anti-A. baumannii AYE or ATCC 17978, activity value is MIC = 1||Anti-P. aeruginosa NCTC 13437 or PAO1, activity value is MIC = 16||Anti-E. coli NCTC 12923, activity value is MIC = 1 ug/ml||Anti-methicillin-sensitive S. aureus ATCC 9144, activity value is MIC = 8 ug/ml||Anti-S. aureus MRSA NCTC 13616 or MRSA NCTC 13277, activity value is MIC = 64||Anti-vancomycin-sensitive and resistant E. faecalis NCTC 775 or NCTC 12204, activity value is MIC = 32||Anti-Gram+ & Gram-||Anti-MRSA
Crucial residues:||Antimicrobial||Anticancer"	amino acid substitution, amphibians, animal-derived, natural derivatives|||Synthetic	Helix	Hemolytic values of D-pleurocidin-KR: At effective antibacterial concentrations, none of the analogs showed significant hemolytic activity (Supplementary Figure 13). For most isolates, the in vitro therapeutic index of D-pleurocidin-KR was 18 to 150 times higher than the concentration causing hemolysis of red blood cells (the concentration causing 10% hemolysis was 75 µg/ml).	2020 Nov 27;3(1):697. doi: 10.1038/s42003-020-01420-3.|||Commun Biol. 2020 Nov 27;3(1):697. doi: 10.1038/s42003-020-01420-3. PubMed|||Commun Biol. 2020 Nov 27;3(1):699.	25	
FPDB01417	AP05237|||AP05237|||NZX	"	
GFGCNGPWSEDDIQCHNHCKSIKGYKGGYCARGGFVCKCY"	Anti-S. aureus ATCC43300 MRSA or TCC25923, activity value is MIC = 0.46||Anti-Gram+||Anti-MRSA||Antibacterial	amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||amino acid substitution, fungal defensin analog, fungi-derived, natural derivative|||Pseudoplectania nigrella [Ebony cup]	Bridge	Hemolytic activity of NZX: At a concentration of 128 µg/ml, the hemolytic activity of NZX was 1.90%. Hemolytic activity of CRO: At a concentration of 128 µg/ml, the hemolytic activity of CRO was 0.21%.	2020 Feb;104(4):1555-1568. doi: 10.1007/s00253-019-10313-3. Epub 2020 Jan 3.|||Appl Microbiol Biotechnol. 2020 Feb;104(4):1555-1568. doi: 10.1007/s00253-019-10313-3. PubMed|||30514507	40	
FPDB01418	AP05250	"	
GGGVITTFTHECYYNSVSPASWGGCCK"	Anti-L. lactis MG1363, activity value is MIC = 4 ug/ml||Anti-L-onocytogenes LMG10470, activity value is MIC > 64 ug/ml||Anti-S. aureus LMG10147 or LMG15975 MRSA, activity value is MIC = 4||Anti-E. faecalis LMG16216 or LMG16003, activity value is MIC = 64 ug/ml||Anti-B. ereus ATCC14579, activity value is MIC = 8 ug/ml||Anti-C. botulinum CECT551, activity value is MIC = 32 ug/ml||Anti-bowel infection-associated C. perfringens CECT376, activity value is MIC = 1 ug/ml||Anti-and C. tetani CECT4629, activity value is MIC = 4 ug/ml	Clostridium estertheticum CF016	N/A	N/A	2025 Feb 28;88(2):262-273. doi: 10.1021/acs.jnatprod.4c00814. Epub 2025 Jan 15.	27	
FPDB01419	AP05251	"	
GGGVINTFTHECYYNSVSPASWGGCCK"	active against L. lactis||S. aureus MRSA||and B||cereus (agar diffusion assay).	Clostridium tagluense CM008	N/A	N/A	2025 Feb 28;88(2):262-273. doi: 10.1021/acs.jnatprod.4c00814. Epub 2025 Jan 15.	27	
FPDB01420	AP05252	"	
GNGVITTFTHECYYNSVSPASWGGCCK"	active against L. lactis||S. aureus MRSA||and B||cereus (agar diffusion assay).	Clostridium estertheticum CF011	N/A	N/A	2025 Feb 28;88(2):262-273. doi: 10.1021/acs.jnatprod.4c00814. Epub 2025 Jan 15.	27	
FPDB01421	AP05271	"	
VTCDVLSFEAKGVKLNHAACAAHCLAMGKRGGRCNNGVCVCRR"	Anti-S. aureus ATCC 29213 or MRSA ATCC 43300, activity value is MIC = 25||Anti-E.coli, activity value is MIC > 100 ug/ml||Anti-P.aeruginosa atcc 27853, activity value is MIC > 100 ug/ml||Anti-B.cereus, activity value is MIC > 100 ug/ml||Anti-C.albicans, activity value is MIC > 100 ug/ml||Anti-C.tropicalis, activity value is MIC > 100 ug/ml	Mylabris quadripunctata	Bridge	N/A	2025 Aug;27(8):1146-1160. doi: 10.1080/10286020.2024.2448011. Epub 2025 Jan 9.	43	
FPDB01422	AP05283	"	
SIGGALLSAGKSALKGLAKGLAEHFAN"	Anti-S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 4||Anti-E. faecalis NCTC 12697, activity value is MIC = 64 uM||Anti-E. coli ATCC 8739, activity value is MIC = 2 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 8 uM||Anti-and A. baumannii BAA 747, activity value is MIC = 16 uM	skin secretions, Bombina variegata , Europe	Helix	Native peptide BH2000 ml: HC₅₀ 17.2 µM (strong hemolysis). Optimized peptide [Arg8,15]BH2000 ml: HC₅₀ 280.4 µM (significantly reduced hemolysis). Optimized peptide [Lys7,8]BH2000 ml: HC₅₀ 414.1 µM (lowest hemolysis). Other variants: some >512 µM (almost no hemolysis).	2025 Apr 29. doi: 10.1007/s12602-025-10542-1. Online ahead of print.	27	
FPDB01423	AP05284|||Cath-A|||DRAMP20883	"	
KRFKKFFRKLKKSVKKRKKEFKKKPRVIKVSIPF"	Anti-S. aureus ATCC 25923, activity value is MIC = 16 ug/ml||Anti-S.aureus ATCC 33591, activity value is MIC = 128 ug/ml||Anti-E. coli ATCC 25922 or ATCC 51446, activity value is MIC = 8||Anti-K. pneumoniae ATCC 13883 or ATCC 700603, activity value is MIC = 16||Antibacterial||Anti-MRSA PS-2, activity value is MIC = 64 ug/ml||Anti-MRSA PS-7, activity value is MIC = 64 ug/ml||Anti-MRSA PS-18, activity value is MIC = 32 ug/ml||Anti-MRSA PS-45, activity value is MIC = 32 ug/ml||Anti-MRSA PS-46, activity value is MIC = 32 ug/ml||Anti-MRSA PS-50, activity value is MIC = 32 ug/ml||Anti-MRSA PS-59, activity value is MIC = 64 ug/ml||Anti-MRSA PS-70, activity value is MIC = 32 ug/ml||Anti-MRSA PS-84, activity value is MIC = 128 ug/ml||Anti-MRSA PS-106, activity value is MIC = 32 ug/ml||Anti-MRSA PS-131, activity value is MIC = 128 ug/ml||Anti-MRSA PS-139, activity value is MIC = 32 ug/ml||Anti-MRSA PS-162, activity value is MIC = 128 ug/ml||Anti-MRSA PS-165, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus ATCC 33591, activity value is MIC = 128 ug/ml||Anti-##Gram-negative bacteria: Escherichia coli ATCC 25922, activity value is MIC = 8 ug/ml||Anti-Escherichia coli ATCC 51446, activity value is MIC = 16 ug/ml||Anti-Klebsiella pneumoniae ATCC 700603, activity value is MIC = 64 ug/ml||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 16 ug/ml	Amino acid substitution, reptile cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	N/A	MIC range (32–128 µg/ml): hemolysis is extremely low (<10%). 500 µg/ml: Hemolysis of Cath-A significantly increases (>20%), Cath-B/Cath-BF is relatively low. 1000 µg/ml: Hemolysis of Cath-A is the highest (≈50%), Cath-B/Cath-BF is about 20–30%.|||Human Erthoryctes (55% hemolysis at 1000 ug/ml)|||[Ref.29392557] 0% haemolysis at 1 ug/ml, 0% haemolysis at 2 ug/ml, 0% haemolysis at 4 ug/ml, 0% haemolysis at 8 ug/ml, 0% haemolysis at 16 ug/ml, 0% haemolysis at 31.2 ug/ml, 2% haemolysis at 62.5 ug/ml, 4% haemolysis at 125 ug/ml, 15% haemolysis at 250 ug/ml, 23% haemolysis at 500 ug/ml, 53% haemolysis  at 1000 ug/ml against human red blood cells	2018 Feb;56(2):128-137. doi: 10.1007/s12275-018-7444-5. Epub 2018 Feb 2.|||29392557|||J Microbiol. 2018 Feb;56(2):128-137.||Ref.29392557	34	
FPDB01424	AP05285|||Cath-B|||DRAMP20884	"	
KRFKKFFRKLKKSVKKRKKEFKKKPRVIGVSIPF"	Anti-S. aureus ATCC 25923, activity value is MIC = 32 ug/ml||Anti-S.aureus ATCC 33591, activity value is MIC = 256 ug/ml||Anti-E. coli ATCC 25922 or ATCC 51446, activity value is MIC = 2||Anti-K. pneumoniae ATCC 13883 or ATCC 700603, activity value is MIC = 8||Antibacterial||Anti-MRSA PS-2, activity value is MIC = 256 ug/ml||Anti-MRSA PS-7, activity value is MIC = 32 ug/ml||Anti-MRSA PS-18, activity value is MIC = 128 ug/ml||Anti-MRSA PS-45, activity value is MIC = 64 ug/ml||Anti-MRSA PS-46, activity value is MIC = 128 ug/ml||Anti-MRSA PS-50, activity value is MIC = 128 ug/ml||Anti-MRSA PS-59, activity value is MIC = 32 ug/ml||Anti-MRSA PS-84, activity value is MIC = 128 ug/ml||Anti-MRSA PS-131, activity value is MIC = 64 ug/ml||Anti-MRSA PS-139, activity value is MIC = 64 ug/ml||Anti-MRSA PS-162, activity value is MIC = 256 ug/ml||Anti-MRSA PS-165, activity value is MIC = 128 ug/ml||Anti-Staphylococcus aureus ATCC 25923, activity value is MIC = 32 ug/ml||Anti-Staphylococcus aureus ATCC 33591, activity value is MIC = 256 ug/ml||Anti-##Gram-negative bacteria: Escherichia coli ATCC 25922, activity value is MIC = 2 ug/ml||Anti-Escherichia coli ATCC 51446, activity value is MIC = 8 ug/ml||Anti-Klebsiella pneumoniae ATCC 700603, activity value is MIC = 32 ug/ml||Anti-Klebsiella pneumoniae ATCC 13883, activity value is MIC = 8 ug/ml	Amino acid substitution, reptile cathelicidin analog, animal-derived, natural derivative|||Synthetic construct	N/A	MIC range (32–128 µg/ml): hemolysis is extremely low (<10%). 500 µg/ml: Hemolysis of Cath-A significantly increases (>20%), Cath-B/Cath-BF is relatively low. 1000 µg/ml: Hemolysis of Cath-A is the highest (≈50%), Cath-B/Cath-BF is about 20–30%.|||Human Erthoryctes (3% hemolysis at 1000 ug/ml)|||[Ref.29392557] 0% haemolysis at 1 ug/ml, 0% haemolysis at 2 ug/ml, 0% haemolysis at 4 ug/ml, 0% haemolysis at 8 ug/ml, 3% haemolysis at 16 ug/ml, 3% haemolysis at 31.2 ug/ml, 3% haemolysis at 62.5 ug/ml, 3% haemolysis at 125 ug/ml, 3% haemolysis at 250 ug/ml, 4% haemolysis at 500 ug/ml, 5% haemolysis at 1000 ug/ml against human red blood cells	2018 Feb;56(2):128-137. doi: 10.1007/s12275-018-7444-5. Epub 2018 Feb 2.|||29392557|||J Microbiol. 2018 Feb;56(2):128-137.||Ref.29392557	34	
FPDB01425	AP05286|||AP00056	"	
ILGPVLGLVGSALGGLLKKI"	Anti-S. aureus ATCC 6538 or 5 strains MRSA NCTC 12493, activity value is MIC = 2||Anti-E. faecalis NCTC 12697, activity value is MIC = 8 uM||Anti-E. coli ATCC 8739, activity value is MIC = 4 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 8 uM||Anti-and A. baumannii BAA 747, activity value is MIC = 32 uM||Active against E. coli D21 (LC 4.8 uM) and S. aureus Cowan 1(LC 3.3 uM). Active also against Gram- Y. pseudotuberculosis YPIII (LC 8.2 uM)||P. syringae pv tabaci (8.2 uM)||E. agglomerans Bo-1S (11.3 uM)||Gram+ B. megaterium Bm11 (0.8 uM)||S. lentus (0.6 uM)||M. luteus (0.2 uM)||fungi C. albicans ATCC 10231 (1.6 uM)||C. guiller-mondii (0.7 uM)||C. tropicalis (0.6 uM)  .	skin secretions, Bombina variegata , Europe|||Yellow-bellied toad, Bombina variegata L, Europe	Helix	"Native peptide BH2000 ml: HC₅₀ 17.2 µM (strong hemolysis). Optimized peptide [Arg8,15]BH2000 ml: HC₅₀ 280.4 µM (significantly reduced hemolysis). Optimized peptide [Lys7,8]BH2000 ml: HC₅₀ 414.1 µM (lowest hemolysis). Other variants: some >512 µM (almost no hemolysis).|||Hemolytic activity test results: Hemolytic activity was measured using human red blood cells, and the results showed that the hemolytic concentrations (LC) of H3, H4, and synthetic peptide B were 15.7 μM, 14.6 μM, and 17 μM, respectively. Previously isolated bombinin-type peptides (such as bombinina) had hemolytic concentrations >50 μM, indicating that peptides like H3 and H4 have relatively strong hemolytic activity.

Sample data:

H3 hemolytic concentration 15.7 μM.

H4 hemolytic concentration 14.6 μM.

Synthetic peptide B hemolytic concentration 17 μM."	"2025 Apr 29. doi: 10.1007/s12602-025-10542-1. Online ahead of print.|||EMBO J
. 1993 Dec;12(12):4829-32. doi: 10.1002/j.1460-2075.1993.tb06172.x.||Mangoni ML et al. 2007"	20	
FPDB01426	AP05287	"	
ILGPVLKLVGSALGGLLKKI"	Anti-S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 2 uM||Anti-E. faecalis NCTC 12697, activity value is MIC = 8 uM||Anti-E. coli ATCC 8739, activity value is MIC = 4 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 4 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 8 uM||Anti-and A. baumannii BAA 747, activity value is MIC = 8 uM	Amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Native peptide BH2000 ml: HC₅₀ 17.2 µM (strong hemolysis). Optimized peptide [Arg8,15]BH2000 ml: HC₅₀ 280.4 µM (significantly reduced hemolysis). Optimized peptide [Lys7,8]BH2000 ml: HC₅₀ 414.1 µM (lowest hemolysis). Other variants: some >512 µM (almost no hemolysis).	. 2025 Apr 29. doi: 10.1007/s12602-025-10542-1. Online ahead of print.	20	
FPDB01427	AP05288	"	
ILGPVLGRVGSALGGLLKKI"	Anti-S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 8||Anti-E. faecalis NCTC 12697, activity value is MIC = 64 uM||Anti-E. coli ATCC 8739, activity value is MIC = 8 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 32 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 16 uM||Anti-and A. baumannii BAA 747, activity value is MIC = 64 uM	Amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Native peptide BH2000 ml: HC₅₀ 17.2 µM (strong hemolysis). Optimized peptide [Arg8,15]BH2000 ml: HC₅₀ 280.4 µM (significantly reduced hemolysis). Optimized peptide [Lys7,8]BH2000 ml: HC₅₀ 414.1 µM (lowest hemolysis). Other variants: some >512 µM (almost no hemolysis).	2025 Apr 29. doi: 10.1007/s12602-025-10542-1. Online ahead of print.	20	
FPDB01428	AP05289	"	
ILGPVLGKVGSALGGLLKKI"	Anti-S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 8||Anti-E. faecalis NCTC 12697, activity value is MIC = 64 uM||Anti-E. coli ATCC 8739, activity value is MIC = 8 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 32 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 16 uM||Anti-and A. baumannii BAA 747, activity value is MIC = 64 uM	Amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Native peptide BH2000 ml: HC₅₀ 17.2 µM (strong hemolysis). Optimized peptide [Arg8,15]BH2000 ml: HC₅₀ 280.4 µM (significantly reduced hemolysis). Optimized peptide [Lys7,8]BH2000 ml: HC₅₀ 414.1 µM (lowest hemolysis). Other variants: some >512 µM (almost no hemolysis).	2025 Apr 29. doi: 10.1007/s12602-025-10542-1. Online ahead of print.	20	
FPDB01429	AP05290	"	
ILGPVLGRVGSALGRLLKKI"	Anti-S. aureus ATCC 6538 or 5 strains MRSA NCTC 12493, activity value is MIC = 2||Anti-E. faecalis NCTC 12697, activity value is MIC = 16 uM||Anti-E. coli ATCC 8739, activity value is MIC = 4 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 16 uM||Anti-and A. baumannii BAA 747, activity value is MIC = 8 uM	Amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Native peptide BH2000 ml: HC₅₀ 17.2 µM (strong hemolysis). Optimized peptide [Arg8,15]BH2000 ml: HC₅₀ 280.4 µM (significantly reduced hemolysis). Optimized peptide [Lys7,8]BH2000 ml: HC₅₀ 414.1 µM (lowest hemolysis). Other variants: some >512 µM (almost no hemolysis).	2025 Apr 29. doi: 10.1007/s12602-025-10542-1. Online ahead of print.	20	
FPDB01430	AP05291	"	
ILGPVLGLKKSALGGLLKKI"	Anti-S. aureus ATCC 6538 or MRSA NCTC 12493, activity value is MIC = 2||Anti-E. faecalis NCTC 12697, activity value is MIC = 32 uM||Anti-E. coli ATCC 8739, activity value is MIC = 4 uM||Anti-K. pneumoniae ATCC 43816, activity value is MIC = 8 uM||Anti-P. aeruginosa ATCC 9027, activity value is MIC = 8 uM||Anti-and A. baumannii BAA 747, activity value is MIC = 16 uM	Amino acid substitution, amphibians, animal-derived, natural derivative	Helix	Native peptide BH2000 ml: HC₅₀ 17.2 µM (strong hemolysis). Optimized peptide [Arg8,15]BH2000 ml: HC₅₀ 280.4 µM (significantly reduced hemolysis). Optimized peptide [Lys7,8]BH2000 ml: HC₅₀ 414.1 µM (lowest hemolysis). Other variants: some >512 µM (almost no hemolysis).	2025 Apr 29. doi: 10.1007/s12602-025-10542-1. Online ahead of print.	20	
FPDB01431	AP05296	"	
LLGMIPWAIKAISALSKL"	Anti-Gram- E.coli, activity value is MIC > 512 uM||Anti-P.aeruginosa, activity value is MIC > 512 uM||Anti-S. aureus MRSA, activity value is MIC = 4 uM	Amino acid substitution, amphibians, animal-derived, natural derivative	Helix	7W Hemolytic activity on red blood cells: HC₅₀ = 22.22 μM, hemolysis rate ≈ 10% at 10 μM	2025 Aug 5:292:117686. doi: 10.1016/j.ejmech.2025.117686. Epub 2025 Apr 29.	18	
FPDB01432	AP05297|||Medusin-PT1	"	
LLGMIPVAIKAISALSKL"	Anti-Gram- E.coli, activity value is MIC > 512 uM||Anti-P.aeruginosa, activity value is MIC > 512 uM||Anti-S. aureus MRSA, activity value is MIC = 8 uM||Anti-Staphylococcus aureus, activity value is MIC = 8 ug/ml||Anti-MRSA, activity value is MIC = 16 ug/ml||Anti-E. faecalis, activity value is MIC = 32 ug/ml||Anti-Candida albicans, activity value is MIC = 16 ug/ml||Anti-Escherichia coli, activity value is MIC = 256 ug/ml||Anti-Pseudomonas aeruginosa, activity value is MIC > 512 ug/ml	Amino acid substitution, amphibians, animal-derived, natural derivative|||Phyllomedusa tarsius [Tarsier Leaf Frog]	N/A	7W Hemolytic activity on red blood cells: HC₅₀ = 22.22 μM, hemolysis rate ≈ 10% at 10 μM|||Horse blood (HC50 = 102.2 ug/ml)	2025 Aug 5:292:117686. doi: 10.1016/j.ejmech.2025.117686. Epub 2025 Apr 29.|||28469603	18	
FPDB01433	AP05362	"	
KNRLNFLKKISQRYQKFALPQYLKTVYQHQKAMKPWIQPKTKVIPYVRYL"	Anti-Gram- E. coli ATCC 25922, activity value is MIC = 1.25 uM||Anti-5 strains P. aeruginosa PA14 or KK27 or O1 or AA2 or RP73, activity value is MIC = 1.25||Anti-S. enteritidis 706 RIVM, activity value is MIC = 1.25 uM||Anti-A. baumannii ATCC 17878, activity value is MIC = 1.25 uM||Anti-B. multivorans LMG 17582, activity value is MIC = 1.25 uM||Anti-B. cenocepacia LMG 18863, activity value is MIC = 1.25 uM||Anti-S. enterica ATCC 14028, activity value is MIC = 1.25 uM||Anti-K. pneumoniae ATCC 700603, activity value is MIC = 1.25 uM||Anti-S. aureus ATCC 12600 or 6538p or MRSA WKZ-2, activity value is MIC = 0.63||Anti-L. monocytogenes ATCC 7644, activity value is MIC = 1.25 uM||Anti-and E. faecalis ATCC 29212, activity value is MIC = 1.25 uM||Anti-Gram+ & Gram-||Antiviral||Anti-MRSA||Antibiofilm	other methods predicted from bovine milk protein casein alphaS2	N/A	"Significant hemolysis occurred only at 50 μM (≈70%). The IC₅₀ was calculated to be ≈31 μM.|||The document mentions the hemolytic-related results of the antimicrobial peptide KNR50, specifically as follows:

- In hemolysis experiments with sheep red blood cells, KNR50 showed significant hemolysis at a concentration of 50 μM, with a hemolysis rate of approximately 70%;

- Its half-maximal hemolytic concentration (IC_{50}) is 31 μM.

It should be noted that the concentration at which KNR50 exerts its antibacterial effect is significantly lower than the concentration that causes hemolysis, indicating that it has good safety at effective antibacterial concentrations."	2025 Jun;311(Pt 3):143718. doi: 10.1016/j.ijbiomac.2025.143718. Epub 2025 May 7.|||Int J Biol Macromol. 2025 May 6:143718. doi: 10.1016/j.ijbiomac.2025.143718. PubMed	50	
FPDB01434	AP05428|||DPK-060	"	
GKHKNKGKKNGKHNGWKWWW"	diffusion assay at 100 uM: active against C. albicans ATCC 90028 (7.8 mm)||E. coli ATCC 25922 (9.4 mm)||S. aureus ATCC 29213 (7.2 mm).||Antibacterial	Designed, Peptide conjugates|||Homo sapiens	Rich	GKH17-WWW (3×Trp): At 60 µM, hemolysis of red blood cells ≈ 10%, HaCaT cell penetration < 20%. GKH17-WWWWW (5×Trp): At 60 µM, hemolysis of red blood cells ≈ 40% (comparable to LL-37). In the presence of serum, hemolysis and cytotoxicity of all labeled peptides are reduced to very low levels (< 5%).	2009 Jun 26;284(26):17584-94. doi: 10.1074/jbc.M109.011650. Epub 2009 Apr 27.|||31192163|||J Biol Chem. 2009 Jun 26;284(26):17584-94. doi: 10.1074/jbc.M109.011650. PubMed	20	
FPDB01435	AP05456|||OLAP-371|||Peptide 66	"	
RWR"	active against S. aureus MRSA 155 isolates (2-4 ug/ml)||including vancomycin-resistant strains. MBC is slightly higher||indicating bacterial killing||S. aureus (MIC = >400 uM)||P. aeruginosa (MIC = >400 uM)||C. albicans (MIC = >400 uM)||Antibacterial||Antifungal ; S. aureus (MIC = >400 uM)	Designed, AMP mimic|||Synthetic construct	N/A	Low hemolytic activity against Horse RBCs	2017;17(5):576-589. doi: 10.2174/1568026616666160713130452.|||https://pubmed.ncbi.nlm.nih.gov/34021253	3	
FPDB01436	AP05457	"	
WNDTGKDADGSEA"	Anti-C. difficile strains, activity value is MIC = 0.06||activity value is MIC = 50||activity value is MIC = 90	Library screen of daptomycin analogs with diffeetnt acyl chains	N/A	N/A	. 2012 Oct;56(10):5023-30. doi: 10.1128/AAC.00057-12. Epub 2012 Jul 16.	13	
FPDB01437	AP05516	"	
ILGRIWKGIKDIL"	Anti-Gram- E. coli ATCC 25922, activity value is MIC = 6.25 uM||Anti-K. pneumoniae ATCC 27736, activity value is MIC = 50 uM||Anti-P. aeruginosa ATCC BAA-427, activity value is MIC = 25 uM||Anti-S. aureus ATCC 25923 or MRSA ATCC 33591, activity value is MIC = 6.25 uM	amino acid substitution, scorpion peptides, animal-derived, natural derivative	N/A	Spiniferin: Low hemolysis rate Spiniferin (E4R): 100 uM hemolysis >80% Spiniferin (E4dR): 100 uM hemolysis ≈0%	2025 Mar 20;5(3):387-402. doi: 10.1021/acsbiomedchemau.4c00119. eCollection 2025 Jun 18.	13	
FPDB01438	AP05518	"	
AWQAIARLIKGRGRKKYGRIIIIG"	Anti-E. faecium QF31, activity value is MIC = 4 ug/ml||Anti-E. faecalis SF23-1, activity value is MIC = 8 ug/ml||Anti-S. aureus ATCC 29212 and 40 strains, activity value is MIC = 4||Anti-S. suis P1/7, activity value is MIC = 4 ug/ml||Anti-S. pyogenes DL02 ermB, activity value is MIC = 4 ug/ml||Anti-actiae DL03 ermB, activity value is MIC = 4 ug/ml||Anti-K. pneumoniae, activity value is MIC = 16 ug/ml||Anti-A. baumannii AB11 or 7979, activity value is MIC = 8 ug/ml||Anti-P. aeruginosa PAO1 or PA14, activity value is MIC = 8 ug/ml||Anti-E. coli ATCC 25922 and 40 strains, activity value is MIC = 4||Anti-and S. enteritis S1, activity value is MIC = 16 ug/ml	AI predicted, BroadAMP-GPT predicted	Helix	AMP_S4: At a concentration of 8 µg/ml, it causes 21.12% hemolysis, with an HC50 (half-hemolysis concentration) of 18.25 µg/ml. AMP_S13: At the same concentration (8 µg/ml), the hemolytic activity is negligible, with an HC50 of 928.6 µg/ml.	2025 Dec;17(1):2523811. doi: 10.1080/19490976.2025.2523811. Epub 2025 Jun 26.	24	
FPDB01439	AP05531	"	
RCWKRWWRWWKRCWR"	Anti-S. aureus ATCC 25923 or MRSA 6390 or 3811487 or 3811495, activity value is MIC = 1.25||Anti-5 strains A. baumannii ATCC 19606 or 3811494 or 3811502 or 16 or 17, activity value is MIC = 5 ug/ml||Anti-E. coli 8739, activity value is MIC = 5 ug/ml||Anti-P. aeruginosa ATCC 27853, activity value is MIC = 20 ug/ml||Anti-and three strains K. pneumoniae 9883 or 6183 or 9409, activity value is MIC = 10	Designed	Helix	N/A	2025 May 12;16(6):1114-1123. doi: 10.1021/acsmedchemlett.5c00140. eCollection 2025 Jun 12.	15	
FPDB01440	AP05553|||DRAMP35858	"	
GLLGKILGAGKKVLLGVSGLL"	Anti-493 or B038 V1S1A or B042 V2E1A, activity value is MIC = 4||Anti-697, activity value is MIC > 512 uM||Anti-S. constellatus B003 VISIT, activity value is MIC = 4 uM||Anti-418, activity value is MIC = 8 uM||Anti-816, activity value is MIC = 8||Anti-853 or ATCC 9097 or B004 V2S2B, activity value is MIC > 256 uM||Anti-and fungus C. albicans NYCY 1467, activity value is MIC = 32 uM||Antimicrobial||Anticancer	amino acid substitution, amphibian peptides, animal-derived, natural derivative|||Synthetic	Helix	Nigrocin-PN: At the highest tested concentration of 512 µM, it shows limited hemolysis. Nigrocin-M1: Due to the absence of the disulfide bond, the hemolytic index is significantly increased. Nigrocin-M2: After the complete removal of the 'Rana box,' hemolysis is reduced, especially at concentrations above 100 µM.|||~20% hemo.lytic at 100 uM (HC50>100 uM).	2022 May 23;20(1):76. doi: 10.1186/s43141-022-00366-9.|||J Genet Eng Biotechnol. 2022 May 23;20(1):77.|||J Genet Eng Biotechnol. 2022 May 23;20(1):76. doi: 10.1186/s43141-022-00366-9. PubMed	21	
FPDB01441	AP05582	"	
FLGTVLKLGKAIAKTVVAMLTNAMQPKQ"	Anti-E. coli DSM 787, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 12.5 ug/ml||Anti-P. aeruginosa DSM 50071, activity value is MIC = 50 ug/ml||Anti-K. pneumoniae ATCC BAA 1705, activity value is MIC = 25 ug/ml||Anti-A. baumannii PA01 DSM 30008, activity value is MIC = 6.25 ug/ml||Anti-E. faecalis MF 06036, activity value is MIC = 12.5 ug/ml||Anti-E. faecium NCTC 12201, activity value is MIC = 12.5 ug/ml||Anti-and C. difficile R20291 DSM 27147 or 630 ATCC BAA 1382, activity value is MIC = 6.25	amino acid substitution, amphibian-derived, animal-derived, natural derivative	Helix	Figainin-2PL: Hemolytic activity against mouse red blood cells is 105±11 μM. [P18A] Figainin-2PL: Hemolytic activity against mouse red blood cells is 10±2 μM. [P18K] Figainin-2PL: Hemolytic activity against mouse red blood cells is 12±3 μM. [P18k] Figainin-2PL: Hemolytic activity against mouse red blood cells is 8±5 μM.	2025 Jul 12:192:171430. doi: 10.1016/j.peptides.2025.171430. Online ahead of print.	28	
FPDB01442	AP05584	"	
FLGTVLKLGKAIAKTVVKMLTNAMQPKQ"	Anti-E. coli DSM 787, activity value is MIC = 6.25 ug/ml||Anti-S. aureus ATCC 43300, activity value is MIC = 12.5 ug/ml||Anti-P. aeruginosa DSM 50071, activity value is MIC = 100 ug/ml||Anti-K. pneumoniae ATCC BAA 1705, activity value is MIC = 25 ug/ml||Anti-A. baumannii PA01 DSM 30008, activity value is MIC = 6.25 ug/ml||Anti-E. faecalis MF 06036, activity value is MIC = 12.5 ug/ml||Anti-E. faecium NCTC 12201, activity value is MIC = 6.25 ug/ml||Anti-and C. difficile R20291 DSM 27147 or 630 ATCC BAA 1382, activity value is MIC = 6.25	amino acid substitution, amphibian-derived, animal-derived, natural derivative	Helix	Figainin-2PL: Hemolytic activity against mouse red blood cells is 105±11 μM. [P18A] Figainin-2PL: Hemolytic activity against mouse red blood cells is 10±2 μM. [P18K] Figainin-2PL: Hemolytic activity against mouse red blood cells is 12±3 μM. [P18k] Figainin-2PL: Hemolytic activity against mouse red blood cells is 8±5 μM.	2025 Jul 12:192:171430. doi: 10.1016/j.peptides.2025.171430. Online ahead of print.	28	
FPDB01443	AP05586	"	
KLLKIGLKSFARVLKKVL"	Anti-A. baumannii ATCC 19606, activity value is MIC = 16 uM||Anti-E. coli ATCC 11775 or AIC221, activity value is MIC = 4||Anti-K. pneumoniae ATCC 13883, activity value is MIC = 8 uM||Anti-P. aeruginosa PAO1 or PA14, activity value is MIC = 8 uM||Anti-S. aureus ATCC 12600 or ATCC BAA-1556 MRSA, activity value is MIC = 16 uM||Anti-and vancomycin-resistant E. faecium ATCC 700221, activity value is MIC = 16 uM	AI predicted from fragments of venom proteins	N/A	N/A	2025 Jul 12;16(1):6446. doi: 10.1038/s41467-025-60051-6.	18	
FPDB01444	AP05594	"	
KRRRASPLWKRRRFLSMLKARAK"	Anti-P. aeruginosa PAO1, activity value is MIC = 64 uM||Anti-S. aureus ATCC 12600 or ATCC BAA-1556 MRSA, activity value is MIC = 32 uM||Anti-and vancomycin-resistant E. faecium ATCC 700221, activity value is MIC = 32 uM	AI predicted from fragments of venom proteins	N/A	N/A	2025 Jul 12;16(1):6446. doi: 10.1038/s41467-025-60051-6.	23	
FPDB01445	AP05610	"	
KRLRAKMLNSKFIKLIKR"	Anti-E. coli AIC221, activity value is MIC = 16 uM||Anti-P. aeruginosa PAO1 or PA14, activity value is MIC = 32 uM||Anti-S. aureus ATCC BAA-1556 MRSA, activity value is MIC = 32 uM||Anti-and vancomycin-resistant E. faecium ATCC 700221, activity value is MIC = 32 uM	AI predicted from fragments of venom proteins	N/A	N/A	2025 Jul 12;16(1):6446. doi: 10.1038/s41467-025-60051-6.	18	
FPDB01446	AP05643	"	
RRFTFWFTFRR"	Anti-E. coli 25922 or UB1005, activity value is MIC = 8||Anti-P. aeruginosa 27853, activity value is MIC = 32 uM||Anti-S. epidermidis 12228, activity value is MIC = 32 uM||Anti-S.aureus 29213, activity value is MIC = 128 uM||Anti-S. aureus MRSA43300, activity value is MIC = 64 uM||Anti-L. rhamnosus 1.0385, activity value is MIC = 8 uM||Anti-L.plantarum 7469, activity value is MIC > 128 uM||Anti-C. albicans cgmcc 2.2086, activity value is MIC = 2 uM||Anti-C. parapsilosis CGMCC 2.3989, activity value is MIC = 2 uM	designed	N/A	Hemolytic activity of peptides F1 to F4: All four peptides induced less than 10% hemolysis of fresh healthy human red blood cells at concentrations below 32 µM. Specific hemolysis rates: Figure 5 shows the hemolysis rates of peptides F1 to F4 at different concentrations. The numbers in each square represent the percentage of hemolysis for the corresponding concentration and peptide. The color bar (red gradient on the right) indicates hemolysis rate: the deeper the color (stronger red), the higher the hemolysis rate; conversely, the lighter the color, the lower the hemolysis rate.	2025 Aug 8;25(1):489. doi: 10.1186/s12866-025-04160-8.	11	
FPDB01447	AP05645	"	
RRITIWITIRR"	Anti-E. coli 25922 or UB1005, activity value is MIC = 8||Anti-P.aeruginosa 27853, activity value is MIC = 128 uM||Anti-S.epidermidis 12228, activity value is MIC = 128 uM||Anti-S.aureus 29213 or MRSA43300, activity value is MIC = 128 uM||Anti-L. rhamnosus 1.0385, activity value is MIC = 2 uM||Anti-L.plantarum 7469, activity value is MIC = 128 uM||Anti-C. albicans cgmcc 2.2086, activity value is MIC = 2 uM||Anti-C. parapsilosis CGMCC 2.3989, activity value is MIC = 2 uM	designed	N/A	Hemolytic activity of peptides F1 to F4: All four peptides induced less than 10% hemolysis of fresh healthy human red blood cells at concentrations below 32 µM. Specific hemolysis rates: Figure 5 shows the hemolysis rates of peptides F1 to F4 at different concentrations. The numbers in each square represent the percentage of hemolysis for the corresponding concentration and peptide. The color bar (red gradient on the right) indicates hemolysis rate: the deeper the color (stronger red), the higher the hemolysis rate; conversely, the lighter the color, the lower the hemolysis rate.	2025 Aug 8;25(1):489. doi: 10.1186/s12866-025-04160-8.	11